0001104659-15-002031.txt : 20150113 0001104659-15-002031.hdr.sgml : 20150113 20150113113243 ACCESSION NUMBER: 0001104659-15-002031 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20141031 FILED AS OF DATE: 20150113 DATE AS OF CHANGE: 20150113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO REFERENCE LABORATORIES INC CENTRAL INDEX KEY: 0000792641 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 222405059 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15266 FILM NUMBER: 15524001 BUSINESS ADDRESS: STREET 1: 481 EDWARD H ROSS DR CITY: ELMWOOD PARK STATE: NJ ZIP: 07407-3118 BUSINESS PHONE: 2017912186 MAIL ADDRESS: STREET 1: 481 EDWARD H ROSS DRIVE CITY: ELMWOOD PARK STATE: NJ ZIP: 07407-3118 FORMER COMPANY: FORMER CONFORMED NAME: MED MOBILE INC DATE OF NAME CHANGE: 19891115 10-K 1 a14-21858_110k.htm 10-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C.  20549

 

FORM 10-K

 

[Mark One]

 

x      ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended October 31, 2014

 

OR

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to                 

 

Commission file number 0-15266

 

BIO-REFERENCE LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

New Jersey

 

22-2405059

(State of incorporation)

 

(I.R.S. Employer

 

 

Identification No.)

 

481 Edward H. Ross Drive, Elmwood Park, New Jersey

 

07407

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code 201-791-2600

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Name of each exchange on which registered

Common Stock, $.01 par value

 

NASDAQ Global Select Market

 

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes o No x.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o.

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o.

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or in any amendment to this Form 10-K. o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer.” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o

 

Accelerated filer x

 

 

 

Non-Accelerated filer o

 

Smaller reporting company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x.

 

The aggregate market value of the voting stock of Bio-Reference Laboratories, Inc. (consisting of Common Stock, $.01 par value) held by non-affiliates of the registrant was approximately $623,605,643 based upon the last sale price for the Common Stock on April 30, 2014, the last trading date of the registrant’s most recently completed second quarter, as reported on the NASDAQ Global Market System.

 

On January 9, 2015, there were 27,749,644 shares of Common Stock issued and outstanding.

 

 

 


 

PART I

 

Forward Looking Statements

 

Statements included in this Annual Report on Form 10-K (Annual Report) that are not historical in nature, are intended to be, and are hereby identified as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Bio-Reference Laboratories, Inc. and its subsidiaries. Such statements concern matters that involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods, performance or achievements, or industry results, to be materially different from any future results, performance or achievements described, implied or suggested herein. Although we believe our expectations are based upon reasonable assumptions, there can be no assurance that our financial goals will be realized.

 

Factors could cause actual results, performance or achievement to differ materially from those expressed or implied from these forward-looking statements include, but are not limited to, the factors discussed under “Risk Factors” as well as elsewhere herein, which may include:

 

Loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA, or those of state laboratory licensing laws;

Failure to comply with HIPAA, which could negatively impact profitability and cash flows;

FDA regulation of Laboratory Developed Tests and clinical laboratories;

Failure to comply with federal and state anti-kickback laws;

Failure to maintain the security of patient-related information;

Failure to comply with the Federal Occupational Safety and Health Administration requirements and Needlestick Safety and Prevention Act;

Failure to comply with federal and state laws and regulations related to submission of claims for our services;

Changes in regulation and policies, including increasing downward pressure on health care reimbursement;

Changing relationships with payers, including the various state and multi-state Blues programs, suppliers and strategic partners; Efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;

Failure to timely or accurately bill for our services;

Failure to integrate newly acquired businesses and the costs related to such integration;

Increased competition, including price competition;

Ability to attract and retain experienced and qualified personnel;

Failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;

Adverse litigation results; and

Failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this filing.  We assume no obligation to update the forward-looking statements to reflect actual results or changes in the factors affecting such forward-looking statements.

 

Item. 1. — Business

 

Overview

 

We are a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units.  We believe that we are the third largest full-service laboratory in the United States and the largest independent regional laboratory in the Northeastern market. We offer a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases.  We primarily focus on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health and correctional health care.

 

We currently process approximately 9.6 million laboratory test requisitions each year. A requisition form accompanies a patient specimen, indicating the tests to be performed and the party to be invoiced for the tests. We have a network of approximately 175 patient service centers located in the Northeast (primarily in New York metropolitan super-regional area) for collection of patient specimens.  We currently conduct business in twenty two states.  Most of the business is however concentrated in larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts. We primarily offer laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, extensive phlebotomy services and phlebotomy draw stations scattered around our geographic area.  In October 2012, we launched Laboratorio Buena Salud (“LBS”), the first national testing laboratory dedicated to serving Spanish-speaking populations in the United States.  All business for LBS is conducted in Spanish, including patient and physician interactions.

 

In addition to our clinical testing operations, we operate a clinical knowledge management service through our PSIMedica business unit.  This system uses customer data from laboratory results, pharmaceutical data, claims data and other data sources to provide administrative and clinical decision support systems that enable our customers to provide quality and efficient healthcare to their populations.  We believe that we have a valuable source of data that will represent a significant asset in the future.

 

We also operate a web-based connectivity portal solution for laboratories and physicians through our CareEvolve subsidiary. We use this portal ourselves to provide laboratory ordering, results and patient analytics as well as connectivity to our physician customers.  We also market and license this connectivity solution to other laboratories throughout the country.

 

We are a New Jersey corporation. We are the successor to Med-Mobile, Inc., a New Jersey corporation that was organized in 1981. Our executive offices are located at 481 Edward H. Ross Drive, Elmwood Park, NJ  07407, and our telephone number is 201-791-2600. In this Form 10-K, we may at times refer to ourselves and our subsidiaries as “we,” “us” or “the Company.”

 

2


 

The Clinical Laboratory Testing Market in the United States

 

We believe that the U.S. market for clinical laboratory testing generated approximately $73 billion in annual revenue in 2014.  Nearly all laboratory tests are performed by one of three types of laboratories: hospital laboratories, physician office laboratories or independent clinical laboratories. We believe approximately 60% of the clinical laboratory tests done in the United States are currently performed in a hospital laboratory, approximately 35% performed by an independent clinical laboratory and the balance in a physician office or other laboratory.

 

Commencing with the advent of managed care cost containment in the 1990s, the industry has been impacted by the rapid growth of managed care arrangements, increasingly stringent government regulation and escalating numbers of investigations into fraud and abuse. Among other things, these factors have led to revenue and profit declines for many smaller and mid-sized clinical laboratories, and industry consolidations. As a result, fewer but larger commercial clinical laboratories have emerged with greater economies of scale, more effective compliance with government billing regulations and other laws and a better approach to pricing their services.  These changes have resulted in improved profitability for these larger commercial laboratories.  In addition, new and emerging technologies continue to provide greater testing opportunities for clinical laboratories.

 

We believe that the clinical laboratory testing industry will continue to experience growth in testing volume due to the following factors:

 

the aging of the population of the United States;

patient awareness of the value of laboratory tests;

a decrease in the cost of tests;

the development of sophisticated and specialized tests for early detection of disease and disease management;

the diagnosis and monitoring of infectious diseases, such as AIDS and Hepatitis C;

increased recognition of early detection and prevention as a means of reducing healthcare costs;

the emergence of employer-sponsored wellness programs; and

Ongoing research and development in genetics and genomics.

 

In addition, new and emerging technologies continue to provide greater testing opportunities for clinical laboratories.  As the result of health insurance coverage to uninsured Americans under the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010 (the “Health Care Reform Law”) the demand for our services may increase.

 

Business Strengths and Focus

 

We operate as a national oncology laboratory through our GenPath business unit.  Our expertise in cancer pathology and diagnostics as well as molecular diagnostics has enabled GenPath to grow as a national provider.

 

Our innovative technology platform for sexually transmitted infections has enabled us to expand from a regional service offering to a national offering with specimens coming from throughout the contiguous 48 states in the area of Women’s Health, through our GenPath Women’s Health business unit.

 

GeneDx, our wholly owned subsidiary, is our primary genetics laboratory and is typically recognized as an industry leading national laboratory for testing of rare and ultra-rare genetic diseases.

 

We have one of the largest regional marketing staffs of any laboratory in the country. We have groups dedicated to the Metropolitan regional market, the Oncology market, the Women’s Health market, the Genetic testing market and the Correctional Health market, as well as cross-over groups selling to large institutions and national accounts.

 

We believe that our large marketing staff and strong infrastructure within our designated area can be leveraged to bring new technologies to physicians and healthcare providers. Over the past year, our volume of testing in the area of molecular diagnostics has increased by approximately 35%.

 

We believe that laboratory data has great value in managing the healthcare of a population, but can only be properly utilized when combined with medical claims and pharmacy data. Our medical information unit, PSIMedica, as well as our connectivity solution, CareEvolve, seek to combine laboratory data with these other data elements in order to provide actionable analytics designed to help to improve the quality and efficiency of healthcare.  We believe that there is great value to the genetic and genomic data that we generate through our various laboratory services and we intend to leverage the value of this asset as well.

 

Strategy

 

We seek to continue our strong growth not only through our marketing organization, new technologies and superior service, but also by providing value-added analytics in conjunction with laboratory results.  Our mission is to be recognized by our clients as the best provider of clinical laboratory testing, information and related services. We believe that it is critical for us to deliver our provider-customers actionable medical knowledge at affordable costs to the patient and providers.  The principal components of our strategy to achieve our mission are as follows:

 

capitalize on our position within the clinical market

lead in providing medical information and knowledge;

provide the highest quality service; and

pursue strategic growth opportunities, both through development of new testing services and through acquisitions.

 

Our Testing Services

 

Our laboratory testing business consists of routine testing and esoteric testing. Routine testing generates approximately 32% and esoteric testing generates approximately 68% of our net revenues.

 

Routine Testing

 

Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid and other organs. Below is an abbreviated list of some commonly ordered routine tests:

 

3


 

Blood cell counts

Cholesterol levels

Pregnancy

Substance abuse

Urinalysis

 

We perform these tests at our main processing facility in Elmwood Park, New Jersey, as well as at our satellite facilities in Florida, Texas, Maryland, Ohio, New York and Connecticut.  We typically operate 24 hours a day, 365 days a year. We perform and report most routine tests within 24 hours. Tests results are delivered via driver or electronically.

 

Esoteric Tests

 

We also perform esoteric tests that require sophisticated equipment and materials, highly skilled personnel and professional attention.  These tests are ordered less frequently than routine tests.  They are also generally priced higher than routine tests. Esoteric tests are typically related to the following medical fields:

 

Endocrinology (the study of glands and their hormone secretions)

Genetics and Genomics (the study of chromosomes, genes and their protein products)

Immunology (the study of the immune system)

Microbiology (the study of microscopic forms of life)

HIV-related tests

Molecular diagnostics (the study of genetic content for disease information)

Oncology (the study of abnormal cell growth)

Serology (the study of body fluids)

Toxicology (the study of chemicals and drugs and their effects on the body)

 

We perform cancer cytogenetic testing at our main processing facility in Elmwood Park, and at our leased facilities in Clarksburg, MD and Milford, MA and genetic testing at our GeneDx leased facility in Gaithersburg, MD, as well as at our Elmwood Park facility.  We perform cytology testing in Frederick, MD, Milford, MA, Columbus, OH, Houston, TX, Melbourne, FL, and Campbell, CA, and at our Elmwood Park facility.

 

PSIMedica—Medical Information

 

Our PSIMedica business unit is based on a clinical knowledge management, or CKM, system that uses data derived from various disparate sources to provide both administrative and clinical analysis of a population. The source data consists of enrollment (demographic) data, claims data, pharmacy data, laboratory data and any other data that may be available. The system uses sophisticated algorithms to cleanse and configure the data to facilitate comprehensive and meaningful analysis. The data is maintained on multiple levels enabling review of data from the global level to the granular transactional detail.  The system includes a base set of queries that provide basic functionality and also provides on-line real-time ad hoc query capability enabling the user to customize analysis to the needs of the user’s organization. In addition to the basic queries provided by the system, PSIMedica Quality Indicators, or PQI, provide comprehensive, disease-state-oriented queries that disclose the quality and efficiency of the care and service. These indicators have been designed to provide the user with standards and outcome predictors on a medical standards basis.  We are using PSIMedica to market value-added clinical laboratory services to bulk purchasers of clinical laboratory solutions, as well as marketing our PSIMedica programs to businesses such as health plans, integrated delivery networks, disease management companies, insurers, clinical trial companies and other healthcare providers that benefit from the ability of the system to combine both clinical and administrative analysis.

 

CareEvolve—Connectivity Solutions

 

Through our CareEvolve subsidiary, we offer a physician-based connectivity solution.  This system provides a complex, sophisticated portal for ordering laboratory services and delivering laboratory results, along with ancillary connectivity services.  The system is designed to be physician-centric and to provide a highly flexible, scalable, comprehensive desktop solution for physicians to manage their day-to-day practice needs, as well as to handle their clinical laboratory ordering and reporting.  In addition, we have developed analytical tools that allow providers to query and understand their patient population better and to identify practice trends and patient outliers.  This product has been designed to work as a platform with plug and play capability that can easily be used by other laboratories that also need a web-based solution for their physician customers.

 

Payors and Clients

 

We provide laboratory services to a range of healthcare providers. A “payor” is the party who pays for the tests while the “client” is the party that refers the tests to us. An organization that has a contract with us, such as a clinic or governmental agency, may be both a payor and a client. Some states, such as New York and New Jersey, prohibit us from billing physician clients.  During fiscal year 2014, no single client accounted for more than 10% of our net revenues.

 

The following table reflects our estimate of the breakdown of net revenue by type of payor for the fiscal years ended October 31, 2012, 2013, and 2014.

 

 

 

Fiscal Year Ended October 31,

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Direct Patient Billing

 

2

%

2

%

2

%

Commercial Insurance

 

69

%

64

%

62

%

Professional Billing

 

12

%

16

%

17

%

Medicare

 

16

%

17

%

18

%

Medicaid

 

1

%

1

%

1

%

 

 

100

%

100

%

100

%

 

4


 

Physicians who order clinical tests for their patients represent one of the primary sources of our testing volume. Fees invoiced to patients and third parties are based on our fee schedule, which may be subject to limitations imposed by third-party payors. Fees invoiced to federal health care programs such as Medicare and Medicaid, are based on fee schedules set by applicable governmental authorities, such as the Center for Medicare and Medicaid Services (“CMS”).

 

We provide laboratory services to governmental agencies and large employer groups. We believe that we are the largest provider of  laboratory testing services to correctional facilities in the United States. All of these clients are charged on a contractual basis.

 

Billing

 

Billing for laboratory services is extremely complicated. We must bill various payors, such as patients, the Medicare program and state Medicaid programs, insurance companies and employer groups, all of which have different billing requirements. Compliance with applicable laws and regulations as well as internal compliance procedures adds complexity to this process.

 

Our bad debt expense is not the result of credit-related issues, as is the case in most industries. Our bad debt expense is due primarily to missing or incorrect demographic and billing information on our requisitions.  We depend on the healthcare provider to supply us with this information. We perform the tests and report the test results as requested on the requisition regardless of whether the demographic and billing information is correct or even missing altogether. We then attempt to obtain missing and to correct incorrect information. This adds to the complexity, slows the invoicing process and generally increases the aging of our accounts receivable. In addition, we perform all tests requested by the healthcare provider even though all of the tests ordered by the healthcare provider may not be reimbursed by the payor; it is our obligation to provide all tests requested by the healthcare provider. When all issues are not resolved in a timely manner, the item is written-off to bad debt expense through the allowance for doubtful accounts. Other items such as pricing differences and payor disputes also complicate billing. Adjustments to receivables as a result of these types of matters are accounted for as revenue adjustments and are not written-off to bad debt expense.

 

Sales and Marketing

 

We employ full and part-time sales and marketing representatives. With nearly 400 managers and sales and service representatives working for us, we have groups dedicated to the regional markets in larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts in the areas of oncology, the women’s health, the genetic testing, the correctional health, institutional and national accounts.

 

All of our sales and marketing personnel operate in a dual capacity, as both marketing and client support representatives. This ensures that all of our salespersons are intimately involved with the client. We believe that this is extremely helpful in client retention, since it provides a strong connection between our clients and us.

 

Client Service Coordinators

 

We utilize the services of full and part-time client service coordinators at our Elmwood Park, Clarksburg and Gaithersburg facilities, all of whom are trained in medical and laboratory terminology. This staff is used as an interface with physicians and nurses and supplements the client support provided by our sales force. They also report highly abnormal and life threatening results to the ordering physician via telephone in order to assist speedy medical resolution of patient problems.

 

Logistical Support

 

We employ full and part-time couriers. Our couriers pick up patient specimens from and deliver printed reports to physician offices, nursing homes, clinics and correctional facilities.

 

Competition

 

We compete with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Our major competitors in the New York metropolitan area are two of the largest national laboratories, Quest Diagnostics and Laboratory Corporation of America. Although we are much smaller than these national laboratories, we believe that we compete successfully with them in our region due to our innovative testing services and our level of service.  We believe our responses to medical consultation are faster and more personalized than those of the national laboratories. Our client service staff deals only with basic technical questions and those that have medical or scientific significance are referred directly to our senior scientists and medical staff.

 

Quality Assurance

 

In order to provide accurate and precise clinical information to the physician, it is essential that we maintain a well structured and vigorous quality assurance program. We hold the required Federal and state licenses necessary for the operation of a clinical laboratory at our facilities in New Jersey, New York, Maryland, Massachusetts, Texas, Connecticut and Ohio. We submit to vigorous proficiency tests (or surveys) for all tests that we perform. We are also subject to unannounced inspections from the various state and federal licensing agencies.

 

Our laboratories are accredited by the College of American Pathologists, or CAP.  This accreditation includes on-site inspections and participation in the CAP (or equivalent) proficiency testing program. CAP is an independent organization of board certified pathologists approved by the Center for Medicare and Medicaid Services (CMS), to inspect clinical laboratories in order to determine compliance with the standards required by the Clinical Laboratory Improvement Amendments of 1988, or CLIA.

 

We have a Quality Assurance Committee, headed by a Quality Assurance Coordinator and composed of supervisors from all of our departments.  The Committee meets each day to assess and evaluate our laboratory quality.  Based on the information received from the Committee, recommendations are made to correct conditions that have led to errors.  Management, department supervisors and members of the Committee continually monitor laboratory quality.  Depending on the test, two or three levels of quality control materials are run in each analytical assay to enhance precision and accuracy.  Patient population statistics are evaluated each day. Testing of highly abnormal samples is repeated to maximize accuracy.

 

5


 

We believe that all of these procedures are necessary, not only in maintaining Federal and state licensing, but also in assuring a quality product.  We believe that our high standards of quality are an important factor in client retention.

 

Regulation of Our Clinical Laboratory Operations

 

The clinical laboratory industry is highly regulated and subjected to significant and changing Federal and state laws and regulations. These laws and regulations affect key aspects of our business, including licensure and operations, billing and payment for laboratory services, sales and marketing interactions with ordering physicians, security and confidentiality of health information, and environmental and occupational safety.  Oversight by government officials includes regular inspections and audits.   Failure to comply with applicable requirements, which are sometimes vague or indefinite, may result in substantial fines, criminal penalties, or other enforcement actions, such as suspension or revocation of a clinical laboratory’s license. Changes in regulations often increase the cost of testing or processing claims.  Also, these laws may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations, including in our pricing, billing and/or marketing practices in a manner that could adversely affect operations.  We seek to and believe that we do conduct our business in compliance with all applicable laws and regulations.  Set forth below are highlights of the key regulatory areas applicable to our business.

 

The Company provides clinical laboratory services in the State of Connecticut.  In connection with the provision of such laboratory services, the Company operated a number of blood collection stations in Connecticut, as it does throughout the country.  Due to a misunderstanding by BRLI personnel charged with the responsibility for the Connecticut blood collection stations regarding the process for opening and obtaining approval for the operation of a blood collection station, some of the blood collection stations were opened prior to receipt of written approval from the State of Connecticut Department of Public Health.  At the request of the State of Connecticut Department of Public Health, BRLI’s ceased operation of those collection stations that had not received written approval certificates.  Thereafter, BRLI voluntarily entered into an agreement with the State of Connecticut Department of Public Health wherein BRLI agreed on the procedure for applying to open new blood collection stations, including third-party regulatory review, and maintenance of quality assurance controls for the clinical laboratories and collection stations in Connecticut during a probationary period, and the payment of a fine.  BRLI continues to operate in Connecticut and participate in the Connecticut Medicaid Program.

 

Reimbursement for Laboratory Services

 

We typically bill third party payors such as Medicare, Medicaid, Governmental programs and private insurers for our services.  Billing for clinical testing services is very complicated, and our payors often have different coverage, billing and reimbursement requirements, and change those requirements on an ongoing basis.  Also, submissions of our claims are particularly complex because we provide molecular diagnostic services, anatomic pathology services and clinical laboratory tests, all of which generally are paid using different reimbursement principals.  The clinical laboratory tests are often paid under a clinical laboratory fee schedule, and the anatomic pathology services are often paid under a physician fee schedule; molecular diagnostic testing, including genetic testing, usually has highly specific rules for reimbursement. If ordering physician requisitions contain incorrect or incomplete information, we may also be unable to collect reimbursement from payors.  The increased use of electronic ordering reduces, but does not eliminate, the incidence of missing or incorrect information.

 

In addition, both government and private sector payors have engaged in ongoing efforts in recent years to contain or reduce health care costs, including reimbursement for clinical laboratory services.  The combination of complex billing requirements and ongoing pressure with respect to reimbursement levels, presents substantial challenges to the clinical laboratory business.  Through the Health Care Reform Law substantial changes are being made to the current system for paying for healthcare in the United States, including programs to extend medical benefits to millions of individuals who currently lack insurance coverage, coupled with measures to cut Medicare spending for most health care services, including clinical laboratories.  The changes contemplated by the Health Care Reform Law are subject to rule-making and implementation timelines that extend for several years, and this uncertainty limits our ability to forecast changes that may occur in the future.

 

The U.S. Congress has considered, at least yearly in conjunction with budgetary legislation, changes to one or both of the Medicare fee schedules under which we receive reimbursement, which include the physician fee schedule for anatomical pathology services, and the clinical laboratory fee schedule for our clinical laboratory services. For example, currently there is no copayment or coinsurance required for clinical laboratory services, although there is for our physician services. However, Congress has periodically considered imposing a 20 percent coinsurance on laboratory services. If enacted, this would require us to attempt to collect this amount from patients, although in many cases the costs of collection would exceed the amount actually received.

 

For most of the tests performed for Medicare or Medicaid beneficiaries, laboratories are required to bill Medicare or Medicaid directly, and to accept Medicare or Medicaid reimbursement as payment in full. Part B of the Medicare program contains fee schedule payment methodologies for clinical laboratory services, and the Medicare approach and reimbursement levels often serve as a benchmark for commercial payors.  Payment under Medicare is generally the lesser of billed charges, the local fee for a geographic area, and a national limitation amount that is set at a percent of the median of all local fee schedule amounts for each laboratory test code.  Each year, subject to federal legislation, fees may be updated for inflation based on the percentage change in the Consumer Price Index, or CPI.  From 2004 through 2008 the clinical laboratory fee schedule remained frozen, with no CPI increases.  Then, for the first time in five years, as of January 1, 2009 laboratories received a 4.5% across the board increase in reimbursements.  For 2010, the clinical laboratory fee schedule was decreased by 1.9 percent. For 2011, under the Health Care Reform Law, it was decreased by 1.75 percent, the first of a series of such annual reductions effective from 2011 to 2015, and in 2011, certain “productivity adjustments were instituted that have functioned to decrease rate increases under the CPI update. For 2012, the clinical laboratory fee schedule was increased by .65%, and in February 2012, Congress passed legislation that reduced payment rates under the clinical laboratory fee schedule by 2%, effective January 1, 2013 and an additional 2% reduction in Medicare rates is scheduled to take effect on March 1, 2013 under a “sequestration” mandate, unless Congress acts to prevent this reduction.  In March 2014, Congress enacted the Protecting Access to Medicare Act (“PAMA”).  Pursuant to this legislation, CLFS fees will be stable until 2017, during which time Congress has mandated CMS to perform a market study to make sure that CMS is being fees commensurate with those being paid by commercial payors.  There is no certainty regarding the effects of PAMA or even whether PAMA will survive through completion.  At this point in time, however, the CLFS should be relatively stable through the year 2016.

 

Under the CMS framework, the national limitation amount for clinical laboratory services had been reduced in a number of instances over the past several years to a present level equal to 74% of the national median of laboratory charges, and a number of proposals for legislation or regulation are under discussion which could have the effect of substantially reducing reimbursements to clinical laboratories through reduction of the present allowable percentage or through other means.  We are unable to predict the outcome of these discussions. Depending upon the

 

6


 

nature of congressional and/or regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, we could experience a significant decrease in revenues from CMS, which could have a material adverse effect on us.

 

Also, CMS and other payors have expressed some concern regarding “billed charges” reporting by large clinical laboratories, in light of the common practice, among major clinical laboratories, of providing discounted pricing to certain clients that order testing services on a “bulk” basis, such as certain physicians, hospitals, and other institutions, resulting in economies of scale and relatively low administrative costs, as compared with the higher fees charged to individual patients and third party payors, including Medicare, who generally require separate bills or claims for each patient encounter and which involve relatively high administrative costs).   If this issue were decided in a manner that required the downward adjustment of billed charges reporting, it could adversely affect the Company.

 

Clinical Laboratory Improvement Amendments of 1988 (“CLIA”)

 

CLIA extends Federal licensing requirements to all clinical laboratories (regardless of the location, size or type of laboratory), including those operated by physicians in their offices, based on the complexity of the tests they perform.  CLIA also establishes a stringent proficiency testing program for laboratories and includes substantial sanctions, such as suspension, revocation or limitation of a laboratory’s CLIA certificate (which is necessary to conduct business), cancellation or suspension of the laboratory’s approval to receive Medicare and Medicaid reimbursement, and significant fines and/or criminal penalties.

 

CLIA, and its implementing regulations, includes quality standards (establishing Federal quality standards for all clinical laboratories); application and user fee requirements; and enforcement procedures.  The quality standard regulations establish varying levels of regulatory scrutiny depending upon the complexity of testing performed.  Under these regulations, a laboratory that performs only one or more of routine “waived” tests may apply for a waiver from most requirements of CLIA.  We believe that most tests performed by physician office laboratories will fall into either the “waived” or the “moderately complex” category.  The latter category applies to simple or automated tests and generally permits existing personnel in physicians’ offices to continue to perform testing under the implementation of systems that insure the integrity and accurate reporting of results, establishment of quality control systems, proficiency testing by approved agencies, and biannual inspection.

 

Under CLIA, the company remains subject to state and local laboratory regulations.   CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and some states require additional personnel qualifications, quality control, record maintenance and other requirements.

 

Our laboratory completed its first CLIA inspection under CLIA guidelines and received its certificate of compliance effective February 7, 1996. It has been reinspected since on a bi-annual basis and found to be in compliance.  We believe the Company is in compliance with all applicable federal and state laboratory requirements.  Noting that pursuant to the terms of the Connecticut Consent Order discussed above, the Company has agreed to exceed normal state requirements in the State of Connecticut for patient service center compliance.

 

Compliance Program

 

The Office of Inspector General has published a Model Compliance Program for the clinical laboratory industry. This is a voluntary program for laboratories to demonstrate to the Federal government that they are responsible providers. In addition, certain states, such as New York, require that health care providers, such as clinical laboratories, that engage in substantial business under the state Medicaid program have a compliance program that general adheres to the standards set forth in the Model Compliance Program. Also, under the Health Care Reform Law, the U.S. Department of Health and Human Services, or HHS, will require suppliers, such as the Company, to adopt, as a condition of Medicare participation, compliance programs that meet a core set of requirements.  We have implemented a comprehensive voluntary compliance program adhering to the standards set forth in the Model Compliance Program .

 

Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”)

 

Both as a health care provider of clinical laboratory services, and in connection with the services we furnish to health plans and others as a business associate though medical information services, we are required to comply with federal and state laws that protect the privacy and security of certain healthcare and personal information.  These include HIPAA, which establishes comprehensive standards with respect to the privacy and security of medical information, including requirements for safeguarding electronic protected health information, and comprehensive standards regarding uses and disclosures of protected health information.  The HIPAA standards create a complex regulatory framework, including penalties for non-compliance, requirements to respond to patient requests to review and amend their medical records, certain limitations regarding the use of patient information, and notification obligations in the event of certain breaches of patient information.   In addition to HIPAA, we are required to abide by various state laws protecting healthcare information, that impose standards that are stricter than those of HIPAA, such as state laws governing sensitive health information regarding HIV status and genetic testing.

 

HIPAA provides for significant fines as well as substantial criminal penalties for violations of the Act.  The federal Health Information Technology for Economic and Clinical Health, or HITECH, Act, strengthened and expanded HIPAA, including to require certain breach notification obligations, to extend a number of HIPAA requirements directly to business associates, to heighten penalties and enforcement provisions (including requiring HHS to conduct periodic audits to confirm compliance), and to extend enforcement authority over HIPAA to state attorney generals.

 

In addition, the HITECH Act established a program of Medicare and Medicaid incentive payments available to certain health care providers including, among others, physicians and dentists, if they meaningfully use certified electronic health record technology (“EHR”).  Also, eligible providers that fail to adopt certified EHR systems may be subject to Medicare reimbursement reductions beginning in 2015.  Qualification for the incentive payments requires the use of EHRs that are certified as having certain capabilities for meaningful use pursuant to standards adopted by the Department of Health and Human Services.  Initial (“stage one”) standards addressed criteria for periods beginning in 2011.  CMS has also issued a final rule with “stage two” criteria, for periods beginning in 2014, which are more demanding, and new, incrementally more rigorous criteria are expected to be issued for stage three compliance, however final standards have not yet been issued and so these criteria are not yet certain.

 

                In March 2014 CareEvolve, the Company’s wholly owned connectivity subsidiary, became aware that there had been a HIPAA breach with regard to one of its servers managed at an internet service provider site called XAND.  CareEvolve immediately identified and resolved the breach issue, but in the meantime an Internet data googlebot, a data collection “robot” operated by Google, Inc. had briefly acquired data from a server and made it available to Internet searches.  To the best of the Company’s knowledge, there were no known disclosures of this Patient Health Information (“PHI”) to unauthorized parties and the Company took immediate steps to have the PHI removed from the Internet.  The

 

7


 

Company self-reported this incident to the appropriate government agency, the Office of Civil Rights (“OCR”) and is awaiting further discussions, investigation and action by OCR.

 

In addition, HIPAA requires health care providers, such as clinical laboratories, and other covered entities, to use certain transaction and code set rules for specified electronic transactions, such as transactions involving claims submissions.  The Company believes it is in compliance in all material respects with the current rules.  With respect to these rules, commencing July 1, 2012, CMS required that all HIPAA-covered entities, such as the Company, conduct electronic claim submissions and related electronic transactions under a new HIPAA transaction standard, called Version 5010.  CMS has required this upgrade in connection with another new requirement applicable to the industry, the implementation of new diagnostic code sets to be used in claims submission.  The new diagnostic code sets are called the ICD-10-CM, and were to be implemented on October 1, 2014.  That date has been extended to October 1, 2015.  The Company has been aware of these changes for some time, and believes it is prepared to timely adopt the new standards.  However, it is expected that these changes, in particular the adoption of new diagnostic codes — which must be provided to us accurately by referring physicians in order for us to receive payment from payors, such as Medicare — will result in a degree of disruption and confusion, which may adversely affect Company operations, including the timeliness of reimbursement.

 

Laboratory Developed Tests (LDTs)

 

The federal Food and Drug Administration, or FDA, has regulatory responsibility over, among other areas, instruments, test kits reagents and other medical devices used by clinical laboratories to perform diagnostic testing.  High complexity and CLIA-certified laboratories, such as ours, frequently develop internal testing procedures to provide diagnostic results to customers. These tests are referred to as laboratory developed tests, or LDTs.  LTD’s are subject to CMS oversight through its enforcement of CLIA.  The FDA has also claimed regulatory authority over all LDTs, but indicates that it has exercised enforcement discretion with regard to most LDTs offered by high complexity CLIA-certified laboratories, and has not subjected these tests to the panoply of FDA rules and regulations governing medical devices.  However, the FDA has stated that it has been considering changes in the way it believes that laboratories ought to be allowed to offer these LDTs, and during 2010 publicly announced that it would be exercising regulatory authority over LDTS, using a risk-based approach that will direct more resources to tests with the highest risk of injury.  In September 2014, the FDA announced its framework and timetable for implementing this guidance.  Through the American Clinical Laboratory Association (“ACLA”) the industry has announced its intention to oppose the guidance proposed by the FDA and has engaged the services of Professor Lawrence Tribe and former Solicitor General Paul Clement to represent the interests of the industry in this matter.

 

Fraud and Abuse Regulations

 

Since we supply services that are reimbursed by federal health care programs such as Medicare and Medicaid, our activities are also subject to regulation by CMS and enforcement by the Office of Inspector General, or OIG, within the HHS. A provision of the U.S. Social Security Act known as the “Anti-Kickback Law” prohibits providers and others from directly or indirectly soliciting, receiving, offering or paying any remuneration with the intent of generating referrals or orders for services or items covered by a federal health care program. Many states have similar laws. Courts have interpreted this law very broadly, including holding that a violation has occurred if even one purpose of the remuneration is to generate referrals, even if there are other lawful purposes. There are statutory and regulatory exceptions (known as safe harbors) that outline arrangements that are deemed lawful. However, the fact that an arrangement does not fall within a safe harbor does not necessarily render the conduct illegal under the Anti-Kickback Law. In sum, even legitimate business arrangements between the Company and referral sources, such as physicians, could lead to scrutiny by government enforcement agencies, and require extensive company resources to respond to government investigations. Violations of the Anti-Kickback Law may be punished by civil and criminal penalties and/or exclusion from participation in federal health care programs, including Medicare and Medicaid. The Health Care Reform Law strengthened provisions of the Anti-Kickback Law.

 

The federal “Stark Law” or “self-referral” prohibition, subject to certain exceptions, prohibits payment under Medicare or Medicaid for certain designated health services, including, among others, clinical laboratory services, where the referring physician has a financial relationships with the entity that furnishes the clinical laboratory service.   The applicable exceptions permitting federal reimbursement generally require written agreements and fair market value payments that do not vary based upon the volume or value of referrals.   Many states have similar self-referral laws that regulate the financial relationships between referring physicians and clinical laboratories, which extend to all referrals, not only referrals for services reimbursed by Medicare or Medicaid.   Another federal law, known as the “Anti-Markup Rule,” and similar state laws, address the practice of an independent clinical laboratory performing and then billing to the ordering physician a component of a diagnostic test, such as diagnostic pathology services, where the ordering physician bills the test to Medicare.  In this circumstance, penalties may apply to the physician if Medicare or other payor is billed at a rate that exceeds the laboratory’s charges to the physician, and the laboratory could be at risk under false claims laws, described below, for causing the submission of a false claim, if it advised the physician to submit claims to payors in violation of these provisions.

 

The federal False Claims Act, or FCA, is violated by any entity that “presents or causes to be presented” knowingly false claims for payment to the federal government and many states have similar laws that apply to governmental and private payors. In addition, the Health Care Reform Law amended the FCA to create a cause of action against any person who knowingly makes a false statement material to an obligation to pay money to the government, or knowingly conceals or improperly decreases an obligation to pay or transmit money or property to the government. For the purposes of these recent amendments, an “obligation” includes an overpayment, which is defined broadly to include “any funds that a person receives or retains under Medicare and Medicaid to which the person, after applicable reconciliation, is not entitled . . . .”

 

The FCA is commonly used to sue those who submit allegedly false Medicare or Medicaid claims, as well as those who induce or assist others to submit a false claim. Courts and government officials have found that “false claims” can result not only from noncompliance with the express requirements of applicable governmental reimbursement programs, such as Medicare and Medicaid, but also from noncompliance with other laws, such as provisions of the Food, Drug and Cosmetic Act, or laws that require quality care in service delivery. In addition, the Health Care Reform Law amended the FCA to specify that a claim to federal health care programs that includes items or services resulting from a violation of the Anti-Kickback Law constitutes a false claim under the FCA.  The qui tam or whistleblower provisions of the FCA allow private individuals to bring actions on behalf of the government alleging that the government was defrauded, with tremendous potential financial gain to private citizens in the event they prevail. When a private party brings a whistleblower action under the FCA, the defendant is not made aware of the lawsuit until the government starts its own investigation or makes a decision on whether it will intervene. Many states have enacted similar laws that also apply to claims submitted to commercial insurance companies. The bringing of any FCA action could require us to devote resources to investigate and defend the action. Violations of the FCA could result in enormous economic liability. The law provides that all damages are trebled, and each false claim submitted is subject to a penalty of up to $11,000.

 

8


 

Historically, the clinical laboratory industry has been the focus of major governmental enforcement initiatives, and within the past few years federal and state governments continue to strengthen their enforcement efforts, such as through new laws that increase funding, powers and remedies to pursue suspected cases of fraud and abuse.  We believe we operate lawfully within these statutes; however, we cannot predict if some of our practices may be interpreted as violating these statutes and regulations.

 

Waste Management, Health and Safety

 

We are subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.  For example, federal regulations require licensure of interstate transporters of medical waste. In New Jersey, we are subject to the Comprehensive Medical Waste Management Act, or CMWMA, which requires us to register as a generator of special medical waste. All of our medical waste is disposed of by a licensed interstate hauler.  The hauler provides a manifest of the disposition of the waste products as well as a certificate of incineration which is retained by us. These records are audited by the State of New Jersey on a yearly basis. We are also subject to the Federal Hazardous Materials Transportation Law, 49 U.S.C. 5101 et seq., and the Hazardous Materials Regulations, or HMR, 49 CFR parts 171-180.   In addition, the federal Occupational Safety and Health Administration, or OSHA, has established extensive requirements relating specifically to workplace programs to protect workers from exposure to blood-borne pathogens, such as HIV and the hepatitis B virus, including work practice controls, protective clothing and equipment, training, vaccinations and other measures designed to minimize hazardous exposures.

 

Intellectual Property Rights

 

The Company maintains a combination of patent licenses, trademarks, copyrights, trade secrets and nondisclosure and non-competition agreements to establish and protect its proprietary technology. The Company believes, however, that no single patent, technology, trademark, intellectual property asset or license is material to its business as a whole.

 

Insurance

 

We maintain professional liability insurance.  We believe that our present insurance coverage is sufficient to cover currently estimated exposures, but we cannot assure that we will not incur liabilities in excess of the policy limits.  In addition, although we believe that we will be able to continue to obtain adequate insurance coverage, we cannot assure that we will be able to do so at acceptable cost.

 

Employees

 

At October 31, 2014, we had 3,406 full-time and 941 part-time employees serving in executive positions, as technicians and technologists (including physicians, pathologists and PhDs), in marketing, in logistics and in bookkeeping, clerical and administrative positions. None of our employees are represented by a labor union. We regard relations with our employees as satisfactory.

 

Available Information

 

Our Internet website address is www.bioreference.com.  Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available free of charge through our website as soon as reasonably practicable after we electronically file with or furnish them to the Securities and Exchange Commission, or SEC, and are available in print to any stockholder who requests a copy.  Additionally, the charters of the standing committees of our board of directors are available on our website under “Board Committee Charters”. Information on our website shall not be deemed incorporated into, or to be a part of, this Annual Report on Form 10-K.

 

The public may also read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549.  You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.  Additionally, the SEC maintains a website that contains reports, proxy statements, information statements and other information regarding issuers, including us, that file electronically with the SEC at www.sec.gov.

 

Item 1A. Risk Factors

 

You should carefully consider each of the following risk factors and all other information set forth in this report. Any of the following risks could materially and adversely affect our business, financial condition or results of operations. They are not, however, the only risks we face. Additional risks and uncertainties not presently known to us or that we currently believe not to be material may also adversely affect our business, financial condition or results of operations. This report also includes forward-looking statements that involve risks or uncertainties. Our results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face described below and elsewhere. See “Forward Looking Statements”.

 

Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.

 

The clinical laboratory testing industry is highly regulated and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation:

 

federal and state laws applicable to billing and claims payment;

federal and state laboratory anti-mark-up laws;

federal and state anti-kickback laws;

federal and state false claims laws;

federal self-referral and financial inducement prohibition laws, commonly known as the Stark Law, and the state equivalents;

federal and state laws governing laboratory licensing and testing, including CLIA;

federal and state laws governing the development, use and distribution of diagnostic medical tests known as laboratory developed tests or “LDTs”;

HIPAA, along with the revisions to HIPPA as a result of the HITECH Act, and analogous state laws;

federal, state and foreign regulation of privacy, security, electronic transactions and identity theft;

 

9


 

federal, state and local laws governing the handling, transportation and disposal of medical and hazardous waste;

Occupational Safety and Health Administration rules and regulations;

changes to laws, regulations and rules as a result of the Health Care Reform Law; and

changes to other federal, state and local laws, regulations and rules, including tax laws.

 

We have adopted policies and procedures designed to comply with these laws.  In the ordinary course of business, we conduct internal reviews of our compliance with these laws.  The growth of our business and sales organization may increase the potential for violating these laws or our internal policies and procedures, despite our ongoing vigilance in maintaining and updating our compliance procedures.  The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many of them are extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations.   Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Any determination that we have violated these laws or regulations, or the public announcement that we are being investigated for possible violations of these laws or regulations, could harm our operating results and financial condition. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could be required to curtail or cease our operations. In addition, a significant change in any of these laws or regulations may require us to change our business model in order to maintain compliance with these laws or regulations, which could harm our operating results and financial condition.

 

Our business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or changing interpretations of, CLIA or state laboratory licensing laws to which we are subject.

 

The clinical laboratory testing industry is subject to extensive federal and state regulation, and many of these statutes and regulations have not been interpreted by the courts.  The Clinical Laboratory Improvement Amendments of 1988, or CLIA, are federal regulatory standards that apply to virtually all clinical laboratories (regardless of the location, size or type of laboratory), including those operated by physicians in their offices, by requiring that they be certified by the federal government or by a federally approved accreditation agency.  CLIA does not preempt state law, which in some cases may be more stringent than federal law and require additional personnel qualifications, quality control, record maintenance and proficiency testing. The sanction for failure to comply with CLIA and state requirements may be suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as well as significant fines and/or criminal penalties. Several states have similar laws and we may be subject to similar penalties.

 

We cannot assure you that applicable statutes and regulations will not be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that would adversely affect our business. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on our business. In addition, compliance with future legislation could impose additional requirements on us, which may be costly.

 

Failure to comply with HIPAA, including regarding the use of new “standard transactions,” may negatively impact our profitability and cash flows.

 

Pursuant to HIPAA, we must comply with comprehensive privacy and security standards with respect to the use and disclosure of protected health information, as well as standards for electronic transactions, including specified transaction and code set rules.   Under recent HITECH amendments to HIPAA, the law was expanded, including requirements to provide notification of certain identified data breaches, direct patient access to laboratory records, the extension of certain HIPAA privacy and security standards directly to business associates, and heightened penalties for noncompliance, and enforcement efforts.

 

In addition, the HIPAA transaction standards are complex, and subject to differences in interpretation by payors. For instance, some payors may interpret the standards to require us to provide certain types of information, including demographic information not usually provided to us by physicians. As a result of inconsistent application of transaction standards by payors or the our inability to obtain certain billing information not usually provided to us by physicians, we could face increased costs and complexity, a temporary disruption in receipts and ongoing reductions in the timeliness of reimbursement. In addition, new requirements for additional standard transactions, such as claims attachments, Version 5010 of the HIPAA Transaction Standards and the ICD-10-CM Code Set, could prove technically difficult, time-consuming or expensive to implement. We are working closely with our payors to establish acceptable protocols for claim submission and with our trade association and an industry coalition to present issues and problems as they arise to the appropriate regulators and standards setting organizations.

 

FDA regulation of laboratory-developed tests (“LDTs”) may result in significant change, and our business could be adversely impacted if we fail to adapt.

 

High complexity, CLIA-certified laboratories, such as ours, frequently develop testing procedures internally to provide diagnostic results to customers, which are offered as laboratory-developed tests.   The FDA claims to have regulatory authority over these LDTs and has stated that it intends to issue guidance to the industry regarding its regulatory approach. In such discussions, the FDA has indicated that it would use a risk-based approach to regulation and would direct more resources to tests with wider distribution and with the highest risk of injury, but that it will be sensitive to the need to not adversely impact patient care or innovation. .  In September 2014, the FDA announced its framework and timetable for implementing this guidance.  Through the American Clinical Laboratory Association (“ACLA”) the industry has announced its intention to oppose the guidance proposed by the FDA and has engaged the services of Professor Lawrence Tribe and former Solicitor General Paul Clemente to represent the interests of the industry in this matter.  We cannot predict the ultimate timing or form of any such guidance or regulation and the potential impact on our existing tests, our tests in development [or the materials used to perform our tests].If adopted, such a regulatory approach by the FDA may lead to an increased regulatory burden, including additional costs and delays in introducing new tests. While the ultimate impact of the FDA’s approach is unknown, it may be extensive and may result in significant change. Our failure to adapt to these changes could have a material adverse effect on our business.

 

A failure to comply with any of federal or state laws applicable to our business, particularly laws related to the elimination of healthcare fraud, may adversely impact our business.

 

             Federal officials responsible for administering and enforcing the healthcare laws and regulations have made a priority of eliminating healthcare fraud. For example, the Health Care Reform Law includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. Federal funding available for combating health care fraud and abuse generally has increased. While we seek to conduct our business in compliance with all applicable laws and regulations, many of the laws and regulations applicable to our business, particularly those relating to billing and reimbursement of tests and those relating to relationships with physicians, hospitals and patients, contain language that has not been interpreted

 

10


 

by courts. We must rely on our interpretation of these laws and regulations based on the advice of our counsel and regulatory or law enforcement authorities may not agree with our interpretation of these laws and regulations and may seek to enforce legal remedies or penalties against us for violations. From time to time we may need to change our operations, particularly pricing or billing practices, in response to changing interpretations of these laws and regulations or regulatory or judicial determinations with respect to these laws and regulations. These occurrences, regardless of their outcome, could damage our reputation and harm important business relationships that we have with healthcare providers, payors and others. Furthermore, if a regulatory or judicial authority finds that we have not complied with applicable laws and regulations, we could be required to refund amounts that were billed and collected in violation of such laws and regulations. In addition, we may voluntarily refund amounts that were alleged to have been billed and collected in violation of applicable laws and regulations. In either case, we could suffer civil and criminal damages, fines and penalties, exclusion from participation in governmental healthcare programs and the loss of licenses, certificates and authorizations necessary to operate our business, as well as incur liabilities from third-party claims, all of which could harm our operating results and financial condition. Moreover, regardless of the outcome, if we or physicians or other third parties with whom we do business are investigated by a regulatory or law enforcement authority we could incur substantial costs, including legal fees, and our management may be required to divert a substantial amount of time to an investigation.

 

To enhance compliance with applicable health care laws, and mitigate potential liability in the event of noncompliance, regulatory authorities, such as the United States Health and Human Services Department Office of Inspector General (“OIG”), have recommended the adoption and implementation of a comprehensive health care compliance program that generally contains the elements of an effective compliance and ethics program described in Section 8B2.1 of the United States Sentencing Commission Guidelines Manual, and for many years the OIG has made available a model compliance program targeted to the clinical laboratory industry.  In addition, certain states, such as New York, requires that health care providers, such as clinical laboratories, that engage in substantial business under the state Medicaid program have a compliance program that generally adheres to the standards set forth in the Model Compliance Program.  Also, under the Health Care Reform Law, the U.S. Department of Health and Human Services, or HHS, will require suppliers, such as the Company, to adopt, as a condition of Medicare participation, compliance programs that meet a core set of requirements. While we have adopted U.S. healthcare compliance and ethics programs that generally incorporate the OIG’s recommendations, and train our employees in such compliance, having such a program can be no assurance that we will avoid any compliance issues.

 

Failure to maintain the security of patient-related information or compliance with security requirements could damage our reputation with customers, cause us to incur substantial additional costs and become subject to litigation.

 

Pursuant to HIPAA, and certain similar state laws, we must comply with comprehensive privacy and security standards with respect to the use and disclosure of protected health information.   Under the HITECH amendments to HIPAA, HIPAA was expanded to require certain data breach notification, to extend certain HIPAA privacy and security standards directly to business associates, to heighten penalties for noncompliance, and enhance enforcement efforts.

 

In March 2014 CareEvolve, the Company’s wholly owned connectivity subsidiary, became aware that there had been a HIPAA breach with regard to one of its servers managed at an internet service provider site called XAND.  CareEvolve immediately identified and resolved the breach issue, but in the meantime an Internet data googlebot, a data collection “robot” operated by Google, Inc. had briefly acquired data from a server and made it available to Internet searches.  To the best of the Company’s knowledge, there were no known disclosures of this Patient Health Information (“PHI”) to unauthorized parties and the Company took immediate steps to have the PHI removed from the Internet.  The Company self-reported this incident to the appropriate government agency, the Office of Civil Rights (“OCR”) and is awaiting further discussions, investigation and action by OCR.

 

We receive certain personal and financial information about our clients and their patients. In addition, we depend upon the secure transmission of confidential information over public networks. A compromise in our security systems that results in client or patient personal information being obtained by unauthorized persons or our failure to comply with security requirements for financial transactions could adversely affect our reputation with our clients and result in litigation against us or the imposition of penalties, all of which may adversely impact our results of operations, financial condition and liquidity.

 

Failure to comply with environmental, health and safety laws and regulations, including the federal Occupational Safety and Health Administration Act, the Needlestick Safety and Prevention Act and the Comprehensive Medical Waste Management Act, could result in fines and penalties and loss of licensure, and have a material adverse effect upon our business.

 

We are subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials, as well as regulations relating to the safety and health of laboratory employees. The federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for health care employers, including clinical laboratories, whose workers may be exposed to blood-borne pathogens such as HIV and the hepatitis B virus. These requirements, among other things, require work practice controls, protective clothing and equipment, training, medical follow-up, vaccinations and other measures designed to minimize exposure to, and transmission of, blood-borne pathogens. In addition, the Needlestick Safety and Prevention Act requires, among other things, that we include in our safety programs the evaluation and use of engineering controls such as safety needles if found to be effective at reducing the risk of needlestick injuries in the workplace.

 

Waste management is subject to federal and state regulations governing the transportation and disposal of medical waste including bodily fluids.  Federal regulations require licensure of interstate transporters of medical waste. In New Jersey, we are subject to the Comprehensive Medical Waste Management Act (“CMWMA”), which requires us to register as a generator of special medical waste. All of our medical waste is disposed of by a licensed interstate hauler.  The hauler provides a manifest of the disposition of the waste products as well as a certificate of incineration, which is retained by us. These records are audited by the State of New Jersey on a yearly basis. We are also subject to the Federal Hazardous materials transportation law, 49 U.S.C. 5101 et seq., and the Hazardous Materials Regulations (HMR), 49 CFR parts 171-180. The federal government has classified hazardous medical waste as hazardous materials for the purpose of regulation. These regulations preempt state regulation, which must be “substantively the same,” “the non-federal requirement must conform “in every significant respect to the federal requirement. Editorial and other similar de minimis changes are permitted,” 49 CFR 107.202(d).

 

Failure to comply with such federal, state and local laws and regulations could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions, any of which could have a material adverse effect on our business. In addition, compliance with future legislation could impose additional requirements us, which may be costly.

 

11


 

Failure to comply with complex federal and state laws and regulations related to submission of claims for clinical laboratory services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs.

 

We are subject to extensive federal and state laws and regulations relating to the submission of claims for payment for clinical laboratory services, including those that relate to coverage of our services under Medicare, Medicaid and other governmental health care programs, the amounts that may be billed for our services and to whom claims for services may be submitted. These rules may also affect the Company in light of the practice management products that we market, to the extent that these products are considered to affect the manner in which our customers’ submit their own claims for services.  Submission of our claims is particularly complex because we provide both anatomic pathology services and clinical laboratory tests, which generally are paid using different reimbursement principles. The clinical laboratory tests are often paid under a clinical laboratory fee schedule, and the anatomic pathology services are often paid under a physician fee schedule.

 

Our failure to comply with applicable laws and regulations could result in our inability to receive payment for our services or result in attempts by third-party payors, such as Medicare and Medicaid, to recover payments from us that have already been made. Submission of claims in violation of certain statutory or regulatory requirements can result in penalties, including substantial civil money penalties for each item or service billed to Medicare in violation of the legal requirement, and exclusion from participation in Medicare and Medicaid. Government authorities may also assert that violations of laws and regulations related to submission or causing the submission of claims violate the federal False Claims Act (“FCA”) or other laws related to fraud and abuse, including submission of claims for services that were not medically necessary. Violations of the FCA could result in enormous economic liability. The FCA provides that all damages are trebled, and each false claim submitted is subject to a penalty of up to $11,000. For example, we could be subject to FCA liability if it was determined that the services we provided were not medically necessary and not reimbursable, particularly if it were asserted that we contributed to the physician’s referrals of unnecessary services to us. It is also possible that the government could attempt to hold us liable under fraud and abuse laws for improper claims submitted by an entity for services that we performed if we were found to have knowingly participated in the arrangement that resulted in submission of the improper claims.

 

Changes in regulation and policies, including increasing downward pressure on health care reimbursement, may adversely affect reimbursement for diagnostic services and could have a material adverse impact on our business.

 

Reimbursement levels for health care services are subject to continuous and often unexpected changes in policies, and we face a variety of efforts by government payors to reduce utilization and reimbursement for diagnostic testing services. Changes in governmental reimbursement may result from statutory and regulatory changes, retroactive rate adjustments, administrative rulings, competitive bidding initiatives, and other policy changes.

 

The U.S. Congress has considered, at least yearly in conjunction with budgetary legislation, changes to one or both of the Medicare fee schedules under which we receive reimbursement, which include the physician fee schedule for anatomical pathology services, and the clinical laboratory fee schedule for our clinical laboratory services. For example, currently there is no copayment or coinsurance required for clinical laboratory services, although there is for our physician services. However, Congress has periodically considered imposing a 20 percent coinsurance on laboratory services. If enacted, this would require us to attempt to collect this amount from patients, although in many cases the costs of collection would exceed the amount actually received.

 

Our reimbursement for our pathology services is paid primarily under the physician fee schedule of Medicare and Medicaid and is therefore governed by a complex formula, referred to as the Sustainable Growth Rate, or SGR. As the use of this formula could result in a significant reduction in reimbursement for all physician services, Congress usually acts each year to prevent the full amount of such reductions from taking effect. In 2011, Congress acted to prevent reductions in for 2012, and 2013.  In March 2014, Congress enacted the Protecting Access to Medicare Act (“PAMA”).  Pursuant to this legislation, CLFS fees will be stable until 2017, during which time Congress has mandated CMS to perform a market study to make sure that CMS is being fees commensurate with those being paid by commercial payors.  There is no certainty regarding the effects of PAMA or even whether PAMA will survive through completion.  At this point in time, however, the CLFS should be relatively stable through the year 2016.   The SGR has currently been postponed until March 2015 and Congress continues to work on both a short term and a long term fix to this annual problem.  If Congress fails to take such action in the future, implementation of this formula could adversely affect our business.

 

The Center for Medicare and Medicaid Services (CMS) pays laboratories on the basis of a fee schedule that is reviewed and re-calculated on an annual basis.  CMS may change the fee schedule upward or downward on billing codes that we submit for reimbursement on a regular basis. Our revenue and business may be adversely affected if the reimbursement rates associated with such codes are reduced. Even when reimbursement rates are not reduced, policy changes add to our costs by increasing the complexity and volume of administrative requirements. Medicaid reimbursement, which varies by state, is also subject to administrative and billing requirements and budget pressures. Recently, state budget pressures have caused states to consider several policy changes that may impact our financial condition and results of operations, such as delaying payments, reducing reimbursement, restricting coverage eligibility and service coverage, and imposing taxes on our services.

 

Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition and results of operations.

 

The Health Care Reform Law makes changes that are expected to significantly impact clinical laboratories, among others.  Beginning in 2013, each medical device manufacturer is paying a sales tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices that are listed with the FDA. Although the FDA has contended that LDTs are medical devices, none of our products are currently listed with the FDA. We cannot assure you that the tax will not be extended to services such as ours in the future.  The Health Care Reform Law also mandates a reduction in payments for clinical laboratory services paid under the Medicare Clinical Laboratory Fee Schedule, or CLFS, of 1.75% through 2015 and a productivity adjustment to the CLFS.

 

                Other significant measures contained in the Health Care Reform Law include, for example, coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The Health Care Reform Law also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. In addition, the Health Care Reform Law establishes an Independent Payment Advisory Board, or IPAB, to reduce the per capita rate of growth in Medicare spending. The IPAB has broad discretion to propose policies to reduce expenditures, which may have a negative impact on payment rates for services. The IPAB proposals may impact payments for clinical laboratory services beginning in 2016. We are monitoring the impact of the Health Care Reform Law in order to enable us to determine the trends and changes that may be necessitated by the legislation that may

 

12


 

potentially impact on our business over time.

 

In addition to the Health Care Reform Law, various healthcare reform proposals have also emerged from federal and state governments. For example, in February 2012, Congress passed the “Middle Class Tax Relief and Job Creation Act of 2012” which in part reduced the potential future cost-based increases to the Medicare Clinical Laboratory Fee Schedule by 2%. Overall the expected total fee cut to the CLFS for 2013 was 2.95% not including a further reduction of 2% from implementation of the automatic expense reductions (sequester) under the Budget Control Act of 2011 which went into effect for dates of service on or after April 1, 2013.  Reductions made by the Congressional sequester are applied to total claims payments made.  While these reductions did not result in a rebasing of the negotiated or established Medicare or Medicaid reimbursement rates, rebasing could occur as a result of future legislation.  In 2015, the total fee cut to the CLFS will be 0.25% .

 

We cannot be certain that these or future changes will not affect payment rates in the future.  We also cannot predict whether future healthcare initiatives will be implemented at the federal or state level, or the effect any future legislation or regulation will have on us. The taxes imposed by the new federal legislation, cost reduction measures and the expansion in government’s role in the U.S. healthcare industry may result in decreased profits to us, lower reimbursements by payors for our products or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations.

 

Change in the billing and/or reimbursement procedures by the federal government could affect our ability to be paid as we have in the past for services rendered.

 

CMS has changed or discussed making changes to certain types of reimbursement which could affect our rate of reimbursement.  Certain cases are comprised of both a technical component (TC) and a professional component (PC).  In certain specified areas of testing, primarily in the area of anatomic pathology, CMS has determined that some providers have over-utilized these testing procedures and CMS has introduced changes in reimbursement policies to discourage over-utilization.  While the Company does not currently over-utilize services for self-gain and does not perform any significant amounts revenue for the areas of testing currently being changed by CMS, we are always subject to review by CMS and cannot be certain that CMS won’t interpret our practices differently than we do.  In addition, CMS may extend this logic and approach to other areas of testing that might affect work performed by us.

 

CMS has announced planned changes in the area of Molecular Diagnostics’ reimbursement, primarily designed to improve transparency in billing.  Molecular Diagnostics is a rapidly changing and evolving area of clinical testing.  Whereas other areas of clinical testing are well vetted and established with specific codes for reimbursement, Molecular Diagnostics has moved at a faster pace than CMS can proceed.  Clinical laboratories accordingly use a process called cross-walking to get reimbursed by CMS.  Cross-walking requires that the clinical laboratory identify the individual processes used to process the patient’s specimen and identify diagnostic results that are already reimbursed in established tests.  CMS seeks to specifically identify the testing routine being done and reimburse providers universally for the test actually being performed.  CMS has not established all of the molecular diagnostic tests that will be included in this revised schedule for reimbursement and it has not determined how much will be reimbursed to providers for these tests.  We expect CMS to implement fair and reasonable reimbursement for such tests, but until such pricing decisions are disclosed we cannot be certain what CMS will finally implement.

 

Effective July 1, 2012, CMS eliminated an exemption that had been in place since 1999, which allowed commercial laboratories to bill for certain diagnostic tests performed on in-patient and certain outreach recipients by commercial laboratories.  From 1999 through July 1, 2012, commercial laboratories were allowed to bill CMS for such tests despite the fact that the recipient was a hospital patient as long as the hospital had been submitting such tests for diagnosis to commercial laboratories prior to 1999.  Upon termination of the exemption, we were required to find out from the hospital submitting the test whether the recipient’s bill for diagnostic testing will be reimbursed by the hospital or should be billed to CMS.  We have systems in place to manage this change, but these systems are dependent upon our getting proper information from the hospital clients.

 

The Federal Government is faced with significant economic decisions in the coming years.  Some solutions being offered in the government could substantially change the way laboratory testing is reimbursed by government entities.  We cannot be certain what or how any such government changes may affect our business.”

 

Healthcare plans have taken steps to control the utilization and reimbursement of healthcare services, including clinical test services.

 

We also face efforts by non-governmental third-party payors, including healthcare plans, to reduce utilization and reimbursement for clinical testing services.

 

The healthcare industry has experienced a trend of consolidation among healthcare insurance plans, resulting in fewer but larger insurance plans with significant bargaining power to negotiate fee arrangements with healthcare providers, including clinical testing providers. These healthcare plans, and independent physician associations, may demand that clinical testing providers accept discounted fee structures or assume all or a portion of the financial risk associated with providing testing services to their members through capped payment arrangements. In addition, some healthcare plans have been willing to limit the PPO or POS laboratory network to only a single national laboratory to obtain improved fee-for-service pricing. There are also an increasing number of patients enrolling in consumer driven products and high deductible plans that involve greater patient cost-sharing.

 

The increased consolidation among healthcare plans also has increased the potential adverse impact of ceasing to be a contracted provider with any such insurer. The Health Care Reform Law includes provisions, such as the creation of healthcare exchanges, which may encourage healthcare insurance plans to increase exclusive contracting.

 

We expect continuing efforts to reduce reimbursements, to impose more stringent cost controls and to reduce utilization of clinical test services. These efforts, including future changes in third-party payor rules, practices and policies, or ceasing to be a contracted provider to a healthcare plan, may have a material adverse effect on our business.

 

Increased competition, including price competition, could have a material adverse impact on our net revenues and profitability.

 

                Our industry is characterized by intense competition. Our major competitors in the New York metropolitan super-region, Quest Diagnostics and Laboratory Corporation of America, are large national laboratories that possess greater name recognition, larger customer bases, significantly greater financial resources and employ substantially more personnel than we do. Many of our competitors have long established

 

13


 

relationships with their customers and third-party payors. Despite a long established history of successfully competing in these markets, we cannot assure you that we will be able to compete successfully with such entities in the future.

 

The clinical laboratory business is intensely competitive both in terms of price and service. Pricing of laboratory testing services is often one of the most significant factors used by health care providers and third-party payors in selecting a laboratory. As a result of the clinical laboratory industry undergoing significant consolidation, larger clinical laboratory providers are able to increase cost efficiencies afforded by large-scale automated testing. This consolidation results in greater price competition. We may be unable to increase cost efficiencies sufficiently, if at all, and as a result, our net earnings and cash flows could be negatively impacted by such price competition.   Additionally, we may also face changes in fee schedules, competitive bidding for laboratory services or other actions or pressures reducing payment schedules as a result of increased or additional competition.

 

Additional competition, including price competition, could have a material adverse impact on our net revenues and profitability.

 

A failure to obtain and retain new clients and business partners, a loss of existing clients or material contracts, or a reduction in tests ordered or specimens submitted by existing clients, could impact our ability to successfully grow our business.

 

To offset efforts by payors to reduce the cost and utilization of clinical laboratory services, we need to obtain and retain new clients and business partners. In addition, a reduction in tests ordered or specimens submitted by existing clients, without offsetting growth in our client base, could impact our ability to successfully grow our business and could have a material adverse impact on our net revenues and profitability. We compete primarily on the basis of the quality of testing, reporting and information systems, reputation in the medical community, the pricing of services and ability to employ qualified personnel. Our failure to successfully compete on any of these factors could result in the loss of clients and a reduction in our ability to expand our customer base.

 

Failure to timely or accurately bill for our services could have a material adverse effect on our business

 

Billing for clinical testing services is extremely complicated and is subject to extensive and non-uniform rules and administrative requirements. Depending on the billing arrangement and applicable law, we bill various payors, such as patients, insurance companies, Medicare, Medicaid, physicians, hospitals and employer groups. Changes in laws and regulations could increase the complexity and cost of our billing process. Additionally, auditing for compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further cost and complexity to the billing process. Further, our billing systems require significant technology investment and, as a result of marketplace demands, we need to continually invest in our billing systems.

 

Missing or incorrect information on requisitions adds complexity to and slows the billing process, creates backlogs of unbilled requisitions, and generally increases the aging of accounts receivable and bad debt expense. We believe that much of our bad debt expense in recent years is attributable to the lack of, or inaccurate, billing information. Failure to timely or correctly bill may lead to our not being reimbursed for our services or an increase in the aging of our accounts receivable, which could adversely affect our results of operations and cash flows. Failure to comply with applicable laws relating to billing government healthcare programs could lead to various penalties, including: (1) exclusion from participation in CMS and other government programs; (2) asset forfeitures; (3) civil and criminal fines and penalties; and (4) the loss of various licenses, certificates and authorizations necessary to operate our business, any of which could have a material adverse effect on our results of operations or cash flows.

 

There have been times when our accounts receivable have increased at a greater rate than revenue growth and, therefore, have adversely affected our cash flows from operations. We have taken steps to implement systems and processing changes intended to improve billing procedures and related collection results. We believe that we have made progress by reorganizing our accounts receivable and billing functions and that our allowance for doubtful accounts is adequate. However, we cannot assure that our ongoing assessment of accounts receivable will not result in the need for additional provisions. Such additional provisions, if implemented, could have a material adverse effect on our operating results.

 

Our failure or the failure of third-party payors or physicians to comply with ICD-10-CM Code Set, and our failure to comply with other emerging electronic transaction standards could adversely impact our business.

 

We are within the assessment and inventory phase to adopt the ICD-10-CM Code Set issued by HHS on January 16, 2009. Compliance with the ICD-10-CM Code Set is currently required to be in place by October 1, 2015. The Company will continue its assessment of information systems, applications and processes for compliance with these requirements. Clinical laboratories are typically required to submit health care claims with diagnosis codes to third party payors. The diagnosis codes must be obtained from the ordering physician. Our failure or the failure of third party payors or physicians to transition within the required timeframe could have an adverse impact on reimbursement, days sales outstanding and cash collections.

 

Also, the failure of our IT systems to keep pace with technological advances may significantly reduce our revenues or increase our expenses.  Public and private initiatives to create healthcare information technology (“HCIT”) standards and to mandate standardized clinical coding systems for the electronic exchange of clinical information, including test orders and test results, could require costly modifications to our existing HCIT systems. While we do not expect HCIT standards to be adopted or implemented without adequate time to comply, if we fail to adopt or delay in implementing HCIT standards, we could lose customers and business opportunities.

 

Failure in our information technology systems could significantly increase testing turn-around time or billing processes and otherwise disrupt our operations.

 

Our laboratory operations depend, in part, on the continued performance of our information technology systems. Our information technology systems are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptions. In addition, we are in the process of integrating the information technology systems of our recently acquired subsidiaries, and we may experience system failures or interruptions as a result of this process. Sustained system failures or interruption of our systems in one or more of our laboratory operations could disrupt our ability to process laboratory requisitions, perform testing, provide test results in a timely manner and/or bill the appropriate party.  Breaches with respect to protected health information could result in violations of HIPAA and analogous state laws, and risk the imposition of significant fines and penalties.  Failure of our information technology systems could adversely affect our business, profitability and financial condition.

 

14


 

Adverse results in material litigation matters could have a material adverse effect upon our business.

 

We may become subject in the ordinary course of business to material legal action related to, among other things, professional liability and employee-related matters, as well as inquiries from governmental agencies and Medicare or Medicaid carriers requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. Legal actions could result in substantial monetary damages as well as damage to our reputation with clients, which could have a material adverse effect upon our business.

 

In December 2013, the Company instituted an action against Horizon Blue Cross Blue Shield (New Jersey) (“HBCBS”) in which the Company identified a significant portion of business that the Company has billed to HBCBS has refused to pay the Company even though the Company believes it is entitled to payment. In the Spring 2014, HBCBS was denied a Motion for Summary Judgment it had made to dismiss the case and the case is currently in the discovery phase and is unlikely to be concluded any time soon. The Company continues to operate as an in-network provider in the HBCBS Preferred Provider network (“PPO network”) and has seen no disruption of service with HBCBS to date.

 

In October 2013, Myriad Genetics, Inc., sued GeneDx alleging that GeneDx has infringed certain patent rights of Myriad with regard to its inherited cancers testing program. There are six other companies being sued on the same basis, including Quest Diagnostics and Laboratory Corporation of America. The seven defendants began offering tests for the breast cancer susceptibility genes BRCA1 and BRCA2 after a decision in June 2013 by the United States Supreme Court, in which the Court invalidated a portion of the claims included in the asserted patents. Myriad sought a Preliminary Injunction against one of the other defendants in the case and that Preliminary Injunction application was denied by the trial judge, and recently by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”), which held invalid several additional claims of the asserted patents. GeneDx has in turn filed a series of Inter Partes Review petitions in the United States Patent and Trade Office (“USPTO”) to invalidate several claims in 13 of the patents that Myriad alleges GeneDx has infringed.

 

These actions have been outside the course of ordinary legal business of the Company and have significantly increased legal fees for the Company during the pendency of these cases.

 

We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business.

 

We may be unable to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully enforce our proprietary rights. In addition, we may be subject to intellectual property litigation and we may be found to infringe on the proprietary rights of others, which could force us to do one or more of the following:

 

cease developing, performing or selling products or services that incorporate the challenged intellectual property;

obtain and pay for licenses from the holder of the infringed intellectual property right;

redesign or reengineer our tests;

change our business processes; or

pay substantial damages, court costs and attorneys’ fees, including potentially increased damages for any infringement held to be willful.

 

The Company believes that no single patent, technology, trademark, intellectual property asset or license is material to its business as a whole.

 

If patent regulations or standards are modified, such changes could have a negative impact on our business.

 

At present, other than patent rights obtained by license from third parties, the Company does not have title to any patent rights of its own. Should that change, there are a number of uncertainties to the procurement and maintenance of patent rights. For example, from time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress, or the USPTO may change the standards of patentability and validity and any such changes could have a negative impact on our business. In addition, competitors may develop their own versions of our test(s) in countries where we did not apply for patents, including encouraging the use of their test(s) by physicians or patients in such countries.

 

There have been several cases involving “gene patents” and diagnostic claims that have been considered by the U.S. Supreme Court. On March 20, 2012, the Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., a case involving patent claims directed to optimizing the amount of drug administered to a patient. According to that decision, Prometheus’ claims failed to add enough inventive content to the underlying natural laws to allow the processes they describe to qualify as patent-eligible processes. In Association for Molecular Pathology v. Myriad Genetics, Inc., the Court issued a decision on June 13, 2013, ruling that claims to “isolated” naturally-occurring DNA molecules, and the information they encode, are not patent eligible. The Court indicated, however, that DNA not a “product of nature,” e.g., a complementary DNA or cDNA not found in nature, may be patent eligible. This decision invalidated certain claims of Myriad’s U.S. patents related to the breast cancer susceptibility genes BRCA1 and BRCA2. And, recently the Supreme Court confirmed in a 2014 software case (Alice Corp. Pty. Ltd. v. CLS Bank International) that the framework for analyzing the eligibility of patent claims, including those that encompass genes and genetic diagnostics, follows a two-step process that proceeds through a determination of whether a claim is directed to a law of nature, a natural phenomenon, or an abstract idea.

 

We cannot assure you that any patents that we might obtain in the future on our products and services or any licenses that we might obtain to the patent rights of third parties will not be negatively impacted by these decisions, rulings in other cases, or changes in guidance or procedures issued by the USPTO.

 

We may enter into license agreements with third parties to obtain patent rights that we deem to be necessary to the performance of our business, only to find that because of subsequent changes in the patent law or regulations, such licenses are later no longer necessary. We may then have to withdraw from or terminate any such licenses. Since termination of a license is a contractual matter, there are risks involved—including litigation risks—in such terminations.

 

We are facing, and may in the future face, intellectual property infringement claims that could be time-consuming and costly to defend, and could result in our loss of significant rights and the assessment of treble damages.

 

                As described above, Myriad Genetics has sued GeneDx alleging infringement of certain asserted patents by offering, among other things, OncoGeneDx, our comprehensive series of inherited cancers testing, including testing for the breast cancer susceptibility genes BRCA1 and BRCA2 and colon cancer susceptibility gene MUTYH. We may from time to time receive additional notices of claims of infringement and misappropriation or misuse of other parties’ proprietary rights, such as the one we received from Myriad Genetics. Some of these additional

 

15


 

claims may also lead to litigation. We cannot assure you that we will prevail in such actions, or that other actions alleging misappropriation or misuse by us of third-party trade secrets, infringement by us of third-party patents and trademarks, will not be asserted or prosecuted against us.

 

We may also initiate claims to defend our intellectual property or to seek relief on allegations that we use, sell, or offer to sell technology that incorporates third party intellectual property. Intellectual property litigation, regardless of outcome, is expensive and time-consuming, could divert management’s attention from our business and have a material negative effect on our business, operating results or financial condition. If there is a successful claim of infringement against us, we may be required to do one or more of the following:

 

Cease developing, performing or selling products or services that incorporate the challenged intellectual property; obtain and pay for licenses from the holder of the infringed intellectual property right that may not be available on acceptable or commercially practical terms, if at all; redesign or reengineer our tests to develop non-infringing technology; change our business processes; or pay substantial damages, court costs and attorneys’ fees, including potentially treble damages for any infringement held to be willful.

 

Our failure to develop non-infringing technologies or license the proprietary rights on a timely basis could harm our business.

 

The Company believes that no single technology, trademark, intellectual property asset or patent license held by the Company is material to its business as a whole.

 

Failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services and in the design, manufacture and marketing of our products could adversely affect the results of our operations and adversely impact our reputation.

 

The provision of clinical testing services, including anatomic pathology services, and related services, and the design, manufacture and marketing of diagnostic products involve certain inherent risks. The services that we provide and the products that we design, manufacture and market are intended to provide information for healthcare providers in providing patient care. Therefore, users of our services and products may have a greater sensitivity to errors than the users of services or products that are intended for other purposes.

 

Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of the products can lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or required by governmental authorities) and could result, in certain cases, in the removal of a product from the market. Any recall could result in significant costs as well as negative publicity that could reduce demand for our products. Personal injuries relating to the use of our products can also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals.

 

Similarly, negligence in performing our services can lead to injury or other adverse events. We may be sued under physician liability or other liability law for acts or omissions by our pathologists, laboratory personnel and hospital employees who are under the supervision of our hospital-based pathologists. We are subject to the attendant risk of substantial damages awards and risk to our reputation.

 

Discontinuation or recalls of existing testing products, failure to develop, or acquire, licenses for new or improved testing technologies; or our clients using new technologies to perform their own tests could adversely affect our business.

 

From time to time, manufacturers discontinue or recall reagents, test kits or instruments used by us to perform laboratory testing. Such discontinuations or recalls could adversely affect our costs, testing volume and revenue.

 

The clinical laboratory industry is subject to changing technology and new product introductions. Our success in maintaining a leadership position in genomic and other advanced testing technologies will depend, in part, on our ability to develop, acquire or license new and improved technologies on favorable terms and to obtain appropriate coverage and reimbursement for these technologies. We may not be able to negotiate acceptable licensing arrangements and it cannot be certain that such arrangements will yield commercially successful diagnostic tests. If we are unable to license these testing methods at competitive rates, our research and development costs may increase as a result. In addition, if we are unable to license new or improved technologies to expand our esoteric testing operations, our testing methods may become outdated when compared with our competition and testing volume and revenue may be materially and adversely affected.

 

In addition, advances in technology may lead to the development of more cost-effective technologies such as point-of-care testing equipment that can be operated by physicians or other healthcare providers in their offices or by patients themselves without requiring the services of freestanding clinical laboratories. Development of such technology and its use by our clients could reduce the demand for our laboratory testing services and negatively impact our revenues.

 

Currently, most clinical laboratory testing is categorized as “high” or “moderate” complexity, and thereby is subject to extensive and costly regulation under CLIA. The cost of compliance with CLIA makes it impractical for most physicians to operate clinical laboratories in their offices, and other laws limit the ability of physicians to have ownership in a laboratory and to refer tests to such a laboratory. Manufacturers of laboratory equipment and test kits could seek to increase their sales by marketing point-of-care laboratory equipment to physicians and by selling test kits approved for home or physician office use to both physicians and patients. Diagnostic tests approved for home use are automatically deemed to be “waived” tests under CLIA and may be performed in physician office laboratories as well as by patients in their homes with minimal regulatory oversight. Other tests meeting certain FDA criteria also may be classified as “waived” for CLIA purposes. The FDA has regulatory responsibility over instruments, test kits, reagents and other devices used by clinical laboratories and has taken responsibility from the Centers for Disease Control for classifying the complexity of tests for CLIA purposes. Increased approval of “waived” test kits could lead to increased testing by physicians in their offices or by patients at home, which could affect our market for laboratory testing services and negatively impact our revenues.

 

Clinicians or patients using our services may sue us, and our insurance may not sufficiently cover all claims brought against us, which will increase our expenses.

 

                The development, marketing, sale and performance of healthcare services expose us to the risk of litigation, including professional negligence. Damages assessed in connection with, and the costs of defending, any legal action could be substantial. We may be faced with litigation claims that exceed our insurance coverage or are not covered under any of our insurance policies. In addition, litigation could have a material adverse effect on our business if it impacts our existing and potential customer relationships, creates adverse public relations, diverts management resources from the operation of the business, or hampers our ability to otherwise conduct our business.

 

16


 

A failure to integrate newly acquired businesses and the costs related to such integration could have a material adverse impact on our net revenues and profitability.

 

The successful integration of any business that we may acquire entails numerous risks, including, among others:

 

issues related to revenue recognition and/or cash collections;

loss of key customers or employees;

difficulty in consolidating redundant facilities and infrastructure and in standardizing information and other systems;

failure to maintain quality of services that we and any such acquired companies have historically provided;

coordination of geographically separated facilities and workforces; and

diversion of management’s attention from our day-to-day business.

 

We cannot assure you that current or future acquisitions, if any, or any related integration efforts will be successful, or that our business will not be adversely affected by any future acquisitions. Even if we are able to successfully integrate the operations of companies or businesses that we may acquire in the future, we may not be able to realize the benefits that we expect to result from such integration, including projected cost savings.

 

Our operations may be adversely impacted by the effects of extreme weather conditions, natural disasters such as hurricanes and earthquakes, health pandemics, hostilities or acts of terrorism and other criminal activities.

 

Our operations were adversely impacted by the effects of Hurricane Sandy, and may be adversely impacted by other extreme weather conditions, natural disasters, health pandemics, hostilities or acts of terrorism or other criminal activities from time to time. Such events may result in a temporary decline in the number of patients who seek clinical testing services or in our employees’ ability to perform their job duties. In addition, such events may temporarily interrupt our ability to transport specimens, to receive materials from our suppliers or otherwise to provide our services. The occurrence of any such event and/or a disruption to our operations as a result may adversely impact our results of operations.

 

An inability to attract and retain experienced and qualified personnel could adversely affect our business.

 

The loss of key management personnel or the inability to attract and retain experienced and qualified employees at our clinical laboratories and research centers could adversely affect our business. Our success is dependent in part on the efforts of key members of our management team, including Marc D.  Grodman, M.D., our founder, president and chief executive officer. Success in maintaining our leadership position in genomic and other advanced testing technologies will depend in part on our ability to attract and retain skilled research professionals. In addition, the success of our clinical laboratories also depends on employing and retaining qualified and experienced laboratory professionals, including specialists, who perform clinical laboratory testing services. In the future, if competition for the services of these professionals increases, we may not be able to continue to attract and retain individuals in its markets. Our net revenues and earnings could be adversely affected if a significant number of professionals terminate their relationship with us or become unable or unwilling to continue their employment.

 

Our outstanding debt may impair our financial and operating flexibility.

 

As of October 31, 2014, we had approximately $37,049 of debt outstanding.  Our debt agreements contain various restrictive covenants. These restrictions could limit our ability to use operating cash flow in other areas of our business because we must use a portion of these funds to make principal and interest payments on our debt.

 

We or our subsidiaries may incur additional indebtedness in the future. Our ability to make principal and interest payments will depend on our ability to generate cash in the future. If we incur additional debt, a greater portion of our cash flows may be needed to satisfy our debt service obligations and if we do not generate sufficient cash to meet our debt service requirements, we may need to seek additional financing. In that case, it may be more difficult, or we may be unable, to obtain financing on terms that are acceptable to us. As a result, we would be more vulnerable to general adverse economic, industry and capital markets conditions as well as the other risks associated with the indebtedness.

 

Possible volatility in our stock price could negatively affect us and our stockholders.

 

The trading price of our common stock on the NASDAQ Global Select Market has fluctuated significantly in the past. During the period from November 1, 2011 through October 31, 2014, the trading price of our common stock fluctuated from a high of $37.73 per share to a low of $12.03 per share. In the past, we have experienced a drop in stock price following an announcement of disappointing earnings or earnings guidance. Any such announcement in the future could lead to a similar drop in stock price. The price of our common stock could also be subject to wide fluctuations in the future as a result of a number of other factors, including the following:

 

changes in expectations as to future financial performance or buy/sell recommendations of securities analysts;

our, or a competitor’s, announcement of new products or services, or significant acquisitions, strategic partnerships, joint ventures or capital commitments;

the operating and stock price performance of other comparable companies; and adverse publicity.

 

In addition, the U.S. securities markets have experienced significant price and volume fluctuations. These fluctuations often have been unrelated to the operating performance of companies in these markets. Broad market and industry factors may lead to volatility in the price of our common stock, regardless of our operating performance. Moreover, our stock has limited trading volume, and this illiquidity may increase the volatility of our stock price.

 

In the past, following periods of volatility in the market price of an individual company’s securities, securities class action litigation often has been instituted against that company. The institution of similar litigation against us could result in substantial costs and a diversion of management’s attention and resources, which could negatively affect our business, results of operations or financial condition.

 

17


 

Certain provisions of our charter, by-laws and New Jersey law may delay or prevent a change of control of our company.

 

Our certificate of incorporation, as amended, requires the approval of 80% of our outstanding shares for any merger or consolidation unless the business combination has been approved or authorized by our board of directors. As a New Jersey corporation with a class of securities registered with the SEC, we are governed by certain provisions of the New Jersey Business Corporation Act that also restrict business combinations with shareholders owning 10% or more of our outstanding shares (or other “interested stockholders” as the term is defined by the New Jersey Shareholders’ Protection Act) for a period of five years after such interested shareholder achieves such status unless the business combination is approved by our board of directors prior to the shareholder becoming an interested shareholder. The New Jersey Shareholders’ Protection Act also restricts business combinations with an interested shareholder after the five-year period unless the transaction receives the approval of two-thirds of the shares outstanding, exclusive of the shares held by the interested shareholder or the transaction satisfies certain fair price requirements. In addition, with certain limited exceptions, federal regulations prohibit a person or company or a group of persons deemed to be “acting in concert” from, directly or indirectly, acquiring more than 10% (5% if the acquirer is a bank holding company) of any class of our voting stock or obtaining the ability to control in any manner the election of a majority of our directors or otherwise direct the management or policies of our company without prior notice or application to and the approval of the Federal Reserve.

 

A significant deterioration in the economy could negatively impact testing volumes, cash collections and the availability of credit.

 

Our operations are dependent upon ongoing demand for diagnostic testing services by patients, physicians, hospitals and others. A significant downturn in the economy could negatively impact the demand for diagnostic testing as well as the ability of patients and other payors to pay for services ordered. In addition, uncertainty in the credit markets could reduce the availability of credit and impact our ability to meet our financing needs in the future.

 

Item 1B. - Unresolved Staff Comments

 

None.

 

Item 2.   -Properties.

 

We operate through a regional network of laboratories. The table below summarizes certain information as to our principal facilities as of October 31, 2014.

 

Location

 

Purpose

 

Type of Occupancy

Clarksburg, MD

 

Pathology Laboratory

 

Leased

Elmwood Park, NJ

 

Main Laboratory

 

Leased

Elmwood Park, NJ

 

Corporate Headquarters

 

Leased

Gaithersburg, MD

 

Genetics Laboratory

 

Leased

Houston, TX

 

Pathology Laboratory

 

Leased

Milford, MA

 

Oncology Laboratory

 

Leased

Poughkeepsie, NY

 

Pathology Laboratory

 

Leased

Campbell, CA

 

Routine Laboratory

 

Leased

Miami, FL

 

Routine Laboratory

 

Leased

Melbourne, FL

 

Routine Laboratory

 

Leased

 

We perform cancer cytogenetic testing at our leased facilities in at our main processing facility in Elmwood Park, Clarksburg, MD and Milford, MA and genetic testing at our GeneDx leased facility in Gaithersburg, MD, as well as at our Elmwood Park facility.  We perform cytology testing in Frederick, MD, Milford, MA, Columbus, OH, Houston, TX and at our Elmwood Park facility.  We believe that each of these facilities as presently equipped has the production capacity for its currently foreseeable level of operations. We also lease additional space for patient service centers throughout the New York metropolitan area to collect specimens from physician-referred patients for testing at our processing facilities.

 

Item 3. - Legal Proceedings

 

In the normal course of business, we have been named, from time to time, as a defendant in various legal actions, which may include lawsuits alleging negligence or other similar legal claims, which could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on our client base and reputation.  We may also be involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding our business.  In addition,  as a health care provider and in connection with health care billing-related products, the Company may also be named from time to time in suits brought under the qui tam provisions of the False Claims Act and comparable state laws in which allegations may be made that the Company has submitted or cause to be submitted false claims in connection with claims for payment from federal or state health care programs.  In addition, the Company may, from time to time, receive subpoenas from state agencies and from the Office of the Inspector General of the U.S. Department of Health and Human Services seeking documents relating to the Company’s billing-related activities.  These types of legal proceedings could result in adverse judgments, including substantial monetary settlements, significant fines and penalties, as well as injunctions or other relief.

 

Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey

 

On December 18, 2013, the Company filed an action in the Superior Court of New Jersey against Horizon Blue Cross Blue Shield of New Jersey (“Horizon”), captioned Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey, Docket No. BER L-009748-13 (N.J. Super. Ct. Bergen Cnty.).  The Company has been an in-network provider to Horizon’s preferred provider organization (“PPO”) members for more than 20 years and filed the lawsuit after attempts to resolve its dispute with Horizon were unsuccessful.

 

The Company currently provides services to Horizon pursuant to an Ancillary Services Provider Agreement entered into in 2003 and amended in 2007.  The central claims in the lawsuit arise from the Company’s performance of laboratory services since at least 2008 for members of Horizon’s NJ DIRECT plan, who receive benefits under a program that Horizon has bid, promoted, and represented to be a PPO product for New Jersey state, county, and municipal workers and teachers.  The lawsuit alleges that, despite these representations, Horizon has been improperly treating NJ DIRECT as a Managed Care program in its dealings with the Company, thereby costing the Company more than

 

18


 

$20,000,000 in unreimbursed services and depriving state beneficiaries of valuable rights and benefits to which they are entitled.  The lawsuit alleges that Horizon furthered its fraud against the Company by means of a sham Request for Proposal issued in 2011 and through false and incorrect communications to the Company and other providers.  The Company asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud against Horizon.  In addition to compensatory damages, the Company seeks to recover punitive damages from Horizon due to Horizon’s intentional and malicious misconduct.  The Company also seeks declaratory and injunctive relief.

 

On February 5, 2014, Horizon filed a motion to dismiss the complaint, which the Company opposed.  On March 28, 2014, the Honorable Robert C. Wilson of the Superior Court of New Jersey issued an oral ruling denying Horizon’s motion to dismiss without prejudice pending the completion of discovery.  The Company and Horizon are conducting discovery, which is currently scheduled to close in mid 2015.  The Company intends to vigorously prosecute its claims against Horizon.

 

University of Utah Research Foundation, et al. v. GeneDx, Inc., Civil Action No. 2:13cv00954 (D. Utah)

 

On October 16, 2013, Myriad Genetics, Inc., Endorecherche, Inc., HSC Research and Development Limited Partnership, Trustees of the University of Pennsylvania, and University of Utah Research Foundation (“Plaintiffs”) filed a complaint for patent infringement against GeneDx, Inc., a wholly-owned subsidiary of Bio-Reference Laboratories, Inc., in the United States District Court for the District of Utah, Central Division in Salt Lake City, Utah (“District of Utah litigation”). The complaint alleges that GeneDx offers laboratory services, including testing and analysis of BRCA1, BRCA2, and MUTYH genes, that infringe sixteen (16) U.S. Patents owned or controlled by the plaintiffs. Plaintiffs seek to recover damages, including enhanced damages, together with attorney’s fees, interest, and costs. Plaintiffs also seek other relief, including enjoining GeneDx from continuing its allegedly infringing activity.

 

On December 9, 2013, GeneDx filed its answer, affirmative defenses, and counterclaims alleging, among other things, that the asserted patent claims are invalid, unenforceable, and/or not infringed.

 

Plaintiff Myriad and several of the other Plaintiffs have previously and subsequently filed complaints against other laboratories or have been named as defendants in declaratory judgment actions by certain laboratories. Those cases involve some of the patents and claims asserted against GeneDx. The parties involved in those cases who are adverse to Plaintiffs are: Ambry Genetics Corp. (filed July 9, 2013, D. Utah); Gene by Gene, Ltd. (filed July 10, 2013, D. Utah); Counsyl, Inc. (filed September 20, 2013, N.D. Cal.); Quest Diagnostics Inc., et al. (filed October 10, 2013, C.D. Cal.); Quest Diagnostics Inc., et al. (filed October 22, 2013, D. Utah); Invitae Corp. (filed November 25, 2013, D. Utah); Invitae Corp. (filed November 26, 2013, N.D. Cal.); Laboratory Corporation of America Holdings (filed December 3, 2013, D. Utah); Counsyl, Inc. (filed June 13, 2014, D. Utah); and Pathway Genomics Corp. (filed June 13, 2014, D. Utah) (collectively “Defendants”).

 

On November 8, 2013, Plaintiffs filed a motion with the Judicial Panel on Multidistrict Litigation requesting centralization and consolidation in the District of Utah of each of the outstanding district court actions. On February 19, 2014, following briefing and a hearing, the Panel ordered centralization in the District of Utah before District Court Judge Robert J. Shelby, including the action against GeneDx. The Court held an initial scheduling conference on April 25, 2014.

 

In the first-filed actions against Defendants Ambry Genetics Corp. and Gene by Gene, Ltd., on July 9 and July 10, 2013, respectively, Plaintiffs filed a motion for preliminary injunction with each complaint. The parties in each action provided the Court with briefing on the issues, as well as a technology tutorial on August 23, 2013, and the Court held multi-day hearings on the motion in September and October 2013. Prior to any decision, Plaintiffs and Defendant Gene by Gene entered a stipulated dismissal of that action on February 7, 2014. On March 10, 2014, the Court denied Plaintiffs’ request for a preliminary injunction against Defendant Ambry Genetics Corp.

 

Plaintiffs appealed that decision denying their request for a preliminary injunction to the Court of Appeals for the Federal Circuit. Plaintiffs submitted their appeal brief on April 18, 2014, and Defendant Ambry Genetics Corp. submitted its appeal brief on June 2, 2014. Plaintiffs filed their reply appeal brief on June 13, 2014. The Court of Appeals heard oral argument on the denial of Plaintiffs’ request for a preliminary injunction on October 6, 2014, and a decision is expected soon.

 

On August 18, 2014, GeneDx filed eleven petitions for Inter Partes Review (“IPR”) with the U.S. Patent and Trademark Office, challenging the validity of certain of the patents asserted against it in the District of Utah litigation. The eleven patents involved in these petitions are U.S. Patent Nos. 5,654,155; 5,753,441; 6,033,857; 6,051,379; 6,083,698; 6,951,721; 7,470,510; 7,563,571; 7,622,258; 7,670,776, and 7,838,237. On October 24, 2014, GeneDx filed two additional petitions for IPR challenging the validity of U.S. Patent Nos. 5,747,282 and 5,837,492, which are also asserted against GeneDx in the District of Utah litigation. IPR is a relatively new procedure established by the America Invents Act of 2011 as a means to challenge patentability at the U.S. Patent and Trademark Office; and these petitions are the first, and so far only, use of the IPR procedure by any of the Defendants in the Myriad cases.

 

Since the filing of these IPRs, Plaintiffs have narrowed their asserted claims to 40 across 14 patents from the 67 claims across 16 patents originally asserted in Plaintiffs’ complaint against GeneDx.

 

We intend to vigorously defend ourselves in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against us and we could be required to pay substantial damages. During the pendency of the litigation, we expect to incur significant costs, and the defense of this litigation may divert, and until resolved will continue to divert, the attention of our management and other resources that would otherwise be engaged in other activities.

 

Item 4. — Mine Safety Disclosure

 

Not Applicable.

 

19


 

PART II

 

Item 5. - Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our Common Stock is listed for trading on The NASDAQ Global Select Market under the symbol “BRLI.”

 

The following table sets forth the range of high and low closing prices on the NASDAQ Stock Market for our Common Stock for the periods indicated.

 

Fiscal Year

 

 

 

Prices ($)

 

2013

 

High

 

Low

 

First Quarter (11/1/2012-1/31/2013)

 

31.05

 

24.68

 

Second Quarter (2/1/2013-4/30/2013)

 

28.22

 

23.58

 

Third Quarter (5/1/2013-7/31/2013)

 

31.90

 

25.25

 

Fourth Quarter (8/1/2013-10/31/2013)

 

33.46

 

25.78

 

 

2014

 

High

 

Low

 

First Quarter (11/1/2013-1/31/2014)

 

37.73

 

24.39

 

Second Quarter (2/1/2014-4/30/2014)

 

28.61

 

24.76

 

Third Quarter (5/1/2014-7/31/2014)

 

32.74

 

24.74

 

Fourth Quarter (8/1/2014-10/31/2014)

 

32.60

 

27.14

 

 

On January 7, 2015 the last sale price for the Common Stock on NASDAQ was $31.31 per share.

 

Stockholders

 

At January 7, 2015, the number of record owners of the Common Stock was 227. Such number of record owners was determined from our shareholder records and does not include beneficial owners whose shares are held in nominee accounts with brokers, dealers, banks and clearing agencies.

 

Dividends

 

We have not paid any dividends on our Common Stock since our inception and, do not contemplate or anticipate paying any dividends in the foreseeable future. Furthermore, our loan agreement with PNC Bank prohibits us from paying any cash dividends or making any cash distributions with respect to shares of our Common Stock.

 

Performance Graph

 

We have presented below the cumulative total return to our stockholders during the period from November 1, 2009, through October 31, 2014 in comparison to the cumulative return on the S&P 500 Index and a customized peer group of eight companies during that same period.

 

Peer Group

Covance Inc

Enzo Biochem Inc.

Genomic Health Inc

Laboratory Corporation of America Holdings

Myriad Genetics Inc

Neogenomics Inc

Quest Diagnostics Inc

Response Genetics Inc

 

20


 

 

The results assume that $100 (with reinvestment of all dividends) was invested in our common stock, in the peer group, and in the index on October 31, 2009 and its relative performance tracked through October 31, 2014. The comparisons are based on historical data and are not indicative of, nor intended to forecast, the future performance of our common stock. The performance graph set forth above shall not be deemed incorporated by reference into any filing by us under the Securities Act of 1933 or the Securities Exchange Act of 1934 except to the extent that we specifically incorporate such information by reference therein.

 

21


 

Item 6. -  Selected Financial Data

 

The following is a summary of our historical consolidated financial data for the periods ended and at the dates indicated below.  You are encouraged to read this information together with our audited consolidated financial statements and the related footnotes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this Annual Report.

 

The historical consolidated financial data for the years ended October 31, 2014, 2013, and 2012, 2011 and 2010 has been derived from our audited consolidated financial statements.  The historical consolidated financial data for the years ended October 31, 2010 and 2011, has been derived from our audited consolidated financial statements, which are not included in this Annual Report.

 

We believe that the comparability of our financial results between the periods presented in the table below is significantly impacted by factors which are more fully described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the Consolidated Financial Statements and the notes thereto included elsewhere in this Annual Report.

 

All comparisons to prior periods are adjusted in accordance with the Accounting Standards Update 2011-7 under Topic 954 of FASB codification.  The appended table reflects the adjustments for the prior period.

 

 

 

Fiscal Years Ended October 31,

 

 

 

2014

 

2013

 

2012

 

2011

 

2010

 

 

 

[In Thousands Except Per Share Data]

 

Operating Data:

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 

$

832,282

 

$

715,354

 

$

614,255

 

$

522,081

 

$

424,559

 

Cost of Services

 

462,283

 

392,815

 

337,644

 

287,853

 

232,252

 

Gross Profit

 

369,999

 

322,539

 

276,611

 

234,228

 

192,307

 

General and Administrative Expenses

 

286,574

 

240,566

 

200,480

 

174,454

 

143,929

 

Income From Operations

 

83,425

 

81,973

 

76,131

 

59,774

 

48,378

 

Other Expenses [Income] - Net

 

2,458

 

876

 

1,615

 

-5,072

 

1,415

 

Provision for Income Tax Expense

 

34,209

 

35,272

 

32,360

 

28,487

 

20,582

 

Net Income

 

$

46,758

 

$

45,825

 

$

42,156

 

$

36,359

 

$

26,381

 

Net Income Per Share - Basic

 

$

1.69

 

$

1.65

 

$

1.52

 

$

1.30

 

$

0.95

 

Net Income Per Share - Diluted

 

$

1.68

 

$

1.65

 

$

1.51

 

$

1.29

 

$

0.94

 

Other Data:

 

 

 

 

 

 

 

 

 

 

 

Net Cash - Operating Activities

 

$

16,575

 

$

17,662

 

$

53,098

 

$

30,946

 

$

14,305

 

Net Cash - Investing Activities

 

$

(17,826

)

$

(44,113

)

$

(21,390

)

$

(15,542

)

$

(18,411

)

Net Cash - Financing Activities

 

$

806

 

$

19,260

 

$

(29,056

)

$

(11,170

)

$

5,790

 

 

 

 

As of October 31,

 

 

 

2014

 

2013

 

2012

 

2011

 

2010

 

Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

478,863

 

$

421,528

 

$

312,347

 

$

283,259

 

$

244,131

 

Total Long-Term Liabilities

 

$

15,397

 

$

14,382

 

$

13,626

 

$

10,978

 

$

8,405

 

Total Liabilities

 

$

159,961

 

$

149,934

 

$

85,100

 

$

93,492

 

$

91,743

 

Working Capital

 

$

207,285

 

$

161,116

 

$

151,625

 

$

124,266

 

$

89,459

 

Shareholder’s Equity

 

$

318,902

 

$

271,594

 

$

227,247

 

$

189,767

 

$

152,388

 

 

Item 7.   - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You are encouraged to read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and related footnotes included at the end of this Annual Report.  This discussion and analysis contains forward-looking statements that involve risks and uncertainties.  See “Risk Factors” included elsewhere in this Annual Report for a discussion of some of the important factors that could cause actual results to differ materially from those described or implied by the forward-looking statements contained in the following discussion and analysis.  See “Special Note Regarding Forward-Looking Statements” included elsewhere in this Annual Report.

 

All amounts are presented in thousands, except share and per share amounts and per patient data.

 

Overview

 

We are a clinical diagnostic laboratory headquartered in the northeastern New Jersey. We are a national laboratory in certain focused areas of laboratory testing and a full service laboratory in the larger metropolitan areas of New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts.

 

22


 

We have developed a national reputation for our expertise in certain focused areas of clinical testing. GenPath Oncology, the name by which we are known for our cancer and oncology services, is recognized for the superior hematopathology services it provides throughout the country. Our Women’s Health initiative, through which we provide dedicated services for obstetrics and gynecology practices, including a technically advanced multiplex process for identifying sexually transmitted infections, is offered as GenPath Women’s Health.  We are a full-service laboratory that primarily services physician office practices; our drivers pick up samples and deliver reports and supplies, we provide sophisticated technical support, phlebotomy services or patient service centers where appropriate, and electronic communication services in many cases.  Physicians outside of our regional footprint send samples to our laboratory in order to take advantage of the expertise that we are able to provide in blood-based cancer pathology and associated diagnostics or to take advantage of the superior service, support and technologically advanced testing we offer in our Women’s Health initiative. These accounts frequently send routine testing to us for processing along with specialized testing in order to simplify their diagnostic ordering and review procedures and to take advantage of our outstanding capability, service and support.  Our correctional healthcare services are used throughout the country at prisons and jails. The focused markets we serve on a national basis outside of our regional footprint do not require many of the logistical and other ancillary support services required within the region. Even within our regional footprint, we provide the same services that we provide on a national basis as well as some regional focused diagnostic services, such as histology and pathology support services, substance abuse testing, fertility testing, hemostasis testing, women’s health testing, and molecular diagnostics that are unavailable from many of the smaller regional competitors; testing in some of these areas may be provided outside of physician offices.  In October 2012, we launched Laboratorio Buena Salud, the first national testing laboratory dedicated to serving Spanish-speaking populations in the United States.  All business is conducted in Spanish, including patient and physician interactions.

 

Over the last few years, there have been fundamental changes in the laboratory services industry. In the 1990s, the industry was negatively impacted by the growth of managed care, increased government regulation, and investigations into fraud and abuse. These factors led to revenue and profit declines and industry consolidations, especially among commercial laboratories. There are currently only three US publicly traded full service laboratories operating primarily in the U.S. While that means that the two national mega-laboratories and Bio-Reference Laboratories are the only remaining publicly traded full service commercial laboratories, there are numerous hospital outreach programs and smaller reference laboratories that compete for the commercial clinical laboratory business scattered throughout the country. Clinical laboratories have had to improve efficiency, leverage economies of scale, comply with government regulations and other laws and develop more profitable approaches to pricing. Moreover, there has been a proliferation of technology advancements in clinical diagnostics over the last decade that has created significant opportunities for new testing and growth.

 

As a full service clinical laboratory, we are constantly looking for new technologies and new methodologies that will help us to grow. Since the turn of the century, our size alone has made us attractive to companies that are driving the advances in technology. We represent a significant opportunity for these companies to market their products with a nationally recognized specialty provider in our focused areas of specialty or in one of the major population centers of the world—the New York Metropolitan area. We have had several successful strategic relationships with such technology opportunities. In addition to new technology opportunities, we have an extremely seasoned and talented management staff that has been able to identify emerging laboratory markets that are under-served or under-utilized. We have recently developed programs for cardiology, histology and women’s health to go along with our existing hemostasis, hematopathology and correctional healthcare initiatives which have already been established and in which we have been increasing our market share for the past several years. We offer a comprehensive pre-natal program to leverage our presence in the women’s health environment and we will continue to vigilantly seek focused diagnostic marketing opportunities where we can provide information, technology, service or support that expand and grow our clinical laboratory.

 

While we recognize that we are a clinical laboratory that processes samples, we also understand that we are an information company that needs to effectively communicate the results of our efforts back to healthcare providers. Laboratory results play a major role in the implementation of physician healthcare. Laboratory results are used to diagnose, monitor and classify health concerns. In many cases, laboratory results represent the confirming data in diagnosing complicated health issues. Since laboratory results play such an important role in routine physician care, we have developed informatics solutions that leverage our role in healthcare. We built a web-based solution to quickly, accurately, conveniently and competitively collect ordering information and deliver results.  That solution is called CareEvolve.  CareEvolve has been essential to our own operations. We license the technology to other laboratories throughout the country that they utilize to more effectively compete against the national laboratories. These other laboratories licensing our technology are typically not our competitors since they are outside our regional footprint.

 

We have also created our PSIMedica business unit that has developed a Clinical Knowledge Management (CKM) System that takes data from enrollment, claims, pharmacy, laboratory results and any other available electronic source to provide both administrative and clinical analysis of a population. The system uses proprietary algorithms to cleanse and configure the data and transfer the resulting information into a healthcare data repository. Using advanced cube technology methodologies, the data can be analyzed from a myriad of views and from highly granular transactional detail to global trended overview. Events such as the Hurricane Katrina in Louisiana and general pressures from the government have made development of an electronic medical record system and Pay-for Performance reimbursement priority goals in the healthcare industry. A large portion of an individual’s medical record consists of laboratory data and a key performance indicator in any Pay-for-Performance initiative is laboratory result data. Our CKM system is a mature, full functioning solution that will allow us to play a role in these important national initiatives.

 

To date, neither our PSIMedica business unit nor CareEvolve has produced significant revenues relative to the primary laboratory operations.

 

Results of Operations

 

Fiscal Year 2014 Compared to Fiscal Year 2013

 

NET REVENUES:

 

Net revenues for the year ended October 31, 2014 were $832,282 as compared to $715,354 for the year ended October 31, 2013; this represents a 16% increase in net revenues. This increase is due to a 13% increase in patients serviced and a 3% increase in net revenue per patient. Our laboratory operations had net revenues of $824,031 in fiscal 2014 and $709,592 in fiscal 2013.  The remaining revenues were associated with non-laboratory services such as licensing fees for CareEvolve, training services for the National Institutes of Health (“NIH”) and other non-laboratory services.

 

23


 

The number of patients serviced during the year ended October 31, 2014 was 9,632, which was 13% greater when compared to the prior fiscal year.  Net revenue per patient for the year ended October 31, 2014 was $85.55 compared to net revenue per patient for the year ended October 31, 2013 of $83.00, an increase of 3% as a result of increases in esoteric testing.

 

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry.

 

COST OF SERVICES:

 

Cost of services for the year ended October 31, 2014 was $462,283 as compared to $392,815 for the year ended October 31, 2013, an increase of 18% as compared to a 16% increase in net revenues.  This is mainly due to additional costs incurred as the result of integrating operations of our recently acquired businesses in Florida and California.

 

GROSS PROFIT:

 

Gross profit on net revenues increased to $369,999 for the year ended October 31, 2014 from $322,539 for the year ended October 31, 2013, an increase of $47,460 (15%).  This increase is proportional to the  increase in net revenues and consistent with our growth pattern.. Gross profit margins decreased to 44% for fiscal 2014 from fiscal 2013 rate of 45%.    This decrease is largely attributable to an increase in direct costs related to expenses associated with our recently acquired operations in Florida and California as well as an industry noted decrease in reimbursement.

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

General and administrative expenses for the year ended October 31, 2014 were $286,574 as compared to $240,566 for the year ended October 31, 2013, an increase of $46,008 or 19%.  This increase is 3% more than the increase in net revenues due to additional legal expenses the Company recorded as the result of  the Horizon and University of Utah Research Foundation cases, as well as of additional expenses incurred as the result of integrating operations of our businesses acquired in Florida and California.

 

Our legal expenses, a part of general and administrative expenses increase by about 48% mainly as the result of the above mentioned litigations.  We expect this trend to continue.

 

Legal Expenses associated with two large ongoing lawsuits noted above will exceed the normal growth of legal expenses associated with our growth as a Company.  We cannot predict the full extent of these expenses, but we expect that they will increase our legal expenses for the next few fiscal years until these matters are resolved.  The expenses for these specific cases — Horizon Blue Cross Blue Shield and Myriad — could run easily between $5,000 up to $10,000 over the next two fiscal years.

 

Fuel costs and expense have been dramatically affected by current global conditions.  After several years of substantial increase on an annual basis, there has recently been some diminishment of these costs.  These are highly volatile expense categories for the Company and it is difficult to accurately predict their pattern.  We believe that the current conditions are favorable on a national basis, but there is no stability in this expense category and that could easily change in the future.

 

INTEREST EXPENSE:

 

Interest expense increased from $1,606 during the year ended October 31, 2013 to $2,446 during the year ended October 31, 2014; an increase of $840 or 52%. This increase is due to an increase in utilization of the PNC Bank line of credit.   Management believes that this trend will continue in the near term as our ongoing needs, particularly for biweekly payroll expenses, continue to increase commensurate with the overall growth of the Company.

 

NET INCOME:

 

We realized net income of $46,758 for the fiscal year ended October 31, 2014 as compared to $45,825 for the twelve month period ended October 31, 2013, an increase of 2%.

 

Pre-tax income for the period ended October 31, 2014 was  $80,967, as compared to $81,097 for the period ended October 31, 2013. The provision for income taxes decreased from $35,272 for the period ended October 31, 2013, to $34,209 (3%) for the current twelve month period.  This decrease is attributable in part to additional tax benefits associated with our recent Florida and California acquisitions as well as developing additional business in states with lower tax rates as the Company continues to grow on a national basis throughout all states in the United States.

 

Our diluted net income per share went from $1.65 in fiscal 2013 to $1.68 in fiscal 2014.

 

Fiscal Year 2013 Compared to Fiscal Year 2012

 

NET REVENUES:

 

Net revenues for the year ended October 31, 2013 were $715,354 as compared to $614,255 for the year ended October 31, 2012; this represents a 16% increase in net revenues. This increase is due to a 10% increase in patients serviced and a 6% increase in net revenue per patient. Our laboratory operations had net revenues of $709,592 in fiscal 2013 and $609,763 in fiscal 2012.

 

The number of patients serviced during the year ended October 31, 2013 was 8,549, which was 10% greater when compared to the prior fiscal year.  Net revenue per patient for the year ended October 31, 2013 was $83.00 compared to net revenue per patient for the year ended October 31, 2012 of $78.16, an increase of 6% as a result of increases in esoteric testing.

 

Despite continued strong volume growth, the Company believes there is an ongoing recalibration of reimbursement for the industry, which has resulted in substantial downward pressure from many payers regarding reimbursement in FY13.  Over the past year, the Company has

 

24


 

had to negotiate contract modifications to reimbursement rates, conditions of payment and / or eligibility with dozens of health plans representing a substantial numbers of lives nationwide; most of these changes became effective toward the end of FY13 and especially in Q4FY13.

 

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry as well as a failure to continue the sizeable annual percentage increase in base business from significantly higher levels after 19  years of sustained growth.

 

COST OF SERVICES:

 

Cost of services for the year ended October 31, 2013 was $392,815 as compared to $337,644 for the year ended October 31, 2012, an increase of 16% as compared to a 16% increase in net revenues.  This is basically in line with the increase in our net revenues.

 

GROSS PROFIT:

 

Gross profit on net revenues increased to $322,539 for the year ended October 31, 2013 from $276,611 for the year ended October 31, 2012; an increase of $45,928 (17%), primarily attributable to the increase in net revenues. Gross profit margins remained consistent at 45% from fiscal 2012 to fiscal 2013.

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

General and administrative expenses for the year ended October 31, 2013 were $240,566 as compared to $200,480 for the year ended October 31, 2012, an increase of $40,086 or 20%.  This increase is slightly more than the increase in net revenues due to additional bad debt expenses the Company recorded as the result of the ongoing reimbursement changes in the marketplace.  We expect this trend to continue in the near future.

 

INTEREST EXPENSE:

 

Interest expense increased from $1,455 during the year ended October 31, 2012 to $1,606 during the year ended October 31, 2013; an increase of $151 or 10%. This increase is due to an increase in utilization of the PNC Bank line of credit.   Management believes that this trend will continue in the near term.

 

NET INCOME:

 

We realized net income of $45,825 for the twelve month period ended October 31, 2013 as compared to $42,156 for the twelve month period ended October 31, 2012, an increase of 9%.

 

Pre-tax income for the period ended October 31, 2013 was $81,097, as compared to $74,516 for the period ended October 31, 2012, an increase of $6,581 (9%) and was caused primarily by an increase in net revenues.  The provision for income taxes increased from $32,360 for the period ended October 31, 2012, to $35,272 (9%) for the current twelve month period.

 

During this fiscal year the Company received a refund of $1,062 for its New York State clinical laboratory inspection fee that was included in other income.

 

Our diluted net income per share went from $1.51 in fiscal 2012 to $1.65 in fiscal 2013.

 

Liquidity and Capital Resources

 

Our working capital at October 31, 2014 was approximately $207,285 as compared to approximately $161,116 at October 31, 2013, an increase of $46,169 (29%). Our cash position decreased by approximately $445 year ended October 31, 2014. We increased our short term borrowing by approximately $7,241 and decreased our long term debt by approximately $463.  We had current liabilities of approximately $144,564 at October 31, 2014. We generated approximately $16,575 in cash from operations, a decrease of approximately $1,087 as compared to the year ended October 31, 2013.

 

Accounts receivable, net of allowance for doubtful accounts, totaled approximately $263,346 at October 31, 2014, an increase of approximately $57,085 from October 31, 2013, or 28%. This increase was primarily attributable to increased revenue and slowdown in the collection cycle.  Cash collected over the year ended October 31, 2014 increased 29% over the prior twelve month period.

 

Net service revenues on the statements of operations are as follows:

 

 

 

($)

 

 

 

Year Ended October 31

 

 

 

2014

 

2013

 

2012

 

Gross Service Revenues

 

4,185,052

 

3,524,108

 

3,052,431

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

391,659

 

354,638

 

320,697

 

All Other Third Party Payors*

 

2,899,374

 

2,393,872

 

2,070,073

 

Total Contractual Adjustments and Discounts

 

3,291,033

 

2,748,510

 

2,390,770

 

Service Revenues Net of Contractual Adjustments and Discounts

 

894,019

 

775,598

 

661,661

 

Patient Service Revenue Provision for Bad Debts**

 

61,737

 

60,244

 

47,406

 

Net Revenues

 

832,282

 

715,354

 

614,255

 

 

 

 

 

 

 

 

 

Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.

 

80.1

%

79.7

%

79.9

%

 

25


 

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising our client base.  We have significant receivable balances with government payors and various insurance carriers.  Generally, we do not require collateral or other security to support customer receivables. However, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable and to establish an allowance for uncollectible accounts. As a consequence, we believe that our accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

 

A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to clinical laboratories.  Depending upon the nature of regulatory action, and the content of legislation, we could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on us. We are unable to predict, however, the extent to which such actions will be taken.

 

LABORATORY GROSS RECEIVABLES BY PAYOR GROUP

 

 

 

($)
FY 2014

 

Payer Type

 

30 Days

 

%

 

60 Days

 

%

 

90 Days

 

%

 

>90 Days

 

%

 

Total

 

%

 

Self Pay

 

11,595

 

13

%

12,980

 

15

%

10,615

 

12

%

53,430

 

60

%

88,619

 

100

%

Medicare

 

35,303

 

42

%

12,058

 

14

%

5,126

 

6

%

31,902

 

38

%

84,389

 

100

%

Medicaid

 

8,700

 

19

%

6,714

 

15

%

5,299

 

12

%

24,756

 

54

%

45,469

 

100

%

Pro Bill

 

16,787

 

57

%

5,223

 

18

%

1,924

 

6

%

5,674

 

19

%

29,608

 

100

%

Commercial Insurance

 

249,771

 

41

%

93,751

 

15

%

55,902

 

9

%

212,578

 

35

%

612,002

 

100

%

Grand Total

 

322,157

 

37

%

130,725

 

15

%

78,866

 

9

%

328,341

 

38

%

860,088

 

100

%

 

 

 

($)
FY 2013

 

Payer Type

 

30 Days

 

%

 

60 Days

 

%

 

90 Days

 

%

 

>90 Days

 

%

 

Total

 

%

 

Self Pay

 

12,723

 

18

%

12,934

 

18

%

11,244

 

15

%

35,367

 

49

%

72,269

 

100

%

Medicare

 

35,783

 

45

%

12,801

 

16

%

4,732

 

6

%

25,841

 

33

%

79,158

 

100

%

Medicaid

 

5,625

 

20

%

4,377

 

15

%

4,321

 

15

%

14,145

 

50

%

28,469

 

100

%

Pro Bill

 

16,103

 

51

%

6,162

 

20

%

3,085

 

10

%

6,140

 

19

%

31,491

 

100

%

Commercial Insurance

 

196,097

 

46

%

59,571

 

14

%

33,559

 

8

%

137,204

 

32

%

426,432

 

100

%

Grand Total

 

266,332

 

42

%

95,847

 

15

%

56,942

 

9

%

218,698

 

34

%

637,819

 

100

%

 

Billing for laboratory services is complicated and we must bill various payors, such as the individual, the insurance company, the government (federal or state), the private company or the health clinic. Other factors that may complicate billing include:

 

Differences between fee schedules and reimbursement rates;

Incomplete or inaccurate billing information as provided by the physician;

Disparity in coverage and information requirements;

Disputes with payors; and

Internal and external compliance policies and procedures.

 

Significant costs are incurred as a result of our participation in government programs since billing and reimbursement for laboratory tests are subject to complex regulations. We perform the requested tests and report the results whether the information is correct or not or even missing. This adds to the complexity and slows the collection process and increases the aging of our accounts receivable (“A/R”). When patient invoices are not collected in a timely manner the item is written off to the allowance.

 

Days Sales Outstanding (“DSO”) for fiscal years 2013 and 2014 were 99 and 106, respectively, an increase of approximately 7%, computed under the new method taking into account the change in presentation for patient service revenue provision for bad debts.  Depending on the period in question, our actual collections represent between 98% and 102% of our net collectable revenues after giving effect to our DSO lag.

 

Overall, the components of A/R as shown above for the two most recently completed fiscal years under review have not varied much year over year. The percent of A/R over 90 days has increased to 38% as of October 31, 2014 as compared to 34% as of October 31, 2013, an increase of 4%.

 

See Note 5 and Note 6 to our consolidated financial statements for information regarding outstanding loans.

 

See Note 18 to our consolidated financial statements describing our merger and acquisition activities.

 

The weighted average interest rate on short-term borrowings outstanding as of October 31, 2014 was 3.50% and as of October 31, 2013 was approximately 3.50%.

 

We intend to expand our laboratory operations through aggressive marketing and while also attempting to diversify into related medical fields through acquisitions.  These acquisitions may involve cash, notes, Common Stock, and/or combinations thereof.

 

On December 19, 2013 the Company approved a new stock repurchase program authorizing buyback of up to 2,000,000 shares of Common Stock in the over the counter market at prevailing market prices through October 31, 2015.  As of October 31, 2014 no shares were repurchased under the plan.  The Company currently has no specific plans to repurchase shares based on the market conditions.  The plan

 

26


 

continues to remain in place, but the Company has no current intention of repurchasing shares pursuant to the plan.

 

We expect increased legal expenses associated with the two major lawsuits described above to have significant impact on the company’s liquidity in the future periods.  We cannot predict the full extent of these expenses, but we expect that they will increase our legal expenses for the next few fiscal years until these matters are resolved.  The expenses for these specific cases — Horizon Blue Cross Blue Shield and Myriad — could run easily between $5,000 up to $10,000 over the next two fiscal years.

 

Contractual Obligations

 

The following table summarizes our significant contractual obligations as of October 31, 2014:

 

 

 

 

 

 

 

 

 

 

 

 

 

FY 2019

 

 

 

Total

 

FY
2015

 

FY
2016

 

FY
2017

 

FY
2018

 

and
thereafter

 

Long-Term Debt

 

3,669

 

524

 

557

 

592

 

1,996

 

—

 

Capital Leases

 

19,413

 

6,624

 

5,749

 

4,186

 

2,368

 

486

 

Operating Leases

 

13,546

 

8,909

 

2,325

 

894

 

689

 

729

 

Purchase Obligations

 

185,399

 

63,692

 

55,615

 

36,188

 

21,241

 

8,663

 

Long-Term Liabilities under Employment and Consultant Contracts

 

13,695

 

4,582

 

3,706

 

3,706

 

1,701

 

—

 

 

No one supplier who is counterparty to any particular supply agreement is contracted to provide more than five percent of our Cost of Services in any future period. Such contracts are made in the ordinary course of business. No directors, officers, promoters, voting trustees or individuals known to security holders of the Company are counterparties to these agreements. Management does not believe that BRLI is substantially dependent upon these supply agreements, as the goods may be obtained from different suppliers or wholesalers, if needed.  In case of reagents in particular, the company was able to take advantage of better prices by entering into these purchase contacts. None of these agreements are leases or call for the acquisition or sale of property, plant and equipment.

 

Our cash balances at October 31, 2014 totaled approximately $17,507 as compared to approximately $17,952 at October 31, 2013.  We believe that our cash position, the anticipated cash generated from future operations, and the availability of our credit line with PNC Bank, will meet our anticipated cash needs in fiscal 2015.

 

Off-Balance Sheet Arrangements

 

As of October 31, 2014, we did not have any off-balance sheet items.

 

Impact of Inflation

 

To date, inflation has not had a material effect on our operations.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.

 

Accounting for Intangible and Other Long-Lived Assets

 

We evaluate the possible impairment of our long-lived assets, including intangible assets on annual basis or earlier if events or changes in circumstances occur that indicate that the carrying value of the asset(s) may not be recoverable. The Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.  Under ASU No. 2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit’s carrying value is greater than its fair value based on an assessment of events and circumstances. The “more likely than not” threshold is when there is a likelihood of more than 50% that a reporting unit’s carrying value is greater than its fair value.  No impairment loss was recognized in the years ended October 31, 2014, 2013 and 2012.

 

Accounting for Revenue

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.  The majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly.  In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

27


 

 

 

($)

 

 

 

Year Ended

 

 

 

October 31,

 

 

 

2014

 

2013

 

2012

 

Gross Service Revenues

 

4,185,052

 

3,524,108

 

3,052,431

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

391,659

 

354,638

 

320,697

 

All Other Third Party Payors*

 

2,899,374

 

2,393,872

 

2,070,073

 

Total Contractual Adjustments and Discounts

 

3,291,033

 

2,748,510

 

2,390,770

 

Service Revenues Net of Contractual Adjustments and Discounts

 

894,019

 

775,598

 

661,661

 

Patient Service Revenue Provision for Bad Debts**

 

61,737

 

60,244

 

47,406

 

Net Revenues

 

832,282

 

715,354

 

614,255

 

 

 

 

 

 

 

 

 

Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.

 

80.1

%

79.7

%

79.9

%

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

Accounting for Contractual Credits and Doubtful Accounts

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses.  This represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information.  In the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.  BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

513,466

 

342,297

 

Doubtful Accounts

 

83,276

 

89,261

 

Total Allowance

 

596,742

 

431,558

 

 

Accounting for Employee Benefit Plans

 

See Note 21 to our consolidated financial statements for a discussion on Employee Benefit Plans.

 

28


 

New Authoritative Pronouncements

 

See Note 22 to our consolidated financial statement that discusses new authoritative pronouncements.

 

Item 7A. - Quantitative and Qualitative Disclosures about Market Risk

 

We do not invest in or trade instruments which are sensitive to market risk. We also do not have any material foreign operations or foreign sales so we have no exposure to foreign currency exchange rate risk.

 

We do have exposure to both rising and falling interest rates. At October 31, 2014, advances of approximately $33,380 under our Loan Agreement with PNC Bank were subject to interest charges at the bank’s then prime rate of 3.50%.

 

We estimate that our monthly cash interest expense at October 31, 2014 was approximately $204 and that a one percentage point increase or decrease in short-term rates would increase or decrease our monthly interest expense by approximately $28.  However we expect to utilize the credit line in the future and we thus expect exposure to short term interest rates changes that will depend on the utilization rate at the time.

 

See Note 5 and Note 6 to the Consolidated Financial Statements contained herein for information on our loans.

 

Item 8. -  Financial Statements and Supplementary Data

 

Financial Statements are annexed hereto.

 

Item 9. -  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None

 

Item 9A. -  Controls and Procedures

 

(a)         Evaluation of Disclosure Controls and Procedures

 

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer as to the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, the principal executive officer and the principal financial officer of the Company have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective at a reasonable assurance level.

 

(b)         Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that:

 

(i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

 

(ii) provide reasonable assurance that the transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with the authorization of management and/or our Board of Directors; and

 

(iii) provide reasonable assurance regarding the prevention or timely detection of any unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

 

Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework published in 2013. Based on its evaluation, our management concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report on Form 10-K.

 

MSPC, Certified Public Accountants and Advisors, A Professional Corporation, an independent registered public accounting firm, has audited the Consolidated Financial Statements included in this Annual Report on Form l0-K and, as part of their audit, has issued its attestation report, included herein, on the effectiveness of our internal control over financial reporting. See “Report of Independent Registered Public Accounting Firm” included in this filling.

 

(c)          Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting that occurred during the fourth quarter of fiscal 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

29


 

Item 9B. - Other Information

 

Effective as of January 13, 2015, the Compensation Committee of the Board of Directors adopted the 2015 Senior Management Incentive Bonus Plan (the “2015 Senior Management Bonus Plan”), which it believes incentivizes senior management to push to achieve operating results that the Compensation Committee believes will inure to the benefit of stockholders as well as management.  The 2015 Senior Management Bonus Plan provides goals which the Compensation Committee believes could only be achieved through extraordinary team efforts by senior management and that are designed to incentivize senior management to operate the Company in the most efficient manner possible.  In developing the 2015 Senior Management Bonus Plan, the Compensation Committee took into consideration the economy in general and the goals of the Company that it wished to reward, namely to improve Company margins within attainable goals for management.

 

The 2015 Senior Management Bonus Plan is based on two separate financial formula calculations. The first formula provided for bonuses (up to a maximum of 10% of the participant’s annual gross wages for 2015) based on the level of the Company’s achievement of total operating income (TOI) as a percentage of our net revenues for fiscal 2015 as follows:

 

If TOI is greater than
or equal to:

 

and less than:

 

Percent Bonus:

 

10.75

%

11.25

%

4

%

11.25

%

11.75

%

6

%

11.75

%

12.25

%

8

%

12.25

%

N/A

 

10

%

 

The second formula for bonuses (up to an additional 15% of the participant’s annual gross wages for 2015) based on the percentage increase in the Company’s operating income on a year-over-year basis as follows:

 

If PC is greater than
or equal to:

 

and less than:

 

Percent Bonus

 

20.00

%

25.00

%

6

%

25.00

%

30.00

%

9

%

30.00

%

35.00

%

12

%

35.00

%

N/A

 

15

%

 

The two portions of the bonuses under the 2015 Senior Management Bonus Plan are calculated separately and are not dependent upon each other.  However, participants may receive a maximum bonus no greater than 25% of their annual gross wages.  A copy of the 2015 Senior Management Bonus Plan is attached hereto as Exhibit 10.5.

 

30


 

PART III

 

Item 10. - Directors, Executive Officers and Corporate Governance

 

Executive Officers and Directors

 

The following table sets forth certain information with respect to each of our directors and executive officers.

 

Name

 

Age

 

Position

Marc D. Grodman, M.D.

 

63

 

Chairman of the Board, President, Chief Executive Officer and Director

Howard Dubinett

 

63

 

Executive Vice President, Chief Operating Officer and Director

Sam Singer

 

71

 

Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Director

Joseph Benincasa(a)(c)(f)

 

65

 

Director

Harry Elias(a)(c)(d)

 

84

 

Director

Gary Lederman, Esq. (b)(c)(e) (g)

 

79

 

Director

John Roglieri, M.D. (b)(c)(e)

 

75

 

Director

 

(a)         Member of the Audit Committee

(b)         Chairman of the Audit Committee

(c)          Member of the Compensation Committee

(d)         Chairman of the Compensation Committee

(e)          Member of Nominating Committee

(f)           Chairman of Nominating Committee

(g)          Mr. Lederman passed away in November 2014.

 

Marc D. Grodman, M.D. founded the Company in December 1981 and has been our Chairman of the Board, President, Chief Executive Officer and a director since our formation. Dr. Grodman is an Assistant Professor of Clinical Medicine at Columbia University’s College of Physicians and Surgeons and Assistant Attending Physician at Presbyterian Hospital, New York City. Since January 2005, Dr. Grodman has been a member of the board of directors, served as Chairman and currently serves as Vice Chairman of the American Clinical Laboratory Association, an industry organization comprised of the largest and most significant commercial clinical laboratories in the United States. From 1980 to 1983, Dr. Grodman attended the Kennedy School of Government at Harvard University and was a Primary Care Clinical Fellow at Massachusetts General Hospital. From 1982 to 1984, he was a medical consultant to the Metal Trades Department of the AFL-CIO. Dr. Grodman received a B.A. degree from the University of Pennsylvania in 1973 and an M.D. degree from Columbia University’s College of Physicians and Surgeons in 1977.  Except for his part-time duties as Assistant Professor of Clinical Medicine and Assistant Attending Physician at Columbia University and Presbyterian Hospital, Dr. Grodman devotes all of his working time to our business.  We believe that Dr. Grodman is qualified to serve on our board of directors because of his extensive medical expertise, his experience on the faculty at Columbia University College of Physicians and Surgeons, his leadership role in our industry and his knowledge of trends in the healthcare industry.

 

Howard Dubinett has been our Executive Vice-President and Chief Operating Officer of the Company since our formation in 1981. He became a director in April 1986. Mr. Dubinett attended Rutgers University. We believe that Mr. Dubinett is qualified to serve on our board of directors because of his extensive knowledge of and experience in our business and his knowledge of healthcare regulation.

 

Sam Singer has been our Chief Financial Officer since October 1987, a director since November 1989, and a Senior Vice President since 2007.  Mr. Singer was the Controller for Sycomm Systems Corporation, a data processing and management consulting company, from 1981 to 1987, prior to joining us.  Mr. Singer also serves on the boards of several not-for-profit institutions. He received a B.A. degree from Strayer University and an M.B.A. from Rutgers University.  We believe that Mr. Singer is qualified to serve on our board of directors because of his extensive experience in financial matters, including financial reporting, and his experience with our business gained through his tenure as our Chief Financial Officer.

 

Joseph Benincasa joined our board of directors in June 2005. Mr. Benincasa currently serves as the executive director of The Actors’ Fund of America, a position he has held since 1989. The Actors’ Fund is the leading national, non-profit human services organization providing comprehensive social and health care services, employment, training and housing support to the entertainment profession. For six years, from 2000 to 2006, Mr. Benincasa served as a director of St. Peter’s University Medical Center, a major hospital in northern New Jersey. He also sits on the board of directors of Broadway Cares/Equity Fights AIDS; the National Theatre Workshop of the Handicapped; Career Transition for Dancers; the Times Square Alliance; the New York Society of Association Executives and the Somerset Patriots, a minor league baseball team. Mr. Benincasa holds a B.A. degree from St. Joseph’s University, an M. Ed. Degree from Rutgers University and also attended the Fordham University Graduate School of Business. We believe that Mr. Benincasa is qualified to serve on our board of directors because of his familiarity with healthcare issues gained through his board service at St. Peter’s University Medical Center and his extensive experience with administrative matters.

 

Harry Elias became a member of the board of directors in March 2004. Mr. Elias commenced his employment in sales and marketing with JVC Company of America (“JVC”), a distributor of audio and video products, in 1967, subsequently being appointed as JVC’s Senior Vice President of Sales and Marketing in 1983 and as Executive Vice President of Sales and Marketing in 1990. In 1995, Mr. Elias was named as JVC’s Chief Operating Officer, a position he occupied until April 2003 when he resigned his positions upon his appointment as JVC’s “Honorable Chairman.” In January 2005, after retiring from JVC, Mr. Elias was appointed Chairman of the Board of and commenced to serve as a consultant to AKAI USA, the sole distributor in the United States of electronic products produced by AKAI, a Chinese manufacturer. Mr. Elias retired from AKAI in 2007 and currently is self-employed as a business consultant. We believe that Mr. Elias is qualified to serve on our board of directors because of the experience and skills he gained in running a large business operation.

 

Gary Lederman, Esq (deceased) became a member of our board of directors in May 1997. He received his B.A. degree from Brooklyn College in 1954 and his J.D. degree from NYU Law School in 1957.  He was manager of Locals 370, 491 and 662 of the U.F.C.W. International Union from 1961 to 1985.. During the 1970s, Mr. Lederman also served as a member of the New York Attorney General’s Consumer Fraud Advisory Committee. He is retired from the unions and has been a lecturer at Queensboro Community College in the field of insurance.  He

 

31


 

served on an institutional review board for RTL, a pharmaceutical drug testing laboratory until his retirement in February 2007. We believe that Mr. Lederman is qualified to serve on our board of directors as a result of his legal expertise, his union manager experience and responsibilities and his experience with RTL, including his involvement with health and welfare funds and his familiarity with consumer regulation and the activities of pharmaceutical companies.

 

John Roglieri, M.D. became a member of our board of directors in September 1995.  He is an Assistant Professor of Clinical Medicine at Columbia University’s College of Physicians and Surgeons and an Assistant Attending Physician at Presbyterian Hospital, New York City.  Dr. Roglieri received a B.S. degree in Chemical Engineering and a B.A. degree in Applied Sciences from Lehigh University in 1960, an M.D. degree from Harvard Medical School in 1966, and a Masters degree from Columbia University’s School of Business in 1978.  From 1969 until 1971, he was a Senior Assistant Surgeon in the U.S. Public Health Service in Washington, D.C.  From 1971 until 1973 he was a Clinical and Research Fellow at Massachusetts General Hospital.  From 1973 until 1975, he was director of the Robert Wood Johnson Clinical Scholars program at Columbia University.  In 1975 he was appointed Vice-President, Ambulatory Services at Presbyterian Hospital, a position which he held until 1980.  Since 1980, he has maintained a private practice of internal medicine at Columbia-Presbyterian Medical Center.  From 1988 until 1992, he was also director of the Employee Health Service at Presbyterian Hospital. From 1992 through 1999, Dr. Roglieri was the corporate medical director of NYLCare, a managed care subsidiary of New York Life Insurance Company. Dr. Roglieri was chief medical officer of Physician WebLink, a national physician practice management company, from 1999 to 2000. Since 2001, he has been a medical director for New York Life in Manhattan. He is a member of advisory boards to several pharmaceutical companies, a member of the Editorial Advisory Board of the journals Managed Care and Seminars in Medical Practice. We believe that Dr. Roglieri is qualified to serve on our board of directors due to his extensive medical background, his role as director of the Employee Health service at Presbyterian Hospital, his role as corporate medical director of a managed care organization and the skill and expertise gained through his many other activities.

 

There are no family relationships between or among any directors or executive officers of Bio-Reference Laboratories.

 

Director Independence

 

Our board of directors has determined that each of Messrs. Benincasa, Elias and Dr. Roglieri are independent within the applicable rules of the SEC and the NASDAQ Stock Market, and that each of them is also an independent director under Rule 10A-3 of the Exchange Act for the purpose of audit committee membership.

 

Audit Committee

 

We have a separately-designated standing Audit Committee established in accordance with Section 3(a)(58)(A) of the Exchange Act and the Nasadq Listing Rules.  The Audit Committee is comprised of John Roglieri (Chairman), Joseph Benincasa and Harry Elias. Our Board has determined that Mr. Roglieri is an audit committee financial expert within the meaning of the applicable rules of the SEC and the NASDAQ Stock Market.

 

Code of Ethics

 

We adopted a Corporate Integrity Program Code of Conduct, applicable to all employees, and a Code of Ethics for Executive Officers and Key Financial and Accounting Personnel, each of which is available on our internet Web site (www.bioreference.com) and will be provided in print without charge to any stockholder who submits a request in writing to Bio-Reference Laboratories, Inc. Investor Relations, 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407. Any amendment to and waivers from the Code of Ethics with respect to the Company’s Chief Executive Officer or Chief Financial Officer will be posted on the Company’s Web site.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Based solely on a review of Forms 3 and 4 and any amendments thereto furnished to us pursuant to Rule 16a-3(e) under the Exchange Act, or representations that no Forms 5 were required, we believe that with respect to fiscal 2014, our officers, directors and beneficial owners of more than 10% of our equity timely complied with all applicable Section 16(a) filing requirements.

 

32


 

Item 11. — Executive Compensation

 

The table below summarizes the total compensation paid or accrued by us with respect to the fiscal years ended October 31, 2012, 2013 and 2014 to our named executive officers (“NEOs”).  Our NEOs for fiscal 2013 are Marc D. Goodman, our President and Chief Executive Officer; Howard Dubinett, our Executive Vice President and Chief Operating Officer; and Sam Singer, our Senior Vice President and Chief Financial Officer.  This table does not include any amount for our group life, health, hospitalization or medical reimbursement plans, if any, as such benefits do not discriminate in scope, terms or operation, in favor of any or our officers, senior management members or directors, and are generally available to all salaried employees.

 

SUMMARY COMPENSATION TABLE

 

Name and
Principal
Position

 

Fiscal
Year

 

Salary($)

 

Bonus
($)(1)

 

Stock
Awards($)

 

Option
Awards($)

 

Non-Equity
Incentive Plan
Compensation
($)(2)

 

Change in
Pension
Value and
Nonqualified
Deferred
Compensation
Earnings ($)

 

All Other
Compensation
($)(3)

 

Total($)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marc D. Grodman M.D., President and Chief Executive Officer

 

2014

 

1,157,161

 

70,000

 

0

 

0

 

0

 

0

 

243,274

 

1,470,435

 

 

2013

 

1,136,700

 

70,000

 

0

 

0

 

0

 

0

 

233,832

 

1,444,532

 

 

2012

 

1,092,933

 

70,000

 

0

 

0

 

131,152

 

0

 

245,359

 

1,539,444

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Howard Dubinett, Executive Vice President and Chief Operating Officer

 

2014

 

457,286

 

0

 

0

 

0

 

0

 

0

 

47,703

 

504,989

 

 

2013

 

449,200

 

0

 

0

 

0

 

0

 

0

 

45,685

 

494,885

 

 

2012

 

431,911

 

100,000

 

0

 

0

 

51,829

 

0

 

42,474

 

626,214

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sam Singer, Senior Vice President and Chief Financial Officer

 

2014

 

457,286

 

0

 

0

 

0

 

0

 

0

 

42,893

 

500,179

 

 

2013

 

449,200

 

0

 

0

 

0

 

0

 

0

 

47,145

 

496,345

 

 

2012

 

431,911

 

300,000

 

0

 

0

 

51,829

 

0

 

48,998

 

832,738

 

 

(1) The amounts shown in this column for fiscal 2013 and for fiscal 2014 represent (i) with respect to Dr. Grodman, a cash bonus of $70,000 paid in connection with his payment of the premium costs for an insurance policy owned by the Company insuring the life of Dr. Grodman pursuant to an Endorsement Split-Dollar Insurance Agreement among the Company, Dr. Grodman and an Insurance Trust established by Dr. Goodman (“Premium Payments”).  The amounts shown in this column for fiscal 2012 represent (i) with respect to Dr. Grodman, a cash bonus of $70,000 paid in connection with his Premium Payments; and (ii) with respect to Mr. Singer and Mr. Dubinett, a one-time cash bonus for their entering into new employment contracts during the year.

(2) The amounts shown in this column represent amounts earned under the Senior Management Incentive Bonus Plan adopted by the Compensation Committee for the applicable fiscal year.  No payments were made to NEOs pursuant to the 2014 Senior Management Incentive Bonus Plan.

(3) The amounts in the “All Other Compensation” column for fiscal 2014 are detailed below.

 

Name

 

Personal Use of
Company
Leased
Automobile
($)(a)

 

Personal Use
of Company
Airplane ($)
(a)

 

Life
Insurance
Premium
($)(b)

 

401(k) Plan
Contribution
($)

 

Total ($)

 

Marc D. Grodman

 

29,724

 

12,550

 

200,000

 

1,000

 

243,274

 

Howard Dubinett

 

21,703

 

0

 

25,000

 

1,000

 

47,703

 

Sam Singer

 

16,893

 

0

 

25,000

 

1,000

 

42,893

 

 

(a) Represents our aggregate incremental costs for personal use of a Company leased automobile or the Company’s aircraft, as applicable.

(b) See “Split Dollar Life Insurance” below.

 

33


 

GRANTS OF PLAN-BASED AWARDS

 

This table provides information regarding awards that could be granted to our NEOs under the 2014 Senior Management Incentive Bonus Plan.

 

 

 

Estimated Future Payouts Under Non-Equity Incentive Plan
Awards (1)

 

Name

 

Threshold ($)

 

Maximum ($)

 

Marc D. Grodman M.D.

 

46,286

 

173,574

 

 

 

 

 

 

 

Howard Dubinett

 

18,291

 

68,592

 

 

 

 

 

 

 

Sam Singer

 

18,291

 

68,592

 

 

(1) The amounts represent the range of annual cash incentive awards the NEO was potentially entitled to receive based on the achievement of the performance goals for fiscal 2014 under the 2014 Senior Management Incentive Bonus Plan.  These cash incentive awards were granted with no specified target level, as defined under SEC Regulation S-K, rule 402(d).

 

Employment Agreements with NEOs

 

Dr. Grodman

 

On December 31, 2010, the Company executed an employment agreement with Dr. Grodman (the “Grodman Contract”), employing him as President and Chief Executive Officer through October 31, 2017. The Grodman Contract is automatically renewable for one additional two year period subject to the right of either party to elect not to renew at least four months prior thereto. The Grodman Contract provides Dr. Grodman with a minimum annual base compensation of $1,059,044, subject to annual percentage increases based on the Consumer Price Index as well as to increases at the discretion of the Compensation Committee. Dr. Grodman’s minimum annual base compensation for fiscal 2012 as determined by the Compensation Committee was $1,092,933, for fiscal 2013 was $1,136,700 and for fiscal 2014 was $1,157,161 . Under the Grodman Contract we agreed to lease and insure an automobile for his benefit and agreed to provide him with access for personal use our airplane, which use will be taxable to him. The Grodman Contract also provides Dr. Grodman with participation rights in any fringe benefit and bonus plans available to the Company’s employees to the extent determined by the Compensation Committee. The Grodman Contract provides that in the event of Dr. Grodman’s total disability we may continue to employ him and compensate him at his then current base compensation for the month the disability occurs and a period of 36 months thereafter followed by an unpaid 3 month period, following which his employment will terminate unless we grant an additional leave of absence. If Dr. Grodman incurs a partial disability then his base compensation will be equitably adjusted based on the time he is able to devote to the Company. In the event of Dr. Grodman’s termination due to his death, the Company will pay his estate a death benefit equal to 24 times his monthly base compensation in effect at the date of his death, paid over 24 months. Under the Grodman Contract we may terminate Dr. Grodman’s employment for “Cause” and Dr. Grodman has the right to terminate his employment for “Good Reason”. If he terminates for Good Reason he will be entitled to continuation of his base compensation and employee benefits through the end of the period he otherwise would have been employed under the Grodman Contract.

 

“Cause” is defined in the Grodman Contact to mean: any act or acts of dishonesty by Dr. Grodman constituting criminal acts resulting or intending to result directly or indirectly in his gain or personal enrichment at our expense; his commission of a crime involving fraud, embezzlement or theft; or his material breach of the Grodman Contract. “Good Reason” is defined in the Grodman Contract to mean: a material diminution of Dr. Grodman’s base compensation; a material diminution in his authority, duties or responsibilities; a material diminution of the authority, duties or responsibilities of any supervisor he reports to; a material diminution in the budget over which he retains authority; a material change in the geographic location at which he provides services; or any other action or inaction that constitutes a material breach by us of the Grodman Contract.

 

In the event of a Change in Control of the Company, Dr. Grodman can elect to terminate his employment by providing written notice within 30 days following the Change in Control, with a termination date effective at the earlier of 45 days after the Change in Control or the next to last day of the calendar year in which the Change in Control occurs. In that event, he will be entitled to be paid a lump sum severance payment equal to 2.99 times the average of the annual compensation paid to him by the Company for the five calendar years preceding the earlier of the calendar year in which the Change of Control occurred or the calendar year of the date of termination, reduced by the amount of any other payment or the value of any other benefit received or to be received by him in connection with the termination of his employment or contingent on a Change in Control that are not deductible by us pursuant to Section 280G of the Internal Revenue Code of 1986, as amended (the “Tax Code”). “Change in Control” is defined in the Grodman Contact to mean a “change in effective control” or a “change in the ownership of a substantial portion of a corporation’s assets” as such terms are defined under Section 409A of the Tax Code, and means either the acquisition within 12 months by a person or group of ownership of 30% or more of the total voting power of our stock; the replacement of a majority of the member’s of our Board of Directors during any 12 month period by directors not endorsed prior to their appointment or election by a majority of the Board of Directors; or the acquisition by a person or group within 12 months of our assets with a total gross fair market value equal to more than 40% of the total gross fair market value of our assets prior to such acquisition.

 

Dr. Grodman is also subject to certain non-competition restrictions preventing him from competing with the Company after termination of his employment.  Such restrictions will run for one year from the date of his termination, other than following a termination by him for Good Reason in which case they will continue until the greater of one year from the date of termination or ½ of the period remaining from the date of termination through October 31, 2017.

 

Pursuant to the Grodman Contract, the Company agreed to transfer to an Insurance Trust (the “1999 Trust”) established by Dr. Grodman, an insurance policy (“Policy A”) owned by the Company insuring the life of Dr. Grodman pursuant to an Endorsement Split-Dollar Insurance Agreement (“Split-Dollar Agreement No. 1”) among the Company, Dr. Grodman and the 1999 Trust, by paying a $1,202,411 bonus (the “Initial Bonus”) to Dr. Grodman, which is equal to the amount of the premiums paid by the Company on Policy A through the date of the Grodman Contract. Split-Dollar Agreement No. 1 required the Company to pay the annual premiums on Policy A and provided that in the event of Dr. Grodman’s death while serving as a full time Company employee, the Company would receive that amount out of the policy death proceeds equal to its “interest in the policy” (i.e. the greater of the premiums it had paid on the policy or the policy cash value at the date of death) and the balance of the death proceeds would be paid to Dr. Grodman’s designated beneficiaries. Pursuant to the Grodman Contract, Split-

 

34


 

Dollar Agreement No. 1 was terminated and in a “book entry” transaction, the Initial Bonus was “paid” to Dr. Grodman who in turn “transferred” the Initial Bonus amount to the 1999 Trust which in turn “repaid” the Initial Bonus amount back to the Company. The Company then, in accordance with Split-Dollar Agreement No. 1, transferred ownership of Policy A to the 1999 Trust. To facilitate these transactions, the parties agreed that the actual monetary funds did not need to change hands but agreed to treat the transactions appropriately for tax and accounting purposes. The Company also agreed to pay bonuses to Dr. Grodman of $119,000 in 2011, $70,000 in 2012 and $70,000 in 2013 unless his employment was terminated for “Cause” prior to a payment. These three bonuses were equal in amount to the remaining premiums payable on Policy A. The Company will expense the Initial Bonus ratably over the term of the New Contract. If Dr. Grodman’s employment is terminated for “Cause”, he is obligated to pay back the unexpended portion of the Initial Bonus back to the Company.

 

The Company also agreed to obtain a second insurance policy, a second-to-die policy (“Policy B”) insuring the lives of Dr. Grodman and his wife. Policy B will be owned by the Company pursuant to a second Endorsement Split-Dollar Insurance Agreement (“Split-Dollar Agreement No. 2”) among the Company, Dr. Grodman and an Insurance Trust established by Dr. Grodman. Policy B provides for seven years of annual premiums of approximately $200,000 each, to be paid by the Company unless Dr. Grodman’s employment is terminated for “Cause.” At Dr. Grodman’s death, if his wife survives him, or in the event his employment is terminated for “Cause”, Dr. Grodman’s estate or Dr. Grodman, as the case may be, will cause the premiums paid by the Company under Policy B up to said date, to be paid back to the Company and the Company will transfer ownership of Policy B to Dr. Grodman’s estate, or to Dr. Grodman, as the case may be. If Dr. Grodman survives his wife, and assuming his employment has not been terminated for “Cause,” at his death, the Company will be paid the greater of the premiums it paid on Policy B or the Policy B cash value out of the death proceeds and Dr. Grodman’s estate will be paid the balance of the death proceeds, provided, however, that if Dr. Grodman survives his wife and assuming his employment has not been terminated for “Cause,” at his wife’s death, Dr Grodman or his designee shall have the option, exercisable within 90 days of her death, to purchase Policy B from the Company for the greater of the premiums paid or the cash value at the date of her death.

 

Mr. Singer

 

On June 14, 2012, effective February 1, 2012, the Company executed a new employment agreement with Mr. Singer (the “Singer Contract”), employing him as Senior Vice President, Chief Financial Officer and Chief Accounting Officer through January 31, 2015.  The Singer Contract replaced Mr. Singer’s employment agreement that expired January 31, 2012.  Mr. Singer’s minimum annual base compensation under the Singer Contract was $431,911 subject to increases based on increases in the Consumer Price Index as well as to increases at the discretion of the Compensation Committee. The Singer Contract provides for the leasing of an automobile for his use and participation in fringe benefit, bonus, pension, profit sharing, and similar plans maintained for the Company’s employees. In consideration for his entering into the Singer Contract, the company paid Mr. Singer a sign-on bonus in the amount of $300,000 subject to a pro rata claw-back provision in the event Mr. Singer is terminated for “cause” or if he resigns prior to the earlier of a “change of control” or January 31, 2015. In the event of Mr. Singer’s total disability we may continue to employ him and compensate him at his then current base compensation for the month the disability occurs and a period of 12 months thereafter followed by an unpaid 3 month period, following which his employment will terminate unless we grant an additional leave of absence. If Mr. Singer incurs a partial disability then his base compensation will be equitably adjusted based on the time he is able to devote to the Company. In the event of Mr. Singer’s termination due to his death, we will continue to pay his beneficiary his base salary for 12 months. Under the Singer Contract we may terminate Mr. Singer’s employment for “Cause” and Mr. Singer has the right to terminate for “Good Reason”. If he terminates for Good Reason he will be entitled, subject to his execution of a release, to continuation of his base compensation and employee benefits through the end of the employment period he otherwise would have been employed under his employment agreement.  In the event of termination due to a Change in Control of the Company, Mr. Singer will be entitled to the same severance payment described above for Dr. Grodman.  Mr. Singer’s agreement does not contain non-competition restrictions.

 

“Cause” is defined in Mr. Singer’s employment agreement to mean: an act or acts of dishonesty by Mr. Singer constituting criminal acts resulting or intended to result directly or indirectly in his gain or personal enrichment at our expense; his commission of a crime involving fraud, embezzlement or theft against us; or his engaging in competition with us.  Good Reason and Change in Control under Mr. Singer’s employment agreement has the same meanings as provided in the Grodman Contract.

 

Mr. Dubinett

 

On June 14, 2012, effective February 1, 2012 the Company executed an employment agreement with Mr. Dubinett’s (the “Dubinett Contract”), employing him as Executive Vice President and Chief Operating Officer through January 31, 2015.  The Dubinett Contract replaced Mr. Dubinett’s employment agreement with us that expired on October 31, 2011.  The Dubinett Contract is substantially identical with the Singer Contract except that Mr. Dubinett’s sign-on bonus was $100,000.

 

Potential Payments Upon Termination or Change in Control as of October 31, 2014

 

The following table sets out the estimated payments that would have been paid to each of our NEOs upon termination of employment due to Death, for Good Reason or following a Change in Control in accordance with their employment agreements as described above as in effect, and in each case assuming such termination had occurred, as of October 31, 2013.  We have calculated these estimated payments to meet SEC disclosure requirements. The estimated payments are not necessarily indicative of the actual amounts any of our NEOs would receive in such circumstances. The table excludes compensation amounts accrued through October 31, 2013 that would be paid in the normal course of continued employment, such as accrued but unpaid base compensation, and vested account balances under our retirement plans that are generally available to all of our salaried employees.

 

35


 

 

 

Base Compensation
Continuation/ Lump
Sum ($) (a)

 

Benefits Continuation
($) (b)

 

Total ($)

 

Marc D. Grodman M.D.

 

 

 

 

 

 

 

Good Reason

 

3,471,483

 

12,975

 

3,484,458

 

Death

 

2,314,322

 

 

 

2,314,322

 

Change in Control

 

3,264,646

 

 

 

3,264,646

 

Howard Dubinett

 

 

 

 

 

 

 

Good Reason

 

114,322

 

1,012

 

115,334

 

Death

 

457,286

 

 

 

457,286

 

Change in Control

 

1,290,131

 

 

 

1,290,131

 

Sam Singer

 

 

 

 

 

 

 

Good Reason

 

114,322

 

1,012

 

115,334

 

Death

 

457,286

 

 

 

457,286

 

Change in Control

 

1,290,131

 

 

 

1,290,131

 

 

(a) For a Good Reason termination this payment reflects a continuation of base compensation through the end of period the NEO otherwise would have been employed under his employment agreement.  For death this payment reflects a continuation of base compensation for 24 months in the case of Dr. Grodman and 12 months in the case of Messrs. Dubinett and Singer.  For Change in Control this payment reflects an amount equal to 2.99 times the NEOs five-year average compensation, without reduction.

(b) For a Good Reason termination this payment reflects our estimated costs for a continuation of the NEOs benefits under our medical plan through the end of period the NEO otherwise would have been employed under his employment agreement.

 

Split-Dollar Life Insurance

 

We have established split-dollar life insurance programs for each of our NEOs under which we are entitled to receive the net cash surrender value of the policies.  We have entered into Endorsement Split-Dollar Life Insurance Agreements with each of the NEOs pursuant to which we have agreed to continue to pay the annual premiums on the policies during the period of the NEO’s full-time employment by the Company ($200,000 under Dr. Grodman’s policy and $25,000 each under Messrs. Dubinett’s and Singer’s policies). In the case of Dr. Grodman, the insurance policy is a second-to-die policy on the lives of Dr. Grodman and his wife.  In the event of an NEO’s death while serving as a full-time employee of the Company, we will be entitled to receive that amount of the death proceeds equal to our interest in the policy (the aggregate amount of premiums paid by the Company with respect to the policy less the amount of any loans, if any, from the Insurer to the Company against the cash value or policy proceeds, and less the aggregate amount of any premiums paid by the NEO to the Company in reimbursement of premiums paid by the Company) and the balance of the death proceeds will be paid to the NEO’s designated beneficiaries. The premiums paid by the Company on such policies are approximately $250,000 at October 31, 2014. As of such date the aggregate net cash surrender value of the three policies was approximately $1,415,000 and is recorded on the books of the Company at such value.

 

Stock Options

 

See Note 11 of Notes to the Consolidated Financial Statements for information on the company’s stock option plans.

 

Option Grants to Our NEOs in Last Fiscal Year

 

No options to purchase shares of our Common Stock were granted to any of our NEOs in fiscal 2014.

 

Option Exercises and Stock Vested

 

At October 31, 2014, there were no outstanding options held by our NEOs or any of our directors. During fiscal 2014 no options were exercised by any member of the Board of Directors.

 

Director Compensation

 

During fiscal 2014, each director who was not a Company employee was compensated for his services as a director with a quarterly fee of $16,250. In addition, Gary Lederman as chairman of the Audit Committee, was compensated with an additional quarterly fee of $4,500. For his service as chairman of both the Nominating Committee and the Compensation Committee, John Roglieri M.D., was compensated with additional quarterly fees of $3,000 and $2,000, respectively.  No director’s fees were paid to our employee directors.

 

The following table sets forth the compensation paid to our directors in fiscal 2014.

 

Fiscal 2014

 

Fees Earned or paid in

 

 

 

 

 

Director Name:

 

Cash ($)

 

Chairman Fees ($)

 

Total ($)

 

Joseph Benincasa

 

100,000

 

—

 

100,000

 

Harry Elias

 

100,000

 

—

 

100,000

 

Gary Lederman (a)

 

100,000

 

18,000

(a)

118,000

 

John Roglieri M.D (b)

 

100,000

 

20,000

(b)

120,000

 

 

(a) Mr. Lederman served as Chairman of the Audit Committee for the year ended October 31, 2014.

(b) Chairman of the Nominating Committee and the Compensation Committee

 

Compensation Discussion and Analysis

 

Executive Compensation Philosophy

 

The objective of our compensation program for our NEOs is to reward them for their leadership and efficiency in their areas of responsibility and for their overall contribution to the Company’s performance.  Our NEOs for fiscal 2014 are Dr. Grodman, our President and

 

36


 

Chief Executive officer, Mr. Dubinett, our Executive Vice President Chief Operating officer who is responsible for healthcare regulatory compliance and insurance matters, and Mr. Singer, our Senior Vice President and Chief Financial Officer who is responsible for all financial matters.

 

We seek to maintain a uniform approach in how we compensate our NEOs.  Accordingly, as Dr. Grodman already owns a substantial equity interest in the Company and we believe that further equity compensation would not provide him with an effective incentive, we do not currently provide equity compensation to any of our NEOs.  Our compensation program for our NEOs therefore focuses primarily on the following cash based incentives:

 

(i)    Annual base compensation consisting of a set annual cash amount that is subject to annual increase based upon a review of the NEO’s and the Company’s performance and increases in the Consumer Price Index; and

 

(ii)   Participation in the annual Senior Management Incentive Bonus Plan (“Annual Bonus Plan”), which provides cash incentives based on the level of achievement of specific performance objectives.  We annually establish targets under the Annual Bonus Plan that are designed to assist in the Company’s profitability by encouraging a “team effort” that rewards participants based on the level of achievement of Company financial targets set by the Compensation Committee with no reward if minimum targets are not achieved.  Annual Bonus Plan targets were achieved with respect to fiscal 2012 so that bonuses were earned and paid to our NEOs under the Annual Bonus Plan for fiscal 2012 (the “2012 Bonus Plan”). Annual Bonus Plan targets were not achieved with respect to fiscal 2013, or fiscal 2014 so no bonuses were paid to our NEOs under the Annual Bonus Plan for fiscal 2013 (the “2013 Bonus Plan”) or fiscal 2014 (the “2014 Bonus Plan”). See “Senior Management Incentive Bonus Plan” herein.

 

Advisory Vote on Executive Compensation

 

The Company provides its stockholders with the opportunity to cast an annual vote on executive compensation. At the 2013 Annual Meeting of Stockholders held in July 2014, 57.6% of the votes cast on the advisory vote on executive compensation proposal were in favor of our NEO compensation as described in the proxy statement for the 2014 Annual Meeting of Stockholders. The Compensation Committee reviewed these final vote results and took them into account when considering its compensation decisions for fiscal 2015. The Compensation Committee determined that given the leadership role of the NEOs in the Company’s continued steady performance the Company’s executive compensation program remains appropriate and no changes were necessary. However, the Compensation Committee continues to review our executive compensation program consistent with the compensation goals set forth herein and will continue to consider the outcome of the stockholder votes on the annual executive compensation proposal when making future decisions regarding our executive officers.

 

Process for Determining Executive Compensation

 

Our Compensation Committee reviews and approves the annual base compensation and other compensation of our NEOs. Our Compensation Committee also establishes and reviews the achievement of performance goals and other matters relating to the Annual Bonus Plans.  There were no changes to our executive compensation structure in fiscal 2014.

 

In connection with its review of NEO compensation in fiscal 2014, the Compensation Committee considered an executive compensation study furnished by Compensation Resources, Inc., an independent executive compensation consulting firm (“CRI”) engaged by the Compensation Committee.  After taking into account the compensation paid to similar executive officers of a peer group of eleven publicly owned clinical testing laboratories (including the two major national laboratories, Quest Diagnostics, Inc. and Laboratory Corp. of America Holdings), CRI concluded that Dr. Grodman’s total direct compensation was then above the total direct compensation provided to the chief executive officers in the peer group, and that the total direct compensation provided to Messrs. Singer and Dubinett were below the total direct compensation provided to similar executive officers in the peer group.  Notwithstanding the report, the Compensation Committee believes that Dr. Grodman’s compensation level is reasonable as the current levels were determined based on a CRI report for fiscal 2011 which showed that Dr. Grodman’s total direct compensation was 20% below the peer group.

 

Base Compensation

 

In accordance with the Grodman Contract, the Compensation Committee determined that Dr. Grodman’s base compensation be increased to $1,157,161 for fiscal 2014, which reflects a 1.8% increase based on increases in the Consumer Price Index.

 

Since fiscal 2008, the base compensation and the increase in base compensation in each year for Mr. Dubinett and for Mr. Singer have been identical. This is because the Compensation Committee continues to believe that Mr. Dubinett and Mr. Singer perform their duties equally well and to distinguish between them in compensation could cause the Company to lose the services of one of them. The increases in their base compensation in each of the past three fiscal years have been as follows, which reflect annual increases for each fiscal year based on increases in the Consumer Price Index.

 

Increases in Base Compensation for Each of

Mr. Dubinett and Mr. Singer Over the Prior Three Fiscal Years

 

Period

 

Amount ($)

 

Percentage Increase

 

 

 

 

 

 

 

Fiscal 2012

 

13,393

 

3

%

Fiscal 2013

 

17,289

 

4

%

Fiscal 2014

 

8,086

 

1.8

%

 

Benefits

 

Our policy is to provide health benefits as well as access to our 401(k) Plan to which we contribute a maximum of $1,000 per employee each year, to all of our employees including our NEOs.

 

                All senior officers of the Company, including our NEOs, are entitled to an automobile leased by the Company and access to the Company’s airplane for personal use to the extent the airplane is not in use for business purposes.  The costs for insurance and maintenance of such automobiles are paid by the Company.  All amounts reflecting the personal use of such perquisites are reported as income to them subject to tax in accordance with the Tax Code.  The amounts reflecting the Company’s incremental costs for the NEO’s personal use of the Company leased automobile and the Company’s airplane are reflected in Footnote (3) to the “Summary Compensation Table” below.

 

37


 

Change in Control Benefits

 

The employment agreements with our NEOs provide for substantial severance payments to them in the event of a change in control of the Company.  This provision provides an additional level of financial security for our NEOs as they may be asked to evaluate a transaction purportedly expected to maximize shareholder value while resulting in the elimination of their jobs.  The severance payment provision (2.99 times the annual average of the preceding five years of compensation) is designed to minimize the distraction caused by concerns over personal financial security in the context of a proposed change in control.

 

Annual Bonus Plans for fiscal years 2014 and 2013

 

The Compensation Committee adopts an Annual Bonus Plans for each year which it believes incentivizes senior management to push to achieve operating results that the Compensation Committee believes will inure to the benefit of stockholders as well as management.  Each Annual Bonus Plan provides goals which the Compensation Committee believes could only be achieved through extraordinary team efforts by senior management and that are designed to incentivize senior management to operate the Company in the most efficient manner possible.  In developing the Annual Bonus Plan for each year, the Compensation Committee takes into consideration the economy in general and the goals of the Company that it wished to reward, namely to improve Company margins within attainable goals for management.

 

The Compensation Committee has at all times sought (and continues to seek) to provide a mechanism to reward outstanding efforts that enhance shareholder value.  The following is a description of the Annual Bonus Plan for fiscal 2013 (the “2013 Bonus Plan”) and fiscal 2014 (the “2014 Bonus Plan”).  The Compensation Committee has adopted an Annual Bonus Plan for fiscal 2015 that is substantially similar to the 2014 Bonus Plan and is attached hereto as Exhibit 10.5.  Any bonuses required to be paid under the provision of any Annual Bonus Plan is required to be paid to each participant on the pro-rata formula established upon the adoption of the plan and not at the discretion of the Compensation Committee.

 

2013 Bonus Plan

 

The 2013 Bonus Plan was based on two separate financial formula calculations. The first formula provided for bonuses (up to a maximum of 10% of the participant’s annual gross wages for 2013, less any bonus, auto or airplane usage expense charge-back or other unearned revenue (“2013 Wages”)) based on the level of the Company’s achievement of total operating income (TOI) as a percentage of our net revenues for fiscal 2013 as follows:

 

If TOI is greater than or equal to:

 

and less than:

 

Bonus equal to the following percentage of the
participant’s 2013 wages:

 

12.25%

 

12.75

%

4

%

12.75%

 

13.25

%

6

%

13.25%

 

13.75

%

8

%

13.75%

 

N/A

 

10

%

 

The second formula provided for bonuses (up to a maximum of 15% of the participant’s 2013 Wages ) based on the percentage increase on a year over year basis in the Company’s operating income before interest and taxes (“OIBIT”) from fiscal 2012 to fiscal 2013, determined by subtracting the Company’s fiscal 2012 OIBIT from the Company’s fiscal 2013 OIBIT and dividing the difference by the Company’s OIBIT for fiscal 2012  to determine the percentage of change (“2013 PC”) , as follows:

 

If 2013 PC is greater than:

 

and less than:

 

Bonus equal to the following percentage of the
participant’s 2013 Wages:

 

25.00%

 

30.00

%

6

%

30.00%

 

35.00

%

9

%

35.00%

 

40.00

%

12

%

40.00%

 

N/A

 

15

%

 

Actual results under the 2013 Bonus Plan were as follows:

 

 

 

 

 

Bonus equal to the following percentage of the
participant’s 2013 Wages:

 

TOI as a percentage of our net revenues for fiscal 2013

 

11.46

%

0

%

2013 PC

 

7.67

%

0

%

Total Bonus Percentage:

 

—

 

0

%

 

2014 Bonus Plan

 

The 2014 Bonus Plan was based on two separate financial formula calculations. The first formula provided for bonuses (up to a maximum of 10% of the participant’s annual gross wages for 2014, less any bonus, auto or airplane usage expense charge-back or other unearned revenue (“2014 Wages”)) based on the level of the Company’s achievement of total operating income (TOI) as a percentage of our net revenues for fiscal 2013 as follows:

 

If TOI is greater than or equal 
to:

 

and less than:

 

Bonus equal to the following percentage of the
participant’s 2014 wages:

 

12.25%

 

12.75

%

4

%

12.75%

 

13.25

%

6

%

13.25%

 

13.75

%

8

%

13.75%

 

N/A

 

10

%

 

The second formula provided for bonuses (up to a maximum of 15% of the participant’s 2014 Wages ) based on the percentage increase on a year over year basis in the Company’s operating income before interest and taxes (“OIBIT”) from fiscal 2013 to fiscal 2014, determined by subtracting the Company’s fiscal 2013 OIBIT from the Company’s fiscal 2014 OIBIT and dividing the difference by the Company’s OIBIT for fiscal 2013  to determine the percentage of change (“2014 PC”) , as follows:

 

38


 

If 2013 PC is greater than:

 

and less than:

 

Bonus equal to the following percentage of the
participant’s 2014 Wages:

 

25.00%

 

30.00

%

6

%

30.00%

 

35.00

%

9

%

35.00%

 

40.00

%

12

%

40.00%

 

N/A

 

15

%

 

Actual results under the 2014 Bonus Plan were as follows:

 

 

 

 

 

Bonus equal to the following percentage of the
participant’s 2014 Wages:

 

TOI as a percentage of our net revenues for fiscal 2014

 

10.02

%

0

%

2014 PC

 

1.77

%

0

%

Total Bonus Percentage:

 

—

 

0

%

 

Tax Compliance Policy

 

Section 162(m) of the Code generally disallows a tax deduction to public corporations for compensation in excess of $1,000,000 paid for any fiscal year to a corporation’s chief executive officer and to the three other most highly compensated executive officers in office as of the end of the fiscal year, other than the chief financial officer.  The statute exempts qualifying performance-based compensation from the deduction limit if certain requirements are met.  However, shareholder interests may at times be best served by not restricting the Compensation Committee’s discretion and flexibility in developing compensation programs, even though the programs may result in non-deductible compensation expenses.  Accordingly, the Compensation Committee may from time to time approve elements of compensation for certain officers that are not fully deductible.

 

Compensation Committee Interlocks and Insider Participation

 

During fiscal 2014, the members of the Company’s Compensation Committee were:

John Roglieri M.D. – Chairman

Joseph Benincasa

Harry Elias

Gary Lederman

 

No member of the Compensation Committee was an officer or employee of the Company in fiscal 2013 or was formerly an officer of the Company.

 

Compensation Committee Report

 

The members of the Company’s Compensation Committee hereby state:

 

We have reviewed and discussed the Compensation Discussion and Analysis contained in this Annual Report on Form 10-K for the year ended October 31, 2014 with the Company’s Management, and

 

Based on such review and discussions, we have recommended to the Company’s Board of Directors that the Compensation Discussion and Analysis be included in the Company’s Annual Report on Form 10-K for the year ended October 31, 2014.

 

 

 

COMPENSATION COMMITTEE

 

 

 

 

By:

John Roglieri M.D., Chairman

 

 

Joseph Benincasa

 

 

Harry Elias

 

39


 

Item 12. - Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth information as of January 7, 2015 with respect to the ownership of Common Stock by (i) each person known to us to be the beneficial owner of more than 5% of our outstanding Common Stock, (ii) each of our directors, (iii) each of our executive officers, and (iv) all directors and executive officers as a group.

 

Name and Address of
Beneficial Owner*

 

Shares of Common Stock
Beneficially Owned(1)

 

Percentage
Ownership

 

 

 

 

 

 

 

Marc D. Grodman(2)

 

2,741,800

 

9.88

%

Howard Dubinett(3)

 

345,138

 

1.32

%

Sam Singer(4)

 

13,132

 

**

 

Joseph Benincasa

 

0

 

0

%

Harry Elias

 

0

 

0

%

John Roglieri

 

10,000

 

**

 

Executive Officers and Directors as a group (seven persons) (2)(3)(4)

 

3,110,070

 

11.21

%

 

 

 

 

 

 

Black Rock, Inc(5)
40 East 52nd Street
New York, NY 10022

 

2,169,368

 

7.82

%

 

 

 

 

 

 

Riverbridge Partners LLC(6)
801 Nicollet Mall, Suite 600
Minneapolis, MN 55402

 

2,072,010

 

7.47

%

 

 

 

 

 

 

The Vanguard Group (7)
100 Vanguard Blvd.
Malvem, PA 19355

 

1,758,357

 

6.34

%

 

 

 

 

 

 

Manulife Financial Corporation (8)
200 Bloor Street East
Toronto, ON, Canada M4W 1E5

 

1,400,155

 

5.05

%

 

*

The address of all of the Company’s directors and executive officers is c/o the Company, 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407.

 

 

**

Less than one (1%) percent.

 

 

(1)

Except as otherwise noted, each holder named in the table has sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned.

 

 

(2)

Includes [1,937,502] shares owned directly. 32,210 of these shares are pledged as security in a brokerage margin account. Also includes 159,464 shares held in a successor trust to a grantor retained annuity trust created by Dr. Grodman that terminated in 2014, of which Dr. Grodman’s wife is a co-trustee, 145,834 shares owned directly by Mrs. Grodman, and 200,000 shares held in trust for the benefit of Mrs. Grodman, of which Dr. Grodman is trustee, 200,000 shares held in trust for the benefit of Dr. Grodman and his children, of which Ms. Grodman is a co-trustee, and 99,000 shares owned by their children. Dr. Grodman disclaims beneficial ownership of these 444,834 shares.

 

 

(3)

Includes 365,138 shares owned directly. All of these shares are pledged as security in a brokerage margin account.

 

 

(4)

Includes 1,000 shares owned directly and 12,132 shares owned by trusts for the benefit of Mr. Singer and his family members, of which Nancy Kelly-Singer, Mr. Singer’s wife, and Mr. Singer are co-trustees.

 

 

(5)

The number of shares beneficially owned is based on a Schedule 13G filed with the Securities and Exchange Commission by Black Rock, Inc. on January 28, 2014.

 

 

(6)

The number of shares beneficially owned is based on a Schedule 13G filed with the Securities and Exchange Commission by Riverbridge Partners LLC (“Riverbridge”) on February 4, 2014.

 

 

(7)

The number of shares beneficially owned is based on a Schedule 13G filed with the Securities and Exchange Commission by The Vanguard Group and certain of its affiliates on February 11, 2014.

 

 

(8)

The number of shares beneficially owned is based on a Schedule 13G filed with the Securities and Exchange Commission by Manulife Financial Corporation (“MFC”) and certain of its affiliates on February 13, 2014.

 

Equity Compensation Plan Information

 

The following table provides information as of October 31, 2014 regarding shares of Common Stock that may be issued pursuant to the Company’s equity compensation plans:

 

40


 

 

 

(a)
Number of Shares Issuable
upon Exercise of Outstanding
Options

 

(b)
Weighted-Average Exercise
Price per Share of Outstanding
Options

 

(c)
Number of Shares Remaining
Available for Future Issuances Under
Equity Compensation Plans
(Excluding Shares Reflected in
Column (a))

 

 

 

 

 

 

 

 

 

Equity Compensation Plans Approved by Stockholders

 

222,000

(1)

$

9.97

 

—

(2)

 

(1) Reflects shares issuable upon exercise of outstanding ISOs granted pursuant to the Company’s 2003 Employee Stock Option Plans.

(2) No additional options may be granted under the Company’s stock options plan.

 

Item 13. — Certain Relationships and Related Transactions and Director Independence

 

No material transactions occurred between the Company and related parties during fiscal 2014.

 

It is the Company’s policy that transactions involving related persons (excluding executive officer compensation which is determined by the Compensation Committee) are to be presented to and assessed by the independent members of the board of directors. Related persons include the Company’s directors and executive officers, immediate family members of the directors and executive officers, and certain large security holders and their family members. If the determination is made that a related person has or may have a material direct or indirect interest in any Company transaction and that the amount involved equals or exceeds $120,000, the Company’s independent directors will review, approve and ratify the transaction, if appropriate, and the transaction will be disclosed if required under SEC rules. If the related party at issue is a director of the Company or a family member of a director, then that director will not participate in the relevant discussion and review.

 

Information considered in evaluating such transactions include the nature of the related person’s interest in the transaction, the material terms of the transaction, the importance of the transaction to the Company and the related person, whether the transaction would impair the judgment of a director or an executive officer to act in the best interests of the Company, and any other matters that management or the independent directors deem appropriate. Corporate policy requires all directors and employees, including all executives, to disclose their interests (including indirect interests through family members) with individuals or entities doing business with the Company, to management and/or the Board of Directors, and to remove themselves from all decisions related to that organization. No such transactions with related parties occurred in fiscal year 2012 through 2014.

 

On November 17, 2014, Mr. Gary Lederman, an independent member of the Board of Directors (the “Board”) of the Company passed away.  Pursuant to the rules of The Nasdaq Stock Market (“Nasdaq”), the Company immediately notified Nasdaq of this event and that the Board was no longer comprised of a majority of independent directors.  Following the Company’s notice to Nasdaq, on November 21, 2014, the Company received from the staff of the Listing Qualifications Department of the NASDAQ Stock Market a letter (the “Staff Letter”) indicating that the Company was not in compliance with Listing Rule 5605(b)(1), which requires a majority of the Board of the Company be comprised of independent directors as defined in Rule 5605(a)(2).

 

Consistent with Nasdaq Listing Rule 5605(b)(1)(A), the Staff Letter indicated that Nasdaq will provide the Company a cure period in order to regain compliance with the majority independent board requirement.  Pursuant to the Staff Letter, the Company will have until the earlier of the Company’s next annual shareholders’ meeting or November 17, 2015 to regain compliance with this listing rule.  However, if the Company’s next annual shareholders’ meeting is held before May 19, 2015, then the Company must evidence compliance no later than May 19, 2015.  The Company shall use its best effort to regain compliance with the majority independent board requirement before the cure period ends to ensure continued listing on Nasdaq.

 

Item 14. -  Principal Accountant Fees and Services

 

The firm of MSPC, Certified Public Accountants and Advisors, A Professional Corporation (“MSPC”) audited our accounts and the accounts of our subsidiaries for the fiscal years ended October 31, 2014 and 2013. MSPC and its predecessor firm have been our auditors since 1988. The table set forth below lists the fees billed to the company by MSPC for audit services rendered in connection with the audits of our consolidated financial statements for the years ended October 31, 2014 and 2013, and fees billed for other services rendered by MSPC during these periods.

 

 

 

In Thousands ($)

 

 

 

2014

 

2013

 

(1) Audit Fees

 

263

 

288

 

(2) Audit-Related Fees

 

92

 

90

 

(3) Tax Fees

 

57

 

49

 

(4) All Other Fees

 

0

 

0

 

Total

 

412

 

427

 

 

(1)                                 Audit Fees

 

MSPC billed us approximately $257 for professional services rendered in connection with the audit of our annual financial statements for the fiscal year ended October 31, 2014 and the review of the financial statements included in our quarterly reports on Form 10-Q for such fiscal year compared to approximately $288 in billings for such services for the fiscal year ended October 31, 2013. MSPC billed us approximately $6 in fiscal 2014 for its audit of our 401(k) Plan for calendar year 2012 as compared to approximately $9 of such fees in fiscal 2013 with respect to calendar year 2012.

 

(2)                                 Audit-Related Fees

 

MSPC billed us approximately $92 during fiscal 2014 and approximately $90 during fiscal 2013 for Sarbanes-Oxley (“SOX”) related audit fees.

 

41


 

(3)                                 Tax Fees

 

MSPC billed us approximately $57 for tax services for fiscal 2014 and approximately $49 for tax services for fiscal 2013.

 

(4)                                 All Other Fees

 

No fees were billed to us by MSPC with respect to fiscal 2013 or fiscal 2012 other than for services described in Item 14 (1), (2) and (3) herein.

 

(5)         Pre-Approval Policies and Procedures

 

The engagement of MSPC to render the above audit and tax services was approved by our audit committee prior to the engagement.

 

42


 

PART IV

 

Item 15. — Exhibits and Financial Statement Schedules

 

(a)         1.              Financial Statements

 

The following financial statements of the Company are included in Part II, Item 8, “Financial Statements and Supplementary Data:”

 

Report of Independent Registered Public Accounting Firm

 

Consolidated Balance Sheets - October 31, 2014 and 2013

 

Consolidated Statements of Operations for the Years ended October 31, 2014, 2013 and 2012

 

Consolidated Statements of Shareholders’ Equity for the Years ended October 31, 2014, 2013, and 2012

 

Consolidated Statements of Cash Flows for the Years ended October 31, 2014, 2013 and 2012

 

Notes to Consolidated Financial Statements

 

 

2.              Financial Statements Schedule

 

The following is included in Item 8, “Financial Statements and Supplementary Data:”

 

Schedule II — Valuation and Qualifying Accounts for the Years ended October 31, 2014, 2013 and 2012

 

(b)                                 Exhibits

 

Exhibit No.

 

Item

 

 

 

3.1*

 

Amended and Restated Certificate of Incorporation dated November 15, 1989 (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

3.1.1*

 

Amendment to Certificate of Incorporation dated August 23, 1993 (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

3.1.2*

 

Amendment to Certificate of Incorporation dated August 23, 1993 (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

3.1.3*

 

Amendment to Certificate of Incorporation dated March 27, 1998 (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

3.1.4*

 

Amendment to Certificate of Incorporation dated March 31, 1998 (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

3.1.5*

 

Amendment to Certificate of Incorporation dated September 26, 2003 (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

3.2.2*

 

By-laws, as amended. (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

4.1*

 

Form of Common Stock Certificate, $.01 par value (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2004 (SEC File No. 0-15266)).

 

 

 

10.1*

 

Lease Agreement for Elmwood Park, New Jersey Premises, expiring in February, 2004 (Incorporated by reference to exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 1999 (SEC File No. 0-15266)).

 

 

 

10.1.1*

 

Fifth Amendment dated as of July 16, 2004 to Lease for Elmwood Park, New Jersey Premises (Incorporated by reference to exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 2004 (SEC File No. 0-15266)).

 

 

 

10.1.2*

 

Sixth Amendment dated as of October 27, 2004 to Lease for Elmwood Park, New Jersey Premises (Incorporated by reference into exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 2004 (SEC File No. 0-15266)).

 

 

 

10.2*

 

Employment Agreement between the Company and Marc Grodman expiring on October 31, 2017. (Incorporated by reference to exhibit filed with the Company’s current report on Form 8-K for December 31, 2010 (SEC File No. 0-15266)).

 

 

 

10.3*

 

Employment Agreement between the Company and Sam Singer expiring on January 31, 2015 (Incorporated by reference to exhibit filed with the Company’s current report on Form 8-K for June 15, 2012 (SEC File No. 0-15266)).

 

 

 

10.3.1*

 

Employment Agreement between the Company and Howard Dubinett expiring on January 31, 2015 (Incorporated by reference to exhibit filed with the Company’s current report on Form 8-K for June 15, 2012 (SEC File No. 0-15266)).

 

 

 

10.4*

 

The Company’s 2000 Employee Incentive Stock Option Plan. (Incorporated by reference to exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 2000 (SEC File No. 0-15266)).

 

 

 

10.4.1*

 

The Company’s 2003 Employee Incentive Stock Option Plan. (Incorporated by reference to exhibit filed with the Company’s Registration Statement on Form S-8 (File No. 333-111578)).

 

 

 

10.5

 

The Company’s 2015 Senior Management Incentive Bonus Plan.

 

 

 

10.6*

 

Amended and Restated Loan and Security Agreement as of September 30, 2004 between the Company and PNC Bank, National Association. (Incorporated by reference to exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 2004 (SEC File No. 0-15266)).

 

 

 

10.6.1*

 

Fourth Amendment as of October 31, 2006 to Loan and Security Agreement as of September 30, 2004 between the Company and PNC Bank, National Association (Incorporated by reference to exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 2006 (SEC File No. 0-15266)).

 

43


 

10.6.2*

 

Fifth Amendment as of October 31, 2007 to Loan and Security Agreement as of September 30, 2004 between the Company and PNC Bank, National Association (Incorporated by reference to exhibit filed with the Company’s annual report on Form 10-K for the year ended October 31, 2007 (SEC File No. 0-15266)).

 

 

 

10.6.3*

 

Sixth Amendment as of May 12, 2008 to Loan and Security Agreement as of September 30, 2004 between the Company and PNC Bank, National Association (Incorporated by reference to exhibit filed with the Company’s current report on Form 8-K (for December 31, 2010) (SEC File No. 0-15266)).

 

 

 

10.6.4*

 

Seventh Amendment as of October 22, 2010 to Loan and Security Agreement between the Company and PNC Bank, National Association. (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

10.6.5*

 

Eighth Amendment as of November 2, 2011 to Loan and Security Agreement as of October 31, 2010 between the Company and PNC Bank, National Association. (Incorporated by reference to exhibit filed with the Company’s annual report on form 10-K for the year ended October 31, 2011. (SEC File No. 0-15266).

 

 

 

14

 

Code of Ethics for Executive Officers ad Key Financial and Accounting Personnel

 

 

 

21

 

Subsidiaries of the Company

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

31.1

 

Certification of Chief Executive Officer

 

 

 

31.2

 

Certification of Chief Financial Officer

 

 

 

32.1

 

Certification pursuant to 18 U.S.C. Section 1350 of Chief Executive Officer

 

 

 

32.2

 

Certification pursuant to 18 U.S.C. Section 1350 of Chief Financial Officer

 

 

 

101

 

Interactive Data File

 

The exhibits designated above with an asterisk (*) have previously been filed with the Commission and, pursuant to 17 C.F.R. Secs. 201.24 and 240.12b-32, are incorporated by reference to the documents as indicated.

 

44


 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BIO-REFERENCE LABORATORIES, INC.

 

 

 

 

 

By

/S/ Marc D. Grodman

 

Marc D. Grodman

 

Chairman of the Board, President,

 

Chief Executive Officer and Director

 

Dated:   January 13, 2015

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

 

/S/ Marc D. Grodman

 

Marc D. Grodman

 

Chairman of the Board, President,

 

Chief Executive Officer and Director

 

January 13, 2015

 

 

 

/S/ Howard Dubinett

 

Howard Dubinett

 

Executive Vice President,

 

Chief Operating Officer and Director

 

January 13, 2015

 

 

 

/S/ Sam Singer

 

Sam Singer

 

Sr. Vice President, Chief Financial Officer,

 

Chief Accounting Officer and Director

 

January 13, 2015

 

 

 

/S/ Joseph Benincasa

 

Joseph Benincasa

 

Director

 

January 13, 2015

 

 

 

/S/ Harry Elias

 

Harry Elias

 

Director

 

January 13, 2015

 

 

 

/S/ John Roglieri

 

John Roglieri

 

Director

 

January 13, 2015

 

 

45


 

Index to Financial Statements and Financial Statement Schedule

 

 

Page

 

 

Report of Independent Registered Public Accounting Firm

47

 

 

Consolidated Financial Statements:

 

 

 

Consolidated Balance Sheets

48

 

 

Consolidated Statements of Operations

50

 

 

Consolidated Statements of Stockholders’ Equity (Deficit)

51

 

 

Consolidated Statements of Cash Flows

52

 

 

Notes to Consolidated Financial Statements

54

 

 

Financial Statement Schedule:

 

 

 

Schedule II- Valuation and Qualifying Accounts

66

 

46


 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders

Bio-Reference Laboratories, Inc.

 

We have audited the accompanying consolidated balance sheets of Bio-Reference Laboratories, Inc. and its subsidiaries (the “Company”) as of October 31, 2014 and 2013, and the related consolidated statements of operations, shareholders’ equity, and cash flows for each of the years in the three-year period ended October 31, 2014.  We also have audited the Company’s internal control over financial reporting as of October 31, 2014, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting.  Our responsibility is to express an opinion on these consolidated financial statements and an opinion on the Company’s internal control over financial reporting based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects.  Our audits of the consolidated financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall consolidated financial statement presentation.  Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.  Our audits also included performing such other procedures as we considered necessary in the circumstances.  We believe that our audits provide a reasonable basis for our opinions.

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  A company’s internal control over financial reporting includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (b) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respect, the financial position of Bio-Reference Laboratories, Inc. and its subsidiaries as of October 31, 2014 and 2013, and the results of their operations and their cash flows for each of the years in the three-year period ended October 31, 2014 in conformity with accounting principles generally accepted in the United States of America.  Also in our opinion, Bio-Reference Laboratories Inc. and its subsidiaries maintained, in all material respects, effective internal control over financial reporting as of October 31, 2014, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

 

MSPC

Certified Public Accountants and Advisors,

A Professional Corporation

 

Cranford, New Jersey

January 13, 2015

 

47


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands, Except Share Data]

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

Cash and Cash Equivalents

 

$

17,507

 

$

17,952

 

Accounts Receivable - Net

 

263,346

 

206,261

 

Inventory

 

20,791

 

19,095

 

Other Current Assets

 

10,165

 

9,416

 

Deferred Tax Assets

 

40,040

 

42,154

 

TOTAL CURRENT ASSETS

 

351,849

 

294,878

 

 

 

 

 

 

 

PROPERTY AND EQUIPMENT - AT COST

 

156,342

 

133,599

 

LESS: Accumulated Depreciation

 

(89,954

)

(67,950

)

PROPERTY AND EQUIPMENT - NET

 

66,388

 

65,649

 

 

 

 

 

 

 

OTHER ASSETS:

 

 

 

 

 

Investments

 

5,153

 

5,237

 

Deposits

 

1,056

 

1,017

 

Goodwill - Net

 

35,185

 

35,185

 

Intangible Assets - Net

 

14,403

 

16,320

 

Other Assets

 

1,415

 

1,165

 

Deferred Tax Assets

 

3,414

 

2,077

 

TOTAL OTHER ASSETS

 

60,626

 

61,001

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

478,863

 

$

421,528

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

48


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands, Except Share Data]

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts Payable

 

$

71,166

 

$

61,614

 

Accrued Salaries and Commissions Payable

 

15,822

 

19,601

 

Accrued Taxes and Expenses

 

15,620

 

18,292

 

Other Short Term Acquisition Payable

 

1,924

 

2,438

 

Revolving Note Payable - Bank

 

33,380

 

26,139

 

Current Maturities of Long-Term Debt

 

524

 

493

 

Capital Lease Obligations - Short-Term Portion

 

6,128

 

5,185

 

TOTAL CURRENT LIABILITIES

 

144,564

 

133,762

 

 

 

 

 

 

 

LONG-TERM LIABILITIES:

 

 

 

 

 

Capital Lease Obligations - Long-Term Portion

 

12,252

 

10,712

 

Long Term Debt - Net of Current Portion

 

3,145

 

3,670

 

Other Long Term Acquisition Payable

 

—

 

1,789

 

TOTAL LONG-TERM LIABILITIES

 

15,397

 

16,171

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

 

Preferred Stock $.10 Par Value;

 

 

 

 

 

Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock

 

 

 

 

 

None Issued

 

—

 

—

 

Common Stock, $.01 Par Value;

 

 

 

 

 

Authorized 35,000,000 shares:

 

 

 

 

 

Issued and Outstanding 27,727,644 and 27,683,213 at October 31, 2014 and at October 31, 2013, respectively

 

277

 

277

 

 

 

 

 

 

 

Additional Paid-In Capital

 

39,979

 

39,430

 

 

 

 

 

 

 

Retained Earnings

 

278,646

 

231,888

 

 

 

 

 

 

 

TOTAL SHAREHOLDERS’ EQUITY

 

318,902

 

271,595

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$

478,863

 

$

421,528

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

49


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

[Dollars In Thousands, Except Share Data]

 

 

 

Years Ended

 

 

 

October 31,

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

NET REVENUES:

 

$

832,282

 

$

715,354

 

$

614,255

 

 

 

 

 

 

 

 

 

COST OF SERVICES:

 

 

 

 

 

 

 

Depreciation and Amortization

 

19,515

 

15,598

 

13,101

 

Employee Related Expenses

 

206,198

 

173,137

 

146,292

 

Reagents and Lab Supplies

 

158,296

 

135,486

 

121,446

 

Other Cost of Services

 

78,274

 

68,594

 

56,805

 

 

 

 

 

 

 

 

 

TOTAL COST OF SERVICES

 

462,283

 

392,815

 

337,644

 

 

 

 

 

 

 

 

 

GROSS PROFIT ON REVENUES

 

369,999

 

322,539

 

276,611

 

 

 

 

 

 

 

 

 

General and Administrative Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

5,649

 

4,141

 

3,562

 

Other General and Administrative Expenses

 

208,934

 

177,508

 

154,928

 

Bad Debt Expense

 

71,991

 

58,917

 

41,990

 

 

 

 

 

 

 

 

 

TOTAL GENERAL AND ADMIN. EXPENSES

 

286,574

 

240,566

 

200,480

 

 

 

 

 

 

 

 

 

OPERATING INCOME

 

83,425

 

81,973

 

76,131

 

 

 

 

 

 

 

 

 

OTHER (INCOME) EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Expense

 

2,446

 

1,606

 

1,455

 

Other (Income) Expense

 

83

 

(612

)

323

 

Interest Income

 

(71

)

(118

)

(163

)

 

 

 

 

 

 

 

 

TOTAL OTHER EXPENSES - NET

 

2,458

 

876

 

1,615

 

 

 

 

 

 

 

 

 

INCOME BEFORE INCOME TAXES

 

80,967

 

81,097

 

74,516

 

 

 

 

 

 

 

 

 

Provision for Income Taxes

 

34,209

 

35,272

 

32,360

 

 

 

 

 

 

 

 

 

NET INCOME

 

46,758

 

45,825

 

42,156

 

 

 

 

 

 

 

 

 

NET INCOME PER SHARE - BASIC:

 

$

1.69

 

$

1.65

 

$

1.52

 

WEIGHTED AVERAGE NUMBER OF SHARES - BASIC:

 

27,716,608

 

27,690,677

 

27,742,257

 

 

 

 

 

 

 

 

 

NET INCOME PER SHARE - DILUTED:

 

$

1.68

 

$

1.65

 

$

1.51

 

WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED:

 

27,855,125

 

27,851,720

 

27,920,920

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

50


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

[Dollars In Thousands Except Number of Shares]

 

 

 

Series A

 

 

 

 

 

Additional

 

 

 

 

 

 

 

 

 

Preferred Stock

 

Common Stock

 

Paid-in

 

Retained

 

Deferred

 

Total Shareholders’

 

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Capital

 

Earnings

 

Compensation

 

Equity

 

Balance on October 31, 2011

 

 

 

 

 

27,949,900

 

$

279

 

$

45,581

 

$

143,907

 

—

 

$

189,767

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Options - Employees

 

 

 

 

 

31,500

 

$

1

 

$

226

 

 

 

 

 

227

 

Stock Based Compensation

 

 

 

 

 

11,432

 

$

0

 

$

290

 

 

 

 

 

290

 

Net Income

 

 

 

 

 

 

 

 

 

 

 

$

42,156

 

 

 

42,156

 

Common Stock Repurchased and Canceled

 

 

 

 

 

(285,450

)

$

(3

)

$

(5,190

)

 

 

 

 

(5,193

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance on October 31, 2012

 

 

 

 

 

27,707,382

 

$

277

 

$

40,907

 

$

186,063

 

 

 

$

227,247

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Options - Employees

 

 

 

 

 

46,000

 

 

 

$

263

 

 

 

 

 

263

 

Stock Based Compensation

 

 

 

 

 

11,431

 

 

 

$

290

 

 

 

 

 

290

 

Net Income

 

 

 

 

 

 

 

 

 

 

 

$

45,825

 

 

 

45,825

 

Common Stock Repurchased and Canceled

 

 

 

 

 

(81,600

)

 

 

$

(2,030

)

 

 

 

 

(2,030

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance on October 31, 2013

 

 

 

 

 

27,683,213

 

$

277

 

$

39,430

 

$

231,888

 

 

 

$

271,595

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of Options - Employees

 

 

 

 

 

33,000

 

 

 

$

259

 

 

 

 

 

$

259

 

Stock Based Compensation

 

 

 

 

 

11,431

 

 

 

$

290

 

 

 

 

 

$

290

 

Net Income

 

 

 

 

 

 

 

 

 

 

 

$

46,758

 

 

 

$

46,758

 

Common Stock Repurchased and Canceled

 

 

 

 

 

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance on October 31, 2014

 

 

 

 

 

27,727,644

 

$

277

 

$

39,979

 

$

278,646

 

 

 

$

318,902

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

51


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS   [Dollars In Thousands]

 

 

 

Years Ended October 31,

 

 

 

2014

 

2013

 

2012

 

OPERATING ACTIVITIES:

 

 

 

 

 

 

 

Net Income

 

$

46,758

 

$

45,825

 

$

42,156

 

Adjustments to Reconcile Net Income to Cash Provided by Operating Activities:

 

 

 

 

 

 

 

Depreciation and Amortization

 

25,164

 

19,739

 

16,663

 

Deferred Income Taxes (Benefit)

 

777

 

(17,041

)

(3,638

)

Stock - Based Compensation Expense

 

290

 

290

 

290

 

Loss on Disposal of Property and Equipment

 

220

 

1,408

 

537

 

Undistributed Equity Method (Income) Loss

 

83

 

450

 

323

 

Change in Assets and Liabilities:

 

 

 

 

 

 

 

(Increase) Decrease in:

 

 

 

 

 

 

 

Accounts Receivable

 

(51,100

)

(91,002

)

(11,240

)

Provision for Doubtful Accounts

 

(5,985

)

37,988

 

6,053

 

Inventory

 

(1,696

)

(4,193

)

(5,211

)

Other Current Assets

 

(749

)

(4,043

)

(916

)

Other Assets

 

(250

)

(299

)

(141

)

Deposits

 

(39

)

(61

)

(74

)

Increase (Decrease) in:

 

 

 

 

 

 

 

Accounts Payable and Accrued Liabilities

 

3,102

 

28,601

 

8,296

 

 

 

 

 

 

 

 

 

NET CASH - OPERATING ACTIVITIES

 

16,575

 

17,662

 

53,098

 

 

 

 

 

 

 

 

 

INVESTING ACTIVITIES:

 

 

 

 

 

 

 

Business Acquisitions Related Costs

 

(2,303

)

(19,013

)

(5,675

)

Acquisition of Equipment and Leasehold Improvements

 

(15,523

)

(25,100

)

(15,715

)

 

 

 

 

 

 

 

 

NET CASH - INVESTING ACTIVITIES

 

(17,826

)

(44,113

)

(21,390

)

 

 

 

 

 

 

 

 

FINANCING ACTIVITIES:

 

 

 

 

 

 

 

Payments of Long-Term Debt

 

(494

)

(464

)

(1,270

)

Payments of Capital Lease Obligations

 

(6,200

)

(4,648

)

(3,710

)

Increase (Decrease) in Revolving Note Payable

 

7,241

 

26,139

 

(18,632

)

Proceeds from Exercise of Options

 

259

 

263

 

227

 

Common Stock Repurchased

 

—

 

(2,030

)

(5,193

)

 

 

 

 

 

 

 

 

NET CASH - FINANCING ACTIVITIES

 

806

 

19,260

 

(28,578

)

 

 

 

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

(445

)

(7,191

)

3,130

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS

 

$

17,952

 

$

25,143

 

$

22,013

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT END OF PERIODS

 

$

17,507

 

$

17,952

 

$

25,143

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

 

 

Interest

 

$

2,419

 

$

1,503

 

$

1,547

 

Income Taxes

 

$

36,505

 

$

44,312

 

$

36,697

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

 

52


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

[Dollars In Thousands]

 

Supplemental Schedule of Non-Cash Investing and Financing Activities:

 

During fiscal 2014, 2013 and 2012, the Company wrote-off approximately $1,463, $4,464 and $2,508 of property which was fully depreciated.

 

During fiscal 2014, 2013, and 2012, the Company incurred capital lease obligations totaling approximately $8,683, $7,125, and  $7,777  in connection with the acquisition of property and equipment.

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

 

53


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

[Dollars In Thousands Except Share Data or Unless Otherwise Indicated]

 

[1] Organization and Business

 

Bio-Reference Laboratories, Inc. [“Bio-Reference”, “BRLI”, or the “Company”] was incorporated on December 24, 1981.  Bio-Reference is principally engaged in providing laboratory testing services, primarily to customers in the in larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts as well as to customers in a number of other states.  Bio-Reference offers a comprehensive list of chemical diagnostic tests including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology (including drug screening), pap smears, tissue pathology (biopsies) and other tissue analysis.  We perform cancer cytogenetic testing at our facilities in Elmwood Park, NJ, Smithtown, NY, Clarksburg, MD and Milford, MA, Miami Florida, Campbell California and genetic testing at our GeneDx leased facility in Gaithersburg, MD, as well as at our Elmwood Park facility.  We perform cytology testing in Frederick, MD, Milford, MA, Columbus, OH, Houston, TX and at our Elmwood Park facility.  Bio-Reference markets its laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.

 

The Company’s laboratory testing business currently represents its one reportable business segment. The laboratory testing business accounts for over 98% of consolidated assets, net revenues and net income in each of the three years ended October 31, 2014.   All other operating segments include the Company’s non-clinical laboratory testing businesses and consist of our clinical knowledge management service through our PSIMedica business unit and a web-based connectivity portal solution for laboratories and physicians through its Care Evolve subsidiary.

 

[2] Summary of Significant Accounting Policies

 

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.

 

Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.  The Company had $17,507 and $17,952 in cash and cash equivalents at October 31, 2014 and 2013, respectively.

 

Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.  Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.

 

Property and Equipment - Property and equipment are carried at cost.  Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.  Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.

 

The statements of operations reflect depreciation expense related to property and equipment of $23,246, $18,745 and $16,082 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.  Repairs and maintenance are charged to expense when incurred.

 

Goodwill - Effective November 1, 2011, the Company adopted revised Financial Accounting Standards Board (“FASB”)  rules promulgated under Accounting Standards Update (“ASU”) No. 2011-08 issued on September 15, 2011, Intangibles—Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.  Under ASU No. 2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit’s carrying value is greater than its fair value based on an assessment of events and circumstances. The “more likely than not” threshold is when there is a likelihood of more than 50% that a reporting unit’s carrying value is greater than its fair value.  No impairment loss was recognized in the years ended October 31, 2014, 2013 and 2012.

 

The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October 31, 2014 and 2013, respectively.

 

Other Intangible Assets - Intangible assets are amortized using the straight-line method.  The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $1,917, $994, and $581 for the years ended October 31, 2014, 2013 and 2012, respectively.  The balance sheet reflects accumulated amortization of $10,763, and $8,846 as of October 31, 2014, and 2013, respectively. During the 2014 and 2013 fiscal years, the Company did not write off any intangible assets.

 

Accounting for Revenue

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.  The majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly.  In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment

 

54


 

and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

 

 

($)

 

 

 

Year Ended October 31,

 

 

 

2014

 

2013

 

2012

 

Gross Service Revenues

 

4,185,052

 

3,524,108

 

3,052,431

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

391,659

 

354,638

 

320,697

 

All Other Third Party Payors*

 

2,899,374

 

2,393,872

 

2,070,073

 

Total Contractual Adjustments and Discounts

 

3,291,033

 

2,748,510

 

2,390,770

 

Service Revenues Net of Contractual Adjustments and Discounts

 

894,019

 

775,598

 

661,661

 

Patient Service Revenue Provision for Bad Debts**

 

61,737

 

60,244

 

47,406

 

Net Revenues

 

832,282

 

715,354

 

614,255

 

 

 

 

 

 

 

 

 

Percent of Contractual Allowances, Discounts and Patient Service

 

 

 

 

 

 

 

Provision for Bad Debts to Gross Revenue.

 

80.1

%

79.7

%

79.9

%

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

Accounting for Contractual Credits and Doubtful Accounts

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses.  This represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information.  In the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.   BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

Contractual Credits/Discounts

 

513,466

 

342,297

 

Doubtful Accounts

 

83,276

 

89,261

 

Total Allowance

 

596,742

 

431,558

 

 

55


 

Current Income Taxes — The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.  For the fiscal years 2011 through 2014, no material amounts for interest and penalties have been recorded.

 

Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.

 

The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.  Under these rules the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.  For the years ended October 31, 2012 through October 31, 2014 the Company had no material uncertain tax positions to report.

 

Earnings Per Share - Basic earnings per share [“EPS”] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.  Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.  The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.  This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.  Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.  Securities that could potentially dilute earnings in the future are disclosed in Note 10.

 

Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets — The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.  The Company reviews the recoverability of its long-lived assets on an annual basis.  Evaluation of possible impairment is based on the Company’s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.  No impairment loss was recognized in the fiscal years ended October 31, 2014, 2013 and 2012.

 

Advertising Costs -Advertising costs are expensed when incurred.  Advertising costs amounted to approximately $3,188, $3,200 and $2,366 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

Other Income — During the year ended October 31, 2014, the Company recorded a loss of $83 on its investment in IncellDx.  The loss represents the Company’s share of IncellDX undistributed net loss under the equity method of accounting.

 

Subsequent Events — The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.

 

[3] Property and Equipment - Property and equipment - at cost is summarized as follows:

 

 

 

$

 

 

 

October 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Medical Equipment

 

77,682

 

65,762

 

Leasehold Improvements

 

32,157

 

27,974

 

Furniture, Fixtures and Office & Computer Equipment

 

26,076

 

21,621

 

Automobiles and Aircraft

 

20,427

 

18,242

 

 

 

 

 

 

 

Sub Totals

 

156,342

 

133,599

 

Less Accumulated Depreciation

 

89,954

 

67,950

 

 

 

 

 

 

 

Totals — Net of Accumulated Depreciation

 

66,388

 

65,649

 

 

[4] Intangible Assets

Intangible assets are summarized as follows:

 

October 31, 2014

 

 

 

Weighted-Average

 

 

 

Accumulated

 

Net of 
Accumulated

 

Intangible Asset

 

Amortization Period

 

Cost

 

Amortization

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$

8,738

 

$

3,275

 

$

5,463

 

Covenants Not-to-Compete

 

3

 

11,131

 

5,738

 

5,393

 

Patents and Licenses

 

17

 

5,297

 

1,750

 

3,547

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$

25,166

 

$

10,763

 

$

14,403

 

 

56


 

October 31, 2013

 

 

 

Weighted-Average

 

 

 

Accumulated

 

Net of 
Accumulated

 

Intangible Asset

 

Amortization Period

 

Cost

 

Amortization

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$

8,738

 

$

2,878

 

$

5,860

 

Covenants Not-to-Compete

 

3

 

11,131

 

4,560

 

6,571

 

Patents and Licenses

 

17

 

5,297

 

1,408

 

3,889

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$

25,166

 

$

8,846

 

$

16,320

 

 

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of October 31, 2014 is as follows:

 

October 31,

 

 

 

2015

 

$

1,852

 

2016

 

1,540

 

2017

 

1,063

 

2018

 

946

 

2019

 

904

 

Thereafter

 

8,098

 

 

 

 

 

Total

 

$

14,403

 

 

[5] Revolving Note Payable - Bank

 

In October 2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $45,000 or (ii) 50% of the Company’s qualified accounts receivable [as defined in the agreement].  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  At October 31, 2014, the Company had elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.50%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent, thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures, fixed charge coverage, and the prohibition of the payment by the Company of cash dividends. As of October 31, 2014 and October 31, 2013, the Company utilized $33,380 and $26,139 of the credit line, respectively.

 

[6] Long-Term Debt - Bank

 

In December 2010, the Company issued a seven year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in eighty-four equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of  December 29, 2017.  The balance on this note as of October 31, 2014 is approximately $3,669.

 

Principal repayment for each of the five succeeding fiscal years and thereafter as of October 31, 2014 is as follows:

 

Year Ended October 31,

 

 

 

2015

 

524

 

2016

 

557

 

2017

 

592

 

2018

 

1,996

 

2019

 

—

 

Thereafter

 

—

 

Totals

 

$

3,669

 

 

[7] Related Party Transactions

 

There were no material related party transactions during fiscal 2014 and fiscal 2013.

 

[8] Income Taxes

 

The reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company’s effective income tax rate is as follows:

 

 

 

October 31

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

U.S. Federal Statutory Rate

 

35

%

35

%

35

%

State and Local Taxes, Net of U.S. Federal Tax Benefit

 

6.15

%

11.20

%

8.87

%

Permanent differences and Other

 

0.94

%

(2.78

)%

(0.44

)%

 

 

 

 

 

 

 

 

Actual Rate

 

42.09

%

43.42

%

43.43

%

 

57


 

The provision for income taxes shown in the consolidated statements of operations consists of the following:

 

 

 

$

 

 

 

October 31

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Current:

 

 

 

 

 

 

 

Federal

 

25,732

 

38,295

 

25,794

 

State & Local

 

7,700

 

14,018

 

10,203

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

Federal

 

598

 

(10,803

)

(2,183

)

State and Local

 

179

 

(6,238

)

(1,454

)

 

 

 

 

 

 

 

 

Total Provision for Income Taxes

 

34,209

 

35,272

 

32,360

 

 

At October 31, 2014 and 2013, the Company had a net deferred tax asset of approximately $43,454 and $44,231, respectively.  The deferred taxes primarily relate to timing differences associated with the deductibility of depreciation and amortization, bad debts and certain accrued expenses and deferred costs.  For fiscal years ended October 31 2012 through October 31, 2014, the Company had no material net operating loss carry-forwards available to reduce current year taxable income.

 

 

 

$

 

 

 

October 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Deferred Tax Asset:

 

 

 

 

 

Bad Debt Allowance

 

36,642

 

39,275

 

Depreciation and amortization

 

3,009

 

1,815

 

Accrued Expenses

 

3,803

 

3,141

 

 

 

 

 

 

 

Deferred Tax Asset - Net

 

43,454

 

44,231

 

 

 

 

 

 

 

Current Deferred Tax Asset - Net

 

40,040

 

42,154

 

Long Term Deferred Tax Asset - Net

 

3,414

 

2,077

 

 

 

 

 

 

 

Deferred Tax Asset — Net

 

43,454

 

44,231

 

 

During fiscal year ended October 31, 2014 the Company recorded a net deferred tax expense of $777.  This reflects an expense of approximately $2,633 in allowance for bad debts, a benefit of approximately $1,194 from depreciation and amortization timing differences, and a benefit of approximately $661 in certain accrued expenses. Although realization is not assured and dependent upon things such as generating sufficient taxable income in future periods, management, through sufficient positive evidence,  believes it is more likely than not that all of the deferred tax asset will be realized. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income or changes in the accrued expenses during the future periods are reduced.

 

At October 31, 2014, fiscal 2011 through 2014 are generally subject to examination by US federal and state tax authorities.  In certain instances examinations that were ongoing on October 31, 2014 are still open for years 2009 and 2010.  Through the issuance of these financial statements the outcome of all of these examinations has not been determined.

 

[9] Capital Transactions

 

[A] Preferred Stock and Common Stock - The Company is authorized to issue an aggregate of 1,666,667 shares of preferred stock, $.10 par value.  None was outstanding as of October 31, 2014 and October 31, 2013.

 

Holders of the Company’s Common Stock are entitled to one vote per share on matters submitted for shareholder vote.  Holders are also entitled to receive dividends ratably, if declared.  In the event of dissolution or liquidation, holders are entitled to share ratably in all assets remaining after payment of liabilities.

 

On December 19, 2013 the Company announced that its board of directors has approved a new Stock Repurchase Program authorizing the buyback of up to 2,000,000 shares of its Common Stock in the over-the-counter market at prevailing market prices through October 31, 2015.  As of October 31, 2014 no shares have been repurchased under this plan.

 

[B] Equity Transactions for Services — For the fiscal years ended in 2014, 2013 and 2012, the Company issued 11,431, 11,431 and 11,432 shares of the Company’s common stock for employment or consulting services [See Note 11 for common stock options issued for employee and consulting services].

 

[10] Earnings Per Share

 

The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:

 

58


 

 

 

$

 

 

 

For Years Ended October 31,

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Income Available to Common Stockholders

 

46,758

 

45,825

 

42,156

 

Weighted Average Common Shares Outstanding

 

27,717

 

27,691

 

27,742

 

 

 

 

 

 

 

 

 

Effect of Dilutive Securities:

 

 

 

 

 

 

 

Warrants/Options

 

138

 

161

 

179

 

 

 

 

 

 

 

 

 

Weighted Average Diluted Common Shares Outstanding

 

27,855

 

27,852

 

27,921

 

 

 

 

 

 

 

 

 

Net Income Per Share - Basic

 

1.69

 

1.65

 

1.52

 

Net Income Per Share - Diluted

 

1.68

 

1.65

 

1.51

 

 

[11] Stock Options and Warrants

 

Employee Incentive Stock Options - In June 2003, the Board of Directors adopted, and in July 2003, the stockholders approved, the 2003 Employee Incentive Stock Option Plan [the “2003 Plan”].  The 2003 Plan authorizes the grant of stock options, which may be designated as  incentive stock options, to purchase up to a maximum aggregate 1,600,000 shares of Company common stock.  The 2003 Plan provides that the exercise price of an option granted there under shall not be less than the fair market value of the Common Stock on the date the option is granted.  However, in the event an option is granted under the 2003 Plan to a holder of 10% or more of the Company’s outstanding Common Stock, the exercise price must be at least 110% of such fair market value.  Under the 2003 Plan, options must be granted before the June 2, 2013 Termination Date.  No option may have a term longer than ten years (limited to five years in the case of an option granted to a 10% or greater stockholder of the Company).  The aggregate fair market value of the Company’s Common Stock with respect to which options are exercisable for the first time by a grantee under all of the Company’s Stock Option Plans during any calendar year cannot exceed $100.  Options granted under the 2003 Plan are non-transferable and must be exercised by an optionee, if at all, while employed by the Company or a subsidiary or within three months after termination of such optionee’s employment due to retirement, or within one year of such termination if due to disability or death.  The Board (or a Stock Option Committee, if designated), may, in its sole discretion, cause the Company to lend money to or guaranty any obligation of an employee for the purpose of enabling such employee to exercise an option granted under the 2003 Plan provided that such loan or obligation cannot exceed fifty percent (50%) of the exercise price of such option. Options issued under the 2003 Plan must have been granted before the June 2 2013 termination date.  No additional options may be granted under the 2003 Plan. A total of 27,000, 4,000 and 23,500 incentive stock options issued under the 2003 Plan were exercised in fiscal years ended in October 31, 2014, 2013 and 2012, respectively.  A total of 0, 6,000 and 13,000 options were cancelled in fiscal years ended October 31, 2014, 2013 and 2012.

 

In August 2000, the Company adopted, and on December 15, 2000, the stockholders approved, the 2000 Employee Incentive Stock Option Plan [“2000 Plan”]. The 2000 Plan provided for the granting of stock options, which may have been designated as incentive stock options, to purchase an aggregate of 1,600,000 shares of the Company’s common stock at a price   not less than 100% of the fair market value per share of the common stock at the date of grant.  However, in the event an option was granted under the 2000 Plan to a holder of 10% or more of the Company’s outstanding common stock, the exercise price must have been at least 110% of fair market value at the date of grant.  Employees of the Company or its subsidiary, as determined, were eligible for the 2000 Plan.  The term of the options could not exceed ten years from the date of grant.  Options issued under the 2000 Plan must have been granted before the August 2010 termination date.  No additional options may be granted under the 2000 Plan. A total of 6,000, 44,000 and 8,000 incentive stock options issued under the 2000 Plan were exercised in fiscal years ended in October 31, 2014, 2013 and 2012, respectively. A total of 0, 2,000, and 0 options were cancelled in fiscal years ended October 31, 2014, 2013 and 2012, respectively.

 

The following is a summary of Employee Incentive Stock Option Plan transactions:

 

 

 

2003 Plan

 

 

 

Shares Under Options
[In Thousands]

 

Weighted Average 
Exercise Price Per Share

 

Outstanding at October 31, 2011*

 

295

 

$

9.80

 

Granted

 

—

 

—

 

Expired

 

(13

)

9.13

 

Exercised

 

(23

)

8.52

 

Outstanding at October 31, 2012**

 

259

 

$

9.95

 

 

 

 

 

 

 

Granted

 

—

 

—

 

Expired

 

(6

)

8.64

 

Exercised

 

(4

)

7.25

 

Outstanding at October 31, 2013***

 

249

 

$

10.02

 

 

 

 

 

 

 

Granted

 

—

 

 

 

Expired

 

—

 

 

 

Exercised

 

(27

)

7.92

 

Outstanding at October 31, 2014****

 

222

 

$

10.28

 

 

*Eligible for exercise at October 31, 2011 were 275 at a weighted average exercise price per share of $9.80

**Eligible for exercise at October 31, 2012 were 244 at a weighted average exercise price per share of $9.95

***Eligible for exercise at October 31, 2013 were 239 at a weighted average exercise price per share of $9.97

****Eligible for exercise at October 31, 2014 were 217 at a weighted average exercise price per share of $10.28

 

59


 

 

 

2000 Plan

 

 

 

Shares Under Options
[In Thousands]

 

Weighted Average
Exercise Price Per Share

 

Outstanding and Eligible for Exercise at October 31, 2011

 

60

 

5.19

 

Granted

 

—

 

—

 

Expired

 

—

 

—

 

Exercised

 

(8

)

3.39

 

Outstanding and Eligible for Exercise at October 31, 2012

 

(52

)

5.47

 

 

 

—

 

—

 

Granted

 

—

 

—

 

Expired

 

(2

)

3.60

 

Exercised

 

(44

)

$

5.25

 

Outstanding and Eligible for Exercise at October 31, 2013

 

6

 

7.67

 

Granted

 

—

 

 

 

Expired

 

—

 

 

 

Exercised

 

(6

)

7.67

 

Outstanding and Eligible for Exercise at October 31, 2014

 

—

 

 

 

 

Summary of outstanding options at October 31, 2014:

 

 

 

Weighted Average

 

Exercisable

 

 

 

Shares

 

Remaining

 

Exercise

 

Shares

 

Exercise

 

Exercise Price Range

 

Outstanding

 

Life

 

Price

 

Outstanding

 

Price

 

$

7.25

 

to

 

$

7.25

 

Per Share

 

0

 

0.00

 

7.25

 

0

 

7.25

 

$

7.41

 

to

 

$

7.67

 

Per Share

 

46

 

0.42

 

7.41

 

46

 

7.41

 

$

9.12

 

to

 

$

9.12

 

Per Share

 

136

 

1.00

 

9.13

 

136

 

9.13

 

$

17.50

 

to

 

$

17.50

 

Per Share

 

40

 

3.08

 

17.50

 

35

 

17.50

 

 

 

 

 

 

 

 

 

222

 

 

 

 

 

217

 

 

 

 

Compensation cost recognized for the years ended October 31, 2014, October 31, 2013 and October 31, 2012 was $40 for each one of the years, with a related tax benefit of $-0- with respect to these options.

 

[12] Employment Contracts and Consulting Agreements

 

The Company has multiple employment contracts with its key executives with expiration dates ranging from January 31, 2015 through October 31, 2018.  At October 31, 2014, the approximate aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases, is as follows:

 

October 31

 

Employees
and
Consultants

 

2015

 

$

4,582

 

2016

 

3,706

 

2017

 

3,706

 

2018

 

1,701

 

2019

 

—

 

Thereafter

 

—

 

 

 

 

 

Total

 

$

13,695

 

 

Some of these agreements provide bonuses and commissions based on a percentage of collected revenues ranging from 1% to 10% on accounts referred by or serviced by the employee or consultant.

 

In addition to the above, in fiscal 2014 the Company has entered into thirty two at — will employment and consulting agreements which together with prior at — will agreements provide for annual aggregate minimum commitments of approximately $39,254 which have no termination dates.

 

[13] Capitalized Lease Obligations

 

The Company leases various assets under capital leases expiring in fiscal 2020 with interest rates ranging between 2% to 7% as follows:

 

60


 

 

 

($)

 

 

 

October 31

 

 

 

2014

 

2013

 

Medical Equipment

 

20,774

 

15,013

 

Automobiles

 

12,674

 

10,581

 

 

 

 

 

 

 

Totals

 

33,447

 

25,594

 

Less: Accumulated Depreciation

 

17,656

 

13,125

 

 

 

 

 

 

 

Net

 

15,791

 

12,469

 

 

Depreciation expense on assets under capital leases was approximately $6,889, $6,494, and $3,792 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

Aggregate future minimum rentals under capital leases are:

 

October 31,

 

($)

 

2015

 

6,623

 

2016

 

5,749

 

2017

 

4,186

 

2018

 

2,368

 

2019

 

485

 

Thereafter

 

1

 

 

 

 

 

Total

 

19,412

 

 

 

 

 

Less Interest:

 

1,032

 

 

 

 

 

Present Value of Minimum Lease Payments

 

18,380

 

 

[14] Commitments and Contingencies

 

The Company leases various office and laboratory facilities and equipment under operating leases expiring from 2015 to 2020.  Several of these leases contain renewal options for one to five year periods.

 

Total expense for property and equipment rental for the years ended October 31, 2014, 2013 and 2012 was $13,411, $10,568 and $8,787, respectively.  There were no contingent rental amounts due through October 31, 2014.

 

Aggregate future minimum rental payments on non cancelable operating leases [exclusive of several month to month leases] are as follows:

 

October 31,

 

Property($)

 

Equipment($)

 

 

 

 

 

 

 

2015

 

8,564

 

345

 

2016

 

2,122

 

203

 

2017

 

831

 

63

 

2018

 

689

 

 

 

2019

 

626

 

 

 

Thereafter

 

103

 

 

 

 

 

 

 

 

 

Totals:

 

12,935

 

611

 

 

The Company has entered into several purchase agreements for reagent supplies through October, 2019.  Minimum purchase commitments as of October 31, 2014 are as follows:

 

October 31

 

Reagents ($)

 

2015

 

73,709

 

2016

 

62,534

 

2017

 

36,188

 

2018

 

21,241

 

2019

 

8,663

 

Thereafter

 

—

 

 

 

 

 

Totals:

 

202,335

 

 

Reagent supplies expensed under purchase agreements amount to $60,777, $7,873, and $13,338 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

61


 

[15] Litigation

 

In the normal course of business, the Company is exposed to a number of asserted and unasserted potential claims.  In the opinion of management, the resolution of these matters will not have a material adverse effect on the Company’s financial position or results of operations.

 

Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey

 

On December 18, 2013, the Company filed an action in the Superior Court of New Jersey against Horizon Blue Cross Blue Shield of New Jersey (“Horizon”), captioned Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey, Docket No. BER L-009748-13 (N.J. Super. Ct. Bergen Cnty.).  The Company has been an in-network provider to Horizon’s preferred provider organization (“PPO”) members for more than 20 years and filed the lawsuit after attempts to resolve its dispute with Horizon were unsuccessful.

 

The Company currently provides services to Horizon pursuant to an Ancillary Services Provider Agreement entered into in 2003 and amended in 2007.  The central claims in the lawsuit arise from the Company’s performance of laboratory services since at least 2008 for members of Horizon’s NJ DIRECT plan, who receive benefits under a program that Horizon has bid, promoted, and represented to be a PPO product for New Jersey state, county, and municipal workers and teachers.  The lawsuit alleges that, despite these representations, Horizon has been improperly treating NJ DIRECT as a Managed Care program in its dealings with the Company, thereby costing the Company more than $20,000,000 in unreimbursed services and depriving state beneficiaries of valuable rights and benefits to which they are entitled.  The lawsuit alleges that Horizon furthered its fraud against the Company by means of a sham Request for Proposal issued in 2011 and through false and incorrect communications to the Company and other providers.  The Company asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud against Horizon.  In addition to compensatory damages, the Company seeks to recover punitive damages from Horizon due to Horizon’s intentional and malicious misconduct.  The Company also seeks declaratory and injunctive relief.

 

On February 5, 2014, Horizon filed a motion to dismiss the complaint, which the Company opposed.  On March 28, 2014, the Honorable Robert C. Wilson of the Superior Court of New Jersey issued an oral ruling denying Horizon’s motion to dismiss without prejudice pending the completion of discovery.  The Company and Horizon are conducting discovery, which is currently scheduled to close in mid 2015.  The Company intends to vigorously prosecute its claims against Horizon.

 

University of Utah Research Foundation, et al. v. GeneDx, Inc., Civil Action No. 2:13cv00954 (D. Utah)

 

On October 16, 2013, Myriad Genetics, Inc., Endorecherche, Inc., HSC Research and Development Limited Partnership, Trustees of the University of Pennsylvania, and University of Utah Research Foundation (“Plaintiffs”) filed a complaint for patent infringement against GeneDx, Inc., a wholly-owned subsidiary of Bio-Reference Laboratories, Inc., in the United States District Court for the District of Utah, Central Division in Salt Lake City, Utah (“District of Utah litigation”). The complaint alleges that GeneDx offers laboratory services, including testing and analysis of BRCA1, BRCA2, and MUTYH genes, that infringe sixteen (16) U.S. Patents owned or controlled by the plaintiffs. Plaintiffs seek to recover damages, including enhanced damages, together with attorney’s fees, interest, and costs. Plaintiffs also seek other relief, including enjoining GeneDx from continuing its allegedly infringing activity.

 

On December 9, 2013, GeneDx filed its answer, affirmative defenses, and counterclaims alleging, among other things, that the asserted patent claims are invalid, unenforceable, and/or not infringed.

 

Plaintiff Myriad and several of the other Plaintiffs have previously and subsequently filed complaints against other laboratories or have been named as defendants in declaratory judgment actions by certain laboratories. Those cases involve some of the patents and claims asserted against GeneDx. The parties involved in those cases who are adverse to Plaintiffs are: Ambry Genetics Corp. (filed July 9, 2013, D. Utah); Gene by Gene, Ltd. (filed July 10, 2013, D. Utah); Counsyl, Inc. (filed September 20, 2013, N.D. Cal.); Quest Diagnostics Inc., et al. (filed October 10, 2013, C.D. Cal.); Quest Diagnostics Inc., et al. (filed October 22, 2013, D. Utah); Invitae Corp. (filed November 25, 2013, D. Utah); Invitae Corp. (filed November 26, 2013, N.D. Cal.); Laboratory Corporation of America Holdings (filed December 3, 2013, D. Utah); Counsyl, Inc. (filed June 13, 2014, D. Utah); and Pathway Genomics Corp. (filed June 13, 2014, D. Utah) (collectively “Defendants”).

 

On November 8, 2013, Plaintiffs filed a motion with the Judicial Panel on Multidistrict Litigation requesting centralization and consolidation in the District of Utah of each of the outstanding district court actions. On February 19, 2014, following briefing and a hearing, the Panel ordered centralization in the District of Utah before District Court Judge Robert J. Shelby, including the action against GeneDx. The Court held an initial scheduling conference on April 25, 2014.

 

In the first-filed actions against Defendants Ambry Genetics Corp. and Gene by Gene, Ltd., on July 9 and July 10, 2013, respectively, Plaintiffs filed a motion for preliminary injunction with each complaint. The parties in each action provided the Court with briefing on the issues, as well as a technology tutorial on August 23, 2013, and the Court held multi-day hearings on the motion in September and October 2013. Prior to any decision, Plaintiffs and Defendant Gene by Gene entered a stipulated dismissal of that action on February 7, 2014. On March 10, 2014, the Court denied Plaintiffs’ request for a preliminary injunction against Defendant Ambry Genetics Corp.

 

Plaintiffs appealed that decision denying their request for a preliminary injunction to the Court of Appeals for the Federal Circuit. Plaintiffs submitted their appeal brief on April 18, 2014, and Defendant Ambry Genetics Corp. submitted its appeal brief on June 2, 2014. Plaintiffs filed their reply appeal brief on June 13, 2014. The Court of Appeals heard oral argument on the denial of Plaintiffs’ request for a preliminary injunction on October 6, 2014, and a decision is expected soon.

 

On August 18, 2014, GeneDx filed eleven petitions for Inter Partes Review (“IPR”) with the U.S. Patent and Trademark Office, challenging the validity of certain of the patents asserted against it in the District of Utah litigation. The eleven patents involved in these petitions are U.S. Patent Nos. 5,654,155; 5,753,441; 6,033,857; 6,051,379; 6,083,698; 6,951,721; 7,470,510; 7,563,571; 7,622,258; 7,670,776, and 7,838,237. On October 24, 2014, GeneDx filed two additional petitions for IPR challenging the validity of U.S. Patent Nos. 5,747,282 and 5,837,492, which are also asserted against GeneDx in the District of Utah litigation. IPR is a relatively new procedure established by the America Invents Act of 2011 as a means to challenge patentability at the U.S. Patent and Trademark Office; and these petitions are the first, and so far only, use of the IPR procedure by any of the Defendants in the Myriad cases.

 

                Since the filing of these IPRs, Plaintiffs have narrowed their asserted claims to 40 across 14 patents from the 67 claims across 16 patents originally asserted in Plaintiffs’ complaint against GeneDx.

 

62


 

We intend to vigorously defend ourselves in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against us and we could be required to pay substantial damages. During the pendency of the litigation, we expect to incur significant costs, and the defense of this litigation may divert, and until resolved will continue to divert, the attention of our management and other resources that would otherwise be engaged in other activities.

 

[16] Insurance

 

The Company maintains professional liability insurance of $3,000 in the aggregate, with a per occurrence limit of $1,000.  In addition, the Company maintains excess commercial insurance of $5,000 per occurrence and $5,000 in aggregate over the primary limits.  In addition, the Company also maintains excess umbrella coverage of $15,000.

 

[17] Significant Risks and Uncertainties

 

[A] Concentrations of Credit Risk - Cash - At October 31, 2014 and 2013, the Company had approximately $15,314 and $14,720, respectively, in cash and certificate of deposit balances at financial institutions which were in excess of the federally insured limits.

 

[B] Concentration of Credit Risk - Accounts Receivable - Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base.  The Company does have significant receivable balances with government payors and various insurance carriers.  Generally, the Company does not require collateral or other security to support customer receivables.  However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

 

A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to clinical laboratories.  Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company.  The Company is unable to predict, however, the extent to which such actions will be taken.

 

[18] Acquisitions

 

The Company did not make any acquisitions during the fiscal year ended October 31, 2014.  The company still carries certain acquisition payable balances on its books that relate to prior period acquisitions.

 

[19] Fair Value of Financial Instruments

 

For certain financial instruments, including cash and cash equivalents, trade receivables, trade payables, and short-term debt, it was estimated that the carrying amount approximated fair value for the majority of these items because of their short maturities.  The fair value of the Company’s long-term debt is estimated based on the quoted market prices for similar issues or by discounting expected cash flows at the rates currently offered to the Company for debt of the same remaining maturities.

 

Due to the non-interest bearing nature and unspecified payment terms, it was not practicable to estimate the fair value of amounts due from related parties [See also Note 7].

 

[20] Health Insurance Plan

 

The Company has a limited self-funded health insurance plan for its employees under which the Company pays the initial $150 of covered medical expenses per person each year.  The Company has a contract with an insurance carrier for any excess up to a maximum of $50,178 in the aggregate.  Health insurance premium expense for the years ended October 31, 2014, 2013 and 2012 amounted to approximately $7,346, $6,797 and $5,792, respectively.  Uninsured employee medical expenses incurred by the Company amounted to approximately $43,459, $32,016 and $25,994 for the years ended October 31, 2014, 2013 and 2012, respectively.  During fiscal years ended October 31, 2014, 2013 and 2012, employee contributions of $6,063, $4,713 and $4,124 offset the above health plan costs.

 

[21] Employee Benefit Plan

 

The Company sponsors a 401(k) Profit-Sharing Plan [the “Plan”].  Employees become eligible for participation after attaining the age of eighteen and completing one year of service.  Participants may elect to contribute up to ten percent of their compensation, as defined in the Plan, to a maximum allowed by the Internal Revenue Service.  The Company may choose to make a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year, at a percentage determined each year by the Company. The Company elected to make a matching contribution which amounted to $2,130 for 2014, $1,358 for 2013 and $1,106 for 2012.  These amounts were charged to the Statement of Operations. The Employer contribution will be fully vested after the third year of service.

 

[22] New Authoritative Accounting Pronouncements

 

In May the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09 titled Revenues from Contracts with Customers. The update calls for a number of revisions in the revenue recognition rules. The update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. At this time the company is studying this update and has not yet determined the effect this may have on our consolidated financial statements.

 

63


 

[23] Selected Quarterly Financial Data [Unaudited]

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2014

 

4/30/2014

 

7/31/2014

 

10/31/2014

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 

181,270

 

201,366

 

222,053

 

227,594

 

832,282

 

Gross Profit

 

72,154

 

88,549

 

102,443

 

106,853

 

369,999

 

Net Income

 

2,954

 

10,273

 

15,250

 

18,281

 

46,758

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

0.11

 

0.37

 

0.55

 

0.66

 

1.69

 

Diluted

 

0.11

 

0.37

 

0.55

 

0.66

 

1.68

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 

27,700

 

27,717

 

27,722

 

27,728

 

27,717

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 

27,848

 

27,857

 

27,864

 

27,869

 

27,855

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2013

 

4/30/2013

 

7/31/2013

 

10/31/2013

 

2013

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 

161,256

 

176,452

 

185,427

 

192,219

 

715,355

 

Gross Profit

 

70,922

 

80,676

 

85,660

 

85,282

 

322,539

 

Net Income

 

8,665

 

11,338

 

14,701

 

11,120

 

45,825

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

0.31

 

0.41

 

0.53

 

0.40

 

1.65

 

Diluted

 

0.31

 

0.41

 

0.53

 

0.40

 

1.65

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 

27,716

 

27,698

 

27,672

 

27,677

 

27,691

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 

27,912

 

27,879

 

27,842

 

27,844

 

27,851

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2012

 

4/30/2012

 

7/31/2012

 

10/31/2012

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 

$

138,793

 

$

151,443

 

$

160,532

 

$

163,487

 

$

614,255

 

Gross Profit

 

$

60,118

 

$

67,534

 

$

74,279

 

$

74,681

 

$

276,611

 

Net Income

 

$

7,365

 

$

9,306

 

$

12,596

 

$

12,889

 

$

42,156

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.26

 

$

0.34

 

$

0.45

 

$

0.47

 

$

1.52

 

Diluted

 

$

0.26

 

$

0.33

 

$

0.45

 

$

0.46

 

$

1.51

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 

27,888

 

27,685

 

27,695

 

27,705

 

27,742

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 

28,041

 

27,878

 

27,888

 

27,906

 

27,921

 

 

64


 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of

Bio-Reference Laboratories, Inc.

Elmwood Park, New Jersey

 

Our report on our audit of the basic consolidated financial statements of Bio-Reference Laboratories, Inc. and its subsidiaries appears earlier in this document.  That audit was conducted for the purpose of forming an opinion on the consolidated basic financial statements taken as a whole.  The supplemental schedule II is presented for purposes of complying with the Securities and Exchange Commission’s Rules and Regulations under the Securities Exchange Act of 1934 and is not otherwise a required part of the basic consolidated financial statements.  Such information has been subjected to the auditing procedures applied in the audit of the basic consolidated financial  statements, and in our opinion, is fairly stated in all material respects in relation to the basic consolidated financial statements taken as a whole.

 

 

 

MSPC

 

Certified Public Accountants and Advisors,

 

A Professional Corporation

 

 

Cranford, New Jersey

January 13, 2015

 

65


 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED OCTOBER 31, 2014, 2013 AND 2012

[In Thousands]

 

 

 

(b)

 

(c)

 

(d)

 

(e)

 

(a)
Description

 

Balance at the
Beginning of a Period

 

Charged to Cost and
Expenses

 

Deductions Charged to Valuation
Allowance Accounts

 

Balance at the End
of a Period

 

 

 

 

 

 

 

 

 

 

 

Year Ended October 31, 2014

 

 

 

 

 

 

 

 

 

Allowance for Doubtful Accounts

 

89,261

 

133,728

 

(139,713

)

83,276

 

Contractual Credits/Discounts

 

342,297

 

3,291,033

 

(3,119,864

)

513,466

 

 

 

 

 

 

 

 

 

 

 

Total Allowance

 

431,558

 

3,424,761

 

(3,259,577

)

596,742

 

 

 

 

 

 

 

 

 

 

 

Year Ended October 31, 2013

 

 

 

 

 

 

 

 

 

Allowance for Doubtful Accounts

 

51,274

 

119,161

 

(81,174

)

89,261

 

Contractual Credits/Discounts

 

267,921

 

2,748,510

 

(2,674,134

)

342,297

 

 

 

 

 

 

 

 

 

 

 

Total Allowance

 

319,195

 

2,867,671

 

(2,755,308

)

431,558

 

 

 

 

 

 

 

 

 

 

 

Year Ended October 31, 2012

 

 

 

 

 

 

 

 

 

Allowance for Doubtful Accounts

 

45,220

 

89,396

 

(83,342

)

51,274

 

Contractual Credits/Discounts

 

235,922

 

2,390,770

 

(2,358,771

)

267,921

 

 

 

 

 

 

 

 

 

 

 

Total Allowance

 

281,142

 

2,480,166

 

(2,442,113

)

319,195

 

 

66

 EX-10.5 2 a14-21858_1ex10d5.htm EX-10.5

Exhibit 10.5

 

2015 Senior Management Incentive Bonus Plan

 

Participants:

 

Marc D. Grodman, MD, CEO

 

Wendy Chung, CSO Howard Dubinett, COO

 

Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing

 

Gary Reeves, VP, Women’s Health Scott Montgomery, VP, Clinical Warren Erdmann, SVP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP

 

Chris Smith, VP Sam Singer, CFO

 

Sally Howlett, VP Billing

 

Nick Papazicos, SVP Financial Operations James Weisberger, MD, CMO Maryanne Amato, Director, Genpath Sherri Bale, CCO GeneDx

 

Dean Gaalaas, COO GeneDx Richard L. Faherty, CIO John Mooney, VP

 

Cory Fishkin, COO CareEvolve

 

J. David Liss, VP, External Relations Joseph Donahue, SVP

 

Proposed Plan:

 

A.           The Senior Management Incentive Bonus Plan (the “Plan”) will be based on two (2) separate financial calculations.  The first formula will be based on “Operating Income” as a percent of “Net Revenues” pursuant to the Consolidated Financial Statements of the Company. The second formula will be based on the percentage increase of “Operating Income” from fiscal 2014 to fiscal 2015 pursuant to the Consolidated Financial Statements of the Company.

 

B.           There will be one class of participation.

 

C.           Calculations for the first portion of the program will be as follows:

 

1.              Operating Income shall consist of the Total Operating Income (hereinafter referred to as “TOI”) for the Entire Company including all divisions and subsidiaries.

 

2.              In the event that TOI shall be equal to or greater than 10.75%, then and in such event, the participants will be entitled to a bonus based on the participant’s annual gross wages including any CPI adjustment paid to him or her in fiscal 2015 exclusive of any bonus, option exercise, auto or airplane usage expense charge-back, or other unearned revenue (“Annual Gross Wages”), pursuant to the following schedule:

 

If TOI is greater than

 

and less than

 

Percent Bonus or equal to:

 

10.75

%

11.25

%

4

%

11.25

%

11.75

%

6

%

11.75

%

12.25

%

8

%

12.25

%

N/A

 

10

%

 

3.              The maximum bonus to be paid under this portion of the program will be 10% of the Annual Gross Wages paid to the participant in fiscal 2015 regardless of TOI.

 

D.            Calculations for the second portion of the program will be as follows:

 

1.                                      Operating Income will consist of Operating Income before interest and taxes for the Entire Company including all divisions and subsidiaries.

 

2.                                      Percentage increase on a year over year basis will be determined by subtracting the Operating Income as reported in the Company’s Consolidated Financial Statements for the 2014 fiscal year (“Base Year”) from the Operating Income as reported in the Company’s Consolidated Financial Statements for the 2015 fiscal year (“Current Year”). This will result in a difference (“Diff”). The Diff will be divided by the Base Year to determine the percentage

 


 

of change (“PC”) in Operating Income between the Base Year and the Current Year.

 

3.                                      In the event that the PC is positive (an increase) and equal to or greater than 20%, then and in such event, each participant will be entitled to a bonus based on the participant’s Annual Gross Wages pursuant to the following schedule:

 

If PC is greater than

 

and less than

 

Percent Bonus or equal to:

 

20.00

%

25.00

%

6

%

25.00

%

30.00

%

9

%

30.00

%

35.00

%

12

%

35.00

%

N/A

 

15

%

 

4.                                     The maximum bonus to be paid under this portion of the program will be 15% of Annual Gross Wages regardless of Operating Income.

 

E.            The two portions shall be calculated separately and shall not be dependent on each other.  Participants may earn a bonus from either or both financial calculations.  Regardless, however, of the Company achievements, the maximum bonus to be paid under the Plan will be 25% of Annual Gross Wages in fiscal 2015.

 

 EX-14 3 a14-21858_1ex14.htm EX-14

Exhibit 14

 

CODE OF ETHICS FOR EXECUTIVE OFFICERS AND KEY FINANCIAL AND ACCOUNTING PERSONNEL

 

This code of ethics applies to Bio-Reference Laboratories, Inc., its Chief Executive Officer, its Chief Operating Officer, its Chief Financial Officer, its Vice President — Financial Operations and all key accounting personnel having responsibility in connection with the preparation, review, or disclosure of any aspect of the Company’s financial statements or other financial information or data (each is referred to as a covered person).

 

The purpose of this code of ethics is to deter wrongdoing and to promote:

 

·                  Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

·                  Full, fair, accurate, timely, and understandable disclosure in reports and documents that Bio-Reference Laboratories files with, or submits to, the Securities and Exchange Commission and in other public communications made by Bio-Reference Laboratories;

·                  Compliance with applicable governmental laws, rules, and regulations;

·                  The prompt internal reporting to an appropriate person or persons identified in the code, of violations of the code; and accountability for adherence to the code.

 

Each covered person must deal honestly and ethically with Bio-Reference Laboratories and on behalf of Bio-Reference Laboratories in all matters. Each covered person must not take unfair advantage of anyone through manipulation, concealment, abuse of privileged or otherwise undisclosed information, misrepresentation of material facts, or any other unfair practices.

 

Each covered person must avoid business, financial, or other direct or indirect interests or relationships that conflict with those of Bio-Reference Laboratories or that divide a covered person’s loyalty to Bio-Reference Laboratories.

 

Each covered person must strive to ensure that Bio-Reference Laboratories’ public disclosures comply with all applicable securities laws and to ensure that in all reports and documents filed with or submitted to the Securities and Exchange Commission by Bio-Reference Laboratories and in other public communications made by Bio-Reference Laboratories, the disclosures are full, fair, accurate, timely, and understandable.

 

Each covered person is required to familiarize himself or herself with all the laws, rules, and regulations that apply in the areas within his or her responsibilities. Each covered person is expected to comply with all applicable laws, rules, and regulations and to ensure that Bio-Reference Laboratories complies with such laws, rules, and regulations in all activities within the scope of such person’s responsibilities.

 

Each covered person is encouraged to talk to supervisors, managers, or other appropriate personnel when in doubt about the best course of action in a particular situation. Covered persons are required to report violations of this code promptly to their supervisor or manager, or to Bio-Reference Laboratories’ Securities Counsel. Bio-Reference Laboratories will not allow retaliation for reports made in good faith.

 

Violation of this code may result in disciplinary action, including termination of employment. The Board of Directors shall determine, or designate appropriate persons to determine actions to be taken in the event of violations of this code.

 

Any amendment or waiver of this code may be made only by the Board of Directors.

 

CORPORATE INTEGRITY PROGRAM CODE OF CONDUCT

 

PURPOSE STATEMENT

 

The Corporate Integrity Program is effective only if it has the full understanding and support of all Bio-Reference personnel (directors and employees). Since the Code of Conduct is the core of our Integrity Program, it is vital that all personnel read the Code of Conduct carefully. The Code of Conduct clarifies the high standards of our professionalism expected under the Corporate Integrity Program. A written version of our Code of Conduct is necessary to ensure that all personnel share our commitment to producing accurate high quality services in an honest and ethical fashion.

 

CODE OF CONDUCT

 

All personnel are required to adhere to the following Code of Conduct.

 

HONESTY

 

Be straightforward and honest in all of your dealings. It is necessary to accurately and thoroughly provide all information necessary to clients enabling them to fully understand the services that Bio-Reference offers and the full financial consequences of these services to Medicare/Medicaid and other third party payers. Therefore, when you prepare any document, never misrepresent any information, never make a false statement, and never omit material information. Dishonesty is strictly prohibited. It includes, but limited to, theft of services, theft of any materials belonging to the company (even in small amounts) and employee time theft.

 

LAWFUL CONDUCT

 

It is vital that you comply with all applicable laws and regulations. Therefore, if any question should arise, it is your responsibility to consult

 


 

with the Chief Compliance Officer before engaging in the questionable activity.

 

CONFIDENTIAL INFORMATION

 

Do not divulge any confidential Bio-Reference information pertaining to: pending or contemplated business transactions, trade secrets, or medical records. In particular, the results of laboratory tests are considered strictly confidential and must not be discussed with any persons without prior authorization.

 

INSIDER TRADING

 

Those who have access to and in possession of the company’s confidential information are not permitted to use or share that information for securities trading purposes (“insider trading”) or for any other purpose except the operation and transaction of the Company’s business. All non-public information about the Company should be considered confidential information. While all personnel are prohibited from insider trading, the Company has adopted specific “Insider Trading Policies and Procedures” (“Insider Trading Policy”) applicable to the company’s directors, employees and independent contractors or consultants.  It is always illegal to trade in Company securities while in possession of material, non-public information (defined in the Insider Trading Policy), and it is also illegal to communicate or “tip” such information to others whether or not they may trade company’s securities on such information. This document is sent to all personnel, independent contracts, and new hires for review, and in connection with certification of compliance when applicable.


GIFTS

 

According to the Stark Statute, there is an exception for compensation relationships with physicians or physician’s family members, which involve de minimums amounts of compensation. The exception applies only to non-cash items or services that do not exceed $75 per gift and an aggregate of $380 per year if the entity providing the compensation makes it available to all similarly situated individuals referring patients to the entity for services, and the compensation is not determined in any way that takes into account the volume or value of the physician’s referrals to the entity.

 

Therefore, as a general rule, do not accept and/or give gifts or favors to anyone outside of Bio-Reference that could influence actions or decisions pertaining to Bio-Reference. This does not preclude you from giving and/or accepting items of nominal value that are clearly tokens of friendship or business hospitality.

 

Since there are not clearly defined answers under the law, if you have any questions pertaining to the propriety of a gift, you must raise the issue with the Chief Compliance Officer prior to giving any gifts of substantial value.

 

SALES AND MARKETING

 

Be honest and truthful in all representations that you make about Bio-Reference and never agree to give anything of value in return for referrals. Do not give anything of value, including bribes, kickbacks, gifts in violation of the above rules.

 

BILLING

 

Any technical question pertaining to the proper CPT code selection, remaining after scrutiny from our technical employees should be directed to our Medicare Carrier. In addition, billing employees are expected to make a concerted effort to handle all credit balances (over payments) generated by the receipt of duplicate payments in an expedient manner.

 

PHLEBOTOMY

 

Phlebotomist must never provide free services in return for physician’s referrals. Phlebotomist must never perform clerical or medical services that are normally the responsibility of the physician’s office staff.

 

THE CORPORATE INTEGRITY PROGRAM

 

Read your department’s employee training materials and attend your employee training sessions when scheduled.

 

You are encouraged to voice any questions or concerns about the Integrity Program to the Chief Compliance Officer, Sam Singer. In addition, you are expected to report possible violations of the program to the compliance officer, either in person, through an email, voice mail, regular U.S. mail or through our toll free number 1-866-IT’S-WRONG.

 

 EX-21 4 a14-21858_1ex21.htm EX-21

Exhibit 21

 

The following are the Company’s wholly-owned subsidiaries:

 

 

 

Jurisdiction of Incorporation

 

Name under which it
Conducts of Conducted Business

CareEvolve.com, Inc.

 

New Jersey

 

CareEvolve

GeneDX, Inc.

 

New Jersey

 

GeneDx

BRLI-GENPATH Diagnostics, Inc.

 

New Jersey

 

BRLI-GENPATH Diagnostics, Inc.

Genome Diagnostics, Ltd.

 

Canada

 

Genome Diagnostics, Ltd.

Florida Clinical Laboratory, Inc.

 

Florida

 

Florida Clinical Laboratory, Inc.

Meridian Clinical Laboratory Corporation

 

Florida

 

Meridian Clinical Laboratory Corporation

 

 EX-23.1 5 a14-21858_1ex23d1.htm EX-23.1

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-111578) of Bio-Reference Laboratories, Inc. and its subsidiaries (the “Company”) of our report dated January 13, 2015, relating to the Company’s consolidated financial statements and the effectiveness of the Company’s internal control over financial reporting, which appears in this Annual Report on form 10-K.

 

 

MSPC

 

Certified Public Accountants and Advisors,

 

A Professional Corporation

 

Cranford, New Jersey

January 13, 2015

 

 EX-31.1 6 a14-21858_1ex31d1.htm EX-31.1

Exhibit 31.1

 

CHIEF EXECUTIVE OFFICER CERTIFICATION

 

I, Marc D. Grodman, certify that:

 

1. I have reviewed this report on Form 10-K of Bio-Reference Laboratories, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                 Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

(a)                                 All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: January 13, 2015

 

 

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman

 

President and Chief Executive Officer

 

Principal Executive Officer

 

 EX-31.2 7 a14-21858_1ex31d2.htm EX-31.2

Exhibit 31.2

 

CHIEF FINANCIAL OFFICER CERTIFICATION

 

I, Sam Singer, certify that:

 

1. I have reviewed this report on Form 10-Q of Bio-Reference Laboratories, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                 Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)                                 All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: January 13, 2015

 

 

 

 

/S/ Sam Singer

 

Sam Singer

 

Senior Vice President, Chief Financial and

 

Chief Accounting Officer

 

 EX-32.1 8 a14-21858_1ex32d1.htm EX-32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “registrant”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(a)                                 the Annual Report on Form 10-K of the registrant for the fiscal year ended October, 31 2014, which this certification accompanies (the “Periodic Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

(b)                                 based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

 

 

Dated: January 13, 2015.

 

 

 

 

 

 

/S/ Marc D. Grodman

 

Marc D. Grodman

 

Chief Executive Officer

 

Bio-Reference Laboratories, Inc.

 

 EX-32.2 9 a14-21858_1ex32d2.htm EX-32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “registrant”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(a)                                 the Annual Report on Form 10-K of the registrant for the fiscal year ended October 31 2014, which this certification accompanies (the “Periodic Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

(b)                                 based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

 

 

Dated: January 13, 2015.

 

 

 

 

 

 

/S/ Sam Singer

 

Sam Singer

 

Chief Financial Officer

 

Bio-Reference Laboratories, Inc

 

 EX-101.INS 10 brli-20141031.xml XBRL INSTANCE DOCUMENT 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2013-11-01 2014-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2013-11-01 2014-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2012-11-01 2013-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2012-11-01 2013-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2011-11-01 2012-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2011-11-01 2012-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2014-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2014-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2013-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2013-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2012-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2012-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2011-10-31 0000792641 brli:AllowanceForContractualCreditsAndDiscountsMember 2011-10-31 0000792641 2013-12-19 0000792641 2012-12-06 0000792641 2011-11-11 0000792641 us-gaap:AdditionalPaidInCapitalMember 2013-11-01 2014-10-31 0000792641 us-gaap:AdditionalPaidInCapitalMember 2012-11-01 2013-10-31 0000792641 us-gaap:AdditionalPaidInCapitalMember 2011-11-01 2012-10-31 0000792641 us-gaap:CommonStockMember 2013-11-01 2014-10-31 0000792641 us-gaap:CommonStockMember 2012-11-01 2013-10-31 0000792641 us-gaap:CommonStockMember 2011-11-01 2012-10-31 0000792641 us-gaap:RetainedEarningsMember 2014-10-31 0000792641 us-gaap:AdditionalPaidInCapitalMember 2014-10-31 0000792641 us-gaap:RetainedEarningsMember 2013-10-31 0000792641 us-gaap:AdditionalPaidInCapitalMember 2013-10-31 0000792641 us-gaap:RetainedEarningsMember 2012-10-31 0000792641 us-gaap:AdditionalPaidInCapitalMember 2012-10-31 0000792641 us-gaap:RetainedEarningsMember 2011-10-31 0000792641 us-gaap:AdditionalPaidInCapitalMember 2011-10-31 0000792641 us-gaap:CommonStockMember 2014-10-31 0000792641 us-gaap:CommonStockMember 2013-10-31 0000792641 us-gaap:CommonStockMember 2012-10-31 0000792641 us-gaap:CommonStockMember 2011-10-31 0000792641 brli:ExercisePriceRangeTwoMember 2013-11-01 2014-10-31 0000792641 brli:ExercisePriceRangeThreeMember 2013-11-01 2014-10-31 0000792641 brli:ExercisePriceRangeOneMember 2013-11-01 2014-10-31 0000792641 brli:ExercisePriceRangeFourMember 2013-11-01 2014-10-31 0000792641 brli:ExercisePriceRangeTwoMember 2014-10-31 0000792641 brli:ExercisePriceRangeThreeMember 2014-10-31 0000792641 brli:ExercisePriceRangeOneMember 2014-10-31 0000792641 brli:ExercisePriceRangeFourMember 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member brli:ShareholderWithMinimumSpecifiedPercentageOfStockMember 2013-11-01 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2013-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2012-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2011-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2012-11-01 2013-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2012-11-01 2013-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2011-11-01 2012-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2011-11-01 2012-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2013-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2012-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2011-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2014-10-31 0000792641 us-gaap:LeaseholdImprovementsMember 2013-11-01 2014-10-31 0000792641 us-gaap:TransportationEquipmentMember 2014-10-31 0000792641 us-gaap:LeaseholdImprovementsMember 2014-10-31 0000792641 brli:FurnitureFixturesAndOfficeAndComputerEquipmentMember 2014-10-31 0000792641 us-gaap:TransportationEquipmentMember 2013-10-31 0000792641 us-gaap:LeaseholdImprovementsMember 2013-10-31 0000792641 brli:FurnitureFixturesAndOfficeAndComputerEquipmentMember 2013-10-31 0000792641 brli:PropertyMember 2014-10-31 0000792641 brli:LaboratoryTestingBusinessMember 2013-11-01 2014-10-31 0000792641 us-gaap:RetainedEarningsMember 2013-11-01 2014-10-31 0000792641 us-gaap:RetainedEarningsMember 2012-11-01 2013-10-31 0000792641 us-gaap:RetainedEarningsMember 2011-11-01 2012-10-31 0000792641 brli:IncellDxIncMember 2013-11-01 2014-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2013-11-01 2014-10-31 0000792641 us-gaap:CustomerListsMember 2013-11-01 2014-10-31 0000792641 brli:PatentsAndLicensesMember 2013-11-01 2014-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2012-11-01 2013-10-31 0000792641 us-gaap:CustomerListsMember 2012-11-01 2013-10-31 0000792641 brli:PatentsAndLicensesMember 2012-11-01 2013-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2014-10-31 0000792641 us-gaap:CustomerListsMember 2014-10-31 0000792641 brli:PatentsAndLicensesMember 2014-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2013-10-31 0000792641 us-gaap:CustomerListsMember 2013-10-31 0000792641 brli:PatentsAndLicensesMember 2013-10-31 0000792641 2014-08-01 2014-10-31 0000792641 2014-05-01 2014-07-31 0000792641 2014-02-01 2014-04-30 0000792641 2013-11-01 2014-01-31 0000792641 2013-08-01 2013-10-31 0000792641 2013-05-01 2013-07-31 0000792641 2013-02-01 2013-04-30 0000792641 2012-11-01 2013-01-31 0000792641 2012-08-01 2012-10-31 0000792641 2012-05-01 2012-07-31 0000792641 2012-02-01 2012-04-30 0000792641 2011-11-01 2012-01-31 0000792641 us-gaap:MediumTermNotesMember 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateEurodollarMember 2013-11-01 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember 2013-11-01 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember brli:DebtInstrumentVariableRateEurodollarMember 2013-11-01 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember brli:DebtInstrumentVariableRateBaseRateMember 2013-11-01 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember brli:DebtInstrumentVariableRateEurodollarMember 2013-11-01 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember brli:DebtInstrumentVariableRateBaseRateMember 2013-11-01 2014-10-31 0000792641 2012-10-31 0000792641 2011-10-31 0000792641 us-gaap:EquipmentMember 2014-10-31 0000792641 us-gaap:AutomobilesMember 2014-10-31 0000792641 us-gaap:EquipmentMember 2013-10-31 0000792641 us-gaap:AutomobilesMember 2013-10-31 0000792641 2014-04-30 0000792641 2015-01-09 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member brli:ShareholderWithMinimumSpecifiedPercentageOfStockMember 2013-11-01 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member us-gaap:MaximumMember 2013-11-01 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member us-gaap:MaximumMember 2013-11-01 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2003Member 2013-11-01 2014-10-31 0000792641 brli:EmployeeIncentiveStockOptionPlan2000Member 2013-11-01 2014-10-31 0000792641 us-gaap:SeriesAPreferredStockMember 2014-10-31 0000792641 us-gaap:SeriesAPreferredStockMember 2013-10-31 0000792641 us-gaap:MinimumMember brli:LaboratoryTestingBusinessMember 2013-11-01 2014-10-31 0000792641 us-gaap:MinimumMember brli:LaboratoryTestingBusinessMember 2012-11-01 2013-10-31 0000792641 us-gaap:MinimumMember brli:LaboratoryTestingBusinessMember 2011-11-01 2012-10-31 0000792641 brli:HorizonBlueCrossBlueShieldOfNewJerseyMember us-gaap:MinimumMember 2013-12-18 2013-12-18 0000792641 brli:GeneDxMember brli:InterPartiesReviewMember us-gaap:MinimumMember 2014-08-18 2014-08-18 0000792641 brli:GeneDxMember brli:InterPartiesReviewMember us-gaap:MaximumMember 2014-08-18 2014-08-18 0000792641 brli:GeneDxMember brli:InfringementOfPatentMember 2013-10-16 2013-10-16 0000792641 brli:GeneDxMember brli:InterPartiesReviewMember 2014-08-18 2014-08-18 0000792641 us-gaap:RevolvingCreditFacilityMember 2014-10-31 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember 2014-10-31 0000792641 us-gaap:MediumTermNotesMember 2010-12-01 2010-12-31 0000792641 brli:HorizonBlueCrossBlueShieldOfNewJerseyMember us-gaap:MinimumMember 2013-11-01 2014-10-31 0000792641 2014-10-31 0000792641 2013-10-31 0000792641 us-gaap:MinimumMember 2013-11-01 2014-10-31 0000792641 us-gaap:MaximumMember 2013-11-01 2014-10-31 0000792641 2013-11-01 2014-10-31 0000792641 2012-11-01 2013-10-31 0000792641 2011-11-01 2012-10-31 iso4217:USD xbrli:shares xbrli:shares brli:item brli:agreement brli:installment brli:Vote xbrli:pure iso4217:USD 41990000 58917000 71991000 0.07 0.02 1 14720000 15314000 2390770000 2748510000 3291033000 2070073000 2393872000 2899374000 320697000 354638000 391659000 20000000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Current Income Taxes &#x2014; The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.&nbsp; For the fiscal years 2011 through 2014, no material amounts for interest and penalties have been recorded.</font> </p> <p><font size="1"> </font></p> </div> </div> 5408000 84 0.0350 -661000 -2633000 -1194000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.&nbsp;&nbsp;Under these rules&nbsp;the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.&nbsp;&nbsp;For the years ended October&nbsp;31, 2012 through October&nbsp;31, 2014 the Company had no material uncertain tax positions to report.</font> </p> <p><font size="1"> </font></p> </div> </div> P18Y P1Y 3792000 6494000 6889000 -0.0044 -0.0278 0.0094 70 39254000 0.10 0.01 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[12] Employment Contracts and Consulting Agreements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company has multiple employment contracts with its key executives with expiration dates ranging from January&nbsp;31, 2015 through October&nbsp;31, 2018.&nbsp;&nbsp;At October&nbsp;31, 2014, the approximate aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases, is as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 33.00%;margin-left:180pt;"> <tr> <td valign="bottom" style="width:53.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Employees</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">and</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Consultants</font></p> </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:32.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,582&nbsp; </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,706&nbsp; </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,706&nbsp; </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,701&nbsp; </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:32.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,695&nbsp; </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Some of these agreements provide bonuses and commissions based on a percentage of collected revenues ranging from 1% to 10% on accounts referred by or serviced by the employee or consultant.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In addition to the above, in fiscal 2014 the Company has entered into thirty two at &#x2014; will employment and consulting agreements which together with prior at &#x2014; will agreements provide for annual aggregate minimum commitments of approximately $39,254 which have no termination dates.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 5000000 5000000 15000000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[20] Health Insurance Plan</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company has a limited self-funded health insurance plan for its employees under which the Company pays the initial $150 of covered medical expenses per person each year.&nbsp; The Company has a contract with an insurance carrier for any excess up to a maximum of $50,178 in the aggregate.&nbsp; Health insurance premium expense for the years ended October&nbsp;31, 2014, 2013 and 2012 amounted to approximately $7,346, $6,797 and $5,792, respectively.&nbsp; Uninsured employee medical expenses incurred by the Company amounted to approximately $43,459, $32,016 and $25,994 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.&nbsp; During fiscal years ended October&nbsp;31, 2014, 2013 and 2012, employee contributions of $6,063, $4,713 and $4,124 offset the above health plan costs.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0 0 0 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[5] Revolving Note Payable - Bank</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In October&nbsp;2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.&nbsp; The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i)&nbsp;$45,000 or (ii)&nbsp;50% of the Company&#x2019;s qualified accounts receivable [as defined in the agreement].&nbsp; The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank&#x2019;s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.&nbsp; The additional interest percentage charge on bank&#x2019;s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.&nbsp; At October&nbsp;31, 2014, the Company had elected to have all of the total advances outstanding to be subject to the bank&#x2019;s base rate of interest of 3.50%.&nbsp; The credit line is collateralized by substantially all of the Company&#x2019;s assets. The line of credit is available through October&nbsp;2016 and may be extended for annual periods by mutual consent, thereafter.&nbsp; The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures, fixed charge coverage, and the prohibition of the payment by the Company of cash dividends. As of October&nbsp;31, 2014 and October&nbsp;31, 2013, the Company utilized $33,380 and $26,139 of the credit line, respectively.</font> </p> <p><font size="1"> </font></p> </div> </div> 0.5 2 16 16 14 11 67 40 800 800 800 P20Y <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Other Income &#x2014; During the year ended October&nbsp;31, 2014, the Company recorded a loss of $83 on its investment in IncellDx.&nbsp;&nbsp;The loss represents the Company&#x2019;s share of IncellDX undistributed net loss under the equity method of accounting.</font> </p> <p><font size="1"> </font></p> </div> </div> 0.98 0.98 0.98 1666667 3000 1666667 3000 47406000 60244000 61737000 13338000 7873000 60777000 0.799 0.797 0.801 661661000 775598000 894019000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:49.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:49.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Service Revenues</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,185,052&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,524,108&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,052,431&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Adjustments and Discounts:</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medicare/Medicaid Portion</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>391,659&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>354,638&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>320,697&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">All Other Third Party Payors*</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,899,374&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,393,872&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,070,073&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,291,033&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,748,510&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,390,770&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service Revenues Net of Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>894,019&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>775,598&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>661,661&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patient Service Revenue Provision for Bad Debts**</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61,737&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,244&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,406&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>832,282&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>715,354&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>614,255&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Percent of Contractual Allowances, Discounts and Patient Service</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Provision for Bad Debts to Gross Revenue.</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80.1&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.7&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.9&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&nbsp;2011-7.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513,466&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,297&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,276&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,261&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,742&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431,558&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 4124000 4713000 6063000 5792000 6797000 7346000 150000 50178000 0.1 0.10 P1Y P3M 0.5 100000 P10Y P5Y P10Y 200480000 240566000 286574000 25994000 32016000 43459000 2508000 4464000 1463000 false --10-31 FY 2014 2014-10-31 10-K 0000792641 27749644 Yes Accelerated Filer 623605643 BIO REFERENCE LABORATORIES INC No No 61614000 71166000 206261000 263346000 18292000 15620000 -67950000 -89954000 39430000 39979000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets &#x2014; The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.&nbsp;&nbsp;The Company reviews the recoverability of its long-lived assets on an annual basis.&nbsp;&nbsp;Evaluation of possible impairment is based on the Company&#x2019;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.&nbsp;&nbsp;No impairment loss was recognized in the fiscal years ended October&nbsp;31, 2014, 2013 and 2012.</font> </p> <p><font size="1"> </font></p> </div> </div> 2366000 3200000 3188000 40000 40000 40000 581000 994000 1917000 421528000 478863000 294878000 351849000 61001000 60626000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[18] Acquisitions</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company did not make any acquisitions during the fiscal year ended October&nbsp;31, 2014.&nbsp;&nbsp;The company still carries certain acquisition payable balances on its books that relate to prior period acquisitions.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 25594000 10581000 15013000 33447000 12674000 20774000 5185000 6128000 7777000 7125000 8683000 10712000 12252000 12469000 15791000 19412000 6623000 485000 2368000 4186000 5749000 1000 1032000 18380000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[13] Capitalized Lease Obligations</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company leases various assets under capital leases expiring in fiscal 2020 with interest rates ranging between 2% to 7% as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"> <tr> <td valign="bottom" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medical Equipment</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,774&nbsp; </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,013&nbsp; </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Automobiles</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,674&nbsp; </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,581&nbsp; </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,447&nbsp; </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,594&nbsp; </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Less: Accumulated Depreciation</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,656&nbsp; </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,125&nbsp; </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,791&nbsp; </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,469&nbsp; </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Depreciation expense on assets under capital leases was approximately $6,889, $6,494, and $3,792 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Aggregate future minimum rentals under capital leases are:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 40.00%;margin-left:162pt;"> <tr> <td valign="bottom" style="width:61.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,623&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,749&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,186&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,368&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>485&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,412&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Less Interest:</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,032&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Present Value of Minimum Lease Payments</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,380&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 13125000 17656000 22013000 25143000 17952000 17507000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.&nbsp;&nbsp;The Company had $17,507 and $17,952 in cash and cash equivalents at October&nbsp;31, 2014 and 2013, respectively.</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:2.3pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[14] Commitments and Contingencies</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company leases various office and laboratory facilities and equipment under operating leases expiring from 2015 to 2020.&nbsp;&nbsp;Several of these leases contain renewal options for one to five year periods.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total expense for property and equipment rental for the years ended October&nbsp;31, 2014, 2013 and 2012 was $13,411, $10,568 and $8,787, respectively.&nbsp;&nbsp;There were no contingent rental amounts due through October&nbsp;31, 2014.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Aggregate future minimum rental payments on non cancelable operating leases [exclusive of several month to month leases] are as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 37.00%;margin-left:169.2pt;"> <tr> <td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Property($)</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Equipment($)</font></p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,564&nbsp; </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,122&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203&nbsp; </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>831&nbsp; </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>689&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>626&nbsp; </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals:</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,935&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611&nbsp; </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company has entered into several purchase agreements for reagent supplies through October, 2019.&nbsp;&nbsp;Minimum purchase commitments as of October&nbsp;31, 2014 are as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 33.00%;margin-left:180pt;"> <tr> <td valign="bottom" style="width:53.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Reagents&nbsp;($)</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,709&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,534&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,188&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,241&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,663&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals:</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>202,335&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Reagent supplies expensed under purchase agreements amount to $60,777, $7,873, and $13,338 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.01 0.01 35000000 35000000 27683213 27727644 27683213 27727644 277000 277000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[17] Significant Risks and Uncertainties</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[A] Concentrations of Credit Risk - Cash -</font><font style="display: inline;"> At October&nbsp;31, 2014 and 2013, the Company had approximately $15,314 and $14,720, respectively, in cash and certificate of deposit balances at financial institutions which were in excess of the federally insured limits.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:38.6pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[B] Concentration of Credit Risk - Accounts Receivable -</font><font style="display: inline;"> Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base.&nbsp;&nbsp;The Company does have significant receivable balances with government payors and various insurance carriers.&nbsp;&nbsp;Generally, the Company does not require collateral or other security to support customer receivables.&nbsp;&nbsp;However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to clinical laboratories.&nbsp;&nbsp;Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company.&nbsp;&nbsp;The Company is unable to predict, however, the extent to which such actions will be taken.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.&nbsp;&nbsp;All significant intercompany accounts and transactions have been eliminated.</font> </p> <p><font size="1"> </font></p> </div> </div> 13695000 1701000 4582000 3706000 3706000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 33.00%;margin-left:180pt;"> <tr> <td valign="bottom" style="width:53.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Employees</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">and</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Consultants</font></p> </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:32.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,582&nbsp; </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,706&nbsp; </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,706&nbsp; </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,701&nbsp; </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:35.92%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:07.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:32.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,695&nbsp; </td> <td valign="bottom" style="width:02.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 337644000 392815000 462283000 13101000 15598000 19515000 121446000 135486000 158296000 25794000 38295000 25732000 10203000 14018000 7700000 0.04 0.04 0.01 0.01 base rate Eurodollar 0.0612 61000 P7Y -2183000 -10803000 598000 -3638000 -17041000 777000 -1454000 -6238000 179000 44231000 43454000 42154000 40040000 2077000 3414000 1815000 3009000 3141000 3803000 39275000 36642000 1106000 1358000 2130000 0.10 1017000 1056000 16082000 18745000 23246000 3562000 4141000 5649000 16663000 19739000 25164000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[11] Stock Options and Warrants</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Employee Incentive Stock Options -</font><font style="display: inline;"> In June&nbsp;2003, the Board of Directors adopted, and in July&nbsp;2003, the stockholders approved, the 2003 Employee Incentive Stock Option Plan [the &#x201C;2003 Plan&#x201D;].&nbsp;&nbsp;The 2003 Plan authorizes the grant of stock options, which may be designated as&nbsp;&nbsp;incentive stock options, to purchase up to a maximum aggregate 1,600,000 shares of Company common stock.&nbsp;&nbsp;The 2003 Plan provides that the exercise price of an option granted there under shall not be less than the fair market value of the Common Stock on the date the option is granted.&nbsp;&nbsp;However, in the event an option is granted under the 2003 Plan to a holder of 10% or more of the Company&#x2019;s outstanding Common Stock, the exercise price must be at least 110% of such fair market value.&nbsp;&nbsp;Under the 2003 Plan, options must be granted before the June&nbsp;2, 2013 Termination Date.&nbsp;&nbsp;No option may have a term longer than ten years (limited to five years in the case of an option granted to a 10% or greater stockholder of the Company).&nbsp;&nbsp;The aggregate fair market value of the Company&#x2019;s Common Stock with respect to which options are exercisable for the first time by a grantee under all of the Company&#x2019;s Stock Option Plans during any calendar year cannot exceed $100.&nbsp;&nbsp;Options granted under the 2003 Plan are non-transferable and must be exercised by an optionee, if at all, while employed by the Company or a subsidiary or within three months after termination of such optionee&#x2019;s employment due to retirement, or within one year of such termination if due to disability or death.&nbsp;&nbsp;The Board (or a Stock Option Committee, if designated), may, in its sole discretion, cause the Company to lend money to or guaranty any obligation of an employee for the purpose of enabling such employee to exercise an option granted under the 2003 Plan provided that such loan or obligation cannot exceed fifty percent (50%) of the exercise price of such option. Options issued under the 2003 Plan must have been granted before the June&nbsp;2 2013 termination date.&nbsp;&nbsp;No additional options may be granted under the 2003 Plan. A total of 27,000, 4,000 and 23,500 incentive stock options issued under the 2003 Plan were exercised in fiscal years ended in October&nbsp;31, 2014, 2013 and 2012, respectively.&nbsp;&nbsp;A total of 0, 6,000 and 13,000 options were cancelled in fiscal years ended October&nbsp;31, 2014, 2013 and 2012.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In August&nbsp;2000, the Company adopted, and on December&nbsp;15, 2000, the stockholders approved, the 2000 Employee Incentive Stock Option Plan [&#x201C;2000 Plan&#x201D;]. The 2000 Plan provided for the granting of stock options, which may have been designated as incentive stock options, to purchase an aggregate of 1,600,000 shares of the Company&#x2019;s common stock at a price&nbsp;&nbsp;&nbsp;not less than 100% of the fair market value per share of the common stock at the date of grant.&nbsp;&nbsp;However, in the event an option was granted under the 2000 Plan to a holder of 10% or more of the Company&#x2019;s outstanding common stock, the exercise price must have been at least 110% of fair market value at the date of grant.&nbsp;&nbsp;Employees of the Company or its subsidiary, as determined, were eligible for the 2000 Plan.&nbsp;&nbsp;The term of the options could not exceed ten years from the date of grant.&nbsp;&nbsp;Options issued under the 2000 Plan must have been granted before the August&nbsp;2010 termination date.&nbsp;&nbsp;No additional options may be granted under the 2000 Plan. A total of 6,000, 44,000 and 8,000 incentive stock options issued under the 2000 Plan were exercised in fiscal years ended in October&nbsp;31, 2014, 2013 and 2012, respectively. A total of 0, 2,000, and 0 options were cancelled in fiscal years ended October&nbsp;31, 2014, 2013 and 2012, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The following is a summary of Employee Incentive Stock Option Plan transactions:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2003&nbsp;Plan</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Under&nbsp;Options</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">[In&nbsp;Thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price&nbsp;Per&nbsp;Share</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2011*</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.80 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.13 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.52 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2012**</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.95 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.64 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2013***</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>249 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.02 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.92 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2014****</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.28 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">*Eligible for exercise at October&nbsp;31, 2011 were 275 at a weighted average exercise price per share of $9.80</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">**Eligible for exercise at October&nbsp;31, 2012 were 244 at a weighted average exercise price per share of $9.95</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">***Eligible for exercise at October&nbsp;31, 2013 were 239 at a weighted average exercise price per share of $9.97</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">****Eligible for exercise at October&nbsp;31, 2014 were 217 at a weighted average exercise price per share of $10.28</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="border-bottom-style:solid;border-bottom-width:1pt;height:100%;text-indent:0pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:28.8pt;"> <tr> <td valign="bottom" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:39.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2000&nbsp;Plan</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Under&nbsp;Options</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">[In&nbsp;Thousands]</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price&nbsp;Per&nbsp;Share</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2011</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.19 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8 </td> <td valign="bottom" style="width:02.74%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.39 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(52 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.47 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:02.74%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.60 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(44 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.25 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Summary of outstanding options at October&nbsp;31, 2014:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:54pt;"> <tr> <td colspan="9" valign="bottom" style="width:37.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:33.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:21.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercisable</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td colspan="9" valign="bottom" style="width:37.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Remaining</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td colspan="9" valign="bottom" style="width:37.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price&nbsp;Range</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Outstanding</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Life</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Price</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Outstanding</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Price</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:00.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41&nbsp; </td> <td valign="bottom" style="width:00.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67&nbsp; </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.42&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12&nbsp; </td> <td valign="bottom" style="width:00.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12&nbsp; </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.00&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.13&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.13&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:00.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.08&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td colspan="2" valign="top" style="width:09.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Compensation cost recognized for the years ended October&nbsp;31, 2014, October&nbsp;31, 2013 and October&nbsp;31, 2012 was $40 for each one of the years, with a related tax benefit of $-0- with respect to these options.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.26 1.52 0.34 0.45 0.47 0.31 1.65 0.41 0.53 0.40 0.11 1.69 0.37 0.55 0.66 0.26 1.51 0.33 0.45 0.46 0.31 1.65 0.41 0.53 0.40 0.11 1.68 0.37 0.55 0.66 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Earnings Per Share - Basic earnings per share [&#x201C;EPS&#x201D;] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.&nbsp;&nbsp;Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.&nbsp;&nbsp;The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.&nbsp;&nbsp;This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.&nbsp;&nbsp;Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.&nbsp;&nbsp;Securities that could potentially dilute earnings in the future are disclosed in Note 10.</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[10] Earnings Per Share</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:51.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:43.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:43.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">For&nbsp;Years&nbsp;Ended&nbsp;October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Income Available to Common Stockholders</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,758&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,825&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,156&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,717&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,691&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,742&nbsp; </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Effect of Dilutive Securities:</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Warrants/Options</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Weighted Average Diluted Common Shares Outstanding</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,855&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,852&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,921&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Net Income Per Share - Basic</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.69&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.52&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Net Income Per Share - Diluted</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.68&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.51&nbsp; </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.4343 0.4342 0.4209 0.3500 0.3500 0.3500 0.0887 0.1120 0.0615 19601000 15822000 0 0 0 5237000 5153000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[19] Fair Value of Financial Instruments</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">For certain financial instruments, including cash and cash equivalents, trade receivables, trade payables, and short-term debt, it was estimated that the carrying amount approximated fair value for the majority of these items because of their short maturities.&nbsp;&nbsp;The fair value of the Company&#x2019;s long-term debt is estimated based on the quoted market prices for similar issues or by discounting expected cash flows at the rates currently offered to the Company for debt of the same remaining maturities.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Due to the non-interest bearing nature and unspecified payment terms, it was not practicable to estimate the fair value of amounts due from related parties [See also Note 7].</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 8846000 1408000 2878000 4560000 10763000 1750000 3275000 5738000 8098000 1852000 904000 946000 1063000 1540000 25166000 5297000 8738000 11131000 25166000 5297000 8738000 11131000 16320000 3889000 5860000 6571000 14403000 3547000 5463000 5393000 P17Y P20Y P3Y P17Y P20Y P3Y -537000 -1408000 -220000 154928000 177508000 208934000 35185000 35185000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Goodwill - Effective November&nbsp;1, 2011, the Company adopted revised Financial Accounting Standards Board (&#x201C;FASB&#x201D;)&nbsp;&nbsp;rules&nbsp;promulgated under Accounting Standards Update (&#x201C;ASU&#x201D;) No.&nbsp;2011-08 issued on September&nbsp;15, 2011,&nbsp;Intangibles&#x2014;Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules&nbsp;the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.&nbsp;&nbsp;Under ASU No.&nbsp;2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit&#x2019;s carrying value is greater than its fair value based on an assessment of events and circumstances. The &#x201C;more likely than not&#x201D; threshold is when there is a likelihood of more than 50% that a reporting unit&#x2019;s carrying value is greater than its fair value.&nbsp;&nbsp;No impairment loss was recognized in the years ended October&nbsp;31, 2014, 2013 and 2012.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October&nbsp;31, 2014 and 2013, respectively.</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Other Intangible Assets - Intangible assets are amortized using the straight-line method.&nbsp;&nbsp;The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $1,917, $994, and $581 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.&nbsp;&nbsp;The balance sheet reflects accumulated amortization of $10,763, and $8,846 as of October&nbsp;31, 2014, and 2013, respectively. During the 2014 and 2013 fiscal years, the Company did not write off any intangible assets.</font> </p> <p><font size="1"> </font></p> </div> </div> 2401000 2401000 0 0 0 60118000 276611000 67534000 74279000 74681000 70922000 322539000 80676000 85660000 85282000 72154000 369999000 88549000 102443000 106853000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets &#x2014; The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.&nbsp;&nbsp;The Company reviews the recoverability of its long-lived assets on an annual basis.&nbsp;&nbsp;Evaluation of possible impairment is based on the Company&#x2019;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.&nbsp;&nbsp;No impairment loss was recognized in the fiscal years ended October&nbsp;31, 2014, 2013 and 2012.</font> </p> <p><font size="1"> </font></p> </div> </div> 74516000 81097000 80967000 -323000 -450000 -83000 -83000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[8] Income Taxes</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company&#x2019;s effective income tax rate is as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:44.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:47.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">U.S. Federal Statutory Rate</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:04.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">State and Local Taxes, Net of U.S. Federal Tax Benefit</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.15&nbsp; </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.20&nbsp; </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.66%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.87&nbsp; </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:44.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Permanent differences and Other</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.94&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.78&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)%</font></p> </td> <td valign="bottom" style="width:13.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.44&nbsp; </td> <td valign="bottom" style="width:04.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)%</font></p> </td> </tr> <tr> <td valign="top" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Actual Rate</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42.09&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43.42&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43.43&nbsp; </td> <td valign="bottom" style="width:04.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The provision for income taxes shown in the consolidated statements of operations consists of the following:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:39.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:55.62%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:55.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Current:</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Federal</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,732 </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,295 </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,794 </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">State&nbsp;&amp; Local</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,700 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,018 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,203 </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred:</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Federal</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>598 </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,803 </td> <td valign="bottom" style="width:03.36%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:16.24%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,183 </td> <td valign="bottom" style="width:01.72%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">State and Local</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,238 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:16.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,454 </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Provision for Income Taxes</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,209 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,272 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,360 </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">At October&nbsp;31, 2014 and 2013, the Company had a net deferred tax asset of approximately $43,454 and $44,231, respectively.&nbsp;&nbsp;The deferred taxes primarily relate to timing differences associated with the deductibility of depreciation and amortization, bad debts and certain accrued expenses and deferred costs.&nbsp;&nbsp;For fiscal years ended October&nbsp;31 2012 through October&nbsp;31, 2014, the Company had no material net operating loss carry-forwards available to reduce current year taxable income.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:36.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:36.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Tax Asset:</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Bad Debt Allowance</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,642&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,275&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Depreciation and amortization</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,009&nbsp; </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,815&nbsp; </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Accrued Expenses</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,803&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,141&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Tax Asset - Net</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,454&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,231&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Current Deferred Tax Asset - Net</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,040&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,154&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Long Term Deferred Tax Asset - Net</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,414&nbsp; </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,077&nbsp; </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Tax Asset &#x2014; Net</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,454&nbsp; </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,231&nbsp; </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">During fiscal year ended October&nbsp;31, 2014 the Company recorded a net deferred tax expense of $777.&nbsp;&nbsp;This reflects an expense of approximately $2,633 in allowance for bad debts, a benefit of approximately $1,194 from depreciation and amortization timing differences, and a benefit of approximately $661 in certain accrued expenses. Although realization is not assured and dependent upon things such as generating sufficient taxable income in future periods, management, through sufficient positive evidence,&nbsp;&nbsp;believes it is more likely than not that all of the deferred tax asset will be realized. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income or changes in the accrued expenses during the future periods are reduced.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">At October&nbsp;31, 2014, fiscal 2011 through 2014 are generally subject to examination by US federal and state tax authorities.&nbsp;&nbsp;In certain instances examinations that were ongoing on October&nbsp;31, 2014 are still open for years 2009 and 2010.&nbsp; Through the issuance of these financial statements the outcome of all of these examinations has not been determined.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 36697000 44312000 36505000 32360000 35272000 34209000 8296000 28601000 3102000 11240000 91002000 51100000 -74000 -61000 -39000 5211000 4193000 1696000 916000 4043000 749000 141000 299000 250000 179000 161000 138000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[16] Insurance</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company maintains professional liability insurance of $3,000 in the aggregate, with a per occurrence limit of $1,000.&nbsp; In addition, the Company maintains excess commercial insurance of $5,000 per occurrence and $5,000 in aggregate over the primary limits.&nbsp; In addition, the Company also maintains excess umbrella coverage of $15,000.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:2.25pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[4] Intangible Assets</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Intangible assets are summarized as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;text-decoration:underline;">October&nbsp;31, 2014</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:31.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,275&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,463&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">3</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,738&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,393&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,750&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,763&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,403&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;text-decoration:underline;">October&nbsp;31, 2013</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:31.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,878&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,860&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">3</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,560&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,571&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,408&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,889&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,846&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,320&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of October&nbsp;31, 2014 is as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.20%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,852&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,540&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,063&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>946&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>904&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,098&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,403&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 16320000 14403000 1455000 1606000 2446000 1547000 1503000 2419000 19095000 20791000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.&nbsp;&nbsp;Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.</font> </p> <p><font size="1"> </font></p> </div> </div> -323000 612000 -83000 146292000 173137000 206198000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:2.3pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[15] Litigation</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In the normal course of business, the Company is exposed to a number of asserted and unasserted potential claims.&nbsp;&nbsp;In the opinion of management, the resolution of these matters will not have a material adverse effect on the Company&#x2019;s financial position or results of operations.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-style:italic;">Bio-Reference Laboratories,&nbsp;Inc. v. Horizon Healthcare Services,&nbsp;Inc.</font><font style="display: inline;"> d/b/a Horizon Blue Cross Blue Shield of New Jersey</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On December&nbsp;18, 2013, the Company filed an action in the Superior Court of New Jersey against Horizon Blue Cross Blue Shield of New Jersey (&#x201C;Horizon&#x201D;), captioned Bio-Reference Laboratories,&nbsp;Inc. v. Horizon Healthcare Services,&nbsp;Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey, Docket No.&nbsp;BER L-009748-13 (N.J. Super. Ct. Bergen Cnty.).&nbsp;&nbsp;The Company has been an in-network provider to Horizon&#x2019;s preferred provider organization (&#x201C;PPO&#x201D;) members for more than 20 years and filed the lawsuit after attempts to resolve its dispute with Horizon were unsuccessful.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company currently provides services to Horizon pursuant to an Ancillary Services Provider Agreement entered into in 2003 and amended in 2007.&nbsp;&nbsp;The central claims in the lawsuit arise from the Company&#x2019;s performance of laboratory services since at least 2008 for members of Horizon&#x2019;s NJ DIRECT plan, who receive benefits under a program that Horizon has bid, promoted, and represented to be a PPO product for New Jersey state, county, and municipal workers and teachers.&nbsp;&nbsp;The lawsuit alleges that, despite these representations, Horizon has been improperly treating NJ DIRECT as a Managed Care program in its dealings with the Company, thereby costing the Company more than $20,000,000 in unreimbursed services and depriving state beneficiaries of valuable rights and benefits to which they are entitled.&nbsp;&nbsp;The lawsuit alleges that Horizon furthered its fraud against the Company by means of a sham Request for Proposal issued in 2011 and through false and incorrect communications to the Company and other providers.&nbsp;&nbsp;The Company asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud against Horizon.&nbsp;&nbsp;In addition to compensatory damages, the Company seeks to recover punitive damages from Horizon due to Horizon&#x2019;s intentional and malicious misconduct.&nbsp;&nbsp;The Company also seeks declaratory and injunctive relief.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On February&nbsp;5, 2014, Horizon filed a motion to dismiss the complaint, which the Company opposed.&nbsp;&nbsp;On March&nbsp;28, 2014, the Honorable Robert C. Wilson of the Superior Court of New Jersey issued an oral ruling denying Horizon&#x2019;s motion to dismiss without prejudice pending the completion of discovery.&nbsp;&nbsp;The Company and Horizon are conducting discovery, which is currently scheduled to close in mid 2015.&nbsp;&nbsp;The Company intends to vigorously prosecute its claims against Horizon.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-style:italic;">University of Utah Research Foundation, et al. v. GeneDx,&nbsp;Inc.</font><font style="display: inline;">, Civil Action No.&nbsp;2:13cv00954 (D. Utah)</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On October&nbsp;16, 2013, Myriad Genetics,&nbsp;Inc., Endorecherche,&nbsp;Inc., HSC Research and Development Limited Partnership, Trustees of the University of Pennsylvania, and University of Utah Research Foundation (&#x201C;Plaintiffs&#x201D;) filed a complaint for patent infringement against GeneDx,&nbsp;Inc., a wholly-owned subsidiary of Bio-Reference Laboratories,&nbsp;Inc., in the United States District Court for the District of Utah, Central Division in Salt Lake City, Utah (&#x201C;District of Utah litigation&#x201D;). The complaint alleges that GeneDx offers laboratory services, including testing and analysis of BRCA1, BRCA2, and MUTYH genes, that infringe sixteen (16) U.S. Patents owned or controlled by the plaintiffs. Plaintiffs seek to recover damages, including enhanced damages, together with attorney&#x2019;s fees, interest, and costs. Plaintiffs also seek other relief, including enjoining GeneDx from continuing its allegedly infringing activity.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On December&nbsp;9, 2013, GeneDx filed its answer, affirmative defenses, and counterclaims alleging, among other things, that the asserted patent claims are invalid, unenforceable, and/or not infringed.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Plaintiff Myriad and several of the other Plaintiffs have previously and subsequently filed complaints against other laboratories or have been named as defendants in declaratory judgment actions by certain laboratories. Those cases involve some of the patents and claims asserted against GeneDx. The parties involved in those cases who are adverse to Plaintiffs are: Ambry Genetics Corp. (filed July&nbsp;9, 2013, D. Utah); Gene by Gene,&nbsp;Ltd. (filed July&nbsp;10, 2013, D. Utah); Counsyl,&nbsp;Inc. (filed September&nbsp;20, 2013, N.D. Cal.); Quest Diagnostics Inc., et al. (filed October&nbsp;10, 2013, C.D. Cal.); Quest Diagnostics Inc., et al. (filed October&nbsp;22, 2013, D. Utah); Invitae Corp. (filed November&nbsp;25, 2013, D. Utah); Invitae Corp. (filed November&nbsp;26, 2013, N.D. Cal.); Laboratory Corporation of America Holdings (filed December&nbsp;3, 2013, D. Utah); Counsyl,&nbsp;Inc. (filed June&nbsp;13, 2014, D. Utah); and Pathway Genomics Corp. (filed June&nbsp;13, 2014, D. Utah) (collectively &#x201C;Defendants&#x201D;).</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On November&nbsp;8, 2013, Plaintiffs filed a motion with the Judicial Panel on Multidistrict Litigation requesting centralization and consolidation in the District of Utah of each of the outstanding district court actions. On February&nbsp;19, 2014, following briefing and a hearing, the Panel ordered centralization in the District of Utah before District Court Judge Robert J. Shelby, including the action against GeneDx. The Court held an initial scheduling conference on April&nbsp;25, 2014.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In the first-filed actions against Defendants Ambry Genetics Corp. and Gene by Gene,&nbsp;Ltd., on July&nbsp;9 and July&nbsp;10, 2013, respectively, Plaintiffs filed a motion for preliminary injunction with each complaint. The parties in each action provided the Court with briefing on the issues, as well as a technology tutorial on August&nbsp;23, 2013, and the Court held multi-day hearings on the motion in September&nbsp;and October&nbsp;2013. Prior to any decision, Plaintiffs and Defendant Gene by Gene entered a stipulated dismissal of that action on February&nbsp;7, 2014. On March&nbsp;10, 2014, the Court denied Plaintiffs&#x2019; request for a preliminary injunction against Defendant Ambry Genetics Corp.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Plaintiffs appealed that decision denying their request for a preliminary injunction to the Court of Appeals for the Federal Circuit. Plaintiffs submitted their appeal brief on April&nbsp;18, 2014, and Defendant Ambry Genetics Corp. submitted its appeal brief on June&nbsp;2, 2014. Plaintiffs filed their reply appeal brief on June&nbsp;13, 2014. The Court of Appeals heard oral argument on the denial of Plaintiffs&#x2019; request for a preliminary injunction on October&nbsp;6, 2014, and a decision is expected soon.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On August&nbsp;18, 2014, GeneDx filed eleven petitions for </font><font style="display: inline;font-style:italic;">Inter Partes </font><font style="display: inline;">Review (&#x201C;IPR&#x201D;) with the U.S. Patent and Trademark Office, challenging the validity of certain of the patents asserted against it in the District of Utah litigation. The eleven patents involved in these petitions are </font><font style="display: inline;">U.S. Patent Nos. 5,654,155; 5,753,441; 6,033,857; 6,051,379; 6,083,698; 6,951,721; 7,470,510; 7,563,571; 7,622,258; 7,670,776, and 7,838,237. On October&nbsp;24, 2014, GeneDx filed two additional petitions for IPR challenging the validity of U.S. Patent Nos. 5,747,282 and 5,837,492, which are also asserted against GeneDx in the District of Utah litigation. IPR is a relatively new procedure established by the America Invents Act of 2011 as a means to challenge patentability at the U.S. Patent and Trademark Office; and t</font><font style="display: inline;">hese petitions are the first, and so far only, use of the IPR procedure by any of the Defendants in the Myriad cases.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Since the filing of these IPRs, Plaintiffs have narrowed their asserted claims to 40 across 14 patents from the 67 claims across 16 patents originally asserted in Plaintiffs&#x2019; complaint against GeneDx.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">We intend to vigorously defend ourselves in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against us and we could be required to pay substantial damages. During the pendency of the litigation, we expect to incur significant costs, and the defense of this litigation may divert, and until resolved will continue to divert, the attention of our management and other resources that would otherwise be engaged in other activities.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> P5Y P1Y 421528000 478863000 133762000 144564000 16171000 15397000 18632000 -26139000 -7241000 45000000 26139000 33380000 3669000 3669000 493000 524000 524000 1996000 592000 557000 3670000 3145000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[6] Long-Term Debt - Bank</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In December&nbsp;2010, the Company issued a seven year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.&nbsp;&nbsp;The note is payable in eighty-four equal monthly installments commencing on January&nbsp;29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of&nbsp;&nbsp;December&nbsp;29, 2017.&nbsp;&nbsp;The balance on this note as of October&nbsp;31, 2014 is approximately $3,669.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Principal repayment for each of the five succeeding fiscal years and thereafter as of October&nbsp;31, 2014 is as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;">Year Ended October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>524&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>557&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>592&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,996&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,669&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 1789000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 33.00%;margin-left:180pt;"> <tr> <td valign="bottom" style="width:53.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Reagents&nbsp;($)</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73,709&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62,534&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,188&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,241&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,663&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:53.56%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals:</font></p> </td> <td valign="bottom" style="width:07.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:36.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>202,335&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 3000000 1000000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[1] Organization and Business</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Bio-Reference Laboratories,&nbsp;Inc. [&#x201C;Bio-Reference&#x201D;, &#x201C;BRLI&#x201D;, or the &#x201C;Company&#x201D;] was incorporated on December&nbsp;24, 1981.&nbsp;&nbsp;Bio-Reference is principally engaged in providing laboratory testing services, primarily to customers in the in larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas,&nbsp;Illinois and Massachusetts as well as to customers in a number of other states.&nbsp;&nbsp;Bio-Reference offers a comprehensive list of chemical diagnostic tests including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology (including drug screening), pap smears, tissue pathology (biopsies) and other tissue analysis.&nbsp;&nbsp;We perform cancer cytogenetic testing at our facilities in Elmwood Park, NJ, Smithtown, NY, Clarksburg, MD and Milford, MA, Miami Florida, Campbell California and genetic testing at our GeneDx leased facility in Gaithersburg, MD, as well as at our Elmwood Park facility.&nbsp;&nbsp;We perform cytology testing in Frederick, MD, Milford, MA, Columbus, OH, Houston, TX and at our Elmwood Park facility.&nbsp;&nbsp;Bio-Reference markets its laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company&#x2019;s laboratory testing business currently represents its one reportable business segment. The laboratory testing business accounts for over 98% of consolidated assets, net revenues and net income in each of the three years ended October&nbsp;31, 2014.&nbsp;&nbsp;&nbsp;All other operating segments include the Company&#x2019;s non-clinical laboratory testing businesses and consist of our clinical knowledge management service through our PSIMedica business unit and a web-based connectivity portal solution for laboratories and physicians through its Care Evolve subsidiary.</font> </p> <p><font size="1"> </font></p> </div> </div> 3130000 -7191000 -445000 -28578000 19260000 806000 -21390000 -44113000 -17826000 53098000 17662000 16575000 7365000 42156000 42156000 9306000 12596000 12889000 8665000 45825000 45825000 11338000 14701000 11120000 2954000 46758000 46758000 10273000 15250000 18281000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[22] New Authoritative Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36.3pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">In May&nbsp;the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-09 titled Revenues from Contracts with Customers. The update calls for a number of revisions in the revenue recognition rules. The update is effective for annual reporting periods beginning after December&nbsp;15, 2016, including interim periods within that reporting period. Early application is not permitted. At this time the company is studying this update and has not yet determined the effect this may have on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 1 76131000 81973000 83425000 12935000 611000 8564000 345000 626000 689000 831000 63000 2122000 203000 103000 0 8787000 10568000 13411000 0 0 0 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[2] Summary of Significant Accounting Policies</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.&nbsp;&nbsp;All significant intercompany accounts and transactions have been eliminated.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.&nbsp;&nbsp;The Company had $17,507 and $17,952 in cash and cash equivalents at October&nbsp;31, 2014 and 2013, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.&nbsp;&nbsp;Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Property and Equipment - Property and equipment are carried at cost.&nbsp;&nbsp;Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.&nbsp;&nbsp;Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The statements of operations reflect depreciation expense related to property and equipment of $23,246, $18,745 and $16,082 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.&nbsp;&nbsp;Repairs and maintenance are charged to expense when incurred.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Goodwill - Effective November&nbsp;1, 2011, the Company adopted revised Financial Accounting Standards Board (&#x201C;FASB&#x201D;)&nbsp;&nbsp;rules&nbsp;promulgated under Accounting Standards Update (&#x201C;ASU&#x201D;) No.&nbsp;2011-08 issued on September&nbsp;15, 2011,&nbsp;Intangibles&#x2014;Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules&nbsp;the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.&nbsp;&nbsp;Under ASU No.&nbsp;2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit&#x2019;s carrying value is greater than its fair value based on an assessment of events and circumstances. The &#x201C;more likely than not&#x201D; threshold is when there is a likelihood of more than 50% that a reporting unit&#x2019;s carrying value is greater than its fair value.&nbsp;&nbsp;No impairment loss was recognized in the years ended October&nbsp;31, 2014, 2013 and 2012.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October&nbsp;31, 2014 and 2013, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Other Intangible Assets - Intangible assets are amortized using the straight-line method.&nbsp;&nbsp;The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $1,917, $994, and $581 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.&nbsp;&nbsp;The balance sheet reflects accumulated amortization of $10,763, and $8,846 as of October&nbsp;31, 2014, and 2013, respectively. During the 2014 and 2013 fiscal years, the Company did not write off any intangible assets.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Accounting for Revenue</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.&nbsp;&nbsp;Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.&nbsp;&nbsp;The majority of services provided by BRLI are to patients covered under a third party payor contract.&nbsp;&nbsp;In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly.&nbsp;&nbsp;In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.&nbsp;&nbsp;Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.&nbsp;&nbsp;Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.&nbsp;&nbsp;The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.&nbsp;&nbsp;This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.&nbsp;&nbsp;The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:49.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:49.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Service Revenues</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,185,052&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,524,108&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,052,431&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Adjustments and Discounts:</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medicare/Medicaid Portion</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>391,659&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>354,638&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>320,697&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">All Other Third Party Payors*</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,899,374&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,393,872&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,070,073&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,291,033&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,748,510&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,390,770&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service Revenues Net of Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>894,019&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>775,598&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>661,661&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patient Service Revenue Provision for Bad Debts**</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61,737&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,244&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,406&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>832,282&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>715,354&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>614,255&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Percent of Contractual Allowances, Discounts and Patient Service</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Provision for Bad Debts to Gross Revenue.</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80.1&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.7&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.9&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&nbsp;2011-7.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.&nbsp;&nbsp;The remaining bad debt expense is presented as part of operating expenses.&nbsp;&nbsp;The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Accounting for Contractual Credits and Doubtful Accounts</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses.&nbsp;&nbsp;This represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information.&nbsp;&nbsp;In the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.&nbsp;&nbsp;&nbsp;BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer&#x2019;s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513,466&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,297&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,276&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,261&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,742&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431,558&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Current Income Taxes &#x2014; The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.&nbsp; For the fiscal years 2011 through 2014, no material amounts for interest and penalties have been recorded.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.&nbsp;&nbsp;Under these rules&nbsp;the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.&nbsp;&nbsp;For the years ended October&nbsp;31, 2012 through October&nbsp;31, 2014 the Company had no material uncertain tax positions to report.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Earnings Per Share - Basic earnings per share [&#x201C;EPS&#x201D;] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.&nbsp;&nbsp;Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.&nbsp;&nbsp;The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.&nbsp;&nbsp;This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.&nbsp;&nbsp;Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.&nbsp;&nbsp;Securities that could potentially dilute earnings in the future are disclosed in Note 10.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets &#x2014; The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.&nbsp;&nbsp;The Company reviews the recoverability of its long-lived assets on an annual basis.&nbsp;&nbsp;Evaluation of possible impairment is based on the Company&#x2019;s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.&nbsp;&nbsp;No impairment loss was recognized in the fiscal years ended October&nbsp;31, 2014, 2013 and 2012.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Advertising Costs -Advertising costs are expensed when incurred.&nbsp;&nbsp;Advertising costs amounted to approximately $3,188, $3,200 and $2,366 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Other Income &#x2014; During the year ended October&nbsp;31, 2014, the Company recorded a loss of $83 on its investment in IncellDx.&nbsp;&nbsp;The loss represents the Company&#x2019;s share of IncellDX undistributed net loss under the equity method of accounting.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Subsequent Events &#x2014; The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 9416000 10165000 1165000 1415000 56805000 68594000 78274000 2438000 1924000 -163000 -118000 -71000 -1615000 -876000 -2458000 5193000 2030000 5675000 19013000 2303000 15715000 25100000 15523000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:2.3pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[21] Employee Benefit Plan</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The Company sponsors a 401(k)&nbsp;Profit-Sharing Plan [the &#x201C;Plan&#x201D;].&nbsp; Employees become eligible for participation after attaining the age of eighteen and completing one year of service.&nbsp; Participants may elect to contribute up to ten percent of their compensation, as defined in the Plan, to a maximum allowed by the Internal Revenue Service.&nbsp; The Company may choose to make a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year, at a percentage determined each year by the Company. The Company elected to make a matching contribution which amounted to $2,130 for 2014, $1,358 for 2013 and $1,106 for 2012.&nbsp; These amounts were charged to the Statement of Operations. The Employer contribution will be fully vested after the third year of service.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.10 0.10 1666667 1666667 0 0 0 0 227000 263000 259000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[3] Property and Equipment -</font><font style="display: inline;"> Property and equipment - at cost is summarized as follows:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 60.00%;margin-left:108pt;"> <tr> <td valign="bottom" style="width:49.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medical Equipment</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,682&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65,762&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Leasehold Improvements</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,157&nbsp; </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,974&nbsp; </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Furniture, Fixtures and Office&nbsp;&amp; Computer Equipment</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,076&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,621&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Automobiles and Aircraft</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,427&nbsp; </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,242&nbsp; </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Sub Totals</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156,342&nbsp; </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,599&nbsp; </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Less Accumulated Depreciation</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,954&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67,950&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals &#x2014; Net of Accumulated Depreciation</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,388&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65,649&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 133599000 21621000 65762000 27974000 18242000 156342000 26076000 77682000 32157000 20427000 65649000 66388000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Property and Equipment - Property and equipment are carried at cost.&nbsp;&nbsp;Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.&nbsp;&nbsp;Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The statements of operations reflect depreciation expense related to property and equipment of $23,246, $18,745 and $16,082 for the years ended October&nbsp;31, 2014, 2013 and 2012, respectively.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.&nbsp;&nbsp;Repairs and maintenance are charged to expense when incurred.</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 60.00%;margin-left:108pt;"> <tr> <td valign="bottom" style="width:49.90%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medical Equipment</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,682&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65,762&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Leasehold Improvements</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,157&nbsp; </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,974&nbsp; </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Furniture, Fixtures and Office&nbsp;&amp; Computer Equipment</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,076&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,621&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Automobiles and Aircraft</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,427&nbsp; </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,242&nbsp; </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Sub Totals</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156,342&nbsp; </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,599&nbsp; </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Less Accumulated Depreciation</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,954&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67,950&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:49.90%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals &#x2014; Net of Accumulated Depreciation</font></p> </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:19.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,388&nbsp; </td> <td valign="bottom" style="width:04.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>65,649&nbsp; </td> <td valign="bottom" style="width:01.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> P5Y P15Y P2Y 6053000 37988000 -5985000 202335000 8663000 21241000 73709000 62534000 36188000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:2.3pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[23] Selected Quarterly Financial Data [Unaudited]</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Month&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Audited</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fiscal Year</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">1/31/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">4/30/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">7/31/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">10/31/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,270&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>201,366&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222,053&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>227,594&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>832,282&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Profit</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,154&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88,549&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102,443&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106,853&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>369,999&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,954&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,273&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,281&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,758&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income Per Common Share:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.11&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.37&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.66&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.69&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.11&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.37&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.66&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.68&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding &#x2014; Basic [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,700&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,717&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,722&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,728&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,717&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding - Diluted [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,848&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,857&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,864&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,869&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,855&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Month&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Audited</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fiscal Year</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">1/31/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">4/30/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">7/31/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">10/31/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161,256&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>176,452&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185,427&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>192,219&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>715,355&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Profit</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,922&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,676&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,660&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,282&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>322,539&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,665&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,338&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,701&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,120&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,825&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income Per Common Share:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.31&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.41&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.53&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.40&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.31&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.41&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.53&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.40&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding &#x2014; Basic [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,716&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,698&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,672&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,677&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,691&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding - Diluted [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,912&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,879&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,842&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,844&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,851&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Month&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Audited</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fiscal Year</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">1/31/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">4/30/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">7/31/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">10/31/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138,793&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>151,443&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160,532&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163,487&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>614,255&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Profit</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,118&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67,534&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,279&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,681&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>276,611&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,365&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,306&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,596&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,889&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,156&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income Per Common Share:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.26&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.34&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.45&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.47&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.52&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.26&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.45&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.46&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.51&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding &#x2014; Basic [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,888&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,685&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,695&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,705&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,742&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding - Diluted [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,041&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,878&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,888&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,906&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,921&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[7] Related Party Transactions</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">There were no material related party transactions during fiscal 2014 and fiscal 2013.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 3710000 4648000 6200000 1270000 464000 494000 231888000 278646000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Accounting for Revenue</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.&nbsp;&nbsp;Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.&nbsp;&nbsp;The majority of services provided by BRLI are to patients covered under a third party payor contract.&nbsp;&nbsp;In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly.&nbsp;&nbsp;In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.&nbsp;&nbsp;Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.&nbsp;&nbsp;Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.&nbsp;&nbsp;The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.&nbsp;&nbsp;This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.&nbsp;&nbsp;The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:49.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:49.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Service Revenues</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,185,052&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,524,108&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,052,431&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Adjustments and Discounts:</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medicare/Medicaid Portion</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>391,659&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>354,638&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>320,697&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">All Other Third Party Payors*</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,899,374&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,393,872&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,070,073&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,291,033&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,748,510&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,390,770&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Service Revenues Net of Contractual Adjustments and Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>894,019&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>775,598&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>661,661&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patient Service Revenue Provision for Bad Debts**</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61,737&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,244&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,406&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>832,282&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>715,354&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>614,255&nbsp; </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Percent of Contractual Allowances, Discounts and Patient Service</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.60%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Provision for Bad Debts to Gross Revenue.</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80.1&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.7&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:14.40%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79.9&nbsp; </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&nbsp;2011-7.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.&nbsp;&nbsp;The remaining bad debt expense is presented as part of operating expenses.&nbsp;&nbsp;The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.</font> </p> <p><font size="1"> </font></p> </div> </div> 3052431000 3524108000 4185052000 138793000 614255000 151443000 160532000 163487000 161256000 715354000 176452000 185427000 192219000 181270000 832282000 201366000 222053000 227594000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"> <tr> <td valign="bottom" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:44.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Medical Equipment</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,774&nbsp; </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,013&nbsp; </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Automobiles</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,674&nbsp; </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,581&nbsp; </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33,447&nbsp; </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,594&nbsp; </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Less: Accumulated Depreciation</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,656&nbsp; </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,125&nbsp; </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:48.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net</font></p> </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,791&nbsp; </td> <td valign="bottom" style="width:04.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:20.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,469&nbsp; </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:39.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:55.62%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:55.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:39.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Current:</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Federal</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,732 </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,295 </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,794 </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">State&nbsp;&amp; Local</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,700 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,018 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,203 </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred:</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Federal</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>598 </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,803 </td> <td valign="bottom" style="width:03.36%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:16.24%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,183 </td> <td valign="bottom" style="width:01.72%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">State and Local</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,238 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:16.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,454 </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:39.32%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:39.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Provision for Income Taxes</font></p> </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,209 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,272 </td> <td valign="bottom" style="width:03.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,360 </td> <td valign="bottom" style="width:01.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:59.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:36.14%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:36.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:59.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Tax Asset:</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Bad Debt Allowance</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,642&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,275&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Depreciation and amortization</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,009&nbsp; </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,815&nbsp; </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Accrued Expenses</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,803&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,141&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Tax Asset - Net</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,454&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,231&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Current Deferred Tax Asset - Net</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,040&nbsp; </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,154&nbsp; </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Long Term Deferred Tax Asset - Net</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,414&nbsp; </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,077&nbsp; </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.48%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Deferred Tax Asset &#x2014; Net</font></p> </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43,454&nbsp; </td> <td valign="bottom" style="width:03.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,231&nbsp; </td> <td valign="bottom" style="width:01.48%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:51.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:43.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">$</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:43.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">For&nbsp;Years&nbsp;Ended&nbsp;October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Income Available to Common Stockholders</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,758&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,825&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,156&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,717&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,691&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,742&nbsp; </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Effect of Dilutive Securities:</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Warrants/Options</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Weighted Average Diluted Common Shares Outstanding</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,855&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,852&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,921&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Net Income Per Share - Basic</font></p> </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.69&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:03.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.52&nbsp; </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:51.80%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">Net Income Per Share - Diluted</font></p> </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.68&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.46%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:03.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.51&nbsp; </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:72pt;"> <tr> <td valign="bottom" style="width:44.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:47.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31</font></p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">U.S. Federal Statutory Rate</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.66%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:04.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">State and Local Taxes, Net of U.S. Federal Tax Benefit</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.15&nbsp; </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.20&nbsp; </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.66%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.87&nbsp; </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:44.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Permanent differences and Other</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.94&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.78&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)%</font></p> </td> <td valign="bottom" style="width:13.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.44&nbsp; </td> <td valign="bottom" style="width:04.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)%</font></p> </td> </tr> <tr> <td valign="top" style="width:44.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:44.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Actual Rate</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42.09&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43.42&nbsp; </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> <td valign="bottom" style="width:13.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43.43&nbsp; </td> <td valign="bottom" style="width:04.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of October&nbsp;31, 2014 is as follows:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;text-decoration:underline;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.20%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,852&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,540&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,063&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>946&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>904&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,098&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,403&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;text-decoration:underline;">October&nbsp;31, 2014</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:31.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,275&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,463&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">3</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,738&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,393&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,750&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,547&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,763&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,403&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;text-decoration:underline;">October&nbsp;31, 2013</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 80.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:31.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Net&nbsp;of&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Accumulated</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Intangible&nbsp;Asset</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization&nbsp;Period</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Cost</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Amortization</font></p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Customer Lists</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">20</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,738&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,878&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,860&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Covenants Not-to-Compete</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">3</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,131&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,560&nbsp; </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,571&nbsp; </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Patents and Licenses</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">17</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,297&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,408&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,889&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:31.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,166&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,846&nbsp; </td> <td valign="bottom" style="width:03.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,320&nbsp; </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 40.00%;margin-left:162pt;"> <tr> <td valign="bottom" style="width:61.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,623&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,749&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,186&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,368&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>485&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,412&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Less Interest:</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,032&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:61.26%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Present Value of Minimum Lease Payments</font></p> </td> <td valign="bottom" style="width:06.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,380&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 37.00%;margin-left:169.2pt;"> <tr> <td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Property($)</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Equipment($)</font></p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,564&nbsp; </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,122&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>203&nbsp; </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>831&nbsp; </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63&nbsp; </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>689&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>626&nbsp; </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:06.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:26.82%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals:</font></p> </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:28.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,935&nbsp; </td> <td valign="bottom" style="width:06.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611&nbsp; </td> <td valign="bottom" style="width:02.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-size:8pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 53.00%;margin-left:126pt;"> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;">Year Ended October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2015</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>524&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2016</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>557&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2017</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>592&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2018</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,996&nbsp; </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">2019</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:04.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:22.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.88%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:70.94%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Totals</font></p> </td> <td valign="bottom" style="width:04.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:21.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,669&nbsp; </td> <td valign="bottom" style="width:01.88%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Month&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Audited</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fiscal Year</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">1/31/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">4/30/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">7/31/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">10/31/2014</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,270&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>201,366&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222,053&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>227,594&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>832,282&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Profit</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,154&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88,549&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102,443&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106,853&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>369,999&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,954&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,273&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,281&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,758&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income Per Common Share:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.11&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.37&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.66&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.69&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.11&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.37&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.66&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.68&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding &#x2014; Basic [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,700&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,717&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,722&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,728&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,717&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding - Diluted [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,848&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,857&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,864&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,869&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,855&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Month&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Audited</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fiscal Year</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">1/31/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">4/30/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">7/31/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">10/31/2013</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161,256&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>176,452&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185,427&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>192,219&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>715,355&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Profit</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,922&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,676&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,660&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,282&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>322,539&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,665&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,338&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,701&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,120&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,825&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income Per Common Share:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.31&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.41&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.53&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.40&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.31&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.41&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.53&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.40&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.65&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding &#x2014; Basic [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,716&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,698&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,672&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,677&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,691&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding - Diluted [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,912&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,879&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,842&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,844&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,851&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="11" valign="bottom" style="width:47.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Month&nbsp;Ended</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Audited</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Fiscal Year</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">1/31/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">4/30/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">7/31/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">10/31/2012</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2012</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Revenues</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138,793&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>151,443&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160,532&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>163,487&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>614,255&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Gross Profit</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60,118&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67,534&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,279&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,681&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>276,611&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,365&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,306&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,596&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,889&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,156&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Net Income Per Common Share:</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Basic</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.26&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.34&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.45&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.47&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.52&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Diluted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.26&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.45&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.46&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:08.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.51&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding &#x2014; Basic [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,888&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,685&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,695&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,705&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,742&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:36.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Weighted Average Common Shares Outstanding - Diluted [in thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28,041&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,878&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,888&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,906&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,921&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:54pt;"> <tr> <td colspan="9" valign="bottom" style="width:37.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:33.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:21.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercisable</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td colspan="9" valign="bottom" style="width:37.90%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Remaining</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td colspan="9" valign="bottom" style="width:37.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price&nbsp;Range</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Outstanding</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Life</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Price</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Outstanding</font></p> </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Price</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:00.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.00&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41&nbsp; </td> <td valign="bottom" style="width:00.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67&nbsp; </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.42&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12&nbsp; </td> <td valign="bottom" style="width:00.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12&nbsp; </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.00&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.13&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.13&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:01.30%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="top" style="width:07.80%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:00.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">to</font></p> </td> <td valign="bottom" style="width:01.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:06.68%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Per Share</font></p> </td> <td valign="bottom" style="width:02.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.08&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="bottom" style="width:02.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17.50&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td colspan="2" valign="top" style="width:09.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:04.20%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:07.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:12.44%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217&nbsp; </td> <td valign="bottom" style="width:02.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:09.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="border-bottom-style:solid;border-bottom-width:1pt;height:100%;text-indent:0pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:28.8pt;"> <tr> <td valign="bottom" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:39.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2000&nbsp;Plan</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Under&nbsp;Options</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">[In&nbsp;Thousands]</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price&nbsp;Per&nbsp;Share</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2011</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.19 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8 </td> <td valign="bottom" style="width:02.74%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.39 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(52 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.47 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:02.74%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.60 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(44 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:18.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.25 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.72%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.67 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.22%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding and Eligible for Exercise at October&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:02.72%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="4" valign="bottom" style="width:32.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2003&nbsp;Plan</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Shares&nbsp;Under&nbsp;Options</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">[In&nbsp;Thousands]</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Weighted&nbsp;Average&nbsp;</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Exercise&nbsp;Price&nbsp;Per&nbsp;Share</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2011*</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.80 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.13 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.52 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2012**</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.95 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.64 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2013***</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>249 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.02 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Expired</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&#x2014;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.92 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Outstanding at October&nbsp;31, 2014****</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>222 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">$</font></p> </td> <td valign="bottom" style="width:13.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.28 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">*Eligible for exercise at October&nbsp;31, 2011 were 275 at a weighted average exercise price per share of $9.80</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">**Eligible for exercise at October&nbsp;31, 2012 were 244 at a weighted average exercise price per share of $9.95</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">***Eligible for exercise at October&nbsp;31, 2013 were 239 at a weighted average exercise price per share of $9.97</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">****Eligible for exercise at October&nbsp;31, 2014 were 217 at a weighted average exercise price per share of $10.28</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED OCTOBER 31, 2014, 2013 AND 2012</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;">[In Thousands]</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:29.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(b)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(c)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(d)</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(e)</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:29.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(a)</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Description</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Balance&nbsp;at&nbsp;the</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Beginning&nbsp;of&nbsp;a&nbsp;Period</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Charged&nbsp;to&nbsp;Cost&nbsp;and</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Expenses</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Deductions&nbsp;Charged&nbsp;to&nbsp;Valuation</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Allowance&nbsp;Accounts</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Balance&nbsp;at&nbsp;the&nbsp;End</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">of&nbsp;a&nbsp;Period</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Year Ended October&nbsp;31, 2014</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Allowance for Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,261 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133,728 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(139,713 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,276 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,297 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,291,033 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,119,864 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513,466 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-style:italic;text-decoration:underline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431,558 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,424,761 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,259,577 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,742 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Year Ended October&nbsp;31, 2013</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Allowance for Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,274 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>119,161 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(81,174 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,261 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>267,921 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,748,510 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,674,134 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,297 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-style:italic;text-decoration:underline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>319,195 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,867,671 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,755,308 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431,558 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Year Ended October&nbsp;31, 2012</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Allowance for Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>45,220 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,396 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83,342 </td> <td valign="bottom" style="width:02.50%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,274 </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>235,922 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,390,770 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,358,771 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>267,921 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:29.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-style:italic;text-decoration:underline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,142 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,480,166 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,442,113 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">)</font></p> </td> <td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>319,195 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 290000 290000 290000 1600000 1600000 275000 244000 239000 217000 9.80 9.95 9.97 10.28 0 13000 2000 6000 0 0 0 0 60000 295000 52000 259000 6000 249000 222000 5.19 9.80 5.47 9.95 7.67 10.02 7.67 10.28 1 1.1 1.10 3.39 8.52 5.25 7.25 7.92 9.13 3.60 8.64 17.50 7.25 9.13 7.41 17.50 7.25 9.12 7.41 217000 35000 136000 46000 222000 40000 136000 46000 17.50 7.25 9.13 7.41 P3Y29D P1Y P5M1D 17.50 7.25 9.12 7.67 27949900 27707382 27683213 27727644 189767000 45581000 279000 143907000 227247000 40907000 277000 186063000 271595000 39430000 277000 231888000 318902000 39979000 277000 278464000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[9] Capital Transactions</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[A] Preferred Stock and Common Stock -</font><font style="display: inline;"> The Company is authorized to issue an aggregate of 1,666,667 shares of preferred stock, $.10 par value.&nbsp;&nbsp;None was outstanding as of October&nbsp;31, 2014 and October&nbsp;31, 2013.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Holders of the Company&#x2019;s Common Stock are entitled to one vote per share on matters submitted for shareholder vote.&nbsp;&nbsp;Holders are also entitled to receive dividends ratably, if declared.&nbsp;&nbsp;In the event of dissolution or liquidation, holders are entitled to share ratably in all assets remaining after payment of liabilities.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">On December&nbsp;19, 2013 the Company announced that its board of directors has approved a new Stock Repurchase Program authorizing the buyback of up to 2,000,000 shares of its Common Stock in the over-the-counter market at prevailing market prices through October&nbsp;31, 2015.&nbsp;&nbsp;As of October&nbsp;31, 2014 no shares have been repurchased under this plan.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;font-weight:bold;font-style:italic;">[B] Equity Transactions for Services &#x2014;</font><font style="display: inline;"> For the fiscal years ended in 2014, 2013 and 2012, the Company issued 11,431, 11,431 and 11,432 shares of the Company&#x2019;s common stock for employment or consulting services [See Note 11 for common stock options issued for employee and consulting services].</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 23096 11432 11431 11431 23096 11431 11431 8000 23000 31500 44000 4000 46000 6000 27000 33000 482000 482000 290000 290000 290000 290000 290000 290000 227000 226000 1000 263000 263000 259000 259000 285450 -285450 81600 -81600 5193000 5190000 3000 2030000 2030000 1000000 714550 2000000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Subsequent Events &#x2014; The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Accounting for Contractual Credits and Doubtful Accounts</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses.&nbsp;&nbsp;This represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information.&nbsp;&nbsp;In the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.&nbsp;&nbsp;&nbsp;BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer&#x2019;s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 7pt"> <font style="display: inline;font-size:7pt;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:31.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">($)</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">October&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2013</font></p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Contractual Credits/Discounts</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513,466&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>342,297&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Doubtful Accounts</font></p> </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83,276&nbsp; </td> <td valign="bottom" style="width:03.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,261&nbsp; </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:64.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Total Allowance</font></p> </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,742&nbsp; </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:14.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:12pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>431,558&nbsp; </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</font> </p> <p><font size="1"> </font></p> </div> </div> 281142000 235922000 45220000 319195000 267921000 51274000 431558000 342297000 89261000 596742000 513466000 83276000 2480166000 2390770000 89396000 2867671000 2748510000 119161000 3424761000 3291033000 133728000 2442113000 2358771000 83342000 2755308000 2674134000 81174000 3259577000 3119864000 139713000 28041000 27920920 27878000 27888000 27906000 27912000 27851720 27879000 27842000 27844000 27848000 27855125 27857000 27864000 27869000 27888000 27742257 27685000 27695000 27705000 27716000 27690677 27698000 27672000 27677000 27700000 27716608 27717000 27722000 27728000 EX-101.SCH 11 brli-20141031.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Intangible Assets (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Revolving Note Payable - Bank link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Long-Term Debt - Bank link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Capital Transactions link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stock Options and Warrants link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Employment Contracts and Consulting Agreements link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Capitalized Lease Obligations link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Insurance link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Significant Risks and Uncertainties link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 12001 - Disclosure - Health Insurance Plan link:presentationLink link:calculationLink link:definitionLink 12101 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 12201 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 12301 - Disclosure - Selected Quarterly Financial Data link:presentationLink link:calculationLink link:definitionLink 12401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Long-Term Debt - Bank (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stock Options and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Employment Contracts and Consulting Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Capitalized Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 32303 - Disclosure - Selected Quarterly Financial Data (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of Significant Accounting Policies (Details 5) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Revolving Note Payable - Bank (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Long-Term Debt - Bank (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Capital Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stock Options and Warrants (Details 2) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Employment Contracts and Consulting Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Capitalized Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Significant Risks and Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 42001 - Disclosure - Health Insurance Plan (Details) link:presentationLink link:calculationLink link:definitionLink 42101 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 42301 - Disclosure - Selected Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 42401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 brli-20141031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 13 brli-20141031_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT EX-101.PRE 14 brli-20141031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 15 brli-20141031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT GRAPHIC 16 g218581bgi001.gif GRAPHIC begin 644 g218581bgi001.gif M1TE&.#EA<`*(`7<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+`````!P`H@!AP``````````,P``9@``F0``S```_P`S```S,P`S M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9 M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,` M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_ M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;, M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D` M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9 M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_ M_\P``,P`,\P`9LP`F/($.*'$FRI,F3*%.J7,FRIO8,.*'4NV MK-FS:-.J7//JW/'D"-+AME*$(LK5UI>+MF*!0M!!5M=N9S9H^C2"T>WFBAHM&L6V#"#CM@9 M=6=!JRV*OLP;,\7.N07N?AT\8?')R$-V#L`\`(OCG*_,%MF*^97BRYL_]^A< MX75LK:$W_Q34O'GE[[19!)BM?KK%\LU1&Q2=D+Q\;/"9BQ^(.[G_D%<$<-UR MMF$37"NY'9B@@0P2M!J"PC'XX$`3SA>:@1!:&!QYL#G8'F[J95:AA"1&Z""% M!JI'88;8M$?B<0H:%.!UN(UX8(,E\M<=ARO"R.*#+!J(FW,UHIB@-^_V59G7S36<;<=ARJ)Z"8LSDG9FG9K6>@<\SQZ&6; MP@4(9VQF(EF0G`*N:1Z%>0HW&WD/[LAFFV2NV6&`H'679F9X8A;`DW_FF=UV M.AX7(*3"*2HFI0/-J)Z29PHGIJ3JN1@:E`*19]UJHR)8'FCV.?^(ZI8"X0E: MH]6Q]RA^9(;X99;`%A2K098]YZ9^JH(80(KK/;F:9>"IN%R-`C:Y6ZW-7DJG ML7UB>]V,X-G9J9HRJMD9;*I6AJRTGJ7Z:'7+AM=DBVI^2BN]H'FVFKATLOD9 MG4.6AFB+V_$K4'.19A8K9@A^BI^D!\U:;:S5;<J@MZHY\)3#!LAL M?U-.&6RP2QZD+<#W0JEMNVN6UEJIKG98,;V7S7;OS0/?+&J'!,ZW1YW*68F/(MY*/4@RSR.<.5.V,K74- M,ZV[_3HLK\[&'!RJ(@?NKGRY]:PBQ4NGV"&@RVT[+;ZH+YFKH9Y=%ES/#`YL MW^H5]W;]_?R^Z MRS:=;*Y/._*8&M`,";7_O4E2?/A`;ZCK;N M1;^!.&QRU/,/O+(VK0#!341H0UR(O-2P]T91\6:HU]'"H6K-#7 M/HZ%ZS.EDIZA_X!7PNPM:X5PFM'IPM4M),IG8`2!HJI0X\3;26P]+D*B_;`D M,;*5Z3->,V'&9+4LOL'M,W828PF9PRP/[@J$(4S.N?CU)')9ACT"VXYGQ"@J M`=VQ16C:3!TYI2I*C49^FPD;S40U/=&YKE.>L0S2Y-%-ME'-.:K@:ELX!R[I"\O6:TRJO2@?*+G)4J= M2V%VTR-J++FZ.!H3128R#M4N(AXL.<29.#I1,J6)HQLETYK57`@T68)-DC3S M)-L\ICA]!\MQFO.MKSGOC,IS[WR?_/?OKS MGP`-J$`'2M""&O2@"$VH0A?*T(8Z]*$0C:A$)TK1BEKTHAC-J$8WRM&.>O2C M(`VI2$=*TI*:]*0H3:E*5\K2EKKTI3"-J4QG2M.:VO2F.,VI3G?*TY[V!9<' M$D1_4J7.!PG5IT@M2YKR]RLFPFE328TJ6)8TFOM-DDX`3%$CI#6UG M1PM:TG[VM*(MK6I1:]K4LE:SX<1+;^#2YP MAROYSHTN=*I2][K6S2YVMZO=[G+WN]Z5+GH` M-F$*+%M:#C_,;V-+$X48SC>M:8>C?N\3QAO&,9 M"UF>/_Y;D(\,3QT?D\=,AF>23[;D*+>3R$\VLI7;.>5@57G+YW2R,:$,9G1V M&5A?+K,XL3QF+:MY_YQGSE*:WQQ',<>1S'0^9IS_,^<\9\F$_G).@X&%9S\' M*S_Q$6>?#8V<-,%GT%DJ-*/_@VCK*!K2D^9SI3'M'TEG6C+JVO2E/WTR7(X* MT9RNGIM)S1A<"CI1HL9PJEE=F)FM<)65+N??/$WKP#CMD3+"C&N$'5OD++K7 M>VGR(U%NVK7)J(.$TR(4\&]XOD61-WD3NC9@[+E35 MU\2:U:Y+D6[)[P:X2MXT:^4X*I+R9C:XZW+(`54FK.DMU@`5\F^)3_S1W/\T M6\XR#I&#PP5>G'+7&,]UN#(B).(F+\F;YH:2R.F+Y1*Y-[XMO;EP4;*J&$1( MM<;']*8[_>E0C[K4IT[UJEO]ZEC/NM:WSO6N>_WK8`_[U'<.'](`5NQ.$JK* M5X[VJ;L\+K,MNM%C-AK<)H2_V,P[,K-YS;WKO>^`Y[O@_SYXOQL^\(1/_.$+ MC_C%*[[QD&>\Y!\_><=;/O*$3[?9\D,:`NY1.NHVSM[7K?(!70CSE^>[M_4B MFR&-,89KFEG=!EWRG'_$U--V]'3T^FL"RB9(QBD]T`T^?+94;-KUM9B`D+0E M4]V\XK;OB*W]F$HB:5.=E]&.V>6'(;,56"9"OXO_+:/%OS\!^UQNKGWT*^+J M/>:5;A+1:U4]3T#FU^3M+X?^0W"^_F?ZO.#>I"KYY2^D`2'%=Q&K1SWJUW_: M1'#X-Q'MIT":5U7:IT`'&!$/"!G\QX#"`FC?9Q*X)X':!!ZGX7EF,)SH[9^;F@= M&5@1C&B(/]&)[%6')G<>I2*"*U%'DC@5C7)./LAD0&A"`+@2WE>*7E6+C5&) M1W:)4M@2RO8=FMA4LGB&B^&+).:&<*B,$%@L!7>,J?@4BMAICNABYZ$\V2A] M9]),3F<5H^@8S`A7MWB"W=@1WI>.49&`N\:.//4_+_@VK@@3Q0B-33&./6B* M2%5(5^A[PT@9N*B#9G&-3IABG6@L]`B/'-%^!MD5^L@8Y4A3H59VG\&0#;F. MVH:1BP&,.35"*&<36(B/XDB2AS&1,^5HR`A^`RE^)FD8'GE3O<2'+TD;O?20 M9O\1DEAB+R-C'1,"%2DUKACI3(D2X5.?%E22[AR6_0B+I?2.65D5OOEEQFUFP*YAB'_9)IIP2%HLEM@,RIB MU2'\E9W)R(O$J!6,J`"6J`$>J`& MFJ`(NJ`*VJ`,^J`.&J$0.J$2BB%D0J$8&J'TEJ$<6J$=^J$>&J(@NJ#!:1RA=,.7I.XB#;E)H$%9HG M5VE4"F!RZFL@D9OY9&IU:AJG_\&(?@H9;7I.C^I/@!J`:\>%@OI.O`@TH7D/@:&Q.21891\8F/6_@EF'@0I;HGP`*(%(BC2CB( MIUH7B`I/ASF$X%$L;'(QX[$QR-JK9,%[O(&L*\=]0Q.E,491\3F%SMB%5MIJ M?G6#V!IZ[E9IX_2K,B&D3*%LV2A_)L@PRGIN&"*JSFJLP_=Q5?AQTWH58K*N M/J&6\5>"8_6!QB1_D9A?2C@2V2J5GNH3IX:O.J&7+7B.B0BM\M41N!IHGX>" M*5&PB3&I-H&*`520A3J/FYEA)$R5*:6#:E-0XA_S3>BK;%)6J>?4GLCJ; M%2/$).+0]F\3F.[Y8 M.Q-5K!95*[H2+)8^C!;RJVR5ZQ%'B[EN"&@_V[EP"ZQ1C(YS/!C:2Q@L'#8N M/!+YB[3"UE=GG$Y)7%\R'!E`G!>__ZK&K'F.N7:VF@J!=1Q)3"P983P9W(O% M(#'&HDNG/K:D=\B%4/LWB8P7:%F&S2)]DXQ).7N=G%=/;R5 M3_EKIMF_)[R^?!.+\_0V1L4_KS;(9U'*=\&,VX9_$SNZ0FC$D:Q7K:;=7Y2O*]0?.X63"R&J!QHRP;PDDLDO.\^>L M$MT;K>?-M8P0'$O/7+;09-%G[FQDU)N(\ERE:G5]R7NRJAIH^YRD_FRVXW/' M$%AI`7T8U_^GRUIS`]$C0W M?QG\3NLL%6KJ1D"!'V;3/4=7 M=UAU)Z7H>V/;S;[\*C M"=0_(9M\_#J^D2IYRMO@BA,+_E=(7,9L=9#RI$JIQT\E(_Y`>4O MZ^->\2""].1$H9)WJN6A.N**;.8G<;U9O\>9X?A6=_1AWWN<06>=>P>>"3A52_^X7@7[H6J'G;F'HC-Z.:'X7BQ[I M5^'H\6O!EEX6B=X7E;[I[XM.D`[JY3KI=O'II,Z)A-X5HY[J2='I?('JKNX4 MF,X6K3[K1O'GCB'KN+X4M;X6M][K0P'K>\'KPHX4OZX6P7[L0*'KOVCJS$X4 MR9X6RQ[M/4'L>F'LUCX4TX[&FK[M)`[M=*'MX`X4W7X6U5[N.('M>4'NZMX3 MYVX6Z?[N`R?N<^'N]*X3\5X6\Y[OX+?J7('O_JZU`+\5_3[P`6?OF>)5\6#V\47_^=/T,>Y[7\[D]XE?YF_OJ0P_^2A!]&$A^9A_P8M_%9??^26A M^6#!^:*O@G7O%J%_^B)!^OA)\JR_L)^?5JD?^Q_A^H4.^[9OE;7/%JN_^^HX M^U5A^L!?$3I_ZKU?_!F!^ZRN^\H/?LF_PM'__!7!_%Q!_-3?FL)/%;__G_T[ M*.K.[_VJBT[=+_X38?T&'_[F3^?D/_WK[Q#HKQ78__[UX?YG4?[T#__;/Q7S MG__$LO\`@4W@0((%#1Y$F%#A0H8$`PAJ&%'B1(H5+5[$F%'C1HX=/7X$&5+D M2()76I%$F5+E1Q975KZ$&5/F3)HU;=Z$*0@B3IX],3[T&53H4*)%C1[M:!+I MTIXMF3Z%&E7J5*H-!9VLFC4D4*U=O7X%&W:C4K%E(SHUFU;M6K9(=;:%BXUK M7+IU[=[-2!:O6+1[_?X%7/=JX*]S"1]&G'BJ7L52^S:&'%FRS;>3GQJVG%GS MYK%8.1=]_%GT:-($!Y<.BAGU:M:0&;?FZ%EB_VC8M6WCK7S[8JLK`5A@;<6" MQ M?=#EZP<&;XE5N,#>"LV[QY__96[]`P4%\`VB^;`13K:"XHLN00479+!!!Q^$ M,$())Z2P0@LOQ#!##3?DL$,//P0Q1!%'S+`]_8(#4#P6Z`O`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`+'UUS?U-<^HT`G M='$SFT#H!S.J7]@@XE).IKVL()%7%5K@42HTN?'.!(`D/QI7HV8IO MP;+>\TC%O_CYCV81J]]<#*V5T&]B`QK.8P*=*Z$P1/Z!XP+ M9`J*WC,?"%)N>Q*4&[@\A3G%746#:6QC??@V.I?HQ%M18U:,0/@BK-S-28'; MFR`)I"K(\0]N,Q3*W=S6.,QAL6]P9,IS8+0]`+V,<)I452)AY!)-7O!D+.KD M5."6(K$1+8E)/)&OPK,37Y&O.^&IBAUU@I5=H@IRW2F<+FD)S"O]BIA/F64O M<^$9SSE.4]ZUM.>]\1G/O6Y3W[VTY__!&A`!3I0@A;4H`=%:$(5 MNE"&-M2A#X5H1"4Z48I6U*(7Q6A&-;I1CG;4HQ\%:4A%.E*2EM2D)T5I2E6Z M4I:VU*4OA6E,93I3FM;4IC?%:4YUNE.>]M2G/P5J4(4Z5*(6U:A'16I2E;I4 MIC;5J4^%:E2E.E6J5M6J5\7J41-TE>APM99=W6I8P3K6KY;5JV<5JUG3BE:R MLE6M;5UK7.$ZU[?6U:UWE:M=\XI7NO)5KWW=:V`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`>'F$40US;*N5WEX2CLO_0".0@]6>7V MMCO>3HJVNG,-Y87NV6;)G*64$PST91;[ROD&&KF[1:H/BRK"S[8MN._TEO^R M^-L2MK6^/ERVCA,ZS%H&]WAP?F[.@1G$3HI/E*.C%&?/D.CA:76YWSXO0`\, MQ#@;>D*HQ^M]Y=K9],GZ%44]-:V]',]='_39>VQR$ MXZ;V1E%_7;FJE[];/IXK,N'?UNY^&=G<=\YZC6U]\W$6 M;G*#RP[_[('M.&&ZXE?(!:YEGA.DU>VC]:]/*3PFMOG@WK.[R!#S>(,PYVSU9_(3ZG"%[M`K!`?U?75O'Z(,S MR<`1K*Z*V>SB;;&FFB4.VP:@F M'7P;7@(:*22T]X"LM<,F,[NU>,&S\,"9*@&]8JK"3-N7AL$8_VIJIM_C.C"L M"#L3L0$QWB4QWFDQWJTQWO$QWS4QWWDQW[TQW\$R(`4R($DR((T MR(-$R(142(H````0B(9\2(?$!HB<2%J)I,B+M,B,C,B-K$B.Q$B/U,B.%,F/ M',F0),F3-,F4!,F5+$F61$F75,F6E,F7G,F8I,F;M,FQ$F?U,F> 9%,J?',J@),JC-,JD!,JE+$JF1$J6#`@`.S\_ ` end XML 17 R39.htm IDEA: XBRL DOCUMENT v2.4.1.9
Employment Contracts and Consulting Agreements (Tables)
 12 Months Ended
Oct. 31, 2014
Employment Contracts and Consulting Agreements  
Schedule of aggregate minimum commitment under employment contracts and agreements, excluding commissions or consumer price index increases

 

                                                                                                                                                         

October 31

 

Employees
and
Consultants

 

2015

 

$
4,582 

 

2016

 
3,706 

 

2017

 
3,706 

 

2018

 
1,701 

 

2019

 

—

 

Thereafter

 

—

 

 

 

 

 

Total

 

$
13,695 

 

 

XML 18 R54.htm IDEA: XBRL DOCUMENT v2.4.1.9
Capital Transactions (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Vote
Oct. 31, 2013
Oct. 31, 2012
Dec. 19, 2013
Dec. 06, 2012
Nov. 11, 2011
Capital Transactions            
Preferred Stock, Authorized shares, including Series A Junior Preferred Stock 1,666,667brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior 1,666,667brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior        
Preferred Stock, Par Value (in dollars per share) $ 0.10us-gaap_PreferredStockParOrStatedValuePerShare $ 0.10us-gaap_PreferredStockParOrStatedValuePerShare        
Outstanding shares of preferred stock 0us-gaap_PreferredStockSharesOutstanding 0us-gaap_PreferredStockSharesOutstanding        
Number of votes per share for holders of common stock 1brli_CommonStockNumberOfVotesPerShare          
Number of shares of common stock authorized to be repurchased       2,000,000us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased 714,550us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased 1,000,000us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
Number of shares of common stock repurchased   81,600us-gaap_StockRepurchasedAndRetiredDuringPeriodShares 285,450us-gaap_StockRepurchasedAndRetiredDuringPeriodShares      
Cost of shares of common stock repurchased   $ 2,030us-gaap_StockRepurchasedAndRetiredDuringPeriodValue $ 5,193us-gaap_StockRepurchasedAndRetiredDuringPeriodValue      
Number of shares of common stock issued for employment or consulting services 11,431us-gaap_StockIssuedDuringPeriodSharesIssuedForServices 11,431us-gaap_StockIssuedDuringPeriodSharesIssuedForServices 11,432us-gaap_StockIssuedDuringPeriodSharesIssuedForServices      
XML 19 R48.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 5) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets      
Impairment loss $ 0brli_ImpairmentOfIntangibleAssetsAndOtherLongLivedAssets $ 0brli_ImpairmentOfIntangibleAssetsAndOtherLongLivedAssets $ 0brli_ImpairmentOfIntangibleAssetsAndOtherLongLivedAssets
Advertising Costs      
Advertising Costs 3,188us-gaap_AdvertisingExpense 3,200us-gaap_AdvertisingExpense 2,366us-gaap_AdvertisingExpense
Equity method investment      
Share of undistributed loss 83us-gaap_IncomeLossFromEquityMethodInvestments 450us-gaap_IncomeLossFromEquityMethodInvestments 323us-gaap_IncomeLossFromEquityMethodInvestments
IncellDx Inc      
Equity method investment      
Share of undistributed loss $ 83us-gaap_IncomeLossFromEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= brli_IncellDxIncMember		    
EXCEL 20 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#8O%`R5`(``%HH```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,VL&.VC`4!=!]I?Y#Y&U% M3.PXG5:$64S;93M2IQ_@)@\2D=B1[9G"W]<),Z@:41`J4N^&")*\=XG$V7`7 MM]N^2Y[(^=::DF7IG"5D*ENW9EVR'P]?9CQH_W21QUGB5W^PO'7273P]"UE0XQ*7\R]:LML^<-:;QS MNL8W[>#?Q1B,']TPGOG[@N?[OL5'X]J:DGOMPE?=QQA\V_%?UFU^6KM)3P\Y MDM*N5FU%M:T>^_@$4C\XTK5OB$+?I=,Q[75K7G*?V#]=[/ETR*X<9/Q^T^`+ M+3Z[__<*PVWCT; MXB!RH:5#W>U8;>RP,?;H+E_XJK=&8U.OIOK(;CXU`Y>_`0``__\#`%!+`P04 M``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D M[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6 M#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P M4P>J/OH\^;*W-$UO>"_F?6*73HQ` MGA,[RW;E0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;',@H@0!**```0`````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````"\FLUN MVD`4A?>5^@[6[(NY\T=2Q631JE*V;?H`EAFP%;"19_K#VW=$6X=(S2D+ZVR0 M/(CQU=QSSG<-W-W_/.R+[V&,W=!72A9+582^&39=OZO4U\=/[VY4$5/=;^K] MT(=*G4)4]^NW;^X^AWV=\H=BVQUCD7?I8Z7:E([ORS(V;3C4<3$<0Y_?V0[C MH4[YAU,NE+\?+/=3ZQ9[%PZ92X\-&>U4\GH[YUO_??-ANNR9\ M')IOA]"G?]RC_#&,3[$-(>5-ZW$74J6FI5B>W]%^D6M6Y2OE"+L<0>5832[' M:EC.BEW."I7C#;D<;V`YV4OS23EECX6\X1\9GR_+\RM4#+M#L$&K6=W4U/OF M0UMW_?.I3$NH+VP/00L).^\$Y]WMG)J=LO:Y0]/2W_B]1:V2604SW?OU<@2: M25OVZ5AT.H:M9`.E;-A98V#8V#S;S!>_5VC'+E&SK&.7XU`YCLU*!UGI9F7E M%?G]? M(X"SM8*EPB:F@\1DVQJZ6MB`$@@H80-*(*`TFP@:$L'0I0.U8]@N-]#FEDT$ M"XG@9HW@:QZIX&#LV<[RV%GLT4_#T<^R$6$A(AQ[FG!XFF!#PD-(K&;53FSK M,6R^I#'_!G%M+3L>GI(#UEU@2\8K802$_#SD`#0]"RZ6DA/1V;G@[2T[.UXZ%V/!L2 M'D*"+ATT6K`S$$:@L/$I$)_"QJ=@?+)[96"S#%O'!D<@.W,&PO M=V]R:V)O;VLN>&ULE)A=;^(Z$(;OCW3^`\K]6?)%"E7;%06J(K'`%MJ]M-Q@ MP&KB%JQ:-$B5OK(%+K^]W??]WL$_WVFB1O+1!0Z:VU-69W MW6ZGX5;$//V6[(2"7]:)CKF!H=ZTTYT6?)5NA3!QU'9M.VC'7"KKJ'"M_X]& MLE[+4`R3,(N%,D<1+2)N(/QT*W>I=7>SEI%X.6;4XKO=E,<0]T=DM2*>FM%* M&K&ZM3HP3/:B](7.=O>9C.#7GF=[5OONE.1SS?X72'DXC#P+8%S_]DBNSA=]MVSY]]RCD9FN^ MO@3Y-M(O*@CK%)\M5:3W51$&.\5&RDAS8&-UK+Y,8`OSJH\A,\=JZ6L)?^CQ MRLD#QRJ#V70QFXR'_>5HR.[[D_YT,&*+Q]%HN4`2`2!QTG#_0(/-.9+QD$I1 M[(N1+)80T(_1=+E@LP'F\IPZ!=)*HS5+HF`W%JR%SH85. M!70(G$^Y58@5K)SGO]1D6>SY+ZXA\]+& M=3%X#B%O%.^BY)!CP@:),AJ*EA92,$HS%$L7D^<0]`;'*LC?L`<3P5/!9J^1 MW!SM&\M@`AV"X"")8VGR<$Y1&"@/'%RRM"==C"/X;\7N)M)\KHV7QO2YA+XQ MY`O%"_$&=#%T+H$.]^J33-^.,3^#AC9"X!KQ]"KZ80,]0^%1)M@/J'BFX?RJ[#UFSR7L/0H>F2V<)I^)LWG$X=`^G2A=C-_Q,,2V M=T1'0)<+)=;25*?W,'DN(6\J]E\&E_L&>)<"LPM)$CT,GDO`6XA(A'GG_\R@ M]86.#NQ!*MA'"3TY1-GT,'DN(6\Q>!P-GRUA'CW"8[,0)',6PI1ZA-+Z4P%L#AP:X];#D'H$4G(Z MU"A@8#T"+/7W&@F,+%RE*HV-+;IF,@;6(WY)O99*P&4-N;U'J+WLN;D6VA3' MQMQZA-MFX\6<.#8FUR/D-EHO*X6$T?4)NHWF6Q;"Z/H4W<:>+.>&V?4)NQ>O M5G!',!SEYI=2(_`V-Q/,/3637TJ-,-PL!'//0J7,",G-0C#W).38N#%]@G6S M$LP]*?FX/V%0::YF(9A[%L)=ZA.V+SA.OF4RPI;CV*6("-K4@=##(-*")^-7KII%GU0+2JV MP0Y!N,8&:T+!]'8HO1>OGGE`N*J8W0YEMU$'.T4'DP*#2FV:[12?E@X\O9R? M)#H$WF8[+854JC.!M]E.L5"`(X)!);?S;;9NM^$YZIQ.0+@]W^[H)@?X8(%! M9=WFZRU.P($',A0$(;?VIEF33(#-%P:5@&IOG'4R&-Z`PMMX/&%6`DPO#"KQ M--\9<8$"3"\,0*A=N"F\[0EY%,)KJ/RC>(_C=X+CTTG[ZTW&PO=V]R:W-H965T&ULG%A=;YPX%'U?:?\#XCT#-MA`E$E50-VMM)56J_UX)@PS@SH, M(R!-^^_W&CMCWTN3DN8AR>#CR[F?Q^.[=U^[D_>E&<:V/V]]M@E]KSG7_:X] M'[;^/W]_N$E];YRJ\ZXZ]>=FZW]K1O_=_:^_W#WUP^?QV#23!Q;.X]8_3M/E M-@C&^MATU;CI+\T95O;]T%43?!P.P7@9FFHW;^I.`0]#&715>_:UA=MAC8U^ MOV_KINSKQZXY3]K(T)RJ"?B/Q_8R/EOKZC7FNFKX_'BYJ?ON`B8>VE,[?9N- M^EY7WWX\G/NA>CB!WU]97-7/MNW9;\LP/[N_F`/W;-D^C\[\W'ONGWX9V]T=[;B#:D">5@8>^ M_ZR@'W?J$6P.%KL_S!GX<_!VS;YZ/$U_]4^_-^WA.$&Z!7BD'+O=?2N;L8:( M@ID-%\I2W9^``/SVNE:5!D2D^CK_?6IWTW'K1W(CDC!B`/<>FG'ZT"J3OE<_ MCE/?_:=!S)C21K@Q$@-[LPZ/7M\<:"*S7V4U5?=W0__D0;'`J\9+I4J/W8+! M9X?TZZ\NON0AN*:,O%=69EM`?H2T?+E/P[O@"T2R-I!<0Z`1KA"&$<4S0H5- M62V=!P'0O7(&;RGG"%+Y_20\4U2;"$5"(%]".*'X'42*(>42DEHKR(WH9]Q0 MFZ!JG#"F$6:0:T@\UXR*8T$?E,X#Q`@*P`WLZP%5X*T/[EX3FL:$B89(71`1 MYTXDY@P7+B!A(A+$0ND")(NY$-=7(.;0/>N9*S")H34[$\LUQ(DA?5`Z#Q`3 M^18F"DQB**\.:B8:DLPQ9)E@A&F!UH7(:#VB]8B%MN@1[>0MM!68T$X(;0W1 MM'DH&>55N`"61"PB%DH$B"7/7F@CI:W.!'N]:!68,"NFN"YF&MM00 M;0:S=GW$9S0FGBVT05G<^IHYI)K3F588*QH193RE?5!B1)3(V+J'Z2M965TP M3(N0.^8RVT*Z10W&D),9_.#,%!C!N8@(HD0(GDC)[%LP?24PZ^EK.7+UPNDC M0U]CG&''Z)/2?8+I*"U93TE5>NY:V6#!KRV;T:2 MGS.-<:<)?5*Z&$Q'2=!Z.EJP4"AMFYA*<$6-NU)L(NFN,QF25)0,K<[5:+UB-OR0.'F;Y+"&8U9L]"VMHZW M`6G:-XDM.QUNO,P825=)UN5+Q"'G;IVLFQQ<[:(.$(:Y`9GI'0O"L##K)B\) MK1>TG4GGF((CKT1L=:%S+7ENH;.0I#PW($T\#3-).K/``!;2UBT1((D%L\YA M\D0Z7Q]X7'^'P^1M7DW9:)`F#P,O).U0&"L&('A"W"\Q@$?25B8F_R;!5-&\MD63/:B@'`=PHRSTML@3/Q4N1_2C'Y4C&9<[@W&="@3'_1 MW,A%`LCZP@6\+FQ^KS:UTY+[03C#=KE\Q\UZ%- MP4O6[-?NC_^>/BU<1\B\*?.*-W3MOE'A?M[\^IXH#K3.Q8RWM(&3'>_J7,+7;N^)MJ-YJ2_5E1?X?NS5.6M<9%AV]W#PW8X5 M])$7QYHV$DDZ6N42](L#:\4[6UW<0U?GW?.Q_53PN@6*+:N8?-.DKE,7RZ_[ MAG?YMH*X7\D\+]ZY]9<+^IH5'1=\)V=`YZ'0RYA3+_6`:;,J&42@TNYT=+=V MOY!E1A:NMUGI!/UD]"2,SXXX\--?'2O_80V%;$.=5`6VG#\KZ-=2F>"R=W'[ M25?@>^>4=)BS57KD240JH!"2,O'`4$DZLX7=4E?!;2` M*KQLDG2^\EX@4`,-/Z`"6Q$]@%B,4`\T#>(A/"FBU27;)%!,M#K.!X0 MHOM%&S+#8`F`S)@"KF='@2&+1N1)E(X\(V:NZZI2FAD&R_-\BF<%7KL0Q)#S M,!XY1DBLBT:B.)R/JV(!PC!*S](M8="O]Z=$@4?"QK5`2**%+=(T&O539I[' M21KY0V"6K'B*+`4>R3IW(+8(0E!6'(>+T7EFG4?Q_#?92J;(4F!;%L0[A(NZ M$&,TD&&P$J)>/<8#?KUU%?A6ZR+&\&P8+,_I%,\*;,=\T;H(P5(D2;P8=ZYY M'D=)?#ZW9!$8;_=G1*-M84%T9L9B]"`C)Z;%]CX:N-?K07!&7I\E/T MQ?:N!MS=W4!P'%Z=)ST&JQ(&)!H]UYD%")(T.3_8MC0U`0UI=[Z)<&Z:$I-T M//.(,5QQSIL66\6D>4MP6-XH#X+,\A@6V_NDH:H6CUO/3(_!\@2QGXQRD]D` M$@=DVM$F#E5Q.5JC\P-P_-0@R$V-8;.^3YB?!67BC+,;`[)O"L-C>)\U0 MV#]OEP4Q^!H._/EX,U%+K"+IW].+P'A-HS1<47&5JVFWIQFM*N$4_*C6SP!> MHX,55^,'LH1]!U;2D3V#E5G;O>$`-M8VW]-O>;=GC7`JN@-*?Y9`OW6X\^(7 MR5N]8&VYA%U5?SS`;Q,*^XP_`_".<_G^16W5PZ^=S?\```#__P,`4$L#!!0` M!@`(````(0#^8*!+:`8``%@<```9````>&PO=V]R:W-H965T?O MIR^IZ[1=?M[EI_K,-NY/UKI?'W_]Y>&];E[:(V.=`Q'.[<8]=MUE[7EM<615 MWB[J"SN#9U\W5=[!Q^;@M9>&Y3NQJ#IY@>\OO2HOSRY&6#=38M3[?5DP6A>O M%3MW&*1AI[P#_NVQO+1]M*J8$J[*FY?7RY>BKBX0XKD\E=U/$=1UJF+]_7"N MF_SY!/O^(%%>]+'%!RM\519-W=;[;@'A/"1J[WGEK3R(]/BP*V$'/.U.P_8; M]QM9TW#E>H\/(D'_ENR]5?[OM,?Z_;>FW/U1GAED&\Z)G\!S7;]PZ/<=-\%B MSUK])$[@S\;9L7W^>NK^JM]_9^7AV,%QQ[`COK'U[B=E;0$9A3"+(.:1BOH$ M!."O4Y6\-"`C^8?X][W<=<>-&RX7<>*'!.#.,VN[IY*'=)WBM>WJZC\$$1D* M@P0R2`3LI1],MQ=[2$3LB^9=_OC0U.\.%`M\57O)>>F1-03L-X1?/VSQLQW" MUGB0;SR*B`7D6SB6M\=DE3YX;Y#*0F*VB(%.&#!$1V0]@N>-AZ6*P0.^`VG8 MKDDZA+,(U^DP,PT4,6@48&C5S-ZFPH';US8YW"206)20HM\FFLPARL$ZT61IGCQB)-$5,7HL0WJ-TZM`:#7`IZFA6??;GR_2^R?UK_&Q?Q"C](]IH(I!H[32*=WN M'P[F6>0Z&?@DUG.P1;=,8!I?Q4.0S-!])4D5@\:)@"2J>;I-2J`55D:A;Z5? MTHHCH[XRZ5=XJ1:=&-=UY0#O$,,I,*3+**@M0;\DYEL-+/TJ,5PA+#HQKMW3 MB:'2#\2,0;`EZ)>E;BI'-KBOXZY?P*\@ZKPC7+:G\T*1'WB9#2JB;5S)RS=: M,!O<5UZ?30W"57HZ+]1TV.0P-^#>8Q2_"+EQ\313W[Q%9-*OGN9GHX)?S&:P M0R57V=DB+$+V[,B("NN`$1F6@)':XP(]/95WV"@JWF*?6MFNM5 M_4H^M>:KC`3%-NS0`M$!9'4P%VF%_1W)0TE76=LW+((@V2E):,A/=L=/I=^N MQW!!HXTY@7;(D"+F&06*,O$SS!VEB[(5*_PC76:,DZ$>)>H;&(-M*$'*- M(VN>Z/YT::RGTC_"%8?R:'TC^30F#6W:S/$&0-_A[M-D)J/#1*D MY@Z772U4Q>BYFS5C0I1_^#OPL752@J[?GED6JEIT/L8RZ'F'\DA^I4?!%2L>;`,G8ZM4Y1O_*7-P1^F1NL^&)I"R^6Q%L8 M;W#`>YU+?F`_\N90GEOGQ/:PU%\DT)L-OAG"#UU]$:\=GNL.WNB(_Q[A#1Z# MW^?]!8#W==WU'WBC#^\$'_\'``#__P,`4$L#!!0`!@`(````(0#$S0')9@0` M`,P1```9````>&PO=V]R:W-H965T*CGW=VU;3\-0YCM>9C(0-:_@SD8T9=;"9;,-9=WP M;*V-RGT81]$H++.B\M'#M+G%A]ALBIP_B?RUY%6+3AJ^SUK@+W=%+8_>ROP6 M=V76O+S6#[DH:W"Q*O9%^Z&=^EZ93[]M*]%DJSWL^YT-LOSH6U]TW)=%W@@I M-FT`[D(DVMWS8_@8@J?%;%W`#E3:O89OYOY7-DWCL1\N9CI!_Q;\(*WOGMR) MP^]-L?ZSJ#AD&^JD*K`2XD5!OZW5$AB''>MG78&_&V_--]GKOOU''/[@Q7;7 M0KF'L".UL>GZXXG+'#(*;H)XJ#SE8@\$X+]7%JHU("/9N_X\%.MV-_>343`< M1PD#N+?BLGTNE$O?RU]E*\K_$,2,*W02&R?P:9RP43"(A^/)/5X2XP4^CU[` MX74*(6Y'9^$:ILP.9$"39S/R5EY%***:,+$,+H`F)R@C@< M(54VQ^OI4F!(J^]9Z3K[U2E=(F:@VT7E.+46G,B#>R(K\-R';5F1'T\[PLB( M&>LR)DDRB=S[*=X?Z?OQB"5G>X<73,'M&5%@PHN1N$O$6!FQ%IS(HWLB*W!? M+1!C1;86G,AC-[(:G@&PO-X-RHCNG8S&$C%8D\$PBDAN4KRO&3J$U-/J[FE6 M1I10[#;!$C&3B>Z"*!BZMU.\W>7S^#-\E!'ED[@!EXBQ2F0M.!EA(&9V2J[7 M1J/[VL.`K.#VBAN=R&M/=%1$9US9@.R<(0BF\CS3C-;C!*+:RI3$61W20P@% MT24THH009'HC"52[6G_);P^DF5)-`D9%/[!MY6=*]"QVMPV4MJ(-0\7?@.RB M?::P3"F>Q:(G1ZB/X.QT4A,AI1(8\99\)*OLI1=569$)B\DQ9&I`](9^):GR7J&IT MGZ@:D!7=7G$*$M\EJAI-]MX150-R1#6F4W("45&-E0):(WO;E&@K0BPF4KDT M(#LM*+?=68V)>%[O4XWN+8HED3@EQNQ"]+M$,T;1=!6"3HD!?2Y;!G"!#-'0 M&PMR04MC^N*A3GM'J30IL5;W9>N M3D$0="X(E2WCQ2H(GL?QQ%EG6_Y7UFR+2GI[OH''912,(7D-GL;QHA6U/L:M M1`NG:/UU![^:<#@2P6NG[VV$:(\7:@Y/O\,L_@<``/__`P!02P,$%``&``@` M```A`&W&=C$G!```ZPX``!D```!X;"]W;W)K&UL ME%==;Z,X%'T?:?\#XKV`(1`2)1E-Z'9WI%UI-)K9?2;@)*B`$7::]M_/MX_MQ;&\^OU:E]8);6I!Z:R/'LRU<9R0OZM/6_OGCZ2&V+X\-B+-B;,&I;5;;^>JI)FQY*6/%Z+G)VW M=A`YX=(+$,"M`Z;LJ>`F;2N[4$:J_R5(K&@PXG=&X-D90:&S\,-E/,=*T%F! M9V\%#-ZFX,KEB.@\IBS=;5IRM:#D@#!M4E[`:`T&>5@"".[[88%X\#E?^"0Q M%=`4)M0Q28_AB0,^`RE8SGQ2?)).RE_J_O932.Q' M.B:1&&C[86W^@-!(0K14DK.9@ MR*FRGMB/AQ5),A*S&-@ERH"V9BCU^]?,P5L;XCE$,O97AF>)43S+@4@451!% M(U[C$>D\>-4N8.;M'/!)1B0"S^`C,0H?94!CL-09W/;,P3P2O%-\#QEML)>? M%:?]`,>'2F=I#/C.I'3N;08%0.MF55LS,V:9="54YC(YY)9^*=>!D">^?1J%=:E9$I M=DB5U\AHMV3X.JFF68*+>L55F$SVWPZD-I><]CN9\0WEO6\+%K-^MP=W((63 M.J)5BS]+>`5:%[NI\'8@U;L4W@_/)/+.(4_5%6Y/.,%E2:V,7/A]`D$'#*/R MKI/X:SC;\>P.'^"JT:0G_&_:GHJ:6B4^PE3/64*SM_*R(E\8:<09]T`87#+$ MSS-<*C$<*3T'P$="6/_"'0S7U-TO````__\#`%!+`P04``8`"````"$`0V(3 M]JH%```9%@``&0```'AL+W=OG>D76FUVLLS39P$=0@1T+>_W[++25PFW4-V'F:Z M[>/BU*DJEZ?NOKPU>^=%='W='E8N\P+7$8>J7=>'[HZ_5`>UN6^ M/8B5^RYZ]\O]SS_=O;;=4[\38G#`PJ%?N;MA."Y]OZ]VHBE[KSV*`^QLVJXI M!_BUV_K]L1/E6AUJ]CX/@MAOROK@HH5E-\5&N]G4E2C:ZKD1AP&-=&)?#L"_ MW]7'_F2MJ::8:\KNZ?DXJ]KF""8>ZWT]O"NCKM-4R^_;0]N5CWOP^XU%976R MK7X9F6_JJFO[=C-X8,Y'HF.?%_["!TOW=^L:/)"R.YW8K-RO;%GPQ/7O[Y1` M_]3BM3=^=OI=^_I+5Z]_JP\"U(8XR0@\MNV3A'Y?RR4X[(]./Z@(_-$Y:[$I MG_?#G^WKKZ+>[@8(]QP\DHXMU^^%Z"M0%,QX?"XM5>T>",#?3E/+U`!%RC?U M[VN]'G8K-XR]>1*$#.#.H^B'AUJ:=)WJN1_:YE\$,6T*C7!M)`+V>A^6/C_L M(Q'E5U$.Y?U=U[XZD"SPJ?Y8RM1C2S!X<@@_?W;Q(P_!-6GDJ[2B;`'Y'L+R MP*A"+R*PC+SV(,2?G9"G$C'+L1_]`->0C2QI`Q#1=G^TJW##&1RAHI M9&XO%,8"H00I<+NR\M#*!;_/D4VCP**$F#15R1%XX9SNYS_8+S[>)_RABF[G M+P_9_*WBQ;DS[?9)<8J!CDY$'B,68""`%(O30+S#S,M$A?C_^.B M/&2[:!'*$*-=7'B122<(HF^ST(H9.3#C7I(035+3!2QH>B*ROQ&:WR!.)]3I MSRM=@FUG+>X98L[Y&/'`*J+<1H01,]VS[HYB#`]-`2]B$[_DP\"X?C_W2X)I MZ8>1=?MDB#%*WUXHC`5"97$+%0FF$H>1)6"&F%A5/)\GX44"K!!S/TSYPKH2 M"G,?SB^B<_H1W@RNS.D:*C1EGD87RWA_:E"BJ"=0F.?/`4%L&A^230JN^QNTZEC+S2I,UNUC"$(N857KC<*F//$*L^"`G@87ZJ` MDI>-;#IY;'LF^32*:7UE\DD-UPOFS.6SNO@^V2P^.$D)RRXTG3#V+`CU^75C M2J$O#`2916>O%,Q8H7QDZYC.!QN-*6`8VZ\5AB`=_3B.K.#F%+#@B97ZA08H MCRA;V3^FL\5N0]E>JD"KAR#--AAU8F;NLY2-N.+^%:ZRA4SGB@V'GCLLE*8&%+O M_*;>I-!4O32R(I5I$%[OB1W(7&^CN#.6!*,BHH@P-AHOY7Y3:Y(C&"ORZ>A] MK4%(CL>A57.YWC>5/?4K.5@B4PS9$(Q(R]G+A#$&MA&SEM+1TYLC"%DR9CR= M=?R-7J0KW5BA+&_J3C!\&VDX'U4/@O!_!K'=O')MPY00#Z@5)(<3.IQD-:+; MBESL][U3M<]R^L;@L7E>QIPM(>_#.U1S8T>VP%&&PO=V]R:W-H965T M>NN_B& MP?(SJ3.VH!?2P,B1MG76P6-[,MBE)5G1&]6582V7KE%G9:,+#W[[$1_T>"QS M$M'\6I.F$TY:4F4=Q,_.Y86-WNK\(^[JK'VZ7K[DM+Z`BT-9E=UK[U37ZMS_ M?FIHFQTJT/UBVED^^NX?9N[K,F\IH\=N`>X,$>A<\\;8&.!IORU*4,#3KK7D MN-._F7YJ6KJQW_8)^J^E_;V71G7?ZRETXZ^7*!+IV(*Q+2NY2U_(KZVC]KR"9@ROAQ!J< MV!#],`[0!XWA-7T$KF2\L#S'=-Q/A+`>O,#O%,)'=1@B)WV*HZS+]MN6WC28 MMZ":73*^"DP?'(^Y%9F8LOVS9$.6N9-OW$OO"_+(8(8\[T']'S\FP+4ASXZK%"03'%KK4L?#.6#2.C:LSQD""@50" M%$V\JT('QN.2<2.L#4V\0'"$-ERQ<6R,/\)`C($$`ZD$*((V_T<0-\*"T*X> M",[;1`HQ$&$@%H!8GM!E\H]:Y41FK$W;<1`AE0DFRNL?*,& M&0PD2?J`"&6>Z6)=D4*`ULC&PN*9TV2&I#*BBN5]P:>GK2FZ"7E']5R4\&`@ MR6*%F=LO4VNY0A;18"'&'7.#SO%XYC&9(:F,J$KY"8^4/CXZH'^?36@7K<)@ M(`VGAVFO$"%\1(AF!'0^Q0/A+9G)#.%W#1YKSQ'2Q=5!]+4U:4\D)%7%M)Q> M^;6`YWE"Q94E,'UH+F$W07AH^="4S/'(\J$WF>.QY4.+,L<3RX=.98ZGE@\- M"^#&]&*XJ5RR$_D]:T]EP[2*'"'DY6(-1V8K[CKBH:.7OA4]T`[N*/W?,]Q) M"?3)RP60CY1VXP-_P73+W?\'``#__P,`4$L#!!0`!@`(````(0`*UH]`10,` M`$D*```9````>&PO=V]R:W-H965TI6:9.F:1_/)G&(U22.;%/:?[]K&X+M4$9?@-Q[?#CWW!O; MB_O7NO)>,..$-DL_&H2^AYN,YJ39+?W?OQ[OIK['!6IR5-$&+_TWS/W[U>=/ MBP-ES[S$6'C`T/"E7PK1SH.`9R6N$1_0%C>0*2BKD8!'M@MXRS#*U:*Z"H9A M.`EJ1!I?,\S9+1RT*$B&4YKM:]P(3<)PA03HYR5I^8FMSFZAJQ%[WK=W&:U; MH-B2BH@W1>I[=39_VC64H6T%=;]&(Y2=N-5#C[XF&:.<%F(`=($6VJ]Y%LP" M8%HM<@(52-L]AHNE_Q#-TRCR@]5"&?2'X`,W?GN\I(B3[,"6 MTF<)?OF*R*P6T>PP5R<+F^5N*>0:.`LU@ M.)9,&:U``'QZ-9&C`8Z@5_5](+DHEWX\&8R3,(X`[FTQ%X]$4OI>MN>"UG\U M2%74D0R/)"-0?\Q#Z/KB0`M1=:5(H-6"T8,'PP)_Q5LD1R^:`^&I(/WW78GO M50BE29('R:*X0#R'MKRLDEFX"%[`RNR(66L,O`D=)K(1FQ-"^B9I4R,0@-Y. M-)3KBHZAEY>[<-(H%]D:AXDM8'T!8B,V%Q!3&Y+V(=-A!['*B/MEC-X=IE,9 M.E#O5U'DXEKJ<9, MU$PX$[&YDDLOYRRM8-7M6B78M6WBV*8QAFUN(#4"EI3)1Z1(L&-;Y$K1F$39 M%D=39\8V5AK.`+N0U$P/X\F9W!*=?$2T!#O^S9SW=ZTQAG]N(#4"EA1Y/AJ[ MT/6QDV#'O]GY#=-O@,:,E'_3V+9G8R9'8]<\,QL/SVLMP;./")9@5_"95PO6 M&,,[-Y`:`4M*!#O?[>8I]/\:>009:GJ1U(S8>N2N?7,SX;3NF^-V\PC2NTBO MGX*KB7D;W\K2.8$ZZJ+Y)K.5-0MT%N@0< MY"W:X>^([4C#O0H7L#0<)+`I,'T5T`^"MNJRV1NANV MB]I2V@*[0%&TN\^T1-M")%$0Z3CY^QV*OI!4FKB;A\0:'Q[.F3DB)XN/SVWC M/-&!UZQ;NFCFNP[M2E;5W7[I_OSQ\"%U'2Y(5Y&&=73IOE#N?ES]^QXO#[0E?,9ZVL$W.S:T1,#CL/=X/U!2C8O:QL.^'WLM MJ3M7,SC8;E>7-&?EL:6=4"0#;8B`_/FA[OF%K2WOH6O)\'CL/Y2L[8%B M6S>U>!E)7::C$6Z)^:GKCVV>$'=OH\U-5?=4>AVM`GV8$M M8X\2^K62(5CL358_C!WX-C@5W9%C([ZSTQ=:[P\"VAV!(BEL7KWDE)=04:"9 MX4@RE:R!!."WT];2&E`1\CS^/=65."S=()Y%B1\@@#M;RL5#+2E=ISQRP=I_ M%0B=J10)/I/`BC,)2'YGL:<2&77E1)#58F`G!\P"6_&>2.NA.1!>!*GMKQ)_ MI1"D29)/DF7D@N0YM.5IE:3)PGN"4I9GS%IAX$VX8I")V%P0LFZ2-K<#Q64? MV2,0<%4!^FT5`33W];93^#96_!"P<>"&>I!J6[& MMTTHP69GDDEG%$;KC!W([4"A!8S*Q(5$6)Z$%V.B` M,$"1YFOUDNN``&4HL[I8Z`"<(J1M86A+3&WR*'O_$)"+3(U)FIF^6"N,5G\[ MD-N!0@L8.I-Q0F4=Y` M01C'9F$W.B`(,VHH:NFPIQO:--PIV5$.<@C<>XVJ(7.-YC"9R!'D^@7,>#W9T[_)L*\[ M[C1T!TO]60+'\*"F1/4@6#].'%LF8+H;/QY@FJ=PW?HS`.\8$Y<'N<'U_X/5 M?P```/__`P!02P,$%``&``@````A`""U`O(R!P``-A\``!D```!X;"]W;W)K M&ULG)EMUVBC(^;N-]=DSNNS^2HOO'P^^_W;UE^=?B M)4G*#EDX%O?=E[(\^?U^L7E)#G'1RT[)D7ZSR_)#7-+7_+E?G/(DWE:##OL^ M-XQ!_Q"GQZZTX.>WV,AVNW23!-GF]9`<2VDD3_9Q2?=?O*2GHK%VV-QB[A#G M7U]/7S;9X40FGM)]6OZHC'8[AXT?/1^S/'[:T[R_,RO>-+:K+YKY0[K)LR+; ME3TRUYX4 M+]G;.$^W\_28D+W=%N^W'?- M0<]V#).1O/.4%&68"I/=SN:U*+/#?U+$:E/2"*^-T+4VPNCCC8/->C!=F\&L M9W';<3]R"U9MA:Z-%=YCEC'XP#1HPI4OZ-K88#W7MJV!Z]SNC$%MA:Z-E=N= MX=2#Z=H,_H0S:'%7$Z%K8^7#SO!J&W1M;'S"&8P26N:7R.PZ=VYW!SNG)WUH MAG_"(2(=Y6W0A\;.AUW"FE05'QHKGW%*DZSL(SG2ERNW*@1!7,8/=WGVUJ'J M2JXI3K&HU'(?=];]1\=G4 MFJ'44%JU-%S5/#8:46N$X0#!"$&(8(Q@@B!",$4P0S!'L$"P;,!E>N"`5:-H M)K=N@3[%XQP4RC,M*":M@>MUN8F!&*7&@#NJ>X=2T@X!!D!7.(ZI6@ETC:4J M1KK"<4`3ZAKNJF;&NL1Q;%4SN:89J)KHF@9<,]4U+OAFIDLS MN*)Q#56SE!I*D/-B@;M975'`S:QU26M.2L9135(R[OU,$VJ1:4TB#R5PS^`1 M08!@A"!$,$8P01`AF"*8(9@C6"!82M#V/&TFU.BL;M"LW]2KGA?%.%? MKW;:AHVEIJTP;6XQ`RN-HB`#EGE9,DHH:(NAA.*V5!>CU%1G M+MS"4&I:(4$0(!@A"!&,$4P01`BF"&8(Y@@6")8(5@C6+:#XE_;^BG_?3W6A MQE2'I]50:EI^11`@&"$($8P13!!$"*8(9@CF"!8(EA(X5:J;'AO8,-F5(J!W M-Q.R;*T(N#'P+OL()0ZTQ_I`'(1:C8/CPJYK*#6M."`($(P0A`C&""8((@13 M!#,$!HK16%(9C&*U]JA(*>@E50G%;R1&C MU)"P5JSETU5J6B%!$"`8(0@1C!%,$$0(I@AF".8(%@B6$M1+@WO,,"$!5VT% M=RS79K!I72L*TS,[#\1DVJ8&A1N7!XT,BBUJ!45C00:&6DDU,A8 M(Q.-1!J9:F2FD;E&%AI9UD1&R/4L@V'Q4A3TIF1[6+T4Q6#`Z-]Y9ZL&2+R: M8E_@UUM2T7*!5>-H>Z=:U`Z0''8A@:89:234R%@C$XU$&IEJ9*:1N486&EG6 M1`9HP!SS\FBH,G.E"@QNP:YRK0@LAQJ0/XF.>+%K1^?]I[QH8$%4N`'),ZQ% M/H."B4!4&,P>7"50N&"D*1DW:5H6H%*&J\#C'-!^K"M>V ML,TQ417.P,(=;:0J!M0LACN=@L*T7`CG#!3D#GA$S56%S2P+/+90%?24\T"Q M5!2NR3F^XZT4A<-LTX;(K17%@%%__-)%49>]>&EM)Y9X5EJTN?]%@LEWW?8K MD^->_D1=EZ7HLL@?12>4\O)"`HV,-!)J9*R1B48BC4PU,M/(7",+C2QKXKK5 MKM+HN08SVC_@AQ7J'8_V+JT?+7C22V?[CN>UU(9QT:NA%"_#&,H;*KA\AU9# M"6MC2&=2:N`>-1)H9*214"-CC4PT$FEDJI&91N8:66AD>2:B@>T:E\U+7;^; M:5_]M3BIDU[!7\NXR%,XV7P_)/ES\ICL]T5GD[V*$S8:_'!WQO+X;\I]ZFA1 MDPWXC/O4V-+YG/O4W]+Y@OO4YM+YD/G4QM;Y4AP[7N%#[E.G3]<_>H,XC[E-KD'C_[#@ZM3S%S\DB MSI_38]'9)SORN=$3)W.Y//>47\KL5+70G[*2SBNKCR]T/IW04831(_$NR\KF MB_@#YQ/OA_\!``#__P,`4$L#!!0`!@`(````(0#V4J-50`0``+\.```8```` M>&PO=V]R:W-H965T&ULE%==CZLV%'ROU/^`>$_`A$`2);E: M0-M>J96J?CX38A*T@%/,;G;__3T'8\=V;K?D)0F'\7B88T_P]LM[4SMOM.,5 M:W!XOSK3)^9Q=:`MW2M8U>0^7WDU>M M*Q@VW10.5I9503-6O#:T[05)1^N\!_W\7%VX9&N**71-WKV\7F8%:RY`<:CJ MJO\82%VG*39?3RWK\D,-S_U.PKR0W,/%'7U3%1WCK.SG0.<)H??/O/;6'C#M MM\<*G@!M=SI:[MPGLLE(['K[[6#0WQ6]VO9;YQQI MF;_6_>_L^C.M3N<>9EJ"#>C&YOB145Y`&V"N>;!$UH+50`&?3E/A>@(;\W>A MKCKVYYV[B.;+V%\0@#L'ROOG"BE=IWCE/6O^$2`R4@F28"2![^M($LS#8!FO M'F%9C"SP/;(0,E\MEV&TBJ=K"4<6^)8LP=0'\H0Y@^]9WN?[;<>N#JQZ>'Q^ MR7$/D0T02Y.%)3A-A1,F(^%RAXM`6H1H%D4R!F\W2!(LD-@5:2)41@#(%6ZJ0* M_@D1 MF%O[TKM*-E:B89-'P2+REY&60V:/,;(U"_&E90$[Y_.XP7='6ZF=-R-&5RI& MQ8.N(([#=11:>RS31YE",<`UH?\C4,2]WNO`3ATB_Q(P:`*?6%)2=?_69SGB MKL\8XM/%B<@WQ%F3)W"$0(?UG1+<98W$W`1J%>&>.!Z(U]2&=B>:TKKF3L%> M\76?0"M459U?QH.%N@$G@4M^HK_FW:EJN5/3$H;Z`X><9#HH47D#].8!+QGIY@0ZJH^?^&P```/__`P!02P,$%``&``@````A M`"-$D0@2!P``DAX``!D```!X;"]W;W)K&ULK%E= M;ZM&$'VOU/]@\7Z-`6,GENVKF*]6:J6JZL\[HIJO/&JK.^<;ZGC?6U^W//ZW?JOJY.>9Y.P$/YV9C'=OVLK+M)COF9=I,JTM^ MAC.'JB[3%G[63W9SJ?-TWY'*D^W.9@N[3(NS)3RLZFM\5(=#D>5AE;V4^;D5 M3NK\E+80?W,L+HWR5F;7N"O3^OGE\B6KR@NX>"Q.1?N]PVI`GS,!C53VCZ:][A(!L&^RX MR\`?]62?']*74_MG]?9+7CP=6TBW#XI0V&K_/)<%3$^=2]\QU_@9=_ASF73#@JYF+JS&.BG?E M%1>2"4?%7%X7ZU(RX:B8[U_3%DGJ4^BH$ZAVSDX@ MH$:3[+$4!KV1HH4&$AE(;"")CA"!4*T,@5#@(:ACD3WO*E';1Y+G06$0Y0)= M4&D"\:`"]=ET79]F,Y"T19_-4"+W&LWGM,B@Q:.T!;U:HM/(`D"0Q@+X5^Q8 MY%'5`G&]7E`@;40S[&J@M!FV<&38Q(9-HMN0X'%*,^K]%<$CCP8OD(73E7MW MYO!LB?.N)D4B4,WZ)/ONDBY[9-#B41KK+HE.(X)A;]PD&'E4L$`6N(U?MR"8 M;9A`,C3!`G%A)VF"68V*#%H\1N/W>:+3B&`')KZ;%'=$*EE"0Y)9M@)IH&=9 M023-'NOUD;(:5BM6$"6R?IHHJXY(A6/OOV5O.V)H@%ZB:N9.0D.RV7X+%&>( M/Y003;?GL?UM$F-%'.[QA%A1E3@,W*02B2R]`AK2R_9FX`@#DEX)P6'8U-Z< MJS2(L?(EGAFPMB4*&LDES@LWJ12#!LFE@""70\3P,$(C#G"2P.71$RH@EE!6 MYR*3&$O(U1.JNZ<)Q5'B)JEB!B%2!>1V3WA=KPT<">FZ)#1D(C*M8@4-5HF" M1O*%XP(7\#XH(D8&>;@85I- M0-HUH@K30H-*'(A&(32@A$(\.?V&V;IL^%Z M)ZVTY0],*#2AR(1B$TH(1'5ANQ_7]V:M:)`&NCM6D&D7<_Y-*:LS,+N8B,?WWCO5X6.R)(@AH)A MJ.*%7'&T0BXAVH/GK'E'A$C7'_ON3?'+AJW=)]B&H$$-Z\_Z22`-R/H+#@:H M[1\^%!(BC1][]4WQBR:O3P#`%U_=N-$A$CCO[6?XXKQ^`7TP2"JB/I-((BX MROTF\HSW'(1(1;!^?G57=,W6+B&H>.IA*5"0'K$@PKHJJXA8T?#&FO9G:W[? MO]4%=SC#008^&!ZE%=GSD@B'?KG].2M6$2%2/3]NUA_43+,WNWUO5KH"$PI- M*#*AV(02`A$1\(F)%)[W(^^L:;67D#;P!284FE!D0K$)X2#G*GAXV:Y[6'U+NUL]@"=86W8&1KT5SF-C9^[AS/W8 M&1?.P(J.<+R9^FC'K@-?\QZZU^T,W\%7ONY^XK@+EQB]`EQ@!'^8KQY@7!X) M:;Z"E]@CN+^"=[\CN+.`B+H!AX?D+.%,=PV[/P5?!"_I4_Y[6C\5YV9RR@^0 M@EGWHK$6WQ3%C[:Z0&K@NV#5PK?`[M\C?/O-X?7`#%\J'ZJJ53\@*+O_FKS] M#P``__\#`%!+`P04``8`"````"$`,3-%4%,2``"08P``&0```'AL+W=O[_94_]WCT[<=1WNY/R7-^^_*-0OSV]/RT_ZL+>GGQ MZ;G_K,WO+OGV-U?(/S+T_W;=K?]LG]'X:YL1?&9;Z]NKRC2 MIP\/3_0$IMDOWC9?/EY^[DW6H^'EU: M-]3:E">3@=^VV]^-M'PPB,Q7X,ZZ#"S?+AXV7^Z^/^_7VQ_%YNGKXY[2/:(G M,@\V>?@KV>SNJ44IS+O^R$2ZWSY3!>B_%R]/IFM0B]S]^?&R3S_XZ6'_^/%R M,'XWNKD>]$A^\=MFM\^>3,C+B_OON_WVY=]6U'.A;)"A"S(^!+D]V7OCO/1_ M5X'^N][P>OP+/Y[ZL1?=U.S6;=OO]MW_?>CWNA7 M'J`WX##TAW-;H<=9,'_X]2>AW-DG\4G\Y43T.)GF#Z=6X@T*#4H-*@UJ#1H-5@KL%" M@Z4&*PW6`;BB]!QR1-W^OY$C$\;DB%MWRL`GK2]3-F,%6Q(-4@TR#7(-"@U* M#2H-:@T:#5H-YAHL-%AJL-)@'0"1$)I`1$+BZP"/#:.F&3\8&Z/;:]G04Z?I M'Y(S`Y(`28%D0'(@!9`22`6D!M(`:8',@2R`+(&L@*Q#(E)!T[!(A9V_WMW\ M[>K,63%&FO0H<#!EJ?X_M:)!M[7H9J09D`1("B0#D@,I@)1`*B`UD`9("V0. M9`%D"60%9!T2D19J_O/28HQ=6GC*F5H2Y@!(`B0%D@')@11`2B`5D!I(`Z0% M,@>R`+($L@*R#HG(`>TQ1`Z.SU)&+1O>DF&W-;:=WQ&[+^T6:$L&M+\[C*+1 MK1I%Z4'$.G M^]^G6XI*"W>D<0>T#[*[(Q-$MJTE8=LZXBN>6#+P)`62`94_:`!&=$6-)BV1K)/I:SRQHR1 M-(ZE,6>5-Q:,I/%&&DM6>6/%2!K?2V/-*F]L&(7&?D^-SI95G5%FRAR8\/!Z M0JF,6-ZII(T=C$3>J M5;=$8Q4WZED'C4WGWU^+.>58DQY1#]+\@4 MC"DP9AQ+&F%,@;&(&V%,@;&*&V%,@;&)&0>W*L4MJR)CRIRTSAM3]HQ&)RK> MYDW-Z8J2)\;4&&<_9_1#(W'&?K!^.$1]C,-GJ,I15:"J1%6%JAI5#:I:H9*= MWIR.SFM*>ZZBT/RL4W/?2$U)G9[1S"'1PZV*KG59E:(J8^15.2/?N@4CKRH9 M>57%R*MJ1E[5,/*JEE&GDNUF3C3GM9L]"XEVLVA$&R,_YO4:,S.7^6:6\55. M')+3>D_-SBD:L[A134\Y&HNX40W=$HU5W*AFYQJ-3[A%HW`!'O?4[#SK697H]`Z)V1DS!<:,8TDC9`J,1=P(F0)C%3="IL#8 MQ(Q#V/VS*C*FS+GLO$RY8U^8*8MH6N=99F9.A7H`623F<%!ESABH6/%2!K5+KIFE3P5GEC04C:=0S.*N\L6(DC7H&9Y4W-HQ"([V!EZ?DEE6=42;J[,,N M325Z*G(HO%1'E"!*$66(U04-7&(;.H'K;< M(SB""J-LTB-'T-/OBNE^$EK:(M'2#OF!FCAC>.^.*$.4(RH0E8@J1+5#HEG= M`\EF53-/*XRR6:/'T5^\@:?%#EK5(7^VF[$JN(1WZ'`+/[A6._L431F8;M7C MYF@JM&GX7DVR)9HJ;1K=J,U.C::&T>$V7JT?+0NZ=I#),`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`V,2,D4R%1IDI<[([ M:ZLT<&?"8*OD4'AWR:IP`%EC.(>C*G,H4.6H*E!5HJI"58VJ!E6M4,EVBYUH M3[F[I'LOZ.`6F?LWWT_A?=@=XVG5(='"G\E5.G"KH MNBG'\JH,53FJ"E25J*I05:.J054K5++=S+%,3PPG=7![G@L/NP-WQ!,='"[G M6>7;*&$4)G\\5-ODE%7>F#&21M5K*_B MO&:(%CJQN+E5?Q8Z]%+)FQ(R?LDIU5 M[3M67L4ML1:Q1-:H5>4XZWY+XA=?+71!Y*F#D3^9SA@%KQ8<>C^T'_"_OAVH MI2+U"GZ8#./D7F5_4>"ZK^(47L%Q2HQ3>96-T]-OLFNOX#@-QFF]RL;I]]30 MFGL%QUE@G*5#U*E-'/JE`76D67D!AUF+,#+79U\`4"?4NVZ'PC<7K/)#,'%H MZ$\Y*:(,C3FJ"D0E&BM4U8@:-+:HFB-:H'&)JA6BM3#*M-#612QUP2\J'5_U MAL:IQIU%XA(77XPX8W@8\LBO"'W8*[)*[K94K\Q8Y3M"[M&1\`6K9'@U=DI6 M^?"51T?"UZR2X=7\V;#*AV\].A)^SBH97IWN%JSRX9<>'0F_8E48OJ]GA#6K MNO"RGYU]5T'#%_J91>(*&E_KL-$_:^+1D6=-G4K>$H[4>3?SL7CVRSTZ$KZ( MAU<'H]+'XO"51T?"U_'PZOC4^%@G0D_"H:?JR. M8FL?B\++?A:[VSGII=00+W<<$O,9OI1R*C&?NG0D_(I58?C!K9HNUZSJPLM^=O;5U!"OIAP2\QF^4F.C?];$(9IV>9BE MB#(TYJ@J$)5HK%!5(VK0V*)JCFB!QB6J5HC6PB@S%;L,.VU&P-NPH47A&SN' MQ/"WJN%-D!9`&1ISAP)C@:A$8X6J&E&#QA95"+(Q'$`NUD\F:JN2&X*QFBPR#)][=&0N*IQ*A5?[C=+'XK%>>70D M?!T/K_8;C8_%X5N/CH2?Q\.K_<;"Q^+P2X^.A%_%P@]QXWG((X67_4S?Y9U^ MP,%KO:%%/WF=Z51B1K!&0D>>-65CN"B-L9\=8G%3YFP\&KY@E0ROMFXEJ_PH MJ3PZ4ON:53(\]#.H?0/SE(XZWCT*+P795#X8?4'!*KO[N;]!N"#(TY&@M$)1HK5-6(&C2V MJ)HC6J!QB:H5HK4PBK2,8E>,I[P*ZXSR>L.AG[SK997O@8E#IO,3A6@#(TY MJ@I$)1HK5-6(&C2VJ)HC6J!QB:H5HK4PRK30=`MI.6EX&J/*BD5R>,*;ZI%3 MA8FR2`U/M;U+G9%4W-TRC)5[E>^ZXQNUERN\BF.5&*ORJC"6FC9JK^)8#<9J MO2J,I1;GN5=QK`7&6GJ5CS6\5CN^E5=QK+6()?O!V=>#([P>="A\$8XH090B MRA#EB`I$):(*48VH0=0BFB-:(%HB6B%:"R33HF_3CN]DZ+N485!:1!^!X%XP M/W]/KN0.VWVL]'4[6W:=`-!_1]UV;1&C>IR_" MML<573*XF9@/2D0\HP$%ZUZM:<^(?CP]!WJ247]BYE$LH7ES8F9%+*%9<&+F M."RA.6UB9BPLH1EJ8N8?+*%O_/X>_?-P\OEO M'OV:'KW[%A;U(VA'1X\>*Z']&3UZK(1V6_3HL1+:.]&CQTJ248]J$'M(VG!0 M#6(EM*.@&L1*:,M`-8B5T)Z`:A`K28;C24HW0I@6NOB:F)LN+*&;K8FYRL(2 MNKJ:F+LJ+*&[J8FYC,*29'A+->B^?T)G@4K,(0@]=.BA&L1*Z%1#-8B5T+&% M:A`KH9?25(-8Z]!;9ZI!K(1>*U,-8B7TWIAJ$"NA%\-4@U@)71I3#6+3`-T* M4PUB)73M2S6(E="]+M4@5D(7MU2#6`E]CH=&3[QU:)309P@P"_0I"ZI;K(0^ M-T%UBY70)R&H;K$2^FP#U2U6,J6Z3:-UFU')+%I"G^.:F`_18*WITT\3\UD: M+*$/04W,1YQB)=1WHI[I>#*-3<6S\606X\EX0E_0B3^AIB$5X^UXTL;XM-^? M3.UG+=2HF5')+%I"OW@^,;^@'/GI5&)^3QE+6BHQOXA,)5>''T3_'L*WNZ^; M]N[MZ]/K[N)Y\X46O>ONN_K>[+^H8/^RWWZCXP#]RP;;/?U+"-T?'^E?OMC0 M=WM>FZ]=^;+=[ODOY@<<_BV-3_\1````__\#`%!+`P04``8`"````"$`DL/" M>LL"``#+!P``&0```'AL+W=O[QH$!Z=KT)<'7Q\?G MGGNYK&^>98&>N#9"E1$.@Q%&O&0J$646X5\_[ZZ6&!E+RX06JN01?N$&WVP^ M?UH?E7XT.><6`4-I(IQ;6ZT(,2SGDII`5;R$G51I22TL=49,I3E-ZD.R(./1 M:$XD%27V#"M]"8=*4\%XK-A!\M)Z$LT+:D&_R45E&C;)+J&35#\>JBNF9`44 M>U$(^U*38B39ZCXKE:;[`O)^#J>4-=SUXHQ>"J:54:D-@(YXH>8;-:U/[\%/YK.,S*Y.G[1(ODF2@YF0YE<`?9*/3KH M?>)"<)BV[LG7"4&+&#L4K^\:#P1.5) MQB>2*:@_[4/H[9BKK."U=`V"3DKV]3_%^&D)HC MN74L$88F!_$&JO*T6EV1;_N M?J/-@9VVAG7K`\#=BAT/A+R"6/8A\3ED^8^E)W;R$;$.#$W1T1;.AT9ZS+1- M:#<,Q)U`3PH4^'+?'#C"D&=KTV(V[;NP]9AI7?%A-9N]QO>X$^BI@LZ_7)4# M#U7-!JH\IF/0,!!W`CTI\X](<>#W:N4Q'2G#0-P)]*0L^E+?5VK[M# M0W?F`W<\9KFLBS8*K@>=O7MG'\:KN^.U\UZ_'YY^R$BN,[[C16$04P/,7``#__P,`4$L#!!0`!@`(```` M(0"8<7*0YP,``+P-```9````>&PO=V]R:W-H965T\ZK,EY43;'C?O7G\]?GEQ'2-H4 MM.(-V[CO3+A?MS__M+[P[D6<&),.6&C$QCU)V:X\3^0G5E,QXRUK8.7`NYI* M^-H=/=%VC!;]IKKR`M^/O)J6C:LLK+I';/##HV_4=>I\]?W8\([N*_#[C2QH/MCNOTS, MUV7><<$/<@;F/"5TZO/26WI@:;LN2O``P^YT[+!QOY%51D+7VZ[[`/U=LHO0 M/COBQ"^_=&7QHVP81!ORA!G8<_Z"U.\%0K#9F^Q^[C/P>^<4[$#/E?R#7WYE MY?$D(=TA>(2.K8KWE(D<(@IF9D$O(^<5"("_3EUB:4!$Z%O__U(6\K1QY]$L MC/TY`;JS9T(^EVC2=?*SD+S^1Y$(BAJ-!%*!8X2+<72(RLP.#BDCA]=_"\/014:^896>EL@7D!:7K=Q&*^]5PAE?N7L M%`=NPL@A)B,9&.@LFDUM(!O.P1R!`Z,7X+_MQ1R2^W%:!M&XR10=V)H_H%B: M/V`\F91T2GD*3$HVI<3AS8SAZMQT];Z+2(8:TV(^]\VC=XJRZ"L,@Y[80&H# MF088TA:?D8;DC0N.C^4PD:8H45]/)`Y]*SN)N;X,K:BF^GH0DL7<=#TSU@.? MW-8-M^!:Z,5U/^)(-B,>ATOSW)WB:"&W@=0&,@TPM$6?T89D,^1Q9)>#XJB8 M!_-@$9G:$WV=/,6+T%Q/C?7(GU2Z6N]]-QR)/^,(DDU'`COY.\71@FP#J0UD M&F!HP^ZMO9'W"P#)_U<`BJ-ILX'4!C(-,+0M/Z,-R6;*`U=CO)=Q M9%VL9.",#[4-9!I@R"7P*C\>RYYM"0ZMBMM=25HT)T@Z03(=,15BCWDXVT1U M)'@1;^&:W/HMMV0=,+)=,14B-WB<86JM^@/[33I.$!`99A9OSV'?3=. M1M*8]@F2Z8@I&IO&XZ)5BS%%+\RG9D>T/G15:"/IA)/IB*D0V\'C"E7S@`/O M)5Z1;FE.B(VD$R33$5,A=H''%:J>8<;0ONTXO$X2;]VP9"3=$C]L&Q"'^<0%FYY8>V6^T.Y:- M<"IV@*W^+(;#.C5]JR^2M_TDM^<2IN;^XPE^)3&89_P9D`^@"```/"```&0```'AL+W=O+1TD%6YS7/.6)LXKE<[]]N.'S9&+)UE1JA`PM#)Q*J6ZM>=) M4M$&2Y=WM(5(P46#%2Q%ZU^#[ M)0@Q.7.;Q05]PXC@DA?*!3K/"KWTO/)6'C!M-SD#!SKM2-`B<1Z"=18[WG9C M\O.;T:,,GP?*OK*60;"B3+L">\R<-_9+K+3CL79Q^-`7X+E!."WRH MU0]^_$Q962FH]@(,:5_K_#6CDD!"@<:=+303X34(@%_4,-T9D!#\8OZ/+%=5 MXLPC=Q'[\P#@:$^E>F2:TD'D(!5O_EA0<**R)+,320CJ3W'8NGW8LT*,KPPK MO-T(?D30*_`JV6'=><$:",^&[.M[B_]S"-8TR8-F,5P@7D)5GK=Q%&V\9T@E M.6%V%@,?0H\)QHCTC-!YT[398,,#O;UHL#L5/8=:7J_"6:,^--8XB\<"=E<@ M8T1Z!;$<0[)+R'+60T8VYF,;M^5K,+3+('UQX/>\)E\[BPE-M^@$IM.-;+`Q MD@*E'V;TMA0-3ASPV5REQ-JFLQ5F:P"B893VTX-"Y6JW!\.!M& M%\M_%D>2X_=(UN")Y'A2Z9W%V"X(_#B:CU6EP_AR&4Y&!DQR_8I!:NU@M@.L MH:*D*:UKB0@_Z*$;@/=^U]X'.[@/S/3T^@#,XPZ7]!L6)6LEJFD!1WTWACH* M.]'M0O'.C(L]5S")S6,%%R^%[\IW`5QPKLX+?6?T5_GV+P```/__`P!02P,$ M%``&``@````A`"5K$YWQ!0``*QD``!D```!X;"]W;W)K&ULG%G;CIM($'U?:?\!^3V&YHXUGB@>W^]:[>69L;&-8HP%3";Y^U2# M\5"GG+[JI3U=!Y^/P].6K?HBR/TU.W)=I&2XM.FW0;G_;=UC]_ M#S_Y+2TOPM,V/*:GJ-OZ$>6MSX]__O'PFF9?\T,4%1IY..7=UJ$HSAU=SS>' M*`GS=GJ.3H3LTBP)"_J9[?7\G$7AMAR4''73,%P]">-3J_+0R=[C(]WMXDW4 M3SU[_*'XCZ)-UF:I[NB3>[T:J+JF@,]T,G3X\,VIA7( ML&M9M.NVOHC..FCICP]E?/Z-H]>\<:_EA_1UE,7;>7R**-B4)IF`YS3]*JF3 MK3318%T9/2P3L,ZT;;0+7X[%7^GK.(KWAX*R[=""Y+HZVQ_]*-]00,E-VW2D MITUZI`G0OUH22V500,+OY?4UWA:';LMRVXYG6(+HVG.4%\-8NFQIFY>\2)/_ M*I*XN*JU%[N M"4HM5O$1C>A5Y9:-H!\6X>-#EKYJU%PI-/DYE*U:=*3'N@54!7MM"K_J"=0, MI)DD,Z4I%A4`[?[ M&\/9Z) MAUX;[Q"/',7%X[O0P7L5QRO%8](N[!L&)/`)*?1E!I0^4(2G4`9`(0)Z&7** MZZE>1DA1YS(&2J"N:,(IGG"5N4R!8C@*9<8I;J!2YD#Q5Z24VBZ MKH$ZXQ0W,"AZ?!]9A6GL16@H8^&`1J& M:!BA88R&"1JF:)BA88Z&!1J6E:&J'&&I:5LQ@BL4`:T9P0N:!)8/^HJ[(Q]R M%.8#VD^OXM35[Y-NL"B?D&(KE#Y0Z+,?O0R`8JOA&B)%?=`(*3>J'R@\JN6' MQ(13`MJQ<+I3H!AJ@YAQRJVZG0/%4Q>]8!3?L%65+!G%HW,$.L^XUFVYHA52 MA(>[\)I3`M.@OU-K-RFKV*$Y1[C=%V`7[BL"-[ M9>,/M)(^9UMOK:Q\UH##`EXZAAP&WR...K!GCCEL@^\)ARV`IQRV8>(S@"'5 MFG.IRNSJ22*-M'3]'QF&N;]$4>/)O4-J[6 MZDR\)SIT^$)G*&!?TEEY:=>O`)U5G\-]M`BS?7S*M6.T(Y=&6Y['9M5I=_6C M2,_EP9>F1?V#'JQ?_YOC\2<```#__P,`4$L# M!!0`!@`(````(0#+,&DRB0@``,0I```9````>&PO=V]R:W-H965TV;K8DH(DBY7(;0NT0%'T\JS8 M5L>G^_D_?W^Y2>:SMBN.VV)?'\O[^8^RG7]Z^/FGN]>Z^=H^EV4W4R,=;A>+=O-<'HK6JT_E4;7LZN90=.K/YFG1GIJRV/:=#OM%L%RN%X>B.LYA MA-OFFC'JW:[:E*+>O!S*8P>#-.6^Z)3^]KDZM>?1#IMKACL4S=>7T\VF/IS4 M$(_5ONI^](/.9X?-[6]/Q[HI'O%N6ZD(]+3/FG)W/__LW\I5,%\\W/43]&]5OK;H]UG[7+_^TE3; MWZMCJ69;K9->@<>Z_JJIOVTUI#HOK-Y?^A7XLYEMRUWQLN_^JE]_+:NGYTXM M]TI%I`.[W?X09;M1,ZJ&\8*5'FE3[Y4`]>_L4.G44#-2?.__?ZVVW?/]/%Q[ MJW@9^HH^>RS;[DNEAYS/-B]M5Q_^`Y)OAH)!`C.(ZF$&\15TN?,"A/1QB:(K M'NZ:^G6FDD5]5'LJ=.KYMVK`5G!`GC]'KY$*8(A"Q<^C"-7BNI?E+%IW M8J*9HLRF!$RS@\$"%S8E8:-(FQ*OQF%(J.%'0M6=[N?J4X:YCZ,EC20#3M2G MFI[]G`."`Q(!1&-$-5Y>!DU6^P!K"\?8^T3(@(.T<4!P0"*`:%-)_OY4T9WH M_"7KE,T?<.(^^_WU4O]01@Z,,0K!`8D`(GIMBXX5]_+$ZDY,=,PD9_%)W7-5!H2[+D@2NTM1QDKFR$H(UU98TC#Z"># M1J;M"&7+Y6GWP;QP$4[BF$<$)#3QIAO$>*/K"NTB*,$/+88T#$<`VG>N#P!< MB@;`*[4^BJCL,G*#V%*34T9D$00E!*Z`X$,<`6E'0@'IX\P5N08^1@/CY=T' MDLFU0!V\V4+DE.'(1D$9CFR4AN&(3/L9BFPBU\#]L*DF"=.;^4#"N<8187$D M1NANT.:%%%XY]V!Y9.X37O/U$5LE50K>NO26O.`30NJE48I_6"T6C)VHI40_ M;$M*PW8LB?8^%/#$DH!3TD!9')F/[+0_^>0&@=`3;\T\0Y#VU.NW_Q@,VYT2 MCT\73QOB];&`?=)8V"QG/I!`>>RE+-:S'[3[C]&Y(IR;[#:R@C=-@_942V'4G*B,D!@4;*C@,Z M[Z+)4WK@.!8DK`9EAO1VWA&"2BL]%^,/FSC!V1?+I63L-\LEG0RUD=Z?H('N MQ9>=[;',D)!O68BP$(D1JE0;.]I*E\MX`,<`O(5BZW'5D+!"Z#8BPN)(C%"% M[_+^`$R<%C)^FC$D11T?HU)V0,@'TO!`8B$2(U2TXS@P_2BEK\%X`J3\.&!( M:W,&R$:_9P2P?2$/9L!")$2K:8:*:?#E+0MM$XXCIR@QIG,S<0H2%2(Q0ID@9[ON(!R"5:D/'JW!NNPT)#AZN6\[#64, M1EB(Q`B5SBSO2ND.Z[.V8`BD\Q:DMRFY:<6J@3\B$G.H:H?G39M'Z/`\ZZ+6 MD`;SX)7"M(\JA85(C%#=S/0F4AE<":>R?8$8BPMRO*@L/> M8G88SD(@02K;]VLY:5_9]SZ"$/J+?YI3TA#ZM:%1:4]"&W1BWL'!R,9,V2$B M"\\VI[^$XR>C2XWB4J,<&E5-IR$PKYP(P>&1UAUH"*0(OI.@CIZ`,_>!%9T,:@IU9T8=LM._% MX^)G`$,:*TUND+=VD"#MCATD\9`DNR)M?U=OD)[-OMFP;CT-"EWNZ@.U&8 M'N=P0FNRT8A4/?/>ZTXZ$=@K\8*$/VP8TML)!(.\U2Y(?SO!I&EW)-"'W#IR MN'7*\B(S)+PRT&U$A,61&*&S_RX'CL!<\"Q$6 M(C%"E3*CO%P\5O"<>3D!#`DKA&XC(BR.Q`A5R#SPN@*AWH*S+])X@3"D\Z/0 MU&V$H>,PN'7JM^^&R@EAP,MT\-+9H6R>RKS<[]O9IG[1+\KYZI0WH/`27^;? MBOZ-M\70H-ZA.Q5/Y1]%\U0=V]F^W*FN2T\_6S7P%A[\T=6G_HVNQ[I3;\_U MOSZKMR5+]3K3TE/D75UWYS_T$7!X__+A?P```/__`P!02P,$%``&``@````A M`)O[2]Y3!@``=1T``!D```!X;"]W;W)K&ULG)G; M;J-($(;O5]IW0-R/<8-CQU&]95>?E8>6JR=1ULD-:KO/#=N7^\_?SIWO7 MJ9ODL$[VY2%;N3^SVOW\].LOC^]E]5KOLJQQ(,.A7KF[ICD^>%Z=[K(BJ2?E M,3O`RJ:LBJ2!7ZNM5Q^K+%FW%Q5[SY].YUZ1Y`<7,SQ48W*4FTV>9G&9OA79 MH<$D5;9/&N"O=_FQ[K(5Z9AT15*]OAT_I65QA!0O^3YO?K9)7:=('[YN#V65 MO.SAOG^H69)VN=M?K/1%GE9E76Z:":3S$-2^YZ6W]"#3T^,ZASO097>J;+-R MOZB'>*9<[^FQ+="_>?9>DY^=>E>^_U;EZS_R0P;5AC[I#KR4Y:N6?EWK$%SL M65<_MQWXLW+6V29YVS=_E>^_9_EVUT"[[^".](T]K'_&69U"12'-Q+_3F=)R M#P#PKU/D>FM`19(?[??W?-WL5FXPG]PMIH$"N?.2U[`E@/@ M^ICH#:P>(&%7%KR)OE#GZ@0%TDF^Z"QM+BA!#\/33<[F7'J"^2C$M.$-H:GRNB$PIQH[$M MN1^RL/N`3M+[N,ROQ;#K2/V6TRFG"U$S:_>OKF`D`S$),!3H_7@4+5ZY<)]] M*Y=3T:!!@7'*[Q7%HLN<1?#E%CN-2"%S#J5GLN M$F!<\UNXM%BV+N!_.40-:9T,Q"3`4!8<11_AZZ=!7R1+-1-(J)FW+9R)K19= M6HS/+#)L/5F%\US'UA=)[#N!C1K$EM07UN+3:XQYR9DO'U@MEJQSP8H:TG49 MB$F`H2@P/%J_RRRM6FY!49S0B`B-%8EIA/-HL[ZYGPHMGEN).)2A$2W;C;B` M^3HTT_ M-\+)'CH969&81CB/MO'Q/&CZT`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`16,+BFI:4!+AS&+D7"GH MJ5$C/L^%@1PED16):83SW#1<`APNE\W)PAD9TGA*34$H2X91BR%S9:Z>& MBS3LH!L.[?.U>.B)^M7A['9ZRPQO&B;!B6%B^;41P18=-H&2(Z47#8CG1DH@ M1LK(K7ABM$PMOT;1^2:3&8)/ARV,^1#-FCP34^5RDUNU,#_K^=J(T*$#>4SZ MU;Z"-,+9Q/085T%XKW7=H(WH;`7-.CDF-(*4^/8+W^\46;7-HFR_KYVT?--O MMA3\_UD?Q;=N(;QU:U]1>?T"O/0Z)MOL6U)M\T/M[+,-7#J=+,!K*GQMAK\T MY;%]F_)2-O"ZJ_UQ!Z\W,WCK,)V`>%.63?>+/BO]"].G_P$``/__`P!02P,$ M%``&``@````A`*=/9NVX!```L!```!D```!X;"]W;W)K&ULE%C;CNHV%'VOU'^(\CXDMG,S`HX.1-,>J96JJI?G$`Q$D\0HR0PS M?]_M.`1OAV'HRPPQRSMK[:O-XMM[53IOHFD+62]=,O-=1]2YW!7U8>G^_=?S M4^(Z;9?5NZR4M5BZ'Z)UOZU^_FEQELU+>Q2B<\!"W2[=8]>=YI[7YD=19>U, MGD0-W^QE4V4=/#8'KSTU(MOUFZK2H[X?>556U*ZV,&\>L2'W^R(7J3T^YK$Y@8EN41??1&W6=*I__.-2RR;8E MZ'XG099?;/RE?MN!N8\372JF7O<`TNKQ:X`!$ MN]YJT3OHGT*<6^.STQ[E^9>FV/U6U`*\#7%2$=A*^:*@/W9J"39[D]W/?03^ M:)R=V&>O9?>G//\JBL.Q@W"'H$@)F^\^4M'FX%$P,Z.ALI3+$@C`7ZRZ42=?)7]M.5O]J$!E,:2-T,!(`^^%[ M6+J_V=-$>EUIUF6K12//#B0+O*H]92KUR!P,7@3IUX\2/U,(TI21[\I*;PO( MMQ"6MQ6/HX7W!J[,!\Q:8Z`21@S!B,T%H?RFS*;&@@=\1](@UR;-():WHW#A MJ#9ACC3&!-8W(!BQN8%(,"2=0A(Z0I`,AF78H,\6Y<"- MO9`:"X@*A-[TZ'TJ"KQT0><821Y;7EAK3-3G0L!(&%J`C0E@A!,>CD[2P3&(TY*&=+AL$H7$8,M^*4HHA04`)8>.+D)`8 M"[F?00IL"[!I*S"F'O%K M;'MF:XTQZM!>2(T%1(7_'RH*_%5+T!B#BKV0&@N("H&.^KA;>C3VR[0I#"`= MTX3326$A0$AH'(S)-DP$16KI:@M!2.DU[3%Y-3H>CBG1@P9W-+LM#"#]:L)8 M3*UBV6`$]#1;7XH0"6=&YF#Z:H@8]!]K"T2/'B1CTA<&D);Q1!B/C8K6A84A MT'JG8=!O&HPD#-KD&"@L1`T<0\C]VB)Z/&$!=E\80/K=":/V06.#`=,L2Q$` M9QDFKT:00?[!*.C!98J(DTDR:9!1E\1>2R4U,9B/FA*/\]$SQ?3/C4YA#A[(+LHMQAMB(F@43%4]AI"4:)N)5RZF9YM6&EG.:O+X[Z@E6)YB`V MHBQ;)Y>OZE)(X$@YKNH+ZUI=6/LKY_@%W!=/V4'\GC6'HFZ=4NQAJS^+H1X; M?>/4#YT\]=>9K>S@IMA_/,(O`P+._?X,P'LIN\N#NM..OS6L_@,``/__`P!0 M2P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N M>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T; MVN.``<.Z89UC1" MSF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F" M\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7. M=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB( MACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO M/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1 MLFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3 M"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&< M33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PED MQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VW MA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.) M$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"L MS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5 M"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2 M]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(A MU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+ M(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F* MEV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*# M4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7G MY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]@``#0```'AL+W-T>6QEA39\NAVX'#%WUU5>/ M?MANWWWSXGO:9R?:N6$PTP?7?5US@E6X=H.GF?[71^MJHFN[V`[6MA<&SDQ_ M=7;Z-_>__M7=+G[UG.^?'2?60$2PF^G/<;R][?5VJV?'MW?7X=8)X)M-&/EV M#!^CI]YN&SGV>H>-?*]G]/LW/=]V`SV1<.NO1(3X=O1IO[U:A?[6CMVEZ[GQ M*Y.E:_[J]OU3$$;VT@.H+P/37F6RV8>2>-]=1>$NW,37(*X7;C;NRBFCG/:F M/9!T?Q?L?B]30V2"#^IE7O=KQ<+7B>1>:L']W28, MB"%3H`G9NOT4A%\""[^#8`#S\&?W=[N?M,^V!T<&"&\5>F&DQ>!EL(\="6S? M27ZQL#UW&;GXLXWMN]YK(ZNW%=$3_2TG.F6 M!35DT.\CK=1A'2F;+OJ@[V+*;D87LVQH#:VQ5,NX6"S[#14.+9E4-BBTWH[? M78Q.^A;P=(+.W4V*^Y/AD#C_.1?!69^\?7Y?[Q`+Z<\<48S9;*4F9" M>3!Q8,!)_'`<)[GI>/FD9FCBL MAR/W=S!_BITHL."#EKY_?-W"H#Z`J1ZF2"_Y7<.OGR+[=6"PU!5KL`L]=XTH MGA9L*I$.Y18W#];B@>DER$115`BUK,6X`Z$/\^E"/M+%="I;J&'!2[+0MR-\ M219JP7\+:9RFG;DI"V0N3XM=G/KWK\?3Z70RN)E,)E-S.#!-1O(RC6@W6#LO M#JX&2*.IC&`$"*;#R?3&`"!]<\)4713!$`",1Z/):#`U3/B?]77=(Y#-Z4A7 M[56"0)%7"0)%7F6SSYZ$RI]F"BS$*)0@4>94@N+17LVG5 MXN'!8BMHY9%9]?B8S>1@[K@,HS6<'0UP]I@MRW4=C!6A$;IL-)QP&N9(T'(H% MU1YZ(76?8`OF:N9IP080$UE("+:086-QI+*3?F M!K[8FL$12QM:E.UL:'#$RH86HC;R<9-YEQ.>+R=@>3Z"Y(!O[N>GP0!%2<,, MST$13.L3GE]*SC`)ESO>W)*>`U-DZ1$V@[`+V-IUBZTRX81P,KQ MO.^Q3_[[)A\&P&K7_=W+AERB`M<-X34<>`4,OH4EY?1MTN4G'\#\JD9&92/- MWFZ]UX][?^E$%KN8B*E@1W'INO@T9V.5XO-;SWT*?(>MU^F)F&^C,'96,;O8 MB9V!J\(SK,`S2`6)X#E'OUFA'W@2YN,<_;`>=-2)P(M2_1!UI4& M-;B`!G4='ID(8-:?(0`GJ$"`EZ&E'$!XJD``LZD,`01H@0#@U$3%.7DP(-4, M8J!0"?J[4@DU)K.24]FAE57E%_376&EQY?(O*@D-1=T%@#J&9E+ M'(>0H,!2I!H"P%$"@3@"+O)0CT%1#TRC05$73"%P??`%)1D M13%.&'`]Q@5I(!!454@2#8:J$DDQJ*J1A2L,52620%!5(:DG5)5(BD%5C22N M4%4B"01@1$F%I)Y052(I!E4ULG#%4%6))!!454CBB6'');)'ETV3152R?CJ9 MGK1^JKUL&A=2!U63)O![UCR9/24S1_`%FTN1J33>^&=G:Z?:,-H[*[HD2^1O7UT7F`JFIQZ>ME4K_4"DFQ]XS`8>825F`K]L+BN M:VV42^?G#"SG$]%H.9O4-R[,'T0&O[C=&"&-(#`D56/`!2;5&-#?*0;I82@I M3:&3S"`*1Z?L<*$T08\X3`W@.$+50?*<2JC M3+FP[BXJ-,Y>E%END(7HB_L<9_%2+3]6%-ID@'0V?M:`\)H/?C"AX8T<25V! M<]>]ND%-)56X;%M7+>;I:G%CZ3J7.QI=P\/I>1U"BRVHM\*74%DS-&K!;->X MVR1$UUBHC]D%1>QBI+JXHXBD%"P*H2LW2@>:<-5N(D"*;=?I<":\CNAJ*FDT MM'B&FFH:7S%.JG!G1G\3P@MA.J`-:JAXH>T08F5GU=!750[W:-'(%@G:U-5* M0)WX\12$P(S8T*R2HS9\#/Y_YSV0(V)$_](F7=WG0*L(O&#W>$H^UG1.W539 M-N15NO+4^MI&.65&^LCA7%=)!R1S:(67EM3USV?TR" M@A]G-609/SJM[*_IF*:KB5#7N,_,CLO`:XI%H^9*S;IT;>%96E_SI8GD+N>Z MR;?:I4IRIJ]K1W45_UQU@^U%Y91?ZLVFX*KL+:6AH76D_:R6]VS3=(@O;9WV M5^2$6B6'I4)\_%21X$A>D,@*8#R1)R'CV14J+S4.%\)9CD(1"GF@9X3!R=E3 MXO<$'XL7';;;;.WR/`W1ADC@D?)4"OE<)FXZR.&*Y64);KZHXY($9Y.0FO,+ M;0*7CX>.2JR4/DF&TR63QP5E$W?"E4@*6YU,YS+ZVB"L7`[XV2"DV=N-1P4[ M;U"^R2Z1J5R!:J*-K]G"05>&J';6WDEY:R@A/'65W9TD:)<*M9/]>-`UP)"M M;L+)DW=&W+7IO7@.&Q`JP=00J6]\'I\< M=@WXND-4V;/*0)2,XVE'GR\--8^'*Y$I'R-U'5KBTY\S6)3AWVPHQR=!JY0U MR"T%`&G)KN5*=SZIZRDJ,X)&V]%TA!W8\A%2BQ@3634XJ1!G)$H"7NJ_U`,' MOV9#4J-R2-H0CX(5NFTDBBTAE;")<,HC/BDT:M:^**=D&1L.7R*%B'9\*W2) M]W'.6N4QNR<([@(B>RKQ.RKE]PQI^,`.>,!8_[?:E?9VA3F6KXWCI2'+O>O! MUII8:/!^KM5^!_L"SI.#Z1TX=;+RTYQ80*@LJ"UM9>4)BZ60RH)4:2L+U"=% M"W!]65#[B#<&(3Z04OH-WA",<98MPE$@IO,9' M^5`PRA,IA;_X^#8%XSN14G@*Y!&+3/A"W*+<1T.>75.0W;F]SJHN'S#8SXC` M@$=%K?8>/"(TQ`>,LAMG\60:,0C/W@M)>G96G[0%[(.8"^+S`;M1$4$/+UO/ M#NPXC%XUO%DV%\<[?20H[H]AF'/$2S#@HPB@/\'C6.%)KQKPDC#$QS#>I-A& M3)X+/#T#08]E:*!U@H://URC;H,&6B=B^***XR<1,>^#[3[W$%]+L>L6$?'! M#3XY:SYR>(;QTA8121^=?1S9>?SQ*86S$B$AN'MF+H,O$6PSS,,QXT?8+#,C M$6\D)KF#JQ@B.O^RCPF-V(H(,03KTJ,;PS['61)S(A"6"(['$&Y@ST4<5!1! M&7^SHP"SA4O=@QBML*C8#@!&_^N78B=5QGN,#RQF>ZSF\P$@:NUL[+T7/^9? MSO3B_9_9#N(03.FOOG4_AS$3,=.+]Q]P:W;(8EA)@'+S80?;?<-?;1^Y,_T_ M#_/Q]-V#95Q-^O/)E3ET1E?3T?S=U^A<<#G_'T M9/:49]@08&#>[CQXQG*4&IN"_[XX-M/)AP0^NP4*8,,->)D1O5W^].G[_P$` M`/__`P!02P,$%``&``@````A`"K#^]"*9@``!D(!`!0```!X;"]S:&%R9613 M=')I;F=S+GAM;.R=W7(;1[+G[S=BWZ'#(>^1'"!%\)L>CT]`)"33AR*Y!&6/ M0Z$+$&B2&(,`!A^2.%?S$.?F1.Q&Z%GT*/,D^_MG5G4WNAND[)V=N=DX,V\.YH]L>O;N?SR;?/G\]ZM^E= M=[8^GJ0COKD>3^^Z<_XYO7D^FTS3;G]VFZ;SN^'SS8V-W>=WW<'HJZ0W7HSF M?_QJ+B1>CP5\6Z:%_=+"_^=7WW\T&WW\W__YHW%OS0?S.^3 MXY%/`-W)TS>=H^3)L^^>S[__[KE>\=>:F\GK\6A^.^.=?MHO?WW6FZ\G6\U& MLKG1W"Y_^6-WM)YL'-B7.^4O6Y,I;V[4O_D(L>6QPG(NTIO!;#[MLLC3[EU: M?NK%\5ERT7[9OFB?'K:3D]:+LXO6Y=G%<;N3')\>EI\.8Q["LFEW"*OZZ+ MZ132DI>#60_R?DF[TY4CA:7\G`Z':[^.QA]&22?MSA#%?G(\FRW2:7GPTW'Y MDS#$3^/A8C3O3N^9=XC`KW@L$G>13L;3.6J0=.;=^:+R^"]IY:,PD0V?',*6 MF_&TPO-6KYU. MTUERMIB;OD)Y^;5LNXN,?XEN5592?C)L=^VS+W\ISW-X=MHY.SD^:EVVCY(7 MK9.69+;S0[M]V5FEJL>CY/)VO)BAX+,&AF"8SF;)>'Z;3C\,9FDRFZ2]P?7@ M81W>JM#QY@)]N4Q:G0Y3?UOYNCN[-8MRJ#_:?UD,WG>'Z6A>X09;)ILT2R[2 M7LI#5\,T64M.T\J^'(_>\W[-II]I)4D4K=9LEE9G.4JO4_2BGUQV/R;UCUR> M7;9.DL.E9957=7YQ=MZ^N/PE:9T>)>W_^>;X_+5XL):T+I/#L\YE^?D3./UM MPA(7=XNA2>51BK7N#;IS3&OYZ96CG[8K(Y]=_M"^6,5\L6HVEXF8)8-1\@:? M,YJ-AX.^D="ZOAX,H:!B6*!M/!M4F?=J/.Y_&`R'J_8%#W8ST+XY8^L?\UVJ M9WUU=\JL\P5@@7Z?OQ\+T,Z>EXGL:GV($7W=&OY25$%7F-R9TR+/2,KY.3\>AFS>8[ M2J\J6G?8G0SF^)$3'$.:G&$V;TQV9\QAI/JKYS+G58E>UJD"^\NDG9R=OEJ[ M;%^\3@H/5?;H(6+R9:R@10\X7[5.%U*M/W+ET=>^8#M\O;6+*:^X\T/KHOW# MV)C]UAXOT#TEK,4=0.`0:;WTI^)"H<3Y/R-*>$`!X! M],MD?_[T^5/YLV57^61]H[F"QJT=$5(@YMLPBRE3P;DFFWN-/?Z[N[UM7^G/ M_:W&9G,KZ%0HT87MHC?$[,.;["%83/MQH)/AOG-A^\3X?56*'?-]5" MN,^[@_X:7C+(5WE]%^F<>!H>M[O3$?RL^##?]KH=+0\5!"2W0^9)ON3-!_T^ M(I$2BZ?S`3'?LU5Q0&F;&_DN)4]Q$_WQ$-,V2R:PT&3H69GZR@`%^:M*W2-2 M]ML'?_0-"UK[0=#+3R]+::9$7[CTY;)@IC6Y3&1Y"I160X9TX^]=#+W(#@AB.C^WBAR\W<167Z) M<(A\[:?VZ9L:/ZXP3&OLM"]^.CZL>:`8@9GE:-W)>?VU-B1KWTV&X_LT)3KU M^&V5\[Y(NS>HH(<%)]VKI+.83(98V3+Q(5H=D^&[)7X_Z%6?LH./H^.0-(__C*%E+EH9<0P..NB#,>JGBGR*VUESUG#QZ6.RC[R!)0(C$]T^/4O_KF?)&BSEOQ\,^@`XA M*LG(O!)%M3^FTYY0!(S9V40Y@#*#:#8KUN^1QTW^5FR11\`O(-/R+N50M29[ MU7./CQWSCUS_[T!Q`&D%ERR,6I09',UE,>[>V3$LQM>O#*CCS M12\]1,\*@:JXZ/C<`P*U\IV2L&Z55_X%8Z]\IS3V]N\8N_+.`V;@L-7Y(7EY M/`,($"PX2HX&,W`@ MP@54^N7@(_/7HS9O1GW%$8.KA>!6-P_)ZY2,M)]D7E2#EG=&7YJ]>4:@$"S/ M8%1938;(Y,A@>:1EAW@T7ES-KQ=#`6Z&*98?C_,NV[G5$P?0Q>.F@/^<#+I7 MP&="3\K#RZ69F*S%")N8)9>%\N/'IS^U.Y?'2\_4T))C0.R'N#S)JC4&RLA` M)\=W$V*#U""_\CPO%C.R5_:V8-0$MWI`>T@D^M!*ZJ@LS_#R^!08^I&5P$Q' M)%E&#M;484[%)U="/F4:ZO>694:`[`0F2*0/@8$'59RK`/<7;'!Y%@2NEZ;] M67(]'=\1(E:<7_F%@DS4<:GN<>*VBW:KTT9*V_[7,V(YERSASB9B`I]_:ITH MHRN/8=_7/2B4^D7[U?'IJ;:*8(T`\/CLZ+<-T(:"!UX5VC\!3DGZ0(Q8*T`) M`0JJ9^%7*^(=H^GR&HH&K/Q=Y\WY^8DEL^0/G<,?VD=O3MJBZ?3L=,T67Y!9 MJ*WC>X60)3FKZ,//P*7IVOCZ6@*$IK&B:BAT-KWICD(>:28C*EYY`<0P`X-> MR>!G)(VU8;#?7!`QT22O>!O]+1:'8_?,^N@6@< M81`_\'XC^1DAAI:YEGK84)5P2NFD@5,>#A!B>_HR_=@UY@Z'@]&8Q2I6>]V= MS;J]VP45*"$!L^0#E57];WD%W62T$`Q5WC[$]>IMM04(]$OZ@^[-"%M.65.\M%T+\._5D`*.$2B=)(48=8?WB&`C M\6]L##PYS%&3P7P\'-_<%W:"/;&/P%.[?61H<'>W&(T+P\S''P<]?XLH,:+. M_>F"_<2_IP)-G[&CW4DRNZ,@S3)/K+L&5ESJ0F/;P[H-8`?@G MH?B1NN[=8'X[I_+-/W]AAY&I7V=7B^D-J-D":7G=XK^#[MV@*!!W MDRMM<2X9]LX*8@2F''U,ADJU,(=.VKU$F0!,4I#-W"@*3UA*D?CLY0I'8(6Q M,^H3@[_$X6&!5<9^?:0U%!9T2-W^[FK!AIS]T$A^H$B,U#>2RS_9.AZ=>5GE M4==?J;TFE!!1SF"#JJJ-J%("G;MB3VZ11.JA(T@(;$.R^&:5)_[LH6*# MGOX84\,E_!TCP`4IN4V[P_EMY`DBM%ZVN)=8C,RJ_5-U!`WE2U M6AEH7Y**(GP$6&A%ZNR%67JCP&:=(CMZ65UW]F`WEKH1J(1H;9H<[']M2EPL MSV)#8&(C09Z9CIKW(M0-]8%,,9@/NYIB:/0N*S<$Z206S-]5A M0B)[DR9W*/2-!:O1RF@)X\4-*^*-\\[Q:V*T7C?)6$>=RAN4NMC4J[4KTR`F M&EEU1RU+MB_#A#+W0@)B"%E&*S)A\I)+6S:AA/40LY^T%2C2#;&XFN&=HL[A#Q>W&],[@9T3.!`9K';$/>ZQPWU&.RLOR]W7P'(/Q[WSYW/TK;AJ8^ MS(1%RUPSJ1/+L_K^]6"$71RP5^94/.AVL^Q[F\EA$)^@&<8AL>,#)GEXOX95 M1)(R?DBOY.8E0K/"\@>"5>6<"!GPO*&;0^Y0'5?X0P>%;KLP]PI?D*3#`1"T M@HD*ARWM==1CN6N$==IW*?E/:"21KW>G"/S4-S4B*B.336X'-[>H[Y"&-P+1 M0:$9X@-F%E>*C\,3(C3&`.D.K3YJ94,OK3GF`VXVR7`86W;!A"2W0-Q/FGN- MG8T]8YK^/MC9E%KV%`!K!?;'$KD&W*E`F6NE/4F'W-9RJ;+"EZSW!3[D?Q-U MV`[CV^>FM,/Q!XP*B^JIO/"VG[(SL%K<(31*K@?3V7QM@'WWO\:+>8(F#6;O MM'"WWK;6?(J@RR9X&3^*-F`6RAP-I&:`18(FPA^+\Z3*[XG@<"J96RYJ9&65 M)%<66!M7\DQWC?ITX0OQ-*3`$H#NE##7.*!%&_E+%1X(DG`:1@&.(MNF5D!$ M9+Z&7V'K';$P>ZQO%8@B((S)0H0F#(FWC`'Z-J\HXZ+=4/O"Y;RF%NHB]=@X M2Q`W%?DU=]PT&VUYRCXHI.PFRUVO0VFWY!LT&_&FY:SVMR&T;%3AQ0+7Y_<3 MQ8'(_;7B0W,&%0Y?VNI97):)!S>`_6!IUT/,:=(OM"@EJ5=!^-+A`M83\Q_; MIGPW$+LGF]3HMW<;*,=^8V][QYYXTMQM;.QOFD'6.AYT4];UN1758O,1M3@# MXJ:K3-([)?J;VK*(+9G%-L?U0-H8R<<^9:U82^MDB,!_R\9L0QB/G2!24ZYO M@P;K1GC&F+)W<=P;V1W&&"KO0.0"+WF9SX-H^$O+Y;?`7K>L0+]=5-2>4P?O M/)4A9RV2F<9K_KW5E M#J`_GDCP"3O,IK[,/$G+5RX?U[&&Y6E_EKP8=Z=`?62,+UN=%Z2+S^0?I@M, MZ.=/2`D];S0+,=Z"F$28NOF&Y3'>3-249H.T.F\T!D2B*1C%YMK&/KPD33#[ MU:$$'8G?"=0KN8W=9[.__^T_LT5K?T(][W*,8B1;.QO/DDOI-DO('E,@!G0& MUSV"`])TS:.@,4//T#\9EYO8`,='X=G,HH7E+K$1P\!_^LE?%F2,2N]A/>$^ M&;FE@IE=QF9B?)A181Z.U_S&8(J(8M?9>0)5.KNUYQH>6TQJ9>6_^2T6GX@( M22,"8C*%)5+-=&J)D1Z??QBOS>;I9"7UN#'H&J,1UAFIR3/*F%13D.7-%ECU M0)_\7GS>K)GSBXU;VK0&02AMY!9T(;JCL0)9K+;Z+R$2*]5;R)K8JJYA*&Z" M=B8YKBY/3E2.9YRY6,S929_I<%''X]L-OM>/-`0?__; M?^$"$0R'+D/`-W`%1]PB#L$3I">KH M8U]QJH'M&A-51]^%'[!\H!#XP[T:'[_$[>A0HC-C2)Q/;.H-W-&6-!L'1+K) MDX.#;7>!3W;VF_\(QRZ_(6ZN$)L'Y:2YT=C;)8"6_7JRW]C?WETE-/Y,C=0D M1P+&?+?Y>CN3+F(I.T5A^K#L*_ND%K)L'P0-(Z/8+N*!"M\JVE'P@O(^U">4 MX9<31IJ\!(.B.1$`P%84\52/*4R2%)UD<74-W)(C#PQ,Z%A.RX_GM@+!NTJ7$HN,S^WK7_3/H MNZ?JF8R$H:TPKOJ%[96QAJ!#@51/&11+]<"SRSSE)<5MLHF.R=L#=D#:3M'$ MV)5S$%X1:,DJQL6Q[/X8)LH"!&H*WPX*Q^>T[_#?03<;W33'Y2L7=*VS+<&[V7,L!<(5#*VF^(66"JYDV:4USU+TU]YS0N_>1I5W`U?MPT(5A%" MX#&RZZA1(*3XAHND-"#@OE'Z`WG$V(H';9FVNG:.E++ZRE`SD(][,&G566P_ MQR-B2=.%:7JC#(?-4.T+L:#5(4&AQN6O"21K:8]+UWXX>6*322<`:/(TVQ3% ME\],K;-X0`B^YX7M#)%8<@=\C\$;$&*A"`:(&LH#.Q1YP[F`@WDL\5$$]%+* MLGPI>OZ\Z!MN34JB<#I$Z.QA?Z%:4#P6UBNK)Z-;4LH06`_;/V4K5M!C4M\> M!U5\HCE5R3ZN@<*-$DM*<08+ARP`Z898P5.&P<%Z@Z1,9Z;!?-QUV<^HH4;M M!\^*61(JQ#L8E_$'\59R(6E:`)0/!6>83RB8',WM%CQ([8Q2-6*1Y5B/6V]C MGY&AP=@&PXL41TM_@+0QWY;S,:@`,$_E3"?)4&[@OZ1+1H'7G5]0M)CX;E]" M?;0#YD2T-+.H,7$2[HLZWG5)A?A3RW6>V9Y3P:'8(^^3O6C2F[$F8G*9I!5) MJ-N*X!=BQO0A%7A&U&G.D-S6@E!188X'9V^>RG;]#](WLQS*4BW;,9]8%-GP M`@B'\0:^F%`-+5^+G'#U\9-6XB05VFL,/0]K8NF*J'&:,JL:O`@$E%@'MWE> M.:.5%I7Y@`V:G2LS-+KRR$PMPB`)7C#&!2&'BO`HGSJ\9AN$#&11!*8832M$ M!1S2L;B1R!3G-Z*SA`@^!L.AS)2R_2QW_$&*RB2%F").L"(B86JAHR3YS%HL M)P6(S`(EI%;:`0=8N002979\4"8D3QTJ\=33ZIGP7ZA`$=>H`O7Y4S%G*X>W MKRR$ZH0@-\3`E:K)=J.YSXFAG*.QO=6L?G58B,U: M!3Y*H.AZ\]BLTAH2HY[G6=!S+H2B>MIMZX!#6#L'U7FW=K8;NUMUM&YN-'8/ M]JIOM`B6/'>]-#][;M'8N:*QV3=E;FXV]@\.&EM[V]5Q-AM;!UN-_;T:%FXV M-O8XB[6W57W+&I!5:,ILX4INE6D!`(8+&ULUHVX"">\W=IH;U0E%)FG<7LU7 M92&Q1DDD\W=1MT_BNM&LV:&]O9W&SD'-#NWNZF!=C2R=`^O)SI7H4ZVBT*,? M#T/,OJGL&@/O;=5L_>X&&'K-5F[O`8CL5GEW2MZQ2H/VMS8;F_LUF[_7W&D@ ME=71=IO;CH7YP3X6F^9]9E=I(,FJI`YR!*#RH*R@D]RQ&X=PIHJ=F=_ M8[UF.[XNC[]WL%[#7#ZMV?UODGI]<[N`?YK3,B+5DV-6;=O"J^[0_)U[PUM\ MEC*./M^2<),5V`O%4YC$83%+"I&KY1/6W:-@*J\,:"8RCM@]1)23Y0&*CXBV MF0E0Q`_./Y(+A#S`]L2S$(_]R^-4&/W--\C5A'"1;0^^QST&(A#E.IZ2P37A M8W"T1:#W2DF@O2YR61*>L+_H>7E>J,4DZ-!L&>U(GM;ETIF@V4K@LR__F>JT MLX4*\8C.,A2]5UG3SRKLC@A!L\X"HUDW#T!CB`$:65<"\:KW7]015'(@&47F MRV/`X:,B&8N>A4OUV`$3R[?'4)+DK6![LSC.L;V27D7=7V5XY-_K]S!"'3'I MMO_M*1*`D0;S*R18M4>><2PF(6I0XNZ901:_>#AL85D`5;*9+"0L2,8$]U8( M-XCD*D!`A=HET5HY0'GYE6$*H*<"4;^!(O3WEN223"&OJ'>O2?J2>?=7+1#8 MCUC+%=*"*.\1MYI,R$/$2]/4(%,5T;3H$Q(B%&_!GF-9"G/5AT$11298G![W MH5'@2T":,NUXGLLA--5&AG\@77"4RU+?O#/#8TL$("M`S[I@SG$^]-YQNS'O M">F$+`%(JB`1,S*J'U&Z2N2T+D(I*=EPG>/O>1.F$DF=>7"F#G5?$!4J M)5KP&!A`]2K]2WHY`*\-PUFB(IM/?ZH5YARIQS+1DV]\-;6V^JOD6YM(KCQG M?@QY9A5BA,DG`:3Q!$(;G+5/97B?9?>T`1"=C8-9L7X/G9N2,-I*=>(#0$Y0 MP#JMK9/4$W335]%$_PU(@&@*J^-B%0D3B\R3DJRE`S%G/\5;O2LFA%"@P*F: MU[I>3UX&SITYN;W`+13;B?KYB1!("^;7*O`9ET1'C,5C!T2!Y=;?8WN,3P4' M!/1)PPYXMAC*W6Y.PS_DNQ8C`PO@WX2M&?3FPM0^0,/45Y!^M&7SO3/&':_Q M3"D](3L>SUA54>X2ZG]8,.]^'L&SR,=/L)B3S7L]M!U8=ZSP_P5BC![^:1BL'%Q"(:V&J[93*8(IKT` M:@;GOYX<_[]#@\TW,KYOVS\.;>4\/B&0;$J()*BX<.GV<:BBXX8D&Q5 MB`#D/P(2%QJ*6+[CSK*F*+7#MIXYK"]EN$741T/F3E[`D;PB6*D%V>949,;- MY=7Z?[C%2IOM1&$4RX^$?SCA:^JR8%?UQ8(_71(0#XAJ*8;]38Y%!%B(K M@L'.EV,8WL.Q^I3!V.>+L5>H>6(-/`()9E1)EY6VQBU.K$Z"WQ,OA*_1VL`=[`I1L[.S5`XZ&Z\%#<8S_AX=?% MT=)H_3PQ2)5IM4XM53[(8P`,S&X1WB.NEABH_C2?#[VB+R_+A8?<]H<]R(Y! M:<3__,F,B.T^W$=%O!5,[9C(BY_14(L,YU.4!7HNM20?*PC+ MLTSW#S4MJ_7'U[G`(SJF0+26%'NV,-K%U;DY#NW>W1'WA%E'M$R%%7A5NJ3+ M)22HOLS*:0ECJ281QN%0G[5ZV^?%V;P4J<"?G5@,U70A?ILI->MD:)<,:U0@ M/2#-6ECVY1B*C.V(U$O*K,WJ4NF1,_)8H:MKA'HQ,='+,1UGK-`8QH?%Y8D) MRJ\BEM/U["=2YERLI"B7C!+E+"1NR:M6ZSRYX12%U1]#35S!$CYK+.\3NB9$ MM]T=:7&'V2@Z6J[2GN`#3[X`V,PCOBFTV-;TSLK,9E)NO-+85WZ#@8LKD$/] MS$`LV#XJ:LQ]QVW('L.HG9).?W6(KK%AH[41/1L]=6T!`R1/#>I0HZ4]8DV8 MSQ1$N)G&-]+UP\ZP22&OLJ_QTCJ.NT[#%5ZZ'I)3=S0@^GUV$BF_ M+,;.";?/.W;V-VO;U&)<@L69H(7=N=_]$$73#J0)@PCMCW9]+L7HWJ^F1\Y" M9`,,&%U7A(AU+SNX$.P`=EI@?1C MO!T`%&?,*22[!UP[& M+C"%=5MZ8TM@PPU,ST&\G$))(6;>4?7\`9-.4OZ%7;!C@INM-V>%$U18I;/- MUL=2X[9ZH;Z3;R7'YH@3"SOMW#''A^T0[+>6D9@C4A)@*8W,4IS)!T'B;>&% M.4Q:7=PRR<;FV;"0%O5YVL=EN`]?HLS6,D)C2W#KR,GP3#T4*QQ%D^9'\$+H=^M2"^$KR,4Y5MO2!JE.I9#,AN,'E^Z$6+.^32.GYN>Q[*YQ5LZ M3\1"622AC\D=YW?6MOC/CI&_M;NQQA7Z6SN9M3P,!U"7H9JE=:^DPGV[1XOR M58/0=N?-^D'JZ]:%/(;>ZGW*=ANPOEO/)%CU0^QRY M(#WE"FCHBYN#[CZ&.FQG8F"2N(L<,6NT4I M:E467X8W_T0J@'IDMY`)O;`Q^#AHG$Z>X9+B,=\,'F0+*]O;R=`=K@,P`J*Q M*[@F?`4W!!`Q^N'X4)15J.WO[,C<[=3]=CGQ9/1[7@R>AF-F.I77MYNO5L^1IT]G*SYXSRF_YSS_V9_ MU3DY?K%F\ZOGWW\'D.6Z>\=/U#3UR?0E[M(?N01P\IMV+L;P2-]>DR,ANCZ" M/GAN@]HOVGP[FW1[#&,;/'V??O7],E7:+#_J:V!'"5H)&2\3@E>-2 MLX`O06_^LS3ZU9SJ'.JH_/__]ULYD"R+T?S[)^4/"N:S_)779X?YA77E!_9T MI7L-0+:[PW&NFL_S@_/$+L*DK41>'I5^M^9.3=\7%\@?U/5'OER0`0N+X9JG MP4?]X='B&;^1T4L_?_H?W;O)'\RTD7_R0SI1/,OS;G+&O0X^W*1[<+.F78T+ MQ,=W8P*R,%^+4[]3\.'*N!N-[#1:F-? M_B&[E/]45D%-S"%7 MKAW]V7H(T_Y:RS/D\N0%UI2_.DWGGS^-KZO;FA/,E2T*.LMOM@#&XK7GGS\! M#I%OE)]1B%/^K/A>^;O#!;`#38[)B9HDR]]R)T1M$S3(>TW#Z0X0?TT7\2&J M#V*+JST=S]?FXS6%![1EE2=K-AO-NAYPS$L=$;3#'M3,=DX8IKD4>)U@$>I^ MMV6GON1`>V^=X*-LVS4*7:^TFSN-9EV=P\^\5C<=7'Y[HV8990G<*G.+%O*] M&IW::>SOUBCO=F.G[N/=QLY>C:UK0E/-V+2E[]>HJYW@K5D96K]90\HEX56> M.Y";9#(=0_"D4&,F92H=:U9:8LAER)WL\A2KNGKM.!@NZ96=;!1T]`-@P*]Y3W? M;VS4=;R_W7F77&2WIJ)DC_VLT/$HYX'J1,OM7J@/!"BP57(##(;?5NI%HAY^ MN6BD*2CJ&A['+[+QS/*1U//30P#KD:[L6V^1*A@H=0?V?K>X*^#2BK2](`G8 MHVL.WW<'-,T!13"SOHP92K%A6)^7YF3[[%/<'Y:,'7XZ>/;YTY-M^_$:]28] M'>@#U0R"T!0S%+OSPVX-`?7R!FV<9FQ#>+L;+'OXM*,1=:M%`@_,:8@ M?`$)O*?7(1[:52Q$-A*Z095JBM_4!54^LK)%GPLN5?5BL"LK8.N:`3)V![2X M6]P[LI?7PB9RTXS=2FCT+?7M"&2-\$^:%/J0I!H&'"?25J M@<\.[ZG=P:@QQ*";7XF?O^+G#*@29.QX\*EP,XY66D,CEQ!.[6"@FW`>*I-; M>()JO@[G&:;6_%H,V/[:+#\24>C\=K5I0K=6D('I: M4JOF'K!EE5'-Q[:%]R'"`61J&6&'YOIY`+4V^K86RQ9+6ZQW-7<-6Q@I8SA_ M;ZTCS)'=115BX6IC0)*FH0X&IJX6B+R)54669=%Q^,L`/K4VZ'H6M)%GPL@R MC[EJAIIR9D6Q(+O&]-!P84V7,ABRU`&C\Z*``?QW5%+AAG)R+(WQ,9B[N!YH MYVRND:B9,\41Y-L=C!!$"@_A`@-0Z7!Z![$-L+3E&39[;'J67XCY^I!=IFM8 MJPN_E&;(#UT1"[10-ZWI`G5'Z*#2XSL)OWD2S7?+4?\(K6N[8GM+J%Y$HV4S MS%2&D;K;@=K6"O^CP3-^YC^&59##Q&\S@+(G1/];^Q%9VB5F.HC;61"$1^[A M6K[.FZK!BYI?GWN[^ZYT[_>*!_$GA1N&-XAUEJQWQ$RHHA$)&OY%V][T3@44 M]:Q,DR>$CEP=%0Q9S=P-ARY"/9W_X6)&C3Z*/V+&35<'?IF5 MIGRRVT0Q8[M9=M^'&Z%H5!W^8.^0$*[(1`''C!?%AE%,BJB@V=W+R^\6C04O MZ4GS?D!NH4$V%#BTW,(N.(U[&1=BVY"-`3>,*P_%0V54EWS_F_&DU2MVIPQYV#NJR[L;!04T(1SY-5F>8"W>PKHO"3P^-/(.(DM]TA*U/,.GQA$4P@$3+7&-S\M M@&MTE#A$RMCO;9.Y_-];E9U^NZ^4&X58\?-%4C1531!AZG;1.B+1>D,%$O/1 MLN`@_Z_6>^L)]>Z`AG%U.%FH)>I]6YXO!*\9+"SYKRR MCA4I8YS2[(@\2!F`S$-[F^IEF*J3376!_RQORE9-QJLWB`>QWB=CM5Y=ZI>= M"'K!M-'JI<'Y*GGA33'ED;%M-6,WF^MUZ=/^^GY-,@H8`):+/RU4:UBXW`H6 MH_*KT!OK!S6Z\'1SO2ZE?%8YJ?ET8[WNO&LH>]8Q;WMS?:-&);:WUNL`+GU< MDQ-+QC)W;QX@WVRB0)VX5S1M-E+A17:_KF3(T4=M2UYDLR`D'@Z%3XRI]D#$ ML]()>>C-?I7/@^R4M]0$(X*1)AOE)V*+7&7$I[C/_8U*OE_Y.:ZG`*?[E<=* M$EF>]>EN8W-KO_(I"?_.=OE3`SA*AQ0?,@%U8;*)(`9F:SDB4+S,C?JH"5%9 M:&%'/PRGTQ:52FK;-(_NN(UZLLUI9T5(Q&HJQ%*;'MYG3JXX&A*!.U81@M*& M&T.+KW65,=%@H;F0:<<"27'0UC`G22!^73!Z*,!#TM+=HU*L(G+!/3/A?)XK M7C_24QT!)NX1EW(2146?"!#K0J>XNN0(P.4L_2 MK=IF15H"H"D_H-"'Z#R\5_6;M9.9A_Y6*R1BPBTQ=XVKN(!N\6NX=>9@BX[>.KRQB&Z;H!6WI"S-^D7=&@L$ME-G?,%O;>/: MX7:KZFBH:#6:H/:[78.G5;E#((V3*(_J1M%\W[;CR+?S`Z0 M,69-L%6+!M1]L.TQT8.&1<=W2^;*4]&'!N?V"Q&VR@AQNB`>E"#QUB5\%JYY M3B`;3!Z,>3-+19LZJ>L\":=0(46E76^K]&XQ-6'QD:IO?M_=DJ$0';%1QNH5 M1$=Y85Y6RXOOA0&\*YFN3XX6,W$_=X]NW&U]A+9`KK1K_J6 M>.;3%QXOW\1N+%@DV^2FO^*2%$V$!H+`,D#*PEE3[_`"JW/3:4T!&FJDS,12 M77J<(^AM&$!@RK)9%50)\!`O5=((%0\28G=]M\S81.6M,'_%/M?Y9D$==F`` MU[)\5,"&RIL!@8_LGE/B[E([]9M.%J=+7BS.LFB_6VJP/L[%,0,4BX,)P"7Z MMR0&HS.64)&I%AR@U^&,,IH=!6$AFQ8$RAK,\(\;!S':V,"I@F/E?1U"(*PA MWK<8/#3'_PK!H9A*OFT)A'0V`\IXH;!RW<3H%PG:2;H<:*RP/?Y&U8/)WL$[ M?BG!+IU-5C]'SP0M(2VUA$2I[ECGK?A.)J167/_@7]P<<@D/0V9F9147!#7D M(SZ&!+%+@'J@>KIJ7$JG^WIP_;M[67NY?K(K+M/:HNFG6F]N`)F$FZZ7)I']8ZM)TZL@>W.PN+H7I)0 M-UY`$Y4+$Y+=VRE^SN`#YX?N8Y1-DFS]35H%[5;D0@"(R`AS^Z]LF-&7";,? MBS6]*D[G]( MAI@K#]T:J/OLRFZLMT7``;N/7R"D>PHJM^O&65+^HCQL\2JQV M6_'B7?R%SZ)5,>GKQ*M[,_"*5_2??WHKF1(?L;8F^8'I0J8J#9%Z/`I,0):I M8.J47N+_:U[`_MR,7&2["Z^9*O?"@18SHE+)U'XXWHIX_$L>G_-AVM!9Y-;; M#K\[Z9Z1XP<0.*I$;H@#E3J3,#-C7)2="UI"SY*WI@C\ M.@SK(9#3>=:)76[C?%;[)/?>H\)DS^\J"2![_?F3L-K9%]TX&*"&5C$S/2PX MNF"YRKSAQTSVZDYK4@S>WZR!V2SWJ<%U8X=/$CI\,HO@)U7.\A-090KH7-MK MUF0[?+Y[4),=ZOFZM+>=74)S%`]"Y>=**MS]F8LCU63S//RF=YFJ9ET/3;/N MH&QSKR9/KK##:,(`QRWY$K;0%5M-8EE^;7L%GQ_4->*1-T)E M1&(.IN?'Q?"^^,I,MCL+8":"AO7S"[+T&C?[3?L57$C.<9W)6SW.SX#8&_I$ M!RDM')/YS#[-(@FU9?`%T85GC$8$R8@9_WAL+U3":?+@9]<,6.QB]#Y_`CT+ MVU%ZC4@D>O<0F.A.I-`OD\7*!,J58`7]F^A@8#3;XDD-^8:;J^G$\BRM()Z* M$TH*V@?GX8:OPU=G89BJ2K+G%K*2#XTX\W95/FERK0,@(>ZAB9S+MG*'FRO% M7VS+QU;::]R)HR`@F;1">WB9)#0>L./=/G)TFXE*^%DRHW]I/Z232IJ="[DY M?28449FO'U$BNU5BK%\NEH[PL[-=CCU MTV,NY@>0L!S93&'@,F+%HV(S!AILTK2$?F8>5VX@+#1[DF'C-M88TSJQ"&8Y M)+PVFG5W,&6!H&6YN^8>=0Z">]==\I1&L.P<839[9M-M2-_7]2#E68I21Y") M8YYT1I&NFB9L+N?4BGLMPQXM4Z%/T"?746&[CB>.6#.Y+GCT5CE$B?!/F7G" M]<_A&!T_5;C#GRM\:#R953.NPXJ1-Q9*U.>;Y22]FGQ6JHX%BB&6,R6!6"J> M^C,NWH!-ME&'YU!FK\T6CT=):W&#:[+(J-1YE5WG*$LCYT%?:_@U MP1WY%C%8HEVPYSFVDD52&U\827D4M6%6U*(HZR74+!YJ9<(>-,I,SR>H0D2__YD^Q_?LP6 M#V`1@(:H>CEETXZCL3X]4AY9GUDXQ/?&"U.?QR(@(9ZU6A38S/I_9PA4I&]U M")1O2"42JO*`1^I7V3:X)24B#>5?=C%+R*W;S(AH)2ZD$W M=FH]"E,F9YE;D7&*HT=%]$I-P8MS6B1$0MG%$M4M.0L>/N!-2S8F\QPE;HUBF8>`^00 M+`ZSG_R##69IWN]*#8&7TMK8\6/%"J0N^\GO**`/9H\6SH6VN@HDHZR$&77KFYIA-_=^XRC;C%)AWC?MHOF*H4DMX]W< MT0#CONA#.'E(R\[_8>]<=R([DGW_*O6AYQR\16.JN!2,I99HH&VLO@W0WAJU MSH<"BNX:`\6F*'MZZ[S(^>9G\9.=WS\B,U=6KJP+/9Z9+UNCD>E5:^4E,B(R M[F&'WDB<+O/-7#K/]C?V-LOU_L?JD_?"Y-O;7S?Y_DY[\M5GWPJS$^`N!8A_ MJ8T1C&C%K>^WCDI'L3+DM\/T75K&/WUZBO7T6H%VNJ/J'*%%S"7@9G`55CFS MC4A*6FB+ZVQ=]J/VD^V%U/B4W:WF%,\9:36FLZ:NV#<6/N3 M2%\!]7;K"@@'(VV_!)7?`>73T^A;+7^(1SSO>6+QIXH?*=_*3KC\Z34=Z\MG M=EN4#_L;-?_)X[A\+UGERQ]`_=:C#1%$^;2_48NBZV_L5KPJM;1*PI,K`?S[ MI)"TY^IN59P_W>JR&*`2\]?MDXO5'K<69[>U44NK[?4JR^K5/$@2D4EH=BN% M5=I0@%MH!!WE8#?K#>6#:_$"%-J2/6R9X%4^A?$C=#_;WC3KAZ?;>DJ8I'F; M`CD?^2E":I9CQM2PH+DX7;NO'%RYRF0OV MD$P!U:Q%'86(^5?TQJ8\RDF)-1^[/;RBC1?W*X:01!CU$(49W,H%?)],;K8R M_+AA9;9_Z2H_8U+B#K^T:H5J+`!Y+T":(FE,>,KFMJQH\#"IT^ MX,T(R5X[0*8>*+!GZLQ!FZ]SECJ++"PQBZK!`&>YMM+H1EZ\)RDM',"P@5*S M'0$Z)=NY>_=F:BG5-HJURT!;"[YQU0QPB4,-2/\N=1SC,-57L(=BF80HOLGD8>9 MV?FXR4/&5(PT+4LO@`^1",GPZ\>(93<>RHVR/%MDA8DHVN,"#7;H1/R+C*K) M#J50"\.GPZ"&"_WQ5:%JRUQEI#NR1*)?,2\\6AD0"Z;,4$D(!#I%2LW`%JK> MCC\-05FW2@MY6'8^5/9!A+.86D@A;?P);>0V(T)&"5:'BZAQD@9\:K-9$%53 MJMWMIM,A%,\J%UD%F\Z[9!EN(>''+D6:GO1%SF'D10*'8G=/RWY03Q-TPI2; M&MXQ;B+ND9]8;]-934H,AM]DC";63"9ODN/K_VD14=+5L%^KMD/3.F^[/`R%W5SR"2<7=]FZZ&=K%1):Z_WTLN MAB5WMYG<167\L:PTW$'R&H)31B>Z_"?2M(0KC@=DUZLXI')R'/MK5RM;6LR%;O$4@`0N>GZ*I^ M$VY+I_?WH1-("['WE'?=I@4X9KACD["BN#$E#@\K'(/:14_Z8@''H#N%7/?" MB-1KBE8"`^5@6FUY_9(2HL.)9XE`SG\2;S')!-1"&"$P$=Q/1$\C['WY2_\>,N/2.'O_XX(^*MO+[X=I%6^5/#WU"^@.:(] M""F#OW[\3L"AZ+!*6]21$ M+5H4'YJ>JP8B9S](G9T:SU`J.41T*='H]A["87HC6&0#6:<(C%)Y#=<5XTF: M;#/3':SD5/G5%E+!4:O##O#/QZR(9K.*D$I]G0'-@8J!D);T)5&<5Q.0?GN0 MJCK-&!E`2GE-C3_'NG/^+";H$D7!%Q)VG(-)(YZ!Q<,(YI1\^>'(_!R&#X`5 MW@:W@*(RD3EMAC+A_(A10J+3H];B]T,\%CY+J/W_*&CY8^?HY/3X\+QSCY=7 M42M6.UZ]J:,I-"I:&(1"3I)%X,9S,%0:7:WKUUM22_A+9YP*:D,T`/B"-75` M$;VEN@2&'AF=6@XCA*8T5L+B-,+M](Z,W'O@)-P42NGIHTRY_,.$"IUP0B', M4RJEIL6M$YXW(2%1LJW,M6DQ9LZ)^D*_1@>8O.6$% M2]9G++[:"*AH^7\+X9G@=0V'E6:!18W1KA\&4UE'`?@87J*1,N+C%I8A\/>6+\U%MO82MD:#0TDU>M-4R MR9L!C76(''2)@2DTP`]CY$\C@M,QE]%CYW"C\Y\CMF.RH=Y8*#2$("DN`$:Y MZ=`R3(1+*O\7_3>':WO]8@`X6V$0P[_A>X`7<[A7D?!UUC<6XBL<4L"ORO,U MY5\2Z(%QA)6H-!R1+2-^%(&##-W<;A.8X]4TY/-:]QU=+[!Q\ MANHGY,M!7J^45&=T2]H=%S[-/)%MOX=['?W]7RO&OECO',)!;Z@S;LAG\E3O MS]VMRU^0IS"XKQUMV.)#P2*V-BNG)CVUNQO%U#=?:.QV9=MY'%U&Z7U=-=U@ M\;JP^'_8)E1P=M@`1N1TA/7C9NQ-"%ZK@2;,YCU5S^Z`YN?1_3II]<3'9J&& MLY!^/[R[FWRYH3CG:.#,9_;W>2=A@NY[HS2*"4U,?(N4:9@J&C0>>8]=GC]' M=]?JDN6-'B-"S)PATTN&H`/B$!%KV7_`=KN'Y]\^'\KS]TD-S]#D".BS"G8SV]X!'IU[J[WWAEMO=V M*HQDD`8F=H')3Y<<;$AUG*%.E^:YZ6_CZBYE^X62KIUFS<,[ZG@HDSW]]CCC M_4)8'S^0BN!Z,+BIH\,[Q59]*UX<*I_52@+H0@G7M%\=^BX":GCW-RIGB,TY M5OG%IFV%HGL2._PN5<7A3*6W0NPD: M!2O'(HV$[;S^!FQ@=OPDX4?Z*249BZ9F+L9_.SD`XOJE*2B?"X-HI+=Q/"9K45BPGZ]3\+V:.#=C27H!/LT&%HVNW\&-'[Y<^?@ M]@+)1X.*O<.%'NXW.FL.+D_J3)@5+X_O['7M4I_!^U\_7A7?J,RLHV/S$0Q. MO#S<%7&.,_6R\[P'%(7PT=L-/COD)OWFN\Y?3+8^&@T^W4G/8(TGF(_251N6 MVMQ<:9##KQ^D!\\JEW]R!Q$.)&!D$'J+D!,6[Y+@%L:,<,=^QT(7?Y(NV7R_ MKQN&JZED-PN6OP/B.NC@AOAT([&+M$$_IH8),'NY[#K4/8=19BC>1[1LUBS* M@?M^_I64((YW?%O!"F4'M[_MK(5`"D0E*$ZW4"(9NW1**P8R;@._9!?+$#3> MV$$631KHCQ(_U:K\/74U\6XA*RL8"*&3UE5]M6KZRSJ4<9\LH##-"7J/<)X8`!D<^4Z0JBG`IB;B/8+3*&8 M6.'N+(.4$$1)_N4R?M@5Q=&DCA;+GK?(D`66+GX7)X`4#6*#JB`SVN?AS06" M0G,O&2LWOI588LYA?!B^TO7.9X@1P#W(X@95^E0&*R_G<(`*?X/.$M2B%G,_ M<8.098,^#\<;F&9DR`W2U'F3`*85%OR'U-V8A4Y(,N\X\VH8$==W*DJYGM_= M!99)`N,F44;NG>QC42%D>`\>DTJ=+I*2#SNF.![(E")E'=,.=Y9#TH9(A\^8 M^LFTL@GW(U86DM#TWP'FH,O/=S0+^X3=1D5V!7=!.":4;45:UV:;">RH+#;N M^95RCQVQN-1\JD!*8%'&>#5"8J!B($A4^(3-6*JT'W1D$SEGP*:/TEG-G(@L M+X:ZV$<(T9O><*LA;+D:K%WH$D?^"U!B98T^W7>.9!04%.!PA)!/LTLT5IDM M&EZ!K!9IW<1ZF?2J9]A"LRJ6E:RJF4B!(QA#[%#90P0-?[@.S1I)N`]L9_%2 MDI%'K`.@'-C(;E_65F/MXT/:66%*GA5S4\DJG]!7A74'MF)HXH1(9ZO`X6>/ MJWKK-V6P3&RTU30CYFGOVS-K<0**&[^7^%7]-EX93C-.#]FVA:J8N:3CT(&3 MULHJXN!8J^-VQ&D.8N439XR$W'[C@DH"QZ`Y/??6>1#@A`+P!>.2#:#>#.]= M0Y$-K)V!!IF3WA/8UCIT58)W2CH4@W'\DE,K^+5&=/;[5S8*/!&)FB:.^-A: MS3]G)2].D<]QE4E!/7E_:DIYNM.M(+>K?78XYP^#*^+M<=UX]S@LZ)^E'GF@ MKLC#=(Q@D8GBMK$6-($H1Y?"LRI4.DJEBY)/S(K0:,B.G_'+>_OMTG(*:[J3]W=DFQ[MO37<33W@[O$FW'"_T^6"U\QG^^ M12>[K;YQSX3S/=#=I;P9O,0OED)/H:UF-\)/CF''$KX@^L20"7%X#Y5L6M$L$_0GK!H@#YLJE(DISX+#-/,E4IB):7\7_*PH"B MS%+'GV7J!A4G4771K`.HP!@/AU"\P:\*QEK/K&%"*.Z]6$-U="/ M2AV:!A^BW:R>GX^#\*>>X1?DAR,72;R+N#QUS?U76;7#*Z'MC2V56HQF-`SM M?J+Y:2/O#"R3.B$39F;6,3=<"5("P:EY#0*S;TYW2M0Y-8RLK3=+-JN4HYB^ M-&A$[&*7S4A6[N%*!NU'?WV*$0IG@`))5+?1HD:"9XK&FF+W<:E-G9]?@'=**J<1YZ,@35M?$W#C-DGH_=NF@\N3O)(%9 MC=U#VIB`@&X5,5/S(5HR][JFI];Z"PLD*N5GI^P`9O'7+,\G]1N$BW["\H"& M`F",*4X`/<`)?FDQ"YS)D$P3[8ZRC/$F]:SBX$%O\'SOJUPS=GW_#*Z/9"!9N+.H^/;62\:N1MBQ-PU$0( M"\D`T;UP^1*9[7.48W7LUM+11$(_$4<6@X6"MC`GXJ^6;C/(IH]]SQR1 MK?6!HBH1$R5@)UTVI.1N)T!):=!8W&OLU#DJK_F392N]`55`2T/I$IP?N[02R-X% M*5^E:_F$:_G!#%XM"+]B&7$W#8'K'@\?Y+;\1BB0=``#&L%-Q09`>IE3P.%X MA:1'`2S\6V1*GZX'^H"K.-,5_8`8G,8/L#2X(6*ES+C)_RM86]10".7'YA>E MF!`T)E:N*CXNF-X._H8:Z`$TG+*("L>?@G6](B`0X3'`M#6(N^F.D3H0LGX\ M$LT']9?C=6*.>E76;%8NO:Y9=$K]%7K]UU2QG$Q`Z*6BF8AD3/]1W, M\;KN4,+%\22WB/^X]L6W!NAK;@23KS0H\BBCN$;P"`^TZ`F!:S:03\`08,64 M]-ED0#)S4[,_VW2)0$=*9_+!5*LR!B0`/O,<19:H0\3-BI;HD@G':X*!CI0S M#LR(TI8=9Q[.=S?5N?T^WDY:9M$%-&>#8#,OM<3NB.VM8;*++I^2UAN0ZQ^N, MX$%XLG>VJ.^N#-K^/E5YP$/T5!)H9Y47+8T`*&V64>(9M"%IY@V]$LQX\4P< M%ZL+L`Y=!"L\VZ)J66A[_`Q/Y+ZZ.04F])3-MA=^!$>"#7Q%>4C"%:RLP]`" M'O%27P0E3*>(31CC+A4]J$V_Y9##<-S;%A.9P*+L;%44(&*TX;$'(94T=!RG M>8E\?PVYUPF-HN4KO9DC[N0>,<'D="R!W;6?OU%9FS%S/%>Y'`%&!=$XJ9"H+$1Q<.;W.DE<#$S#3Q$.,!005AN?21!D^8KY$8^QS3JAV("4 M@'DNFR`V*P$/]I.0,%*'#2H28;>/K"!`1#:@II%2P]D*VG2W2234L3L[6GPU0O.`HR'4,,`F"=#74^G\:'$2'4*59C["+(S/4B`3 MVDS"Z99$J6R08/XP,GD@B!L5]/%#E.]1K132-B M9I\#!97-OIIT0FUGW'&O#LY>FC\N!(A77_]P3Z#,T-QW!V4Q\-E8^"!\+`/$=2D7S2,I.[(VA?DF!5 M5,DXQ<.4:J]^>&$P"7W6F4,0LS%I2`[YD26#7"O8<^A*=D=LPB&1]4DZ0C+V M0"[,;W*7<94U03(F;8UNT]?CASOR:A3^W*J8>?Z9,NB___8&G"'IX5@"7#G)@7]:/GZ%A,X9_Q4B+'_J M[I'BW*_4A>"`*7I1R4;OX5O=W*EE/U/TNEKSY'OSB/E-6,[?G].\XCX%22P"<[B^QAN/R MED%6/LF6/-M3J86Q($2_5B%/SZL%%?2\4F?E"4M[3O0_S>(@XYEV3[6E[6U7 MIF)IA!ZTRZ3H>:U>A#VO(!>]B4"7"OETB478KO7JZ>[MK&_W*E-WT1!ZW/!_4H5"^HE5I_6F`'O5O8I?.Q6X,)S(D[:Z];S?@4N M]KQR@CS?K]7_X?E>K5V5GM=J0-KS2OD*/:\U::)K%OIEE9?1J^R-#[K="HQVN0QJI3;Z=$"O[9GGNS4VVH->JL5+T*9KN+:_OE4M MH0?&[E>.F'HIE+5J'S'U;RMO@X`5\(-4%:3G:05O+V^\[!X>&[#V_/STH1X(F?=UZ].^V<_W#< M^>OQP>E9Y_CMT?%1Y]WA^3N518C6;Q-0MVP%4G[**:E-KDP3;P78NAO6+D+V M7R/NK5VV'UVU'PW;CP:M1T=#6KV,K*A$N:Z7[I/^_;?!HZDGK=^C3/[[;^-K MWK*2Z$CKY7N'KM4QQOCWWPY)"N'==GW*XSGMX8_DG3*7!Q_G(_UDGD>4CG*^ M@^C[HYI[\!:6KY1;,PFV?&GAIB2^*JF2N[WE[2@'2@LR'>=H/+UX1#^-*F++ MAT!]]WV9ELIAUJC*1VX"-W_EE][./O&&K2K="Y;9'A_IN]MO#VY%"-'Q:[_T M=[CU-UM5L!=,VT+_-4(IM[;;CZE>M,.-T>^V=BNA&TF]#:&LS'0>L9)IQ^]) M'U$MN6D#2(R^B30X[YX._M\-O%$EH)J!%+WW`D((]XSAX?5H8=8H6C@D\ M14BBFYZ@OI)>&`QHK:6:T<:W\5J.FM=HZ%=SMG&@;+5'#Y40>;>FC^#0+DM0 MG:6LO\ZQ17RV7TAM)):>Z;F\(Y/6B9Z1\JQ4=,%HP MOXH<8#"'/:&=8GL(H8S'^`4](7MMWOZ:ZNKX])HOY5'T+Y]K"[)`%TNO!\G+ M@?<__WL:!$)0?G-)MTEJ[O%EZ$.>K<&N* M*O+-2$6,=&CVV__!W'\*35;PMKF,5CIGF7A5G6H4 ML/9:AEC=9RIB;X9E\<&0-=]4H3,+JME&8$TRB5K`_O7P2F%NV%2))[`P(8TB M;WWTI!RZX?5_YZ;C;$*]6J#*BYQ(8)!NJC99K/FP??/F7XG[)V>,5F34V/F8 MXI%;8CM&9>\#_AY)P.QL*P$3P/T#/<9;&\\:<5P9.`)=+VA M'&O516S6/S29Z3#Y2L2E^%>LU)Z*L2%BSKNN,WZ?8@"HC#.GS8#OUV85(36= M')KRG-8__FL:#)0[7%A_?;4-V345P@^I5CBB0#;Q?`3E0;#JXR`VCR\F<'KT MX9;RD!->`Y\GE-YN[6I15>G5=A53"CK592A8S45*[NQEY8;75B\WO%"2C0B3 MRK7".V+Q[!("RUT]JR#K?R7O4N.5PL78\BZ]RRLRBCY2<.+:T9`X@9O)-YVU MK&["N207T"*^UMKV6Y(<8*.([Z?F&;0@J+.A5?%H:1MOG)!*$,"'Q=!"@H1+ M4[I3H*G&VS9'R&IXW%(5I-G@A[.CSK/65C`6;$3#4$NSG9'[D_1>[J160K]\ M)ZJ"1)=-AC(VW,#)6Z#:\5*8Y<>]^N,W'C11ODV-\R\80UJ#9RQ[5:AU>B!& M'6Z9OGHSGK0FBYJX@KNGI-,C!>#WS\3@:FZ19&4="!%`,E>A`HIG\^))2:]*+VI\WP4E15+#%1=/DA!HN M(5+5!;-ROCGSB&.Y!SO`HA7@W/!*0F%AJ\0L,_M1!RKU;11I!HI6!4^);GW MYN;H[[+YE5=`"4%V5"S=W7L[X(W/'Z.&W`A2T MU.H1??S/0SM8TM(SBPJB1,7-$0M+EQ!\BW8,F(>HL(UR4+ZT5;]#Z9=9O5LA M?G)_)3.]500W+,Q$HFB=60;YYO,[?0Y_R#XOE\;6IQYF&7*>"(6]44^G\L5F M5*=5\B>L>\J7\L4@2(38/QVQ]/\P.GE%&%Q_04JT->5UL/76S9B8U:3YS!NY M/A;A6!A'3VY8\BK?\PG]*["71DIM#%Y-[(P4. MT=I#-R/"0C/0MU9O6L?L.[P?"Z(VYGQ)B?/H&K$FN3(I7YRT_;I2)SG^7V@Z MUC5,S.Y33,=FE(Z%O8C$#D9IX^^+3T`O=2'&3:6;&Y2>Z M9'C^Q^)!D3SHN2"]Y(I*NO!]Q,D@U,E3LN0..'!7Y,J+_U^#V_OO?/DE;FH; M,P;Q"U]_[;U@\T=8D41L29]?GN,)^E5![>4'R=\M*_M]4K;6POBM>TT+";^! ME%G6M5Q-%ZAGHL76+"\#M,T]H48&Y-^Y@*L#R\7',G&$PYN7'54)YRJ_HC<<>*AF]ITQ3NW.BH9QL_MLQ. M64=K=4B0G@`3`R@A],`<`.5T#8?Y1:Q0DI5_;)H;A;>O2*S3.%"=8HV7#-+, MF[_?&7A2!=*F-%\RHV'L4TJ8(QZUY,]F17,&6_"MXA:TV*=_N736D*)AKD]S M79@IW\,#HM<@Q!ZT4*?F15K&5*/NLD+HM/2%R>BRLP8V^\Y;]'5L^1D"C84R MRQ]TYN4DB*+YI-C2D9N21Z@D2`&7]"N;0BT0(YY;;^[3[6[^25]<*[L^ M9&I;/G+)-3@H5&?+H@7G?(+8[3*.&B=+R:3^`KF8(9&+2S!4.-"G5=\74JLC[F)52ZH4E<^?P@L>D6IXN(/2.^6+TGH!ZK`,XR/"0MA$9#([,: M2400C5KQ27(TB:$)Z?2?$!UIN6%'$NLO@7YEIJP`J5.?G8FR^8>PAI92) M!W0XH:T?>;86?'9HSF3F_$9BM0SO>$G)*P:3Q%K'=Q1X':@:IA;,GJ58242C M?@F%%LCPIJ;&0^<3'F-6+L\"_T[-WTNP)H1>X3"-$88[RL`;+[RS5$1C%A*V MK=:,LQ=:;CH+'F([X%13(S_5MM1[/4E(8[#,\_FM& M:Q];&A_C'J)GMN?EBQ)7I?557.%31NB3Q^?PVVTE5;07>4KI:R]_\7ITW5+; M=X+$V>E20_9+>1K[&]V>9M)_R]^Z_0U*V/"C_5'^&IQ&G=Z^QFV1@).,:9O1 MD>IDS+^BXMEXI);K*G.]+LVMB%P^NJ5HC=CER'RE(1(,`N>N B.H:_?VXH M6Z.79X+0X/&YE5C+%B*##XN)`$F;;('SP&L3-!%IS29C3:+T<7E2+\=WW)4. M??O,:O)1UD!V#%7-1RS/+N]0K9"?'F(RPF*[X)*XO64F@X/Y07OE3FK!1]I` M"*B:FGXR&_=7#O%J:C[IB"L/B&\4HZJ&#):?OM9M<1(\7N6/\;G;QU=9R0$A MQK?C"UIO33H?WUA!B58@+[PX1M69-5>DA.,5RZNE$2T#[3M.%LLBQL_7%@19 M+OI\K`!)AT&R()J0AO&3;T-4!E9\3^4HOT_+47J*`!DKJI0O1C$IFL\R&FVA M^BG=Y;`QEPWB6^^EB(5YP&LXP^*XR7*QR`G24G458:G]E5T%K:)\,6L=M-3; ML+G<8Q5Z0FR5T]#%!?-I:,Y1_F@A?;$#8_EC[)VY4KMO1\'YGL"&IUE4@.`3 MNBG3F[&<.9HTJQU\RY=57I:H%!^-!1@M6520L!PNI$80_FOY:;.HK">!NMG- M?S'CR$N^::\KZ_O(]N]QLH"I2U=FK\%_0U,V5X!BPV953+2F*.6*R]DC#7TE M?$*]?=H46>7^I;.YVOJTTR`<88H,)DEI&6N">J_AI^ZH3YD,J'MQA%A1O%SH MRA^:A-847B_'.5Y043W._4<,H=Q'-W[-%%N?LYQ60?7RO3R:557,_5K_`,R] M`\%*]\+AX!\N"(Y>OEH5\'(#U9J-R_'E))15Q#TVA>:D^$-[BI##U^XUH9Y4 M:;%<5K*%^_A8U""OH*9SJD3$23:)5>MDR4K3JL#?8H'V MV!`+3WT.P4:7J"YWA22'92SQJ=4?EO+85*3`9$>%8HRNO0KOG-3?4)E`KA4= MR\M88T%W_4#VDQJIG$+GL/FL6683@$O8I:4R MER,4*SQVDT%[;=].)H\O_K\`````__\#`%!+`P04``8`"````"$`$M,\PP4# M``"^"0``&````'AL+W=OX#NY+6I%^LW1__WJXF;H.%ZBO4$M[O'1?,7=O5Y\_ M+7:4/?$&8^&`0\^7;B/$,/=]7C:X0]RC`^YAI::L0P(NV<;G`\.H4D%=ZT=! MD/H=(KVK'>;L&@]:UZ3$][3<=K@7VH3A%@G@YPT9^,&M*Z^QZQ![V@XW)>T& ML%B3EHA79>HZ73E_W/24H74+>;^$"2H/WNKBS+XC):.Q?.BS!T_=5"%>@/P3M^\MWA#=U]8:3Z1GH,U89]DCNP MIO1)2A\K>0N"_;/H![4#/YA3X1IM6_&3[KYBLFD$;/<$,I*)S:O7>\Q+J"C8 M>-%$.I6T!0!X=SHB6P,J@E[4YXY4HEFZ<>I-LB`.0>ZL,1N-H4FRA)1::EB1Z0\VUXO*: M@9.:.-?]%F20A34Q'YUKR:'/`KO1WETVX#(3;KQ64FQ!I1:4ENAMC">!>IF2 M8E1BP,GY=G**C,-)L05G-7>N)1HNRK(H2Q-KKPM3DD[C*'SK5`-N]A$X*;;@ MWDXE?6QHR2B<*1F#"^&PO;YT2FWAS:1(T?>5P7IW>,RL"H-!XN._[_ MQY>*LB#L\VNOV;<7-)<)*8>TK/.%=0VH)[">5`/:X.^(;4C/G1;7P!AX&?R< MF9Z_^D+004VD-14P-]77!OXG8<@_\$!<4RH.%W+"'_]YK?X!``#__P,`4$L# M!!0`!@`(````(0!7&$_AC`8``$T<```8````>&PO=V]R:W-H965T&ULG%E;CYLX%'Y?:?\#XKT3?,%`-)FJ4'6WTJZT6NWEF2$D00TA`J;3 M_ONU.9[8YS"9AGW)#/;GX^]<_-G@^_??VF/PM>Z'ICMM0G87A4%]JKIM<]IO MPK__^O0N#8-A+$_;\MB=ZDWXO1["]P\__W3_W/5?AD-=CX&V7=>WY:@?^_UJ./=UN9T&M<<5CR*U:LOF%(*%=7^+C6ZW M:ZKZ8U<]M?5I!"-]?2Q'S7\X-.?AQ5I;W6*N+?LO3^=W5=>>M8G'YMB,WR>C M8=!6Z\_[4]>7CT?M]S`=1!]SS,R,4"D MF]AK0!/+)1,;\";4/EQ"+B(R,4#4E#*6Q!&)2('[LYA?QB-:NE9OCXS+,KB MBV.(5K*$E@$36N)B%F@!!&BQB"DW+=#R^S/)7#01*[,I>4O_[:HV8,)*$E8` M`58RBB0IO@+U8FA'>VZF! M3.M?I[`N'9::)^4V3%X+GIRH^XU[[USFZ4K+&6#`_9C%1#\*W,^%2STFN$CG MS3F(K$5)]#*W&"#&HI@LB(+TLVO$%ND\FPL]76>YQ0`QHQ)$18HW`#AFB[2> MS<5>DF3E%F-C)F5$``4&*,&OK<-%@L_FBB^=8MMB]R6=238+&NKW]RDHGT?)E3KCBQ1_0F-1I0>9W&*`F#(G&;R)%AC`HL@M M(10SODCO)S2AYGR&9%H,4)-)FBI::!BA=W#N=!>36Z3X'-3@<"H3U@;T8D!-,BBG_;T8?/ ME3^FRF\Q$!C%/(6R@0,;T(_V>430?`.Y740F-)97>K3)+08F9E+J0RF1?HP0 M(E%7%H)8I/T3&G^0B*GV6XPGKWX+C@S1]MM2)T"_?9F-W6J"U6@Q-D*BXP46V&-V#PKEK@=`U-;I/<"M%PG MX+*1>^O'4@.,'R6O!4].--W4D/KAAU$QUW9ZBLHM1J?'$9U)`=BY@L%$B<(; MHHE.P0]J:J[T]"M2+GPIY]X9>0IF<;4;TR-*_P-:Z:^8D&[XVT".XTB)$GN@ZI[,S0S7!Y=+*]P:Y6R=3Y=&I+W0MTE3^^K2H2]SSN6^ M_KWL]\UI"([U3IN,[LR"Z^$Z"![&[CQ=/CQVH[[&F?X]Z&N[6M\R1'<:O.NZ M\>7!7#A=+@(?_@,``/__`P!02P,$%``&``@````A`,YK^B'8!@``E!T``!D` M``!X;"]W;W)K&ULG%G;8NASU%*WCMI">OS]VV'? M^!JE69P04'0G9)NDAS.EK^MK.3FD4 M;HI&AWU;6I;7/H3QL5EZ>$@_XB/9;N-UU$O6;X?HF)=.TF@?YC3^;!>?LLK; M8?T1=XQ_GWPFFS<5@_C%^/21J^["GN;\()UY7OXHOA M_A"OTR1+MGF+W+7+@9HQ!^V@39Z>'S\#]-X,XN/$66;YDG/P$N2?-'4\4:;J'';:#TH9F"5-C;1-GS; MYW\F[Z,H?MWE--TN1:0#>]A\[T79FC)*;EK2U9[6R9X&0/\;AUA+@S(2?BN> M[_$FWSTU;:_E*LL61&^\1%D^B+7+9F/]EN7)X=^25$1T<2+/3NAY=B+HXP<; MV^?&]*P:BY8C7>7?,P3G[(6>E1?9$H[EW1$&!5SD@IZ5#]'R7=?Q?/7Q9'AG M+_2LO'P\&>K,3R1`DZ%)?6MEG[7P\ M';1RSLWI0]7\$PG1G1%12U1\J+Y])2B56<8]&VN7*+0I!+\S# MY\6]0=:749*=0UVKQH#U6):!B\*.:0,5`>_E#NRF9T2@[)ZL)12G).M^+H6J,=]]#01\,`#4,TC-`P1L,$#5,TS-`P M1\.B,ES#$SRX9<6H@EO5#&V:C\NDD,Z,2;%I#=RNR]4DX`28 M#*5L'D?/Y#BB5WT=!#0Q\-`S0,T3!"PQ@-$S1,T3!#PQP-"S0LT;"J&5A>J5C? MD5?-?FK2K%TJI+1`/)V2XQ4U5DKE!K"NNIP@+1>7+R-8PO9@N?3K!$$;*05S M.V"$0$H!@QPR@N\Z$E;;B!&4Y[B@[C$C>+29@T%..,%V?.ABR@F4!NABQ@BN M8>. M-)OKR`U@BCHE1Q4Z$I;GHTRZG""-]/3J!)\F&7KHUW$E!<8^J..^:R1OR''/ M`Q6.&&YY"A0RKN/*(IGR$CMA.&W3X64YY;A4$-^LCGO*M6%NYPRWA(#JO*CC MMA?0'Q_@DA&D=&T@K.H$J3Q/7$-@ZJ%]W1WJT6RN'H&YZY2%$!+<#QGN*.N:EV)=CA@N;!NF9ES'?<^[+LJB M^:0."^G[,"]3CKL!*'-6QP/;`GA>AY6-O2_JL$/"@\$O&>[Z$D:_8CBMRVOW M3#3T*_(.T6@VWQ)XQJNKY-2V!&CHH:&/A@$:AF@8H6&,A@D:IFB8H6&.A@4: MEFA8U0PLK_KP#']Q_7QSKUOQ14FZY/6B4W*"HJ1;+82[''9=B_U!]>IQM@UO MUSZ':X6G6"$##H/O(4?QS3/BL`.+=\QA&^`)AQT8^!1@6!PS#ALUG<,29F!1 MAT7+@[JP!!CZ7G&XMB5B^J$SE4_H1[="_4!J.B7GA_KA\,_TP]F&?CALZ(?# MJ!^.&OKAL*$?#AOZX;`#4SP%&.9PQF$;=HQS#AOZJ<.D'ZSL`$/?*PZ[UX7! M]*-/U3XAH*(9*@C"ZYQ)Y:Y2TO&.3S6&5ZFNP:%#?^#TD".4P>DCIZAFO*\! M<#QE^AD:'',\(^0$9EQCX"CA&6.>(,?219B/>0H<+S`Y,^3X)F<.'-\WQ[P` M#HW9LU!TP/$"VFI#Y5@!1SFT6[URN/STH=?][S]]F&L4,%@`G3.IDI]/8\7T M=@V.8W!ZR*$K#?331XYCIG=@<,R^A@;GEOS*X"]Q*3.N,?@):%.,8YX@QS(E M.@7.+=G,D*/,V.>D3=/%6EZ^=<0#'?+262W8%_I2KKA6 MNP!T)W8*7Z-YF+[&QZRQC[;DTFKI>Y^TO%4KO^3)J3B@?4ERN@TK/N[H]C.B MXS&K1>1MDN35%^JX?;E/??X/``#__P,`4$L#!!0`!@`(````(0"^<9R5YP(` M`/L'```9````>&PO=V]R:W-H965T2'Q][N'<<^W+ MYO:YKIPG*B3C3>(&GN\ZM"$\8TV1N#]_W-_$KB,5;C)<\88F[@N5[NWVXX?- MB8M'65*J'&!H9.*62K5KA"0I:8VEQUO:P$[.18T5+$6!9"LHSDQ27:&9[R]1 MC5GC6H:U>`\'SW-&:,K)L::-LB2"5EB!?EFR5G9L-7D/78W%X[&](;QN@>+` M*J9>#*GKU&3]4#1*&2V\1^6$`<.=`I;IGFM)UR%$J7O^VH.!,94EF M9Y(YJ#_O0^AZ,K)"3%TI5GB[$?SDP%F!5\D6ZY,7K(&P*\B^OB_Q;Q5":9KD M3K,8+A`OH2M/V]5RM4%/8"4Y8W86`Q>AQP1CQ+Y#:-\T;3H((-#;BX9RIZ)# MZ.7;7>@TZJ2QQEDT%K![`S)&[-]`Q&-(>@F)9SUD5$8X+N.Z?`V&XS*P;Q'/ M>U[CU\YBYN:T:`/WTT`Z"(RD0.O_WU&=E+A0;]_15>1/)%D,/`>8:=\[3-_W M06"D$N[(4.5UPS1XJNZU$=8PBQFJBZ.)J?L.TZL;!$;JEF-U^BK]^U3JI*G* M<.*AQ<2QN5B^-[7/;K]V/1T$1@*CL<#K]FGP5-C$FIW%+(VN61!.>K\?;@?A M8GI11MN!O^RKMJ+M$+;#JJ:BH'M:5=(A_*@';``O[:-V]N]@]IM)B?H-F+TM M+NA7+`K62*>B.:3Z7@0M%'9ZVX7BK1D-!ZY@ZIJ_)7QD*=PAWP-PSKGJ%G`. M4/_9WOX!``#__P,`4$L#!!0`!@`(````(0!S@--;'@,``-4(```9````>&PO M=V]R:W-H965TTFPSW<^?^>"#^OKQZZU'C#CA/8;VUNX MMH7[DE:DWV_LW[]NKY:VQ07J*]32'F_L)\SMZ^WG3^LC9?>\P5A8P-#SC=T( M,:P+-_3XA9'J&^DQ)!O*)`NPH_1>0N\JN07.SH7W[5B` M'\RJ<(T.K?A)CU\QV3<"JAU!0#*N5?548%Y"0H%FX4>2J:0M"(!?JR.R,R`A MZ''\/Y)*-!L[B!=1X@8>P*T=YN*62$K;*@]0U4> MMFD232$:XH.H)8O5^&L43KI M&OU$%Y"]`-$1^0N(I0XI+B%+?X)H801Z&&_+EV!HEUGZHJ61P$QAPK%;9`)S MFTL2'>J:)I'$ZACB7,%"8>>\*+7-V:*^NSX&*V MH>D#+?^O3SJ9^B)=0:8PR:@O,SA5'BPR",4CVX?&X/ M?-VTI(NQZIQ>[VO7SJ9^HVR9PJCVC9VS;LLGYO#Q#.N.IA` M\@3E'7J^*5Z-%W4-=YCM<8[;EELE/\T"TH+VUDF->7<(C- MAB?L022[@I4*26J64P7QRXQ7\L!6))?0%;1^WE4WB2@JH%CSG*LW0VI;13)_ MVI:BINL<\GXE`4T.W.;AA+[@22VDV"@'Z%P,]#3GV(U=8%HM4@X9:-NMFFV6 M]AV9WY/(=E<+8]`?SO:R]]N2F=A_J7GZC9<,W(8ZZ0JLA7C6T*=4_P6;W9/= MCZ8"/VHK91NZR]5/L?_*^#934.XI9*03FZ=O#TPFX"C0./Y4,R4BAP#@TRJX M;@UPA+Z:[SU/5;:T)Z$SC;P)`;BU9E(])'-@UIE-P)_QS"`EO>=.;S); M`2VA'"^KF$0+]P4L3!K,_2F&M`@7Q-L(0/7Z"/2F803^<0`CD/$`)L,`SJ>N MP5I8%UE[<7_XP^IY,1L7"H9"VNOP0Z_U)JB)W>>/6WZ,`3&!Z>&^M=!D3GOJ@;W%+O.P!QQ&15)Y+US1.)K%#58*W8-0TA7 M+91%3",[">.NV`-O"71G/U7=L0$TPOF4S:YA!+'O'16W`06FNE&W.M3_O^F$ MHZ?O0.QWSJ(#!$'8SY/8GP9M@,,0]!BYN-H$ATY?.IIVYC;2"#H]KN1H$ETV M(,RNCR9$`QK1'!E*%Y08)TX_S]@_;C*"H-G,U-ASWNMN_2:]PN+#G.KZ.PJ[ MXC46(V@DW:,!=:'%.(K.#V&"H!'-HQ%UX2DZS*HNSQ&+$=1:W'4Y-C'>:/"% M7]$M^T[K+2^EE;,-'&7/B<"G&N\S^*!$95ZK:Z'@'F)^9G#O9/"F\QP`;X10 MAP=]8VIOLJM_````__\#`%!+`P04``8`"````"$`^PZ-C5T%``!%%0``&0`` M`'AL+W=OE#6V:.A^.9\;'QZMM;<[1> M:=?7K%W;9.':%FTKMJW;_=K^Y^_'A\2V^J%LM^61M71MO]/>_K;Y^:?5F77/ M_8'2P8((;;^V#\-P6CI.7QUH4_8+=J(M>':L:\H!'KN]TY\Z6F[%H.;H>*X; M.4U9MS9&6'9S8K#=KJYHP:J7AK8#!NGHL1R`?W^H3_TE6E/-"=>4W?/+Z:%B MS0E"/-7'>G@706VKJ98_]BWKRJ)N&;NNI8SW;#`L(Y2'0Z MY]1)'8BT66UKF`%/N]71W=K^3I:%E]K.9B42]&]-S[WRO]4?V/G7KM[^7K<4 ML@UUXA5X8NR90W]LN0D&.Y/1CZ("?W;6EN[*E^/P%SO_1NO]88!RAS`C/K'E M]KV@?049A3`++^21*G8$`O#;:FK>&I"1\DW\/=?;X;"V_6@1QJY/`&X]T7YX MK'E(VZI>^H$U_R&(R%`8Q)-!`F`O_6#Z?+"#1,2\BG(H-ZN.G2UH%GA5?RIY MZY$E!+Q,"%\_3O&C&<+4>)#O/(J(!>1[*,OK)O7\E?,*J:PD)D,,K(010W1$ M?D'PO/&PA6)P@.](&J9KDO:AEK>K<.'(!^D&F$!T"T]@;AH*Q:!1@=*K&?V<"@>O;9CG M6$DO-:N-F$CT@N\'@9'J7/5[89@:4RG0+Z:B$85E,I\H!^M$?8-'AI!8\"1Q M%$9Z2G/-SY>I[B_0/^49W<.3@W6>H6LD)$.,)!K&J;EX-+\71*E!%/U3HK%. ME`O`UVN)#]()IV9F,L0@X2A)##ZYY@XF]5?=?IQ^L(+XOFJHU]?D^2!S)1EE MSQ"CK"334"@&K4%3G=+G*XF#>1ZY8GHN,9HK0[=,860J:H[N*\E",6B<"(BC MFJ?/20FTPLK,C?0CK3`.S,I*O\)+M>C$N,(K!?R"&.X'8[K,M4S0C\0"DAC$ M<^E7B>$(8=&)<16?3PPU?R1F;`D903\2\_S(\.?2KQ+#$3>(<06?3PSU?B1F ME"HCE_V`-V"0&/V7C^[KCGP9P$])ZI9,N&#/YX7R#I,H MS;HS'YU7:A]M&?R`=@2IVDX2/W'-VB)`I:=8 M]+;C,CR?'HJV2B\.C:;/B*+LXEB53RR%:M'Y<`F>SP<%&];4N`RFASJBJ+KD M8UH*%:/Q\>Y2?H$V]W5#K#()2A*Q+MV%:W:7!"CE4RTZO;OTW[OH_S5=<62> MDR3H^O9\8BE4B\X'6F-^^3R.-D\2$SX(4OF8ED(&$AB=#Y?;V>WDH3A#>*6= M)N5#D"Q?O'#UG_B7ATD]<<1U!H5\T0V^=^T"WG07B%-S.4K0]>WYQ%*H%CU_ M=TD__P;_NIZ*CN-RE,.N#`O5HO.Y2^N]J=9//[0D2)XMW#@V&C#7`"1TB?&I M5DC`C6IRU9W??:C1>O>9!PY/$7*9/=-2J!@]>W>)O8WV-*?'8V]5[(7?5!&0\=&*MV@9W**)*R=G=,`EUJG@^'#P$[BCN6)#7!])?X]P'4EAY(N])JM9=G MFC@)ZA`BH&]_OV7*0+GHR<++3*?JN'Q<53XVWGY]+R[6JZSJO+SN;+%P;4M> ML_*07T\[^^^_'K^L;:MNTNLAO917N;,_9&U_W?_\T_:MK)[KLY2-!1&N]*X;.$6:7VV,\%!- MB5$>CWDFDS)[*>2UP2"5O*0-\*_/^:WNHA79E'!%6CV_W+YD97&#$$_Y)6\^ MVJ"V560/WT_7LDJ?+K#N=[%,LRYV^V,4OLBSJJS+8[.`<`X2':]YXVP MRO)90;\?E`D&.Z/1CVT%_JBL@SRF+Y?FS_+M5YF?S@V4>P4K4@M[.'PDLLX@ MHQ!FX:U4I*R\``'XURIRU1J0D?2]_?\M/S3GG>T'BU7H^@+@UI.LF\=2C]^YE48$[;[RN$M!&S;&FS1HX[ M7]^FQ&"P"N:P4F!>WR5CA1A27VY(B,&@$LZAHL`J06H?>ZY8,1;H#EMWZ(?N MQO3'Z!]8)L1@D%*G(M&>^U538$(J,">-T(VD`F_EL]3%Z">DB,$@M9E#2H$) MJ:$[L8O0C:3\0*Q9<\?H)Z2(P2`E0-VFIZI%$UILVDC[D9O0-"0N7AD2:C%Y*,4F/!1MYC_OQ"HB]M(E\(C]T!8D$.`)TQ8C&)*5F>3@Q%O"\@C53P;AW#[RZ`6`Q>'FS#H8630X& M-G&D_7CM"3Q6Y[AW][RHQ>0UZUCPNF-AN$G"%Q$[X34(R0F7:5? M61)J,?DPM9^FKAX*.K`C7P=\@VH0Y<7/@81B3%Y,]>^KJ_K`IG>U48HZ65=[ MTE\R=ZR'#TP3:C%YS5)]CZD^VW21]F/;>^.VQ^&4%[&8O)3H3F][E.A>PT:E MZR2\U;#1;NR\PVXD%I/6+,GW.LD?VNJ3W8@@_.H,1M^<.@;-&3D)3'*S=-_K M='\@%ZY8)T4:-,P>CRP)M1A\U*UF>@U;-/^H9)?]2(,(GY$EH1:3SRR=]\.=B M%+MA4%2DB`^Q^&!9R.HD8WFYU%96OJA'5@%/$+T5'X`C>`!N7TN=W@'OK[?T M)']/JU-^K:V+/,)0=Q&"WE?X@HL_FO+6/@\^E0V\O+9_GN&E7<)#I+L`\+$L MF^Z'(MB_W>__`P``__\#`%!+`P04``8`"````"$`L4U29=D$``!]$P``&0`` M`'AL+W=OOM"NM5OOQ3(F3H`*.@#;MO]\9&]SQT,U''THX'`]GQH,/>/G]O2R\ M-UDWN:I6?C@:^YZL,K7-J_W*__NOIV_WOM>T:;5-"U7)E?\A&__[^N>?EB=5 MOS0'*5L/(E3-RC^T[7$1!$UVD&7:C-115G!EI^HR;>&TW@?-L9;I5@\JBR`: MC^=!F>:5;R(LZFMBJ-TNSZ10V6LIJ]8$J661MJ"_.>3'IH]69M>$*]/ZY?7X M+5/E$4(\YT7>?NB@OE=FBQ_[2M7IZ;-<(@V#@@. M)`1PM,UOT89D7K<9TV8X4`I;V_OQ9ZOI^=WTG/Y)$!Q(".#(O;M%+I*YW#F3 M:SBDE`:8ZR4'W%W_N6,$'Y,0P%&+KQUL*;S+XYD7RI.0V':..`X$!"`$=;"$\R+>!Y<9K-*\C8#1`R0A"*N M0ESXB<(K:VGLPJTE:[8X))YBULX!(@9(8A'=P)]+GJL:+>%VU<9(7-7L=2/& M5W)8)VA].2(&G(0BKE)T`Z+T0@<8[[C0`<1@NKIR1(0<22CB*D0'(`JO[`#C M&VXM!QU`S*53RA$1]HB>;_8FD]BK@S4`/8&HOE!7XR"N6N;L<4ALIE/+$6$Y MJ';XJDWX;HW1)8C:*VMLO,55S2H4A\2`.M4<$0-.0A%':723;6GV)5/M2.2) M&B!B@"04<14RJ[JNEM$7EC7C_=J1J-*!95D.6Y]T[1-[E?+]V)*H6;T+7+F$YJ';.7L5PN\/R38W-[H7Y)BYEO9<;612-EZE7W)E` MG[:HW35YG."'!L,%[*;HK0>&Q]$B_HJ_B1;PO855LP-@\^.8[N7O:;W/J\8K MY`XDC$=WL!S79OO$G+3JJ+_`.[<;;^ M#P``__\#`%!+`P04``8`"````"$`93^]PX@"````!P``&0```'AL+W=O2- M#22:U]1"_J82K3FP278-G:3Z>=W>,"5;H%B*6M@73XJ19+.G5:,T7=;@>Y>, M*#MP^\49O11,*Z-*&P$="8F>>YZ2*0&FQ;P0X,"5'6E>YO@NF=U/,%G,?7U^ M";XU1^_(5&K[28OBBV@X%!O:Y!JP5.K909\*]Q<$D[/H1]^`;QH5O*3KVGY7 MV\]N&%04*")!JEC8JJ&!.`72>$F`PI"=_ZY%86M'(%"PD9>8,/ MU-+%7*LM@J$!3=-2-X+)#)@O.P(K#GOGP#X$DC70A)K`V\(.#`EBU%E/ ML[[U@!GY43IV.CH5NLZI"\HQF.D$IVG6&0E6`R;SG1C&<=Q]/O$)(_;_A79! M??E^I0-F[.635^6S]\B[H+[\I+,7W`=,D$]?E1^_1]X%]>6G/?F`^9>\NP&N MWE\.W)/-_C8UN`Z8T//D@NUPB(4]WM(5_TKU2C0&U;R$28JC,71-AR,L+*QJ M_8Y:*@M'CW^MX*;AL.'C","E4O:P<(=D=W&UL ME%3+;MLP$+P7Z#\0O$>4Y%UM5U&B&$UE]1$JN,MW)1*2VKAJ"MB.LUI MX9-D0](X'A-)18L#0Z;?PZ'*4C"^4FPG>6L#B>8-M5"_J45G+FR2O8=.4KW= M=7=,R0XH-J(1]N1),9(L>ZI:I>FF`=W'9$C9A=L?7M!+P;0RJK01T)%0Z$O- M4S(EP#2?%0(4.-N1YF6.'Y-L.<1D/O/^_!+\8*Z>D:G5X9,6Q1?1$F`PRA1_]_$(6M(Y2N(^QY"H+Z^2)#W_T6Z MI-LBTTE/[W4L`N3>N^N$+:\"-P6`,]<%O.V.`X.+5\I'X[_"PIL#QD^J#RRO M`C=O'MZ^V?5G^,^!N_3')>48Q/3>3\?/W%\$S-AW+QD-DN&M-[!%CN-\/YRD M<7\?Z@L[$F9)/AM5<)!D8#COQ++Z$E?5QTE_`RG2T MXE^IKD1K4,-+H(RC"0C78>G"P:K.=WBC+"R+?ZSAV\BAE7$$X%(I>SFXM>Z_ MMO,_````__\#`%!+`P04``8`"````"$`P6JMXI(%``!_%```&0```'AL+W=O M,;?`'R_8EM*VVR^M]?B8UWM@?N+6_;G_^:7TES4M[PKBS M@*%N-_:IZRZ1X[3%"5=Y.R,77,.;`VFJO(.?S=%I+PW.][U3=7;<^3QPJKRL M;<80-8]PD,.A+'!"BM<*UQTC:?`Y[R#^]E1>6L%6%8_057GS\GKY4I#J`A3/ MY;GL/GI2VZJ*Z-NQ)DW^?`;=[\C/"\'=_S#HJ[)H2$L.W0SH'!:HJ7GEK!Q@ MVJ[W)2B@TVXU^+"QGU"4H=!VMNM^@OXN\;65_K?:$[G^TI3[W\H:PVQ#GF@& MG@EYH:;?]A0"9\?PSOH,_-%8>WS(7\_=G^3Z*RZ/IP[2O0!%5%BT_TAP6\", M`LW,75"F@IPA`/AK524M#9B1_+U_7LM]=]K87C!;+.<>`G/K&;==5E)*VRI> MVXY4_S`CQ*D8B/H<4=X"DW4@BYHR1/E&5CPS*&[+10=V_;I>^MG3>HE8+;[$P;I%K$PH(6 M!J5-="#5@4P"'%`TR(+D_P^R*`N5)0+:"6#4Z6H:A(5P270@U8%,`A0-4(>Z M!@^6Y/1B$IF@3K!LI$SXX5R-<<=MW$%7;"")@:0&DLF($CFL`SURM)C1170_ M>.H'A0B\4AWY6O3,R//'Z`TD,9#40#(94:*',&]$_\E508EZ.:(8=@R!V"6! MGI:>>#`2;HF!I`:2R8@B!U:U+.=^!JBQ&C)#?"B\(2>N'ZHYB;D1VXC[I%&L)-*@@/5*!N80+`B#T&5WLC4?7V]HRJ00\%**-2BB(6/))%#OKPM^*&N M<;0:$J9PJ9)H8YPNOA](8AT5]F`QR@XQ:$R:%EG,#>2L<=EO3) M5D-[IK;4.#2F;:6NAY@;*&EC-#[L:4/:/%=;I"EW!*M1(W-D7*I&VF=UC7"J MAQ$>W@41Z]4PKAAPQR'(H!0ITD]CPE%.(^-:RHMM0N)@)4;,%"Y5(NV]NL1' MSCOTVTC/&H,@:V+@F%LI>6)6P7@T3;F5!&6*HQHQ[;-ZQ)]-"NO52E(8I"0% MF4GACG)2&+2`E3+4G;G+(VX%M398^:%6UAFW@HT$9E!535OU;=7?R>560Y9Z M&F+]7I'-(/E(RJTD*#&AU(0R!5*CI^U9BOX'^SAKYDJ8#/("J;0,*('[`5J3 MDE5J0O068;1B8;);`?9Q6>'FB&-\/K=605[I%S]4[W8]P,-UQ%/_$:+A.WI- M08/4<3>"CZ4)W(O@6\3$G_SHB5UWZ$1^!,=_TV&WB.`?!F2F2"?'@SI29!"W@SJ2>(=OW6 MH<4&PO=V]R:W-H M965T7[+23A98F`$WGM2:U45=?V M[#JE^-XL)UY;(_MR>SJ\_?S:?0MK^JBO*PM M^V%BC?)+5NZ*RV%M_?TU_O1HC>HFO>S24WG)U]:/O+8^;W[]9?5:5L_U,<^; M$5BXU&OKV#17;SRNLV-^3NN'\II?X)=]69W3!KY6AW%]K?)TURJ=3V-G,IF/ MSVEQL:0%K[K%1KG?%UD>EMG+.;\TTDB5G](&UE\?BVNMK)VS6\R=T^KYY?HI M*\]7,/%4G(KF1VO4&ITS[\OA4E;ITPEX?[>G::9LMU\,\^T*8"#\;N)"F+1&V4O=E.=_I9"-IJ01%XW`)QJQWU>8H@)\HL*R?^@[#X(E MM:N%S]L>-$<%^+SK00O4@\]W'S26[FRC$Z9-NEE5Y>L(4A[XU]=4;"#;`R,J M+));%ZBWX@0!$D:VPLK:@KT*(:@AN;YM%M/9:OP-$B)#&=^4L:E$H"1$](79 MD`,1!V(.)!HP!HH=3\B;_X&GL")XJA7Z"NB).XR4DE`J(0+,T M*#I"#Y(6[&HY-Z?.]Z60K&MM2@4&$AI(9""Q@20Z0OC`PM_@<^>>$H9:@BIS M?(D`&XVR.Z&4@TY(J84&$AE(;"")CA""4*+>(/A^_@D]R@<16>[%A@\0F7?Y M%TK$A7[3A=E^9&D;=4**92= MM8T:RFC4$%FVK<"9V%/&RM"(N89+-1)=@W!<#G"0KM5I+P1FL/#-`8+ M1EPI:LP1%B1N3HABI2]Z/(\L6]B+\<#Z!IJ._EB`H1$@+`K M*$!(#[*"^@T=*:AW2*R@7BI14"M%28BN_B$2$IF*\;`BF^@2HDC9BX&`L[^S-HGFS_8P0F03NT8J2ST27X2@E':I M/)OP/H/6-<580521>3Y14@-9(`8)[H>;4EE.(&!9Y:UO2PBR0$$!0I"%"@H1 M8,J!@_"1$`GF;,)Z22!.D9`%6E!"!>D5 M;3;A-5E)];Z)%405>5564@/1%%/&VX[X6EZA]/[T,(6CBAY9">F#K&U`H0E% M)A2;4$(@&EDQ6VB$!L8@.'^K.)P0@LHHWK7`@&VL7^KH11%U'!@"NO7/ M)FSHBI246=N$XAN)]WY5:!59$+IY!=?/2FR@=/K:'")$1Q6;CRI$D?I?M/CA MC?.3]1DGRD>TQ0_5'-E/2T_T>O>V,X\IF M2`A)2)LJ`Y32H-"$(A.*32@A$"7$&NO[TX"8C7G62$@[T`0HI4&A"44F%)N0 MN)853Y2VY,KE-:N\R#OGU2$/\M.I'F7EB[A"A>/<9M7!\G[7MQ>>."U!362_ M;.U';PO/,'^!0P[HM+==3,>WE_!+^YZ!_^*Z<)'<'@"-7Z;JBIG]$LX]>&%O M/C]<>/'PBKUM>T7%[/APA]TF.L<=#Z[03/N^6.H`OIUZVT%7^R@?ML MB"KR9= ML:@OF^7C^\:>\7@\.)M?OE<7XUO1M&5]W9K.S#:-XIK7A_)ZVII__1E]>3:- MMLNNA^Q27XNM^:-HS5]V/_^T>:^;U_9<%)T!%J[MUCQWW6UM66U^+JJLG=6W MX@K?'.NFRCKXV)RL]M84V:$751?+M>VE567EU>06ULT]-NKCL M+N#W=V>>Y=)V_X&8K\J\J=OZV,W`G,4G2GU>62L++.TVAQ(\8&$WFN*X-;\Z MZ]1U3&NWZ0/T=UF\M\K_1GNNW^.F//Q:7@N(-JP36X&7NGYEU/3`(!!;1!WU M*_![8QR*8_9VZ?ZHWY.B/)T[6.X%>,0<6Q]^!$6;0T3!S,Q=,$MY?8$)P%^C M*EEJ0$2R[UO3A8'+0W?>FMYRMGBR/0?HQDO1=E')3)I&_M9V=?4/)_4>#48\ M802>PHACSYX7B_GR^0FL?*"<"R4\A7(UDQ9>WSY8@Z[+=IJG?#=B"L(#M+6,; MVEF#-9DF/,)#XOQ7WD#","-?F96M"6Y`2K20[-]V3]YB8WV#!,T%9T\YCL[P M)8-E(S,;8"#$0(2!&`,)!E(%L"`(0R0@T_^'2#`K+!+2A[T$QM"XR&W)D)(` M`R$&(@S$&$@PD"J`YC;L3=7MZ?H@UYF1H1(HZ^P]/^ON[`7''4+@$R0@2$B0 MB"`Q01*"I"JB^0F51/63);KGS(9BJ,SNP66`<)=>7*`:(*$!(D($A,D(4BJ(EI8(``X+,YBQJKSQYG`='T8Y.3W'`&?)>(3)"!( M2)"((#%!$H*D*J(Y".7\(0>93G=0(/RT9/7)%\AR<#G@B`?'];#P[OQ)7_AP M(,E(102)"9(0).6(TP^O^0PG$?$93F^8U+G,7_U"[>45G)G3W M!3*6-E\@BOL<\<#XX+ZW0F4^'$B#^P2)"9(0).7(A/NLA\5GVB?=9R9T]P6B MN"\0Q7V!K/H3T+6=.5IXHHBPPM,5,5$D6(%.DU15:$D!ISN)RCT[G>GT4'#$ M]8:T]P6'=W_]T2TX8S4("2 M"LA5][&W0J'V)4MQ6T)PVBH[`*UJ*%FC,)*0+D0)%$O6*$PDI`M1\Y5*5B_4 MH\;Z(;1;[HH:[Z/@()3;>.]P"!)#=1Z=C;Y@P4,*`RF$@J9$#9=-*HRFA:@C MB:DPF1:N]-V7:D(]:JR=0E&[Z]QTF!`E&X<@V61`?,%RU1@)UGC\A)0526AD MQ1(:;242&EFIA"82A+54#[G*>S$M0SBT5/?5W,:-$6NN6(S&&0<"\Y8++,M5W3LQ9(TC)A+2A:@JY[%;E$^T6=#&D+'!HKA;%N8T*NR^$6J7@ M0A?Z(R5;4!D.J3"2D"Y$93B6+#5;)D=$93C5A'H(62N'0GA?-14]H+K).*1E MBV"-,PX"<2TH6H@J62-5%/6-?W4-A$NZB&C4/Z(>2@ MHN@[:I\IKJ,XY&H[DC3Y5!@)"`E)V,B(R;00U8!4&U'+-G;4/!2V7JBW*0)2 M?^!3**!02*&(0C&%$@JE&J2[BOK8CWM^V`VXW@K(&W_/^10**!12**)03*&$ M0NR5`)L7GP3WCU_Q\TO;JFA.A5]<+JV1UV_L^AX*T6XSP/S=PMX=7BZ@;X+E M&NX1H"'!^-,:?F!3'-Y2?.TO\A!_#P/TFQ3C+KS5F+"S]]9P,S=A?P[V)PW- MUW!G107[Q1JN>B9PUX:1^2N184[P/N.6G8K?LN947EOC4APA8'9_N=7P-R+\ M0U??()#P5J/NX$U&_^\9WEP5<,5CLUN38UUW\@,,;0WOPG;_`@``__\#`%!+ M`P04``8`"````"$`0SP1/P``&0```'AL+W=OTHB=%Q M%-CNV]]O462)K"JVXWCFI=TY.E5B750\DJV;WW]L7R;?NMU^T[_>3I.+^732 MO:[[A\WKT^WT/W^HWZZFD_UA]?JP>NE?N]OISVX__?WN[W^[^=[OONR?N^XP M`0^O^]OI\^'PMIS-]NOG;KO:7_1OW2L<>>QWV]4!_MP]S?9ONV[U,!AM7V;I M?'XYVZXVKU/K8;D[Q4?_^+A9=U6__KKM7@_6R:Y[61U@_?OGS=L>O6W7I[C; MKG9?OK[]MNZW;^#B\^9E<_@Y.)U.MNME^_3:[U:?7R#N'TF^6J/OX0_A?KM9 M[_I]_WBX`'@:>[FX>-A"!2?MDUSW>3C\ER[8HIK.[FR%!_]UT MW_?!_R?[Y_Z[WFT>_K%Y[2#;4"=3@<]]_\50VP<#@?%,6*NA`O_:31ZZQ]77 ME\._^^]-MWEZ/D"Y"XC(!+9\^%EU^S5D%-Q")8ZQ&#A3.`3V>00!&NBJ08DGO$$A8R+`T^\53SBT4RO\X6L-HCAM?.$#Y/ M.^7,ML/07=7JL+J[V?7?)W#)0L7W;RLS`)(E>,.VLN<>&^U7?0;-89Q\,EYN MIQ`&]-`>+HYO=TEQ?3/[!@V]=IS["(,(KA8XT9$D6%(6DK)L3C-5CJ2Q\@*I!:($H@72"*0-$9(7A7H[7WY"' MV''%]Q8IALUKN&A+@50"J06B!*(%T@BD#1$2%0SO,*KSJVTM-C%G!!6=CZQ:LA3Z\BPM68UDM81%0S4"1DBV4T*U MR@=V+NS-^\1"*<0R]G26L:R7R`JC=X:@*@)#5N#:&WI6FES2QE'(.NI+(PM. M/)Y1^&J0==17BZQ?^:+Y-LJ)Y3M+S,!YI[.,'>LL"T%G^1BRC%U(9>(,PW0[ M0QCU8_!95M!$UM[0LT2*E&.EU!-D\]AY054)0*J):0DI"74 M2*@E$`W5J-:S0G5R-PS50<&-2N*@0*H[*`ME7)WLQ"$?T')^W@@THIA()$(!0DPD'OW+-YUI@("6D)-1)J'11+!`RU/YT( MXX,EPD%A(AP4)L)!O[Q[@\UH\.QM%$*C#=O'-!*\38/0:,,%"1(&&]HH1N.> M./)4IDA=$[0]\XM60IA#Q+(^1]-0AY5HO0P*+1&X5W5O1.&H:%=@(2 M8@ET$U/G)2C'H;G]BBL'P5=VYMN*M%CPN]Y:&BEJE%VEUUQ52:.&&L&9KIFL M:XD13961ERFI`TBA.%I)&*=C-1VF^R6/:U$'%Y9"JQ6+.;&IIHZ@-?,^8 ML%LM+8T:9C1/^7<++3&BF8JIRE/N77CJA#R5WR-D&U2(TL&CT1L:==4E8_4CA#O^(J=8;VDBBN67/7[C@\ M9\*J*V\2G*M@VZ/VAB&+;;Q-W)<8*^.ZX[YH6F,B]:,R3>K5U$*LO]C4+)'E MTU4AM!B&3K)@([W&X]Y$(01=[JM9L'M5C2S0.P%+9-BMF_IB-U3M>[Y(AHT: M/ZMQ!T,J^AP43BAD^814R/*SIY8L)5E:LAK):@F+AFK$)+]&/]A,1K.SN>P@ MUDSLVBN1%2;"^BIL,V5Y.N?M)(V4@]"H2!?\8I5-*LTNV6;;$B&8M)H!] MUDY[,))),>R@X"E(*:%*0K6$E(2TA!H)M02B81L=RIHE7YA?,;E?P)S\S;SY MNIVWC(7H@Q'^TY32&089JB142TA)2$NHD5!+()J.<]6QB9%';Z$@KM*Q`JB2 M4"TA)2$MH49"+8%HJ$9KLLHGIVBVS(K4<"M'R&N($B%_>UHYR$RN M->[>$M+$/8W+R$`>E[^03_J*.G-2TFO0>X3"$!TK#-%"9LSX$%.VX];.%[!\ MB*,A0AK/*&_6LY@&_6B(4HX.;F&K"T-TK#!$!XT/&9CRJ=&-MU$(C39LQ]=( MB,1J=!0OYTEMZ@186$,G'#U49J-,P[Q7#@IN&FK)4I*E"8OV9$S?G12$%'59 M3-3QC:Y$EF^Q"B%?WAHASU((>99&:&"1N/)S5=5@2%65@PHHR'CI9)?\9@@- M_8HK!YE;ML"0R85:&JJX(6]-8DBCCPFM4ZJ:2W7EH`**&P3!+JW2L>`QWMBM M"('R"`SYQ$&6-U0(44,NV)$5J?UQP732G,VE7G(0:P.F_4LT]/%4#C)W9T$B MF#ZMI:&*&S*-JHDA;8.(A#II(\VE8G(0B&PL<(E0&*HU!)&&K%JR%$*>I1&* M5#,F?#ZXI>12`SF(WN,OF"HOT3`,T?HJ(%)?S06;!K4T5`YBAFP::&)(JQF3 M13X1I]T'Y%(B.8A4UK+(U>P@7[,:#7UR%$*>I1&*5-8HBW,VT-Q*DE#G.8B5 MDTW,$@W]BBLT)#-ZP<9;+0U5W)"--TT,:3G_`JF42ZGD('HSO&##LT16F`CK MRSQA"_J:C;=:&BJ$J"$;;QI9D38P0N>L-G`*R8NF^]Q"X0,0!P7/W"ID!0]` M)$M)EB8L6LV8CO(7YVE[CI14>4Q2\8=>);+":CI#^`BJ*::48WE#A;ZHH9A2 MH2%)!/PN6%;3)^*T*34XH2+,07#7B#M+*:%*0K6$E(2TA!H)M02B84<4U^+J MG/<("BG!'&3NF'TQK_A>Y5F8H4I"M824A+2$&@FU!*+IB$FP4P1H(767@TCE M+2N`*LFJ):0DI"742*@E$`TU(K+L[T`_^/L=(PS8@QH'L<*SJ[CT+%]XZRM( M4"U92D):0HV$6@+1;,34VDF%EQ*ML%`01"FA2D*UA)2$M(0:";4$HJ$R/7;\ M2S;X1EE4UT+P-`7K5CI6`%42JB6D)*0EU$C(O)QJUF7/:..S+YO:UP&WW>ZI M*[N7E_UDW7\U+Y+"W>S=S0C;MUSOBQ1>[1)',C@R[-#B2`Y'AG$NCA3X MTBP_DEPMS2^J(%_\2`8K@(?)L2.P`GBN&CL"*[#=Q;T5H?] MDA\!9_%HP"!V]LLEO*(36=5B"2^Y1/`$#.SOA_B9$S"!G]1)F^IJ">^01/#D M>FE^KA4YDLZ7YO=+D2-9L53P<#-VY!*.Q&*!MY\_16L"28SF$(H8Y9L21L[\ M*5]^@@:&)>D>H6GA]5GH\YU]/]K^<7`_*/W< M'^#%9A`;\)8KO,?>P4L^<_,K_L>^/^`?Y@3CF_%W_P<``/__`P!02P,$%``& M``@````A`+41IY`2`P``@0D``!D```!X;"]W;W)K&ULE%;?;YLP$'Z?M/\!^;T0DY"D44B5KNHV:9.F:3^>'3#!*F!D.TW[W^_. M)C0$JK`7`L?=]]UW/NZROGLI"^^9*RUD%1/J3XC'JT2FHMK'Y/>OQYLE\;1A M5)-)53(# MCVH?Z%IQEMJ@L@C"R60>E$Q4Q"&LU!@,F64BX0\R.92\,@Y$\8(9R%_GHM8G MM#(9`U&6R^KJOI&*[`G2_T!E+3MCVH0=?BD1) M+3/C`US@$NUKO@UN`T#:K%,!"K#LGN)93+9T=4]G)-BL;8'^"'[49_>>SN7Q MLQ+I-U%QJ#:<$Y[`3LHG=/V:H@F"@U[THSV!'\I+><8.A?DICU^XV.<&CCL" M12ALE;X^<)U`10'&#R-$2F0!"<#5*P6V!E2$O=C?HTA-'I,P\L-E1*,Y^'L[ MKLVC0$SB)0=M9/G7>=$&RZ&$#0K\-BC3N1\M)E-Z'21P&5F!#\RPS5K)HP== M`Y2Z9MB#=`7`PXI`"OINT3DFT-60JX9C>-Y,E^$Z>(;2)8W/O?.!:^M#6X\` M2%MF8!O/C,[(C+7%5.Z=X9SF+9$.S?1_:-`Y)G!MD^\+=#ZVVSI$LRZ1ZQ%_ M\6Z;G(J*<5#]&(_OL>[#%F]$1'!C8Y6@L MYSTZ74;#RFX':,4 MU`9>$",6F`;D7>?>%%H+Y$'7&8A3/C6VB[:K8V_ MM,]66[>`@_8-+,":[?EWIO:BTE[!,\"-O\```#__P,`4$L#!!0`!@`(````(0!O+#'OYP8` M`+\=```9````>&PO=V]R:W-H965TZV.>-P9XN-0K\]@TUX5EU=DQ/Z?UJ+SF%_AF7U;GM(&/ MU<&JKU6>[EJC\\ERQN.I=4Z+B\D]+*I[?)3[?9'E?IE]G/-+PYU4^2EMX/KK M8W&MI;=S=H^[BE/1?&^=FL8Y6R2'2UFE;R>(^YOMI9GT MW7X@[L]%5I5UN6]&X,[B%TICGEMS"SRME[L"(F!I-ZI\OS)?[47BN*:U7K8) M^KO(/VOE?Z,^EI]15>Q^+2XY9!O6B:W`6UF^,VFR8PB,+6(=MBOP>V7L\GWZ M<6K^*#_CO#@<&UCN"43$`EOLOOMYG4%&P-/9"US*C=-[PA*.PG(^S)E,=PPA&_;X.'XX"FGPA*. MCYWR11C"\<%3PAW;7BP<'SOE7!C"\;Y36KQ&VI+STR9=+ZORTX#[&*J@OJ:L M*]@+\"9KC6>XJ[X?%1]4'7/RRKRL3`@#ZJJ&.^;KVIW-EM97J/),:#948V/% M5BI823.WO@X"'80ZB'00ZR!1@`5)Z#(!E?X_9()Y89F0,6PDZ%/C:&%+A33Q M=1#H(-1!I(-8!XD"4-AP;ZIA#S<9N$)\0@)"0D(B0F)"$I6@`*&?ZP&Z M]@CD#_8XY@<'S`D$K%3"?*PM2>?()"0@)"8D(B0E)5()R`%N3G@-[TA;_ M[45F=CAF3M1%)L0G)"`D)"0B)"8D40D*D,V^9!N[(T!FAP,4A`]6;!?:"C+M MZMKGQ(7)KFL!CO>"%S[H1'+A0T(B0F)"$D[L]O0H9MBN2-[#`+NS0?-]F+G#X@O0;V%80)7Q.7'#>A>_.M`@*I"JHJH*J:J M!*EPJ&RXT4+E/7Z@^N$'A"Q_FP]%L)?+(MT(Y*CWMCO7LKZ5*C5X[LN!@W)7 M:$L<4,-0(FRHU5,D5?T98XFPX00752)5K2'.&IN5GLD:G[%0UCB"^E"#G^)+ MV;*9B;6;/@9?(`=V+B5K>BNEAN&PH?:;(Z*&\;"A-IHER!!GC4U26M;NVDMM M/H*!Y[[8.()BDV@K5(Z:(Z'JMZ2`JD*)>E4D4>\KEJA7)1(-%`B;J9X*E0]C M*%2.INI]Y8WU88D]YM`KA"/45(@J%(:**J*^8JI*D`HO-)NFGHJ>CV$H>HY0 M5_'&VI:YA4V.18_67B#U'O?&6CL*J&$H$3;4VE$D56J%#)Y1:T<),L1I8S/: M4VGCPQU*&T=HVQ&J_HI]6ZC4;8>H0JJ*!%+Z44Q5"5+A4-EHIH7J.NRAW`,C MF"WF.[4M<.3!2G1-T1MKC7TK#%&U<$,'HE<,M38<4,-0(FRHM>%(JOK*>E\+YN*N9"-6TMEA_FIJ\[*`9R0P3.K<<>"=5?M(EGSCRK=9 MVC?^;`%/(Z@O?[Z`G^F4PVNQU\$SP.NRMK`U_QMV20-^-G!!;5?7]*\>^!_Z M8N,MX/$FO:#-9`%/!0?X=`%/RH!;W1G@]=DU/>2_I=6AN-3&*=]#@L?M\Z.* MOX#C'YKR"HF'EVAE`R_.VG^/\*(TA\=$8_;D95^6C?S`3M"]>EW_"P``__\# M`%!+`P04``8`"````"$`L,VO'DH5``#-7^_>_IX M7J]=GI]MG^YV7^Z?OGT\WZRS_UR=G^U?;I^^W#[LGK8?S__:[L__^^G?__KP M:_?\^_[[=OMR1A:>]A_/O[^\_.A>7.SOOF\?;_>UW8_M$UWYNGM^O'VA?SY_ MN]C_>-[>?BF5'A\N&I>7[8O'V_NG M/MR^4/OWW^]_[)VUQ[MCS#W>/O_^\\=_[G://\C$Y_N'^Y>_2J/G9X]WW<&W MI]WS[><'ZO>?]>3VSMDN_P'F'^_OGG?[W=>7&IF[L`W%/E]?7%^0I4\?OMQ3 M#XS;SYZW7S^>_U;O;MJ=\XM/'TH'_=_]]M<^^/UL_WWW*W^^_S*^?]J2MRE. M)@*?=[O?C>C@BT&D?`':61F!^?/9E^W7VY\/+\O=KV)[_^W["X6[13TR'>M^ M^:N_W=^11\E,K=$RENYV#]0`^O_9X[U)#?+([9_ESU_W7UZ^?SQOM,_//F_W M+]F],75^=O=S_[)[_'][LDG*S?;M5;GLEFG>QUKI,E&Z"<;J5_5 MZLEEV]AXX^8)Z]'/R,W?4"2S99?I)RMV:HVK5KUUZ([DF%*1?K)BJ]:I7UXW M.V^WM,-Z-.9.ZN$UZ]%/UFLD1]VP3FEDHVKRB)<"!SS/BP[O$I<*QG70[4?1+4KX]+ MG[K+`_/+B9VDU+$M]CETI&==$M5/SJ*&RR+S"[?WV+XV7!:97X[JZX4M3&6= MZ]^^W'[Z\+S[=48/#S*P_W%K'D7UKK'F*IP=X57->ZWD4:TS5GXS9CZ>D_NH MJNVI3O_Q*:FW/US\0;7UCF5N4*8N)7I.PA128[:O0:I!ID&N0:'!0(.A!B,- MQAI,-)AJ,--@KL%"@Z4&*PW6&FP"<$$1K<)*)>*?"*LQ8\+J`G+C@(]S0\70 M23B5O@:I!ID&N0:%!@,-AAJ,-!AK,-%@JL%,@[D&"PV6&JPT6&NP"8"((15K M$D#Z0%$@&)`=2`!D`&0(9`1D#F0"9`ID! MF0-9`%D"60%9`]F$1`20'IDB@+:VUOP4X>CR:BQ1A:8[O1%=*]240ATU/"NA M:GP"28%D0'(@!9`!D"&0$9`QD`F0*9`9D#F0!9`ED!60-9!-2$3`:<+S6L#? M'KQ&L8ROB\J-)T0+1$M$*T1K01 M2,;3;#Q`/.F(@1Z(W^_O?K_9V2.*R!2I25M\O/%G=R]H:>H&X8W9GS;1M@Y>L2'.;H(-JNRQEQ;9W5N8036<#Q416 MO]Q+.<\4HA&RSV;)&O8YV(HX(=9VX4NW<;>\,<<"IM^A*QB%KF!%>IP$/6K* M'J7.EE?,&*DD:4G%W$NY=A7"EG2%60."*T[->F-$/;,L:LM\5GO@/7,X0HJT MT^Z:VG>H4VZ;-ZY5[U)WW:MDC-HTT"I_-A*UU9,[16OXNG9U*?Y3XH43+^\C M76865N`RNWXZ]6%OUV@BA2QJT'"I.I,T5.MZYD3(>-Q[H<^H0\(BKF7?2J<0H MS(NDH98TJ5?TYILM-1HSEDJNRK2\KM6;(GM4:W(O[KT5-E!ZRZP(P%NGCD&[ MK!".LTBF4A/FC:P8IA(KT@_O\28\C"I%+Q5QG)6BUQ+,,=A5K:5*?EZO!+RK M*LN$I*O,%/QON\K.XX6K+)+EJJF:VC/'FCK'&'&Y:D%V@4K&5@Z5*V'XNG:= M7(?_J?PL1-.$R\RX09<=L]U3:LJRSHA2R@6KYZ2"_'%2?KLV1:F,$=4=9RM' M5`A%V;$W)N`GUF%SU&O*J6_*#2-S>S\&H`X[J;#SUI;9DZD4H9RFJ)@Q2JA. MO*Z8>RGGM4+8DBXRMH4JJ.)4V5P:E7 M]%)83E@J2;B]0 MF`-)4_4Q=5+AY"KB*MN(Q$S>__AD=@G51)'-D("[?^$M$Y*N,I/6O^TJGOF& M6651FQH;)(=J:L_,:HR/0U=9U+!/Y$:B*R^J9(S:I%G="R>*+,6&ZY>U2_4< M*(1IZ24SH04O'37@[%18E"">'0>K"5-5U!/((1_%U"'OK8Q1V[^\D",JA*+L MF)DWOJ]C/.,,8VZ12;8J#CC'->\&ZIBS8AC`2&T%Q8QM)?ZL/T=4B#O*[IO) MV_NZ;Z=](JX6R>J`A92E?!#[#4:4!)7?(MT'Q8P5Z='B1GJ.J'#FRSO*[IL) M&73_U#K)L[HP$2R2B8!U,IP.VC>A:'"6XX!^5)Y(FFIYF;*4V?.II")UTMKB M&6JG=JV&>\YF[)NUY?T+;QGJI)FW_6U7VE)::Y],><9>O!H:%JD8JXF>3TOY1YL?40IH@Q1CJA`-$`T1#1"-$8T031% M-$,T1[1`M$2T0K1&M!%(QMRL*?ZAF-OE2?B,,R\%T8Q/QCS1&U9>RL>\4G0H M1:D,48ZH0#1`-$0T0C1&-$$T131#-$>T0+1$M$*T1K012,;<++3^H9C;-9N( MN44JYFJOL6XC2A%EB')$!:(!HB&B$:(QH@FB*:(9HCFB!:(EHA6B M-:*-0#+F9IWY2LS?WL!OVA6J"+%%=#<7O!Y+!:B/*$64(L5$;8WF7LIYIF!D3]AEG\UR-NSSNPZWFW91+%QA MD7`%H]`5K$BK3M^CANI1RN:#%P0R1C))8,_22WE7A(V0KC!+7^V*9J-\7_+X M<_ZF74`+5U@D%^.)VJ;ML6*XO^N073.WU=0F=9>]/S-&G4:YB]NJU=44./<" MWB.V>?;&PB,4//0(OV-XXIE):4JNTQBUZ?9![/4>A5/TG>PS,ONJE2)N;*%B MQNC`V;67JEPD;$D7_7-+64KO<@WOMS4MZW&:,# MQTI>RKO(MCZ61=&5WXE/$]J+!>=8)/,'M@.=HN]CGY'9E:OR)TG4(4+J%;T4 M;@>R%&\'-FM-/>"\@'<5]Z5LDLRFV(+IY!)D\MMLA8>)9)$J06H'M,>*(I&L MHMGL#7RE!FGJ%;U4Q%?65E6[7A`.LXCV MFEU3>G2*6+HUS"26HA^5=R*5"!0SMF4Z_+IB[J5<(PK1")D[;TS"3RW6."NG M8S_3>56)5![T6$HDD%4T9T6O]S1%Q8S1H4IDS0=G%86P)5T4G=<><]Z6X&26 MD2P_>E.[YQ3#I+&VS/%1Y9$D444]]8I>*C*DK"W*"G-JVZRI$9VS%;KN,XB[ M$AE19JH*(^K40FWGNV(L621S!PNUE1*YPXA^!)Y2%38U&4*I28I>*N(I*W7@ ME,+9LC.N%IR"%TX@XCTSL=3>.[UV\X38UYT;>HO,]$^>>;?49+#'4N&9-R-Z MSIGD4*F1HD+&J&/>4#;O`+35^,Z]@$\G;G#$(69>J1URU"=4$CLC%3EDD,&&%44.6<5#]8>E_##-V%9X!HZH$'<4Q:;UQN3Y[85EJ2F?WXP.%!NGZ'O1 M9W1@KHR*&2.:OKA0YX@*H2B['YT8GUA,6C@E9B03`8H)2X6)X)`H)O!>D9-Z MNYBP%#UI7ADH7L!YK_"6"4E7Q2;()U>.%LZ0&:G*H7=+G6*8-=961WA!KZY3 M5,P8T8=#7;]S1(50E*XPT[UWU8R6G2B&-8-1L&W80]1'E"+*$.6("D0#1$-$ M(T1C1!-$4T0S1'-$"T1+1"M$:T0;@60\S=3WE7B>."EM\2PZ>#(R,AO3?GZ@ M7QGN>2F7DWU$*:(,48ZH0#1`-$0T0C1&-$$T131#-$>T0+1$M$*T1K012,;< M3,E?B?F!!Y^=S(LQ;)$8PX#Z+4`IH@Q1CJA`-$`T1#1"-$8T031%-$,T1[1` MM$2T0K1&M!%(QM,L&"">IS[)>=41CEZ+.OXEPUX+4!]1BBA#E",J$`T0#1&- M&-DS@_*=KC$CN0&M]^(G7LK5GBFB&:(YH@6CH!%++Q460+5]OO)2KA%K1!MA M7B:`63I!`ARS;&[919<8T!:)J`/JLV(@E2+*$.6("D0#1$-$(T:!P\<.48N# M)X[:RI\X*7^H-75(*JH]QYF3\HISAZ2B6LPMG)177#HD%5535T[**ZX=DHKJ MCALG52K*=(DMA.NGU@MA;Y/&NK55.?I8(59LK( M'#H&BNK@.D/%W".O".TJG!2MS0+SJET#)^57^0S*)*@MD/F0W^^@NIV#;PMEV=#CP)%3%`V[SLT=HKRCJJZ3)R45YPZ M)!754)TY*:\X=T@JJK&T<%)><>F05%1-73DIK[AV2"JJ.VZ<5*DH$Y04\1%_ MXGS1G.OH7+7H4#&U4K*8=M2#H^_,^VZG#ATHIMPNKY@[1EL_5ZH[>?*285E).<]3A(%%3SAXKBIA7BJY4IRB5(2P6H MCRA%E"'*$16(!HB&B$:(QH@FB*:(9HCFB!:(EHA6B-:(-@+)>-*B6,3S0!"- MN`JB1?0Q`3?<>O1VIY$*4!]1BBA#E",J$`T0#1&-$(T131!-$6]:H-H_Y:4_1LKC]OG;]O>]N%A?W:W^VG^3A2]CO#I0X7M'[&Z M:2?T5ZS*U]O@2HNNE`]UN-*F*V5\X4J'KI3?>Z"O-"^[YA/-E!-PA?Z.%AT# MQ:XTZ$KY`@WH-.E*>18&5Z@_MEK`%>H/?68G[/9I@X96=HA%-+HI%+!19J][-Z4T?[!R]&D-7HHUJ MME4CID/=I`/]V!73T6A/ MDZ1K7E!&'7ISEZ[$==IT)=9J>O60KL32A=[#HRNQM*17U,BCL;2DSSMU"]I$ MBK2M2=;H,S"1*PE9H\]YQ*Y03.D3#[$K%%/[AIQ*_RQITI68K_M-\H%]DBB= M&VKU3;35/;K2BUY)Z8KY>%2D;73%?!0L=H5\'==I4']H=RRBTZ#^V)?A5:OI MNX+H2C3:#>HI;0;'K%';Z",%L2O4-MJ!P"OT!:W=@KZ9%*_05U)VS1=.QJ[0 M?>AC=K$K=!_Z+L'(E0;E`>UOQJY0'MB%H_(!?1\O68OY[89:;;[G%:W1M]YV M>]$K]+6V7?-]KJA#WVY+]XEE%7W9*UTI=2ZJQM$?4_QQ^VT[N7W^=O^T/WO8 M?J6'Z&7YE=//]L\QVG^\\)KU\^Z%_IQBN7S]3G\V*F(&``"C&0``&0`` M`'AL+W=OJTN^L7_DC?UU^_-/ MZ]>J?FI.>=Y:P'!I-O:I;:^!XS39*2_39E)=\PNT'*JZ3%OX61^=YEKGZ5XX ME6?'G4[G3ID6%QL9@OH>CNIP*+(\JK+G,K^T2%+GY[2%^)M3<6TZMC*[AZY, MZZ?GZY>L*J]`\5B0?<;\].LXQ8_#/JRR.JJJ0[M M!.@<#-34O')6#C!MU_L"%/!AM^K\L+$?6)"XONULUV*`_B[RUT;YO]6&HA MW3-0Q(4%^Q]1WF0PHD`S<6><*:O.$`#\:Y4%GQHP(NF;^+X6^_:TL;WY9+:8 M>@S,K<>\:9."4]I6]MRT5?D/&C%)A22N)(%O1^).EK.9/U\N@.6&IR<]X=MY M0J#+&9O->?\W/'WI"5_IN;AI#VQ"*'REO3N_Z0"MP@&^]X7FX-"*3$5IFV[7 M=?5JP?2'P6NN*5],+`"V+D4HKD_:>SF#9'&2!\ZRL6'=0CH:F&@O6W\Y73LO M,#DR:;,S;1BU"#L+/A,X;:0#L0XD"N"`HEX69/M_D,59N*PNH%T'##I=34-G MT;E$.A#K0*(`1`/,.UV#!VMP?/5TF>!.L$YN9D+:N+VNT$`B`XD-)%$1$CG, M>SUR-IL,R^WN><6)8&9"1SPNY/!B6CLB$#L:GKT M%=$;=9(C`XD-)%$1(@=V4EV.G%NW1Y[[T>@144?>0"(#B0TD41$2*C_'*'OK M[?BX,8T/$1^6?#_Y77^I[3?2"&N>V#01X3M%[^8O/>H6]T9=4A*5B*A8?40% M-Z8J$`$574^A1)20$=%"]K60>Z..*%&)2,@,Q*LCCU5-;$#MJ=A4,#92. MD8QX4+UD3>,D5(O@W=B+U2!&0KZB1D(>=*!D8*;)&:QZ/82+"N)U3IE*BJ`1 M#;"V>Q%8(&$'[7K9,8064U&GW2G3(@NE@:M*0A^`!DFNO]`E22LH:(KP.;5* M"#U5R2OAIU1B"24J$9JO.I5:&"&3/JI*A'RZGQDJ>ZMN2!/"127Q&ODI25A< MB22$AL1ID86\3L*,)8E#R(?5K:1$/,B76)>.[\CUT22SC1A1!DK>LX9`B1Y870?%@XL;12 MH(0XTHAYU=4C_FA2L'*3X!$B26%F4J2CFA2$9K#%]4D9V>>E%6P1O96_U*9U MPE1ZJIH7[O=5?Z^N[U5GM;)A]2>R$5)/=,R`(A.*32@A$(G>'3E<>(POI`_N M%8*('C`D1$_4*^TF'0Y6W=R,3"@VH81`5!0OW7I*[EDZ_$B@G9(DI*;!A"(3 MBDTH(1"-F)=A+>+/I0'KN3J17(2T-.A7RL%J2$/OV$&Q:940B(KB55<3==?M MQL5R340@1-)@0)%T5*QB$TH(1"/F156)^/9&"Z^-QFQ!R)L/&ZVT4J#(A&(3 MXH^9G!X=,4Q\G,0GKS*OCWF8G\^-E57/_.'17<#QL(?Q573G3N%95.S[1@M_ M,!7;I='B0HMX4#%:/&@1QV^CQ8<6<3[16N!=]F&4"[H?[QV(^/!I/#OH>JSG M!Q_XQSK>042C^"R`]X61#N8!7-1'\$4`M^(1G*U`@;@]::%&S`UB.$:;/A'S MH&5,1L1\:!F+-V(S:!F+.&)S:!F+.6(+:!F->AGLX&IFAA8N@W"T(5H&<,,V M':)5$(^KGT+?8UTD2Q@PT>#T(P9/Y-?TF/^>UL?BTECG_``S>2INMS4^LN./ M5M;1QZJ%QW%14D_PQY`<7E:GO%P=JJKM?D"L3O_GE>V_````__\#`%!+`P04 M``8`"````"$`:W)S_M=F?__;YW__Z]'/W^OO^^V9S M.",+S_N;\^^'PTOGXF)__WWS=+>O[5XVSW3DZ^[UZ>Y`_WS]=K%_>=WR,27[>/V\%=I]/SLZ;[3__:\>[W[\DC7_6<] MOKNWMLM_@/FG[?WK;K_[>JB1N0L]4+SFZXOK"[+T^=/#EJY`N?WL=?/UYORV MWEFW6N<7GS^5#OKO=O-S[_W];/]]]S-_W3Z,ML\;\C;%247@RV[WNQ+M/RA$ MRA>@G941F+V>/6R^WOUX/"QV/XO-]MOW`X6[25>D+JSS\%>RV=^31\E,K=%4 MENYWCS0`^O_9TU:E!GGD[L^;\P:=>/MP^'YS'K5JS?9E5"?QLR^;_2';*I/G M9_<_]H?=T_^T4-V8TD8B8X3^-$9:M7;]\CIJO]]&;&S0G\9&O5V[:C;CUM4) M5NA\Y>70G\9*X^21M(P-^M/8B)U'CGBA;?3H3WL%L3OY$46:B^6@Z4^C>+K[ MZI0YI1'U%V/EV@W[G8&L4QIH*RX?ZI>UN-%L7YV2$'4;3?67:C2-JV:]V3HA MK^HV%.HOQDR[5H\O3S)BW5MW_OW(-36LA]5?3AS,A9YUY21.[@YWGS^][GZ> M466D>;5_N5-UMMYIT#_L]-794DWH7\UGFLC*RJTR(/*ASW1J:+,G4NT;,2JDHHLXD$J029!+D$A01]"082#"4823"68"+!5(*9 M!',)%A(L)5A)L/;`!46T"BO-GG\BK,J,"JL-2-<"%^>&B*&5L"J)!*D$F02Y M!(4$?0D&$@PE&$DPEF`BP52"F01S"182+"582;#V`(LAW%D!=6VMJ-7$\EDJ1"C(9]LKIM0BF%HIB%TP@"9`42`8D!U(` MZ0,9`!D"&0$9`YD`F0*9`9D#60!9`ED!6?N$!9."]K%@*L4RF+8B=C7Q(PPR: M7=^W][]W=WI[$9B2$:UD]/I&V>!!U*3M[HT](`F0%$@&)`=2`.D#&0`9:D(K M5YMX(TTB6C14=26.(UY7QI6059L`F0*9`9EKXIU^4VKL<2@G0DFQHDU0-G@ M.:))^YKY6VQ[>I603>@$2`HD`Y(#*8#T@0R`##7QT\80?AEB[3@&M4E03:Q2 MIJ`V"ZFU+D7:@-HBI-84@UR"VBJD)L^V]M58VI!+,&W>4T^4(L\53=36O9J; MC5CFBA9J4WVKA.*6V"4GQI+N@*EM46<&@RI,$*T2?%L MBR'U*TLVQP<5\=5$K1]60E9M%#R;*`YC4)L$U60%`[594$U3&7^LZ6S:Z!0\Y\W))9Z:2LXBA\1E%]QJ@X"2O* M(HF*L["B\/T<%1=A13'4)2JNPHKBC&NFR!-4]:*PE?B.Q5===[%HOVL=WC7H MC7)II'B];(M[26)MN3Q+#7JC8J)B[I#+H$""Z@MJL*(IQ]5WMNQE#QQRY@,) M:LR["QI917Y&45S&5LHI3BSBBF*J3JV44YQ9Q!7%7)I;*:>XL(@KBJ$NK913 M7%G$%<49UU:J5.0)2HJ8H"3%MB[M&8LV[RTXMXM5. M1"BS4DXQ=\@E4R!7];AX,97CZCM;+E>-)R@9O;N#",<0%4<&-=ARI2WNUF-4 MG%A%YHFVJ%!35)R%%87OYZBXL(K^4*-(7.,2%5=6D0]5G''-%'FNJJ8B%--3 MBJ?*9;MC9ZJLU(&>VAQ"!Z'F2CG5JD'^&J56=FD9/*#8K;E6*! MJ(^*`XN<^:%%SOS((EHDN91KBQO_V$HYQ8E%SOS4(B`*H1>20!5KL76M*]U4A63S]EM?([G"8#`"5&T>M1 MIH@R1#FB`E$?T0#1$-$(T1C1!-$4T0S1'-$"T1+1"M&:(1Y;U:KT8QMH/=)# M:MM[5&]3R"":9J?K[?6,5.10@BA%E"'*$16(^H@&B(:(1HC&B":(IHAFB.:( M%HB6B%:(U@SQ(%)I9T%43WKSP_KN9[+JY1U=A;T0QV+;TC52WGVSARA!E"+*$.6("D1]1`-$ M0T0C1&-$$T131#-$N$8LGH`2E M4D09HAQ1@:B/:(!HB&B$:(QH@FB*:(9HCFB!:(EHA6C-$(NGZ@%A/$_<"I5& M>`_4(K<<[UGDK:$,XL],&V+:IT[*9DZ&*$=4&$3W(5+DEZV:/'X:'U]7T$9# M+A(-BKV]GD5N.Y-81;H15;>NN"':"ZF1:CEG91:Q+6Y#;'%S)V4]4Q@4XZ9' M-=2F;/11=9^1,:4+E5U(:O:U>7[#^QNR^L>"![@EMF_;3NQ-=9 M&[AO-DB=OKJ8N"%&U[.*S@N)5223E6+4`/>9,SK%S"C&_AE!,7=2-E0%&P3/ M*KGS]";8&_4%-Z'J/6JUE?$?:<8-L>CM62EW88E%?E[$#?%0)+52?J9&\G61 MS$C%5V5:7M?J$,9KD[SBCZ[<@X@IM1I>@E'#I.2[7TM+NJ-47)S\WY2<"YJK),B">6VL?\[7*E M-T/,51KQE;*SQ^M2/7!2J4HE1E$=<=*Y8@*IL@O3"V0 M(1<^5H?U6IMEA$:BZD`=-E+^Q1M$T_U8'0;%K*$1-;6/*.9.RGJM,$BG)7.1 MZA/]RD7'ZW"IR1L8HTJRN/Q/+I1NH4G13682,5QV4=OJJU MY$+0"53^<98)]'5C]J.2:FB4$\>:#R6BG?5=J6FLV>J\0UID[1205< MI6W%JL-+GY.AC\7QEY]R8X8$G*O,^I)23,MA-O4M1I!%=IU/)7'W$D MAMJSBKZKM"+5!W5YC5A67E3)#&KY2R2LO$;*&*9/4%V*^T#!3',OJ64O>.D] M;W)%2E-,.(THBVQ\>D;*OP-9Y**86N2\E1G46?.OG-JLY/!(UX M(F"=-(KN@A)Z_%1F$%^ABNUE:J34JQI5-0W426W+K%#;M6LQW7-CQE^A.LMP M2U'KMK_M*KWX8TFCD5BAPIS14JP^&&16J-!RB4`E,^B-%:I5U(:I3LJU0&$E MRL#QA/KPHE2]2R7KI$8T>UV=!)0814\J190ARA$5B/J(!HB&B$:(QH@FB*:( M9HCFB!:(EHA6B-8,\7BJM2MD_8?6XI%>!K/Q_*Q5\\H>@%.$*6( M,D0YH@)1']$`T1#1"-$8T031%-$,T1S1`M$2T0K1FB$6<^IR_E,Q+TWQQ8]! M(N9BD==S4G;J)XA21!FB'%&!J(]H@&B(:(1HC&B":(IHAFB.:(%HB6B%:,T0 MC[G:'_PS\YP:V[*0&\1C+M]:Z#DI%W-MRYOZ*4IEB')$!:(^H@&B(:(1HC&B M":(IHAFB.:(%HB6B%:(U0SSFP9W?AVH[K;\AYAJ)F(M>8\\H>@%.$*6(,D0Y MH@)1']$`T1#1"-$8T031%-$,T1S1`M$2T0K1FB$><[F//=XM4L\.Q*+,(%HH MVUG:0Y0@2A%EB')$!:(^H@&B(:(1HC&B":(IHAFB.:(%HB6B%:(U0SR(:ILM MB[5JAKT13+,[]Q9;[5CLB;K4@%,1ITZ("R^@!*521!FB'%&!J(]H@&B(:(1H MC&B":(IHAFB.:(%HB6B%:,T0#Z_L2;P15MUUH)E:K:';<@W=I5X@A!50@E(I MH@Q1CJA`U$DMQ)V4$4!M&6B!"+=-/O>=`E>^^UO/_%L=(([W88 MY'O"(L\35I$\Z2ZH(5X%2%$Q,XBG"#P/=%*5)Y@M[@F_$V`\$374=V^>\'4W M3>P!&,3[W+%X`MHS4GZ?VR+=CI;?O9#:P\Z=F4'M1OD$L5FKB^Y2[@2<0_2( M`\_:F_XVF:?&B6^%E99$?NA=_S`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` MYX@*ILBO7BT#Y8WHQ,6>2GCI"(UX&D`A,8HL#$W7*1XK)$:*NIR_ MFB7Z9"1@G54R=VI;,IGST:*7\]8U"; M55.YGTY1,;.*[K)S1`53Y)Y0JSSK"57,O0;$&U-&KP_9Y6OD=PZI?:(\XJ$$ M48HH0Y0C*A#U$0T0#1&-$(T131!-$+Q5"M7/YYO!-&L MD-U"MTN_N5)&S#4$>X@21"FB#%&.J$#41S1`-$0T0C1&-$$T131#-$>T0+1$ MM$*D?MS&.5H'4?]8C?Z=BZ?-Z[=-;_/XN#^[W_U0/T13;M\JK'\EIQLW.NJQ M.U4X.!+1D3*P<"2F(V5['XXTZ4A92\21V[C5N:41A\[3(IWPD38=*3^&):QU M6W0>2N*`M199"Y^G3CKTM28!G3KIZ':R/$^=1D!]7M2YK5]U;L/>H2/J4_JH M0Q^JIR/7H2,1Z=#+C`&=B'3HE;?`D?B2O%-VJN6H8_KI(]TK%D>R5M3)Z>Z" MUNA&0$=",:7?4;H-Y@>=I%RUB'-T*:&"\I1.H3/?QIW;<%A4E@6&VJ4XAL-( M"O3E0X&+:[8Z.6W`0T?:="04X*QY14="(:$5-[DJY'A:?]*1D%-H;49'0FZA MWGZGH*YV:&QDC3J^H2-DC3J=H2,48.KPA8Y0@*E]%3K2I",AC]*3G(YZ`H,Z M71IU-SAJ>F#2Z06/I'1$/0M`:QD=48\]`D>:Y.NP3D1'Z-V1@$Y$?J,G"Z$C MY!WZ2$GH"'E'+S)$.M-'%>A(R#M91%FE7R<2.O1)_TY!GWH/G*=!Y]$?0Q0Z M](%>.A(\3X/.0VV'D#6*#^T40T?(H_0Q/#R2-,AO^A,\8@1=&G4W..H>'>D% MC]#W(W34%P/@>>AK$N@\P2@T*'N#.MU6A[[.'VV-6AWZGGWDBU9G%>+==H>^ M-A[ENU<=^E[P`*]''?5U@'B$OMBOH[[)CXY<5.ZB7W%[N?NV&=^]?ML^[\\> M-U_IYGI9?M_KJ_X=./V/@_FJNB^[`_U^&^V-:75,O]>WH>\0O%2_PO!UMSO8 M?Z@35+\`^/G_`@```/__`P!02P,$%``&``@````A`)%(A8"=`@``U@8``!D` M``!X;"]W;W)K&ULE%7?;YLP$'Z?M/\!^;T82-(T M**1*5W6KM$K3M!_/CC%@%6-D.TW[W^_.IBQ9HC9[,?@X?]]]=^=C>?VLVNA) M&"MU5Y`T3D@D.JY+V=4%^?GC[N**1-:QKF2M[D1!7H0EUZN/'Y8[;1YM(X2+ M`*&S!6FC@2Z6-8@ZVIJ:V-X*5_I!J:98DEU0QV9&`D)MS M,'1522YN-=\JT;D`8D3+',1O&]G;5S3%SX%3S#QN^PNN50\0&]E*]^)!2:1X M?E]WVK!-"[J?TRGCK]A^:%W1!`6FU+"4HP+1'1E0% M6:?YS16AJZ7/SR\I=G;O/;*-WGTVLOPJ.P')AC)A`39:/Z+K?8DF.$R/3M_Y M`GPS42DJMFW==[W[(F3=.*CV#`2AKKQ\N1660T(!)LYFB,1U"P'`&BF)G0$) M8<_^N9.E:PJ23>-YFBPFM@\9?J MH!-Q2)]]!]#Y$'>P9'\[(LR1<,^4,+7X)-K61EQO<49D<'-&ZSB^UO[\O_9I MOO9-3\U>-SCZQC_2Z@\```#__P,`4$L#!!0`!@`(````(0#I%/+J>@4``/D4 M```9````>&PO=V]R:W-H965T/WUM;Q8+[1N"E9M;#)S;8M6.3L4U6EC__$]_;*TK:;-JD-V817=V&^TL;]N M?_QA?6/U4W.FM+6`H6HV]KEMKY'C-/F9EEDS8U=:P"QR&K/\N:15BR0UO60MQ-^@/PMZ:Z3_K>;,;C_5 MQ>&7HJ*0;:@3K\`C8T_<]-N!0^#L&-YI5X'?:NM`C]GSI?V=W7ZFQ>G<0KE# M4,2%18>WF#8Y9!1H9E[(F7)V@0#@KU46?&I`1K+7[GDK#NUY8WMD%GCA8DG` MWGJD39L6G-.V\N>F9>5?:$4$%[)X@@6>@L6?S\*%ZW]/H[ MGH'PA*?P#&L8JM/`Q'O9^F2^=EY@LN3" M9F?:$-5BWUOPF<%I8QU(=""5``<4#;*@^/^#+,["9?4![7I@U.EI&GJ+WB76 M@40'4@E0-,`\E#5,KZ*^`MQX8\/?.Q40-MZ@9V\@L8$D!I+*B!(QS'\Y8IQ, ML\6P"CX\GS@1S$AXT1TY:.2K1@NM'H/14!`#20PDE1%%(4B1%=ZO"3?N5/3O MWB$2=MMH-\7W!A(;2&(@J8PH\<$2EN/C%5@L/U,!3J3&CH@/J9%JLM32/1CU MDF,#20PDE1%%SD*5WXFW9Q(C1T1 M+=TK+=V#T9!N`TD,))41192)?$F]RE)V!T5 M20B-5=*;%&]T?"W)DA#2JN2KY4V$HU(EF4N5Q+O:IR1A.U0D(31626\$1!C( MDA#2JA3HD@:KL4HRERJ)-\)I2?_V!(LM5=&(T%@V???EWS9ZV1`*8%Y),U%; ME8EP!*M1H\RE:N3=4=<(7S3PAG.1/^T8O`B6],3>P7<%<3['#JNH0P@J*$5* MM#6S)\)*+B-"(13EGL3!:I0H8/]KQ*Q22L2$8("CI%Z*VT-[8EPE"4B M%,I5]`)MU2;",93I?4_;KE*%7E7-^_#[JK^SZWN%A>_*H;+8S!79'B3U="1,A?SXL@CU<3O`%)4&Q"24FQ&\U1D<, M$V\I\%NWI/6)[NGETE@Y>^8W$-W&-&ULE%5=;]L@%'V?M/^`>*^Q':=IK3A5LJI;I56:IGT\$XQM%&,L($W[[W['!]..>>>R]D?O0=?*J4EM;#4 M-3&]YK3TFV1+TCB^)I**#@>&7%_"H:I*,'ZOV%;RS@82S5MJ(7_3B-[LV22[ MA$Y2O=GV5TS)'BC6HA7VU9-B)%G^6'=*TW4+OE^2C+(]MU^=;:5P5>)OEJALEB[NOS0_"=.?B-3*-V'[4H/XN. M0[&A3:X!:Z4V#OI8NA!L)B>['WP#OFA4\HIN6_M5[3YQ43<6NCT%0\Y77K[> M<\.@H$`3I5/'Q%0+"<`32>$F`PI"7_Q[)TK;%#B]B;)T.KM)`(_6W-@'X3@Q M8EMCE?P94,G`%5C2@07>`\OD.IK.XLD%)"1DY`W>4TL73&=S,DS5(X-D%6`P'.$)"."@.8H#&*7"SNP M$W:E=9FL0N!0)CTO,_D?&0B,ZCE%5#&?@9TN#/"PJH>TH1CKRP<=?^S@:N= MPUS'KJ"54G:_<+?2^&>Q^`4``/__`P!02P,$%``&``@````A`%1;L%C/!@`` MGAT``!@```!X;"]W;W)K(1:4MT`)%T8^SUI;70FS+D+39Y-]WJ*%$SG#CE7.)X\?'\9OA MD$\KWG_X>CI.OA1U4U;GAZF8!=-)<=Y6N_+\_##]Y^]/=\OII&GS\RX_5N?B M8?JM:*8?'G_^Z?ZUJC\WAZ)H)Q#AW#Q,#VU[6<_GS?90G/)F5EV*,XSLJ_J4 MM_"U?IXWE[K(=]VDTW$N@V`Q/^7E>8H1UO68&-5^7VX+56U?3L6YQ2!U<2S;;UW0Z>2T7?_V?*[J_.D(>7\5 M4;[M8W=?O/"GQSL)H M.G^\[PKT;UF\-L[_)\VA>OVE+G>_E^<"J@WKI%?@J:H^:^IO.PW!Y+DW^U.W M`G_6DUVQSU^.[5_5ZZ]%^7QH8;ECR$@GMMY]4T6SA8I"F)F,=:1M=00!\._D M5.K6@(KD7[O/UW+7'AZFX6(6)T$H@#YY*IKV4ZE#3B?;EZ:M3O\A29A0&$2: M(/!I@HAH)I>QB!0C)X,F7:3X=-,7KTW=XYU M[)9%Y6W^>%]7KQ/H=:A4<\GUSA%KB*?7(X15?7L]8"'TG(]Z4C<5V`TTT9=' M$:SNYU]@X;><$.[%O+$0'EI&]Q!.4HG[-(*"7S*4+(@3.'3(=T8K=:&^0LNG62 M"5NGU!V-XIAGIMQQ$86K@%>?$):KQ%D>DA>T^OB\-)GG%;&\D)/T>46K5<`; M#"G=>=;50G$@>1@:X0B]OH"Q^TB*`YD#D`DZP<1Y[R\7G--YE*7M*X;Y%@I:0]TE5NQCE;] MZ%#H'N!THAK\8;QJ3>:JV:FQ08[9>V&P8OV0XKC-2G$@*CR@/`)5+MVHM'=(="WR.$MN;$8TO4AF8M0P=J$Q@M&RZ*"6>TV`DE63^HARB"85"3AN8MNBNP*@>K7YN/H'W=, M"[0LF@=W34/"P_".C:9F%#.XBX6W3X?IMH7P5^T4&Y/FI"WI]IS0R&A.W#$% MDHP$>.*-8K974D.QRZ<\)"-A6!2:BG8N)Y7KIZ7^.X`?/)+;IR'ALLB$'?RI M&3:=%7A/*XH0Q'(1+.PRH',1!EB7C.R/T.RTQXW/#AV1+A#K^XU`$LJ'[((D MY(=3:CCN"O5F:WO-0:AF[6N.YI$;!MWP^H.-<"RSJV3J(A2K6Q.4K? MZ1VT05)=X56W]\J^3JGHD2NH8;B?D`T(GT"U:W-SM(^L,EHBS<'V'C[9 M""29!E\$WJ.-(;CMX5BM:7$'(<+E3>;;L9GY"OY\8TA63SH@70V]DW,8'HH^ M('P"U7Z3^NARJ^8?L5HZQ6T.RNE(/41Z2N0A5>I/= MRC%V:TBN0F*W,3MNE3W$DV0=(CP^A])IL%#WVY- M%)ND\I#,18AP_:;5%7Z]I3LV:Y2V;91MN$R*I?S7,FC\EP^%JQ=\=*T*0R3):,`/,"`.._U5@'UEH=LR$ MW\GN#?/EWK.!>RQM'8%50>HN_#=)R.@YKQ>@OO44Y%_5RD MQ?'83+;5B[ZZTF8YH'BMMA'KC=27`PQ/Q3I]"U=B#1<&/C^#Z[D.GP^!X';L MDC\7?^3U@!;RL#69` MWE=5VW^!'YX/-ZN/_P,``/__`P!02P,$%``&``@````A`-01'CAN!P``%R`` M`!@```!X;"]W;W)KC,\/A'$I\ M_.GK8;_X4C9M51^?EN(^6"[*X[K>5,?7I^4_?W^Z2Y:+MBN.FV)?'\NGY;>R M7?[T_.,/C^]U\[G=E66W``_']FFYZ[K3PVK5KG?EH6COZU-Y!,NV;@Y%!S^; MUU5[:LIBTT\Z[%CW53O.PA[J\B+-:# M[_['Q/VA6C=U6V^[>W"W0J+3F--5N@)/SX^;"B*P:5\TY?9I^;-X,*%8KIX? M^P3]6Y7OK??WHMW5[[\TU>;WZEA"MF&=[`J\U/5G"_UM8X=@\FHR^U._`G\V MBTVY+=[VW5_U^Z]E];KK8+DU1&0#>]A\,V6[AHR"FWNIK:=UO0<"\._B4-G2 M@(P47_O_WZM-MWM:JNA>QX$2`%^\E&WWJ;(NEXOU6]O5A_\0U$=T=B*=DQ#8 M.SL,79^\0B)]7*;HBN?'IGY?0+'`H]I384M//(##(2!\_#G$CR*$T*R3GZV7 MWA>0;V%9OCP+)1Y77R"5:X?)$`,[8<101#X@;-ZL6^,-K(#OF32$RTDK6,O+ MJS!PM),H1QE3`MD%"$7D%Q`)A9@I))%G"`E#T3"NT[=@*!<_?6KTV^"K5V3^F$C%>*OF`\08(I8A2NIY*"Z:I M3,9(D0E"XCZ34HLHI$QSWR[26*74;H@]BJ(Q4D([IK1M)K^_I^PD2E\HQB]# M3-CSCV.VY7*T8G1W(@Y"UC8,`:A(C85$Z%N%]?K8]:Q;,*,M1K^8=L0@;9D& M-*GY5:OYR$H8I[E0D$#?S3A-5X3@`J3A->QP00!?JC6K#Z,I\[JI'/?:*]`C%# M)XM25N$Y!80B':GUBV\'-=Q>';%ER M9W>QA4'('!CJ(!5C[)2YU:+YS%&Y?.8A%Q>!&,=<\LZ0,WO*(C/4+CSUH<2M M"LTGCII%B(]KZ78J8AQQ+MJY(.:(S3;4'(]9H:RM#LUGC:I%&IZW]1WM0=J& M,WHN^(CQ1R@?*S(>GYGR@=+D9]-?)\?+ES%/+A6^7211,,NH#$NGM7A*" M9`IX_9S1HYGRA:S?9@Z$FTM$.N8]CP+B*&(>#`%H%:1C4Z3D;Q)`>4$`^<;/ M',@3P,F(\4,.P'IPH*$;:^T="GI$3A%PL.92:2A"Z%B, M*T/CN$D(Y04A#$?/CC\10JD"UG%SYV4(,`T$0QB*T/`.=C[#4O8W2:&<2J$( MQW;OV%,MC!/)$+ES,RA***;TB0\IE'<&I_QODD/[G06JAW8Y?JQS(+^J!X4< M^I[Q,93/32(GIR(GPG'_NGP2E0M35NVY<^+$).2OB,;9AV*1\0B!YIVIW3QUD2A?1%WX*2)S M(.082^^4X&)`)VB7$=0J#=(0!WS MKW4R4&-"^W",FX'A:/^@2KC:SP/SN?9H5BV:*5GF0%C(4K,TYM3L?#W%#N2EV(VXJKZ08PJXDF2K=K,+0EDT3S(3ALR!,,E)P%NS M,R-UDVK-5.^P(DXY9LA)P`XH/##EZ$`Z1\!:!!,(6<& M@9)'*Y\52Z80Y(HEU@&3TIP!)E$:`J!1TB!NDE6%BDED7C-NF0/YVW80VK/, M^QC*YR:M5*AR-)GCMG$5X4LAJ,RD_?EVH?F9T+B'N,70X1@O9%-8MBC69_F+_F9`V%2DVCR49388[A!9"FE=O_3.V5^DQ["[>I$ M8?@+:>9`>/L#KP=,@7)B#Z?G56*'CSKC1D'F>#^+]YB'LGDM\W*_;Q?K^LW> MO0JX:CB/XKUP!O?"_27JZFR`:]E3\5K^432OU;%=[,LM3`WN8VAH#5[LXH^N M/O6WAB]U!Q>R_9\[N(`OX7HMN`?PMJZ[X0=TC=7Y2O_Y?P```/__`P!02P,$ M%``&``@````A``FSS^BS`@``50<``!@```!X;"]W;W)KW$@A"PHI$I7=:NT2=.T'\^.,6`5,+*=IOWO M=[8)A29;LQ>#C[OON_M\/M;73TV-'KG20K89#H,91KQE,A=MF>&?/^ZN/F"D M#6US6LN69_B9:WR]>?]N?9#J05><&P0(K*T]P%-36)9K.$-%2TV".DZA(,612"\5O)]@UOC0=1O*8&\M>5Z/01 MK6&7P#54/>R[*R:;#B!VHA;FV8%BU+#TOFREHKL:ZGX*8\J.V&YS`M\(IJ26 MA0D`COA$3VM>D14!I,TZ%U"!E1TI7F1X&Z8W*TPV:Z?/+\$/>O2.="4/GY3( MOXB6@]AP3/8`=E(^6-?[W)H@F)Q$W[D#^*90S@NZK\UW>?C,15D9..T%%&3K M2O/G6ZX9"`HP0;2P2$S6D`"LJ!&V,T`0^N2>!Y&;*L-1'"R6LWD([FC'M;D3 M%A(CMM=&-K^]4]A#>9"H!X%G#S)/+@4A/B%7WRTU=+-6\H"@9X!2=]1V8)@" M\/F"H!+KN[7.&8:>AEPU',+C)DSF:_((RK'>Y\;[P/KB,W@0(!V8@>UR9NML MF:VT-I4;;QC31.=IYO]#8YTS#.M+\DD\X'IF[Q.[?AG7$T^)?(L$R[]VR5%4 M&P?J3TE?J]H[0>..,EL,F4V$!<:QL!4K56Z*7AO1CS%_SAJN2?^1UK1&3>SNB(KBX@W68GEL7_]H> MIULW5>BWQC909HPVZ2!>>9>*_A]<;B[ M,]LGA93FN+&3=_@A;OX```#__P,`4$L#!!0`!@`(````(0#"+X=72A```--= M```8````>&PO=V]R:W-H965T&ULK)Q=;]LZ$H;O%]C_$.3^ M-)'\E01-#QJ)7\`NL%B\^]W*)(B9UXVM8US4SSWU?;W7KSO+L\/UN]W&\>UB^?;\__\YO^Y>K\;+=? MOCPLGS8OJ]OS/U>[\U\__/UO[[]OME]W7U:K_1GU\+*[/?^RW[_>7%SL[K^L MGI>[=YO7U0NU/&ZVS\L]_;G]?+%[W:Z6#X/3\]-%>WDYOWA>KE_.0P\WVT/Z MV#P^KN]7_>;^V_/J91\ZV:Z>EGLZ_MV7]>LN]?9\?TAWS\OMUV^OO]QOGE^I MBT_KI_7^SZ'3\[/G^QOW^66S77YZHKC_:*;+^]3W\`=T_[R^WVYVF\?].^KN M(APHQGQ]<7U!/7UX_["F"'S:S[:KQ]OSC\V-NVK/+SZ\'Q+TW_7J^Z[X_]GN MR^:[V:X?_K%^65&VJ4Z^`I\VFZ_>U#UX1,X7X*V'"OQK>_:P>EQ^>]K_>_/= MKM:?O^RIW#.*R`=V\_!GO]K=4T:IFW?MS/=TOWFB`Z!_SY[7?FA01I9_W)ZW M],7KA_V7V_/)_-UL<3EIR/SLTVJWUVO?Y?G9_;?=?O/\OV#4Q*Y")Y/8"7W& M3EKZNJM9,YO[7M[PG$9/^DR>DW>+YO)ZLGC;D5J'XZ;/Z#@_[!OGT9$^C_O& M172DS^.^D4ZUX5#I\[AOO(Z.]'G0-UZ$V@Y#I5_NEQ_>;S??S^C\H^KM7I?^ M;&YNJ+,T1D)=QE'SHT%#H\5W\M'W$67;+P0]%WVTN@)-`2&`FL!*X`%Y2$,1,TS/^"3/A>?"92#'<)Y-2T(NQD MD5QZ"90$6@(C@97`%8"%32>F#'M"4TU]DDCU]DXT';Q9[V@S3'!#.3L@/1`% M1`,Q0"P05Q(6+TTG,MYF]BY/*0>/>=\1G37T16\,^F`TX4;78@",1N,(`**` M:"`&B`7B2L+R0K/E#_+R]E#P?D,:TL'?!3*9CN=`!Z0'HH!H(`:(!>)*P@*D M65T&.&G>D?F1B@&@@!H@%XDK"`O3:55S.3BJR[X<''(@H4._%#DT1A95"I!$91!:18XB'ZF6+"/6T MP@?]0]^4ZG?71$G$+]]36?C1*CGVV3$AA4@C,H@L(L<0SX;7."(;AQ4^B",6 M?:F7@DSW>P2\RCTBA4@C,H@L(L<0#]5+&1'J:84/FHB%/LJD4K?-9.%'JU3E MO@&D$&E$!I%%Y!CBV?"Z1V3CL,('P<2B+S54+#R@O@&D$&E$!I%%Y!CBH7IY M(T-MAIVJ8P5[$Y02"WX43V7IY[+THU4N/2`5NR\F18W((+*('$,\'UX-R7R$ M=>O;TKT),HI%7RJK6'I`?70LXE*(-"*#R")R#+%0VXJ\BZ/\R*7:T!/7=Q%1 M5&7E%Z+RV6JL/"*%2",RB"PBQQ!/QZGZKD5]%U%1TPY1CT@ATH@,(HO(,<1# MK>B[.6F.8\N.ZJX==5M9=K%%V66K7/;1,2&%5AJ10601.89X+KS6.N6$;X-( M*T_XB%C90FU5#_78R@>5QF(?A5M9>;D%UXY6JATE0FWI]J(?*L>>\T&2L>!'E5:67F[6M:-5/N@3NIDZ*/2/$U1S">6[C5U"92*"HV\I$B$VME1T MI(^%*A7J3+ MH\\DJ=4TZKN(:%\ZH3Y9Y9N<"JTT6AFTLFCEF!4/U:LW<>$,BNDGD0;55UXE MZ5HQ1,H'B%P3):LR^.B8)V"%5CJA;&42RGW9A+*52ZA2YXI=OI$["E5BT-'6'6%6"<<5#I6/F9JN/';6 M18DY"8A/,-=B@NR25:YYGQ#Y%QD4,Y-*5ME1)\0=Q%\JSKAW4ZA%7\"`NV2D8$!^$UV+BZR;1,0?41^0%99%"<>XJ=-1U1S'L M#3K:FB,]T,DWSAQSY(-0*%S_I-GDZ!2B\)T$Q$8A7=OY<77)JDQA="S'1'LI MSBJ%CCHA[BC&O4E6^1MM0MQ1C'N7K'`43BLB^N@4#IUP01T1&X7MI3BMNN28 M`^J38SD*VTMQ6BETU'5',>X-.MJZHQCWCCFR43CUFE:I10JM-)H9=#*HI5C5CSL MBC(_1'=-49A'Q`=+(^:/+EF5P8>^2+_FX"/*5CHY9BN34+:R"64KE]!@Q8.O MZ.N#@D=Y/1WE=3G@Q1S81:M2=B7'4CVUC9BD5'8LNQ!K5;UZVW47DUU)%_6!2#HY%@OKLF'*F$&E$!I%%Y!CBV2!E\-=DPW`>#9:<:7IIJ-5"KU'I!!I1`:11>08XMGPLK<8&V\O<*=1))<#("!:3Z9@ MNFA5H!Z10J01&406D6.(Q^<%:!&?5\0GW.V<^FY$K0,2M1;BH(N.;.2/CBEC M"JTT(H/((G(,L5S,A+1]N]:#-0\YHJ*P':(>D4*D$1E$%I%CB,=7T9W7TQ.> M/I\%I5DN(B,2U1:*KLM6J;0](H5((S*(+"+'$,^&T)`_J3:*Q5E`K-J`>K12 MB#0B@\@B<@SQ^"IB,5[`C[RY-4/Y&)$HMY2/V2J7._15G.\*K30B@\@B<@SQ M='CQ4TQT/REWE$K%1#X+B)4;4(]6"I%&9!!91(XA'E]%K[67TU-^5#1#!1>1 MJ+=4S-DJUSOTQ>H-2*.C0601.89X/H2H^TF]4;G-HB8K+MR(>D0*D49D$%E$ MCB$>7T6F';N),$.%EE`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`/M2+Q3M+V"U1X M$8G"BW5GEZURX4'T*;32B`PBB\@QQ+-QJL);H,*+B!4>%1Y:*40:D4%D$3F& M>*@5A7=:X5'@+6H";RI7]MDJ%WYT3$BAE49D$%E$CB&>C5,%W@(%7D2L\"CP MT$HATH@,(HO(,<1"O:H)O'!9._)NT]`3UW<1B5->;,UTV2J5N4>D$&E$!I%% MY!CBZ3A5WUVAOHNHK#RB'I%"I!$91!:18XB'*O3=VUOS]*Y1>2V+B!XP3W7K M$/6(%"*-R""RB/P[4/UQA8,(\85WFH8753ZOMI]7W>KI:7=VO_GFWU=*"_H/ M[T<<7J9Z=^7?ICKL\$%+F]ZS*EL6LQM_):78H65.+4-6H&5!+8NJSQ6U#-O] MX'--+=T MNJ^TS"@'].1!K85R0/?L:RT4#]V^KK50/'3CM]9"\=`MT%H+Q4,W#RLM4_*A M9^%J+>1#SX756B@'](Q4K85R0$\7U5IH[-"S-I66&8T=>DJETM)2I.&Q6EGM MEHXZ/',*+734]'/F6F]TU/3KWUH+'37=\:BUT%'3+T@K+0WYA-N'\@@:\J$W MB51\6HJ4[D346FB$A+L/LK>61@B]D:'F0R,D/)HL?1KRH7=T57P:\@D+9O"A M7-/KG6H^E&MZ&U*MA7(=?E$)O5&NZ44Z%1]RJ5:''*KVE.9J92C)U1PWE&-Z M,5WEFQO*<7AZ5QPM_2[WQO]X%GWZ24,MM3.7[GG?^-O7Z$.OT/Y8SSU]?<7^ MSA>XQJE4M?/_X_3F(UV>\(OOJ(+5`OI9P=M?C''3*[5?EY]7_UQN/Z]?=F=/ MJT>ZA%T.2_%M>"EW^&,?GYS_M-G3R[1)A=';F.GEZ2OZ*?>E?U#L<;/9IS_\ M%XRO8__P?P$```#__P,`4$L#!!0`!@`(````(0"^=GG_X`4``#@7```8```` M>&PO=V]R:W-H965T&ULK%A=CZLV$'VOU/^`>+\A0$(V49*K M#5^]TJU45;?M,TN\7CP^NM'>;;> M2=T4M-K8[F1J6Z3*Z;ZHCAO[CQ_)ER?;:MJLVF=G6I&-_4D:^^OVYY_65UJ_ M-B="6@L\5,W&/K7M9>4X37XB9=9,Z(54\,N!UF76PFM]=)I+3;)]1RK/CC>= M!DZ9%97-/:SJ>WS0PZ'(243SMY)4+7=2DW/6POR;4W%II+U8T3I[.8/N#W>6Y=)W]V*X+XN\I@T]M!-PY_") MFIJ7SM(!3]OUO@`%;-FMFAPV]K.[2KVI[6S7W0+]69!KH_QO-2=Z3>MB_[VH M"*PVQ(E%X(725V;Z;<\@(#L&.^DB\%MM[SNWO]/K+Z0XGEH(]QP4,6&K M_6=$FAQ6%-Q,O#GSE-,S3`#^6F7!4@-6)/OHGM=BWYXVMN?;U@MIVJ1@KFPK M?VM:6O[%?W2%"T[V!!F>@NP'D_EBZKLPUKU.8+AN!O`43ER8Z]/69>-C;4``AQ`TG[OO5FL[7S M#HF6"YN=:>/J%J&T8%G%W$88B#&08"!5``/U`D,#B0PD-I#$0%(5 MT33`9E,U\`2<+/J=>G<.,D>0Q3#0#8'-YBADO5$?,P.)#20QD%1%-,T@ M#FOVW:'BB,AAXXF&#` M4Y&_[BB,"W5G1)L/M9!72.9"ER:0H9B$`E&D<<0'YXJT)R2M-^JE&4BJNM:D ML;X-U_\'I3$7NC2!*-($HD@3R)*?%E,7'1>QP4@PP]?7(549FL;EB,9[TI'Q M=&$<@8Y&+G4H;'@?TQU:PF;6V\2&36+8I*J--GD7\MJ(T#VS[XCZ]`4$_:.: M3TM]'4-II6B2$!Q$0R+.ISHQEE8#,9&03D0'?RJM.J*NGIWG.#_O4L\;`3@. M9*AV+H=8/ZJ(\'01H;""AR1&D@CU02&B](M-8C).1)F>:D1=/3OXD7I^4(S4 M&FAN9;%Q><.@B>>0'OHY/OD$T5/%"R(\%/'H2(E-8B(AG8CJ@(!GF5 MZ'W4E>`0?,<,9`8A-*3"C5("VT;.U50;?/VRR!>,>##SB9^>OX(;`'/=Y!OZ[ MLPH[FJW@\]HD[.8K^"P=P=TES&C)?G%Z5W!O>L/A958YW)`19LVGVG MUOSFD[^T(HU?:`LWEUU&G^"&FL#GZ)1]!1XH;>4+&Z"_\][^#0``__\#`%!+ M`P04``8`"````"$`V\(:[A@.``"D1@``&0```'AL+W=O?LM-DF1Q9]1)&-NXOACU=_-XK'8W?[P^X_MR^#/]?ZPV;T^#(.;\7"P M?EWM'C>O7QZ&__DC^^U^.#@'[;O_U\+Q> M'P>D\'IX&#X?CV_1:'18/:^WR\/-[FW]2B5/N_UV>:1?]U]&A[?]>OG8.VU? M1I/Q^&ZT76Y>AU(AVE^BL7MZVJS6R6[U;;M^/4J1_?IE>:3[/SQOW@Y:;;NZ M1&Z[W'_]]O;;:K=](XG/FY?-\:]>=#C8KJ+RR^MNO_S\0O7^$4R7*ZW=_P+R MV\UJOSOLGHXW)#>2-XIUGH_F(U+Z^.%Q0S4081_LUT\/PT]!U$W#X>CCASY` M_]VLOQ^L_P\.S[OO^7[SV&Q>UQ1M:B?1`I]WNZ_"M'P4B)Q'X)WU+?"O_>!Q M_;3\]G+\]^Y[L=Y\>3Y2<]]2C43%HL>_DO5A11$EF9O)K5!:[5[H!NC?P78C MN@9%9/FC__E]\WA\IO_=W4SN;X/;.[(??%X?CME&:`X'JV^'XV[[/V6EM*3* M1*G03Z423FZFD]O9?2!4SGB&RI-^ZNN/;V;!>![.SCM.E2/]U([SRRY)NGV5 MZ:?RG%LU/G.O=\J1?BK'"RLY4X[T\[HKTBCM;Y5^ZDI>%IVYX-27Z#_7W6Z@.Y#XSY4WK'M08+K0I3>L^U!@=:*S\1W)T=,/ MQF1Y7'[\L-]]']`,1S4^O"W%?!E$0DT/0]F;3@/S9^.2!J10^21D'H;4VC3B M#C29_/EQ,AM_&/U)$\!*V2S0)N`6L;80HUW()BY(79"Y('=!X8+2!94+:AZQ=\17R$CXJLCL]#`"K@33&VA71(7I"[(7)"[H'!!Z8+* M!;4+&A>T+N@LP())`X4%T[]6Z#XIK!^&].^9/JEL)J?`QD`2("F0#$@.I`!2 M`JF`U$`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`4((H190ARA$5B$I$%:(:48.H1=0QQ,-*[8%AE9//E4=`@9!R\D*)^"'0 MW)G^8^5(5GJ0)(A21!FB'%&!J$14(:H1-8A:1!U#+-QB!F'A]B2`5G?MS7E( M%;HU272,*$&4(LH0Y8@*1"6B"E&-J$'4(NH8XO$3^:\]"_PB?IA!4WX@>JE] M5*&1F=,2A9S#&F>N3=$Q0Y0C*A"5"CE7=*;?RECIH5*C5F.LK$W*S)EK6V.E MM3JFQ0,O$M4K`B_,G8XK$0N\0G;@);(.<=()6&6( M:.].?B>8_"I$5]-7CK65/214BFP>2Z5HE2ED[\F^5V>HG$RF$Z/9P1*4>:YG3`$X5^=D:$'IE!UJ5@MZZM M:/A;-^0DBH6V,C=4&F0YNO*5MF+RLUMK*R#<&G9%OM167=S+]3EOU\KQM M19[XOK95>:@9$XN)1&)06J%TYMY86=EG1!KYSXATJ0E.IM`OSHB,E>Y%!6J5 MQLK<=3AV3C`J8Z6U:M1JC)6MY9Q@M,9*:W5,B[>02%:AA:Y=?63&:Z=3$Y4$ M\X'H])Q86YG8)PK][(P(/3*%?G%&9*QT5`K4*HV5'6%GN%;&2FO5J-48*UO+ M.2UHC976ZI@6;RUO]GO17(D9[T0BMNPH*[L]%#+K?*HEHH0(= M2W2L$-7HV*!5BZACCCR4WHSWVHZ/N>Y$(KX"P1F1MK(#+1WM,R*TRA0*R=A, M@NZRD&M'9@5G1-K*W$1YD7RE'6WY<.RD1;6V,O+-1?*M=N3RSD3?::M>GC6M M2)YP3I.CI'_L>MDA42_#DQ>%[*P;48(H190ARA$5B$I$%:(:48.H1=0QQ./J M9MWO?VU0Y`C.UDTA]A9;.':RU=A8Z>DR090BRA#EB`I$):(*48VH0=0BZACB MX18IH[TTGS_D"(6YTUTE8MT54*(<+:L4488H1U0@*A%5B&I$#:(64<<0CY\W ML;YDL11OJKJAE&A*>U`S[TZ<.2E6CG9BH=!T=LHU4D09<^2U>'>F*4:26PN5 M0XJ72^CE_'$`%5`^9LY.M`S+ZMT5)U568J-YBD\X=DX;,J-%HY=7\]U98(A9 MH$*T!JMJPBRBTD2[FA)-:==B5<#)I%*E3%9Z^LGTQ3SKD$A8[`%LS9>_&,LR MU;$WU*%$M%M3=7)B&RL#:U>6*,3RF'#L;,)38V7JI*[OJ9,W7[AH4&&2(-Y? MHAYJVLD)=ZP-[':2/KR=`B>?2I4C:R=U,4^=Q$[U?>VD-L=6EDK[M[Y.IW9R MPATK`]9.TH>W4^#D=:ER)"O33NKZGCK1Y@GK=.7V5NPRW1E$(K:]#0,G08J5 M(YL'I2/+TL+`R892Y4A6IH[JBEA'.D/VU/&2OMA[\K52(3L;TE96[U/(2FI2 M1!ES9-/A'G[N5^BC5+`,VB'.UF4>A\/I%J1VJ*T^0XF3NS:J:M M/"WE;F6<,^[+-N13W.$H1.N*[B\QH@11BBA#E",J$)6(*D0UH@91BZACB/>@M*OETX]/DVC3]14>.'%E*+HX[<1 M?0[DL;^+Z%,7#Y]%](D&\B0,([$G]Y7<4HGO&K2UHA+?59)P1B7^Z]Q3B:]Q MDW!.);[&IEY.:KZN3(]]J<3G0X_*J9?[2NAI*-7'UZOHV2;=FZ^$GE32 M=7PE"[K.PGN=F$IB;PF]O1`EWA)Z8R$2S],Q!O3B`MVUKX1>5HC$HW2/3W`; MB5N8S$"Y580B]01N+U2"RAUPU)S=NF5")>($0?>F&0U'PE],X\J?GN MFEZ*)S5?";WU3FJ^$GIYF-1\O9=>!28U7PF]V$MJOI)R3BZ^F;:>1^+[%$\] MYQ%]T./AP9BNX?/HQ*KA*Z`/.J@JOLY.GV?0??E*Z&,+NHRO9#&/%M[+Q/,H M]A8D\RCQ%J0T%7H+LCG=L*\JQ3P2WP%16$:G)87^1LC;\LNZ7>Z_;%X/@Y?U M$ZWK]+<1*,G?R[\R(G\YJM<%/^^.],=!:$]-?_N`_AK,FO[LP%A\I?.TVQWU M+^("I[\O\_'_````__\#`%!+`P04``8`"````"$`_CHZF?@'``#B)```&0`` M`'AL+W=O*,]*0U+J.T9?U^B=R-/_A#,G( M>OCYVV$_^5K435D='Z?!S7PZ*8Z;:EL>7Q^G?_PO_>G3=-*T^7&;[ZMC\3C] M7C33GY_^_:^']ZK^TNR*HIW`",?F<;IKV]-J-FLVN^*0-S?5J3C"E9>J/N0M M?*U?9\VI+O)MYW38S\+Y?#D[Y.5Q2B.LZDO&J%Y>RDV15)NW0W%L:9"ZV.Q^!B,]/6Q+4(#+/JF+E\?I<[#* MHKOI[.FA6Z`_R^*]\?X_:7;5>U:7VU_+8P&K#7'""'RNJB]H^LL6$3C/E'?: M1>#W>K(M7O*W??O?ZOT_1?FZ:R''?6(;(.\.D<8*YG[K"P#O#I'#[=!(OY$L2<\X.KG2SX='[G'9;6`3ZM0S2_ MY$:@M[L1?)Z]T8S6O0MCDK?YTT-=O4_@;,`*-Z<<3UJP@D%<_&A-^HC^**`0 M21SD&4=YG,*AAI@UL`N_/MV&\X?95]@Y&VNSUC8!MXB=!6X3'#:1P$B02I!Y M8`82>YVP1_X!G3@*ZG0S7#LP"`^%*&?A7!()C`2I!)D'F"C8Q[ZH\4/G8H3& M<+S.QLC:A+W`6)%$$:-(JDCF$Z8!CI:O@3;@S5U_7"[>@S@0[&*XT9E-2$81 M-Y+[L#?J8Z:(4215)/,)TPSB?J#Y?`C1KY/H)K8F$BV&@"F2*&(4217)?,(F M#RE*3CX*;L#\@SD#Q^%BB(`8/X+R//5&;@T218PBJ2*93Y@^R()27W#;;('QQ%$D6,(JDBF4_8Y+&O$NG\JN#@.%P,$1&<2"2[WJ@/CB)&D521 MS"=,W[W6=U%PT(_K(>('1Y%$$:-(JDCF$S;Y`-HK&1T[^P^>G6XDKL*55ALPXO"%%#YAB3NIK>VR`^41HE&1J-4HXPA+@*K MKA2QQ$37[LK-EW5%_>E(4HB@`[)]$55NIH<0-.5#E@O#6QDGZ[CL%R()+(+M MY14XX6B"8.L0=E_R.F;/J'/E"8.V6"W%)1L1:+$Z=1>$0X-A946]/?1\Y MAD-9,]HJ=6,-5AFSXB*P&%\E@JHXC#QL24++H.MTPWD@@A`'9!#ZDBR"('K1 MN^-!,-HQ=8@[?N*.F;/J[LB%8R&_2CAU`$PXH25N\*]/(%QLHAC_],.(^\() MA5!O/>'W?/Y&.Z86<<=(_%61,4(!2X2 MO:;1CJE#W%'T09FS&HDX=@=7":>V@@DG-$1<;+PXL#Y^Q`F)P(E6P6C'U"+O MV&?,BH<7>X2K5%)SP502&L(KMF<&NV8.D2/0S#?90Z-Q!*; MB:M44A?"5!*"6`XG,0K$OHH#Z^@'E)`(J$AZ1CNF%K&`^L.S@(8_[HY&:BP\ M@'%%MG/DS9!%\.&2=NR0I\NA(1+&H<$J=6BPRAS2\8(=HN/UP::A&T/HH;X( MRN80NMM(9E_G.$P^L2B$S3IDWTAD+Z,=TW%'?BJHT;HJ-03\AO M`:V5AQ*-C$:I1AE#7`3V(>.G[X,-.T9.JB+$&_9(9A[KR(3VCFYS&VV5:I0Q MQ(5B=S(N]&_.'K4U?IJ!TXY2O1G'&B4:&8U2C3*&N`CL-*2(CYX]V\!XW1X^ MZD4]4-7Z(Q0NQ$F(K15491>4Q"'(>+WC[4(T,,99Z;X;\ZW2$$_36 M7]0[@S\9X,D58X:^:/[4&[%`0&CH,D8)CS-`P#;;^%K$.8R'[*.;(UQ]+ M[57SMS7:7W]"P_JK_6]]_/4G)-9?=DBA[\CF'UW;$'2.?/];-*R_S+/6P%]_ MA_CZBX-CG)7>/_A+UE7KWSF*^5,#\#>]FW/T@F`19LW^$$3R<8-ACCP(6'NO MV401%6W_$%@$W9/+,;%#_HS)$?*BLS+,BD]OK$)_,.?CKP&8`;SM;A$6S'[5 M=+_E'/W)TUB\WUJ(9&68(]=S;2'&-D**T(786GFU.='(:)1JE#'$18P58DK\ M'VR;(EV.+<*[#Z%9R'0Z6+E-E&AD-$HURACB0J^MT!&55K;E"($N-^/86GDH MTB?BWB8K]O)IOJ#5\U@/SR]-!C>@]B'2W@18AN;=656[C2)1MU90E7 M.E7JRIU[K4)>N5_!\W]8!\F#^0H?F(]=@5K9PB5OO$:9C0VH36L^^BRPZJ/ M+CJL^>CXGU;P>Q'<=]:O!;QAX+WJ!_.^GI_P```/__`P!02P,$ M%``&``@````A`+[[Z[X="```=B0``!D```!X;"]W;W)K&ULK%I;C^)6#'ZOU/^`>%\@">&F859#;EVIE:IJVSYG(`S1`D%)9F?W MW]>.STF.CS,C0'U9=CYLQY_M8SLA#Y]_G(Z#[UE9Y<5Y/71&D^$@.V^+77Y^ M60___AI_6@P'59V>=^FQ.&?KX<^L&GY^_/67A[>B_%8=LJP>@(5SM1X>ZOJR M&H^K[2$[I=6HN&1G^&9?E*>TAC_+EW%U*;-TURB=CF-W,IF-3VE^'I*%57F- MC6*_S[=96&Q?3]FY)B-E=DQK\+\ZY)=*6SMMKS%W2LMOKY=/V^)T`1//^3&O M?S9&AX/3=O7EY5R4Z?,1>/]PINE6VV[^$.9/^;8LJF)?C\#GS.(-N0) M,_!<%-]0],L.(5`>"^VXR<"?Y6"7[=/78_U7\?9;EK\<:DBW#XR0V&KW,\RJ M+404S(Q<'RUMBR,X`/\.3CF6!D0D_=%\ON6[^K`>NO/1U/7G"P?D!\]95<LN.5>*\*D5/[[DF#+6%$"8 MUNGC0UF\#>!404JJ2XIGU%F!-9UYHMO6PGNE`#6`1I[0RGH([0"27$']?G^< M+MV'\7>HN:V2V4@9ATL$6@(+#,V&-A#90&P#B0&,@6++$XKJ?^")5I"G]G"C M@8ZX13O0$EHEM('(!F(;2`R`D8(B-TGU'U>=(Q1>#^'?#W*D9-R68""04""1 M0&*!)";".,!Q,SE0`8ZZLWIU#:(AJ&*XT`<$2(=SA^G$/4:BMJQ#2'>M$N80$*!1`*)!9*8"',>FI7MO.>,0/S&GH%V M.!E"@(R9P:F5G%9(QR`42"206"")B3!^T`5M?C!"L"`_3@[J<3Z$F,D12"B0 M2""Q0!(38<[C1B;:^17.HQYW7B$T[K$;!PJ9M;46$N+!OM$>.6=A-<"H%=() MBP62F*89GV4/'U@*X(*'?/MM4\!UH>/W),:#*42S"4UP:@HQJ"G$H$:(!\9; M:NYTP6LQ:H5::@))3-.,F@-A$[FZD5MC@Y-3T()VJR9Q6LJ@IZ%E,ZS=B6,= MLT@+=#JQAEH=JV\F6J#1X5QQ+-]3EP[-<^CJ.L0;!QI\'/V!,T@[(R2,RY+X&C M%#L2H8)[2.DR!DH*JTHJA@E@*_^[@ M#2POC%A#7-&*?**E>JH`EP8[#M?L!@YM&ZP*"((JT/D-M)29NL$L26N_VX!*81TMY\:FZ=):8C9-!<&SW6Z2 MN:[5^P*MV.WBH8;@O+4C4-YZ:2FYD,.HD'RN.D)RGVELK8?0^?'!']Q+"/]) M!TJDJS,%0?):__V)M51&RC(I\GS@<+?S<97_M!6P)!`$DUCY;XV0`)]A8SLT M_2>(KV*.O8HQ1>[_O9L$7M%JS0KJXF]W927`XJ_V"A9_Q]H((Z;(_<>I>E?\ M:1RS^!/4Q5_T*:5CQI\@=+"K'\=>`5U3D?O?-_NOJA\Y[UV"NOA;91PH`19_ MTL&&8_AO;:(14^3^XZ"]*_XTH5G\"6+W(_";"[^M"%RE:":!("L)ULH7,45& M`A\1S7$&0!-UC`@698==0=\\7::CAQ=WKF]`W]GQ\@&0=5P6Q<#LB MW%K1"+>"L"B,FK&:;<04.1^*5K@)8N$FB(5;06:X32GN7M^(O>9( MXM-\VSV"6(Q]Q^[K6M&,,2E:)6TUU(@IJP@,\:F M%'\$#54^/0N.51$.X;1FG:?5PKFMZ3+9\K6@TT8HJ<4-\< M[<[H=?=PGIRI"C*VRD!"H80B"<422AC$">'(,C+4\VC;N/O$Q=&N&H+@"ETC M%%"H%`VI2$*QA/`U!+PB*9+G]%H!_:I\RLJ7+,B.QVJP+5[QE0&X77U\:&%Z MGV'CS>"%AL9#\%MCJ<^.QNX=',T+/L;O'"/ M_8T'H>K!GZ:K)TB3=&@S7<%ODCVXOX*?^WIPR!+=.K0>P5L?E_0E^R,M7_)S M-3AF>TCQI/F!J:3W1NB/6CT\>2YJ>-T#J@!>+8#W>S+X'6F"/]_LBZ+6?\"% MQ^T;0X__`0``__\#`%!+`P04``8`"````"$`GM3EFY,"``#A!@``&0```'AL M+W=OV@=V_[]@.*11:I2^Y3&;.F3,SGBP?7F6-#EP;H9H, MQ]$((]XPE8NFS/#W;YN[>XR,I4U.:]7P#+]Q@Q]6[]\MCTKO3,6Y18#0F`Q7 MUK8I(8957%(3J98W\*506E(+K[HDIM64$6!)!6RUR``E=VI'F1X76$.)\U\XYPS#2D*N!'AQ6R2Q9D@,4CG4^C\$' MKKU/W'L0(.V9@6TXLW-VS*ZR+I7'8#BG&=^FF?P/C7/.,%S[Y*\%!I^I'Y=S M/=-+HC`AT?RO0W(JJHN#ZO^;M'."N3W+;'9;,3">%W9P(B[.)](7N;/X,;SH MW>P&Q30>(-8%7G)TEO-.)K/Y;67S&[3)`%87=\G:6:Z5N7T]^#PXYTOUP8QM7?K8@RGJ+?VFVSMX_^T3].U/P"D_P`;IJ4E?Z&Z M%(U!-2\`<8?@S?W[T5NO9&:9;3UH7F,-C?7!851.K2(3K0$[@M_E^SE+^7%KQPNT"KTP`G?KA3#^G(F4MI6<&*?%K\;):U,U M25";!-[;)'ZT")>N[WV>Q&D6)/D]88YWFYJ>+6@:@&05%BWHK2&QF1`P$;X/ MPGEK0U/#6AE4X6T7!JN-\P8[E[0^CXT/O/8^7N_A`&B/#&C3D86S0!9;*Y;R MV!BN89`9QO\=&.&\M>&U7_R08.,3R'ZYYA.H0$V++):C7=)MJHB#W;\-VCI! MXUZM+#8S!L3KC9V\$!$G%])O;A\1I0*TENLRAJ%KIK4T M8(83]E?$J:BM94A+R/7581`[%T%=;K,206K^QK*"%KT4*QPY!?$0TIO"2L2I MJ*UER,J#KM%IH1!6=YN7#%,A.I-:KY&#YX&7#CN)F@S4@$4N,!G("2'0:A:X M\>+38^>U"N)?-*4SJ?1\KVL7%!: MDTHO&*$W5T7$SZ+6F9W)4#V#D'Q^XKRAD+0F[4E,ZDUBX:X3=75+RAJG2F(3]DD)4X^+PS99QZO#N3RFYI9H?`:];! MDX$:L,AE/'AHKJ[(0`VEE1J5WF5P4GY:T5Q=D8$:<"LUAN+-U14TU)7.I-(; M&4[$J#JO>D-=D;G,U3/H"HIAYH8DMW_UQ!2CR5=G4OA%(U,*FJLM,E`KW^B@ M@@S:@MQ@@K;(2`VFE1N5W\B\@N9JBPS4@$='%M^@+=.T4T:J,)U)Y3, MU&!,8TLT,K;X<^5%!FK`K>(8RJ?)RVU)@8L)75(Z$[K\BVSN'IK_Y@6I#^1/ MDN?,2NA)W"L@^+?=6_L[CP<9K]N#]4-S%^+TW\!=1(4/Y!NN#UG)K)SL(:-]C_"```DRH``!D```!X;"]W;W)K&ULK)I1;^/(#R]FY?UIN?^:=$BL.A9-W]_FV_&WVMCUW3'N[' MT=5T/*H/FW;;'%[NQ__^4_UV.QYU_?JP7>_:0WT__EYWX]\?_OZWNX_V^*5[ MK>M^!!X.W?WXM>_?EI-)MWFM]^ONJGVK#_#-9]7Q]ZX^18[]8]G'_WVKQUZ&V_._A#N]\WF MV';M[K8-1*#3/CK6S_?CQVA9)3?CRVO:+-JVV&H%X(M1JN`+_/(ZV]?/Z?=?_ MJ_THZ^;EM8?+?0,1Z<"6V^]9W6T@H^#F*AY.8]/NX`3@W]&^T:4!&5E_NQ_' M<.!FV[_>CY/9UO>UGHQ1TOP MA25BLGLJFK^J&;C.VLFC]G(_ABB@'#HH]*\/\VAQ-_D*Q;FQ-BMI$U&+%"UT M^6BW&0@==;BZ`;>-<[FMW2L%;6)CZE(A4D$R071`E2 M"%(*4OF$Q`OMA,<;W5SI7O1YR%H'BP3\NAJ/IRQF8Y1JC8=`L1Y7AIB=:EB8J2"9(+D@2I!"D%*0RBQIM;(C'G#/FT);#%><=RP M%`F9"LIF5%8(61F4S:FL\F4D61$$]U/9&H0T71;%R:E-I&CE90>MW*Z02RLE MK0II54JKBEC14/6HPY9+$NEN$6@0,-)CAXC,B`1[':[CE46L,MB6GZ*5'[SQ M9>\O=+7DTDHA2HB0IDT/3CQM%[98/22QQF(1 MK9\%ZXDI6OD9-+YBV!*\#+*6E$NA0D2%K"D5:.6.6"*B0M:6*K0*%)X>PU@& MDUC?85^P24=FEH.CN"5H$"W"!>M[*0I=0)E%,>P?7@K9VLVE4(6%K.P+*2Q# M0GCVPUHT$=(BU#/?+Z=0.V']VB!2A;"9T_-*]2,2$,9^"BWR:R*>LE652Z%" M1(6L[@NT<(7*S4H[(62E$SJI`Y*Q*1,ZJ0C18D>#UJ?Y,\(.. M!F\1[37\UBM%H3OA#(70A;R5PII4[H2^%>M(*NR+MY^S?)5A7[PC_<@737=@ MQC]KS(7MC1>;1?[C*XDRB7*)E$2%1*5$%4$TU,!$;Y;5A4^K8SGA6P2A^[7` MF[*SPL:0291+I"0J)"HEJ@BBV0@,ZC^7#3FMZQ4'C8AF@S_L3)V5R\9)B"B7 M5DJB0J)2HHH@F@TV=']^@QO+Z=HB_R&G1)E$N41*HD*B4J**(!J?'D"]+>4' M\9EQU;][T+Z1;N M/&:SS2JVL0J5Z!,GT3 MK6O`[>.Y1$JB0J)2HHH@&I\>N[SXAJM[X22M;QS,A<;6LD+DXDD1N3+/+&*/ MKMD0FSLK=*\D*HA[&F)@YCMO'Y9#7VR1]T0:D1^7M8*+ZH:<6`PYULH)%?KZ M5%B@U2`DH>K?0'[U:@X^Z+2'R(L:D3OY#-%?/HE'`Z=1B$X:-C\7:!"(]6?' M*UUNK%PMTN.==\'8O)FBE3?.(H*QQ1.R$31'*R=4B*B0S9L%6LE9/@E,7-[] MVUD_-PT^V)4V\Y?>S;UX^+"%0A=/9I%>A4Z8\#M@*51A(=LE"B*D):_GFE]L M8(F9C?RV;1&MB(2UIA2M_$087WJ->HE@99U+H4)$A>RQ4H%6@8I@NYDJ\-@[S=.+56'LHDRB52$A42E1)5!-'K?]'X!1NLB$^.7];*F\@RB7*) ME$2%1*5$^ETS?5[FB"8^\^Z8>2-H7Q]?ZK3>[;K1IGW7[X5!83[R;QWBV?(18 M0F$O@#(+'R69+^-%>*K+Y$G[-#O#X=JG' M"?D-O`+X&,P8)#F<8P@CX&<%"0[E]_$:_`=3!5$'@X:8!_O)*8/P2N#;^J7^ MQ_KXTARZT:Y^AM*8#B]:',U+A>:/WC[.>VI[>!D06CZ\3@8O?];PF]]4_^CX MW+8]_@&9F)Q>)WWX'P```/__`P!02P,$%``&``@````A``W\*-G3!0``R18` M`!D```!X;"]W;W)K&ULK%C?CZ,V$'ZOU/\!\7XA M0$(V49+3!C`]Z2I5U;5]9HF3H`TX`O;7?]\QMHD]IFFVZLMQ^7:^L3_/>#SV M^NM[=79>:=.6K-ZX_F3J.K0NV+ZLCQOWCQ_DRX/KM%U>[_,SJ^G&_:"M^W7[ M\T_K-]8\MR=*.P<\U.W&/77=9>5Y;7&B5=Y.V(76\)<#:ZJ\@Y_-T6LO#\%T&GE57M:N\+!J[O'!#H>RH`DK7BI:=\))0\]Y!_-O3^6E5=ZJXAYW M5=X\OUR^%*RZ@(NG\EQV'[U3UZF*U;=CS9K\Z0RZW_U97BC?_0_+?546#6O9 MH9N`.T],U-:\])8>>-JN]R4HX,ON-/2P<1_]519,76^[[A?HSY*^M=K_G?;$ MWK*FW'\O:PJK#7'B$7AB[)F;?MMS",B>Q29]!'YKG#T]Y"_G[G?V]@LMCZ<. MPCT'15S8:O^1T+:`%04WDV#./17L#!.`?YVJY*D!*Y*_;]P`!B[WW6GCAM%D MOIB&/I@[3[3M2,E=ND[QTG:L^DL8^=*5"NGR]\!\)]0T62"=^!>7.HA23`=R#<',H3:]N'*LF[?+MNV)L#^0^K MUUYROIO\%7A3,1+K,D3MGX(&T>).'KF7C0L;%^+10J:];A=!L/9>(3L*:;.S M;7S3(E86/!6XVP0#*08(!C(-\$#BH!.2Z'_0R;UPG6J&.P56BA$WABVDQ2B8SI0>.&1CP5!;/ M.R9.F)%<#*'.B>K'79C2)'(M%+%$-&D"":%@:=(>D+3!:)!F(9GNVI#&&RE< MVS\IC;LPI4E$DR8139I$EOU)$$Q]E*2IQ2"8@39RIC,,CD(^>9P@02 MA$/RQ=)&-!3]@21MKO4DM6R(99/I-L;D?CXMS7R* ME96F24%PR%P3<3XUB:FRNA*)@DPB.M0S9=433?7\K,;Y>9=Z<[8N<+ M"**GB\!GL;2"CR(FB@CU05./TB^UB62GZH(_7BH!BI-="JJF+C MBV;`$"\@,_3SN1G!6!(#7;PDPD<3'YG$U"82!9E$5)MX.(/'^)TL3 M/_K1%I80R@)44V-%U!="^`J@S&@+@39/:A.)&M$@1FCS9`;1S`+>1^"%N&L/ MB`8$/*M4WOD"@C104*P@7:JTNAZ[J6U%%'2URA0T$DW>+/PG$:++,$0(R`QA MA(I*S*^1//:Z+DDT-G*$*D!J$XF$`I.(*D!F$,T0\M8"J_]L+G,?J)X+R-S4 M$:HOL2^M](60$+0%UUR.4#5(;2)1D$E$U2!35B-IP!L1O!!WY;+L8/1<%I!^ M&OO22IUW0[7.VMS:WI(3":Z<;VU!B0ZD-$1OB;W&\ M"`CW8N;B;4T\V%2T.=*8GL^M4[`7_FX&Y6^['F#QJ+<+INI5#_TEB59P+X*C M`>.+%5F,X/`\^-@_!"#['3P;]MF"\0`&'O&S"U=P^[?'?9R!__ZLPHYF*[A> MVX3=?`77TA'<7\*,EOPOWN`*'A(O^9'^FC?'LFZ=,SW`@DW[>VHCGB+%CTZF M\1/KX`FQS^@3/!E3N(Y.^2WPP%BG?O`!AD?H[=\```#__P,`4$L#!!0`!@`( M````(0#G`CX8)@X``'1&```9````>&PO=V]R:W-H965TG^N]X?-[O6^']P,^[WUZVKWN'G] M>M__SQ_I;]-^[W![M_4KE3SM]MOED?[I_>-Z\';3:=G6)W':Y__;] M[;?5;OM&$E\V+YOC7YUHO[==1<77U]U^^>6%VOTS&"]76KO[`^2WF]5^=]@] M'6](;B`KBFV>#68#4OK\Z7%#+1!A[^W73_?]AR!JQV%_\/E3%Z#_;M8_#M;_ M>X?GW8]LOWFL-Z]KBC;UD^B!+[O=-V%:/`I$S@/P3KL>^->^][A^6GY_.?Y[ M]R-?;[X^'ZF[;ZE%HF'1XU_Q^K"BB)+,S>A6**UV+U0!^K>WW8BA01%9_NP^ M?VP>C\_W_?#NYG8R#`,R[WU9'X[I1DCV>ZOOA^-N^S]I%"@I*3)2(O2I148W MX]'M9-JIG/$,E2=]*L]@>#,)AK-P0I<_XSA6CO2I'6>779)TNQ;3I_**4?Z5(X7-G*B'.GSNBO2).VJ2I^ZD9=%9Z808$90I=66(^AP!I$9^,[D).GFXOQ M\KC\_&F_^]&C!8Y:?'A;BN4RB(2:GH5R-)WFY7O3DN:C4'D0,O=]ZFV:<0=: M2_[\/!G=?AK\2?-_I6SF:!-PBX6V$)-=R,8N2%R0NB!S0>Z"P@6E"RH7U"YH M7-!:8$"A/<67AL7?$5\A(^*K(S/7P`1\Y`136VB7V`6)"U(79"[(75"XH'1! MY8+:!8T+6@NP8-)$8<'TWRKTF!36=%.PQN1H,N1!FBN;T2FP"R`QD`1("B0# MD@,I@)1`*B`UD`9(:Q,60IKB+(1ROM^(>];Y:`I'6B1(V)KB=TXXI5$X-N$$ M$@-)@*1`,B`YD`)(":0"4@-I@+0V8>&DL'TLG,*Q"Z>>GG-)[-@!B8$D0%(@ M&9`<2`&D!%(!J8$T0%J;L-C1;N2]V%UY]Q%*/)B2C&D7<1JMHTG(1^OB9*3[ M(`:2`$F!9$!R(`60$D@%I`;2`&EMPN)+F[;WXGM^J@M''DY)[+$))`:2`$F! M9$!R(`60$D@%I`;2`&EMPF(GDDQ[6W0^8,*:!TR2<9@V-Y*$ MM%VUQNB8C]$$W%(@&9`<2"&)C/2$J$"H/MG8M7;N`\W)2`NUMA"+ M-$W1*R(MK'FD);$CK8@5:4FH\;HZ"=BD0#(@.9!"$DNY!%*!5WVRL6/H=$9S M,M*5;FTA%D.1^[`@=G=URH9I:#UO5M_F.QIAM$/UC.*0-NMJ"R]$>&P[7=I" MT32QANB$#]&%L@KN3N&--:(:6XY3[IAH*^.8ZBM292W'&7?,C)6.38Y:A;&R MM*;.#K`T5EJK0JW:6)W1:HR5UFJ9%N\TD3+8:\S%6S&1K[H])=&H.Z^1"XZV MLN:!1B;@B4;&*E5(GOUT6AFB'!T+M"H15>A8HU6#J&6./)0B8?A8*&6J0=M: MW6-SD0R(Z@AZZ]^\@4BZZB MKS@7QU$X$9U[P4);F=C'"JF)&#B!2M`C56@L;ICZ`<6L'Z6QTEH5:M7&RM9RIGYCK+16R[1X;XE\#'KK]H(3`'$X[]YV)&*W'65E M]X="]FT'K%(ESVX[TLI"N:Z$D2_0L414H6.-5@VBECGR4(K4"T)Y[<"7^1L; M^!+Q.]#,6706M-_JIH>)1*P0#7P]$!*T2K45VYRYMX5,.S*KF;-NY]K*5**X M2+[4CES>68DK;67DZXOD&^W(Y9WEM]56G3SO6I$9GNG:/W9O[^VHZ;N8TY9: MYI>L;^V44VW4`,4!H`11BBA#E",J$)6(*D0UH@91RQ`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`"V.E[P,QH@11BBA#E",J$)6(*D0UH@91 MRQ#O`9$3VSWPBQ$LS)T1+)$UW1O9H^#B!SS$ M3'('A$2TBQ(/UX^&@7.?6F@?NP%*AAV4N#?Q1#F*W>`I/N'0F>,ID^?-_'#R M%6+RI1!M:U0S8151V9G=3(G&M!FQ&N`DIXE2)BO=P:F^&-[:Z<[QT:[#'*43 MZQ)*U28GM@ME8&^'%6*I83AT\IK$6)DVJ>M[VB0VRA\;CFIO;G;P-HD-Z,?:)+>N=J)"6^*N3:E>./UJW4(YL M'92.+/$-`R?!3)0C69DVJBMB&^E8_H/]UGGR>Z5"=H*IK:S1IY"5)R:(4N;( MECGZVL!3Y2N[I1-Q:B^W6*Q;`N@6Y6AWBT+G4[1$.U)7G!;'TDI M=ROC/%IZ68XSQAV.0G1?T>-E@2A&E"!*$66(*CR=WA MG-\ATJAUI[-"=`LP\9-6%HK1*D&4(LH0Y8@*1"6B"E&-J$$D7C\6S98-DO&3 MKQ/+5QBWZ_W7]6+]\G+HK7;?Q:O"$_'LY0G+]YCGP202CR10F*!D2B7=A@!* M9E32/2'@EHRHA')7CUHXC$16AB4/81`]4%NPA%(G\NEFG7N=<$0EW7MI;LF8 M2FAD>=3&H7YEV_&)Q\-(+'?H0V]Y/WBUJ&+>>M'%O?9T:5\+'\;1@S=W$;WJXN'4N[[.C<,P$OMU](C#6RKQ72,.[ZC$=Y4XG%") M_SI3*O$-HCB<48EOJ-!9> MI.8KH7--4O.5T%=[I.:+&WUW1VJ^$OIRCM1\)?0=!ZGY8DW?6)":KX2^?R`U M7PD]MD`^OF%)SR5$XHMTC`X]GD!JOJ%/W[)3B<^'GDR@4>XKH2^?J3V^"4!? M)5/=?"7TQ3!=QU$(G$XPL8`WI.A&KM*Z%G M0R+QY(+')QA'XHE7+*$G7"/Q_"J6T/.JD7@:%4OHZ4Y2\_8IE8CG-=&'GL\D M-5\)O:)`:KY:TSL(I.8KH9<,2,U70L]JDYIO]-*3UZ3F*Z'GJ$G-5U),(WH' M"%M332-Z$PAY/8WH=2D/GT7T"A#RENY9/DZOSE`K?..<7H2A5OA*Z+46:H6O M9#Z-YKZK+*;1PL?C:13[>$*+HX^GTXC>K\+6Y=.(WK(B/CC=P>@W/]Z67]?- M_FJ(_..H'LG\LCO2KWW0)IM^S(!^W65-OR,P M%&]"/>UV1_V'N,#I]V(^_Q\``/__`P!02P,$%``&``@````A`#%[YOGR!``` ME1$``!D```!X;"]W;W)K&ULK%C;;N,V$'TOT'\0 M]+[6W1?!]B*VI':!%BB*;?NLR+0MQ!(-28F3O^^AJ`LOBINF?5FNCV:&<^;" M(;/^^EIJ$EV9AOI#:_ M;G_\87VCU5-])J0Q8*&L-^:Y::ZA9=79F11I/:-74N++D59%VN!G=;+J:T72 M0ZM47"S7MN=6D>:ER2V$U4=LT.,QSTA$L^>"E`TW4I%+VL#_^IQ?Z]Y:D7W$ M7)%63\_7+QDMKC#QF%_RYJTU:AI%%GX[E;1*'R_@_>KX:=;;;G]HYHL\JVA- MC\T,YBSNJ,YY9:TL6-JN#SD8L+`;%3ENS`@F63F8U4(%:!1``L,!IH(?G_`RUFA='J'=KUP,C353CT$KU* MI`*Q"B0"('%`'8HS;KI-Q!SY[#8DT)-:01$0DCU'_ MHL>LF#P4=-\['RXG9@<%B7V$>EHI;+B0AV44\FQ9:#\(#?G0D%A#$A&1"(** M2/!^2IAPRZ+?>\>1H#U$VPK?:TBD(;&&)"(B^8<.%OWCW3QCI]!]5YF>["I' M`O37$%W/5:/+A5Q^_K8=RQ%_,918K"&)J"5YO_BD]TQ/]IXCKM<>1:[M!$I9 M=!J"XQSQD7F!KW)`Q8-0G]%$-"1Q85<:[5S]0":8GLR%(Z[=M]]%[AP MQ,5DH>>DT!"X<4?+BR6KQ(#1P$0U) M7!Q<:CZ5F%919M-!8VJ4D;?O!00^':0DQU<(C5(#(\F63(D-P>E:^[=CG(]3 M'+S]MCN'0V/*E&-XWPE@Z76B#O(QV(0"5'HP'J5ZQ42R)7-D0U+EB+LA=CCG MV=..8B-X.G'*L3.@NZ3P02NQXQ`R*'CJ**VR=SHID2*'`OF\T"@.4B-%T99, MD8W5_TJ1CV:)(H>0P)&BNU(Z:,]F+>M5D2*'`C@\9-'UE8Z-.\5`-.^YRAF5 M2.9EUFS6OL_Z.[V^EU@\"8;,\H$MT>80K@=]Z/>.!D4Z%.M0(D&R]VP2"]Y/ MU)_H)I_;DIL<\N:"FQH4L3<4LB-(Q3K$7G:C%'>3O]3XA;\@U8GLR>52&QE] M9J\P9XX(#C!_(D:.&\8H>$1-^8+'X\,4OF./R@GYG1OB:JO;V7DA;I`Z_N"' M#Z"@?]CY(6YD$W@0XB8T@3M00,ZFOD!EDRVZO#Q5_5O,? M3=<>C[3!<[CME#/^_$'P>++9X7BDM.E_P"EK^(/*]F\```#__P,`4$L#!!0` M!@`(````(0"HJ>;0HPL``)8Z```9````>&PO=V]R:W-H965T)%NPO;!(-DD@`8)@DUQK9-H6QA(-27-Z M^U2SN]EUZ!G3VKU9K3]6E5C5Q>+?'/'V]^_[U\G7]GC:=8>[:70UGT[:P[9[ MW!V>[Z;_^4/]=CV=G,Z;P^/FM3NT=],?[6GZ^_W?_W;[K3M^/KVT[7D"$0ZG MN^G+^?RVFLU.VY=VOSE==6_M`8X\=OF#.=_>MF]G5RT_79,N/WF^/G+ MVV_;;O\&(3[M7G?G'WW0Z62_737/A^ZX^?0*>7^/TLW6Q>[_$.'WN^VQ.W5/ MYRL(-S,G*G.^F=W,(-+][>,.,M!EGQS;I[OI0[1JLF@ZN[_M"_3?7?OMA/Y_ M,_=H<6J@WKI%?@4]=]UJ;-HT;@/!/>JE^!?QTGC^W3YLOK^=_= MM[K=/;^<8;DSR$@GMGK\4;2G+504PES%F8ZT[5[A!."_D_U.MP949//];AK# M%^\>SR]WTV1QE2WG203FDT_MZ:QV.N1TLOUR.G?[_QFC/J,A2&J#P*<-LKRZ MSK)T<;T<'P0L^S.!3QLD_GB0A0T"GS8(-/K(+);6%SZM;_+A2L"W]4G`YU") M^#J+LL4'RGEC@\#G1T]D9I:W[Y9B<]["@Y$!Q4'%0 M<]`@0-).:-KA^>#661O#)$#K',T3FL[:VL1#"7)!"D%*090@E2"U(`TF)$^8 M07)YK_0<^G7*V@\N#HB+>ILMX=H8):G/69!"D%(0)4@E2"U(@PG)&9+#.?\Z M46W<)^KZ<&U(UM]H^@LR%Z00I!1$"5()4@O28$*R@AF.L^I'%MR;8(%>=MO/ MZ\[3].$V]&?3UR%H^I;XN95;@M*WY*:?[_$\2EGFPD-Q#S8J*N%1 M2I8Z'(LM2#4J5AV.M:3GU;P7BY9;BS$N/S\XRR,CZ.`. M[2;NVB+6XFQ2Y\X*E][$BF',H-+?T!1+[^BM`J4/Q4KG-%85BI6D3!G7SHJ< M5\JNV<99P1?[LT>Q:.FU(.2E'S,Q(Z,D2;T-PC/36>'B6BLT-:65LBCV5I6T MJJ550ZQHJEH4\E0_VF5&6)*L#:)=EK*)F&OE"`,XQH6P"`836B;%AT3@KW&7XO&CIM3;]>>G_Z-Y@:+X[7(W`A2_V5SC6 MO$:;1@(5$I42*8DJB6J)&H)HVEJ\HK3?N7D8J4OR,RCQ\BO73V^@D1`J)"HE M4A)5$M42-031_+0Z1?F9QP8CY!;H62M'?%,O$W;-K*T5WD])5$A42J0DJB2J M)6H(HMEK%7I1]E:^XD8VB*0J4!$)5$JD)*HDJB5J"**I:CUZ4:I6R.)4+4)[ MK,@BW^:%10F6IW'*5$;IK=Q(4!)5$M42-1;!>D,LFKV6CCS[C]XXC/PD%[=% MN!`6X4(8],YV,QJL?"$$JJ15+5%C4:`0^A[W9PO1QZ`2V2%4"(=0(1SZZ<;3 M&7@?Y=#@PT9,Y0R\3^W0X,/UE3/H?4BCP-U=UF>,F.H=65%T+!`,_LK)G172 M$!8AF51**R6M*FE52ZN&6-%4+]6-L=2-%NFZ(B'$=;JSPME;*>D;IY16RB%O M53GD8]4.>:O&H=Z*9J_E%I\(HQ;:Z#0\!O3.T"PTSIYM-G)K!=K>7>"%19G> M?GZ]C[,EW[V7TDE1I^0ZON$B43K5U`F^Z8:IU(8XT5*%I-^H4DFY!VW>EXHT M2L;V4KFSPJ4RCMFB+]5R.6<^I?11%EF?*)U'K",KZ50SIWG,GXLWQ(E6BJG% MT6I*_]L1=!!I*H-@65R[Y,X*E\5:^4U6*:V417#B+E8EK6IIU1`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`%R<8C4MPBE:A%,T2(\/GV+,!$1IPX.53W%P=*AR)R&?/21: M*O%[\T=3M'++[QK6?5BXA^$4K15.T:+AF0D3JG*HCT7R2D/*:4Q>O2.52Q9EL&S#I9,L^-[..:*\+-)[ M,.3(U$\I'578D;4?E$'7D^P]G%5A[)H0N^5%6*N611:P-V%8F=XX^G\(BO]E?G*.T?6ID$&EKJXSPQB3AS_!RZT@N5^L('V@UQ92R5KXVRL6BCF)* M84=2"/B%]J\*,6Y*]4&H"+,(=HW#_4>B0J)2(B51)5$M44,039LIKE\_?(&7 MK?@NSB+\\$6B0J)2(B51)5$MD7X)3)^7.0F3GWFIR[RFLV^/SVW>OKZ>)MON MBWYA"RZA^]L!V[?)DF3U`)%@G=@1>,:RTH\X0D=2.-*O+??)YO!R6J\ZQ)'A MM35^!(*%8T&HT+='X``_H`J<5Y3!D9#/0[18/<##JI#/`GSZ_2(_KV@)1Y8A MGP1R,;MN[I/$<"3T/<5B!3_5E]\/OUI9Z9^6A([C"EGPTU@;<"WS;/[3\WQ^?=X31Y M;9^@">?];[V.YKU"\\?9_I;O4W>&]P%ADL#;9/#^9POO4LSU#ZB?NN[L_H"< M9\,;I??_!P``__\#`%!+`P04``8`"````"$`8NM%K=N_O,@!.L`8RP,YGY][?:W4UW57E"@N[+,)R<*MJG3W=5V[[__<=A M/_I>G=NZ.3Z,G;OI>%0=-\VV/KX\C/_\(_DM'(_:;GW^/ M__S'_5MS_M;NJJH;089C^S#>==UI,9FTFUUU6+=WS:DZPE^>F_-AW<'7\\ND M/9VK];8/.NPG[G0ZGQS6]7$L,RS.'\G1/#_7FVK5;%X/U;&32<[5?MW!^-M= M?6IUML/F(^D.Z_.WU]-OF^9P@A1?ZWW=_>R3CD>'S2)_.3;G]=<]7/ MZ-S]%Y;^4&_.3=L\=W>0;B('RJ\YFD03R/1XOZWA"H3LHW/U_##^XBQ*-QI/ M'N][@?Y75V^M]?]1NVO>TG.]_5=]K$!MF"9-LT>!@#_C@ZU ML`8HLO[1?[[5VV[W,/;F=WXP]1R@C[Y6;9?4(N5XM'EMN^;P?TER5"J9Q%5) MX%,GF7TZR4PE@4^5Q`D^G62NDL"G3C*_F[E^$'[F>F!Q]*+`I\KBWI`E4EG@ M4X_E+G"FD1=\7%D'#"'G1SA#:7\U?"(GN??,:MVM'^_/S=L(%B),8WM:BV7M M+!SXHMTBY_;BGU_9!WPCLGP1:1[&H`XXHP7/?W^2Y31 M#!VRHD!,@80"*04R"N04*"A06@!2QAM0Q@.##F\ZVC4B"K:7=UVC..Y%K25# M5@R)&9(P)&5(QI"<(05#2AM!HL"^-6"7.['8/[F\1"98H?!+[ZPO20H#1(J( MD2ZDBY,8$C,D84C*D(PA.4,*AI0V@L0#D?XF\42F7CQ]R4\2P4J%4Z+4A:3# M5@R)&9(P)&5(QI"<(05#2AM!2D%E^Y52[R\_$8B%D8@W,XN-(2N&Q`Q)&)(R M)&-(SI""(:6-(!7`]K>I(`*Q"@J1S9&H0TN%S"^ZK!0"'V9%AJ2>Q2PL&0PC MFWW*PK+!,`\;-F=AQ6#8#(>5=AA25!P([-;@?3,)-I91(>!;2R(?__I2DF:R M>^QKO@J#85EA`0Z+65@R&$9VOY2%94-A$9G'G(45@V%D0DH[#"D+_1]25C9= M?6'H=O7FVU,#EPY-R(#B'C17LN422;#@$O&PW5;7GPBB*R.X9F1!?&)W%P M`"\&H+*Q4$27NF*YMD@R4)U#Q?*/.2O1D-F04PV97)F&#"O7D&$5&C*L4D,] M"XLDVMW;1)*-,A))0C[L"I9(='DZ*M`,>:4@7YCR^V,8N7.R/\4\*,%!CN<% M+EG2*8_*%.1"E;7&2#;?W`0:EN>3W:_`(P@]-R#76IH\X"0LO.BI;Q->=N-( M>`GYL#M<+LIUR6"6HKD&#R-WJL!Y+[PW<]V(2!'SJ$1!OHIR(V?J$6U2'I9I M".;_,LIY1.8LURQ8-Q?6@/1HX+[CS>;D*QDK48$6*^6Y,L[*.:O@K!*QL!M%Z\T4@9MB,`D?+M?B M%ARIUPH*[0[)]4@M7"H6,J;,%4J+S3S']XE18AZ5Z)^[V'D6T)TDY6&9AE!; M$9'.*M>L*\9$`_>C>3`CEUN:1,R8HO=GT^#W;=.5DB5/#5B(6-*7KWVQ01D:2MD1`JXL&4-'1+1[*0&Q5D M2FK,68F&#"O5D!$\TY!AY1HRK$)#AE5JJ&=AD40;?IM(JLNW]S,)72OB*M`, M>>6H0%G$?<<-2/,:*P9T(WKW3'"0XT0.7[#LIS(5A8IX,"4]0VY^[MU*@H8] MT'N4)@];KZ(=OTUXU>W;PDOH6A&7+.1.%2AW/7<>1"Z1(G985*(@5<1ALD+? M(4LAY6&9ANPB'DS)%I=KUI6]$@U\J/LH32*JO7OS@:>/Q#N#@NR]4K.,65<* MLG;!F+,2SDHY*^.LG+,*SBH1"VT#X(D!-WZRB/=)B#@B+]S-?[^(JT#;F`I2 M1=R#Q4U/3#&/2G"4&\Z#>4#\G/*P3$.P55_Z1GBDA^\-Y)KUOC'Q$(:ZC](D M8L84YYN;-@57G8RL34%!R)B*91M30LB8C)6H7!8KU;]HA8621P';A-)'21LVTCH2A$')_0MDAGR2D'J)#[S79?4A)@' M)3@HC+R(G,52'I0IB-1PL M*ULE'OA`\U&:1$Q[<=*X37MU1K$]+R&T5;*3S$KX36AO'<059+>EG)5R5L99 M.6<5G%4B%MX%Q$F#*?+9&BZ/*\B8$KI6PR4+&5,%*F.&CD//L['+HA(%J7A.CE^.2,LB7T>2+18?J_%(MJ_V^'6V: M5_&B&=S2>;R_P/(MN*?9`I[]@[,H[B_@2?<`/E_`L]\!W`WA=;K^71J:R8WT MBW;D+\MP`8_!>*XX7,!S+HZGX0(>9'$\#Q?PI(KC)0QI"((>S@D2OT M\2\```#__P,`4$L#!!0`!@`(````(0#B6!\58Q```'-<```9````>&PO=V]R M:W-H965TYF=]6_CRWIS,MX\F-5DW7IYI\7\>.O?SP] M7OR^>=UO=\^?+IL/D\N+S?/][F'[_.W3Y3_^KG^YOKS8'^Z>'^X>=\^;3Y=_ M;O:7OW[^VW]]_+E[_6W_?;,Y7-`(S_M/E]\/AY?;JZO]_??-T]W^P^YE\TQ; MONY>G^X.],_7;U?[E]?-W>/0X+^N=W\W!?_?['_OOMI7K['X^'_]O]M)OMM^\' M*O><(O*!W3[\V6_V]Y11&N9#._\>Z0#HOQ=/6]\:E)&[/SY=MK3C[+#?#F9-F1^\66S/^BM'_+RXO['_K![^E,ZB)_U-GM,/RV9R,UV^[4A;A^.FO]%Q<=P>%]&1_IZVQV5TI+^G M[9&FVG"H]/>T/=Y$1_I[U!ZO0FV'5NGO#G>?/[[N?E[0_*/J[5_N_&QN;FFP MU".A+F/7_+NFH6[Q@ZS\*)\N*0KJASUU^N^?EY/KCU>_4W?>1YLUVC3OZ&EW8=C*;T9S1JEA-NU(U&8P,` M44`T$`/$`G$E86FA!)1I>;O\WGB(/1WQ.A`*-)$.2`]$`=%`#!`+Q)6$144K M>1G5L+J=4VP_CBCV5)1Q'6Q$K>42-QJE//5`%!`-Q`"Q0%Q)6%;H-%5FY>U: M>V->ZT#*6@/I@2@@&H@!8H&XDK"HO&R59[)S:NW'D;462_8ZV(A:"Z-N-!IK M#40!T4`,$`O$E81EA<[I95;>KK4WYK4.I*PUD!Z(`J*!&"`6B"L)BZJA,U09 MEI_8T^:,57P82%2[G4V[59:NQX(@4(HW((+*('$,\05[ER-DP M_^"5\]LMT`1Y1.>U%,0ZHK()$/6(%"*-R""RB!Q#/%2O;$2HY_5"D$@L](!$ MX45[=,UHE7+6(U*(-"*#R")R#/%L>.$CLM$<5?B@F%CT44059W6O=VB)*'JA M1Z00:40&D47D&.*A>C$C0CVO\$$5T9Y2_=;-*)1*Y3:7,WZT2HY]=DQ((=*( M#"*+R#'$L^%%4)&-=Z9YD$PLY*BB%F,6.G^WP%<[HQZ10J01&406D6.(Q^?E M3!'?H.6:X=9%O(MPM'1O@C+RG37*M4KU[1`J11F00 M642.(9XBKXUDBHZ:^T%4L6XH==9P-=XU@'I$"I%&9!!91(XA'JH7//503[UU M$:03BWU44[D_FN525GZTRI4'I!I`&I%!9!$YAG@ZO%(JTO'.Y`^ZBH4 MZ5T#J$>D$&E$!I%%Y!AB\;45O3>CS)Y8ZV$8H?:6C;A&6TD4*D$1E$%I%CB,=7D7A1U)S: M`:/&*Z>VO&W3CH+N#:LN6^4.&!T34FBE$1E$%I%CB&?(Z[)B`0CW<8_0^VT0 M=.5:$!%K!I1]:*40:40&D47D&.*A_E6RKT79%Q&?^M="&739*E6Y1Z00:40& MD47D&.+9$++O^,*C`O0/9+BX[Q#UB!0BC<@@LH@<0SS4B@)LZ9&4]SAU&1@5 M8*K@N@U(E%Z<&[ILE1Q[1`J11F00642.(9X/(??>6?51X[51T(6'?_Z)2X>H M1Z00:40&D47D&.+Q>>ETUIH6-!=;TR(J0XTH2YZ^#<@__Q@O#)IK<5]/9:O4 M`QJ10601N8A(T]-8/'HAZ8:)/=S//'S?WO^VWM$1THF\4O0I/8`+C^5:%'H) MY2=474)E(J+VHQT4B1`WO%1TG(8GOKY_-"*#R")R$542X:L!;7!B(H8Q^)W- MA(I$)%0D(J&;X:%F.VG$O1^5#+*/3FCT$7DSR2#[V(1&']%T+AD,/JQ1*/V8 MGV.N^@9'D90@#;W2+.HN8NZB(^FU-`'ZA$C_%([B?HE*5ME1)\0=Q56V25;9 MT2;$'<5%FDM6@R-/FY=JYZPN4^\HTA80:9:4D"Y9Y2/N(Z)S>;)2:*71RJ"5 M12O'K'BH%7$8;I155@\ZFZ;E8XK:,"+1(/+:*%F5P8>Q:/0/`5N7C4#5&O!&2=`_+:M.AR'6^$KE3H MJ.N.0I48=+1U1UA58HR5M-5TY:FK+DK,:4"\?V[$`MDEJS*#T9$D2Y%!L3(I M=-0)<4>Q,IEDE?=H$^*.8F5RR:J2P8I",6OBXY MYH#ZB+SD*%(HYJY"1UUW%&UOT-'6'.DE0'XCS3%'/G>]0!5K].DI](.(]3H@ MUH5T;N?'U4VC59G"B.C/F,)V(F:50D>=$'<4?6^25=ZC38@[BKYWR:K2A5[2 M_L^8(^_"OT")3U&)1R2:4,RJ+EF5&0QC><6[0) M<4?1]BY981/.WI;P?]^]T/RL7LL4:F08A,_CB$K=E:SRT??)JM!=:*71RJ"5 M12O'K%CCS"K*_!C=-?B)2"O"O&W$^M%%QU*8)Y2UDDHHIT@GE*U,0MG*)I2M M7$*5FE?T]5'!H[R>C?*Z;'BQ!G;1JEQKDF,IN]I&+%(J.Y;#BQ5)U\>2R\]1 M8]GZ6')%>F\LWFM>3(MU_BB9.PLJO+Q9$A%)R+1J=XAZ1`J11F00642.(1YJ M1=&?]=Q_A@H_(J^>B[55+LK9*B6H1Z00:40&D47D&.+9J`CU\[*!:GT6$,]& M*_1;EZUR-D;'A!1::40&D47D&.+9$*+[[0O<&:KKB$C6IR/O$/6(%"*-R""R MB!Q#/#XO0,4T7]`,/O'^]\P/(\XP`8E:"W'01<=B:>@1*40:D4%D$3F&>"Z$ MM'VGUJAA_1-DR@*K-:`>K10BC<@@LH@<0SP^K_-$K6]F9[SD./,#B6H')*HM M%%T7'5FU1\G,-:H177T4IT@+#JLE5*6H]((=*(#"*+R#'$ M,R04Y3L=@#IR'E`YWQ'UB!0BC<@@LH@<0SR^BH1K)[/A(?Z)Z_L<15U$HMY2 M1&>K7.\P5K$(*+32B`PBB\@QQ/,A=-X[]48Q-P^(U1M0CU8*D49D$%E$CB$> M7T6YA9\B'7]_<(ZB+:%"P224E[X^(O]\9!2Z^*@S6Z5VT(@,&YZ'*.38T6\G MS%&9)50\L$NHC"LZLOMEK;SD0T>=T)N.)EGA8[BYUT_B;'UR-8,&*Z_%AF'I M1%9&':W*J",:'Q^*>:W2,-E')S3ZB+7?)(-*K$)Y'5]6%&'S@/AML%9=7&F49,.P]&MK?MJ6 MEY[1JKS+D1PID3D1\N=I"AUUW5%(?L,Q>"$EVSBL*PQAM M"M0C4H@T(H/((G(,\?I[/54L>6^?H!=!?96+6T2E)$?4(U*(-"*#R")R#/'X M*H+LK-\*^ROT<`&6&W/9B(Y>1RNNT*;BU-5EJW1*[A$I1!J10601.89X@DY2 M:`M4:!$5W=PAZA$I1!J10601.89X?!6%-EN>\\+A8M1I90>(I6D=K40'R'-A MMLH=$(8O\JC02B,RB"PBQQ#/T+D";X$"+Z(BB`Y1CT@ATH@,(HO(,<1#K0B\ M,YL!9=XB(%%Y(6:Z;)4K/SHFI-!*(S*(+"+'$$^'T(#O+/XH_!8!L<4?4(]6 M"I%&9!!91(XA'E]%Y=W,SYK[H];+A&L1`<(JRY;I7+WB!0BC<@@ MLH@<0RQ#2R'_WNZ`P9K+FXC*"8^H1Z00:40&D47D&.+Q551=?/ODQ-LQRZ#C MV!VYI7R5=!VM1`?("X!L-78`(H5((S*(+"+'$,_020)PB0(P(M8!P:I`/5HI M1!J10601.89X?!4!N*"/4-'9]M0.J"I`H>W6RV#%.V`FG[=EJ]P!HV-""JTT M(H/((G(,\0R=I`"7J``C*LK=(>H1*40:D4%D$3F&>'P5!7AF!U05H-!V:]]: M_I$4)2I?PF('C%:IW'UV3$@ATH@,(HO(,<0S)!3@.VD4*D$1E$%I%C MB"?H)"&X1"$8$6N`*`3S&R@]6BE$&I%!9!$YAGA\0@B^T^`5L;=LA(Q;+VMB M;R8N![MLE:L\.B:DT$HC,H@L(L<0RP)]J/*$>SV#-1=[$9551M0C4H@T(H/( M(O*?VXS+*Z4OQ!<^GQF^B?BT>?VVZ3:/C_N+^]T/_VE,NC[X_''$\;N=R_GM MBA8,&D)LH>7[UB\EN&6U7)+/AED-H6JAR]&%'9,I_<^E<*<,MJ3C6M9I0> M_)-/M0ISJ@(]GL;1UG/*-3VHK6V9T99:?59M>[NJ'MN:MOB?LE=&:VD_X6U> MV54M[2?\<@JV4$W#SXI@"U6!?G)3VP]5@7YX6MDRHR.@5P]K6^@(Z#6\VA8Z M`GHE#;>LFL7MBKYJ@5OHZS*W_DLNM2UT;/3AD]H6ZI#P(%!&VE"'5/>S:B>W MJ_`^L/2A+?Z3"Y7]T*'5]K^ZOEU58Z'#JO%50_NF#_I4]D!;_,?+:ENH.\/# M+7F\#74-??>JYD,U"X\5P(=J1I],JOE0S:K'1C\"OO6_U$6?OKVA+;5(Z6GZ MK7\PCC[TC>=5_9AI]Q7[M9\:-4XAUKIR-:-)5K/WT[+"5]200VVOQE31)Y]? M[KYM_N?N]=OV>7_QN/E*Y[W)<)'[&CX:'?YQB&_I?]D=Z&//='*GKP73Q[TW M]+/?B7\I[>MN=TC_H$1&ULE%7;CILP M$'VOU']`?E\,).2"0E;9KK9=J96JJI=GQQBP@C&RG5CGZ\?WA9H$";4A;D$:V+$\%:XT$4:XB!_'7-.WU$$_0:.$'4;M_=4"DZ M@-CRAIL7!XH"0;/'JI6*;!NH^SF>$GK$=B\C>,&IDEJ6)@0X[!,=U[S$2PQ( MZU7!H0+;]D"Q,D>;.+M;(+Q>N?[\Y.R@3YX#7&'J'$WBV+(>J7D(0#-`*7NB%5@G`'PY8*@$NN[ ML7. M&TYIDLLTD_^ALJJ'5V>O#M7$ND:''O<6I\&QTLS%%,IE9Z;_!80//.7K+ MZ2#3Q?)R9?,Q;9Q>49F-.V?M+>/*[+Z^^CA8YW/'GM/X-``#__P,`4$L#!!0` M!@`(````(0#3W#Y6YP(``)8(```9````>&PO=V]R:W-H965T4M(&A12I:NZ3=JD:=K+9P<,6,48V4[3_ON= M;4`0Z))^@?BX>YY[SF=?MGB9"4UPD*7!\YI$YY1NLB0;]_/=[<(DXXC5)T"N1Z&[W\3(M"P[1&%B$6UV#P/*>#ID9%:61!!*JP@?UG21G9H M++T&CF'Q=&QN4LX:@#C0BJI7`XH$93P27/ ME0MPGDUTJGGC;3Q`VFTS"@ITV1U!\@3M@_@^")&WVYH"_:'D)`>_'5GRTV=! MLV^T)E!MV">]`P?.G[3KUTR;(-B;1#^:'?@AG(SD^%BIG_STA="B5+#=$2C2 MPN+L]8'(%"H*,&X8::245Y``/!U&=6M`1?"+>9]HILH$+4+D'(A4CU1#(2<] M2L797_LQ:"%L,'B:8'AWP2LW6ON+`+@N@'@V$:/K`2N\VPI^ M$`/PO!!0H'WWVCE!T,R0JX3J/^^BU>W6>X:*I:W/O?6!9^\3]!X>D/;,P'8] MLW;6S+JD.I5[:QC2A/,TB_?0:&?8DT'R4X'69VGZ9*AG.2;2K;$(W#>;HZNI M#H/B_Y^S=8)^[:L:K3;S@H%Q6%?;HN[Z8B(ZSB32U[BUF"X<;=UJAB(P+7^A M@73@F*.UC)2M_7EEZQG:Z`IE.F[,VEJFRO1%/3@.9A.7<,HNG0P=-Z9H+6-A M;QR%S90UN$:8CANSMI:IL``2.5<6AOYE929P3-*9AJNVX3&!'GA>M,9GC89K=3P-Z6C(B"?")5)9V4'_4-'\+]UUO[ MZ;,W\>?V9;RW4\GKO\!4:'!!OF-1T%HZ%SKGJ%GIR]?\H=O\```#__P,`4$L#!!0`!@`(````(0"-;C_) MH0(``.$&```9````>&PO=V]R:W-H965TGAUCP`K&R'8VNW_?L4UH**MN^L)EF#EG MSLQX6-\]BR9X8DISV>8H"FFT=WF M_;OU2:J#KADS`2"T.D>U,5V&L:8U$T2'LF,M?"FE$L3`JZJP[A0CA0L2#8YG MLP46A+?((V3J&@Q9EIRR>TF/@K7&@RC6$`/YZYIW^HPFZ#5P@JC#L;NA4G0` ML><--R\.%`6"9H]5*Q79-Z#[.4H(/6.[EPF\X%1)+4L3`ASVB4XUW^);#$B; M=<%!@2U[H%B9HVV4[58(;]:N/C\Y.^F+YT#7\O11\>(S;QD4&]ID&["7\F!= M'PMK@F`\B7YP#?BJ@H*5Y-B8;_+TB?&J-M#M%`1975GQ M)>Y1X-ZCS!=ANIS-(R!]`P3[C)S`>V+(9JWD*8"A`4K=$3N"40;`KRL"*=9W M:YUS!$,-N6KHPM,F7<[7^`E*1WN?G?>!Z^`3#1X82`=F8+N>V3I;9EM;F\K. M&RYIXM=IYO]#8YUS!-6RC^ER M\;JNY90T2J\HL(T;L_:6J2Z[KZ\^#=9YC-M;XC^SX5>*/W&"J8I]8$VC`RJ/ M=EW$<(8&Z[#)MB[^;WN2;=WXX^$#;)B.5.P+415O=="P$B!GKB#*[RC_8F0' M:<*&D`96BWNLX5?"X!C-;,]**>T^0T``/__`P!02P,$%``&``@` M```A`#F8PBMJ$@``\6,``!D```!X;"]W;W)K&UL MK)U94QM)LX;O3\3Y#P3WGT$K1F'["Z/>%VUQEFL&9$,,(`+)XYE_?[*Z*E65 M^9:%K#@W@^?I]TU55];>C?CT[[^?G\[^6K]M'SKT[HP@O MV\_G#[O=Z^3B8GOWL'Z^W7[8O*Y?Z,JWS=OS[8[^]^W[Q?;U;7U[WYF>GR[Z MEY?CB^?;QY=S&V'R=DR,S;=OCW?K9'/WXWG]LK-!WM9/MSLJ__;A\77+T9[O MC@GW?/OVYX_7?]UMGE\IQ!^/3X^[?[J@YV?/=Y/R^\OF[?:/)[KOOWO#VSN. MW?T/A']^O'O;;#??=A\HW(4M*-[S]<7U!47Z\NG^D>[`5/O9V_K;Y_.OO5S_W`;_/ML^;'[F;X_WS>/+FFJ;\F0R\,=F\Z>1EO<&D?D" MW%F7@<7;V?WZV^V/I]UJ\[-8/WY_V%&Z1W1'YL8F]_\DZ^T=U2B%^=`?F4AW MFR_,])/-XP^CJ\M!CS[KV"!#%V2\#W)]M/?*>>FG*T#_0V]X.?Z-CZ>. MT%4`_70ACO_X'J7+UA[5T^^[N?IZOOZN/_0_CGJCW[F!WH`+0?\XM19ZG`7S MC]^_$\J=K0>?Q-].1(^3:?YQ;!$N;'/N>D=RN[O]\NEM\_.,AAQ*R/;UU@Q@ MO4F/A'F*B?#5A/I^3G_K"EGKW7U]&UY>?+OZB'GGG-#>H MZ4G%E!6F^YFPB0:I!ID&N0:%!J4&E0:U!HT&K08S#>8:+#18:K`*P`6E9Y\C M:O;_'SDR84R.N'9O&/BD]55"6,&61(-4@TR#7(-"@U*#2H-:@T:#5H.9!G,- M%AHL-5@%0"2$!A"1D/@DPGW#J&FZ.-@WG*:_3\X42`(D!9(!R8$40$H@%9`: M2`.D!3(#,@>R`+($L@J)2`4-PR(5=OSZ<$7SZF\.8282C8+T20?&,"L:2)$> MQO:B?;('!RN>*.6%6_)L%M[VXIWQ"Z`NTGT5K(K M*!-$UJTE8=TZX@N>6$);$:ZV%$@&)`=2`"F!5$!J2\**M$15Y%!59&@3%4GK M1ZQ(VBE16HZN1Q-#UJ,C=E=G6N34D?&^UA)+/IIT_/5EV!M?J<5K"I9,6:Y& MU_(V<[`4RD([&&DIP5(IR_50MF#&2QK$TYJSR MQH*1-%Y)8\DJ;ZP82>-'::Q9Y8T-H]#8[ZG>V;*J,\I,F4T5;G"/:-0]NQVC M!2&/K3<.C:E=!!4.F7)&?Q>),_9I"MD;QY?J+E+^1&_,XD8U;.1H+.)&->N6 M:*SB1CWJH+&)&_7@(XPR4Y3B$S-EG*I/623Z5*^O;G]J#I3(*/J40_0CR!3T M*3!F'$L:H4^!L8@;H4^!L8H;H4^!L8D9!]HC7&7S5"5HZI`58FJ"E4UJAI4M4(E&[W9'9U6 ME79?1:'Y7F_,F235"#5Z1E.'1`NW*IJ^696B*F/D53DC7[L%(Z\J&7E5QU3#RJI91IY+U9G8TI]6;W0N)>K-H1`LCW^?U'#,U3PO,*..+G#@DA_6> M&IU3-&9QHQJ>@=$J,S9@J,&<>21L@4&(NX$3(%QBINA$R!L8D9A[#Z M9U6D3YE]V6F95'_P*1J%QW%/+CY)5WE@QDD:UBJY9Y8T-H]`(16U9%6G@ M9C^G$]4[9H/;"=439PAV0#[ZN=T)15OHX21F'RQWT]U[+*&S-&TJA'<%9Y M8\%(&O4(SBIOK!A)HQ[!6>6-#:/02$_IY2ZY955GE(DZ>;-+0XD>BAP*#]41 M)8A21!FB'%&!J$14(:H1-8A:1#-$OB4/OG+1[%<_,&:(<48&H1%0AJAT*BMHX9";5_9)[!%M08915:C9_ MOQC*CS\KIO-)J&F+1$T[Y#MJXHSAN3NB#%&.J$!4(JH0U0Z):G4W)*M5C3RM M,,IJC6Y'?_,$GB8[J%6'_-YNRJK@$-ZA_2G\X%*M[%,T96"Z5K>;HZG0IN%' M-S-;HM'JSFZIP06[V M]E1OXB`1#^>=BJ8`KMV$43B7T^MJ6-&2-I5.TS9Y4W%HRD4:WD2U9Y M8\5(&J%QXXXS;E0K^995W2?*3)F]WFF9J"5IBL;,(6542](E3)V]R^[C)=4CT*3R<9Z.O\,0AFMQX0$Q1E:$J1U6!JA)5 M%:IJ5#6H:H5*-'JSD#YM>.J<<@GO4'@X[U#8PAGYA5+*R-=NQLBK53#R MJI*15U6,O*IFY%4-(Z]J&74J66\G;T/-._5JZ^/0.X?S;/1%3AQ2H[.:#U(T M9E'C4,T'.1J+N%'-!R4:J[A1S0HOM:(\Y MNZ1S+Z@VB\SYFV^G<#COC**!.R-EUQOUFUPI&C-&TJB6;3FK?.X*1M*H5DHE MJ[RQ8B2-:J54L\H;&T:A<7"M%CPMJSJC3-3)N]T![G8=$@W[`;?%$`X?#>5;Y M.DH8AL\H;&T;2 MJ.:,EE6=42;JY,WN`#>[#E%WXO7U%%&"*$64(889^$0-6H3AWYI0`U,2R_@,"L11N;ZY`,`:H1ZU>U0^.2"5;X+)@X- M_8%PBBA#8XZJ`E&)Q@I5-:(&C2VJ9HCF:%R@:HEH)8PR+;1T$5-=\(M*AV>] MH7&J?F>1.,3%!R/.&&Z&//(S0A_6BJR2JRW5*C-6^8:0>W0@?,$J&5[UG9)5 M/GSET8'P-:MD>#5^-JSRX5N/#H2?L4J&5[N[.:M\^(5'!\(O616&[^L18<6J M+KQL9R>?55#WA7:V/ZOP1<;'.FST]YIXY(V1=N8..<3#GY':[V8^%H]^N4<' MPA=.)0\A1VIC5/I8'+[RZ$#X.AY>;9\:'XO#MQX="#^+AU2RJ,#X6M6R?!JN&Q8Y<.W'AT(/V.5 M#*^&RSFK?/B%1P?"+UD5AA]J\$BP_"Y1P?&HL*I5'BUWBA]+.[K ME4<'PM?Q\&J]T?A8'+[UZ$#X63R\6F_,?2P.O_#H0/AE+/P0%Y[[/%)XV<[T M6=[Q&QP\UAM:],[C3*<2(X(U$CIPKRD;PTEIC.UL'XNK,F?CP?`%JV1XM70K M6>5[2>71@=+7K)+AH9U!Z5LV'BS]C%4BO/Y.ACFK?.D7'ATH_9)58?BA_C6R M%:NZ\+*='3B!?&.0XO"9U4.A2^I.21F?W%) M]Q;%*C%5Y51A+#1NU5W&L M!F.U7A7&4I/SS*LXUAQC+;S*QQI>JA7?TJLXUDK$DNW@Y./!$1X/.A0^"$>4 M($H198AR1`6B$E&%J$;4(&H1S1#-$2T0+1&M!))IT:=IAUK[BT0S4?TA=HF$9KW MZ9NV[79%7QE<3(6^4OQKC-]0!70S@KZ7/E5,),X-W7SLWK\. M)U]_<>N7=.O=M["HCZ`5'=UZ[`JMS^C68U=HM46W'KM":R>Z]=B59-2C$L1N MDA8<5(+8%5I14`EB5VC)0"6(7:$U`94@=B49CB"497E,)NN^?T%F@*V83A![:]%`)8E=H5T,E MB%VA;0N5(':%'DI3"6*U0T^=J02Q*_18F4H0NT+/C:D$L2OT8)A*$+M"A\94 M@M@P0*?"5(+8%3KVI1+$KM"Y+I4@=H4.;JD$L2OT'@_UGGCM4"^A=P@P"_26 M!94M=H7>FZ"RQ:[0FQ!4MM@5>K>!RA:[0F-A1/QY-IC"?C"7U!)WY"35TJQMOQ MI(WQFWY_UM]HTKOLOJOOS?[)!OL_N\TK;0?HKQ]L=O0G%[I_ M/M"?UEC3=WM>FJ]=^;;9[/A_S`?L_UC'E_\3````__\#`%!+`P04``8`"``` M`"$`'1`@FY8"``#A!@``&0```'AL+W=OO3S=+C(RE34YKU?`, MOW*#[]=OWZP.2K^8BG.+@*$Q&:ZL;5-"#*NXI&:B6M[`ET)I22V\ZI*85G.: M>R=9DW@Z71!)18,#0ZK'<*BB$(P_*K:3O+&!1/.:6HC?5*(U)S;)QM!)JE]V M[0U3L@6*K:B%??6D&$F6/I>-TG1;0][':$[9B=N_#.BE8%H95=@)T)$0Z##G M.W)'@&F]R@5DX,J.-"\RO(G2AR4FZY6OSW?!#^;L&9E*'=YKD7\4#8=B0YM< M`[9*O3CH<^Y,X$P&WD^^`9\URGE!=[7]H@X?N"@K"]U.("&75YJ_/G+#H*!` M,XD3Q\14#0'`%4GA)@,*0H_^?A"YK3(<1Y/D=CJ+`(ZVW-@GX2@Q8CMCE?P1 M0%%'%4CBC@3N'0@8N/:8J$<0$.V506V\L@,[95=:%\I#,)S+ MQ-=E9O\CX\`9AFL?_##!@)G[>3G/9WXI%$9D\K@UB:N?610R' MJ+?VFVSC_7^WS].-GW_2?X`-T]*2?Z*Z%(U!-2^`"Y6*B29%H1\@CS:9R%E3INC[MX>;%?*4)DU.:M'0%+U1 MA6ZW[]]MCD(^JXI2[0%"HU)4:=TF&*NLHIPH7[2T@3>%D)QH.,H2JU92DML@ M7N,H"):8$]8@AY#(:S!$4;",WHOLP&FC'8BD-=&0OZI8JTYH/+L&CA/Y?&AO M,L%;@-BSFNDW"XH\GB6/92,DV=>@^S6,XR*90HM`]PV"4ZU;S& M:PQ(VTW.0($INR=ID:)=F-R%`<+;C2W0#T:/:O#LJ4HCRS758JBN1_.@R5X>WNJ]`,SB,C+#DH+_M/Y MA!V2PX@Z#+AW&+.EOXB#67@9!+M\K+Q[HLEV(\71@YD!2M42,X%A`L#G]8`0 MX[LSSBF"F89<%33A9;N(XPU^@<)EG<^=\X%K[Q/V'AA(>V9@NY[9.!MF4UF3 MRITS#&FB\S2S_Z$QSBF":Y_\5*#SF=MQ&>J9CXG,A,Q"_Z\S?`VF=O'J"@H3-Z;H+"-AJ^"\L/64]2IA M)F[,VEFFPF`WCI1=^,Z-]QC9`H`I^CWW;EFZ;<*I+.D'6M?*R\3!+,((]D-O M[9?TSL;_:9\G.[>\L.6K20%>Q0H6%O MVL<*?I,4=H0=R$((?3J8!=__>+>_````__\#`%!+`P04``8`"````"$`W>\5 M`IX"``#C!@``&0```'AL+W=OU,5T6AIK63!`=R(ZU\*642A`#KZH*=:<8*5R0:,(D MBA:A(+S%'B%34S!D67+*[B0]"-8:#Z)80PSDKVO>Z1.:H%/@!%'[0W=%I>@` M8L<;;IX=*$:"9@]5*Q79-5#W4SPG](3M7D;P@E,EM2Q-`'"A3W1<\W5X'0+2 M9EUPJ,#*CA0K<[R-L]L5#C=KI\]/SH[Z[!GI6AX_*EY\YBT#L:%-M@$[*??6 M]:&P)@@.1]'WK@%?%2I820Z-^2:/GQBO:@/=3J$@6U=6/-\Q34%0@`F2U")1 MV4`"<$6"V\D`0H<)U$P3]+E*@9_M&/:W'.+B1$]:"/%+^\5]U@> M)>E1X-ZCS!9!NHQF$T!"GY$K\(X8LEDK>40P-$"I.V)',,X`^/6*H!3KN[7. M.8:AAEPU=.%QDZ[B=?@(TM'>Y];[P'7P>?$(@71@!K;IS-;9,EMM;2JWWG!. MDPR)7-#,_H?&.N<8KD/RXP*]S]P-S'D]\TLB/R/!\LTQ.8EJXT#]OY/V3C"Y M9YF]43$PG@L[.1$;YQ(91.XM;@PO1%V,*6:+Q`[_/R;(!EYR]);S3J:KV>N] M7(YIXW2"Q#;NDK6WC"NS&WOR>;#.E[B])7F9#K]4_)D33%7L`VL:C:@\V(61 MP"D:K,,NV[KX/^WS;.L.0#A\@!W3D8I](:KBK48-*P$R&PO8V%L8T-H86EN+GAM;#R.00H",1`$[X)_ M&.;N9O4@*DD6%'R!/B!D1Q-()DLFB/[>>/'24#14MY[>.<&+JL3"!K?#B$#L MRQSY:?!^NVX."-(J6]2_X27&3H!A:#H;7EI)3X0-G)4!;B MWCQ*S:YUK$\E2R4W2R!J.:G=..Y5[@*TVD,U>#XBQ/X!(?U26:W^(_8+``#_ M_P,`4$L#!!0`!@`(````(0""MWB7"@0``$L/```0``@!9&]C4')O<',O87!P M+GAM;""B!`$HH``!```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````````)Q7 MT7+:.A!][TS_@?%[8Y*FZ9V,<<147^"TP)FY5#DU^*L6 MOIS/608]F94Y".-?M=LW/KP8$#.8?2KV#KW&X^W:G.MT)K.*GWY*-P42#H.H M*#C+J,$HPP>6*:GEW+3BEPQXX!].!L@N@:Q4S&S"=N`?_@9)1CETT7$XIUQ# MX+\.!'V@5=(FE"D=!FMSNX;,2-72[!>F[8@^_V75X\[5&X-#ZA MRE@HWWP]Y%RS:!@WA':[2+`V2"P,YHL,1+/;3!XRW\?0'8^2\7#0B]*X1^ZB M833JQB3IQW&:O!=/)O3O)DF**SW$HS0AXWLRGL3O-4GZT7M-NI$]EK%:4,%^ MU158I^RNU$R`/MKC?::2,L^IVA`Y)PE;"(:RP8(A49;)4A@KIZT>-\U^_"Q9 M46G,"AT(%/2"/7,@D=9_U-F>PR.L)5]C29.1-(`)W]#*XHZ*E=7K4(I%"BHG M/7@VIV&/P*F!&?I36#&IHD+3K-*E/1,#;$8YD)2^@!W0I04SE/_=4TR5P&@T MF8`BR9(JU.\^V$J)35TG1F8K,BYJ2G4R?U"%+(_5N(?'><'EIDHUZ4IA%,:B M:RO\TZ5UA2UC[`LS,@3L"F3\S-FB+HT3,(#>,*3N1@H.2>V1ZU2PZ1;@RE%D=1AE6G,9%3^WC/?9%\D1Y">0!8RX5 MU.%8G6&;XF:)W61+DDPX%59DDWW`J@0!^3Z.A MW<2I],LS;*ZL-O;V@+I"3=M+Z$V7<('?BM^%/A2U"_=6LB[T:>565M:LN-5K MS[Y3OL2Z3->E7[N)N_KLS$Z>,=B2#;4RO1ZTSLZ^GFS*?S*+83L!Z?3B[68]1IX6Y/ M]@UPGXY'L1R]6OYXIPR96.EIDWB-W#['CP:"^WLWPB;*;?QT(^O@&4[QR MTEWB-1AF.\S;B>K9^-2\C&>TM9L[F0EB5J=G*)B3,NWA"^=<1"":#=_KVLZ^J,7CR2]^7A^3[* MQ5XWR2O@ MT;467%#@DT@RG@I;H5T(EF+LQ0XT]UELF!AN6Z=YB$=78\O%.Z\!3_)\AC4$ M+GG@^`A,[4A$`U**$6D_7-,#I,#0@`83/"89P=_=`$[[/R_TR453JW"P<:9! M]Y(MQ2D027R/GNS.R4MQ=[]>(C;)R33-24J*-9G18DKS MF]<2GUO#?38"]2#P+^+\@G@&L-[[YY^S+P```/__`P!02P$"+0`4``8`"``` M`"$`V+Q0,E0"``!:*```$P``````````````````````6T-O;G1E;G1?5'EP M97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+```````````` M`````(T$``!?&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`))KK6C*`P``,@T``!D`````````````````DA<``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`&W&=C$G!```ZPX``!D`````````````````SR8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``K6CT!%`P``20H` M`!D`````````````````B#4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/92HU5`!```OPX``!@````````````` M````<$0``'AL+W=O```9`````````````````.9(``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`#$S15!3$@``D&,``!D````` M````````````+U```'AL+W=OLL"``#+!P``&0````````````````"Y8@``>&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`%&9\&'H`@``#P@``!D`````````````````V6D` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)O[2]Y3!@``=1T``!D`````````````````X'L``'AL+W=O&UL4$L!`BT`%``&``@````A`!CU/+/&#```PWH```T` M````````````````'HX``'AL+W-T>6QE&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`%<83^&,!@``31P``!@`````````````````!@4!`'AL+W=O&UL4$L!`BT`%``& M``@````A`+YQG)7G`@``^P<``!D`````````````````UQ(!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&4_O<.(`@````<``!D````` M````````````?BT!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A``@\^(^A!P``5B$``!D`````````````````O3@! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`+41IY`2`P``@0D``!D`````````````````'%0!`'AL+W=O&PO=V]R:W-H965T2A4``,US```9`````````````````(->`0!X;"]W M;W)K&UL4$L!`BT`%``&``@````A`'*17BIB!@`` MHQD``!D`````````````````!'0!`'AL+W=O@$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.D4\NIZ!0``^10``!D````````` M````````&PO=V]R:W-H M965T.&X'```7(```&`````````````````#IH0$`>&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A``FSS^BS`@`` M50<``!@`````````````````C:D!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-O"&NX8#@``I$8``!D````````````` M````#,,!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`)[4Y9N3`@``X08``!D`````````````````WN$!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``W\ M*-G3!0``R18``!D`````````````````:_(!`'AL+W=O&PO=V]R:W-H965T^;Y\@0``)41```9`````````````````-(&`@!X;"]W;W)K&UL4$L!`BT`%``&``@````A`*BIYM"C"P``ECH``!D` M````````````````^PL"`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%ES)ARC`@``X08``!D````````````````` MZ3$"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`#F8PBMJ$@``\6,``!D`````````````````N3H"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-WO%0*> M`@``XP8``!D`````````````````(5,"`'AL+W=O&PO8V%L8T-H86EN+GAM;%!+`0(M`!0`!@`(````(0""MWB7"@0` M`$L/```0`````````````````+E6`@!D;V-0&UL4$L!`BT` M%``&``@````A`!U<":LU`0``0`(``!$`````````````````^5L"`&1O8U!R B;W!S+V-O&UL4$L%!@````!-`$T`!!4``&5>`@`````` ` end ZIP 21 0001104659-15-002031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-15-002031-xbrl.zip M4$L#!!0````(`")<+48P$;'R"!L!`#QN%@`1`!P`8G)L:2TR,#$T,3`S,2YX M;6Q55`D``[](M52_2+54=7@+``$$)0X```0Y`0``[%UY<^,VLO][MVJ_`]>9 M2;U79=DBJ7N.+5^S\3[/V&5[\O;5JY0+(B$)&8I@0-*V\NFW&SQ$68__?7CWRL5[410$E!;ZXZTKU0(YCC:"1<>%R2`"K1*)2YX3'PH!7?^?7Q] MH1D'>OHDJ8&['4T_U,U#HZK7M5JGVNA4J]K5UZC@8U#O#V`1=]>*EJ'C+7#XAKT;VH9,=A[H\%Q?%Q%^A*BC].E7\P96F]W6X? MRJ=I4:C(9FG9;+V-P^AA4A0NV$2E7<8%[5$!8J4'%A\BPS6]:NK)&\SG-4-O M+F(T*I&\`&KI$^*E+_2(WY6%XP?8@EFIZI5Q&X]39"T6I4V?<.M3ZZ#/[P_A MP:SJ?39+D%"U?OCOKQ]IA5!&BBKL!?0RT&VHA$"6(X(D5WV;VI[W3 M,`+IG:[?Z7?(P]TMO].K=Z:\JMW%TKO[E3BA+'GD./P!"?:/7/N:^E3<4_\6 M"#QZ9'Y:/"WUA8M3'G:#7N@<618/W<#_2H==*B)^@1SJ!BP8Q5=PS6R\TV-4 M:%(.=$*(B30M2UTZ*U2IZ%2"*5=N90A\/,Y5_/(P1LGJX('PGL(*0 M%<0*0N*`3;19@*^=,G\7D8/,=Y9E?A=!9$R`R%0V9TMLCI$/+F:YX*)L3JEL MSH9`I$^`R%`V9TMLCIX/+D:YX*)L3JELSGI`=.3?7?;46&HK;$PT"@\FHMOD MWGJUKDS%IDW%RK"@1C;;80',S6I=68`268!BL:#&&=MA`8S-:EU9@!)9@&*Q MH"L+L!460-^LUI4%*)$%*`8+QIW>EO'@RM6T7'@#]JW]:M8:TL^5B3,#.:LV M7LF9CO\A!,K$FIR^TE^,Q]R+N#J5Z^N5JUJ'5;UR4[UR M5:NIJE>NKU>N:FU4]F0C)^Z>'S*X>X_O'H M[)$*B_GT2C"+7A.WG]D2-OWL]H%O"12*ETF\56R!4'9Q::X,H!L(2A7L%HA% M`6\EP+MT%>SF"T6!;B6@^\)#H5`W7RH[`+OY,Q@JDMO-2&X=*_(J(-LT>E87 MD.T6?E1PH\*C]89'Q:$G=["-(OA&AED8##V'CR@]=RVD]IX^$9@! M:HSX3"NY98%#+WOGKLWNF1T29UR;5,&`.R#X_V7!X"MSV3`1G5FH)3G*+[3G4+$/(3,G'%+U,]+L7\IN%@/U-0[*$BV%*E^O7 MY:J6QY0NUZ_+HA?,YATK>I%NS5W6K;F[!XT*!8'JX-L)@GFGS90EV(0E*%E: M764)-F$)-G((4<4`:^_Y91UW*5WNSKA+Z7*3XZZYRP)*E^O7Y:J6>%20M/[Y MD+4MN`@.-08C9"PX4^'(&_WSH"7XOMUMOR>FV'&R. M-XHOX'/WEB->!H5;05S?XR*0*$M+[B`8%G):7@-0B)95A]]5#4LO_B44+@M" M0;^P1_R#R6XO>SUF4?B!&Q?"@(I=[-O2S;^$^ZU!@ZFL>BFM^JJRORBK7A:K MODD-*ZM>-JM>+!I>X..3@KNFYTF^RNN7ET]Q>QSZS*6^?Q-1[(]U>4&Z'&KC M8G1+_8"Y_:3H=BAW(8>Q6I]A<0>&WP7F/%:)AK9>^2_/?JR4O[,[4Y3RUZG\ MLJ6Z!P79(>ZBQ^`'`YQ@P.US]Q[\(;(X?9?2R<497+=PG--'^+LEN'@%RW'< M,,7S+CJ+>9#YPF#(0R_8/07Q0(S:9UV''OD^#?SCT5?R.Q>RPTU8D&_6+";^4J6FH(4JM46VN&J7@1(6K.6#LRRB227)2EJKJN>$4FSM!+)8TG, M8BV)F;4DY9-('DMB%FQ)C*PE*9E((C;*)))T& M4R>>OE*;A<-;>/R-!]LR6)W%T7CF829+Y9U-S+T/Y40`8\$78C$'"'NRZ?6> M._?,[4^6B7A,2_U*!",PK+\&<(UG+%"(YT"Y")'];)FS4'";.P[9DM3BTP+* M[IY=(*$B\SP_%7(\6Y)?RKNX=Z8TD,;$\_A7`7IU@)Z4L8+S$G`>?^99<[F?)D178Q\J@\67DZ658;RI.I;J8\ MV2YWLIWS9$^S7F]\QG=U2:#+Q-K*RS1Y%`9\R+O, MV9:%AZ5T.<7=UFCS9W8<3%B=>P'\53N_:R%B] M3(SA?HY*M5W.[_F:3\9UM^I[O@5^8&(90F9*_JU_SW>]'[-^9O)C-Z&\@D]3 MOW;FXLT#\ZE5?I/`7(&-5O+^DZ(/_'A M!%#L%;`!L?LUO6?T83>@"]+I/)%.C-BL>(J$Y+2$T^\TS!;QSO0'F='H^?Z0 M%MNU_K`-2P"J/ZQO@6'-_0%B;+V1G;M(KI;L$>"]3Z!^B/NH:X%NCL'7X^-4'WB:SR"O3-.^,4^HJXYHJA6]D6N(B,6VT8(K M5*[,,F^!M9R["//2DSIEA=/*C\Z49NE%99O8-!26(:)D)YM6D>8G3N)5C:>4 MS/AJ'&"I=$VK=275BIXG19DLMHY#H&H.4AU$FUDJR M*:'L)N$-=,#7J'(;IA5+,=]6#E5NW`"5029&F?.EEV,C1+EDLKIU][]7*M]= M%F@WU$)Q5"K1[1#OH9SPH=Y*I2%/6V4:QW+?8%`H-R1D;=*0$C\4]#/S>]_'DU3U?Q\3##051H%L/- ME.'GFYM?2V.J%ED)"^@P;Q7UV560Y.-->>NIS2$%(Q_'6:8FO`S;QU35#Y[]/!#.UK< M@:YI+X<=T;!U632B6[.IQ8;$\3_M54"6-;W=1COQ\7!&2R\DX:EY?X:$>JNM M-PLFX:G7?8:$)DA!ST'""?$8`/8"U$M].0]._0"GGY:B)G6(9X/AQR5^X6!WL-]5_VL,O[5U3(X[:O@H.9I>W\ MVY>]SWI"VC/-3E`HCZE$+5\S_T3RJ\805XPMK^/?2#:#LBQ!?,M["L7Z@Y-,QVM=F< ME.\S[1=([)*&TVC66G5]4\0N:6)-`RRL::Z,V"/'N0P&5-P.F+!Q=7)T149< M%`R/*F"CN103\^A:`W/+PLELFRUI7+:!N27A9[3:;;-96SMSN+QA@:.(_C+[ MB@MDHU!4FD:UT6XNP]H/^Y'WS0XM^:'XP<^FEO2$2?N16']H).U0L^ MQ->"]0?1C3U\ZV]__=0<1KJX18#)]S06X!_97D_PH8;INJ2X_0/9LMOUO0_:%RXT M,+A:#R!/'&U$"3@!-(=P5_"P/\"+VK[F#KT)+>'%6*`@@4][^EZJ_?3MB3?E118DR44"V\6( MS&!W"5G$)D%+EA:QDUQ79L:*K9J,UE>2/UC8H+9"9%$9\/3;A)/Q!Q3E_98<&19(J3V1<;$%.F9*XV&GL7QDK0L MP8?C\`<"[(/=.^5A-^B%#M17_-"K8C2R`Z]7D)6?N5/J@;5EDFZ(8F!<#]'* MGZ3P.*JBZ^U:;MX64+6(-14X8,E$+).10T5+[\<>'OT_D9^.EXXX&PI$$W5# M+PR@.'%=,(W.2/INF_5B8^"#KPX>T%U'L8`+6$1/[R=G4V6MV$@7YPLQXIC3 M6C`@@?;`'`<Z^E_7;&-]`*&$A MQ3*R(0]12Z!VY,C#E6I99<#ER]%:EZSK8<"L@;R990^%0`&6495<(_#("E+* M(BGF"E%FX`'551E0"2"7"^@H*T3$.'9[(;5K1&\VJ"4V]U#X_SPZNM+Z(;/1 MW`%2@@$BQ9/:X&!X+"H"$H%&\[C/9,0*6J48T0),+1@4:52JC]W33"@[_O4= MF)-1K4\U$3K4'S\*,A0-22;4EHB1`(^L5A0S$W<.18!0Z$2LAS0-*78$?!], M&ZTX[`=U1A7H"&[%Y8%F"2;C9NV_^#V05:^^UV01-N#<_F_L2ET*X0*00AP@ M1((?VJ6/1"YC8F/=$3:.A4@8#&`4U(/;$,&">KD"-@GI@Y3<6\C_G3";]#L#5EE,!K!LF::Z. M,%%HD@O+/T'-@227\T%7>NO_Q@3E;N5YXJ[I'R$#:=-X_!U%NDM3]PQQLUN9 MH&[LV*^I`["P;_F1=`NR!V:7F(J=>VNVC6SXD9^,E5"_Y/Q:HS89/&V8^B5C MOT:KU7XU]6>)^4X[*(Y&KL$6NSA:DM4!W,`!@9,Z';MQ"!_E[/"KT/1TL%2! MT5*UE@PH7TO:VKA\!G6SN#2:K6WC\AETSACX5MNK4*6TT3++6CQGC*7@-X:X MX)>/DKTY_I%M2S=(G&0R8OSL5:S6IR9!FDDO+(:ZE[$KQQ/QI#(NW+-H$AU$ M[H0V%)5F8-SL^,UO/+@)N[^#AFXYSO\DLV#TY47\`N:V3HA+[L712RM$7`!S M..X.*>4$S$I&K/+%AV@4W^6.'=>$A3L8Q#`K(NS_=>,W;2Q*+96EG*$82U,; MB_--S"NL9QIA0'QMB`+&'9UTK`4KU8*<4L#%KQ]T!*-H:H48`\3WZ:/'(NAJ MMIQ+$M"+45ERN/\O`FY`C*;&P?5G1\JMF:/QHV#^T'I?CJV)YPD.IA=7'D@? M`-/'7\/(D."T7>R)P)B,YS1FLHW@2[<(^_O`:>RZHEHB4X%30)& M=1K.!#WB!)A<+((7&=2%:WLX)>UW=@ZZ&4/TP.Q@T-&KU?=[R11#(*<#+>HX M'K%1>K@0+J]]CUC)=?Q^%Q'H^P]9>Z>W)@R< MI"@0Z65T;6OW8&[Z+K80!'RX-TEPW3QHU-Y_B%L/N-?1O4!SN4NUGT[;^*^6 M/(S:G/WM9=&UR.L.H%?-\07$^M&'",6UT1MQT=%^.CDY._OR99VF M>EH.>9PWAE^!Z'@3Q/NU%?]/X,1-=]AQ.@@[ZNO1ILDQ5VZ^WC#$*7F__2JK[M=O! MTB,=K%VCU+%F>2/+3798<[]9;1398;=#52H\P0[;5.%)T8/$4GKEPCOYMJOW M+7GEEO+*6^>5=>BPNO+*;],KMY577IM7+GAZ+>K\*P5(]FS=RF8=MQTH;\:_ MWPZHH*074*&\_!M?U=D5V[,=>%.ARKS-"2I@>3L!2\'+/2KXV*[@@P?$47%' M_G7,HF(-(%>S>8@;NDJXL:ET*Z4;%/M&)Y',_4:[_N9GD:)+W/WX5$#)T^W: MYKGAD\\W>"@?\_+(#;OC?;F:)SCF(M:ZT4Y^N6TWNT$W/?].\%![O*L?:[*2 M??V:B#;V/]F[K+_'@[=Z];U\.4EI(9(\`=T1[OWUHZ.<\A*W']-XAUFZ+UCN MTU+GX`NF]1PT$I\=2C(6D"Z_I_N8L"#.O#3CN#4>X`YHE.5!OL9$`'I[X!H) M)K-'R80+F6WA$:K2DP@9_,7I$7B?RL-W,..>8%1:3,XR/N\F3Z7BZ"/Y<"5"G&%VP(2LX94Y](MO<:\C* MPUWR\A45YZXE4_5O@IL99$Q1_WW8%=1QR%@$LOLEKTJ>"Z5=GT5\'BHRI/]" MB1,,TL*844"=*EMPJLRH_J9%,M-2H6DHM=VSAN5)2H,^EF@.0A>\K$^=7J47 MRJ0I@T@5+%4%5.1&&0_!["5QDQ^?RQHG'4IJ]L@HR@D#CC'`;"GOH%-%<5R4 M2V0H4XHZ,BN1BY&@AT>RJ/`Q]Q&!VC"%2S93XS3=R>&OR(L#>6-J+2($?JXD M MM#,U^7]3QB@R"TV4""K.RS09,#3WS5IC7WO7V&^VF_*-=W7X:>PG.8/8/93+ MDIIF-1_'ME.29JX5)D%Q5F<+"*F9^[5Z&R@QC?VJWHA(,>K[[7;M5-CS:3".49.>(/%O M<3]0\5F^^"R?`\QXS'-`(1/1]\7/8=P'@SL8CD?95)*<%)A,\P*P8D>W"TVK MD[C[%]"Q2BZ63*]34BZ6C,"*X>("NL-E+TI$JH*O!<%7_3U$*F]?^W9P]#222B*@R.?_A[UG46X;1_)76+F9JIDI MQLOW(WN;*MFQ9WV;V#[;NW.IK:T4+4(69BE1PX=C[=( M`T8&_@G_7`#_P3!E2(D3G^$G7/X`Z@)F6&2`BFR,^^=8@I+&T$O.+R?W^@B_ M4!3_21Q"G]5Q*SRY#*-_56FGO*2X9A1\IA00'^`!$<\()].B=D6>]HDS5[(H M^`VU.&FNT7_Q:(U-,M@3DF)6#4>&?!)-,0:LN5:%.!D>1Y@FH>#M)YAE@,I;L'$$W\D>(H MR]@"%B/R.'P%9)(;B(#H1T"'[[/Z?"PT(G03[X`,,L"O4.R2J7D_R^_(K`0P M%-N-PB%^PN5)/6$UUJL!%840#R76?W'L$U[W*-S5!4C[?9&MHY,NPH M>K1M;3_!O!WZ)2UAGL&1>9TW7:JZG!L;+%;.K(O`PZ/XQH-5857U[=;I2[/) M9N7-9)?3?"I,:3:)#*4I4S[1!D?]A#4+9%5;H?S[8CM!VMV-!,X)ATZ55J5? MFJ-4$=\:K\/1N"&]>A(T;DB^'I;&K["5XLGJMEI.@7SQZCB=`C_> M:WTY5N(FW?YRD%PWEX/MK&) MJ.G>GJ-#NHGU_WM!K*TEY,8(! ME0WY?[`/3N8(W6,DR(Q1P@:;E2V5(#&13*412H:A3\^&L7".D'ZT6'RUDI8T MN1R"WM.^)A!Z/J!G8"O;4>F\S0FNA7'&2)Q,?T_ M>T\A@1I&A!S6]R][M&YA:C=O$]"4]+UQK;)(":[5XMJ6E#SJ.P7'B+7"@U.&P9"Q9\O(Z)T.BB"+-MB*LP.O=\:#L* MZ'H!#1/AQD*]SM@-3ZT8MJ%892+J8K$'U)MV@E(TPV@)ZDW;0*FV;N^*>AKU MAUZ,;I^"+-&0O\-70U1=+_>S7P.6!W(-=^<:PSJS#ENS8A]M.?9:T8>QO:O]+!8J M^9@;*OD8[IEV;'KWH2,__?#S'I1#/3ZS#E?QAZ,%D?)_ZEI^9!M!TGNUP7(E M+$PG+,SI5#`\OG&#?=]"8I>P75F\7+9O*4RA,(7"%!ZEJ)IJG!G"_'%520B5 MA3(*96R+,NI"&84RMD49->'K[>;K+1:ZS1P];@5_]^D";E?5E.ZB2%DB6\HS MV7LS:UTOG=S(O+6RU98AJXXI*R:G)IA"K.T0JRZ;&A&MX@BQGI98R4R5#9U3 MKRVVG'==K+R6]:H18"XBH@39$MU^:9:^Z& M@$2`O'%U[`6!Q`KIT(I+$BVY)+%22[^(N)B'%WV\XS#MW/S29,=U9=TVQ)ZF MT"A.&J6[NNS8XO"#T"A>&J78"OFGBPUZD5)8WH!>JK6W()(,73!"QST+I+FJ MK.B<3(W0CI/2#DVV#4E&HJL&5RW2(5JG(AJ&+9L*)9(^8B4SX*/`AD>4>VAC2:&H"OY80H%A;L= M(CFZ)FN..&HA%(I7#D).>GK?D)H M0FC'I^@M"$WD&DXJUY!U]EHX41($X7=OW$>Q7)PFH6=+*ALH(C_!P_M_FW?T MA:"%H(6@3TG0(LX^J3A[Q:$(*0DE5ILZVZ4X$V%X)VH(.,H9IU-1+9!.'07^ MD;]BMD",MGMV.L=-WK08.9VA;D%,SE^,E568O81>KE4^YI_R[6![C'Z[^T/M M%VEYC1!V6R1"_20K%P*=D6,,`KC1*+LDX;$GXN0+Y'Q$SPF7YC0 M+\@$3C](0?/(=T0E`\F+I.R)8 MD?\G43A`,7@:7A!,I2<67X@+-8E03*_N$-0E;P2H`O-S=TNZ?)V@<8S(QUXB MX5B*T!\I!DD0-^P)2=G7@4["`LE'?MI/J,\6A2,B)):NB;/SKE%VWO6G,;M& MU"\E?;Q9TH>RTL_S/C]+DS2*4X\,0T#V'OXNW81GA;)#(_;W]K;,[4B/Z4EN M=1@0,M!?WJET&&FU52M;*:G\(F]V7KMA^=(NY__P@I1V+N^-_?\E`L2#*9F% MO4S;1B'[&^H1^QKI[9FF@[QU,]]]5L7;6Z MJY<-4WLK#)5 M738L3C?/A5#;(53=T&2-7W<0=2VAW1`JKR6@\X;^4Y@^)8,TD/*=P5:[KBV; M[6^S.(FCRYK-=8D0JG$JJN'*&K_:>KQBC.XL)R<<4;"."K.K8R*&:).5.9G" M$*9KR;8A2M<(A>)5B4U79=/D5'[X)&,G]O*$SE[G9.SG,&>3L=U` MAZ58AZ"C^E:$1C@=94?.8ZX:9MJN5I.B]5@=@K:&6F?9KMT9VAIJHJT;UD%I MNR988"^X\Z;0TN0JC"["%Q0AG_5^#_+A[E!$_L:T;[(=E45-NI270=Y,J$#KT(/7DQ\B_"$?"#K8L1^>(S`K:=3XM' M,D[VOGN1_P6/\2@=/4P(I@-,OSX*QP\)63*SDB4$8B,N?$OC]\^>-_D&9-QX M(]1[Q?$WP/);;D"OQS`P?D$4SNT$AH.GP6Q]0:,G%%59J95Y>7US]>ZC($'1(XI&>$S' M^92BQ_`3CKTG'.!D>AM]0EXR/`+G/]ZI7\NL/3#%AV7X/4IP1,X3YYR5`BB^%O0]P??@Z]\6WT:^J1(9/I%V]ZCFA-";*V M')[ELT'N@3XZ0O[.%^\5K$%]&V_N*CH>+&PBRG@5(KWGYP@]>PFZ\G#TQ8O^ MC1*(7PD>)9/X&TZ&]R@FQC)Y#"E:F>KU(I1A#U$MP?EQB*YP%"<0W7='Q`M. MH%)V`MO(6RZRG]F/"6;"`;-Q>*>JMM3(ZJ347IZ:47T2_*S.@D><0#[J>NQC M8C!2+RA&HP0,P\!'$2A@U1TJFR<*9R8!4PB`GQDZC$+3?;E?T9A$:4%O[/>* M,@R$B+RZ`,],#^&$X90L:!T$N.+;,'NC&8II64?$MV'`KCF6:1M;XTO&I&4Y M_%RC*QD+OKI@NFX)U4VPN:'94`5T\I!U!#0;2M[0#=/="LW?(IP08SZX'1#W M<8*@^`M?,2NE%-(BL!TP:;H!8%C&GC!IFDHTRBG\59CX"'_H$5ONTRQBX#TW M+-4Q(/#0?_]I89AB](LTBN!-'!/5^(J\Z'+L?R)>:4-`[]^KRGM=9:!6C5E` M_13VT]'L$1:;7I'W&DZ(CU=?&<25XZT""5AM`Q!^+@,Y&V\1(,-F.[;"SS)G MEXZY"/)Q.FD*B0#YVSP,&*08^I)X-CU;ZCAC/@(J[[M:I:1 M4;-TS`60131$/9SX-DWBQ!MG1:4*^+WXV^V`0'8!FEF=?_9"H*[9MN%:AC&' MRQI@"X@Q+;]'DS!*R.O*)Z#OW3,*N0K'*#H@DC^.8R:RJ#7[R/R M;0]J0M%QRN#G!JY"O4N?`MR_@K,22_AN?-.5C89/>??1TG2+.%2&7H9;&KH* M]1X]4V]EG(##W9#8\^M;Z?[RZO+^\N;B4OK<.[^][SW>WE]?/DC7-Q=E#.;! M5)'X1QBD).")&(.:RO@F+$.JC%4%]1L*@K^-P^_C!^3%X1CYUW&G=J.LWCNN:RX8GWU0Z_LXH<4I[SQ, M-.'"HZ4G=Q*5[AIZ15++H>R,RD8^ZJYKN]N@\D)XAV/BPUR$,;&S(5G@IZVL M.%@^":];>RU!2.PH/0_!]C5I(Z"E#Q,J&3L(XID/B M.5B8C!#`F`$=TV-CPMF.B'TM+_!.R[U>]1[.B=1\/,!]*BU)-TE<0OZ:%$?B MU=%`Q2P5_RQ^*R,7H1>,OC/4HGF&K,2*@//@[Q@N)#]Y,8Z7@KE\R4]7PE#+ MZ,:Q1+?[8<2D0*K@I/MGPO,,G23,$63E5P$75CD57J)7V)8A0PW2)(UHK=7$ M>Y7Z7CR4!D%(*/R),#.[-`VD$"Y]Q\DP3`D:<-4=Q<3$D2CC&<4_`[Z,(=0^ M26!Z*"'QF70]F(([+O11&<,BT5D,VJYA*"9.!LB4,! MU.ZGE63[X?.8:+I/"_S#.$3X`X+VN(^D)Y1\1X@-3^@@!H-R@@P"9Z!31*E= M`G?&QZ7RNPD7,/GNS:&"&<@!#;JE*8FZ8PG!<21I664A":8&_:E3A"!A5*L6 M+>;=5!W#;0;W)ASWN:3%%$5=`KD8?GO@=:Z.:%8#X.&_8]:I@X5Y$&!.(DRB MJPG=SYO#__`],[IVL[*9B9HW:UG2ZC,"QXU90-:U;J>US#0K_LPJ,!R0*0ZC MK2&7GS.W,Z'(4()LT[GTR_>[V%T$7AQ?(-V9*5F M6.Y*7#<#WQ?B-3;O;7>U)[,3XE=T`RB[)I$=OH\_I6@W?%UCCZ/ MPPCQX+OJ6-L@7X#?#OOOX>ZXF[:QQ@)N!KX%YH]#%"$/+N_N9E.:HUU`;HKV M=;;'?4U;P,(AJ?R3'6G0FYK%U9@TI>F.]5/-+FJ25:'R^6Z4.;JC-"1M$T)K M"`0K-B9K'O8".&;,KI'=#CXCLOHAD>-=E^/5_R5EK*2'$B@_I9*?=GJIN_8D M?0.JO-*+%^$PC>>/+?6S`V_9,P@N/4(.&(_S%+"F:`H]A5,G.M;$R MN'&H$\UB#8,VBSVY5C[[ZMCJO)U./L*""`M2WX*(/F3\U'/)=KLP9KL9L\4F M`MM9LE*K@#.U9K,`^F"K%$S8O]UHU!16[%[8/&XJJ>VG$>@;44:Q`/-6QOTT M`A4K;FL[.M1)%V4U@:39H9B]6:R6,FD_RV@K>YEHBFS;!I]6)F],IFM[6C MR*;#K7TE+\^X.R:SI4M''6-Z@/Q12[ES8`>8JX*V?*MLMIN^Z- MZ1//R.!T]$F3#TNC^4K(9.!VNN M-$,Y?&\RB<)76G(_F$H_6++CN#+\;[B&3.O<_Z`3RZC-ZO9O4R9?EB+6=QJ_ M$"@G6(SRN+*?=?_.NT>,6-T&">KA>,$*Z7L1$I?0=[B$;BB+E]`M;>=+Z)9Z MIEF=OZ]PQ-L)RXS2'H(&ZTPSNGM;H1:-^M%W$4[NZLQ^+MYK9V:'KW'MG-?( M368['>0Z:QPTF=V;C6HI7_9CJUH9#%JRI7&Z5\&F>M=%RFO*=V%B6ZUV/MHU M?8\Y24W9-C@E;/BMQ]V9BBTU234GJ2U6WY-=?0U9=3B=^1&K;]=67T>LOIU8 M?359MQRQ^K[-U=<5J^_IKKX.IP.28NWMU-I;U'H7*W`G5F!.AU_$ZML:HU1G MFN[U'+-8@]_(%6:Q-G=K;88KS&)9[L(.^%$]`E]DKX8AZ^,I MT4:>4CB0LCZ>66_)O)VG6.`/GP#8XG[C49T+1]8=YQA= M!%XRKJJK>GHOCU6!R=U<[MHVS+7]%#G1VH\[(U] M^`^:A!"#`4K12RZ\*)H2L\!6K#6$J!L;V8-@*X34@,D936TCFJ9J'!_-S3/` M=LUJ@_3#HUE#>TW%W@^:=V&`^]-6]BT_X`UC8`J]S4U_*;%'>L_>0J6WO`BD M.9I$.$8^N)]]%"4>'DM#0ELPE0),'O;)^"\H3EBG>]I$VY-&7I)&.)G"EY)A MA)`T(I@-8RF,I`"24]^':"Q-TJ@_)%;)/RLM>K/?RNV]AYXO_:#^/WM?_N,V M_]!P',`;:+0\==A9`^,9.W'@8S[/[`N"Q<*@R-:(68I4>,Q8^>N_ MJFY2HFY*:DHDU0\O:VE$=E=75=?5U57=%G`'O\H.GX&AL86WG:W(7@$_WGRO M/;O1KA]PH[TTG5N`;9KBK+:VV]+)YG+Z[> MY,2'7Z-2=&T.ZF^J\3O)89-OD3P^BS!&O4S'\PJB_.Y.ZQ@\6:$;)"`CAD/7 MIHP$G@4^E14'X90,+=OUW-BEG#@T:TV6UD0()A09VG_,1J,_)FZ(WX=A,,:M M;I(X@'\U9:VTN:=/,(#'!19XW=DPN&=0Y(74I\_X^P1W3<2J:*!W!V,.072P M:AH$8'`#)[J,NA@E\@9F-]YA>F;Q[1NLTGFCB)7!_Y*RP)Z6#)+%![%9'5I95]NYSZX[T*7WWOMW[R*,+JITJ[^A+LZG(*.EZ.$59INUH75*OFD@A:9:NZ(U2XUYV>TJC>)=S+ M*>K9-*OM_$9UIR>HH';SB"-#V)4BFC2UJU:]]7(LLRJ;VAU-4.7T2R+H+E/[ M`J1^W0DM;?!=US#*+.[;-&/O_):X*BI^VCSB2$N\4D1KCB5>]S2_NNMP,=9W MHP7#)1%:6N6U)W3=K/)R;7"\[AJ54Z:S:3;>V2])G=7VUUI]75#:6O-8X^QW ME-Y7[B8';W/2OA0ZS'D/+* M<*P<0T@M5@(A2B83#VMV+!4^8,4.^FO+*60U+F=#V_FZ+%@>9%M9'WGI7MBE M>WWUTGUO42#L,-O62AA3;YN=VM\I+<@.)[IR7X+IV&T;@@K`5O9VL]XYM\70 MN-O-W[C8C^:4*N>:LUY&J+<^UYPS&7KVR&@SKMEQ65?WF,I>,J^2.0I=O=55 M!"6:Z2<($M9'4C17'I1Q+4N<[5.M77_>_*.6J0NZ0RM.^]=G!U^BKB_CZH_4 M]=70]7JGI?9Z4M=+75]<'I1Q6T3J^A+N^*HMS1!T'B%U_67H^C+N'DA=7PU= MWVMU1%T,E:K^`E1]J4GI357XU MO%7:BKH(ZX[YA`*XTL.U3`#9K]%U$H^"$*CK[(6Y[@I@NLE5U%K@EN<2`M0* MMLH%ZF,4)4=C2>MV>KJFZEL`XO,<#4P![&C=+L!C&,<"\S6)HQCD(G9S*QT] MN8^J=[:/WG=K':";O@_O-C?ZH>,_<4I3N MAJQ>?'BI0V[W=W(/QK`[=&T+QD.$\5:LO_II7^A8]LD]"VFNL7=QCI?9'9F; MD#HN)U/6V_MJQ2C:B2IR7:R)=KS4K-N:3,+@!VS-&`Q/L&7-EIX^_Q*LU*ZF M+)JFK<5.WL!.C,UBUF?3H9,@@J4,+`][<[+&WD/7A\^NY<&+4>S&"5_W\\BU M1[P5*PQ(?]C8:YRW]"5#ZN"5)0`'7DGP)I/G@I5W(=UZ%UBVUSX_T[Y;8MI5 MGKVV;=XX]QNUJ?O$[C8=PL+IJ"&.ROK3IYR'KI>5S1'.YW`C`L9^RBL@P6D8 M`3<"O[`&O@%C)@\P2XF?C`?8>WI()K`&YM79L`E@)M3G^)SMX9^!=2.ZL\F] M$P`)1M83!4]F+F=S@,TV`%O%8P"0^:P/\L2:!B$7QED3;<;C^#1LJS!T80UK MY_];MM#%+/_'?@V>\0K@X+>^=G##$@^)VXVQ5]`G4-\P/ZT(<@D9FMD M4@-`1'D"K`2RQZ8.[/&(M>7%"X7`RF02Q/`>"@U[SA)XIS`*0)2`4\(1BU.L MXPL&2(1!$S<:L3;DQ,)KA@P"=-,3/X.!/9X-@>]9\`\N+P)\@B-)6V1`815/ M[&8DR+--<^8`Q9@",T[@U6D`8T8)R+HY!"ZG&(K<$->8#&G]@)% M7LE-IO.B(`R`3F"3,I[PZ*,;>5S"I>S-A,B`IJ$A&`\V382_<^T%3.`A<0=H MJR.WPF8`+DB`Q)^!&6QVQ17(S[^X#GEU\_G^)WC$'0^2,$JC2S`%;!,?GO!` M6`T"$++@06[8C+=T0KD/DDP`#F0;WV+-LF$](7U,/'Q["AR*Z^#Q*2;=T#@& MU,!3N74N[VE<#L;#8'JV5Q?$&QCP(3;,1GT=PGX`]`#BPF"\;;&M!50QD6G- M&=]R4&130H=#E/+I@E)X=DIAV$:)S_8>H'""V\^.6V24%U?`5Y1'[C@8?"/: MJ0GB>AY2-[;^H'X#-UII(;?=SMB*^\;.'=@;=_#)GE;2;3NA&+H+71#U$]"Y MS)K*(PCLJ0>^8]._@;9;IQI@/-M+',H8?::14A,ZVR.X(U%C/8]`WTVO@F>? M_TS:40QYHY"H!QF]"/_H<@">/1OZ@5 M'@=55U%W`[4T8U$8OP!4#\_4>Z*?X9E1=!2DAMG3"D*Z/&]1>.\I`.@'H']X]$'5,N5E/%5 M4+I?XX)P2^FO!V7+=ZI[/:2(NU9:\2RS`;75AI,E*U97QDEI9^":O.WDO22N74\1+:N52 M&\_`AA767T1JY8J(IX(;MIS*7%(K5[_N1A$&8=@JKXB/U.^UTN\E5^YJOI9O MSJE.4V1//?A-FBIOEI`E#9;+,U@$'_=(XZ->Q@<6`9-V1_%S3%&V!H!+G"#! MA*X*)C95[J3TC&@_:Q!);W7Z@BJOU=@TXU\;5'DM6P8?5N0UJ\/OABQ?,XGB MK\-[&CZY>'M^Z[T1=>'>B+;S#HR.-7>6;L'D9SL<$FT!DIUE=_2^UE.7[X:) M@63Y+LVN2U8=3>OI!T)R2RFJIAK&\GVW+9,+@W-? MSM!-HW<../=E`;.G]0^',PE#ZL$V?!^O'>UYP\QWUZ="-A5)>,[O])1&_ M?7:!H.ZK!`"GYIE`W9/^@%5=.QI45DP2),2GP"Z;#51%4_1U`&^'03C8^\H# M0U%[%0![3_9@E?R.A/J6#N*/?A2'"98V>&=%;G0/>L5ROOK_9X%0`8OQ&XRF M[@7X]W3T[[RLU`?+=CVP0Z]_N-'LIV_T*?">P#59?.8SQ1HQ\Z.#T'._+RXN_PPLE/W+AUE&M);'M,:*M>9J1A9%F40T//,^ M"0,'KZ*%$M6;48W5MT[/TZI$]*EX6C"J;VEDA^X$T?AUN,0#[GXVJ#AT'\FO M;[$`(`%@Z29<;5]UX_&UPG9OYW\1C[*/>.N,1C$^S,N1W]$0[Z)9C]L+$,_6 M]RGP'V&,,8[[,)TL[41`3#)^@)^_!#&-"FPD@VVDCJIM6NLVB+>M%)YR`\>U M[ZPIJQ2YGALTS@T*XP8M7:PB<+'+UEUG,?2R%>9MR\-I3[:FMW?=?VV"&9]= M!G1(P6)U4G?FHV\'8UJNAW*EJ4MQMV)`B`=\3Q_E2E5Z2C4@W]--68["'0/V M25A$[^CK(2X?U+V9HJL8RW+B5+#N[:UVCP=TP;4]"3.HAFFLA;L(*&4M8E\V MZ6@;./JGK=V%^BN.`V'VDI&_B MU/V`2(-(QR%$4PO`DLXD!*3=Z%$40Q$'TI?`MP4@2E,V2,7U M^)#]+95[WVA$PR>*K;FN;3M,``CV+W4^@0N(WJA+MY8)W7V,HFXP/(Z%ZO1K MW4VY399W)=::5;?_$(2W03*(AXDW:PMQ%(7[6G?'!CL:P',B8#?9.QU#.S4" M7)^R;GJA.V`-6U`6X*'O-VH'C_Y*+[6C3^S4I0*UA4`0#O7^!_@K]NP9H-[W M.%?55RP005"GAS77/G8&R?\8W=$P*]V5AL..6M-J;%O=O:!]H%M>+NMK%*4V MAQBC2U749:-K_2S'P[+;JU',Y?U7$)99\H]8>=!1>LLR;S[5H4#LN[U[76-9 M\QP/Q+Z[5=>,%=(4`*+,C#S=[&PFSM8DL%,EW1FK9F'9$.X;CNP8RV;X`1#" M9X^6GH#9Z726#<_=((@&>M_-V^_JFQ%\*J#WSK12.\L.[]Y`S[JQ?!UB%Q"P M!GFG%HIMP1S4ZA%K,HH'GTYZ?_"/QZ1Q5H-G2+IGO M`BMTL*$.SV]E'>Z<8`*;B/?5NF<&>@+PV#W;B2T!YA(D4R8;T;85!F>Q/K\3&DC]@N M5&V!6=/"JU`1:WG,^R!EGL+5J8M78#$#R/->6#E7O8BA2&XMW(AI8;`OCA'S3&JTX)S;580B`Y MW=+69=BMB7U(Y\(&E7RZ[:T57?XZ=E6+*QRQ4KHL)X*^/*;'=DG+#I*3)7;ANPZPX&@CEW&-]HHM;(%PR$9N'*?HF8O^ MGUJX?YA\PBYR40#HPC:8(;-#6T#1)*(+2`.(D.2(',J^X<9(+"3EE+%$,.^O MQG<4S71AQI"@/"8!WW`4^SLB,S$$S)Z$86=B:G5/KN.75$4X7$6PT;P`7PWS M`"TRZ-`=`LR3-%SURE3^_%.V%5;U2X[@[9E!XD91L@$@QJ?SAGF[I1\7?GD> M<+8(/[QOBP]A%^!,T'*]O@5+;7(-J(TMMN.U+BKG%C&8CF;]P_66"1\WZ/UM MBV5MON<[$KAIR*Z'IE(6^(7_=6/_\E3TIUW,M<66Y.M;&,Y7`HOHS!:AZNQC M!C2#S,:HN.=MA*PH6`WL(7K>+IE@G%\GC[!3%FQL9;%M[8)-CC8!M5D6X/P= MU41"9>]MM\V5@K;YDEVNK+'+R4,VY*((RN0Z-FSQOA3&-R8;>]W1"*S[G]C'V$LCE6[9H)-[SGUNKRC#.+ M&GYGR#K(B'ZV-I@2BC`K.@_X9BMZ3LH58WH5.867/^N(LMSZ%1;!=/;,@&DA MWSB4JQ!D>2Z60?NY>7MPAIF-9@2SH]/9,D'*&SSGM.?O@1U61YH MN!6'`9[JHPQR(^:MC,?,51D64V/Y]LVO&T>.$_:U0U]VN;'=\6WM.@8;M.:] MY4HM]ZK))67;)LFSK M&E63<8&47^)8DAWFYT[HV&G+BDNUPJXB^UG^]M'/>XA!$H'%'_TNM\@N=;^K MJJ_<+L*WRS_9S]3)A8J?:&@]TBVB7>1>>9^Z\SF38S&L=I??O6QS2WOD.'MD MM5!R:HP(*QA-LO^I2EO=AJ@T;DZNT@<%8J^(^_PU%[2TXHUQ&_4OI8GNNM?H MKHF54\UV6@2ZP(KNKM;E7I<V^5ZI>)ADKZ5;\=!`_[QWKK22]^^WC M""[M_$;9^5D06UKZM8@&GE53:`(TQ27K@\MDFU[;U*1'<7Z/H@G'6=I?Y'E6 MS358-:UBS>Q+#I+G6?(\JS$[NM\^[HA:^KEB_-S]S([R0]_53_FMB*"OY`F' M8%U61Z+5^XA*N#$BG<,&'3>5G750=W4NYKBI6A*AL.8N.U.A*./'XZ0LR?]PRH8T@S7YKY)TLZJ+N*EHSPW5/($HO'9">?-0>C+PX@*^"I-R$$P_E)F$D+= MC9J:Z+!JIDIIVE%2ZH(XZ/PI#15%\L:W6-7EKZ^>T*Q"Q>#.@Y0;."[VJ M7V+5^^HA87\L:"D6#.,P+/3-"F)A?S3H*1KT_H%HZ%81#?OCP4CQH'8/P0,3 M[`8O`4'8CS+8>U7KNW MH/9VN+IK-:S9:6N:[-2YW:_H"L)0)=H0[NPZ##*N4_MTZ4JU(=1@U7.*E=9U M6+V<+G]2EEVR+-ONBW=EUW3!+'EA78>[1OVW2/&3L3X3"7*[B-LNF[L.E[E# MJM)K^(*LD-7#P]0$.5EBTLD/!GV'+(0:WA>)OY5FR-0],%P3@Z::APN=HYJ1 MJMM*H9'G]U7(/N70Z1U'22U>8G,<91E]RE3W6$3W61E5.;Z7C) M8(L\L)%$EQY1971?$6XH^UR^HJB1!S954`U-80YY8",/;*KH7#3O_+\>Y-Y' M:9PUR"0@QE1)-CQ-).F\!Q?'96-+,[TR6J287"W[(+RBR)&G#:?ISGID>]:+ M.6W8)56-JK)7Y45<&57B>M6MVG?>$Y]C6^1*ITRL4U:WK`==>GAUL#;.*60Z M\NBHLHD(Y^2++I!%>JX7X[G*`R9YP"0/F.0!TVF*M$N_1!X6-=B5J-;NK8R8 MKQ>AZYUB5HK(K@S?HSY+E2FL;#M-IAL,XG9W]5]J-ON[[^G M<]>6"UY:+LZ>->SQTFM2`PMS%\?HC&.:HV/KU,!"!+<:-6X8L<*M^@YNU=1V M3W*K4&Y-O6-F2XGG3[`Q._7ESX(1%:F>I7H6Z9CU63OTQDF:M`^:5(*2)V8\ M\8V.+=>')4FVD&RQIAN;Y`K)%5*!2)XXAZ20OLL:WZ7FKG<5.'53A]%OEE]2 MC.A27*::,V>E!&LNI4)J7,F3E>#)3^Y0N@22&:O!C%Q[2VZ4W%@%;I3J6O)D MU7BR+`EY$8[YYC1M6+\N,EV]FET+CJL@M09K79XZ4-$+#)HYYZ!C]H:R8Y7U M2/E>2=%J M4%1NT$:14Z1QC#&SNE-45.Q,1L@V1\C.R^^&*C(.5@^NWB?:)6-:^9A6D^A[ MD&1J4GSJO(*GTQ49A6H08Z:QILHS9OD1I081-;5ZS[GEC(Y(7T721FRHQ]`D M=:I*'7%6LJ2.E&N71!MQ.T=<#E)]HB8RXZ@Y&4?]MBI(P\N,(YEQ)#..*KK6 M\T9TFB[Z9,911=9:C?A019%S0>>EJB[4^9($/3M!97%&T21:70 M;1A!Q6U1F74DLXZJGW7$^IK(M".9=B33CBKKO3O MLG'6U`"AL8SFL<4Y::.WE9ZD3E6I(U!1-I4\%RI3=:$W&)O'%@W9M0W,MUK7 M!W--?*0OMCEQ-:-*2\@5:T7+#*72,I2JUM&T26E'A?OD*MUVO_0\E`H372;A M7`2A+S#)1I1)#^`2)TBPEVU1F[Z:1Y.:)O1>TD4QTZ5*#4EH2>AF$EJJAV7U MH`JZQ7^!S'294J.1&4K\*VOIO+1!LE]W@>X'X=CR#H/\F(#/#/K)+FCS,2J] M#1A_$<,@Q"$H\HF5(KC`@%@!SRU8Z# M`0WG:]35%M$4U6AM_$DGEK_Y18T\6Q%Y:2AL.FK9(X+2.!C.IVZ19S<>$0M@ M\ZP8@(BM'V1`?3IT8WSPY95RQ1\):32A=DSB`-^.8)@)KBQJ'TB)"O--QOY\ M6)CSEQW;F1[092$].LPSQS?..IO@$4B MEA+PSHJH6R$VP(WN:)B]X]K`9CYR M^#9VUC-T1JZ:R]B*2=(`%C]TMF;"//V`5P MI)1YHHP=A=JLHAC M+)%FBVBH]C%=>B=@=I'FBS!F%VG""&-VH69,(:CN`L^UI[,0S'[L]38]@9B% MA'*G$3P0QL]9,!J6?N?G)@M1XPI$,C.LD-FE%7)%N-5)LY\F\%/$?OJ-!=O^ M]`-PM>.(A2"M<9#X+,[H^G8PAC_$<>@.$A:$QD@C MBUGR8>$A>&0<^``JDF*`03("7ZTG&EJ/=/8K/AV18-[9ECA)B/_@C`"F&SCM M7#QP]BGC0`!Y#B5?)?[I>>0"3(_N$PY%A\,T%FIY'ID$,5#!M3SBX!CNTS(P M\M>MX/$$TI M0NHD-N4L_!@&443\9#R`#0#CSB'FM`-$X6/S!]*_IT`S1I^M?XX:#F!NU1R- M;+V#.:+6`WF?0]8H8(B9<0;'W@C0`L2`_X_=JQG(*5?#4TAPW'1^$,]FYH/$ MN^?,L>ML9WA3CADZEQBNS]8X3.($9L+9'!X@A[G@MR_P*F8;GS%@OT,;;%<= ME50:I>@(]N)J4V=\^+4;6X`S#MAOJO([6=4ES3L_.A7BV9-KQ/:`*2T\&712 M`>Z#Z%M0U7D%@Z(==,XP\+S@.2*_L8T9)!$,$+5`U-AT$N?TNV/%%F&GWM3Y M_77CJ)?;;VGZK*+\>98RPBT3FWI>>L3_RPOE!?L>32P[^YZ^GR;#V(!8:Q+1 MU]F'-WQ@TL/>>']^L[RM%U>WI63(VMP$4SUU,8DRFL"7>K-#9W=C*E:*2,X@YJ6S\WJDY7S2\YE_7)7])P2@%HQ2,9[ML)X6A4);$N(AD M1LF,56%&73+C@;QGMYJY6L$6!T6EU34*E72=.*T-1L]31!A4`OBZ:=K26USDI3 MK:6:@CH+<25>=YI*?SA5XO]DTU,'U#C/"R1]2J%/IZ]*^FS3HN?>/X:PIL;2X6V0PWN"V''=[2HQ_D^CHV"2T)+0 M#23T=N^WT826+G%37&(VE4/M@%](>XWW><+^I$. MLCR;E$231#NW2FXTT:1_W2C_^I]6&%I^'/W\E5?1E5YV8T\955T>&S>+H!VA M,>U+(6AUSXS5;E\>&$OO6"902]=)$DT2K0Y$D_YNA8@F_=TC`LTK65E9T<'3 M9V?5W7#;R[4ZWS7,:CH!6K?5,V4RL&0G@>PD*+?JLMCIS)?$*\M.?4U0V$E& M*624XI)])^GP2J))HLDHA8Q2R"A%T2C%%QJ3]!+X2A,,&8]H[E%ONR/H:%!2 MM#(4E4&>9IW>MT7%6:1CW!3'^#!MGIX\2#>Z%K>+L3V?O%M<8>H(U;/-HLZY M;WYCV^*+O_?-OV(YKV7T9+_6JW/1J=J@;6J`QFZ,N4^4:]8'Z\R5Z_@#!3/.\NYC*T[B()PN/"R8JW1347:M:R_X3KS@O?FP M[@O>FW,KL&`Y^*]T$V*F6N#?WJJJV)S'/O<2] M^57IJ&8I2QQ/O&!*X5W6V_>3:PU@`+SG?9.$(7CK"^NXCKY_'6XA31[L*_W% M6[7?451E8:?MFD\@>"MH70'/[&F:"/#N:?CDVI192.^P-_5-,)Y0/V*$`*R_ MHSX=NO&',!CG?WG_`S\>I[R6U[1F,<=!=_H5[]C_#5SQ#G%PZA7_)W'CZ6?6 MR?NC_T2C>`R<'QTE"4Q-[R[NM/63'`W)3N29JJGO#\D'RPW_S_(2>LO[5"W0"E9'OGH1W&8,-P6<6CKY7ZO@38?\M8[ M99&&/?DA"(E-P]AR?3*<(=R=([P%7VPOP3@-L:UHQ!I$LP\4N/_)\OA#<6@Y ME(34IO"W@4=G?YI8T_0[OAB-@C"^BFDXAKTUB&'PF#Q;$8&M`QL-\_=9&WCL M\&Y;83C%6:UQD,`JK,DD#'ZD3PV14YX8IPQA!?C\V/IW$,)V1-:![R`XW9B. M(S*@MI5$-/VS&W(8X/$X+4NSMC$]]L?.3<)?QLL%$\N?LL?^]`/V9/]-1+S` M?YPO"=MBSUI&#/S(!6S('284UMN$9L3P`Q\F!58!!@&^M$)$O8^HIVQW)'X$=':'+M`/ M]@WN/X*,%P.I7U)X@QBR?TOLP".,IAZ/:.S8*;L/W^I\']/Q_V^9=QWT\\HSF\\*XJN M?[C1]T'HN=_O8![@9W1-07:"]1E]IN,!#7=Z:X;2:QQ&LG=NDB@&#SW\Y$9Q M07QHO6YS\?$EP(C%A,;T^C&DE!DQQ=!BF+AO*HN6W4$)I=O1J[R`,^S\KEEI MDIYZY^L:0T@S\7'XSC>[^ND$8NZE-(AR/00K#_NU?\""F<>(@)[2+[Z0'8`< MLZ)OS+-P:/AU^`'L(\O#08\3;CU3.V)E:P$Z9H5"R-57C"/6)()0;(P@.8XV M_3T,SLT@'+N,AQ%L^B,5Z![ZOKDZ9K?PWA*XW-WFK6$HA>UTD8"=86>91F'U=?:5'K.SC.*>5V76 M>42\2>^7L=Q?(SI,O$_N<+\TJ1+8^NV=VOU7D>7-0:[B(K=Q]-L[36G0$K

MZP!Q64+U]>H&P[LD5:K=K+K/%R6#=DQ$TI=?7 MC2-@#0+GV?6\HX(%NJGV%@]FLV'WGVSGBO>=#/"P$DI)?[H+/->>5BF+^829 M?3-B7)'9M1KR)7AB2FB>I*:V".[VUD(^IN4$$\S$"^F3BRFB\V3G:WN6]GF/ MI:NMT(G(NP#^(:_FB:%V6"AN<197."5TN,9K"SA]9["^I808::8F/]ISE?1 M?'1CCEG,BOP*>`O)JX=@XMI$-Y6?R`/F/`+$L\UDC$7(,=O7H]8L-1>O7'E)Y++L8"O&%$\W(CZ% MYR(KG.)CH(!@:6/V>/P<7$4QG6Q/0/%K&`GSR,]V/"<4CMX-$' M"0E0\RSV*;6`[2EP!FQ-V`,+6USGPLY@_]49VM!Z:&!:\:DNT+`GD=<&EH>< M1Z(1I;C1AAYHG`BO$8#PFPO,>782IG_/LZZ`JUYJ+4-1@<'QRT;294336S`) MYJ.CN/.FA4A84JYU84.DL/VR_/VB[1BN8.*#QG!9>CGD>N?`D3$2YSN-C#^@C MRK$`/LS7P85YA->>^2U!`"685[Y(]]KB?J*I*Y)=J8`AW15LX:936WVUVR(O M^WV#WX%Z:?;4V:VE0Z3I\L;<@.4-`F.KA%"55K>CIW#V6CVCLTM\$$28 ME7$7!D.W4$2U**4Z\,)2!&H^T5$0%&86K=OIJ*H@&+0<=QC?=:48$KKFY\3=`)B=I>2=HSE1WX\(/5/KB>8#/<^).R5S M5^.9X>(A*!Y[[O3A_\1RHI'GQ-U79'JF(0H`,P=`MR@*5$4S#%TL*QK[44%5 M.CVS(`ASW?TUO`7W,8@L[^OP4^`_LB/5S/1-:T2LMX'Y?RM9]>2$?C96V<)N ME:PPU)3Y0W/DHI.UZH+/X]^(\"N&\>RW?,"<.;"9%Y4YS"R<2H!@$1O279@+ M0X*L1&S/_%6BS7]^^`:@XZW=Q;U$WE2H?_-QF,>D>Y M4O';1F\T`PX//.@S!RU<1,A&J-+`K.\GX#8.K,A=7[/C/5]WZLNN6[<;+5;D M6%O/(P,'//H40/8L@X674<"OLY()&9EWAD>CPM!YP,( M942B2PH=E"!)ET0UJ]6'+A:OUK5:/O4=!6K27$V_SZ[/JN9\3%F2A37RHQ0I MI'6LH]0U3'71.#SA2BJ*PCTM?/!QEBZZ2!3N:9KVE'ZGDB@\Q1:\TC5]R]I/ M!?6^V6?&4GF'\T"];^I9KPJHWI2+>6^/J)-@!MSZ85?_2ND7:TSG2;8`'/6\ MVQ_P;[%T>&$(@2TX+\=427?CO$46>[]G#6R8L#KYJ7QO[U6Q]WH99NM4]^TA M=7#F=969@\/1CT8[W_)K^[Y-AKR(.#NG9%7$V2@A M2[`)-KLS=)::EIN;O86))UB`T$/'X76SF2&WB=-V*HKRYUF#$];.@Z#42EN2 M_/)"><&^1Q/+SKZG[Z>=P&W`FS6)Z.OLPQL^,.GJ;1C[35Y6=+6%#B=LRLV] MM=:V3#&,=E=07]1#Z'.X%"I",R$-DGFADU:>L=9^NM-H6NGJ&W M=U/H.IER%1)/@F(5*RUL*[)$231)M`JL*#4$&DTT<2JT/@IS8-E_/(9!XCL8 M9P["U^1/-S?OWW_X4']5RLXRTH:H9-81E6`;RM)TJS!T5ET6;&6=<[:.UTTQ MC>,K3<\B[/]G\4PN"7_!A.\TG?!<_5\,X:7+G:*-=:%F>;NL#S7/6&D1K.@9 M#,F"%0$_D;1-K73/"^N+G9U_OLN9HNAM+N&]*[+#NL(+END>M> M:>UN3[(=>_BG$J,:DN^6^$YI&X+$7>UC*GORG0RJR#P&>20NB2:)5F&BR3R& MZA!-1CQVJM)K.\9R-#)OH6I^)H!+G"#!&YWU-O@-K:WTI:-9E_A&<_@.N$63 M?%=VUH;DNS5\I\L`Q_$'5/PKUC181G'V:_V;;9RXDL>L'"(KAS>OI`'31*/@ MV<]*T]F!SV*-K"#>QHX"^!1V9LQJXO$:',B0!V*CNK2K?>$-O=_6-5EX8[N6 MU\4[[]4MO&&:[8X@CJC4%&U5GKG4AY8>4'VOEA[R]+8X]3U.X M1PHS*4&@*-)IHX%5H?A=G@A+:; M)`QQKM(4:46/X\MQ1TM=:V5%@B2T)'0#":V)3&6N%Z&YDJ\[H:6_G"KYM&2. M=)8+"_AS9D1J9JNK:Y(JU:**WFMI?5-2955'GGNO]`WISTI_-E]`+H=1_(3_ MX_7DI)=;JO-S3DG0;74511*R_H14C9:B]B0EQ;BI9Z6DTM(47?JAT@^5Y[;R M"%`231*MND23Y[85(IKTJTELZI&%('7EP*\_S)*$EH26AY<&M=)B;YC#+ M@]LZ'1&:?0%A2TD2H>635:75.RX&R11?(6()B,0.U7I0Q!;'KE;J!7] MD=>*9NW+94BB2@YE8PKGZT9+4V180G+1<5QDMK2N@,N&E\)%0D,/S>$BK:5W MCKI]T\C$!?Y5MN00!.MU3-:4?&X1+*/*3H"PA&6+]=:X"<83RY^2D>40B_@4 M]EF:,(G].X@51?"G8$BLR20,?KAC*Z;>E+PT=(RAL;%>&J!?NEG(/F&GD/SHL.))"$.&@`%XV\/SJ3@@L3L&!B:..X1'J6_#8P!&8+NL M:\BS&X\8Y`YU$IAMX'IN/$40'3H)*3Z%MB5"9HV#,';_R_[0(@-8H4,'<<1^ MLVD86RX\9]MA`L/2'Q/J1Y3_.`/2#J(X6KN6#V"[#MW(!H-V2JTP(A0HZZQ# M.R);`XAAMSZ.-M-EE1Q^0!#=H0MS(&'2#BF`&B^((F);83B]`AOZV0H=@/O) MT:/I/R0\J.X_)#UML6QYSK[34HS M*D4VR,677;@@0C,GXC()K9Y@\?51$(>J`:TJ:N"=Y9!;.HC)M><%SY9O4VFD MU^*ZO]YI=0QMOBY)GU41?5;Z]%M:UQ1#'VEZBS"]*R-S;[>E.4DCO%0C_*PB MH:4H?9$2^U)(NMWB/"=)U59/%2KDZTY2:5AG&;QI6NK[-"U5FM5U."L^KWKH M*;HTZ"MZ<'M>SE`-5;H2U7$E*A/%/\'9:MTM$AF\EX26P7OI8XC,KJF(]%\] MPR57,'XL?8U:7),_ITG)KW]*;^,DWD;=>(-=!Y;^AO0WI+\A_0WI;TA_0_H; MTM^`AV_2:A32[SA:\I_5OE-:BJ%(V[^JJ4.&UE)%^6;2_FZ4_?TI\!_)`PW' MIY?!==?B-3F!KF:>B]XR5*'1HDOAIC.?6E>3F[26TNW*K"GI8UKO'.NF MO^QVNQOJM;L1##+TJ,VJIN=?6JH'K[4ZNDZPGGIV$9QU]YG57&\!#`/JTZ&[ MKIJ\VE+[!AF&P7A[$?%;_*$M@W![FUQ[\8C59@\I[-AT)EBY M'\18>#Y!E/&J\!/*R$Z2"<(R`E`B$B7V"!XCCP!`6IX]2H9#UW;QR<6BZPC' M,(EA1#*AH1LX`#YPB?5(Q_!P:U8D/C?`)(A<+*E/Z)/KX(I;ZR@UH)Y+GX#S M``,`.:",$L_]`]$KG!([XIGH%U2>`_!L@Z,.66WAGP(/`I;B)@ M.";B>/<'35'Z66<-)0<+;""^8.1(%X0)$XU\*X$@'0(@OHT-'MBB4`I$[-$@ MB3G+#W-;%EY8`'YD<2$UH`"+0W$G`4F:R-Z9-<&'A3E_>:&R8@LLZ@4HZA]@U[SS`ON/M__[/X3\=>5)&MU9+I;@ M]G%_?:/#7UZ`EF8$^:ZJW]7OR.;?'X+OJO)=9]^T%R3Q7?[HK_!!?0&TLD'6 M>=$O+Z[T%V_U3J??!:-X#5Q\MB-`T19`T7>!8ABZJI4$BKX`BK$;*Z9B'@!* M>F/V76H/""64IG>4]2`MSBH`M#T)IYM:=P/AA(.V+R$-3>D?!!H8$Q&]I?S? MC_ZU;:,A`L2?HE5P[3OI+>E/KL6Z`($:$$KOGM;O+`-^`$SEKVM/9M%Z'=!2 M=5C8OJRF*BN;H,1U?:,V=9]X8R&!;*>JFK$B9G:"(!KH/7FJ#PQ5%/?E`;TG MOYBJJHC']$T2Q2#?PEO*G#>Q,NFJ:^P`>'EZL>#NR197G5V"IEQP]V2(*WU% M4QT)[D?_"8QZ<%($ZR934W=A-C>U,"CWM2?5OGX&*/>DNMK9J>?W@/(K>&IA MFNO,3KO$$KZO[H)U%0#1(._+!8JQBPO*AWE/GN@:NR3!@2!_S;HXEL`;JK%+ M)JP#03S8^]JC_4*X+AWL/5E$,W?9#@7!QK"/Y=T$XW'@WX^LD$;7<1RZ@X2= MI#P$-Y;G?9VPF`_8J_^TPM#RC^2<[@KK=-?0X##`3K3"'4RVNL)UIDBE5[B# M'U=7J/?*6F$$L/DV71,GVV\);]/#UEE0+G?PFF^GBO'(]#L_(EXX!MT4P2PE M7,E>7&UC@P^_=@&UKLT!^TWM_$YFF&I>#/:\1PP/N7/-L>7Z&-3']M'!D$81 M<)SE$2_UX*<8[.=48,>;6#A3F9T8/3Z&]-&*:8MWDK;P@(@$-F^5;..QV9@? M([Y4\;U\+/^C3_!0GK>3CM<"1'_8%'LSPW:C(0OL+\)B,EB6IF1=M,T,RAF$ M)'B"YW`>WB5[RF&+"H$$0B%8A2L9#T+J>18`"&-;CQPHU>0K;1S+EG9LL%D< M+@O.V/(?70PT,>5?VY*!:AHG8R#&N0[FN[#]\SH!)@[G2]IXHMLX M>N3D09K,IRA_GB6RQ3R$"BH@32]C7>_Q>S2Q[.Q[^GZ:HF<#ZUJ3B+[./KSA M`Y.>TH:QW^3%#J/XXO+V[?NJJVVM(_N^;D]%5<7?VZA8J\UNVU3.O,8R^.*? M[&?J7%US^TMRQX8USGJ<:SMZG*O:^3GE!->8)$T;L/NOP><;)Q[X=H[<^))) MUC,)7H>:82T8;K$D!B'Y>='%K2IKBK/I:M"/>9M96_/>X6?<%G,O>TXX%A"0 MDO0(`[OF_%@IP7V=[\,UH]8=NW\@F520NI<,*XYA;X)(2D_)F-5CS.NR.QI* M!I4,6F$&O2AW:;4DRF%'`+G")VVU8.D3]N#!&#GB\*9J@JQ:7DE=.;^Y5#MS M5*Y:]:DD`24!)0'/6R'NQ#D"%3"'&EPA+KM413ZY45Q.KV.U]'XI%=D;66#W M5"U#CC6NBO"'IDB>.%)>ZJ7S1*D<\%(\`Z@@5K"*2JDTUVMU]9ZHPH62 MSRNQ5LGGZSH#:%U3\KGD\X;SN=DR.KJHPJ%"O8&:>T7U]WV")^JSNZ!?@O@J M#J[P!A>-JYT97!$Y6,UP<1&JZY*\!T6USBG#5;6EBJK^+&E5MKX5[#])4I5' M*KTOU#2J!ZED6'BGDKRS8E80%^_'?W)M5N%9!@)E<'B12]2NY`G!ZD"V'%S1 M45I?4,M!R5F2L_).1:MK"FNF+3E+U_D%&F1$G M,^(D`24!)0&K0D`9?&Q4\/$AB"U/AALO*MQ8BDB_"$IG&4F5;!E\R=E0E23( M.<,BFME2.QT9<9,;7&[P1FYP56EU1>5:R@U>#7Z2&[QB!#GK!C=:AB*3J3>[ M\_PKEOI>1EWV:[UJFM>[QKQ^V`J/H$=O[V46*EZ^'G19<+X2Y3%K\XLQ*KED30Z*;V.1).W M"B0!)0$E`2M"0'FOIU'W>F2M^V99'IM0* M>9H3/!12:PA>+`R!;VVJ8&\0-\)'AH'G!<_1ZP-15Q.JG["@O:FO%+17M<[" M_M\[6M95VGVCJ=&R`UHPE!!5,]J=7OTE^=Z!=4T[;82M:B'W7@.(?G0P/A4O M=18B[&%0:V9IHJ$>O+"/KW:)7I'&O:+S9NSU3$V4^]&K#6>*DE+--((R^=61 MILW)3)OS"@'3$!:#D$9,LXR8,BZDU-&(V7>KGW=#*Z(:U$JMWC2MWI-:_2*T M>E_4P:'4Z4W3Z7VITVNGT_N*(36ZU.CK3O720S:IUT7K=7D+D+NM\K MC8I&&16EWL*\!-/B`HXVZT%`:7+L-CGP-I&T-@2<>E8S(?*"SV*K29"SQI*- MEJ$(#297E/'JDJ%Z0.;G?DFIV3+XL##G+R]4-@S9O.WRRR;Y+W_].8FN'BUK M\GK>[IHUN8YNW@BSRMR!P MGEW/`SO+1X[_1H>_O+B.OG\=?E>5[[KZ75-4_05)?)?_]"M\4%\0A]HNH#KZ MY<65_N*MVM$UW)F;85PWI5@@C9U`&K#]C@>2AC2"QWB:;QZ>VX2G.GY7U>\, M(O7[0S"'3]L-GVDN@Y>?[`A(M`5("I!3Z90$B;X`R4Z::89Q`"1WENN()8UI M=->"@3,="L.^1#%7N?=H&/8FA]HO#,,36-%!.(5-=9QLZ2O]Y7TQ'_JP27^S%0.E M(WCT!B`"(4-]&Z1+Y56(UM;+TB'LQ=46Z_CP:S<&I]CFH/ZFFK^33V[L/JYV M6M\@C^OE/)Y;BS,MS7$";)B$L&U`D0Z2")Z)0&?BS]B4QO*9=J<_)D'$+SQ: MQ$_&`Z[=\<9CR-2^[\!&FGV=!%C$W<6Q/$F<_@I_`2C'?%,1YC#Z04Q&UA,%H/"V9H@S6LX3Q>70X9#:,=H; MN;6PV?_T`W,[WD1@?/@6;$EX"5;G\GE"G#7QN&$13"C?E<5,`LF"Q87`ZIY_ MYP97(`I!-_HV)9]R]E@KSS1VFSRUR=_AA_\"O?Y.+2\>V59(R3T-GUQ[Y>D5 M:VPG&HGS\^!G:S;%.R\!_@F#*.(?[TWU*;C MA4ND:H_=@M87I=/0]9@`(I;-=K#+-_Q]`GO7A>U\`](M7J06L1XMUP>S;Q\2 MDU=SX7'S)GUS_J?;-S^UB&U-$`:`IR1F/H`U6^06;`WPF+\$.3'\[OTW\NE* M4?I=HW>EZN35E_8_VAQI;7(3M\D[&H*]0F[\>-K^::W\?L@1`;PO,J#PO(4$ MN/)I_!R$?Y!)&#RY#N@*T!LK&$,)/`D11R&JC.S1('RT_.S"_0+.[^Z^+N"; MC!F#\!OWXP"P%H]@?DW)W:WGW,%<4NLY2MR8I!?M08N,)R#E`3*F9D")N/`5 MN3&)*:B7>#1#,_BR%-0;N\,?1.?;1URE['4]6-(F5E!6*U`%@1@I1N`5Q2=\8D% M/SL\.@!_ZVYD>*PV&,[LFDS8S'@K=,'R&(;!>+/1`3MLB*1'N0`;-1^QR``' M(PQ^M&+B40ND%`#4XSR>\CN\MG8W??D'N?WX[?W-`P$,^QCX0.:V*1:@&%"? M#I'#V55],)@`N8^AA8!:B>(=;SZ"/2 M'X!M@8L63=R8IA;A##ANJ;46%X-"R1T#H(!W8*DXI!:+]\QQ!4]9Y#,S/1UR M@\(W0PU0E\D$$,OP2L2%0HZP+5ZZ8S!E82X<-:^8YA+II::TP(7$_^&8B1]2 M=SQ`H]N9$QWQXPPA?,M>,OS2@+E.&A+H`" M=!S,CD9X#`)P+_S.\#<$Q3GBVP7+FH16XLPT9WZAL/XQM7P&H$6B$6#N&_U/ M@G$59`S8AF!>`^7=*$JR+::J:>F3,$@>1V0(#C=E?P'6#V#_VQB3&3.NX63% MU>4GQ6<#!&^F.39ST>P=YI]$V>9%X`9A5JH%G?$0;(A6[F\X(3"/YU*,M/.> MG?CWQR``U6(A.S`E8[EAQB61E2)TDQ>$I[E,V\$2;6P$ZD=<(#C6&)AR MR1N+*/TC55L($JP?(QBXQ=/'N?S)B.B`6;!)^X(41`X)?'2;<).B,W&^FIN+#0*0</<7L!C_A3_78?!E M@^3.'>86303JSDD\KD;Q6)^B.!R[#J+-W#DOV[`.V_U/[F,`LC/B9E)$;;1: MW;EP6Y$]5'+_XU7+X(52A>Y*@2NU MD\4F/D]#UW(8;6/77G;@6^2][X!AB&8O_&_EU[_?W\RY!L7,+7VB7C!AWLLG M=^RB"7YGA;$/K#9R)RWR$"913+EYB#)MD0WOJ.]'4^\)7&J+FR;%V'3)\V;Z MP1T.HT4'/%,L,Q7";*H):^$)*!N&>.C!0,_$T5J6!\#05_&\Z57PC-&3*!E$ MKN.B-PB"11SBS<\M\MAJDX>\MEVTN3E>8(@A^D9K MG$)<6YJ\-#NS9HXK&&_3R&7D?_?MYEIML7\T3NS/OS[\Z^_D$09G5J0UIPHX MF3]B=(Y>J9V?R*_M^S;)6J]R&@"6F$D,9(%O8.,CSB8S1H#'9Y^9^9& MZQQFZH_0Y75R1FWP2)D!S]PJ*X;E^G0Y0D_Y*/S$E*\)?:W%Z6SM$PPRS=)T6^.O4!Z%A4[1EV5P_P^;`LZ=L,SF2.P3#.MO=F3Y% M"D>@"U$^IYJ.DS0G!]A1(%CZ3RXWC-D[H$HP&,',;\Y.,Q$\MY+Y4/D<()1_ M;#P60?*M,2JZB+.<8^&[H!SR#B^X%X]`MF&`QN0C4`-K]M@6< MBTS&8L]1,*;9NB:Y%M@9/\X.6A?T*%"\SDP#(@,G9V,@J#. M"\\0*'0]'L`2,IL%%&4X:9-7'%W_2+SIFAV:&9-OV&NX6OPWIY$_Q;&Z-EB;!.,UW#= M]C'(*RSB2UET"7;V@D$VVZ.+]I>4T<(U^"H;SLYH1D!/X4,SYPHG1U M>*D)M<\B^)N`'=`AGA\L^2Z`L<=9.`T/;$?4&TP7?`,T:G@@8)VNX,.,\)28 M'=6Z+$LG#4LQ[`9^YFG!$->3T/56Q),AMU(Y"5D\&SK=+JD9D5%Q+M76:VMD MO"V:N(7D7%+E[)U-JAD+`8%54P1'6K4"8!+P4EEX MFQU13UEJ:<1B@'G[BP5Y4MHN4'!V6FT![[B3A/<<2"/;F1EL9=(*(5V55=UT MPY+58'U*:J.5PP+P.IYUK8OW]-]D0IB1W-I$]!5^7SERSD:-9!.T#=9@_=N.&=N+&BR&A9#!VXYAO M9IB00\6W\AK-HLY.CA;WPUI1-Q^;10:61EZT'+5L`ZQ(L`P1$_04MXZ169]Y M%9I#!\H*AQ]2`>T3Y@2F8@/W$]^IQVRI8$W`N9/'ES4G,T_6!<&-8=1`'OR4 M8?4NZY0Y\RZ$K:A'GRAH-6!=KLJ1R'L=[VPX:6(W2-@I`*QK__.B;_3)!60L M!+$_WGU;#.W/C/1<:)CQVD-H.12O:)&OPZ%K8Y[/"(-M/%R*;["P67J^D$5` MED,;R_$,-]YH"<_#Z7S_96A-AUJ,>F!"T!SA&/78'S_Y%7\)P`LP6QW3:*FF M^08^=DV]91CJ&])I*;K>ZIE=]M%46WJWSS[V]%:GW\./??AK5X-GNRVCJ[1, M5<&/9D=OF5WVUXZFM32SQS["`]W_W]Z?]S9N9/OC\/\7N.^!CY,`R8!6BXM$ MJ7L2P+W-[2^2M&^W<_,+!D&#EDH6)Q2IX6*WY]4_YU21$K59E%44B]29F4PD MBTM5?4Z=K<[B],6&=O2!-=!-R^&">U.WL+<27/(0+H)),*A]A?``X2>1VC)K MQW9T=_BF2N&)@\*>1J*CDC#E`Z!-T`1'8)%$ MO!.3>^M[\71Y")%[+D2J7(SGGOAP$52$#Q/12'C"GLTW)SSWUO-QNIGS=Q]I M"S]%)&#`B#%^H;C&:1V%#XL%9Y\6V0N7"!'NPNZ.H_6 M-NP%_UI$B_:=A;RES#B_P'/,O0",^1)U.GMOS#TD0JXW.%DBE&.DHC+?;N`@^8)BKM_(1V:6!GQW3B M03#XPIQG,)`QQB-D;#&%\?AY0/Y86U0%\0(1QIA?R[U<21:]R#.UTJB0/E:( M#L5GI=$H/V=_X,O!?WK`6.U;M++O>.@O:BG\ENS(MVPB>+,VS*H,DY:V7BKA M=3U'%C@9^YFY,5QY%45N%BL2?Q19=\$=_L;B3\"['ES_AD6S@S)FOV0O^O() MGWSUU8L7?_G%_>K-TMDOW(]S\=-U[X_B3`X>ECKS\H*5>1E2Y^4)]0D0!80_ M)P#H-/0Q\/H=<);D\:@Z(+9I],RU/.L][Y,WNKU9X+8S&/0M.:-[(X)!CZN: M8EE.W]PUGNP-QXR@3+FE7M]^[@A^#8.1C&7H&XZQ:PS+=QPYC/UKT;.&SN'# M"-C'R1L0R%[RWAUQN^1#,(IP#[YEXM\?41RM%[LYN@K$0)3S*HZV_%"JFL2! M!2,NS;YA#96;Q:&50AS37J=?F9/(Q-SK$`T38/!O7&R-NX<7+H3)ZK-6Y,PG MACX7?.+J^X3Z+0X].SWC7VS5G'^:TR..MVNEI_Q7&#V$L7EF4--E=H MSR#"X`YE]EMV>^3+^_VU!2@\^9GO7!`.WI%D=]P\SM>T%YA<.L,'_AHF+"Y' M3<\T'[]!<8XC2L;ZL$C.6)2?S`W>H_&XE$"?SCL/W\V^1".G,7--&+L.$S6 MBT$]:PC'3N,A/&X2/>?(23R$NZ<@25&U^DYWYRAW:H@'CV,_;S?LWE'C4+)V M575)7F4J5?7_U'"%+KD=SR7AI?;:#?XZN>MH<'@.&]XWR)=8X8RK#]MR!8"R MNNN%JD3&*`\4#W@5$`VU#8S59_P0[-N>;G<'^?E/A#GVX6217X*?^QW#_`Z+ M-&AN$*2S1:Q#5BM*'`/@$16Z4WE:ULZL3?Y6+T9O*\^"Q6@GQ/7Q%FC_SPU6@WI,$8!HX%"^[1N%Z+]YSMNR_.ML M7B).49R@N=HMO"?$<"O!$A=GL]OO+89)9E$-?NAB1&9^_U@LX[9EV(*:&/ON M"ALP.C>+/N3>8KZ*+L]OVC@'M0QQ#LK/$.?S*`2;`08#R_FMI8-B>'K_;8LW MX4)N%J#'W5&,J9U@6@ZOD\,XP4R\>`0W+.OQ)(LV7*4PC3/2C5^V&\F"/!0] M`(QN][M%CP%>-5\;,=_/*O__>-&]X-]C-(JS[]G]6?<$C(YWYS%[F7]X)1ZL M]:P.//M54>P:9G^EDP!_IR*]7#I&R6XN_,)G4?]SM`%^-ZJ/F,^[+0D$R'CW M@0JU?I'<0/8,VD(U'73QG7K`H=[:JXPU-(,6GLL`2@ZMD@8_/9,:RRJE&:BS MG?LDZ4\FZ6ME`3U')@MH.K@DT993C)]&Q,8DDQO08_V,F`OLV?L5Q6`3OI!J_2#F\49%FD)LK4$67W%\7=> M$DB1/N\MY&=-IU%2=7)^%B:N'Y.R4XKR[;Y$+@7#U<9ABJ?[9=E4K:M9AIJ^ ME4](IM'IVO4N>YU&*@]E.GM/E?B*D3#KZY/_2IFX.\-UMT?T_ARZ07R=12<> ME8CG#+8G813?L'T,UUGO[C?A;.;Q+LGG$V.L>L2?MBU&DS[1)_I$G^C3>7S2 M2HBE$X8O6UO"EP>KBNP>0WZK9MRS.CV9EMWA_J<3*N6#8Z.?MX2[;PF`KL"C MX'3LPSTN^QQR(UYG5Q4?@]7G!-YP2GSV\E9!FY^8>\?R=@`^__:$"ZA2L MJ:G4>;0_-.>AM6>!2%R]DD?%501T"U[7="_[03Q/R1@1Q]*=KB3_F[5GGLW` M5!:G:"\_J"(B7)[NH]:NKW-O]TV]9TG*ZY`G_9NS@\]1UE<1ZDVR7@U9;_5U M8S`@64^ROCP_J")6G&2]_+UM&KII&R3K2=:7W]M5A("3K%=#U@_T?M\B44^B MOB0[J#3LNZT"GV*G27-00'.HGF*6"TK:0E7:@EK,1.[D28>H1885^S$?L0Q&F$ M%7:O@B!U_3?A/8O<._:S!T^0VMW$6F_S47(0^T>>]0;)[[IFT8<`^]\%6\)O5VY8_O'VE:RN7??KYP^JO6?GTXD59N?;B=7]J#RYVR1R%T1P'Q,98 M_WM+]7!;UXSAP-A:/7QU:EAX/:]8[3\6NSS.H_#>X^6I_7SZCUK"8NR!I\4L MNH?]'>MX-T`$"/!.PFD,HI9%B]:[\"\?`&21-F-)%,Y!UTC<`%O]NHL&KHC9 M'V'TE\X__3^XFSWJVB]N].@#B>O:-0N"^-&_!\IW=9BM[S[`_;KVNQM/82P) M+L$;77L/=H`WABO>P)Z9A!&_&AB]NP*9#QB'GJBR_8L;Q^YHFL8LX<3/`A+N\V&[$I"V(L_NU[HH[^:,IF M'M;^'GON71#"XH[X&L>%:O6W?AB.1=]/0(K!)]=_C#U8>_$+?T:<1+!H\`EP M\L.[QP)"\(G_2=,`[BH0SF]\B"2PIB-^S8S!9`V\? MNXV-\Z%ABP+M'ZZ'\U^\62\25W9WNT&.&;CX4>-G[B(VQT_=?XDTK M$WP3^D"X*0#V\7]T[7]")&I8FYO_C\_KX)&LDC:V`&=(J?#/$RP"2#MBHT0P MB/D4"&'DN0$,*5M6CW?!G8;Q'*4=?!S!%O5&^"&,\$[1IGU)55/F^LFT0`LM M[#];K_2[678+68J?X:NM,-]F&HB6=<4!G",&G"[F+3J0-M!^A#^%D&$3#USWU9'!!S$)&J0VG#P'>>>H!^B]UM09YCWB%'`1)OG1XT#Z*.[(.7J)X+A%Q0C M?O=R?R]>B"3P!@2V]@Z[(3+>41OT"A#OI?9M1;;AIJ&Q9HBPY`WH%]=<"6+C MUX^_P8)\"$3'YA1`*6NA'-AWU#*L56OJ@(%4-(-#FXXZQM!0;`J'=ARUUQJ` MR9[!^[Q-TM6BB7KEE'5I#GK.H,RT2H[N=#,]D`*-H=DOM8F4F^B!=#KH]D\] MS0_!O1!*)Z5;Z*%LU^GWS49.]%"/=[_GE-(/GCO1#]Q:^3F,XZM[U_/1 M;+H)\?0B##XGX>BO:>B#R1^_=D'7+D.K94G5L?H;\SID+)5/I/2FLTVCM\%= MU)S*HK'W9_0IHLWVQ@=;]N.$/W:MH7SB@KDV?N=&Z),KV?M;Q;4P"QS&_F)U M2X$ZM#;UG9KGT2O,PRE+G(;9&ZHVD<$VEE]B)H.UDF;USV15>I457H.^LJSO M0#%L]P9F0Z92/>M3<"W,@LZ1L[[]NI5A61M*I!J\SRKROOT3L9WNAG=(#=YG M':CN&H:Y890JLL^L(N_;J\^:PYZM]$1*:^9VW^FIMDUV3*5ZWJ?@6F2\SR[R MOA(!1J:SX1-1@_?91=ZW?R(]+HR4FLB@,)$#+."!.9#*Q1^NQ!D?D#<8T0%\ M'/$]$5\%XS=3-[AC\8>@>`T/6?%9?#YE<$O'B9GFG_Q]5VDR#2/X*<&(D^7B M::LK?(:'YQVKTN/S#X'VB_NX'#.>^V8^>-??UM]`)+^97>H)5[BPX,^Y:?DDRB< M:>B9PK#-6'OPDJGV)@^`$N?SJ7C^R/5]<0Y?C(F*V+T7C-%D_!>?$!NLG&.SH:2%?_47/G<]A)(L#2PY/Y!"^8 M>4G"X)JK!.Z&/R=`+WRB(W&60)L-$$GP;" MG-\NIB_NF+F/<"FL!+R9'^L7@QLF"_*)78.?C5 M22[RUWP8Y8?T,\8F MQN]3C'7YQ0LP!/_:?>10OTV?;&:P)$W8+_"XY/':=X,$MLN[?Z?>G)/JX\WC MG"T)-+^PG'EBF$-KQ[2>'G7-4\VO7?Q6;KI]8P>E5S#9-R(2KU9X![V^_9P) M9V-78][/Q-JRGT78QTP=@SSNV1\\DK%.V/MK9_J'#_^YTP>528'IKYV&'#[\ M9T[_!B-9ZY__8)<\+S]^A1;@N:Q^AP)1_1H\A/63@&F8YC/GGPU?F=D_$W^S M^UP".&8!EG5WZE7KGC?YY>B?G/PGN/S=USD+,)F76VKP!_PCO%^JTKU[!D\- MH>S8?V5[4G`/-*0&SL!Y:M577RUME(?&AW5[_4$-PSPTNLNRG];5RPT3C+(W M;A0]3L+H@7OHGMB5>P'>.ICU-\@8R5X03S:2YVW1/2,II$^_6;C7X`OPOVN1 MLL2_?IPLW+4+QTS\UHM'?A@#^X*K/WMW@3?Q1L@[EUXC>-[(HS.);6<2?VJ? MTQD,YQ']Q8756SF7R-:O?7[->M/YEMY,7/P5PM^USO_KB5?CL)'*#V!V) M@%[N*K]E+-"8[\U@R.B@)\J1.U8,:N9+SS^@BGCO^IP>+L6?6.%/F./'L]P] MS!W$]$Q0&UTOT*:PL/ZCYGMP,986P'A^057\I,G59IB,ASF&G*`P)W,&(YO& M6!;!Q^S$ARG@/,_*N(RWDE$A9Q5H8ZQ]:SAZK^OPT>/G8<_$TZE1/J/1QO"3 MW=F?_`YDV;H&8F(NCJS\<@F,1&^'G)S>PULP]?526W[FAVLBQS?A#,WMT#OPO3>)'!6TR4):J1+M^$A>P@"//#8&1N*9+A[2,GPQ@$$J)QB4/! M`B?3<"SRT_G9+B`_XU0+A#%)?>!_]VPA,Y=L9)&X+@@)JR)$O!9+A,>2XFS> MQ-H)1D^DJF\=*S=-,,)&\V98N243VSA5=X8GW?]AA;'YWH3E(^'U*W!C%&XL M4'7R.,?D;C8`H6'K!A8*RA8G]R]2EB$U\C!(8%\F1"0,4?O0YC6%M MC>W4#@_[UK1TT^[K(`@'NF/W,J'8U[L#DP=>(!V4*H/`_]_*Q:%)XK!2LO@8 M:#%H)[@Y(Y9X4;8WN0Z.3$/(/P0C)P/0E]-9*CZOT`M&UP@^D!4/BY!V9K#? MQX+%%!5[752""!X7S[U#/0ZU,3S=]A8T*01>QK+$36,0Q%B-2$2=962ZG6=] M8G/7BX1N/W-1[T?#@PG^/,6R49RN!P8_%M"L-LV>N$19,NOP.^`U.^$B(4U MBHZ(C/LU+%`H3O"R.\CC[6"W?&8POZT!9\9*/3AXZ9UWFX\R*X^^6%FD\X^\ M2,SW-R%(5;7$9,N0/,]P:HCS.;WQNH"(1#!P$&`8KX.B_AX7,,KHO1ZX/R*2MBQ2OO/(27<<+F.V>1 MA<*-Q&[G+U^)G7.Q,"UHX:"D9.-#HR^_?BN[$>L(T&]%6P?1EXC28LA_,&`O M0B$:"28$*M"(\U4^_`D,%>O+IER+<@O1A+R.3AIPJQ6N?,P6AGM.%LL"C!AU ML+\8%L6:N@%_&_\='XZ/6*T/A,HJ#RT4KX0GW$7,33A5P-WHDCT5*#]WKH^E_WQE/'Z75R] MX+4I@1LN.6A!O5E19[B2J]M=`ROLP1?RY-2MNG+1L92(VA6WZ?O;8FX+&Q=U9.0IO+R@V/NPXY%W"&\WT!>O"8?$@#YHM*/^ MA?86YVIH\_L@>,8ZN@J$5DH)&X+\Q`\=:]1MT+%6XPZ;V.U MD-0-?6@X8,X-A[;0U;_M#0RIEMR.5=ZQ39_%!,4S*T#+^ACF>Z[2*S9&"V?J+`@,GM`/`'5R,7] MH!0NY8`H!(H\G]<=A?&D[W7/K)"M&RGW: MF0,>#WEN1=7FS!D^!['%35`P5]W'U1JGBYK:&MR#A8IGZ'V#1?;NO7&*$6B9 M48'A*C`S'CJ2'52C*09&C"C)FIUZ)E,O&L-KT&4++X-7Y;M-%&?%&N?B$T@P MGG$'RLB,1=RQXN6=%;(Z[6@7CB.&19GIX87>%7+T!VX2ZZ):`/D^NE_.D9BUME+&+D^2AQ`)6M*A#'19;,'R?(U:L:UTH98R8-[M-(]#R^`KFQ;%WK8<@ M5?2.CL61)W>VB,7A#_`*L(B:QLLE1SH5B9"KZQ`S]E>,@'!R7+A_B[>FN=-) MPYVZJ#L\]H3ZNBB@O(XO[IBL0'>^6W("C;E?@(]Z^SY=5F:.MSQ:9$B./2RH MS_$.`Y!W?"]%[`X]B@`6BCXLC)^"9NW'X?K/N^:2+P4O8;SH>S#*NI5HWR]` MPZM^X)-7`\"R0,5>ESPU>!R>>)\,(N7$*;'5QS0B(W3 M*"NQ_*]TG&4:9HFLW$F%NR3%)@#+@:UM=W@Z=ZYSS[[`%]T_?*9B"<(H,[+R ME9HXPL70X/E1^Q\CT49.YJY@'>^H_EH'UBF ML:`IY'-F%3[D.J-P?HU"'XT*+K,++`S?+21$1M6Q-DY9P?VX7SJ(64VSLO>Y MHA!G^PL``''`W:'P4#S`%UY.3BTB133/(,;;Q7IA$[KY;BZZ,BR<*F=+A27D MWD!WS)-^$VY?X1IR&H@Q6F"TFB;@]$-=< M^'I<2HK5Y((-^!*7A)P*7HD<94Z*X@1(K'*1A+,;\K7R,B+S'\5>RCCJ0BT0 M*QM/O4FRD)R+@N^SHT*N^"Y5Y2R_?.&:6/5,G%X_=@Z...7W.7G4 MZT'*NCNZER?Z/JXM6^=W>_T3]NW;G!@3\<=,<'XK,$>R%;AJK^S MG\36V0?W@01J`IJ#2?8N]E#$L&/6/=\J:.3[;W^H@#B,^A?K='UC)7*00NO8 MDHUCRSL=B,,T@L/4V'6V=U2R_;CL7(59(K)!882U-MPV[8Q/[ MDTJ2>'9+Q$C$J`HQ6D2,1(RJ$*-)NMYQNAX0XG9%[]8=_87N\6",7KLP>JE] M\^;-NW?OWZND`FZN4YE3^']PUW!^%I]7=JV,K4E;R6,\DZ=B;SOG6G*@.,[B MON',[-4%L+*'R)W_>"'^O7!"%US4$S]TDY?(.Q>_YM5-;=T8]/1NSUQ.FF!M M/JR6WC,!VNZ`8&T7K+!3==LRY,`JQ'G3894EUALOO!OBH5%KHTM69L4V5V2* M!!J!IL",S@$T>99QYX1F6USS#\IIG//V-[&(96G1] MX3!J'GZ9^F`XU"W'IC--HBA)%&4-+7W@4/`#490LBNHZ7?C'H@-ZT27J(.K8JOAV=<>1 M1!WDVVF5;V<]_%_[5=3.JU=Q:;H6W!"VI*9=-1C:>M>0>IA#]'3&].0X/;TW MI.P(HB2*-=I%&5S=MJ4>D1!HM(0W;T>UNGUP^Y/+9T%'0PT/5 M'E1D,3!<;1RF6%"XV2;2P#)UA0-1@0ES:JR=;/7(R<. M.7&HMH8,%M/J=#\"C4"K?T;G`!KY&EKE:[AFT2CK%[024;)HH:0OHTEX;,G: M`0KY)V1H_^>9HT]`$]`$=)N`)CN[57;VCJ`(;$XH:E-GIQ2K_07).%"UAL"@ MVY$4%:4`.F4(^#OYA*D`C,ZPTYYPD[.&45(,M0(VN7P8UZ2P^(J]7-?7,?]5 M;@?;U2D>XY9>C'YOO]WJAO8W;7N-$)$M@NWJLW(AV-0Y]N)$]%/V>==HT5-Z M"OI&(S*Y3VH)RQ&3,#>.LTC.=> MXOKP<03S]$;B'2&?XEA,:>TYSVV#7"$L?P,5:AZQ..O]OFCL#(N?JUO:NZ]S M%L1,=#G'AMBB._P8U;!;[+O.;\=YPA)H8S9.1[QW]B0*9P"2<->L-9C6O@]$ M&M'6;N9K/=9_T.9I%*8WC;THCIN]2LE ME-^G+-`">-AM&L,?1;MV;,[NW2_[H>N;;<2WH;R6+#9>NO>B91][\=0(B8FW MDM_>I1PN0:+%#N\S?L]6.?3-YY9[H'KR[/QF(@)%&%-!)V@Z(P%4]C`<='U'EXZ@8]:XOZ% M+_,"[$,OV"=?+A=8J@=R`_Z,K=&1R<)"K)4G-W$=MZMX#D3'@0H)_ MP+O#>R04&$#LSMCB?4"LP`P8/A>W30+_`)M!(DJ!@I%0?1P"/"MY8)RI)4LZ MY%J"&&S^MX[VBQNX=PP9%HP"^<*]QQ[RN6^;4F%]MJ\)ON:6^1Z\(EY90B%1 MO1DRLPC4F(YVI07I[!8F"O,"+64>QJ!R\$7UV9T7PQY#S@5?(W:79M^0"7K( M:\3C0&_B*DD\2KF*HSU,/=@O,%A_+-:5\]#)A.^F"1]P`L+6X[K0@@7G)5#A M+][L%@0R$SP+U3>7W-5RC&$`0,CQ$H&@.!(AN_)AP7#3`!DIKA_P7WA\ M@JKH`XPA$C,`7L"$HB3>*717OF:@[X)"BB3!E^H,.65UC/%*""DD7]P0Q;/, M-XA3GAD?IK?))/6U[/KX_#`XH;3ZP.V5Y'&.O,D7NB(H+7,T,3-%`L4%_#77 MUG!;@;3A_#5G98\+T83V'`H$9&0P`^_>&Z?(CCVQ97\+/)1+GQ/8V7&VS8$A MW45,2(\'#RQ2%RY%^W?.[5]NPR[LRYQYZ`O.@3RT8-5RAJX[<_\%#RT\$E[%9\"%.;PR6Q!N.,,B+$V`CO8! MY`^+N-@=`8>,!5=:KA:7H4%8F`H\\7!T4`.O/%]*7_Q547,$%0#8!1^`<.1OM)DW@4F=.C)S\LCE$L>9[?[%L MO=^Y0#OB*?&6Y\1<>QI[(%LBOL)A`//BE`@RU8V$@HX$JX-MEP"Z<;C^\ZZ! MY_,6OX`$`C6)*Q!@#J&DA!OC!/:+4!K#%+@CXQH%*E!QMK(%70(HSH?%S?2P MHMXD7I2/@>O]2)E\W(MEA^F+>?*-_#AG^2!A%3HK'/EI$Q35MV@L[)\H]V;L M5E0SK1%MUVQD]V*62#/"`'+CA4JRQ3CERR-V12)4W**'18R&,Y+%J)'AN)N* MY:K-)(;VC$VZT5&LS,PXWU"P$ M;A=&8NOGFPB>'(^?`#>AN,`)8P/A#\062;JBZ'0W;9, M'+?V4E\'>8#3AI%U%FZ+_`VH2P*)KT@M@$-X'#G=9?+-9PMVS27$DD.NRHJ% M?2TL;^0=2`KYYL9E8@'^!7#>(KSTC2EG%CSJ[UPST<9IP-T7H\<1#`HIG7M) M(E2ZD<&%Z=TTV\#(K&`)EJ2-4AL$05S83"MC**PE<)]@])B]_I;A&PO#ZF1^ MYR*/?1HU3@;LZXAE4@/N81$GN6^^FEUC^"KFEB:,<.)QZO>]F8?\+M?MM$_+ M'9-I];GU&4\9X[AE#C+\36P7?%!N#G+3JL`T1@5-DE712KXAF0]U-)3/YPC4!#0'D[0NGIZO970< ML];\\UJ7N@KR_/[;'RJ@2Z-C])M+EP=&DTED7E4&E!%SJX6Y[8MIL>K>*%70 MQ<=1$MYFJA]?+29M>PB1B)&%4A1HO$ MZW'B=3-K*).M+4XVWG(J_X)JU4OE'*BS0!5E@AH/*-_.LQ*-=55L=U^GO5P!Y9N.E)%!)%&6TACJ)ORVCG(LC&: M(TY:;%&()IZ+:D5D0ZC$95I3B[0W[.N.3=62B:!D%?^W#+W7D]3QJI6VD_C: M[G3_$V9BO,%P3[CF0S`*9TR[<;_"PY>QE/:KE32G10(=A@LG+&*Q"#*?L\#U M>10Q)GVR)/%%W#@&4+I?-=\3Z:$BS%CS>$XB?Q\/$<]R6,.@F`C!HWEY]*47 M8P+;(W.C6,.49!(+(^>&AXEDF`22YYJJ@@DP`4 M/22"&--\%OD/^!),[19U*[:_C1=0X"EX0#"IS\/XX3X1'QSEE1/P6R&EEK\T MY7F0(G4GE*4)Y M"KLK\A#SD8E5).J5/-8BO\M24+5_7%U=:W>I-^8QXED6#F;3\,2T-,@3JQ#W M>1AGF3@\6-W#U)$1)D*+-%+O?GM!@=_R="1,T4]]%B]_*N:_8AS^@@N+#"4D M<)ZQFR4ZN<&.$8D4(V^"8YHQEN>4A1&[Q+PE__$2-D)PB=DN(\S8`):J?<^3 MN7O=[WAJD^]-PW#\`R^VP./X(P8:R'\$\<-[V5=`)!#)SIBBY7[E4?-I,@TC MOM6V3CWG](+%LP"S8K8%[B##-Q?;)CF399B!)Q[+2YW,9JB=).'HKR7'=K/LN/Q7O!I$ M19I@ICW/AAJG(B]^P;&WTO!;S^>R"H:\'*68)?X)&#R,Z\AR@ M>8AYX4B;8WP&\(>UP0CIA*E%3PY+7V2K;KE=)+AGTFV1#LF^8OIJS$0R:X#9 M[EGZ4!^WD>A9CW`Q#=XBZ&AVV9S40LQ6(]"[-YX`N!R5RQ$*KS M-!I-L6+`"GVX659:1AVP<_YBF`2+Z85Y'FOQ^G)$DJ7T@C:1E9<0>8O+0A++ M$0OLLC37Y079W[-!^V"/+D8R"H-!8`B=Q$W92F]N_C,55XI!]E]G.VF+-4\8Q>XL1=HOAG9AW7@1C MR[Q!T"YTO((]L)HE7"A:E@U02'T<2U&OR$SP3-@`LT/;8>3&4VWBAS##[V$Q MLV@U[JX8<_8&VMK2"07B.KIC\0\Y9\@K`A1\7]J'R>K[5IZZ^584>CY6_$.K M+2NM$46/RSSEA2+$)X2%,8HKY(>+8H%Y4:Q)9H@MG1`K+I9E-;\)/`2=SZDH MI[3EO8MUW(K?K^'&2![<]?I<&\Z_IRU#F_^_Q0>$AB(Q-=F5E+`<5N)QQ?U- MB)5@+XM_&O$_%'508AH)(]5B+3,$;PBQ]XNE1K$;3]LR73U M($*4@A'<`SC.MP,+F;TX7+AGRX(L\'+F^V^_[A18_`EKE9:VRHN%+R%[Y/\G M6+3P.L!@L&8$?]A2N*+B"A)&6+6%JBTP=:(UR6/]O*R[\^Z>([FA.!7L!U[/ M&F!B*Q6-V'U&`E%>_$0H]+NU^0BK[L2I*(LS9A/NE`"RXXK4FZ(B->CU4'7J MM=$LS0]CQ6/AG3]>&/PQVN[0F^+AK5;\\O<7:7QYY[KSEQ^C.Q<4`KY^;P`P M#$WC7ZZ"\;78K_SKQ\G[')S/"VS>+@PXN/KSLDKDLB3@=5;7Z@:(]+4?CO[Z MZ;__2]/^OG@[,B^A@^?GI+QZY=?D$YO\>'$5?_DX^6)TOUC&%Y0I%[#O/?$3 M5IPS+K`<)4@O/_[QXM*Z^&EH&_UNMUN8W<;SCWF_O>_]1M?H]YX[@%]#(<>/ M7`/CB2$L7W'D*/:OA&T\;Q2H]WRT*YX2-;*D/8BYPQ,YSE#^CET@_C:?427 MJ8R];-K68',86]YR_%CV4_/0W+(DY<8"U+XH(9[W$Y!)U9=&W]H1]:1A;,*QH;`?2^:5CR!B:4+PK`G8;#]WY3XQ$"OLTJ<[\/H$\O/M#Y.WO!#JL_\C$JJL#*&J]MZ__OECO=`(C"[.%P) MX[T)KT;\+.)UUF^#Q;\R$#UOW'B:_3*6K!8XO:TC+S.2JN9PX.H;0[A(N4D< MN#]-JUO9'*YY+7YT064>?YD49/0<8P\)K;]?ZG`/W:H]H[M]KYYFN`>2A='K MF7OH8L]P@9D+@Y;S^VO09".6P&WXD-7EVE*#`BU]BRR]O)(;Z3]/X4WLWF_OA(V-:MH;: MM>\&[7.\J!,LR?LQXCB(3V3W2I%:.].#[% M<*]B-'B.)@;])69/'MU_GST>.'(9C,SR*X>!5@[O[5TKFHR1[@T?R( M+<[!/-XI`'6VK(C]JI\01X=3UT4-Y9G[U9NE,U$06\1*X14?\"`Q-C=?SAC#@'AQ:#YI M<3+#'YBX7R_'>4QW\9'QXD2&/Q075L?P"#=?&42CT%J*OY$O?S;;K3U6UE^_ M:SY9Y%CA'.E;4P?]@P]*'"5\:^A6;Y#_01P&P=^,;C__F[FVL/$R]IN'XHGS MW'&^>`NG(V+^L7"FBQ/(:#=:&V;6\F628@`,'E@LFVPM&@]LT&3K^%=%CN/G M2M4UV9PW"^`6`7"!CQ%'>OQ_>/9]S2(1SWJ((VE05"`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` MG((YV$D&A\?B*DQ,.TZ,"W11JMOU3,R13A)O[O6IE+% MZ3^3DSA.?Z`^MA(XB64:O8WN`!\D-XH\[$X@>A84.GTM M/Q5=3=C48"38^J(?6YQ$+B[()0Y%F[%D&HXU8!:B>1>+$X`?+T]C-DE]S??N M8=*B'YP&$F/.>#](S>4-(?6L9]D="UCD8CLPV)EW3)M$X4PSL<>8T>.MP.*M M8UVF1'L%CL6GZLY@>_-6#(NQ^=Z$Y2/Q\4XMC(HWYH.!22>/.9X&"S M$92P@9IEL=5+P3>\T."Z2(\NZ3T=,N$6!/N;;J1T> M]JUIZ:;=QYYW`]VQ>UFON[[>'9B+-GT<68W!?,?:ENJB>M8V;]$K#QO5Z`4Z M]A^)+"2/]6.@Q:[/-^>R<9TN>EDBTQ#M5A",G`S<@J=\A5[@$1D?R/IC1D@[ M,]CO8\%B^$-'(][>4.?/Q'Z+^7/O7(\_PTF;$L<=-XY@4>6P&+TA8X`8C)OCSLK=B3NH/4P9L.!BEV&:J%*V=V@VS M)HY+"G$EQ;?"&["ZH5$[(/I$G^@3?3KC3]0$J)KC0JI;WX@F':VKW4U-@(X, M1J.^&,1?Y/$7:DL@CSRI"1`Q.V)VJL0_UI_8USH&1TV`GCO'^M,"VTB,U`3H M2/%*284U,RQ%V!,E%380-$HJ5`LT6;RWQ4F%U`2H$A-'R30K:@)TE*6@)*;4 M!(@4;FH"5`T7KW-?4Q,@M6L#4A,@4JFI"9"B_$%I+9R:`+5/"ZW=9(&-0$BZX.:`%$3H(J/9L\":&H"U'R@R=J@)D#-]/-3 M$R#%'?W4!(AT[=TGK-0$J+6N'S4]S=0$J*'N(C7)B9H`D2E!\?H4KW^>H%&\ MOEJ@D?/;3N[&^\ M+/G/6`K\D,*STOLI_'3=^Z/$]);#/='\/F']]959_.)^]6;I;#%NHS$#]X*5 M@9M'COO>BV$@[\/H+;#F!*ZZRBI'/SU@8V7`YMZ6"=V>M=XQ8>>;98W17!GC MWEX3EC/<;.M0^2#7:T'O&>1E;SCH/7>0:32:PN;]>`L22=0./Z8-AMDU+6MM M+!MOV#>"MRG[$+SW)LGT#^9&1XUGT.];>T:S^K9R8PO32,+@3,.TC5*C6[RO MU/!^A0'=/##_GOT"HYL>U[7)L9SNL,P@U]]::JB?&8QM?/1*]LV>99<9Y/)] MI89W,_6BXT=G]8UU)K+G=:N#^]_4C1(6^8_O/:R@[[G^AV""RA#>J&1Y^:)? MP>Q8SW4K[-/:^(V;97WPXI=>`CKV2`SUGZ;UI_:992T-%LNI+=93>^LFKO;/ MWP(W'7MPS9]E%,!&J:LG+&D,3]ZH:;QJJNSQC&VUBJQ^IT<5C9^T&TUI*Z1$ MQ5%G7\51A\^7:J#)(\^;:<0*.9Y]X[\58XP?UH@J(SZ@?F)K+WY)D)0ZUX%`D3>61I/'",EY45..6 M*)(H\G"*M%]87:)(HDAU*-(A'DD4J11%&ETB22))I4BR(F(\*]-W,]SR>79O M(:BR8Y0,J^07-C?<71[34HM%M3IRFD`CT.J?$8%&H!%H!)IJ"FMSU%-%P\#+ M**68V?.)W;,@9544=#%57I]J;&HE4Q^,@:&;CJ0T;`)5#5#-KJ%;?4F%G@E4 M14`U3;W;LPC4=H'JZ+VAI*(J!*H:H`XL4S=E=;LR]DRT&:#6Y.\]O=K\CRB, M8^TZ"B=>%776VVKYUKE='>QW))4%$SY2V>E`[\G*SB9\*C`ANZ9NVU(54P)( M+D!]?2#7DK^5(HT(-`)-C1D1:`0:@4:@R0&-O+K**.5EU-03 MI'0INCHG-D-;O>D):`*:@":@"6@"FH!6$VCR'\NHQV`^B?L)FUR]=F-O1([D M1H1-=3N&U(,]0D0J)E^FQ]Z?)?]PT]"*.9ZS]OY,>X>A>CGQ>_%<@B)\_N M=PNRX!/51LSW,[!^O.A>\._QW!WEW[/[;\-HS")$V7?G,7N9?W@E'@QFA:!\ ML2Z72']KV.\Q@;:2V>D=\(,#S1A^ZX-XU6WHCPO/&N2C;8A[OL!N1F`"LNB$ M3!7("8@.)NEZ"O*\F4:,+2'[!:Z8+K^^"\85YNDVG6YK<,K5 M3S!7Z=C;EKQ]&VDO\L_'ON.]%X]<7_N#N5$%Q"?/E5@'\1WH7"3)2AQJC[E" MTE0:21HO+..%V34LHDBB2"4HTGYA=8DBB2+5H4B'>"11I%(4:72))(DDE2+) MBHCQK$Q?Z=67E8J>:8CUJQ:+:G6('(%&H-4_(P*-0"/0"#35%-;FJ*>*QM64 M44JQ[?0G=L^"E,65J:6*KL\9Q9(9?4,W>U1KM%V@.GW=[E&MAW:!.NCIMDDA M]^T"=6CJID'QV:T"U3%ZND4!V@KX>T^O-O\C"N-8NX["B9>0-[?T1JYUNW;U MH=S"6(2/3'P&7;WO4',P=?'IZ?V^U`*0A(]D?,P!\3=E\;%,4^]9U%_O7+VL M'X)1.&/D8VVM/3@`^4C]N5H%J6'HED4E3=J%J:T[7>IUV2Y,#=TPJ3A]JS"U M>_K`)._J.7I7E^JR=LVBE2IS+\G;2G%&!!J!IL:,"#0"C4`CT.2`1EY=993R M,FKJ"1*Z%%V=$YNAK=[T!#0!34`3T`0T`4U`JPDT^8]E5&,PG\2]4(MA7G$E M!MZZFAS)C0B;ZG8LJ8>UA(Y<=&Q"1V%T>A:AHRXZ-H53*XN.T9$5S$=>71F- M\)11'K.^=N3RK=2<;)/*28C6CZA<-940K1]1N:HM(5H_HG+584*T;D1EJ]!- M1[0F_VLK`R.:@3A%-A%H!!J!1J`1:`1:RT`COZX,OZY2+1I^YP-@8^WJGD7N M'5M)/8NUCVD2)VZ`\]3XVG_SU>P:]BN-!Q1H__0"+9F&:0R7Q'^2@[BUAJWI MZ(Y!Q73;AFE_2*4>6H>I0_61VXZBB^U+&:8/,1G9-$.#?(\M0W3@4,]G%J'J4W[M'V8 MVH1IVS#MD8=XMYHNOKJW/EM?NOS7?4,/PFCF^L\;^3&NWL7HY\5O!;+(R;/[ MW8(L^$2U$?/]#*P?+[H7_'L\=T?Y]^S^VS`:LPA1]MUYS%[F'UZ)!X-9(2A? MK,LETM\:]GM,H*UD=GH'_.!`,X;?^B!>=1OZX\*S!OEH&^*>+[";$9B`+#HA M4P5R`J*#21K&Q=,3MATA300]@N'\$JQ4X(L!T[YY.\3_:OF/G`AW_BJ>SG^/ M0]\;:]]T^7\6%T1B=3;NKW6MJZ#/FVG$V!*S7^"*Z?+KNV!<8:)N:PC7W$.W MU7CHZB>>JW3L;L@Q`/]#22F"5N M59Y;D9251Y[&"\MX878-DZB3J%,YZK1?6%VB3J).-:G3(=Y)U*DL=1I=(D\B M3V7)LR+"/"NS67H99Z7"?V#T+4A97IM(JNC[2*=]2=ZYE:.';"@A@T'&4C?(SK('N#*FN+U%Z MZRF]9^BV391.E-YZ2N]W]9Y%*19$Z>VG=$NW!U2:B"B][93>-VS=[%%M__H/ MY4Y/Z_^(PCC6KJ-PXB65^2>:@?DAW$UY7*OC8;5RJJYN&%*K>A)I$FG*(4T' M["*I:M^06J2B&;0I MR_95U`=0AJ+QU/Y#,`IGK#*;6-'5(5_@>?L"'=V2U>63Z%R1N1*=;]+Y4+>Z MU/*'Z+SM=&Z8>F](A$Z$?@:$/AA0.5<=7'UV[LC3>L97R"['V,4WB MQ`UPGAI?^V^^FEW#?J7QX%;MGUZ@)=,PC>&2^,_*U.:FFU#/929J&LBFHP\& M4ML5$+Z*X=L?D$.[U?@."=\VX^MT"=]6XVM+#:=K.K[DHB;SG,QS`I``)``) M0`*0`#Q;`,E%?>-_!@7\V+T\Y71YM,0 MCX5W_GAA\,=HNU7NXK2UXI>_OTCCRSO7G;_\W]2-$A;YC^^]P`U&GNM_""8X M\\0+@QN@VM=^./KKI__^+TW[>W[/)^:[H/E?PYV/-Y$;Q.X(KX[?>O'(#^,T M8HL;8;L%2/N?V.3'B[=IQ!_[Q3"^&%_,KF%]N0F_&-TO%O]F7_R4;8#%>`N; M0:!TB;N!0Y5]Y[MIE31W@5L)DOS&!T$QMZ$_SIZ$%[_T$MAW(S&P?SI_:MFZ M:7SAM.+*E2$`J>0Z.'B._+Y!OLZ'T>ZIP.!7WDQ9Q+0'_+\@U("06014K479 MXL_YXB>%Q=?&:80F[03(%RY$2M3`EBU\MSHG!ZBI_.0`WK#.5.;NXXP%2?QQ M\G,8W-VP:/;&G>,>^IFY,?MX"S+,%8`]R52,%:8"4CX-/''I;_#!N-#&;.0! M$O&/%Y?6Q4^68W3A/\49E!Y(13,P5V9@[9N!W;<'BLU@G;'OF4'?[%:(P5MV MFT@E&<-T]@\7WRIC;(<3P\F&=B#*]O!Y0TM<8''C=VX4`)>.KT:C=)9R)O.6 M3;R1MSK(J_C+Q\D!ZV5:!AC":^/:]T:9(]R[;*8SZ-O](T=XSX*4?6*C\`Y> M`1A>AZ"9/)Z/FL:OA&4"^R;ALCZ,M&Q5VB?:MXRV>)9@]2M=Y<\LNO=&#!0N MOKRQYH(F-@<-:^3-7=]_U.Y8P"*NBTVB<*;Y[FT(7\,(M#(6,)JRF8?JV-AS[X(0KAOQRV,M3D=3S8VU6S\,QZ"XN?YC[,6ZADH=6WSG M&AV^.;\1'^K.@.UH80(:8]S1M@X\$GOF/S!:-]'@2BV!U1(?UD?+)\HB-)_P M,(\C)+%_5ZDX7TSO@`P'/@=K(3_H*6*XP'ZC%NH;2I&DK<,0$*J#.^] M&%@=YP>W[AA8[VTB@!PS,!QFR&6U-/$`(83Z+@KC.`=\^3B$,9QP)AJ!OIL" MF;KC?Z5QPJ4;IP08UR@#=[EPBT_OX$'\$.UNJH&X`')%`HM8/`<-Q[N%UX/- M`F_`O\Z!.<-CM22$CX]\Y(4ME(\-[O%A$\Q@I\!2`(/VQC`LW%'\(2AI8&:? M$R##6)NZ][A3-/O;)&VOP MJPMK,)NQ"/T(\"I0]]U@E*WSF$7YF($-B*MQ9^#RBZG!UIC"9DBF^&"-?9VS M(&;;%PR,/##M_A5&V<(L]F#VJK%V^ZB]_O3S!XXE?RU?-=1;[\$T!%`#'-"V M*>8P;GWQAT`;L0C%KS8"1126&)=SN<*PEC':G.CW.6+S*?!!`":` M,4_#F"O3\!%?.H*MXHWB'[2'J0<71\R;W:91S,0*CCU@@HG_N&L]!*G.7(^/ M*Z/2;''X`[P"+)QQ%I8,H+/%;LD)--9\[R\Q[>W[U(7E$0^.MSPZ!II\A/6:3&!@B'<8 M@+SC>REB=RY<#&"AZ(.5N4T3V`=QN/[SKKGD2X&_B.%RL1AF)_7?+T##JW[@ MDXSGH$A.!Z$$A>/,6-!$C"Y@98<+D\QD/ M\\`PRMC1S`6\\QW-1_O`,HTEG*-?%)E5^)#KC$A1:3`*?1^V!)?9!1:&[Q82 M(J-J="UQ[L-W1!GI(&:%P\"'Y8I"G.TO``#$0>+=\X?>NY&'/"2CEJD;W,%G M)"><(-PNU@N=^O/=7'1E6#A5SI8*2XC;=^8"TPK%5A=KR&D@!I'#E;+EC9RZ M%TN%0PS3>`EX<4C;H,GD#L@A]-MIPK$*XIH+7X]+2;&:7+`!7^*2D%/!*]R/ ML2!%@`!5/K[*11+.;LC7RLN(S'\4>RGCJ`NU0*QL//4FR4)RYEJ?&-."*^]8 M7QC%VE+"U.%^AH2%JNE_"J)J?8'74<%)Q:FX(>,W@EQ8?FEN4`O`8*D66@RP M=B"J`MWIF@=O"!YU3NT!8^.=DX`G<5*_93`06([P0>@G12K.7[A#0T(A%45( MN#`*H?6*7X3\%(KO4E4.!0''J)YPKH>[:\Z$75J#?NP\SUWN/,M=7K"F\Y/( M[G>+$T`!Q8CY?G8N]^-%]X)_C^?N*/^>W7_+^1P>Z/GN/&8O\P^OQ(.U@<7/ M_M:-]M6Y/A$HM_5`T>YW^J>-#!P<&.RVX]"FS`F'G)`VJXKP4&1M+*KC*+VW MYRC='G;,NN=;!8U\_^T/%1"'4?]BG2[45B('*<34EHRH+>]T(`[3"`Z3R;LD MG+\T@!""$!2?;]X.\;]:_B.7A[XVU;_C15'=Q@?!D;][?.N;V M!W.C@J$(NV:\_/IQE(2WK/"[9>C$"HD5$BNL)1G'L#LVL3^I)(DGG42,1(RJ M$*-%Q$C$J`HQFJ3K':?K;6:89HI>%1FFTE7`YV67_H.[AO.S^"SZ)JZ,K34] MH>$@]J9DDHJM&X.>WI75D)!@50-62^^9`&U74OH@P:H*K+!3==N2EE5FM@!6 M66*]\<*[(1X:M39ZJ^N_$&@$6OTS.@?0Y%G&S1&8+;:#WQ0B[J[6`@'?YH&` M+\DNKE33;C7#(*`):`*Z34"3-=TJ:SK/GGJQ2)ZZ%FD$9%R7Y@2U^LJ&AM[O M#64Z0`D@J0#U;+UO2?50$T!2`3*[>G_HR/0U-P,@,I#W2LIE7?.,I[^172Q#BZXO'$;-PR]3'PR'NN78=*9)%"6)HJRAI0\<"GX@BI)% M45VG"_]8=$!/+H7-LI=AXOI:J;,%767>A67IFO!#6%+:MI5@Z&M M=PVIASE$3V=,3X[3TWM#RHX@>I)#3_V^H<,_Y/4AK\^&.G6=%0->4ZNTZY7* MQJ]=4**PLO'?JCL^:P;A-(01U5&0Q,%QM'*984+C9)M+`,G5S0*$61%"R?#A&3[=Z M%`U&!"7-JK)UL]G%*O]!J&]C=M>XT0D2V"[>JS.OMQ`NPZS._08?WC/PT:ZX^F[%HY+E^WB_> M"^(T8EG?97<\\P*X.W(3WHHYUAX8C,KE/:@G+$9-P_5]T>,>WN2.,K]#G(ZF M_++I8^S!XP-XZS2,YU[B^O!Q!//T1N(=(9_B6$QI[3G/;8-<(2Q_`Q5J'K$X MZ_V^:.P,BY^K6]J[KW,6Q$QT.<>&V*([_!C5L%OLN\YOQWG"$FAC-DY'O'?V M)`IG`))PUZPUF-:^#T0:T=9NYFL]UG_0YFD4IRYV#@^UJ\^_:;^&A<[79M

-O2B.F[U*R64WZAO)8L M-EZZ]Z)E'WOQU`B)B;>2W]ZE'"Y!HL4.[S-^SU9RZFC8$OW`R&OL;;Y]8]S" M)6/<&"S;&/CO42(V1#@:I1&V0]]%^**U?3K/.J;CO1%<"*,LT,-*+_>(S5Q@ M,-C"?OW-7KRZ_>;`5`NMU^&6[,IXY],WGEGN@>O+L_&8B`D484T$G:#HC`53 MV,!QT?4>7CJ!CUKB_H4O\P+L0R_8)U\N%UBJ!W(#_HRMT9')PD)R_AQMLP7/ M@@]4M^UQ5R-\X5T`CQ@7-@(P`%SWVQB$`9(Y4G$XCOD>VF#G+Y9['(#;NI=? M+2EHYCYJ4_<>:(H!TQ'L`MX=WB-=P`!B=\86[P/:A+W/\+FX2Q+X![@*TDP* M!(MTZ>,0X%G)`^,\+%F2'5<*Q&#SOW6T7]S`O6/(GV`4R`;N/?:0SWW;E`KK MLWU-\#6WS/?@%?'*$@H!ZLV0=T6@M72T*RU(9[!VH2UT#B4YMR+4I#V8&/P``49@] M8(2J6SQU(_S"AQ:P"6I/>'$'F"SP":ZU<5Z(8PKA/.YO!SMCA+7@QZ M3`SVC@?C1:UCS$81_OTCCRSO7G;_,9.TGL5-P<->A[XT> M;V#XK_UP]-=/__U?FO;W_/+/+HB*[)Y,7,?"X<=A_II\8I,?+][B#H='?3&, M+\87U`*_W(1?C.X7BW\S+V#Q/''I;_#!N$`<04_PXQ\O+JV+GZQNS[0MH]OM M+@>Z\\U2!FBN#-#:.T`8G]$=G'"`ULH`[7T#M(U!#Q91U@`Q[KP$P&7Q-:R! M,[3V#@[>*FUHI6FO;]AFKU?QV,P"U=E?K&ZY5>L9MEWUJO4*(W-*X]GO]JS] MQ';$ M&T'D=J`O(?LNMA#`J"-@LW*/; M_6X1@,&C"+01\_TL9.+'B^X%_Q[/W5'^/;L_2Y[$TPYW'K.7^8=7XL%:3\30 M%.6X8?970C#VQ`]NC>FP!QWGM#$=@P-#.OBM#^)5MZ$_+CQKL.=H14Z$H"UM MA0J1/9@,P:(3Q@P"/0'5P23!O'N:(F"^9LWSK8)&OO_VAPJ(P^@,^LTEC@,C MD(F#$`Q-)-&G2<3X7&(D`2R;&"V2N!5)7$43.>GXEU6_EJ9D*;>.:,UD-4^_+9<`MP\>L&9^NWAM(ZX8]S$E+;H:6;%FZ M;4LJW--*?&K6DDWL0BG)BB$M61FI48:/_LSB^*5V-1JELZSXQ5LLKS#R>&`_ M:<[-/H%5U,/IZ/V>I`9@9T9.]9ZA*DI.EFZ8TMJED!70("N@(3%""C&0MC=I M:"5H\H/?U0*-;`9E9$P9KOLKHY@2I0R#UK2^,WJZ,Y1T7'=F]"33,F@//9FZ MW9=6:KJ%IH'XVJ+:TODTQ&.EE9$[I$3&SN(:X6P.>R9(XH^3#\$HG+$;]VM6 MXO@U+U&84*V-D]9/K7JT)TS&=C:3L1WSZ%QL:]BQ)!D?-4;*5^HEL#I6@^/E M\SDN,BE[>S(I>[U.OXVYV-]60!I&_6GK-6=B$_\@_K&5?U`BF#SR/%4F-C$S M8F9GP;I_5YU1`#$P>25:45DW$2,2H3%KU>1"C:1,Q2B9&DW2YXW2YS1/8 MYRERZC4I;H@JIPY[DJ6^*QM(0:`1:/7/*%,$6@V:/!':'($I[>Q;/5'Z)HTB M?%=E@K3I<0,'F:/GF4%*0!/0+02:V_3G";00\DT'FNSE3,B_9V,6N3X9RZ49 M?)VQFV9/=RR34%$+%6N@F\,>H;(I(^O>*T.;[%FR9S-1]SEQ$U984?R$_V@_ MAZ,*)6#3524YQD^=G,#1G6Z7@&P^D(:M=XT!(2G'3*T5R:YN=BVR0\D.I7-; M.@(DT`@T=4&C4X+8D2&1"\KW1U0?'^2`%+">'H@Q[^$$^8U#@3/=[4S<&$MS&+8", M#.%R![Z:&XSIA+<-:;6*GF0Y0Z(@HJ!CA%I?-ZU*3[5;(.X.,O")PM957=WN M20B%:S6%D6>!CN+I5)=`(]#4!8V.XA4"C3P0>T4I[\BI74?AO1=[8:!-PD@3 M9:ZU&_=K)1WMR:"D$O^6K9M=-)?U!1:GGDN:7?B$[1JW(AOD[&L3G!'0W(@X3Z"-$TR^.0+BN6+`5$4,O';' MVEMVFVA7OA\^N,&(D9+>B)QXJZ_W;7,Y+\)GDT77BL]0-YV>''Q(]9:A>BO# M<]^R><1&'H]/XCGO[BR,$N\__`^DA%>JA-?*$O1N=RB38Y\+I$]KG'5":N@# M0RJ3;SJDI%AG3/YJ-(I2-M:RL->*\H=:I[;5?%9@";G/=D8,J-K%.'^FV>XVB4\/R%;HQ&YY'6J ME+:%=<;(VCB)M=$TVK!UTR)[@^P-LC?(WB![@^P-LC?(WL"+WZ1@;<`U9'<< MS?EKU>^Z>M?NDNZO:NB0;>J&+-N,].]6Z=\_A\&==L.BV>EY<-.E>$-.H-6, M<[%TVY#J+3H7:JKYU%I-:C+UKN-0U!19&)0K+$-:M=J%T$;0*%=8(=#(ZGC. M.3-?WV^^8BF:5V1VJ&9VM*8DM?QCZG.AI[H/L!6E)^E'VTVGIS7Q)[Y2L?/R MQ^W&W@@>]-;STP2??7Z%SF^F#"8ZFZ>) M2)0,)]HMK@K/F!R+==$"4$58MG;:G$5XQPPNCG$1-2_6W%B;A)C:'FO_]`(M MF89I#`^(=8U]'3'@6GB3N'KL)J[&=S(;__FR#&TU:B>[1 ML;>7$S4Z@RZ5$WU:PS$DK9`2Q9%[>XHCVU;'D=0W3ZF2BM445Y?58K`!]10E M\H\JC7'B+XW@+U0M5AYYO@\+A=?_`,TM7GY]AXK7\NO)ZK038R3&2(QQKTO) M[-C$#*629&5UW(D8B1@5J>-^'L38IQX]LHG1)%WO.%UORT&UDD%"LAB6 M.NS)ED_U:L6;$&@$6OTSRA2!5H,F3X0V1V"V.+)+=.?6KNY=S^ MF/:?C!"L%5-,"NW+BERSGJ3=9F!*]G`FQ'_GKV=C$.,LYU[W71TQY"4($?X5()/?R@IBKB-^*`4K7O_R.J-0P9OJPS> M$_B.FZY7R;%_6NT%(Z`)Z!8"_;3UVVJ@R21NBTG,7S5FHU#D1;W$?)YHJ0"\ MFTS8*,%L(IY;Y=TS[3,;I1%/UJJF!7+[%'PZFR30"#0Z4*8#9;*OUWS1;A2Y M01*_^#A'Z4LGQ^T]930L.C9N%Z!]J3[MWN_$[CBG[;7-EFLNL-R6L?@*NMJ0\1(Q*A,5YNS($92 M_6038Q5=;0>5Y:7M3)'/H=0ZI<:!D3:`J,AM$QNX2C%"E> M)XZ#SD!21RL%C'5U97*+K?IK%L%SX&W:V)M,6,2"$;P`I??'9,HBLNR;??:L MIHG1[0QMLBZK=BL0U:U2W?=FQY&6`]1PLONA0J\&T=T:W74[MB1VUWB?RH%T M1TX5BF.@(W$"C4!3*8U`'-/)X[!6E5Z,D=7V*6U#.SH3A:N,PQ8S.9BO\ MMMGI2BL$I3`YM<2_T1ZZ`VJ15D2:Z*YJ_T:KZ,XB!\?Q!U3B*]48.:#&R,'E M0;87&@DG[[W`2]C/\*CQAR!Q@SL/[KJ*8Y;$[],DC=C5+(P2[S_\D>^^SED0 MLW,L/'(S91J+$V_F8ML5M[`H&A.KHD7,YS\F(=R9+Z7F\K74)F&D,7\BFEV>I7K$,HZJXS.H`6@'^W&RMA+DYD(OQC$6J\RUM`, M6BA+]U;=3MHR>'XK'TP38SEK#B>5U[U*\*]F4*8L+M5.)2CG7WU2;4ZFVM3+ M!'JVI)AR4F+:IL0XI,0\:ZO7NZ&[?4EN79+J;9/J`Y+J9R'5AW:?9#K)]&TL M8$@RO7$R?=B5%(E.$KU5$OUF<\5FLFH#4ZDNV=;LKU9FL*.%1 M>\%LM/DT*@K]E1&PNZOGX!-//L>(W\-P;Q:5/J$H]>RJ5I7?6&QK\8QX46VC M(U`;\#AA4/.@NQ'4S!$O'=.\53A9H`"T"1N(^W%JI&H*FG*T^D:T`ON*;6VX7T+:]P62S_"$CCN42!. M>H2"W7!Z5(IQ%[UE2[2N6>2%).YEB7LB6'D$^R:,B7L28:I'F"NU&KV2NG5A@E`4@` M$H#U1FV>.$9``76HQ8',;](80&:1]K,7)W%EBE+3`QX/JGC;LR2',EH[T'NF-)Z[1&=*[$7(G.-^G,\"-TC@H6%RF827;\+9G%746:EY;H\& MNHO+H&X1O,_R:M7)PPU#-RQ#IK)"6%4G;R7;3P15=5!90ZFJ43.@(K?P7B%Y M[28,%2/L8?.S-\+T8W(.DW-XC4HJJ8S<+IIH4*B8JN:[.73(346454&)<*8_4191UHIKO6=+XEGDGS)4P5PY0*SA.14,%YY0YC M&U!!D0K.4\%Y%3@I%9RG@O/*$VF#XLI;1[!4<)X(4TG"I(+S1*#G3*!G92Y1 M8D_-3$PMBZ350>E-!(VR"@A``I``5`1`RNMI55X/U9H_W_R>,O1!M>:/YI=4 MF[A1M8FIUCS1^3G0N:D/'*)SHO.VTWE/'_0EE11K97K$^?J'J=:\:MYBJC6O MKE>K3AY.M>:;@Y6M]V3)6X*J6JCZ>L^1M*O(+=PJMS#5FB?G\'XJH5KSTL4! MU6W>,-^IUCQ15C6UYNTN.4")LJJH-3\8#,GE2"Y'"DEMH9.1(N(H(HX`)``) M0%4`).=CJYR/5&O^_-R-5&O^".Y'E6I5C(92$I!:(PZIUCQM<-K@[=W@`WU@ MT_ZF_4W[NYW[V^CKEDFQU.J4FC]I:?-Y/B?Q$GC0CQ<&?XRV>P\6UT`K?OG[ MBS2^O'/=^];'I`F:<1^@OS/Z\]3QO!V.'+ M)S;Y\>)M*BK:?S&,+\87+%G_Y2;\8G2_6/R;??%3MF,6,-)4:EZE-]_^T,%M*A` M@X4Z#[K[2KL(RE@U8"WV*N-1BJY+-;Q*27=87^^;DAHOFB0FK2(_D:2O&M+7UHV!I,-FDKY-D[X# MDKZ-D+ZF;O4EY5B2]%6&)97R=XSE+TW4Q8Q=Y*PB"1P(R2P MI/I.)'V584IEMNG:8I$,KDH&MSJODF1SLV0SYDV26&[""7BM&L%0MPV3U`)2 M"T@M(+6`U(*VJP4_LSC6/F#4#XN3EZ0?-,-LU[L6R6B2T22C24:3C#ZQC"Z4 M1.H8)8LB\0LK90S7(+_A;=K_N7[*M'"B97F.&L]HU/),1Q+PIW<`/"/#NU;E M8J!;`TEYW`W6+L37TV5K5YZRFT]#/+:*!.UGYE>7RM?^!,]Q_<(#/\X99F(' M=Y2R70Y_2MFF3_2)/M$G^E3E)\52MBUG2\KVL'-\TK;9[PS,QF?*EE0!&IVT M[30X4;8<*0[J/K)N7=+V=12"@9$\5I.\?0XTZ1!-2J;)=_].O3G:OU55%.A+ M.K%L9$6!3)ZWPAN\MFRJ,B]56)40GZT^\FD?:$[[09/'D9O#?ZMH77(89SYQ MG]S*ZL`X+3CC/S3QIH?Y-5V&R]&^6\T8S@EHTLH;#W33M/)J=7"LZAE74[>K;3I>[4E2 MM>K^ICZT)(6MM8\T:L]5JM6]9T@K`]]8"T-\I6HOSZSV MXK'XX^3G,+B[8='L+;M-SK&V"Q50H4_TB3[1I[/[5*:`BEQM9'"(>%K>MTA, M+\QB_]!/6/NE9VW6?C'[AU1^V?0>.-W.4&:57.7\"OS>8B4"?O[+%%3U&<5UD7I=$9M`#THUV4&9-Y/BLI MR4BJ=D]6E-LL6$,S:.&Y#*!.CU#/E)2Q++9S,X"2M6FKT`S4VAI+QVDNAMD^A5Y-&11%=/HAOZ<"@ICX-D M>MMD>A7I6^<@T]5RQI4!FZ_)-U_Q<+R*J&'2#UJE'U2:XW/F6D)]T69-.5Q0 MAI\UG49)U5F)ER9EIQ3EV_UZNR`JWXWW6_F$9!J=KGV^S2/)&_-DJ']JCAVUO3]P_=5/=*GK9[,!,CNI2B6_FY.V5%@:EL\>@M)VZ M#A646FC?H*Y2L=>LH4H;B/MQ:KV M\_QWO/?BD>MK&(I;B:>C=F!.Y^$@R4H*QN"644I_98GVB=VS(&55 MQ)Z>HF*,(I2?V]1J9M@-#-UTNG+"%PE4-4`UNX9N]24E3A*HBH!JFGJW)ZWA M+(&J!JB.WAM*JEQ$H*H!ZL`R=7,@K7A%]=T_FJ-0*Z\V_R,*XUB[CL*)EY`W MM_1&KG.[.J9N]*2R8,)'*CL=Z#U;4H(5X5.!"=DU==N6JI@20'(!ZNL#N98# M`20U@[0_U(=#:3FDY&=51#TNZV?]$(S"&2,O:VLM0E,?RM4P"=*Z(36ZNNF0 M-ZY=F/9TLT=G(>W"=*";`VG-`@E3%3"U^[K3&Y!_]0S]JTMU6;MFD?8FG,W" M0/L\=2-614?AMEJ[K8XT(M`(M/IG1*`1:`0:@28'-/+J*J.4EU%33Y#2I>CJ MG-@,;?6F)Z`):`*:@":@"6@"6DV@R7\LHQZ#^23N)VRV\-J-O1$YDAL1-M7M M&%(/]@@=N>A8DMKQ$CI5H-/K$3KJHB,W>Y/0D1I2TI'7[X6\NL=W'E1&>7SK M^>FV@NID3LHT)]NDI\;7_YBLV_GBE\8`"[9]>H"73,(WADOA/0J/M95?*EE,B=9CVR$/<.DS[5+2[?9A*;25# MF*J`J:R`_U9ZB,57]]9GZTN7_[IOZ$$8S5S_>2,_QM6[&/V\^*U`%CEY=K]; MD`6?J#9BOI^!]>-%]X)_C^?N*/^>W7\;1F,6(-8@'VU#W/,%=C,"$Y!%)V2J M0$Y`=#!)Y^+I^=J.$":"',%N?@E&*K#%@&G?O!WB?[7\1TZ#.W\53^>_QZ'O MC;5ONOP_BPLBL3@;]]>ZU%60Y\TT8FP)V2]PQ73Y]5TPKC!/M^ET6X-3KGZ" MN4K'WK;D[=M(>Y%_/O8=[[UXY/K:'\R-*B`^>:[$.HCO0.&$9+\RN81%%$D4J09'V"ZM+%$D4J0Y%.L0CB2*5HDBC2R1))*D4259$ MC&=E^DJOOJQ4]$Q#K%^U6%2K0^0(-`*M_AD1:`0:@4:@J::P-D<]532NIHQ2 MBFVG/[%[%J0LKDPM571]SBB6S.@;NMFC6J/M`M7IZW:/:CVT"]1!3[=-"KEO M%ZA#4S<-BL]N%:B.T=,M"M!6P-][>K7Y'U$8Q]IU%$Z\A+RYI3=RK=NUJP_E M%L8B?&3B,^CJ?8>:@ZF+3T_O]Z46@"1\).-C#HB_*8N/99IZSZ+^>N?J9?T0 MC,(9(Q]K:^W!`E2K\MV86KHADG%Z5N%J=W3 M!R9Y5\_1N[I4E[5K%JU4F7M)WE:*,R+0"#0U9D2@$6@$&H$F!S3RZBJCE)=1 M4T^0T*7HZIS8#&WUIB>@"6@"FH`FH`EH`EI-H,E_+*,:@_DD[H5:#/.**S'P MUM7D2&Y$V%2W8TD]K"5TY*)C$SH*H].S"!UUT;$IG%I9=(R.K&`^\NK*:(2G MC/*8];4CEV^EYF2;5$Y"M'Y$Y:JIA&C]B,I5;0G1^A&5JPX3HG4C*EN%;CJB M-?E?6QD8T0S$*;*)0"/0"#0"C4`CT%H&&OEU9?AUE6K1\#L?`!MK5_A!&,]=_WLB/W>\6 M9,$GJHV8[V=@_7C1O>#?X[D[RK]G]]^&T9A%B++OSF/V,O_P2CP8S`I!^6)= M+I'^UK#?8P)M);/3.^`'!YHQ_-8'\:K;T!\7GC7(1]L0]WR!W8S`!&31"9DJ MD!,0'4S2,"Z>GK#M"&DBZ!$,YY=@I0)?#)CVS=LA_E?+?^1$N/-7\73^>QSZ MWEC[ILO_L[@@$JNS<7^M:UT%?=Y,(\:6F/T"5TR77]\%XPH3=5M#N.8>NJW& M0U<_\5RE8V];)O=MI+W(/Q_[CO=>/')][0_F1A40HCR_8AV$>*"GD<0L<:OR MW(JDK#SR-%Y8Q@NS:YA$G42=RE&G_<+J$G42=:I)G0[Q3J).9:G3Z!)Y$GDJ M2YX5$>99FEK_1Q3&L78=A1,OJZU:66 M/T3G;:=SP]1[0R)T(O0S(/3!@,JY$J&WG=!M4S=ZDC@Z'=8WZK!^Z9;0KEFT M4J+^966.BF;00#XCRA4B``E``I``)``)0`*03M[44>C+J+AKBT4G;_*V>;7S M5I8!$.@$.H%.H!/H!#J!W@[0R6\MH_*C^23NA;J/\XJK/KYV8V]$#FR*"%8[ M(KC;,:5&4A!A$F%*(DS*/"/"5)(P;:G!Q$281)BR"%-J91FI&N\JVN16%GLC\W,GE++XR@*O>KG^:T,TFT&XL\-VVEU M<`X!2``2@`0@`4@`GBN`=/@FX_!-J=;DO_,!L+%V=<\B]XZME%^(M8]I$B=N M@//4^-I_\]7L&O8KC0>W:O_T`BV9AFD,E\1_5J8V-]V$>BXS4=-`-AU],)#: MKH#P50S?_H`=DGA.`!"`!2``2 M@`3@V0)(+NIS=E%?:EE""7FFS](R'NA=6VK?/<)7*7P=?>#0R4.K\:63I5;C M.Z3^5.W&UZ3@Z=TJOOCJWOIL?>GR7_<-/0BCF>L_;^3'N)@7HY^OC#:?AG@L MO//'"X,_1MNMGK16__/U%&E_>N>[\Y>?1E(U3GWV<_&_J1@F+_,?W7N`& M(\_U/P037(/$"X,;7,D;(.+7?CCZZZ?__B]-^_OF([B=\-J-V1@,ASD+8GZO ML!ZN4C`2(ACW^#S*XC;\0^N<'=\GVP M:0/<09_8Y,>+MVG$'_O%,+X87\RN87VY";\8W2\6_V9?_)1MH\6L"UM*8'V) M>XH#GGWG>W*5P'>1B"KTT"CJ+2"0,]?N=PNFQK>I-F*^G[&:'R^Z%_P[<.I1 M_CV[_S:,@'R01_GN/&8O\P^OQ(.U@<7961'HGKW"N788_PO!,-PC&"RG,SRB M:J(AOR+$X$!CG]_Z(-Y^&_KCPK,&^6PJ/@`;V-+=8R-8.!;5H4KT]E&,Q2DF M(]TDG+\T@!"",&#:-V^'^%\M_Y$3[,Y?Q=/Y[W'H>V/MFR[_S^("P<@V[Z]U MJ:L@S]Q5M40M\UE50JVV?&=N?=1J[:%6T^@,B%JE4FNFVW!U5#Y]&AVCWUSZ M+.F;)_%,XEGF\=60)T:WCM,(8XN$(-'$DB8^L9GK!3`E(@LBBPVEA#1FH@H2 M($03]7`*LEVVV"X--[U5H-0%A/PX8?F5'RR0R70$=VLX<2K%6`L1=21QB2:5 MH,F?O0F9!$2,:A"CD-Y$C42-*E`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`)7Y.PM%?'^?X M^[7O!O'KQ[RS%Z]WS[MXW0"YO_;ANI_^^[\T[>^EW[=\='PU2KQ[+WF\01@7 MS]-&,%7X\HE-?KQXFT;\MB^&\<7X8G8-Z\M-^,7H?K'X-_M+]MXO.,Y?W1F[ M^NK%7VXCW_OR;C;WPT?&/@08BN/=L[59F2`#?F&S6Q9=_)2QW\4Z%EBQH!XA M9)"$LN]":*QLF5U$IPJ%G7`_K,C>2_['E_R\954J7V8V/XQDP4^ZJ[[9Q0H? M--<"?MDKX+D+4SQW1_GWU:D`S_3=>YA]>%0G# M''0&*]QSAS_\24;=ZW=,\Z0'``ULC>Y(6J$ZF[0LO)[VOH:4P\ZP3PU;9)(G M&K.3,-)RJM/<1/LX2L+;(I%9AJZ97<.H3)%ING^Q(0J-FH<2_>[Q8KXM M!-0@<:\F,?4ZQO!XN==TF7G3'&:NJ%`K0PWOOLZ]J$(VK^C25&-_-"2010$N<>:V M!1'*8>*DZ81R-E9#[NPBNZ$1;JLZ_0G?#XX7($KN@1^>1?L-\D_52356QY+@ MA6H&$VF&>=*TLQ:3;)UF"RTUW>/?]\PJ#2*2=$1JRY,8VR&;JB:;Z@RKF+35 M\")G"QW8$.AD$2DC^\I00]7G\HHN#1W8J"`:VD(<=&!#!S8J&A?M._]O!MR' M"(U:G4P2?$Q*DN%I/$GU'EP<%XU-:KHR4J0<7ZWZ(%S1Q:'3AI,(`MNFTP8I MVJJM*GDIS^(J:(QD#$1++++PF:!MU,ID^'1TI M&XA0)UTX``M9KF=CN=(!$QTPT0$3'3"=J`8RV25T6-1>4T*MW:L,FV\6T,T. M,:N$93<#0-+FZ1RJ+9XA-1W3WTMP&IW%,52#?$UJ4IH<+U33F95*ID;3CD!L MLEN:(.C4TI[)9#J)R43T1M;:FFP37ZF5V-&MQ/:V]FIPJS"+6H6I2N^G:/8E M'JS!DSO8H6P=Z=7I'=HLIV_SAU*SG*=4DPJ?@2L21Y9HV_VK!%ROLF:+O(WBZ[&W_M9NUM M;`%V1OK(YAE$IHQ(.XMY=DFN.D\PGF@&]K?*6'?3C[\:HN6H>8)J#H_*(3LC M"@(&K6P:HO(11U6DA5H=1U4\ZMS1P\[@R)H24N6P&N=&S]9'GJ]UE-0YGGN2 M4';G59FY(\OP4X3#9SJ"6F>_I8]@JHPU:![0A]KS!'IEYFASF'T5QJ][PZH21B7-BA^>1<\'^WJ5Q'O8.0YPTO-;I>=7F]/3/`50 M<6]@K9+"E"`ISED>G"?9##K'=3,BBX*.LQ;]UOY&YUD-EV!J:L5F[ZA.D&=$ M072>1>=93=C1P\YQ1]1DY\JQ<\^GL5T[C5VU3C@DR[(F@M;L(RKIR@@9ARTZ M;JHZZJ#IXES.<9-:'*&TY*XZ4J$MQ"'OG(H(A8R"=A]^51O=T`QR.$2HU'K^ M=&1]N#,_?JKW#*A_5(\I4O-;I>97'W30=!%-ASE'-;2KDH#.6(00I:U1FG-T M+S6R)TY_R*!F;(/UMPJ#&YI!2`V1>K4&*M@2`A5:1`WUAR-0T,&Y[4$0(UT* M:53`G#VOV(*FJXEM/+RJ)!ZA+4"W]2"JDAB&IH->OQ&HB'.3*B<AHIW1] MA:.:4IY]@-N9DHW3&=)AA`*V2AMB$.R_51F$T'2EIB$R3,U0*=,\BDN=$075 M']*@Z#*7872M#'90#)#,'9.JNZ23B:XM:S6X9;75#^]M*)W96HA.[H3VP MB&FFT\.K7.TAZPJDN:(9T/(A<^S.H\U9I,78BT<+)]JW6/5>O44X?!7,;!5L M^WFK,.PIN`J'+X.5+8,U?.8R."HNP^'K8&?K8#C/60?.V,LL1,[AQ"0:T(7Z M_UP_Y8^X"L;_FX)PFCR"@+D:C4#\)/%;+Q[Y89Q&SVP_W<3.T?S&8J,S?NOG M-__S[NUO/[_3/GS0+K7_N_KYMZN;#Q]_U:Y^?:O][V]7/W]X_\>'7_^A7;UY M\_&W7V\^:^\_?M)N_N>=]L>[JT^?M7>_OGWW5OOXYN;CZW>?M)PDLPV*CT"& MI=)&V[X(__P0:#M:()8?K[J"O?$]MN[0;$;O)LL/R?3S5;P,C?$:P;K%,!Z M+E\93@I#67Z\9I$7JAVIM,4E]K MQ+&!(ELB4^5*#J>:IDY#W>P;A,JFWE4G*H9EZ;GM@Z7^#FC?&]90=PSK M>%R4M-TWX_O:`-K`TDWGJ*Z#Y(*245Q'&<7E#5P0N:,D=7WM3<3&7A*_P*S1 M:M66INN]4PBG>Z1GZ4ZO=P.T#C>*= M&@C:&83.$&@-!(V<3J\GX>CH/*BH]NQ?-:D(S'33UAT9)\/G04>U MI_NI24??6[K9&^H]IU*WNVJ:0=6^/:*R-;?BL*\[MH0&*DWG5>16)+N9W(HM M`8W;*Z#9RK..0%-691G`O19)]<1T&<" M-'FJ*(N2[+;IH2HM';A$K]692#H6X-C^K9TCY4ZD_(^WY@Z=9Q M-2\IB;)Q6>+D@*(D2C)OI'BF:@T,LGKZT)3`O,\#2K63**UA5W<<2J*4Y':H M.=#*Z@T`S4HC]LY,XU(3:@EY[.1#HFBG]IJX%.W40-`HVJF!H)U!X`R!UD#0 MR-FDC#:W1[\1]^)OE$1)293*F%A8YU'&$<5Y4!$E4>YPL-F#KF[T)9Q`G@<= M47K;+M^>;9NZ85CDVR,J4[AP0"O=BN*K>^NS]17+?]TW]"",9J[_O)$?XQ]< MC'Z^,MI\&N*Q\,X?+PS^&&WW9BM.6RM^^?N+-+Z\<]WYR\^C*1NG/OLX^3_7 M3[GN?A6,_S<%BID\`NIY1!N>$OMAG$;L!BCXM1^._OKIO_]+T_Z^>-#4C=AK M-V;C-^%LSH*8/TL;P;C@AD]L\N/%VU08!U\,XXOQQ>S"OV["+T;WB\6_F1=: M&GCBTM_@@W&A@4'A`0CQCQ>7UL5/YA`W:F'L6U]Y_+#,E6%9J@S+6AF6?;IA M7461&]RQ&0N2UX_+2Z[=1_S3U8,;C7]-9[%&7S)7OOEVG>#7]T9N_KJQ5]NP6S\\FXV]\-'QCZ`L1@DWCW[G`#%?9SC M:(EM.W6+J%UHB6TAJU=PA-P0[Z$AM/0 M)?R=Z[9L?'7/(O>.9;^PZ\@;L=-SR$%Q8[36U?#<+6OMT%I7PYS7U]KH=LQ!XQ=[[@GC+_X07+/("\<'&=+5&U8H!:6R MZHT)MVE%R^H5AB59K5!M5=<\*Z>A4Y,653ZI]EN^J&O.-N*HZR_X!UR8+)[] MCRB,XW;+J"T3KGE%:^&FK5[1IN_ZRE?T8YK$B1O@>6#E;M6RZ]>7Y)C>-<7F MKF!I?]90KF-:I24\D:#IR=4R6[2"I8FP)]C.6W2M2WQ;.1, MU[J6,[^FKG4URMCZ6CN=/M'UBIU&HZF;/?/C!.Z>A0%?BFMX&5Q5OR_6W(QS75OM2B;>W@5>/.3&2S"IX`,0 MV[TW3EU_^30^F6GHCUGTNY=,?_$";Y;./L\!B(D',Q1C!Z+\..'O*0U=A\`[ MBAO5!)[)H5LWN$Z%W5/L-"X7',06)RZEI4DMIZ/KTL7J6(>X%*2NQID@45+. M#SJ]0_37,T'B%.?;F^X(\Q`3F9"H;$\XA,2)Y/Y^)(;MX4X;85'-DA3#CF%) MQ>*@]5`9C3JDA=7I'W)00&A4K$7U;:70V+!A^%\+.:^_896LM?G&*T_]A*,M M)"%D8WMJ($8YO]7V]2DUPM>/FV,L`+KQV_LPC4HZO)Q.;Z\E>)I5)#QWXODQ M8,_6X0A-U="\F4:L))Y;M`_"4SD\'\*RN]/>ZS&M#U<;(RHI6C?"1(OL(';5DV5ZO!N&CD&QJ'CIYJ:--:?BDTB"I_HCT0:NW M4FH)Z`VN*N'=J',B0EL!B7K"R\%_NC;^(%C;`>N"4?]TW?O%:,1NE66W M_3:?-^J`3(WC_[55(WR4.OXG=-0^_B=\))@,^XL,5(9._"&.TZ?;+BWK$'U. MW(2'D[_QW3C.LE[Y&N17%-)0RW9;,IVA/1QN.#.S@3UOR&;50W:ZCC58WU-' M#=FJ>LC]@65N>"*.&K)=^2K#J.WU-(?M0\8'BU3M^-V_4R]Y?)*B]_63,P9# MI[\6=[+QAJ-&<,#278W''NYQU[]VO?&'X(T[QT;DVY=QXYR@UQL8BDQD+PUL M-A$;*C+T3RP!=9Z-W[D1*O5QN?$;MC7L5DE&^]M(FHYI5SJ"DQ%RM^*EK):0 M51GZ,PEYT._VK0JGL+_QJ&/TUBLWRQW!J0C9&MI65Y&)*$;(APS]>81L6L9@ M,*AP"GM;U<(`AEVSRA&KE:0GYD*$_DY"=@=VWCYS"KV'"MC2[ M/JPU\T]9`_=%X^U",W?1;EQTJ<>>X]EWT79^IM>O5HP2X0D61(*G\$W7V'%AZ_B51($>M"PM$/B"PI"B.^!S6IS%@ER@3]I M,S=)\+%Q>COSX.-8FX39SX)!\WNV$DT^(GP22(-PY6T1&S'OGFF\EAT+QK$& MS-N]]1]US9N@!/'AMO'6YWX(^`S9/9;C@^G""CED"`\D/Q#1W`G.'K<&+4."K?,^]]7Q01%A,!"QY MK!\#[2T0Q6R%71A#P2Z*-`V,)0C38(1(3MU$\P"SV]"-QH(8@+*2$""?`G]R MY_,HO(<+72V`80K"_\3F645"X-/A7>3.%KP40<C?=R2][6W?"U1X.'(3Y<*RGUETSZECR<7M5\]0'-Z'$2?,"2C0H!\^,A>V!_!D=@G7./@Z+.)_T/S\SIJ'>#Z_AMZP\(\SBXK/!+1_)&!_:EB?^V4+Z7B4" M>.>/%\;%PKY9H9/%G?Q+T0S*OSQEH.TPP+;8;>+0`XPQ6'M1GRD[$AS!@V)O M,YVA=`6W:LYNK.ZPOS;S,E,X8.;B[[`+%QOZD.GOGX)AP"XL.86-L50WC[5B M8^7F8:@WCW4W@C+SV'X`W]"]M7TR%:_&KGIXE:S&(611RVKL#$5I_FHLXT\6 ML2>G;#5?ME7@%G__05-JT)*4[ERWY3"O`6M2R9ZQC)[*:U%+YVM[R]%"6]>D M[)YIYI)4LF76LX\56XM:6IN?T9*4EC);SE@;L";52)F32-S_P\.F9_L$]L9@ M#;8$+I08Q`F&?K(PM,J70(+]N3=X8+@E`.F@X9QT.J?"5O5EV>/Z:?AT".52 MCK&&3Z>5*!]MX)8(XRX_F^.4AY-:Z\=!;)92N1NW*`?',F[)[U!F&0Z56=NB MS%6=S,D(7>E%.51>];;$#*LZF9,A7,&B+`-RQE?!^!-+O&B;K2GYU-0<].S> M^DQ*#N5$DZC6SK]4<04./C0>&/T->E1K#A6C>.(%X#M;JLK8,X9;I$:Y@9QF M!J=BKK`26VR!AJ[$PW)P/]MRZO?$J#0[3XYB\,&4_&\S"_]DFJ/8]B])X2^8K,RAB75`+-* MM-+;F/T[A?WR#G,.XNO0]T:/XO^53$4[8=3^XHK>GCPJ MUQLSGGRTO)&)&_,8>`PB'F,"DXA9#MQ@Y+D^C")C6B*;(PO\=6.@A`EF)6(L M\_NKSZ^U-^'8FW@CX?$;]'J71O>RURT5_%M5.&T9`EJEN9O('3/@DQ]A$:*K M$4\EB#_QI!GL@B#N58GFJB.Q;/88RHUAWH4R==H;H"1,P\"([[=A>IM,4E_+ M5^ODT=[.P0D"_#XG7]Z&I#;P*S\DF(.8/,YAH_G^(]^KP%'GN,%YBM1CG@\P M!ZK$79Z$F$G%(?3=VQ"(-8P>\^!\#>[QXX[V2QC#@P.>%08`QWE.#7)]GDT) M/"#+9N&YCA$3C.7!2Z::BZDLT1AS&>'U\#+,5$M'4V02OP"AC(!OZ-DG;ZQE M*07HEP!2\H(8-E``0\D&BAEA<(FKS<-(Y);Q^7B1-F6NGTQ'/*?L*WKA,1ML M2WK.#2;61&P.ZY(Q.&2&_X*'%AZ99Y?ANN`K%_D/F+GD88[&[:/V^M//'SK: MAT`;L0ASL+412*E8I&DL5XNG/`5A82KPS''(\(])_KS"KUXP0?K&D3R5:"?R MX3!3*$,T>SD."HE@,5#\K8@`8HJ[MO`>74OCE!/,;4XSF(R*5\VGC[$'4,`U MN)UCQOZ*EZL3A;.-Y^?I2_!7%LWB/.]CG!W*9Z/=I`E<:H'A@ORR.42QYGM_ ML6R]W[E`.^(I\9;GQ`#FHP:R!F;`5S@,8%Z<$C$#-Q)YCDBPNG:;)B('_Q'-0>$&YP8YS`?N$8@-@$[LC@Y1&[]]A#G*VL-[M-HUAL MD#D*#(^)=Q5D;_:B?`R^SW@"DACW8MECELV3;^3'.'([OA?:9PL M'PG,0W!C+K0C-@JCL1#;P+K3+-D)%N(N"N-X`4>$*D&:C19OS$=V+V:9)3## M?:Z8[*@X!-\/'Y#`L^41NR+)T]_^G7K1(@<51L,9R6+4/!=T98&X;0+7^FZ2 MW\8'MYP,OV4.ET7YU0]3#T@'$Z:![.%/G+]H@9ND$8SJZ@[I'1;0S215E@V+ M@ATW%)C-'C!'L?7S301/CL,`4.9K,@EQDI?I7,.$L7N>D0JO&/DI3\TN`,DF M0.[9\B.-P9J+]0_@G7'L1H];]_[R$U_#A\A+..B3PECAH7?`&8!C(P2+9>?[ M:YQ+X\4<'Z:,\Y-'/I0Q,F[,0,R'"L_K\$RUD<_%139O??D`O`W'D;"`#X0_ M$%EFQ%Q8&KYZ6R;.,T`1MUL&KP-Y@-.&D76TZTPRY6_0\9$16Y%:`(=(*>5T ME\DWGRW8-9<02PZY*BOR)R\2B>%'((5%0C$L$POP+X#S%N&E;TQ9/`>?+#03 M;9SRRNG:Z'$$@T)*#T>C%#<'W`P,+E>H8\:9%2S!DK11:F/*86$SK8RAL);` M?0)0-\7K;QF^L3"L#JCYZSSV:=0X&;"O(Y9)#;@G2V!=9`PFH*[`""B?M%0N&2:8P*FN0& M[;YLMRI9L`,>O'$R?6ETN]]=Y(9.(C86\_VY.T;N\N-%]X)_C^?N*/^>W7^+ M'#&Z1-)QYS%[F7]X)1ZL#:P.//O5NKFQ.M3O$_VKYCYP&=_XJGLY_CT&#&FO?"#_3X@)A(6_>7^M25T&>WW_[ M0P5T:72,?G/I4GR/:F!>6OZ/\>1Z9+X`[=(XP$5#S*T6YO;D'`V[8]6]4:J@ MBVVU2XA"B$).3B$DB$@0$9LIS69(LY9'DG@X1\1(Q*@*,5HD7H\3KT"(VV4K MUA2\B\(T&*.'+(Q>:M^\>?/NW?OW*DG=S74J(G?^XX7X]\+O6_`*3_S035XB"UW\F@>Y M]`Q+M_O]Y90)U.:#:MFF;@X=.:`*UM]T4&6)@,8S^J?#K%13717;[?4IJG6R MDX&EFXY4$4&DT1;2&.IFWY`I:)I!&F11[!4T-R$V,[G*HXK(AE")R\!P>9B, MSTJS&355W=ZPKSNV2?8+$90<@L(:^;W>@&RGG<).?,6HLO6URW^E(ORE4X!6 MLX9^B]G'R;LX\68\?%NA]*`3IJ;`(F#L`?Z\-;',XR6B M,%L!$UAXK/X="UC$,Q;?#T,B%I'GGPD#G&0F>1Y7$QWRT)X=M?3&.+ ML?"`]CA.9UG_"M[!QIU,V"C)HO8QA!A?D@6J8IBXZ$N$MQ8:$"W"ZT5+!KP0 M\891\9CF'?;OK6ZKU2V'6QQ+I+#GW[4S>.\4*-U<7K9/.I]_S0NPMZJ'90R-M3;(M8Q3#:KM.T/3:-YB MR*/:GF$Z=NT+L+>(!VCOH+S7/TXEJ-:R37/H-&\QY%'M8&CVZ]^V>RO5]89] M1P$-P5:":GN&9??[S5L,B51KF4[%"_!F"J8=EDUY$\8)_/V=,`/DEI*U!UWC M("1WC.K4$U-B&YC6L,L[Q[=]]61R>VO8!'([M##9H._TG4/$F"(34V,?.?:@ M9S1A'QVY>O+VD0&FWT%J4UTK=F!!8-"';:>)$U-B(UGFT.BN]99IY>I)W$B6 MY9B'6*,25NSMLBR+7&7.-@WC$/27`SG!\)78(:;5&S@'"6JEUTBF06,=9-Y6 MNRR'JE].KV=U#]G%)QV^&I3?=VPPV]NR1A(IWS`.,K444OKP#\UO-3^*LH!/PQ3>+$ M#;+::7M%8JDF$\+T[MJK\OS`T50^E4,:9CA#LPO_4VDR9H%?VU^L;DE8G($S M4`R67F$F3GD"8/94FDVU[N[CM2\'28B7,(@?55VRN#PDQ*TE<^E>IY M\<9=K]W8&\E5\XXJ$WFN:M\?]!2"X[EJ?7^HTBR> MK=([796F\6QUWC%*62:U3.,@51YX;M]1;8L?K,;WARIQW.>J\'VGE`I_VBU^ MN/K>=THI5R?>&P>K[LY:_S"5IG&0VNY@S-Q`E8D\5V5W#)6HZKGJNF,JN,4/ M5]77@Q">,8W_W^7E^S!,@C!AVF?15>+R$G[Z^XNOMY$/'_[_4$L#!!0````( M`")<+48EGHN"=@P``)[````5`!P`8G)L:2TR,#$T,3`S,5]C86PN>&UL550) M``._2+54OTBU5'5X"P`!!"4.```$.0$``.U=W7/B.!)_OZK['WSLR^X#X2N3 MV4E-;HL0,ILJ$JC`WNT];0E;@&Z-Q4IV$NZO/\G8Q(!E2P:&'C,OFUG3:NO7 MOU:K]>G/O[S-7>L%,TZH=U-I7-0K%O9LZA!O>E,)>!5QFY#*+__\^]\^_Z-: MM3H,(Q\[UGAI/6+&B.M:'']>R_^,Q2NM-TZNN3W# M<]2C=EBGF\K,]Q?7M=KKZ^O%VYBY%Y1-A:IZJ[8NI920_U>-Q:KR4;71K+8: M%V_3C`JM50OK6=9G1EW\C"=6J./:7R[P3863^<*5[PZ?S1B>W%2D M5F&!QF6COL+_P]`71,ZQYW>HQZE+',GK+7*E\N$,8Y]7+*G]M^>'C>J,"14: M,1-^AB]L.J])H9J.MA"@EJUK1P&W?LC[D_X"KYQ^?Y0JM9#@=A"?W;OT];!H M$UJ_(M@[PFV7\H#A83"?([;L3X9DZHEH8R//;]LV#3Q?!,"!J+)-,+_#/B(N M;YE`+_Z.DQCBP1,Q84K&+FYS+MI:5)UBB)7*($'K(-=N'A1?I-$8I"W*!6[8 MZ'OBMPB8?.>APF;">OC-QYZ#G?53XLOWB-ZG7K>JUEJ=^'>G_S3L]Q[NVJ/N MG77;[K6?.EUK^&NW.QH:H`PQ"I0NM3,_5JS$FETTQNY-)7Y8.UF%.@$3Y/E;]4J5 M^>.J]>'#U<>KQJ>KC\VFZ.(O&XF:)QRFS39!(&;'^L4_=WQHDZ-(HL9EA)+: MJD20'Y>?,#I_-UOT$FI28, M+C#SEP-7#E4]1_;^"SDH4`?6K")PR%4GL\;UA]H)*H%\891OCXGT"L'AKS!; M!H2K(0/.:H.YI``[=WC!L$U"^XE_NSBDQ7/:<\I\\K_PN1*Y.@,^B/I2NM%1 MC9,;8ZJG\KA5[T8]6V-*XUT,C@?DS6KDU!EJ3BW=R5\^8G]&'3DPX'XXSZZ@ M1R$-AR4C3G:I-,$'-;:+0$(Y\;EFBU.)EX93(X!0<[0OE#JOQ'45),8_EX:T M3$!08^GV(H_(";IOMAO(G1$Y!.H4+0VYA<%"G=A(S,ODQMM4V=)0JX\.ZDQ& MVHR,1B>:5:@T[!:`&=%\!8WF'D%CXA*?8"X&54.?VG_.J"OJRE(G M!I$]C[HK",KQ^-D!+N7BFMYRX*0R'/T-.U*N)&@"A$MJ= M+URZQ/@9A_,ZVNTRMUR):"Z&%>J`3#@M"[#SX-ETCD5_F,>T4KY$#)MAA#J* M"U/8'D6>7GA6B9>(5R.(4,=H/>)AN7U8I*\D9]4Y3;1$=&K#@SI$ZU%O.L)L M?H?'>4SN2I:)2$UT4,=@';0@/G)[&''<'[MDNCK%D$UI=J$2L5L`:$3T1VA$ M)VR0.Y62*@N'UCU'J]_H\H/"%W/)S"T'AUASLK2;K![IX`:UR>XEO]FF"I>+ M7@.,4!MR#"&9S>8&]F'V`?CL2?Q^[3:&CU[ZW^H/O<'CT(@0KHH^Q/V%^M MP/0HY^T71%R9UXYH(E1'+G.+.+&WFH-QZ=-LM(MK>"_:@W`'GWB!\.-W![C% M$RIO75BO1#T2CS+10!X\7_@5ESOI-[68;83^BC6`$W8*>M;FUK_3V@UJ)AGA M]Z;OT%3KC;N2<#P$"LTI:YB:9H/J(.$9LP&C$V4"DY"`YQ"ZYM\E+@\65,*& MR,7\&;]@+\!#S%Z(C;GZ,*Q"&AZ1>72DS-480(-*9H=ROS^):Z\%RD"= M!B*P!PXWZYX\:;EUP%*+S8SR\(C6H"V/:U.\4!MN#XTI$P"B38?=MP7VN'+% M(U6X)/P:@(,Z7[?EHD1XJ/\HP#""7+V@O%6F)-2:8X0Z>Q?N--3J;%,D2\*F M+K+#;[3R.!=V1R9$IF#5RS5'EI/TI3/U3$OD6.W*.4$9LW)=B.!0R#0+FI-8(+-M=^CU0K&\0.JVRUZ>(EY=@(+M0>?=V)1=AO17ZC7LQ3 M2,,A^&![`?0P&K3OH!8XCG)$QE/=:F\K0?4CG8N#-29I547/U&,*FP;J'$!\7YM9 M[IE3ZFR=P]PJ4,J@B&$D56P$@7/E,O,#`&U(MPOB#BR2ZQ[\F= M>?W)Q@7S>3?[ZQ4^4^?8PSBY5^V<;F;J4(DEOT?!VEF&ER+P,ZE9^$]I(?C[^G[(X&8W\2N#$FA7]D M%3E3OS`V2>0//T/+1W8=//Y`(5'N_LLL!6[> M56'(U8C_P*O(FDKA>-MQ5I'W,0/491W1(,+IH1%MVW\%A&$!V@DD/IR9\.26 M@^,,1V0U92A=R"Y@-XSNP+D-N+SRG8?G[E=[E:)?'%U/R5"Q89R6-$[]+)W& MU$1@-Z,JS'=//.39!^ZE-)7"\;'C]%+[F`'J(O,S7D1-I#])WIRLV7+$M]P>):[. M%RBO53)1<:;NL[>)R:A3!+[/W.R7W7!,_65@H;)W0DE M/63!2'BR,XQ$)UJ6MC%VPOT8(99^6$_>?0U63XB+F]IG?JYK#?K M+:MJO;]$'@%:O<>B$ROQ)NO]55;\+NO'Z&U6ZR?8YX#TKCY42AWD"@2%]M6! M\N3>B>B2@.W\LY@2.$T]AX/U'0F'@0CUG$0:NO`:1-5>9Y4\'&(/R-INS#;# M?WC6%8U9]D(,V7Z`W+;SWR#:'=GV'!E*T_:-:98J.:O[6.$(H\+"Y#Z*L8F- M&%[])"T33V&DJEU(6Q0QU498!*?DM(XC6ZNJ*0^8((6>L3N".U-S;!] M56\:A&WK1ZG;:GZ/WZ=KWPGOC([`/^,Y(H)=UI_<"R*1^Q^,6($&KZFYK!%@ M'_C?8D>QBU?"&[W2@[A.I.M\G"4+,-2=K`40BM>K3A$7U'9F+J*$#'4CF3G& M>QH0/:0]\3$[J)ML:#P? M7\F'G7N;2>90]G-M14TTUA-/_@]02P,$%`````@`(EPM1E,(_!-_'@``FP\" M`!4`'`!BPO0>77^7J=D773LBRW:T)V7++JNZ9 MTP1,01*F*%(#DG[TKQ^`%"52)$"`SZ1*E[)*`A*9^26`1"(!_/S7MZ5EO&#J M$L?^\1BXKQ;[Y^_5X:)Q_.-O\$E%P[,_&V;@O>,B1G)+6D1^]MG_L\S:])X<\EGUUS@)1HZ9L#3 MEZ.%YZT^GYR\OKY^>'NFU@>'SAFITXN332UA"?Z_XZC8,?_J^.S\^.+LPYL[ M/3*8ZFPW:%NAD:@XXS!1^O4B*GMV\O?[X5/`_#&Q70_9YK96JI5UO;.KJZN3 MX-=-4=8\D3"4(LU^G7J;"O'"ER?ACT=,T8;Q,W4L/,8S(VCNL_>^PE^.7+)< M69Q6\-V"XMF7(\X`4];9Q[/34%5_>?(8YDML>WW'=AV+3+D)7".+\_&TP-AS M'Q%E/R^P1TQD'1F\J:_C04*,9^(P\IB5,_$'TUF>\$(GVJ0#J94`.ZE%[,V7 M[FCVM&"\+1QKRCK@[;]]XKV7%CV/?(/BWQ#7M!S7I_C)<\QOHQ7OCV[/GOZ! M*$6,PPEZMK"K([(RR5;$'-$YLLF?P;C#>+KV76)CU[W!'B)603GS:+:#I[]< M(OK.+(S,;39*FTSU/=-T?-MC$\1V2GKGIZ=GII'!L; MVNQS?_3P-!H.;GJ3VQOCNC?L/?1OC:=?;V\G3\8/B2;^3V-D">3GF#EF@C&+ MAZ\=FJGI@-0,N<\!/=\]GB.TXM'QBQ-L>6[T#1^++XY/S];QZK^LO_[G1J@@ M5A:U8*%G;`4A_\Q")VTRVK>0R\.9W#7MO1$WC^=T^0W[6TOKT:0@K`=$=->= MH6`?=^@4TR]'9Q&U&7668L6N67"4Q/!=QI03..?(:@>4.%,WB2EC!XVL@C7! MD)YI%#$0&58*3:9L M`.!ZPI2M*7J/P01&^38-8_D^X<7LCF:R&G6AE?2"Y$B)+3`QFLG$@`!,9&_, M\\`#]C%W=HD5K`F&P+E7["8IMC.GDO5DLZ/OT$'[;+)E+W.$;JV@*'/R\)Q_ MV/[.EE=X^N7(HWY+GD#2>IBS-:*!:%.^T,./F`8[G0+@5"LWVJ?.R\"J*M&* M,H^9>.^!%97J:^FU/?]FAY&@5;?G>PO6ZI]X.K!-R^>9).LQX&^^39S=X:X$ MG48!NR@"6`GAJL.NCBZX*X52UTM7:A3!C]5UN;0D78!KX+J^%E11A49ANJP: MID@*:!#QV+-C%YG1E&HV"MJG,J`IB0,8/<7!4%JC4;1^K`@M^,-@BEGI&"@L MW2@Z/U6*3@=&OY#1D>_QQ%3N"JG"DZC2*$97E6*4D",?J)]/DO'RFF+HN9FD M*G'TB]-361S]:<+^W-\^3)Z,T9WQ]&MO?/OK:'AS.W[Z7^/VMZ^#R3\.L?1# M+/T02S_$TAN:BZ0AV8QRW0G$9C`/0/6]Z92$[3\B,AW8ZPPD*0PY=2#$\=0@ MR1$$`#QCGBICX^DMHC;S3EPI+J+"$.)T:H"()`"`Q&&?H@/[%`/;I#QO\@:' M?P?A>)MPG,>.9=TY]!51T3)4FPJ$$4\-:&W1H"U;T^P*NV&Z(`1GH:"))GMK M6C1P..5'>UH,\0CZ4!78@`[Z!.*$S-WXE!_;PHS#,-0;/WAP^\:6@L050Z=/ M!X(34E7?TY.\(T806FX%5B`E!&$(+MP+%`Q!*GQ'+"%4!!%;EM#H(J>R?J$&T`D M7O^J5H>0UE#S")`4N"-(K[>5"T.=51]Z'\^25KEGPT;Y`7O,RITE'CJNVWM! MQ.)!GHD3"TBOS9T-3L048*U-!4+^2P6]6UMN:/`'+([QRJ?F@D\^/7LZQAZA M&9U`ULU5*4!(I*EJ4%>5N9N0AV-7*&,?&EF:0)<+(&FNZ!K*G1D39^"&D#?UDY?H`^CI?)N5K][@T\S"G MYOI]6^81!7=.]/A@($TDJ8Y^*SG)%K(?T!)+TDZ210!EFE2-;")I.2$T@/$[ M8DB:D[);"$@^2I:192D;4/I)`74GCCE^O+JZNKB"HXK!1>[H.9 M-V:R+DE>XM,89XE/'YGY#=JU(;@CV4:U.92D(TY+8)R6`N,44CI0>3!.(:6B MY$V!HADPE1J0M2-;DG"+J2Z5J26Q+JC.\^AJ5DV>"G:/H7QE"PZZTX68;J*- ML$=*3#SF2ILPN:\9X]\*^MM5-`QA>&K'K8;4XG3#4(J$67CAS7M[L14PHEI MC%<.Y=!9,QHPA\5HR?JE%I-]8VP6K/DJIS7R:X#,I*BBV=FQG"V MO!"F@I`AZ:)^IPR0$(J2_27O^$F(T47E@PZHE`.DL0#+$#WSAX`<^C[!+N_1 M$;OBA7QN%0BAE$QCVBS>\1^;V&F$*U*JIDI8K)!04)^BBI> M`LB,D+*?E(*A&;NJBD&/^ZIJKWZ$KP:)>Z:\I;^48K%3!L)XGV%`<<7O<`Q` MSY+Q,3?DJE2UQ:"JAFB"B(#ZY-%\@%1TKQZ;*UD3:,[X#QGG#*Z9#5_*F3@3 MQT-6^)\LUTJ?!HA0I";>!46%%C=\\+ER,K@7]5M9!1!QOH+]5B97RTE/F@_2 MJ03LSM,!NW4SAC,S8@T9VY:,J*GN1?"BQ\QX9-^+OVBF%K;+JWY866G'X-00 M.2RGON/EU,&);TC/Z"U?S\DR$!RV/#TG.0:@9^&0=_T^86W+DE-5:D*,G^F/ M\DJB0@:36O2.4]:`X*GH6&^<1"E<@%`2BA67DA1I6)[`45UL;+#B7ES:5>3+(5R?77Q MS+>&9"9^7T6A)@17M1CT2N)!BR?>X!7%)I%=E9$L`B%F6`R?I!P=BA%N[H3) M#1)^K"!(:'P$'B;,>;-W([XL5JA)HXV>N671LIQ7_DBI&QSU=3%]P6[."E2U M,IQ08R%4X]U;560`@ZZ<5>E"1JTJD.6HG@FK@PEH25HSE*`7I?7"VU@VXH:' M.X?VF?M-D>FQ`:A/\91XG"\^^`2CD#@]49\&A`6ICO%N]M#U10703>-,WSC^ ML\<<\FAND5\AKU`1PI)%%TH=^0#@I^H=Y(4<"M!I+P)16.CLH5;)K^IJ5$)N M_]?(XE\5FH@W=6%U\TI,0BIOAU;(FSL3N=U3L]F\I;_%..&0P2']%-)B9<_3 M3S=\27<,4J4@.+0%4P]3L@!`H>-_>-AX M-)L1$[,/_!HUW\-4WDM*T`&=>9:-5`EI`?2T"46V&YRNY5RHC7XY=2"\I5:P MM^5(!@"O0R+V(1&;\_@+92M97:C7E4!/AU+`\R2#EGG=,TU_Z5O(P]-X9C+[ M;.'U#F]OR>]$"._D%(HG2ERIC#SH>5=J$M7I`)KQ"%E]P"*#D%! M7.W&[`:VA^PY8=-,>)^,7KSN8SI>MR5HA!2[%ZJ[XWK%0_*"I[OJ40O6Y1-H MHT=*N+I^OT?_KM:D`"?`5 M,')%L+/%_EX!!YVOT*P10#V?WO==SUEB.B1N3O@QLR2$H'!!TXZ#F2D;`'0> M'+ZEN\(>[LTI5H@1RRI`6!-7@)5,Q#JBQ8]LW64')T*&Q&1##):'=O,J M-0KJ96.@`@CPCO&+8[T0>_[@>/@1O7.?X!K9W_0"O9?I0.^&L,$I&VO2[`=. MO2M!7P[L:!:>#+]#)K&BU_1$B3KB\JTL\1.,2"*W607A!&AS44@LZ#-$`3`L M)MF2AMJRBP()H(I-2@P"H&!H21A`AS6+0P,U1+F90Y),RV]!E]>!$+:4&6'B M?G2Y*```^AU1P@?B,?-+I9=Y[1:#TUN22%@08"#GW-:4+`IE61(8D4CZ@ M*:6$^D%/)\4@:>QT[@U^]@:VZU&?QR7CC/`WL?E?<;!>O2Z$Z4)L8)OXO+I` MS4)QZU-GZE@6HD7`2->&$)(M!4=:)``C&.R7?03A5*UY^_"4S^$IG\-3/G7H M^?"43VN!R%3462$8.82PJZTD3.*BLC7H/\ MT'9&DZN"&^R:E`0,C68[*S:A)ZY'`L)6N':7UQ,1-L8!DT\KBM%T9,>Y/U/" M5U8=PHYX26QEXM4^E"=9&4=;Y+SY_"#%3O%&L?A4Q4`K%0=:G^)BN)%L?9]2 M\9G1[**-XO-CA:Y/6I1VDT6&CCV?8+KDYJ.?)/(IG23""1YSB@8GV;'DD&0G MDJ6%9)9LI2LQ?7MK`'/NX,HN"B3H[_D$PA/,I0?D!*4A1#VE1M?(C*9+00`*)+C M<5YL4EBZO:ADC@#B=4S'(Y$[PC#34O-B@H(0HHK%@0M$:'BI.;!-RJ^]&]BW M;`CF[W-L0EN[G46[-H2(GP(:VG)!6Y'N\L[&;NQZ?/7\Y/$3&MO(I%)7DA.` M$,4KW,7DHC7<]1Y\+FMPPS:R&!_$F1+S$;UG72&N7QU"1*Y8Y\L1#';OV^%7 MJ<.EZD"(X!7N8REIH`$6#QM)5E3;(A`"=AIP))EO^=4QSS&_C8(&^7']/Q"E MR-:\M^OL+!VI"^@::\+!9?L1Z:Z$Z[9GXI\6B`:)D<'EM6P=';XEQ\69A[=* M7+]ORZR[5>\5T:G:_5ZEZ;=R(9^%[)R7QI)%X(0"*TQ*`H,"G_!VN;*<=XSYFT>V1U[B0R9OGP]4XFQEG=H00DO9 MUK)Q!'7$:0F,TU)@G$)*.RP/QBF@B-^$NPNCV<">DAH@8_D&\Q1A;@"J:H)L/'TYG.*Y\C#=XC0>T2_8>]W9/G)\38,T[BLBW@3YX\% M,1=1G@+%MV^LEQ"7N[!W#ITL\!VAKC=A"]EJ3;!61B%D$8$RY%JUW7YWR.V_ M`?,XS,_JS3Q,>4Y8(C MJB-Z@Y&W:,DZ,_AHU$A_VBSYV+(OI M@/]8=3PSI[%F-TU..Q'5S%'9'MMA&,^MWP2C=B!LV=7;C6LRR$B!^V:+OP1G M#09VZ.#(7@.KI:5.;_$T;H^9*MPWB]R&YS:2UF21F2UU>JNG<8O,5"$XB^3A ML('K^GAZXU.FE)#1<`\U?K`K`4*=W=/3MJ8"&P)E+==KZ`Y/Y@C\M M^((I6XPEEF)<=OZHK#--N3Q5] M9E,)[AMG8+3YI!D:VY+%Z:7&X M*]Q*.M/V:CR9$IH!:?+JZ(`4*PYW'5^=L%-B+JTJ7W=CW*"CMU]6J:6---;EW#E=SQIK2Y5X; M:W2?6"S?9+W%T83=REK?.U>T.1.6J16D-3]7)'A:X)VMRC'FZ+.?^\R!XCNE M/K+X>?YSF;5#X`[N74ZU]08(:O^^>TNBRC6>$YMKZ1HQW54 M]_M-GNY!=IZJY]A86DP+CE-6ZW"OF^J,XY2E5I#67%5?3PLLZ^N-#/W:+,&] MP0K\4*^MZW9S_,+WO'C`,_+8>*H?^^SZ%G_BNC>G.#S>H/<\YWGZ>!;:+0ZKK)RMDK2^SP=DM.WELU:!T>:OF>'VH)K\26 M/]22+`,AFR7#,A(/M20YAJ!GX`_B"/:(\O1]EA\5NCJ)G$LX#9ZML@\\&'OF/^%K']@1.^1YW,O,^?$I3:5-KMI%>92 M6'!H:]A,`6Y\/+`?F.%.7K'U@N]9F87(M],A`&$2+&CPN:`+1.X.WD^8C593 MK@-MI.-5(4S`M6(<%[8[Z$X6A!8#-U830DY#K=C&9.T.M#QOTEL4PC9>%<)N M?ZW@QH7M!+HZ<,+8GZX+OP;N\U=W"*\=FS$0_KI<$I='.=R>&[_PO>]8%C8] M/!WC%VS[F3&^FAML',J]E!*22.JGITV MYZLV+*]Z#;:[!=A'*^(AB^]Q#C%R\7:VUMSSNTCO^<5H&P%Q(T:]_BV^JJ_Z M6(L32#+MN:Z+L_?^M&JVX:8^4F>%J??.-[$]9NBW__;)*KRY9L+:EFP!*M5L M?W.P`'9QYU5)2@#+#2&?G$OIH7^EFD#V%#6L50G$N(@`0-SP)=T?2Y6"$(35 ML+\X,BE9`*#0\SUGZ3P3"[M2'#+*00B5%D0B0QH`6,#.0Q&=*"PVU1R23@Y) M)X>DDSKT?$@Z:2;DO3/:87$RBEJ5]NXZ4!$E^\8"R9#??$:)(&@5Y]$=L.8I M=KTQ\C*CVI+"$'J)*E)YLH#;/TK+)7M(4%P(&:MX?5CK M:8&Q%_)^_7Z/_N70OH5:_M*WF,U-;_"*8E.Z,5@5=1!;P26,H)3PH&U& M+M(#%B;H:1(!L9E MO?#YB*VI$1<@;@IJ\7-9U4.$0CL8GH_$(41Q"%$<0A2'$,5>A"CV;[LS-P:M M-\(?]CL/^YW%`TM1P^*K M5ZF]0+B:.-FA<-G,T]73E6$NCF2-4=W#;!-$\_B6RU$;G'`H0(NU5 M8IHA(G"$[WS/IWB]QE\_NNC>^#CGQ+LV%0@1]=)(YXO94;3[/J6AZU`"[`T1 M",N4@F9>`/R-V!W%?F!/7AU^/%%Q1%>A`\_SJM,"XI)WUPCX.T'5F$&,$CRG MK69#B,G>65/@)\4KL808(7B>7KV&$!.]NW9`7JH9$6*$X/F!-=O!5O2.VL%D M@2E&,T\8)"U`!\*EZ,U905SRCAI!.>AA7`G>'.!M)U<-&87US2]:N527Z5RJ M+:G.)$YYR`L"IM(4J9U"[5QZX_.DZA6BWOL#6LKVT[.+`DJ1RM1Y\EZ;+`D` M#(!CO/*IN6#&NKER8)=7Z0ZY1GT@^^0RNTND5ZE+]CWAF'A-_!-_3?Q'.(^T M5XYMIK1U9$/\RM\+<.QKR\=]?GJ!?WA:$&Q-1[,'_/HW3%TL2970J@XA0*EM MKYML"BU1Z_$W76Q^F#LOS(4A80]E'W8[)OOJGT,\1]:M[?%+S]*S6V8)0%EA MPDDMD_'&E1LVGCFHI7]N>>Z1&$.DT"2_D+4)<@;0U'!CX_HOV,8W;^*!._E[ MFR.SR`HV`V^256@K>=AG*T1/].8N'`ZG*`ZG*`ZG*.K0\^$412-Z'C(7/7$" M\9HY]SQNR*]DC;[.]7)T[LNO(!0['-:O2D(*T!I"I0=\ZQ1#N M2+AOF(%T^VO'L;&%PL">4;+.=1[-'MGH(3B8C$`#=U[+HHPYR#?K(*[1WR MRQW/7_0=E_EW M7VV*R?+9IPS1)TQ?B(DSGSB1E8:05JVA=)DHM6M]UQ-?&T#H9KL#>SO29J&@ M4QM"CK,&*CJB-8W2(_8"_;EWQ,+3D#4%>+*K0<@Y+HY+MDQ-`[)]F:4@-'D$ M(*0$%POW^Z.O#Y*DKR;LY6MMH0);;JTFCC:70 MED7+_.H3>._^S-?"LR6OEC-PH5(029=&PU\?R-@GQU.#GQ=F,/ MY?8I9MX79YT/)6)X"M*`$.'01:J@J``ZG>I3AP>9>;78897<14"74@+0J]OQ`B$&NB64=S@ MJ6\&8;AB:ZU8=0A[+8U`'Q>Z4!3MYY-0T^OX$?OF/U!+`P04````"``B7"U& MT`H5[,!\``#Z)0@`%0`<`&)R;&DM,C`Q-#$P,S%?;&%B+GAM;%54"0`#OTBU M5+](M51U>`L``00E#@``!#D!``#MO7MSZSB2+_C_1NQWP/:]NUT5H5-5IWNF M>[KNS-Z0;;G*]_I8'MNG>CHJ-B8H$;+139$J/NRC^O2+!/B4"!(D02+IFHCI M.2X)R)>0/R2`1.)?_^>7O4=>:1BQP/^WWWW\YKO?$>IO`Y?YS__VNR3ZX$1; MQG[W/__?__/_^-?_Z\,'@M").0'RX4/:\,*) M>"O^R7]DQ_Q_?P__;<);D2\2^C[8O=._LV0?XZ,/'/WSXX\=OOD3N[P@WG1\)WAI, MLN9/2![HB@\7U\/-!_^UW$]@(O/7D*ZJZ?GA>&WT/];GS[# MCPH6^@M8Z..?P$+_+?WXUME0[W<$6GY^N%&*]I<*K;23T$G+O-].IL]3$#M> M+Z7*/5%JQH&`]M.LU+.S9M*'H?,M_ZNB(/T24]^E;J8B\&P@+402WB`H`^U@ M6R'H`2X$8=5DX#+<)!__Z>-WTKG_&WSRGU?!-ME3/U[Z[LJ/67R\\7=!N!>X MLMQ$<>ALXXR0$%]2TNW7T4R@##!9AE6-G'";"<'_;#%0VN+;;<`AX!!_\-*? M3'3?A<&^FPI2C*!#I__T-CV&2*9[1?&01D$2;FFGL5'6M^MOELO.>\+\2/T/ MGQ\[*//_9DR(X[M$LB$E/O\JQ>LT=%.N@N/.B3:"+9^XGQWG`#/F'[^E7AQE MG\`@_^.'[SZF<]A_2S_^S\>8.S%(]N1L"CQ)[:-LA'0`-RL%H[6^!<*AV2)H MWW&8DR,_"X+_'X*1QZ&?WO`_HS83E!O.902>*5<["O-6NW+F72O_@?IV[%/_I/.;$\T&<&TY8?WSG[ M4TAO:(;4I=H4`X=2M4'H3JVB]AUM:5114"5`=MJA=\D'>^AX-SQP__*_Z5&I M^GD[](-/H5IU])TT0CW\5+(.''\I62+H$DYXJA&8A=A/G&R-TB=?(QYO=8ID MPZS\'=+152OBX'434)MZ)-W3D`5\4>A>\7F\0=/3=C,86[6JG0ZR2B/DHZU> MUL'#3I+E*W:7`.&I1N"2,W=!@&O/>:[1^O1[Q".N5I5LI%6^1#K"ZF7L.[)R M:@3(336>+I,P!`U8M'6\OU$G5(-:0U/$HZQ-P6S`J=HA'7NMXO8=ABEA(BD3 M(#TYR,F`\:_4\_ZW'[SYC]2)`I^Z-U&4T+#&&&WM$0]/+56K2PE%8Z0#54_F M@4L+(/_A'T"?9`R(Y##MD/TI\!(_=L+C-?-H>+IMV=0._1!5J%8=FB>-4`]) ME:P#AV).EDBZ$V^S2/1^H(<@C)G_#!N-B7H<*INC'X[-BI[LO=2V13TX6T0> MNA.3SO$Y>2+I3SM6A7]<\K#B.0C5&X*GK="/S%JUJ@.RT@3U.*R7=.#P$T1) M1G7:07>?;#RVO?8"YS1-0]4&_8"K4:DZW$H-4`^V.CD'#C5)D@B:$\_$P7X? M^(]QL/W'XXO#C;5.8LBR@S1*->PW=T(_%'64/IF;&WJ@'JQ:@@^=IP4/(I@L MB&1#2GRFWO8N=ANN^2=U8:6Z)>*QVZ+>Z>;W23.DH[1-VL$;X.4-(D':SFB4 M^_!ZX[':=C8CLD;%^C%9:CB+45DGKZEQF9[/&!F9!E+9UKMKYCO^EG&M@X@U MI`MW[(IT%/K]46B$>F0M#>IY:"'/DY(V@I1].T5H^/ M")PHW:;3\J7SMK-P*86*YYYUTA"]@ZGD'>9GBWSK%H?#F=;R\O/#P^KNB4C_ M^]Z>`UXZTW4\KF:TC"^=,#SRE?=/CI>H[L3H]D7NH)U,4'98 MK8Z(';B;_+V'.BKA9GUU-B<;-`6/V<,8N3$N5C_@=C=.)4#59-G=!/A'H*%P)V!K: M(X9]+;%[AV\I<5)07Q!./P_H+$5Q$^M,/H#2]GSWQG_EF@7AD4NA,,E)$^2^ M6:=0V1?+WR/VO5HQ^XZ[G-BB;K!-XUCC*&3/<=;Q"PTK:SZ%XK4-D3N16KFR M*YVW0NQ0#<+V'86")#G9A[#C7:-IE^VN2-KVW.V*[BB7Q'URODA16D/,YA[( M'5!#W;(G-C1'[)(Z4O<^_$QI$TX\=U%.GP0[L8,@2[$M/2]X@SI?EMUW8DN, MHN0K#3>!/34SH#I7UW:(K1,DS"P^:`T-YA(5F)TR)PD%RM7QQE?I:?VTO"75 M4PA[KG0?!@<:QL=[KHTH0O9+P@Z05/!#&$2JFDBMG9`[FY[29>]K[H'8'34% M[SN8,_(+(AC(`G,9BP413.P$`&,K_K"^7ST\_4WLHL,&^OTG<.[A2LZOXG.EG=3;>:;((T<)TX8\ MV;\V0ALQ\AA7<<`><28(*4NR(+DL`K?*TG`\JR+;H@IM9C&MO@0Q:J/>TBCZ MGJA,BS">4>_&MW1!CE(Z"FM%,KAW[[7$'BF*&6V'OVWA,:[2J@CF;F4S>I&[ M&'S<=TA,K&V.W&_;%#U?^Y^W1>ROK2(/W1$H2"/)4QQ!U_73CZL'^XF*`#OQ M\1.-7P(7S@FC&#!(M3F@;HW<(UO4+#NDHBEB?VR3N/VF;HM5# MO/JVB/VT5>3^AU:2,#F?0&V=T(VLJ3UG_"$(W#?FJ30O?8W^0R@C9\13C:M@^O[WQ8ZX`VW@T/[1>?=EZ"=2;:/$=S:[(_:J+`:JI MENW]$/MC)_'[AVH9DTJ6RE!CQ:>J+A'FT.:"N*S2^*T`D@9A0[&)]2IPH8]+)"#2HF$T/+9SZV MO:M1\[EXDMI_T'N-(5^QZ1^&O,*V/]PR9\,\%C,:+7U7%$M]"3R7!R+RQ*DE M3:%#=^0^U=409:_3[8O8+SNKT#OT*ACEZ4CQT7JJPW3ZWRPO;FYOGFY6CR)! MZ?''YKA\?GI;RC@0*^`6F.'^;B\1BDU=>MYN+7I3`%E.7LOH@]\X1:H/HE=`Y:XS<09N5K"N;4VV)V#%;!!Y<-B:E MBZ1$SLA:6LP@W!^\X$CI`Q5W!<[A1V$8G7[(G5-;]4I^85LGQ"ZK+WOOG,.4 MPX=0LB!U=.'29+`H8H&/P-E3"6_\;;"G3\Z7 M-B=O:H_.8TF:"-KVI^&1E15$Y7K^RX'Z$;5X*"R. MIF\#Q]<+CAN:(W?2-D7/,C-JVB)VT5:1A^4N",I(XN2157U\"<)8GG#K%G-HK;?S_)IY!X(:E: M=LA1-'R@KX'W"HF:=T%,,_Z@4L*"SQE%K#Y3,B!P5$[Y;*N-QY[%NEV+6OJUD[(_51/Z>J+ M($T]$'NOIN"]![];[W- M[EGM;H^PHSO=[G5;RM8(RE6K798.A5&XG':=F;8^\W%$O8HSC1WFX9XCU&.I M>"JB`C0C:[V^^^'#T^KA$Y*<#D7DT'H50*(CVU? M8[*H/(^2B_6O_2"YM.AO=7-E8^2^W:RD:G=J%E[<(K"I/:KBAC_&W:J1[N5M MTIMXXDP@51N-PY;/ZEI,=-)T)LY:IV"=JY;;SV*1BZY(6LR\VRFMX"6M]O\GX/=K:5:L]3^Q\97#.EP2[ M70N[#M`2& M4%F\/*ZP27U+Y"[;H%[U]8"S9HB=M$G:OL,RITD$T86H@,/#VILH2LX3=Z9* M3YI`4_+?O_GX'>".U/A_D&42OP0AI"N1CXL__>E/_']_)M$+!R8>6C`_6XO_ M\S!?A_XK:Y>TPRYGZL4 MJVP8G[1![.%*47OOB`J"J'Q[9!W_^S???52X]1__&7RWY+_?IZ805QC621S% M_`]P\C_\>?%G_K\__=,_B:_@SW_YX^(/'_](G)C\+\=/G/!(_OAQ0;B_R2;\ M\_4V#C8TS#[_XX)P%@>ZC=DK]2P^1+YT7;%^=[Q[A[DW?KI+KOAYU*V10T&+ MFI6K2_5-$0-#F\2]4W9SN@0(PV,`*6E+=Y:FT?/#C5+/Z?SR@<8.\ZF[0QMQ[9,M9;6ZHC<6_65+SMN>R_$/MQ!^/YW#20+DO$@7U7?M!-L+!6* MMJ$_IATR[3T'_-ZK5JYY)PRQ=S8(.\'.UR@>>>!+T\!=^8U/<(Z@]X7C0>'< M$75ZC)TP?D=:M1XMC*"//%=`6XBLMAY;^\&+JAMR0-55O$O]0<1@JRVZV7J# MUH\%QU$V/2%$76*0(W9,X<&Y2\^)HO5.F&'YA:F*\C:U1^[+K:I68R1%8\3> MVRYS[ZT\("AVU<7>^<]`].PH<,)M\Y)^5\&>+RU4>YIU#9$/4[5RE/IT?0+VO2;<*(0YVG+Z@G@)[K?T%`%1XT]D'NAAKJ5 MZ4+='+%?ZDC=>Y&=G;^>'KS^+!G8RB2QH#*6;))[)UR'(DAPQ2'S(FUAM!!"@.#30.(T)N(97!P@VT"*T)QW<[4;SU\8^2%DKWSA>V3/?$3 MF'LATO4#G\M!Z5YLP1]R1TISNK[B@%+Z4,02I?815]<[0KY'S*D'!W$S@E.% M_V*031)^#5ZW9S%`4AR03?JY2S:\FT^XE5A\_'U$MIP?AQ.Q/[4Y>LZ;W*HJ M4LU:4LN^&07@ZF#>WB]X!G.2;RFK9T%N5`:;=@)`9*12SM-Y`F/+J,(21)[: M3FNZK>F$=+;HIK0Z6#SM,9L@42GX>%"!(2`<7^TSY\?ET3+CLH.M\@XS].2J MLFU>+%O/S(-/A#;MO2/F*O?RW+'431.1;7ML*3F[XRZ.7D_D/MQ!?<4-@QEN MWG21WDR./L)M&SM&,+UA8QP$-*/PYA[S<7J=^+NA^3R!>SNHJ-HBB^RELJ6[AOJVJ?: M96Y.6J-PHZ>6VL_)7>O$-NNS)0Y(''<\GC!_I*_80^TO"5;6ET1Y7%FI2MD0_=%C4KF73U31$/W3:)>Z>3`5V2 M$EZ0C/0"RG!:2IX;2=.[U1-Y6/VTNOM<4_';B&H:]2]&4X[&V8]H-QM)S_?@$<_[CZN&G MFTN[[PI4-+RBAY!NFC5?KZ&#* MT1>DS$TDN)7Y87#^,WZQDY29U M;4O$_MPB<.];TT!6#-.4Z=6BHWS,/5#HA]54]N@_.MX$!R%BBF6,-:/U#GF?JQ3)CG8I#' MY'#P:MY%FUNYHL_$QP\-O&L=J*^EC6*GT5=F3O2-[/O5#&$31?1CLE"5( MJRV0>U.-.F57*GV-V(_JI.P[W@0M(HG9<2"CVCRL'Q_)_#S21WSWP&F\M0!3Q=:+:_Y",W M%RN$P163R/Z7X",^LSEXZG+/,\5YGJZ$"[9WT+I*[8H$Y>0ZCZ-?;J0`II^]?]81&AGLCP)2%,'Y$X+8`:/ILF`)45*KBY%96!TXI M(I;UQ$ZP;6((F\:DPFRV0BC5#N>$^HM3@Q]6=ZL'_B^4_%]>?;JY^X:L_N-^ M=?=H=WF-HB4A^&U+9'BI(9ZE;?K[@=RY_K2RG']R%_A!54N](P?MSM@=LY,1SA)7 M6GMB=M]N"@Q;N9?YY*Z=LOK:^GG#5*9X^G'U0+Z2CO]U/NM:/&*X\;EM:*38 MXU"W0N[5"K6J%Y$K31#[J4K2OJ,PHV=WPW!JK:;TJ54L6A$X0N\YWP2&YBNH]$5B(?Q#&WH"=1?(PUD>[>_ZQ^ M)@'[Y&)UO7Y8I><*Y&GY'S8/]'*[I!/=!?6I^G:0NO4L(%6IYCG\G35%#U5J MB0?""B>A\$KBR#'`E+%RAAHSS/O:%S`TO+581X\ M4_<4E&JTO@2>RTUVX41LJ[!8=RK(/;FG6WI$$8L_OJ\F04H358"-G"B\B MEBO\IGP71'"V`Q?VS&,G&)IGUC@=_&VCWMZLL7)"GX>_ M4?:V3=/;R^\UWV&:"K-&LD`Q-><_-%@`B*-[B.JOE#V_Q-1=<1D\=_9 M<*G`K\)&]B+#*^8EL?(),75KY#C:HF93?)@V18R-;1*;C!%3VCBB1%.**N+$ MJYO;SQSLL$>*QJQ0'RNFY.<2+:;BZCZZUIT*KA\??D]6_?[YY^AN*9U\_40`,A=GJ MVB$?XDK5%*^ZRD:(AZY:UO[5BHLS'_*S)&KMP:LQE;/G8$O799#`Y7CW#G-O M_$OGP&+':W2VMC[('4]+Y;(3-G9`[)!ZD#"R[ZJ1J?V"Y MVO:<^('&#O.IF^UD-'JOLC%RMVU6LNRO]2T1.VJ+P'V':D:6Y!N/=AUS*C6M MYOF&E`MU1>6_-_YY$/\0>-YU$+XYH>I4H#L5Y*[;TRPG^<)=2"!V]KZ:#$BF M$GS(5QG'KPFK)E+]/KNK\#,P)BEG2RB!V#X6MX3$GM1-%"7*L\23)L@AH4ZA MRCY.Z7O$SEPK9M^1*(DMB"0WBO?)BJPKO['^@5&E+AS><4M'WX&6FCW&3AAC MTFW*76,.6%*QJR3D<="]L,A/CI=0\=WZ(&YJK;[0<,LB-8[TH(,=;/J:IKJS MW)$(9MCJK4MO;!-[>)(ED3R)9+H@@NTBW>9+.9.2 MO;9K<5&C,(5$4@/(TDQHGM"B81P-;&F@,C]PT5%F4.3T`?YVX9@7;BW*8L[+ M,.049=GHS9&4V]T[1_'Q$E81B\SE%CGP0+GH%*)L%:*R8,F8X%:%YXK&&<;1CO5HJ\\-C'67&C/84D+T@D#?)_>\Z M"'>4Q4EHZ_EG:W:[.#,*.K!)0=@`VK10FB?>)-$I#Z(8SY;[SPQ2U"B.&+F5^J'!B M9&M`U9X2=72@(&&R/RK4]I\G+*A-H1UVS!L8&G08,\1`"PUCV^,$&Q`%#P_T MP(W\`O'-TG-%1"R/YZR6>XK6]2S@Z M]DR?;W7<7'Z_ANB$EY.9(1+K3`F,\-=6&B82A@D+*;!CIIQ.!IDT)_$N4+-J MD.ZP*?O/'C=/U!@5+Y"<4$UED^+J,V[XR.\O7CK1R[47O$7Z5U;KNJ"'AW:% M%1=4S]JC=G\-L4>XCGJY?/R17-^N_VJQ>O<=C4%G4;[8I>[%\3-WL1L_?Q!U MN8W9*U_VT*BN,GK+Z#=&'+F?F#7B2:%A`Y01^YYA!8?4LP$Y2"8(9-1\!;(0 MYG]-/YX>?ET\]/-TXW5]T^7[M^3]!4&>'V"&TB\ M1?$4/%!P<.;12B'@IT#3ABT(.`%;Y-@XE>&KEYK'Y8D83R=3O?\=XUQ`^1`, MH&[Z+DPR*'&:[&*`,E3K]$,-=)_'[^DB9R8+D;,2&39F1'8B9 MW`2M>D_I]CL:AM3M]@95>R_TSJZE=M7/&[N@=G$]R?L/;4F_]&@3EL>J+*@. M%P$RI4=]#UFCJN)DZL?\)S_D#WA]M5'\Z!-?B==./IYK?K%^"O'LLH1'2F=5 M)/E:.B'ZK=P3^,%A/JS.UOZCX]'UCJ^#^.HG/MYS#6.HGG&`]9/"2MJ=D7MK M-R.4O5>O)V)O[JA`WX$/;+*M#C@@YKS@'#3C1@0[DO.SE5LSD36^`CY?$^`$ MUKABT2&('$]<96!?H/1Q%-'8;CTL0X^5OY-GQGL_$#[WI[TG?)1;^>ZV+328 MQA*??9=%<<@VHI!YU0A?21$D5(QIAB>]MX7'MH5\:X/#8%(QBE>COX*PXH\LJ]EL^")K3)Y0M4!@$S MR"A);-G>,F?#/-LG-0U6D++V!XJS_O/%B7I3:,)$M?,\44*APV@@D?H)8HPP M;)&O,E9?DXP9MP@J8%ANMT'"0Z8'NJ7L%1[+UK9:;=?9P8':`,U(<-YO5B#0 M(+YA_\\XD8*5Q874^&;0T'["6RLUS M%E$H9<-+G&T%^;U'6=G0NK M#="RWC[K-RN';A#?]"H;.)&4E>+YUWGJ?;*XR@ MX?@G/>?G^BH%1G'^TXTV9.YOVA92:7R.?YE$<;"GX14]!!'KX/0U'6?G\"KE MFYW]M->L'%TIO&$GS_B0C!&6W7/C!E`IB.(`K73"U_\4K9[([+Q=QRB:YVDU M%&:%`EJ*C':R5F**^7AM.MN@/&.[=XYP&@#WQK;;,.%15&&/SB<6+<1FAR5= MC*1W,M=$:5;8TDFAL4[O4N;R8J)D7X8=+%@SB:WZ&F4N)8<4UAY,%#DHF3&: MN=)"B$'*D&+V2PF-@UM!['A-N&7;?*LG61CM`ZDK(80.MF1J]TB5TKH3GR>, M]32B!IQUI#P_6.NKX$CPEHLSWTII4UOTYNZGU2.>2FGIVY'14R!JWH>4V\=- MP!2T\:1(IQ]R=-)6O9*EU=8),:;HR]X[>RGE`$6D4AZD8&+Y-&A\]H9Y(XDYH8' M&@9IA(:&_G-""1TU3`)&P2]_SDZ$(!E3-/@QIF$RVI5W>,@#]4!*`L\OX-O3 MT0RE1HG/\,.+&:.96P0AAB!#BME?]*#:TYG,?,6>3MUB!QUL73/?\;ET M)SY/&.MI1`TXZTAY?K#65\&1X"T79[Y[.E-;]/KF;GEWB69/YX$>TE!UO;L- M_.D/W-7V!(C;6EV- MINS]J:I/*E7M>FA:%41L$ZTW'GMN7"UUHS!#/VXQ1YMK*[K/S-O;M#`-`%GQ M',&0E#AB0H6QC%(&"FU#3(<9M\RGZ]UE2%T67SM;2.PYGF8=B9L(/"A26+,C M">2HT<<@9=CHTA\Q;O12HZ^/`#/A'X(=R?@M2$W2WD+>!A*;N+;P8U+C*!(7 M'^AKX+W*Y.BR]>P?_5P'8?'F)S>3>(-35&1NV0)O[(@<-O25KSO<4?="#!$= MA!\\>4+9BH*)&.VE)W!MG]V,:`'%2[^6:I2@T7?2"D-;2EU1CE5(M3Z(D&WU MA89;%JE/L37Z8<H@SRCXR?GPP8S1SAS6(D<608O8/9U"=/4]FON+LN>Y0!AUL#<>H M=P5(`]'G?4"-#5S!CR"CP<7-W>7#:OFX(E]=K>1?7_//)(HL[Z[D'ZM__WSS MT_)V=?=D$4,>D\/!$VG#C@WZ\?/#ZI&L MKR4X7-^N_\HAXWK]\&GY=+.^ZY7ZP9DS$"Z MT7-.6Z%WGEJUSM\RS)N@=J%Z20><;A>OAMOTI/'4LN=06?QZQPD&4A+1ES6>`+'*7-66XLH\/I8D8%(RI-B@4!`D6))6A=)\*KDG7 M[7"30A#KJT[K%JPL1Q\O?UQ=?;Y=P5KT;GWW0:Q'2[>N[JYJ]\$M1MR*[$T. MPU!`715*M/="CU-::E=AJ+$+:I31D[P_B"BR^[U^T+U+9"ZG=-+/N5&VP3L:<)0T?O5Q@\KIY>6$2HW$LE M(3UPN651AA=*7ATO$9D?!\D-IN,W+D),H<;)CK=Q8O+&UZ-DEWC>D;C0?^;4;Q0N1TW@F$$2<)I@@$RJA9VY,92[4,@53LH5)LN+%B'SX[/?A6C_I)C M9N`Q5V[C^^Z]'(_B/]>[-,IRO$?^B2RBT[(*,D4;*=2-8L)R(&*$,.)PQ:Q^ MO2N^.!&+),X4+"TFK#@Q7[6L=^UY*74-D;N*6KE*ELE9*\2#N$'8WMD1@J3, M^BRN_#_1+S&YX"/O'[8N_9O7M(P`8A+1M?^2CL0-R M?VQ7MNR7ZM:(_5-#Z/ZY&ON]$Q[!41_9L\]V;.O`2W0Y1Y*QG&E\5]I%\]V2 MBN0N[^]#GQ840Q"#S.YGFL,UMW'M@#-_-Z^>V1#XZ_9"CL+;J)Q?XFCLA MQCE]V0?<81,-SR4\)\9/"$FJM1K)_]TI8$<+GJ9I(P7 MG0@@!HQ^>@Q(-DU9('CA6J5MV\2IUQ.Y`W10_R3CNZT;XL'>17IC0QS71&C% M!!9O.;X$80QU_BZ",`S>^-*T;>>[N0=RK]90MW*#4=TF*;S;)BCC1 M25G`TN0S<0+5V!90ZFEQDIU$<>,096:F+9?9;IEB%4V1PI>.@I5*L#7M$,^F MC>+V=LY*:7148[-M=:=J.Z/1V;B"JVTXD_%I[> M">/C4^CX$<<:C=>0-+HA]TY=Q:L/$33W0>RSVJ+WCX'DTX6"`RFSP#>X]3<6 MNU&8Z9#7W&CLT'V&CC#.ND#E$S@61[AL@J#*,N\O@>=RRT!Z2GR$G<2V<[&V3L@]6$_IRNE88P_$7JPI^-#"`3C"J7IE M]>>E+OUG.<0U9RSMSK,;^&/`>IG3[XGD)<]C4$UMTQD$W0,^*R?T(37@GH:/ M+T[K&JNA.7*O;U.T[.2JMHA]NE7DOB,V(TPX92)(V_'1T12$*OUIP`DJ9AX* M/"R6[#I5MVU^;FH_,\]LG'^5C6?DF^:FDW/G1#";3JFN/0#",(F+0,*38H,@]?WP/;NC\ MU0GY2M9FEK*V22[*)FF;.8=3?2].UVRV7EY73_(]N%V+9GW]KK0NEL_XYA*0 M[)1.R+"0\]\'X?TD?PG8_NQOVX!F@4N1E[[:'[Q`2`Y/9`'@1DO?A:($B2<* M$S^']*SN0,-K,@/I(04@8Z;*T]V'$$,(.N9TZAU1Y\Q)SETX3<&?%`)8]J#& M>Q]#";XW'U+?&1E$#?N-$C/*&9B]X1R3%MZUK7C7MO`N)Q?H&_+T0HE;D-@[ M1Z@2"T\RDH,CRP#'0=%#D!+9N<%.U`W.OYGX$HM=HW?#,!PG#[,SF\5;":+P M>GJ:VG9E1M$6*;AKJ5BYE5#7$&%@HR?OP)-U]BM?^9P]1X#CE8TH?WZ[7(1L MO;NE440['+L/I8E\X!LQF>K]CLX$$3N2&;W,O(%!F%]?49!'(5(&'',L*MNA M`ZM@OV>QW#,6,0?,]]3?=GKIK",-[QR05\.E"`#/8]-)C2$I,RBT+/PM^ MR!VD=?KN2N0]N$CS!-V)PMR=Q&SBF-)+D,VWB"QCM!9-G$[;>GOZ+>V1>KJV MJJ42-.K&"/U77^;^)5.F%K:0?-ODA'<"\35#=9-#HB M'-G]Y.\]RH$+2=G43$GVYZ&)[(#`VV]\#F!\4=M^0_:\'7(O5JI6O49XT@BQ M=ZIE[7]A,*6(8`!VN>C:V&4NPU+[HJNZ_1P&ZS@775/BN)8OT^ALL0`+B_X! M\^%G+D48.\R/V]\Y:^N#W%NU5*Z456GJ@-A?]>3NG5I7>L1&T1N[>6V'U']'+[2\(B9ODHMD9%_;E+ MN_/\AK/F_*77JQ@XS&\GF MX+@TE$OT$4Q'DZD]U(,5"0L_4L>+7_(=1WC342]S0;RZ#5"Z&G M]A"^[[B57$BQ>0]\IAJUC3<`M7O.=MRJ[_3I=<-^>:^C%@9NZ3&?<$T.=!M# M]KK']@QNV$?4VWW8);[+_WZ1XYWEX_W`N687[D)Z"$)Q4XJK!;7MX-8?BZ/T MYA^ET<0W\2:R8"T(X%A,6C>#U93EO-S"TGXYWI+K=<Q$O7$FXCUANP_PM.WBM^[]F*"-')8/F*P.4`;*(LG0+ M^ZDYXU+=D"LG=I"Z2]MTK]UYSL[1.&7K]9RK*YB;+.H&?HD1@CEU(D,@A@(X M@\^V1[ET'ML=H?:>G.+;5N+:G9%#037JX_WST]6GPI;OM"W<2C MZUVS93J\'3>((G+/,6"NROMR_B0[:1; M-=M<\`K*U08>QW6^ M\6.N$]MX=!E%-(ZRKZ0)%(;KTA\Y-'0V11D;M#LC!H?N.O3U@HR<\(*"%Y', M%B3['A]03&\CE-AP^M]],4))9[Y8T6P:3-#MB]S9.YF@[/!: M'1$[?3?Y^XYXP:5TSRY/!R@XX0.":4QS`@;94[&)XY'+D+HLO3YP%22;>)=X MN>D,E@2Y3,*0^O&-OPWV],GYTCS%:W9!ZO!=%,ZK?[2TQU[V0U=\`_4^@AUQ MB@%]D)X,XWHK92!,"$%BY\ODM3O&-D-*GT@&A'.PCV66%#?Z,-@5W5'.P.V" M3QI],`.4KLHY0K5UP`Y1VO*/B5%N*H1-D!K?$)F2Z&#*ANHV2ZJOG-#G(S"Z MI^'CBQ-2O9V5]EY(@:VCVN5%5DL7Q,LK7)SOI$5MIC* MN#\X+(2@Z5N=DRS]1*7@T/]>8UF%N0HG)#[_(CF MK>1>FF>#&'W&U+9W]F,N$^%+H$PJ<'*0ZX,0K'1HF\HVA^-;C-:&4Z57&CH; MYK$TRZS\`^S.[5K:-3_[0>RA[]+E6L0LXH:[#"+=BR3MO9"CHJ;:981KZ8(8 MK70E[WWR4=`G@@$^")GBPM\>J&(;E^DT-?+ M!)4Z&#H=$03O7:0AYT(D&WPABB5#&`Q4BBH<=S1^I.$KV](T)RYZ@DR; MQL"E4V^DWMS3#'E@H]\5>Z#30Y/>.6G.)O&Q+%LFSK'I+6XH`\ MAT$4D4A*PV,?*0Y\XX0A7XX3)R8^C?-O)HYJ)K19N=8/9T92;ED**Q2Q!8:6 M`Q]+!C$Q=$:!U>;B1ET@MB.E>N M!-&[!L0,`+F[\EIU'[#`;=,ZMH/PH]1ZL(X3$QKB,=GOG?`(J'`HUWF@N3$^ M0#RV#2*+%1\*R+QF/HNI..\[/9QLC-F&44(.$0/,4U\&5IL,8A`9HHV).59R M38^FST^PL4",;3.Q4F5Z_G^L,)1C^3@_DS)HLLQU$L/K%7MXD?=7H<7J"[Q] M23NAD2$6,X$IDP:MPR\3]&<`;$;5'!_Q%D3*1,I"D50J='"(SK@TS2YU8?%6 MV(^F]@NI)[Z,`_[GWF&0_(T13->[3PXW'HL9C63>V1,-]U=T$W<,W[3)S`04 MNQJF/G#3HS$#<.NLB@D?*UCFJ9X<,/8$V*)#*"L6.L@RWH['4>;@',7Z$#:1 MJ+-]@>\AGV4'6_A1LMU2*K)B=RS:\@Y'ZH1R9PGR)*BSXYIBP*/5;D>W,9)&>#4_T-5H]9W>G-`K\&J&7"4W/VY3NM(`&I MBH`0URQ;+JS:1ZQ1LZO/!)Q";)DS/P%P@QTST2[BG^X/B0C08H&#G[]Y_(;L MJ,L;>"*[+X%ZRH)*"+\##]6@V27OYOC'WT>$YC]9B2$TQ0"3(&;@PSGN>I?_ M+FG8FSY]WA$E^U"<#4CV-E<]1G8F-PN([*^5"3\ON,L[)CE*9FO2KU(9OD:( MD79-=PB#5Q8!.D+P5ZX,@0&JLI(&W")RO;[TW5LFKQ>QEO2YX=1F`U&]S%0/ M3YU(S0*:^FEDPK?R@AP`1:7K;B7N"/'(GKT@4RPO4@,1D]CJ(C][*??CF6VL MK#)/ZCU<.!';CB6+2YEYN!RSDJX/XJD%SAAD^43W&QJ> M*-N]-U*_ZFF&_-*1?E?L%XUZ:-*_]-(![@U!Q%).Q(0T\#2'*#VE@GZ$IH+! MCJ^4C$0@&@D.LAN78N)K1Q/:*F-%QX[LRJQD[?A=6BI:0,\WB8\<,G_K*C8R/)1SD$)C),A_,F\"0!:;I;,60F$?,D;.UC'BE-V[7&X\]"VM= MBZMS?Z-.F-[U.V;VU0*[H321XYP1DY4A;A!!Q.AF1J^^_EA^O;E@OR!2``(2 M9#=O^8H[0T$L@&;7=I6B;<_/(7V&FV-[YK-]LAC>@?1>+VFJP$%R5[3N8@@FG&27X!Y`PIEP5%,'CI'%CL M>+<@$+Q5TZ/LDQ8)Y,#7QR"*>V6M_1'#6B\UC-PWHM/$9I$U1E(H MVJ8V\@1X0)T2%LJ:)%E!`.[M_X(!5&0UET\24X6MTMW2Z#H(RR;L7&&N/^'9 M`-!0XRGJS_6D.@NP&JR#GR=:<\3^_J94`/^NA&>'P+VU&\$$)22 M5%$P%V8F.&C1FBU02`Z970.?^/Q_6RA=[PEK!KF5TW#Q*[%(C6##CE..Z*LH MHK+G:]H7R+62?\BV7]M#TZSHUCW_=5^X+)?Y>KP-*_5Z(D?"#NJ7<4ZC&V(4 MZR)]7Z\J*L]E7$C!!@T"36&),KYD<'+(;%)L?Z&(J/X]<4)N-.]XS7P.;1_H,*/A`#U`9&)YMSRUR<4R_U+R4WX'2;%"GLWD4:0^Z9&:!.-VU M,9+8(`F3G&T9;41&5];"^AWYQ^P]Y@N^#O%I%*6210V7YMOZ8'<9'94KSM'4 M`;,;:,G==\!G1+.Q'%F_@)\*TGC__K0-]K%:IU)E;)8;8!Z+M7+V!ML,/JW> MO)]6IP$72KD200BMCT_PP(+_G/FN^A9I>Q>DGM-%X?R^:$M[[)=$=<4W<#,4 M[G]Z.3L22WYDDS)<$`=JYO.H1ZRHHG1,IS7S(3DQ/DY\*W1LXQ3T2P,-D6OY>Z3XI52E/.OG7R*>\<]E[`T_\KZ+Y>A22%$[8=:W MF,/X.I\.:[[&/L9,37)RE%E![!'U&1!-FO&;],BVT7-.VR#WG5J5RMY3:8#8 M?^KE[#OBL@P#NSXTBD[6-S7J=C!OVRI3Z'5%[FQ=#%"S,]+8#[%K=A)_Z)Y# M[48UANH/4QAA'3X[?O;2)%PC&;*.4>S`W-,0KN8YSW2]>\C7QZEZZ>O#P5,0 M.Y[\C[H570\:2%U[D$GR39NN!+#OXO36IW>ISYRA?!#L;-LFO>H`9;^`;?K? M$^_?6#9+P3(_M%OF9A%LT_^VL,=CV33%\(`[=8''7/ERK^5'>.\2B/QJ+*** MDQH[((50?67+,9&Z->)(2$/HON-9DJYWF[\,_JEX2].IXXM8TO MG3`\\C#H)\=+Z'(3B:NO"JMUI8%\G/76>Q<"B+VAGQZ];[5S-B(F%G^4 M&"[@_<^,)Q%,R<\96UN7V'&8!D.NW'T(EPWB(Q17BKE-0+R#?H)<:W?D:-'5 M$/6I<,U]$6-$9Q5,)+UEK!:B<%DL7"-G9S_1[9/SI7T;^J0-\E%>JU)E&[K< M`/%XK9>S]Y:MI&9[&WH,G2P^;J,"DHOC$^?=],225D_DKM9!_>PR!NE;\$GGNSAT?A98VQQE"RN0=RC]=0MW+56=T< ML8?K2-T[.3*C3DTRN,<,J^;:KV]GD"W10?A19BH$ MN1(3FD#H3C/Z"+W\<_7S<_6U'+WH-D=/KY%^I*!40MJPN>T;1!+GWUBE4=M/R]XC]L5;, MOH.N3,R.:XVF#M2&I7YTAA@#D@I_"`+WC7F>(A-`U0:I7S2JE"?]G39`Z!G- M%(F`.(M7R4-D8J5/I*5F>=NI;(G0S38&' M#LP%*0@3H&QG7AI)RY)N7HUNMKR0NLOM-MDG'@2@/1RSN?^L?%7#%&KW;>@\ M&X_6T<&4DU,7'IO*N6%T_2G,09R2#9P]W+WYM38FMU+2F_DLIK=\->K>^#%7 ME&T\NBQ>?5!8L1,!Y`C1W1B*"MPMO1%C1`\EC-32%LP^"&ZD8%=]',7B066# M,=I./C2[(G>-+@8H.X5./\3NT$G\OH[0-OBM'X%,8H62XO4WG8SH^DK#38!` MVW7\0D/"VG2>#N&6I7!DO3M57&&JUD[(44U/Z3*>-?=`C&2:@O<=SV7R,*&? MP9@=Y)I2ZW0CVJ(/-R!7:7%3%KH[!*H)(??U_L;1C&<45!!CP@!EQHEUJKL$ MRX85LO7`9RP#Z1I@P@)M])7Z"7V@V^"9FX/+TG)%MK$#8/$%P5_X/FOE)/-FZN. M1Z-4C$<:OK(MC7X(U=O]3>V1>VZKJI6].E5CQ'[;+G/OG3B@G(W6!3:*?E>$ M_MI7@]X%$^HG5S'QYMSLIK=@L\;WDWK[)^JRK1-2^2]S[R&JKZ]5-H38O+&@ MQ4@=H$%!"7N9NN&*&7J&8%OR(.?$@]P<3T(JUZAQ`"?9XJ,-\SSYR3Z55/39 MI^).7-_.GCWU`#GC3C+V).6/$I_'LE5&]]LV*XP;CWF>"'6?7ECHWCMP!<`Y M!F%MN=!!U.:-T6UFZA*_*4C-'Z5;-<,#TS&(2`Y<1L;7?X$XDHQ?'+\>OQS5Q1*C(GL_N\P>J7L@ M\OR1US3"RN+,>CC+T71#B4O=9`MP"S\6>18;35&ZT13*C29TF#D--HX#?_`# M#8"_P:K+.M6]##``]>JV1N]H?$%W04COP^"51=R'KH/PPG&OZ*8>!/L0P8R) MO8V20V1G"M@1L[]"A@#4>7X.Z3.//S/P(VX2PN$8?'F@(0M2I$PQ$L)5WZ4A M!U#FBT8^/$L!&)SP0`?RBHH'$3="C11R@>@ATTB$-X4PS&]U7+,,9$\'9`B9;L,[).8^P"Q](4X-VG7+K79T]ZNS6J3=FF.YN MAN)=$NVNV(&YAR:F$%GL`63OQFZ3,(0[6"D4IPF,9/OBA,]P0^G987[$6_/O MA2X<=:%;L-M%W(G>7MCVA;"(/%.?-_"\H]Q3X%P\+WAS^$"H(K'X+P']27@( MHO1U%`[?V900TBUEKW#58_+'4*;[111@#,:H1W(;#Z!,:`X^LF`,GN"T[IPU M`)'/\X#*[[ZTKQZ>`I%)D$TL=78TSP(SMH]DT'P",$P?^RPQEKJ&II)#YFAGE\)CW/EZR^!:6W\,6:T?*893!'[W&).04.SB9^_&.:F(I$18*A1L"?&%17Y,F1U= M'K.&_G^\!27<'INF'_GTQW;P0-=Z;6$".8[+XB2D#95].A*`^G4,,@DY;L"G0@@ MS$<>ID=?3\JY";\H^)&,(2DXVJ_O4=@F#P^YE1XH'$S0J.4E'NW.L_$4'2/4 MNTA3SUGXAI8"PYVBX"/\(^.$XV&>9FLTOLRCV776GJ!^FT>GWVR]P-#+-+4^ ML"S[@-W7>>P9P=$QPH#-A9S5=1"6MD0N0^JRTVSOFB=X^M)`ZNN#3)+O%'0E M@'UCH+<^I@XH\Z-#&L&SX2QZ@72Z(*SL,&^E.#(A.95GXM7^Y(;*&1+.L;*E MF?(4(%JZ\&?E423;MMDI;#,XK<-,9%6VS%60;.)=XF4+HL9WS[0Z(D7:[LI7 M*FZU]D(<4740W@PN9$R*9;;=Q]$F-<"NS@`8EE'-&RZW+15$^]!!#@6]3=-G M8^YV!H5&^^LRS0;=K>T:I+8-]$MA($>!+$8,H5&@='I3%(M4#&A:MRZ_<#SX MJ->:ON@[&]34,('^OE3:<1;HJ"/_:)LR"Y*R&L7S91;N8^R$",?67-[MR%M->E;#Z4Z_X@&_XD0?FNN^P?FK%\+U9#Z=!Z[G"=>3#V),?*ICP]S=@(DT`=,$*&_9 M0GU?4U0=B;M\EHA9Q$?I91`UQY<-;3$#:YN*Q5&VHB'6,*Y5WMZ[705A(BC; MC:NFT]/BN6@ARDK>0E:=)]4U1.I^[ M95=*CWM*1D1R(B56]O/^VZQQ_BFE=\Z^Z3;`0)(S]QP=@W7QIR9Z,_8R+;7Z M^EZ=OU&Z(,#`^MT"E>:-MPI:.R'W&CVERW[1W`/QR-<4W.S83H>VU7L#5A1? M-&L^9*.:#VK/N_K"_U7?!JAKA-05FY4JMI!/6Z#?(%8*;&#[-R.^@+^^61#' M)U2.P[TFM[837"4VRJL%T8&%WE7``$1HOQ9RW0N[I M"K5.`_]2$\0^JY)TR"@4]"Q?61E-+X/1^742^BQ.0GK-OL`_XNAUMV-;RO^X M#/:'A*O9[$1#Z"!UL\&FR9![QU)$LE22X$04"9!1-P[*.2D.#%Y<5ZA.CP0VCN^[.K[="NH MIV6(HSA,MJ"IS&?=),QS10IS2)(8$L,8C;[A9U,9!+16)2E!\E+:2TN&&3+G#S[)54(7EO*B(C:S"$5(BP(K.QC MZLL<74Y,R"X?A0?%RN)&QP@"@HG77U8&5LZ49%S%_6?)5_R9<2:V)Q941G(* M(SFU1K(7]#V%CA\=@E!"F%X(V-8'Z4S52>5R>-C8`7&PJ"=W[]L:%>K6'=ZN MTO8<^)K/E#$5F7^GJ8$7QT_.WX/PTN-S7L/A:3<*R)V[ASG*KMZA.V+'[Z-% M[^E.\$I3]\\3:3='(A@2P='Z26B#90J[M!Z-=JAKC2011RW'Q^`K:<[@[/FCYFIK&=/D<4BI.:AK]KK$#K6B)U10^C>Q>9STJ2@;=DUIU;7Y`N+3IR^*7/+MI"VWU#&M*$M4I?34K%X M*U'1$/L91:O*`1OOGP=0MQH%;**\XLO!R]@<(]5')[['08'>B6[9ADZ#EO8D.V>A8AY(I(`J_B<@*>-`IQ0B[IL_"@J1]*'.L'2@F+ MG?N,M,W]^M$5=4J*8MR$^!S17>+=LIWJ,I!F5Z1XVL<`>GL,13_$84TG\4=9 M+R^(Y$2`%;;]`X-&^"L%#*?NAR44)'GFVN^#,,X.5K+0[C1?]RTIK>F\ MO,<\7;4)>9^W&0KYZT,ME@1BEA(#HT&XR.W)8^>>YH!M=(=2)B?IC4DKHW:#0J3[3XHZ(LCC[.>",*4MQE__3K)"%L^]^ M*--&[?VA2]E,`_$%2+TOA*EH9`-C0(#9H(P1:W$`^/.<<.::F]Z8"5-B[PYE MRD8:!C)`Z5UA3$4A"Q`#_.>",$9LQ3W_7V8%,+RM.0M*8N\/8$I&&@@PO.W[ M`IBR0C8`AO>9#<"8L!7W_+_,!6"6.VY%HRAS2O%=04VMN?KC387JVF M11X'9)@7_I@UV],+#:FP@CTHNF4^7>\N0^JR^-K9BE?&F@KG-[5'#B.MJI9! M0MD8,02TR]QWI`)E.+^1M$E&W'[9^ZJR#?48:ALB'[!JY2I70L]:(1ZB#<+V MSED\'9.6JR%456PL>:!H.JMAJ2Y>4-=N-D/3T$7[L\%IMR[\DQ.* MRI(/3MST1%%-,^2.JE*L[)NG;1"[HU+4OF,Q(TB`HO58KJQ>8R17VW!&0U$= MQ9VWFLEP-!3>G`Q(J_&;-?4&%+.XHIOXQH<*QG#)OZS!!1<`_E47M^C0%ZFO M]3)!7OQ"MR/V8AB=]3!4'&/C^/_X?43@.Q+"^!9UJ>.`;!UO*ZY*B6:OF0^( M-FE1#)?+3%@N],35*2:S&#`B!2=2Q0-@EB*#O0(6MFRQ4!EC$G1<)6'@!I[G MA'WPL:;W/!%2908-C#SM.E^45&IB""<+^N\&)HV;K!DH2Q9$B91CF^,4*PM^ MN(XV;UM>8VOK@Q1$.ZG<=LQY.X-GUO3D-G[<>6O[+;5Q]2XV`OT@AKIP1^'1 M'WCHX_\#ER-_(.-4>?`OXF/'>S60&*&;MYFD#:O5_6?&0BT MJF$8$Z!6MN!(5WRL3BQ1R65AO MHC)K9K[ZR8=;L#KB:\:YO0BWNG"_HM$V9`>`DO7N9+]3>13>D03226>(0

#P9GC7FJIEJ`[SH![!2C2OO-_VARI,^LJJCCKJ[3%OO[3$;WON%Q& MV<;+QO'$Z]K1"Z4Q<3GQA7PE9+>#%\5?H:1BREG.9_"NGVK:F+VN;#RS4:K.8J]O.:.1:BC=.R,K,56.5*LI M[2/J>>Z3UF\F?J(N2_9/7*Z[(%8\Z]C6%KE/-JI8=LG:AH@]LEG>WJ<6@BH! MLD30M7S3<$PMI4,*NEB6&K15AC>W%`%8.W&=%.3.S!KK>; M:1T/W/C;D')V-_Z*KSICYC_GZ1>G$UOWWDB=K*<9%&<)35WG=;2@I8FA>T-% MUB=+N?(_R@=C>4I81,2S3E(@\6*T3]].#Q@BJR<,HQKN-+*X*=DK8U!3?>6)")RW/,;PZ%AQV*LU6;000`JB_8VACF":>L\FLM%2 MPEC$DW$3AX\+(AF6,CXQ1$/C6Z28"(H#2G%B.?R44BN*NDM@KV.]6T$RM'S. MG&WOG:.8FMHALZT[4@CH:PA%(-78=UZ1E)XJAD(I7S"#4(H".QCM@A]TE+BP$#R'_FQVXD\-*>4AVJ;ED@J?TD+;A'+?4!+GKUBETFBZ0?8_8,6O% M-'-D;B\;P)A"`EB").8>YH-;C:+2*PTWP81*/04<+RS.\V5E+H[9*_;9@_`: M%JCM-".X4"NM`I#S'C.!E`;!3>7EE!X$)QDS\G/&SF).TH@VN,]G]Y"FJSN1 MAT^=[4N6>K^#7/THV6XI%1'!3MKIR.T4B:`@QO!V3,E.J948C1XRI:+U+E?U MQK^C7^*G-^J]4A'[-*7+#J$Y(R3I;3(5T'0F.!,-V$&0M2[PF"3@S4&WE.7[B?.>"< MJC,QSLAWQ]^"&:"+*4MQ;__3G$`%WEDW9K^4V+L#EK*1AD%+Y5G[]P`N%86L MP`M(,!>`,6(M[OM_GA'$P$/KI@R8TGIO`%,VT2!\J3QJ_P[@I:*/#70!`68" M+D9LQ9W^7^QARRHK_W#C;X,]?7*^0!;/)5_N,3]A_O/Z0$.1%!&E7SU0<$?F M,?%IR^ZN.>K(\<>P&7>%,*209I$W(%6) MK&]38['HB5ED-CA8-N:&`P\BV\*P02X4_W1_2"#1T8G%GO?G;QZ_(3OJ\@8> MB6*.S1P.CX**2`-,RXU"-\<__CXJ5;4I,0Q[/M`R)M*>&#Z^EDH^9CI6&G?Z MM;M2GB7"]C)?.[IV(CL[9.VGG7%4/0'-!3A[*@K)93GMA`E/I[6CP,!S^SR8 M28.>#N-$AOC2=V^Y&%[>CJI._0:2?`>HUF:PKG"FHC=S'&M5:WP`$R*(,W@A M1*G]>5D#/,`UFN%.S2&H+L@=%?<"*W@&)KV@/MTQ$Y7G%'L`A"+/UEBC6F;,A M&QJ_4>J?5/X\62,)EW7Y)U',MC7+KK/F<1RR31++!R$"<%VI7XFS3$T*0$7B MN']/HEAN`"7)V85@ABX9Z+==O= M*T>;H(\\-J[;DQF\J8-W4NEOC'Y;HK.+:1N5F&ICXL:-*F=@UDJ+K@QX56 MR8G?- M^1$R+Q_9$-(`_X^S/_P/:0*;17QVE*OLFELZ#*.('"$,F*M:'J@W.<1H8D*K M_A5`).]9KA]L&@Y.[]W,>'!>MY%,[4-3&ADIC-)BRM;.,P$]9E+G?Q>D\1,O+^+0>HP0*?_#)"@DQJ# M\4"=]8<-%R:QRXDY[*%$&OSXS[=!%%TZ87C&;$[JJ!(O&#L@1H%W9LK^K M6R/V;@VA^X[9G#0!VJ1"W([+CJBLR+_-%?9`X2TP^*#2>/J)G:/2,HIH''%9 M-;<1%%V0NZV.PG43=5U[Q*ZK)?;@B1AF7$E>)IEC6:9/I+7%,[TS3?D?V6=I M>/%`(QJ^BKS/Y78;)HX7+3TO>'.XCUP'X560;.)=XO'OX.$@]:.+(S":&T88 M,VXCL@SF,B<\,J>L412#O_,O4L&@@H843039F7`+DHLG$HXR`4DF(1(,M&_I M"\>5;USG7!`!YWT(H5E\O.?*Q=PBJU\2=FA\**$#@;D!7:LQ&@%,V7M.P-2N MA%'`R=CQOX"A0)B<)1($&=,DAY!NTZLVH+JSAYM4OXH/$(&$'H;"O]2]9:*2D5F(KB,_-X`9:$@#\=,9[3F!TU`5+<9*4BA2D@H)NMFR:6:1E"FR3:`. M*^P9PE!)P;;-GCG!0UEK8O":658@I.!+"L;6 M=GNM6>_9ORKC-D7W*+>R_2&/Y]!F>+%="NTV;`<2G(Q#J8U<' MT\9Q^4#<]'O:MQ_@ES?(8#E:VA[K8;IF:C.&>PTSZ:)]`ZF9@[V.9K:P_J2@ ME1[<'_*]\P/L3"_$EA/--J=Q(?V8QM'VG+ M;R@<\@43&+>OP(;P+UCL\<&;OQ,O1C8TV`K1Y*B>.*89W2J2009@=[E1!!" M5TG(PT@.ZBQPI;7DY]=!^$C#5[95YMMV)C('M.ILE#-XTJ:`'8^Z*S(,@"1= M(AD2R3%;TRVR;R$TR/A:!)SI;-.*,*PP#-T?O$"\\4OX?_$A'R6>N!P=*2PV M:57XD(H%B)<&EA*92WN=3\&EXWGK@ZSSY+M_=<+045^A'$81.189,-=)M?B^ MY!"CE`FM!J3U9;Q)MH9+0Z23[7L0@*02B(.P3`9K)>2M&4V^C`$(=L6\1#SD M\4BWZ?ODW^>&^3:SUE?,3U'/XGL63[`ML=[=^"Y[96[B>,LO3(5)JK;(T:91 MQ3*.U#9$C!#-\O8=QH(JC.*"+OD9*)]E[%H`I6L,-V MO`KV#CO=`>Q/96XC6\\LC6.^F<29]?E;)MGR.*B5:I/-'T\\W%L,Y(.ZHQCZ#WE&X8'2\Y2]8SO571QT*G MJX-S$W$UE*N,,3DB1=P)S5W=(AF-W2RV4L;7WE#B[CY=]4;YJK<*!\J]%"?]!8XE#-C9N\/Y^@C>YT)L\ MTW8GD^?Y3D=Y\BQM>]C:#<)K_4]3NDM,/.KPOS^*/<_=N6>8GI&;%I.1:C69 M'N^OOAR8?-7MB89[Y4]KE`7Z.=>\0:N3K#GZLYA51U"W]WD?;%B(5$$Q;[$] M713E=9XA\86XL`&2^#'SQ(?0!GRZ\/NHM+X)#O)J/4@,%SI9./F-7VPFUIGI MHI:I+LL]*D0C()NMB0V1=255$M=8P\HTLLSV#*_Y+/=)3')02;.Z#):'^##Y MQD_!7\&1LKRVD*9+6TAYNPY"[I_7+(SB)^YU9G^.<05]GU/:!#^N@8EQ1"G? M[_0ZA=%,U>S(CR7.(NEL\5F)V<6Q<"C%AD0$.7,'6?)OF$?N(CDXB_!W(+Z< M[?G^L59K M0"FW'>2-I^6.#PV(+)DOZ%PE]"EXH#&3]PMZC1;#`LPZ-AKCQ]"/>4QRGWTL M,XHQ#,4HZ9X"0!!'C2KR9!N#V7ZAFP%-&C@4J13I74(?=B;A7@Z$%,0!3<2" M+U4%P.^%1>6+AFXB;CF%N7[8(@]4OYV!O?AB@R+=`Y:2IS]6279R)7^:0GR, M\0&JG^>^OR_Q6;N7N\QK>K^"$`8*U!W7X15UXA=+OWF='+_QR5[YTTPYYY\) M\5]3?X--K$0`?>;\$P!S0`FF5^:> M71=!(="[C!%,_EC#@P43TKS;J,&H<>\Z!E,N4'X5DVZF')#P$D53"=WAS*'R4<&'S MEIQLKIZ3I4[(/=>VN&@N\0V*`68@T*G>I"S"G6Q0KD]').@#@R;3B'"58(;. ME)I3U(/B1[QO@841,6'+S04^7P4%-2+,\(YM&MB6*GD_!)['?U?XLNF6R!C, MD$9%TQC9R)7;1D[8[WR-I[#%^UZI@(OR:P#D9Q"2I%):JC.#V>01^2RBH)35 MN\!5>7=Y_!\CY_/;0=.J:4<"4LGDMX&A)[HB@\^LHL$HN"DWL5=^[0M*>$U= MGEV<.%W1NEF24+HSWU#'TJ#M'F,GC&=OO0U]9KXHY*1MP_E,2S^(^J8WOMQ: M_B$,(F5Q]5$XO?.IJ<&\)B>G&C;O>'IJTA;#!"7E@UV%K&2\D'&>P?T8QOXA MW>!\%PA:W&G*K3323U'/Z9TC:(-Y32)H#9MWC*!-VF)`T))\!8Q._4@J9F,+ MFN\%04LQ]U\I>W[AO\?RE8;.,ZT<-<#>TFZJ[6A]0=XY_O;_<4;:?=&4XAVC M]P!C8`#WROY-I@!)-3@]6'UG^^-3_5ZG9GWWDX/=G^Z_IH&3G\$"]O\7X,\6 MY=_%]OVHOXSVIGYZ1[=XNOB][.]/;=ZF7?]V(R.:7_5K\N3+TS$F6O-BS'W& M'>F'Z33U&I9ASG/P6*88/XKA2:&#!.][2NAC""030BKZ;V$ZF/)7RJC-<#IHL>/2=1G\X7A7+-IZ M093`RSN;*`Z=;>,#,2/RG#O8FS"YR;VV1H9SAG(C>F/85RLD)251R<^9L#,] M(QGW!UAE]RV+*Y1GY2H7Q"E,ZQ9"S!>P2^4(1[UR4,?GG0.STK1FN5@=)@U;^;RUGF0V8MZ[)EEA47SB[KO(EFI9$$+Y]'ZW'\[ M`#SU>;0FZ]\&6%O?\>@%X?/R?:%NXM'T M8>&S7T-\6GIN6%Q.%F4EY(]P#W7O+X[5O"[X_9[@9U']\&,SQ3X73&+TRA0P M*D?,R#^-XKT!/Q4O?Z&\!OP7YV^7IY62*N5=A*0+F!U.,DJ%N.1G(?#99HGM M.+2W_9=?6+>+FT,Y8<>4\X>= M%OT;E]/[=>XV\QIR;A6;]^G'6YV, M/:",\+D9UC[]1&L..32:(T4[747S`KD-;;&7K]41W4!QV9/=![&S0@)_ZN?9 MQ]2VU@,Y>?*S9#`QY(VN[Y^_^<,_0UE.^'=4@'EZ"[H`3+GYO`#F3-$&@,G; MS@]@SD4?"V#BM\`ZP)C3MA9@.'E<`&-.WS]_\T\?)<#\Z<_C`@QOWRF&J7:8 M&[57Z_ M&?!5J(T/@A=$R)KBL9#V/0"Q8?NO:A8N"^(%;UD!);F409>(:M*FGP^'J;'Z MG.5O":L5!A\-JT_X_5:P6J4V1JP6LKXSK#9M_WJL?F'/+[\AL);W\M:[TC6+ M=.4PQ4_:R/VW!.'M/\-H:*YF_5L!=@T+8,1X*;9X#+AT1TJQ[I\AWH_XLYS> MR,M_CA(ORP"_,63%<^N=7-=[H)`NR;^^#'Q1_R)QO"<:[O_0]!NCD&X.$P0* M0]5/(/9%PS[!(+(0Q@FH9MJIN>R>LL4\J$UH`XWQ1[,25!'^' M.W$C_"R50EGO=A/NW'!-,^LDBY;N(LUA%K#\@XVV*.DH#_;YPK99,$XB-5/' M;V'1,?5/6)EPD*\OLN3>1QJ^RI"`TU^7(Y4+U*8-^$E:I%VR`Z2_N:#KN6GB!.W7HSK+[`GZH: MI=J=D:-0-R.4H4:O)V(\Z:A`WQ&?LU&B!4E9V<&$B1:"FL MP1[,/#E?+JA/=RR^YHZD#QC&B",'%+-&[!S;M%)&#$B&%9P@RN'"D%0:`L,` M$:PA,>89["TX[GEB.HBY\3:I\88"H*+"15'>6IH#2B=D:1[1TN>V\*/$BYG_ MO.0QGWP]L*XR^V!B2$'+C)'RPAF]*6&OJC%%/R'U*-75?O15OY642]C`!G,^#?`,$7)H.XT$`9B@U49%G+I.\>M MK5H3&"RD@>GVUI"E)-KUQF//8G*ZYI.7X_V-.N$GA\\@+#ZV;']WIX(48`:: MI;S\ZT@"(;P,U:3_&J3(:B\8+HAD28`GR9B.O47]2L--T+QRF]H\Q59]4V`7 M:85V"T*_I,&DI!)%<&!(@E`"U9X3DY=Y&2?\!4+/D'(IL"'654)O_#OZ)7YZ MH]XK_<3;O*BR_#H1F"-.-1JC%:)J>\\-G9J5,`U,G!OW#`+\B&1()$<[6TD3 M6H3[:*^J[6-#P2/ESN,"_':V4:7K;-W_W`!ZCE_TFZ7+UX@_DK-+3B(8P>;E M!HW`'>]/&/W[Z86%_=R[W'.VWGVFOIYSY]UFZ=OGTH_DVH(12L\V9P+N<;U> M0QC;L:$VQXG1UP^,DOL+5R_G<1^$E$Y;?Y%MXRNJW+#G9DRCO($G4R`[XI#S M@IR`C10H/<TV2(`B=W<:AOS;S1%VV".9ZB7^ MLTC%H#3???=B)]_2[Y8D,O6K+JA_TXZGU1>E7[DD)'$B*R1O+'X1_4M\4ZIE_"S-W%*F6<[?Z`9%UTE?#II4`U)2@>0ZI#]> M*3XH$>!ZD%01N$924@5WP(#NAUN>NF^-^V1"6*R?E=^+N70.#/:X(1/37491 M1.NOP77KB71*[Z%^I6A4>S?$AS%=I#=QZRGE0B0;LA1LAEQN,E3Z(HF#?;!A M'HUJGSMO:H=\6"M5J]2N.&V$>,BJ9>T-SP5%2P]YV]5MPG/[$Y"AZLN%FEV0 M>Y^.PI7#_(;VB'U22^S>1_OU<\:M[?>E1U4ZU5(&A]O4`E[OJS&*+:>R"CP^ MAE59%#_P"+4N`F]JC-0-]93,-U.4+;%O=;0+;F@C8L>71/X6%HZA*``0A&)0 MBOV"4#R^*!TK%HS\G0#9E0!PP#2,\$1$QJ:"0X61(I"4EF($&:1K6LV1R($(D(B_G$A M$Y%",0M;\-A,"JR_U[:-)=AKMLP=558[Z4ID3B"F;10E5K52F`LDZ2MB"GGT M((=SMG1Q8EKKU.@Y8"^E#$`/LOC>4R`%%P>.9>7JUFP=^R/U^=ZFR#=ANG3& MOB_32Y?>6X9[N`4`IVQNB6VY$*2CW%2<>"-F4KN4F9&'PAJ5+=8*4EK8L;%G M$2HK^XJ+)&8WG4<(J:Y%Q=$TM^/>$?D@T;W MU]5ZQR%,_=[\\/(JH9=)"-+W-GF%Q.PQ[]P@W5"MZ#]KW*I18V1D@IH9"SQU M[::TD.7*=CJJWOA/;P%,!CHG:'I4W@-4G)NE,UH4).8.:3(`9HHK66R`B M%5(3B%&F\TXPX\PT?5`C)_(.<.-T)'3F#]RG*LR$7``XQG@ACG[6*[RIZDN>S41 M/IA8;4V<7*JW[= MJ;P'T#@W2V?,*$C,'3)J-)D",0JVB.'"H&W4^B+#C"'V>B?XT!L5YHX%4R(` M@N2[T77"2U4*H>^-GW_2V6R/)V:-"N\&Z@86:WJPQ1$.MT=-` M\LM[F1"P.LF^QAILC&@XN$60&P4S*+5EN(R6.O,>`$K7>&8SV68-5MK*X0X"5Y;>3-_8J#QT37])V`$TF?A6C6'[ M9.0LU42SHM)T\[DI4SXJWMLFC3 M*F[QHH4L?P!20/GA4O6KJ@6B!^K3-\>#@L(*D_6CA-S7!YBG#``]R"!&A2': M#-GEHI2D3$F9Z^(TLN:?I*Q%N6\["&+#2/@C2`+)/4D MIC>1W8H2^OJVU93H1^G=0$AC78D>9-X%C)BKG-`#2&R7E[!A)KL%)K0U;BLQ MT8O0>X&2QC(3W:F\!R`Q5TJA.X[8KC9AP4AVZTWH*]Q2<:(7H7>#(DU5)[I3 M>1IC-W@U<#`")^4/#M$C(PGD`-#'(&44Z-(?,13T4J-W(G3*C!3L\.)1C,T0T1MUUFA0[,&1H$A MW63`DH`QE2WL9EXHM'RDW%5<0+]NUJGTFZ>GGZNNX>-%I_EY=XWL8_BU9"/F M?50.;5!]NUD0"OV>7EC8PY/+W>;IR&>*:_AQWF=^;GPN^AA>++C@B\4MW)Z[TFZ<7GZNNX<9%I_GY<8WL8SBR9(//DPVJ;S<#0*4?V_7R MY%*WF3KRJ>(Z?ISUF:$;GXD^BA<#%X1.;$QYN^?OY^IIVV&.?JKGF;/RQ3&\ MS\[)U0BZ]3^DVB@J'I[)F'URNF^LT1RI^^@J6A1&5+=%7R510W1#)1/E!7E9 M-,<1-^>CY'#P&(VR\ALN<9,0#I>A^4'6V)'/I3O%44J02SIUP<01354;`>3D M;912''59]_])^W]-GQ5GX,)WY?V"EN MU;=`"E4-Z@`ZU7R-<&YODK)_&3-.CTB"Y&<@.;AZI^[PDDRO@KW#3B&WYFO$ M`ZM.D6Q4E;]#.J1J1>P[GK*1),E-G,,PM38#XL,?J$^OOJCK89]\CW3T*U7) M0[[RE]ACO%I9#01US-\%X5ZPA6@MYD-)!&\!G]HW$7.=\#AQB&944R!&KK[8 M+&AM7!^NSEY0L_A^#:P":'APPOAXY^QI30C6TA0I:.@H6'DUIJ8=PJE42]S^ M9=0*H@2H&HK5^@]/CF_I0F?Y'%)12?94\]K0KD]_Y`.YLRG*HUN[,^(AWUV' M`;-JM@.0LR(USF$E_)S>'/J:#PA5?PQ"]FO@7W@)O0R#*((_'E\8]5QX?>GM M?X$Y&EYVZ=8=J:OW-40>!W?HBSU,[J.*H:U1=22="D5`&"+$DG]*P>039V]$ MRC9QL#VEO5K,L"Z;P6;`CL@FE:%!/EF.^F^Y>'G-W"VCT06?+^!FUGI7?%RW M'=N+`%*T[6^,RAL7VKT1AU8]E.B]%0R>42)*)"/K*XVJ"5+U&]<6S3UF->AK MU56/\DKSV0SK>JF-CV.KBX(I-5ZTJ3Q@-7#C[^#H6:QJUKM[)^;_JH/_QM9( M'5%3S3RT5S?%'LEK2#[J]G<:TN1*RL0-2W-)7MC%*OIW!,Y`:0AN:2R'OQO[KCV/JRV)%,N>` M(.$N`7]?[T3EL?5.@DOTP@YU<-34&*FKZ2F91PC*EM@#A';!1]_8\X4(,)<< M00CX8Y^+`8G_+W)[)R*E'CE[[G#TSS<+_DG&W@UD%"97U7*9@[I(0A%X2R9USRQUXYH)R`- MOEIK&(-N>[K1D.*0#/.C&[^8\.L,T*DW9K?N;H;V/8%+BG(96%E[>\Y;U'"8O+F\+;,X\[A//,P@#L-T)-(,3$:3&B^ MNS-[9=I+FYU99SS$N*?*#/XR,\9CL^YC,1Y-A>G*P!'.+!JGQ;VM,_NP!E%QI&L6$)$ZKV M&<_WEZXK&#E>3Q1H)3`C/-`SA@H9FGO/#",TE9D&+9QJ-NT/7+6$C,^-*MWMMU7;8;=XUND-N[:6\&GM"Q`N``8 MR29WIT;P4\H63\CRIO)3V\[S M^N1X!WB8@@^H&S]*0H?#P=+W$\>[#%YIZ#S36[9GJF=>]'LCQ;B>9BC'%YI= M$8<;737HZP`E/B1GM""2%G\EL<4_#&W_+7#Y'=;!G(Y$9PD2[4=K00DUA9J"AH8AA[$@Y M%N#!>9*,*1X,&=$PVE`"F_AEOF>+G:[4#1 MIS]2C.AMBGP)U:4S]F55+UT&+[7$OO<^Q83*P*="'O%:FA2H["&PI9REP(I$ M.YE@FWWOA/Q?F7,S\:)K4BM*9J3@5@`M!GRU9I#Z,6,/58L#T$SI-?_G/F1[ M)SR*^+0VW7@@O5FB;@=3M:.P!K'9HG(7W"2"&%Z"K,VP7;!OT!P8>14!+G6ME$%&H/)FH%=,1B-(_SG_2:DGN=T MV'[KWAL_>G,RI'Q:@+\^^V+L47FAC*O-L*1B3DG(@310&/%."JGCB=K3X[LG6B M%W%*Z])#$/$H8<$[P!?0;.-X`BJB%TICXG(:"_ZY$Q,6$3^(2:I#!K77E`>[ M'%*N)*G*(CP\!*&-J[D3_@855@0X+(CD)OZ#Y/R(9&@!:Z>T1C:PMC2,V8YQ M"*4PKM)QEHVMB/#AM&,^_SN-9F,6)S)CF?G9[)V.QYT<8-XQ'WG&(]M'ZNVN M8=7F_D@=+W[)Q_`]%_?&YP&^X]T[1_#[ZR`4TQ-U/W$C;AUOE;[91QDX-SE+G?6RD6V4NY M\D>.Q%;D08A&J+-]$<4.2GLGPLO%#6IO]V$GK$!>A!E*X?R!ZS+QY(+K1P%I MB!2'2'E*,S!(M""I3"052OPHJ5@DE8MD@HD- MPK4-_R.;[,>V(6<0P_.]O]7^X`5'2D\64G6VT>B#&8UU5'ZZ#F:^2#4K#F9;ZP&*H"7)=\UI*OC4]<)'MUQQ,)!Q.-N,L0!^$ZJ=_;)G M@V:J.#53$8JUA&R3]`I.%$0PHV!OH^A%HG44L.-D?X7,1IW;C$510#7SDK.R M1G.//D2LB22)QXP'FT09HIG`^A0J_AT12D4^J?'>UFR>RD6YY;()BG^YU9=J<(, M9:18/H+YRC4M#)!%7.C"I'8CH%-VM)U?1"FO1.'8/Y-E05)I[)3%P&#&BODV MQV+V@WGV*R>"=S8DJZ_181P\AO-`M\&SSWX]6\IW[3M/G*HW@08253O.#VL4 M\H^`)N+)I8(5*J@P;(65.#G[?50-=(L]X+[K2D/EMWB$#^N1&_\GQTO$JF3I M><&;N.VQ]-T'"C$9C1X"S[L.PC2K5N+J308P>0[3IG5F7 M\H358\Z5%&S%Y:6,,?D96).4MZ6"PS:L5%@&S/$+#W78[@BG3\YV"^=4O8YH MS0!-LQ$N7YSPF;I/`8`O_SP]ME:8MB\MY&`SR$1EN.E%"#'@#--GN#,I8(:' M,9(U['")B`:^3=G;`1T[EFHP`UK$N:)NLA4+P%ZFK'2?-:Z<&T(?2HJ^LT6/ M&A5&!(R"FUE\^(LT@T^?8?>^/T(8M$9!J@R3-38BRYK@Y%^_+82_Y7_Q#[./ M4@[\D_\?4$L#!!0````(`")<+4:B;^^B)T@``/21!0`5`!P`8G)L:2TR,#$T M,3`S,5]P&UL550)``._2+54OTBU5'5X"P`!!"4.```$.0$``.U]6W/C M.)+N^XDX_T&G]N'L/E277;?NFI@Y&_*M6[NVY;95W3M/$S`%29BF2`U(VE;_ M^@/P(E$B<2-!`804,]%590-)9.:'1"*12/SU/]^6_N`%X@B%P=_>G?]P]FX` M`R^__]=?_\_[]X!)#$,/IX'D]N(,8(]\?7(9X M%6(0$P*#]^_SAA<@(JW(3_[GXO%V\/&'\\UO"@IA\)?!^8?S3Q\^GIU_&7S^ MR]G7OYS]-'BXVS2\(X.8(6%+'P5__(7^YYE\ZT?OU4M#W_\#]WMT_IX-^C((I!X&U[5;Z2]SO_]NW; MA_2WFZ;D\X@SH`UI(KW!X*\X].$CG`U2&G^)UROXMW<16JY\^NWT9PL,9W][ M1ZD2"9Q_/C_+^/^WJ]!+EC"(BS^'P?0ZB%&\'@6S$"]3Z;\;4/K?'T<[`WI& M(:$),4$:_,$+EQ]HHP]R]%(FI>3]H2V#3S%!*AW)91A$H8^F%+@7P*?2>UI` M&$`4S8]9>N2RR-K'[M""J M6(3^E"P!U_]*R&S3RG8=>9O8OP31XL8/7_4JNT3U@,Q>H)8@98>TI62X!7A-DH7E`_`,/D(7"\\*$K!3!_(%HPT.P M(:>RM(TP_H!#8D+B-5T5R41:4:@U8[.>DA&F1@%Q1>;HV8?#*%)<3WE4C##S M"%]"_X4@Y3Z,X0-8`S*@"T`=LR9,L:D98>XV#.83B)=7\#ENSE25BB%-^=1D M$R\D7D\P""+@*:_X,M0,S2DR1C@!;TW-X`X!(RQ<@A6*@=]>-;6$C+!T#7!` M)G/T`''J$S7CITK%S"(,9 MI(RP]0L$?KS83(<''S2T"+6$#"[1$%[``,Y0W)RE6D)&6+J'KZ5``PX#\E>O M#02Y!,U81.A#CVR3?DW(/@EB?WV#`@(D!/PK$(.&]E!`TPRCW@).$Q^.$+4! M1=B,#-%'LS7U\#*]-%T"I*E;')X[1)C.<+A.;I`3&M7I5`S%%ZR)6;9AF4?/ MBOAE&^98M*P(][5AC$7+='2LG;(J9*P(*[7AB47+IA!3*X/))VEYN*F59I6_ M8EOHJ0WW$F1M"T.U8E=,UL(-0*N)+479II/X*Q@#Y.L]D-_0M-C?;<6WXB?L M%\/'`\CA8Q\$\>D`@OC4!T%\/H`@/O=!$%\.((@O%NV*6QE&+D$K]L6MV&,2 MLRK+IQ6+0J)6!`%:L<@D9CH,T!*;53JVI,RT8HQ'SXI(1RONF,1LBG6T6"G'9#5/V-;:$>'F>+2M2VXTXYA";J&,X[:N0E5,F;SCUJZ M!_M4K,Q&:K?2R!*W)?^E%;<\>K9DPVA84>KI61@W;@==.=)6IY&T$X#J1Y1% MD7);R*-NB.7^W[+Q!7!.+U3<@F?HOQ,*L8Z6C_$.*7IU^QN]NGW^-17S[A?: M#W42$B>D^_&6/Z-AT!!'\`"#+GTF'_0*PXAX,"G>;LE'\D]18C+PE;LG7N(( MOL4PF,+IYJCMC\6E=@A"+ M#`']R3]X'`Z?H]3?+PCY5,(9)5K-_?/WTY?_OZX\>O MW[Y]^_1C:<1E``WQ[N@!]HIOD+]6,+6KKKS%AU5Z(?V]MT#^!B4S'"Z5!)J/ M(E3D*L13B/_V[OS=((G(6,-T*PO\PRGH$M*MHS\B4^3MO^&:J:&]=JZH2(:M M7$BH8&Q"R-:HIOSK_FM$R$VNB$\&%?$`,0H)2U/B)/(TLM/.'=6(V^U"ZI+8[7F(V1NDG5:NJ$G,5+&!/3.FGH?DV4?>C1^"_7A( M;1M75"-BJ5",P=!"N%R&07I$GR9:1.,DIN4G:7U1MMGC=')%=K$WY"=UZQ:C9?^UIL)8H2J308ILG-E>74Y9I;:NJ4O$6J$P5L3BKQ_V3RQT MG&-(%825.<4X/Z.G&!MRY.^7X_NG\>WH:CBYOAI<#&^']Y?7@Z=?KJ\G3UT= M893!.@/1(AUZ7Y MS&O.3):NS!AV?2-K9IZ*(NBD4V"'>=ZQ2B<)SL]E.<-/QQY7SA5-:#??Q$@I M>:^M-;I6T!U+X3*L.:)W6MR7IMZ1/^AMBQ?@0YJ,%U\"C&G.1%KYAX$#J;Z6 MXD)&Q55X-.?8$;@4*32/T(.$_6"$< MAGA-V&5@H-S$*9T+&6.>\/9+Q^-X`?&.H!B:KC9T2M^2[#'/C/NE]:M\L!/P MEO$L-/:<'D[A0)5/YL%UOP`A8P' M]L\XC/9C;W*=+`6"(@(:\.B(DT>O*9 M57)A"HJ]2=!"W@V8=2J-MAYI[;6&%48A1O$Z]7FL,EGL30FOBQLX4N90E]]J M>/W*7;(P\!3BF=7F;H!`B3M'_-3L<;8[&"_"*=VB1W%1++I._XS6EJI?4I-5 M(*BPZ4BXDJR8])0GVI<<<_=:W]PU)"CQZ8@#^W,83E^1[S-47_S:-55S^7(D M.+E?4HMX-]=OGI_0[".!VF6ZN@:)QCP[$M4LQ7"%*T)M6]<`(<^D(^YA7?16 MPCG@=7(-$PVXU17\-!WIDK,,KAL%%7M0O2;4QW@!5]&6JK>14ET^NKA%X!GY MB)9J&@;3-"-]Y\%V02A(MKLU<&B:V=B*44>VA"49R"4^LCM8@PVVYCFX'1+LU-@D]'8%`4DW=PX4:JX[$)=.XRFT(`KD%A-7I(U/&6/FLTGEV2 M\2)!$F5=4_=`(,VE(T''\I,1`OU76SJH?DDF'8DJYJ7=]\NZ\X'`[^0>)AKP MJRL":=HXR.XICF$3H;9KJ-8_ZFW$4CICC=O'9D!HCD6I9;7U?7_),(_"HRIA M/YL1T_@`JQG7CH2LRMZ5$!_UC9T$A0*KCAB-@N/R=EN`@W)3IU$@9-210%2M MS%1>5?JEI M:1TD%'58!8$LDYI\QA>(G\.-_HW?J"O5=.06`=IKYAX,I#C4Y"WN8L#((>9T MBK*Q/P`T'07Y-HIUA%G?VCT0J##JR&KP2)])"^"T>%YXYU;R#'F(Y3:(.[J' MCX8\.W*X616?M$?I'A0D>=1UK&E/^+K6\6Z8:&L=++H+8LOSW]D^U%1)X(=4 M[`L8(V_K8@CK`W^1KP\\^/>=3_S'NU.]X(,S,^&$''<;63/IFV;52[#3P?N( M&G1TZ8,H&L]2.S1\0ZR[,,SVUFA.01,<]4FQ9Y4FRR.^"I?$%V7MURL-[=6= ME!IJ-NQR+#IRU/<$,74B=H-5=W#Y7'GI3**'=5B0U&7-7%9DTA4T%'.'N&MP M1/XJ-.6;AM;IOIT-Y_/ER.GN+KR)KSO&J0"F::3R`>+T.1ZI(#ZKL[VPX&M8 M%,]7XM>X=7BN?U-]EZ7L[:5A$B]"C/Y,KUMD93UR8_A?28#"_56A,9W^`T,O MZTZ:E'UY2)F2_4[]1TH+/ATY#:CC/'U`5@4260>WX<#AT9%H?^E`5-'CD.CI M#CB:,NO(?:?*FY#"1833PTE4J"P?O;__M,\V=^U@M'88!>)5H^]7G!0>SY7I MXC`61%SJNOA4`<0!CP$W/XS&L_$*XNQRAN01X$?^$Z%/$_+'W?7]Y&DPOAF, M'ZX?AY,1:6#WX5]6&V'#%..\C]G*2+`1^#!ZA"\P2"#9'[\@#T;L>ON,UM9, M9($"=H*,"JP8#QWI,M]1/)X5S`H2Q^L;]U'3"IPX$O_9Y;C\_LC>LR-2NN?T MMP8.#70M`HHJVXX8"?+I$!-^\_)/UV\K&$3,ZV:UC=U"A0*/;IH/1*9!?$=X MQPCXK+-(;A^W`*'.JB/QX[3FTR[W##34M'0+`[(,.A,NEE"ZR_J65W7?D\'3 M9Q`?<#ACW@TIM;!&R0K;`='P=1EKTWJ$`<3`IY[K=(D"1`42HQ>8^R^"W9]D M[U[JOP5KCIAS]1UAG_:`;1174^`Z/H<8)]4+4YK)T/Y=5WIA_1^K,Y.=YP3QSK&[9;\;7M+0& M&`I>H2P;CNSRTOC%?1B$NVS+;0[D.O<2!Z];=OB)0OPX`((2%R MV&847L!9B&'IW:$[%*0H+PPOV:#M4LGJK]S!>!%.M]::M8,YX`BLP;*"3VQ: M/(X\4+L13SZU+V``V6=LC-;]Q8\<*YVE11]6U_ M*>H"1,AC8$"12A^QH8/%'#/?>FX?BJJ#Q;TR'C)JV_91__*,%!OLLYZ;AM\A MFB^(VS5\(:OG'-XGM)K)>%:Y-<)3OQ*-/L*B/8,%7/H>D-F?(%?(3V+FG3M& MZSY"0(650ME]S[MEP#YG7?;&G2*5/H)#!XL%:/0?V1JZ@I>R75NW57`5[Y/* M5;RG7X:/U[^,;Z^N'Y_^[^#ZU^^CR=_?67TIKU0(4OKU#,D^IYJ,<'-2Y-9[JJ`<: M^\]$<#%1W]@Y,"BP:3Q3\E2LV6RQYKY?GCB5YSVJ\KRCP,/T_>$KF/TY"JI; ME\?0]V]"_`HP*S*G2,5>H/!U7GOZUYIQ1WQ*EUY8TJ'6.LNB\H9.6SRL($8A M#:'AN)(^]<401,1U]:PNIM<1+"3+Z[5=:GB`^&309F2<7R68N-8/Z1C3"J3I M[\8IK]'U&\0>BMBH4:5S+-#2(A=']C0,86333P/:.(2L@YL>8$@#3E4T+KE$ M+"GG"2%P>ADN:>88[WZZ.B'K$&?`P,D+QIF].V_V:0`O*!LEA[BUO@7,HK>VPEUQ?YI'^[0/KQ#G'2Z/>\[^H;3?R9Y'8[[,/"( M"M(\KTGX"#WR;^3#'6$1&/;B'0=R?PL5_XF?_=ALW+IK*[6 M`=,(5JJ0;2P[1^SP53Y8M8)!@EXGL+'`IBZV#LR;^2"I4NZ#^`3_)RJK+R>( MJ4G+D3S"GP$*J$3'`7UD=3PC,B52C-4>"JU4Y M4A\Q(%]#S#0L;A_GD:+.?5LGQQJC4B/*]/WM!%,E9-*4]W`J78\0.I)"<"DF M4">!/;&J86BO\[&B2$8,#N_O+Y,H#I<07\%5&"$%#.UW/$+\2(G`F8?UF-*\ M1>`9^3+)$FI$CA!1RN+0];J,=>@J-A$/8$UWG?0`W?-P0OC92D9Y*\\CUB>T MR:)#98>O+!M'8D;MPKZ=Y,I:!\5#YS3JEITCKUHS)).=3G64WJU(W!KH:DKO MUL&^(R$OLD"D)Z"3,+U8CB&1U32A8H'<[:>PGS68.0`6:B*HC<332LNVLJ)$[`:R4I9]Z&;B?V3M;3XX9F![+3E3%A MIPMX@P(0>!VY@(K$K8&N)A=0!_N.Y.L\PE6^:(QGMV$PGT"\O(+/+#RQFEN# MD`-HO@HS):DXDUA1QW6>Z71+`U'C9Q_-N0NJ`H43P-H(RAF_[I:XL\3VDP&C M^`9X-)BYW@^`IF>`1#T,T*F0.&[4M9:4,^D>Q<;J)L3;*D-$--L[V8*]*[OC M<4.LH7PZ*/YKO-`3$;@'X32]J:!2VES8[\@1UD@\CE1E/:S=,EQ%RG[#==X^ M=T00Y35DN]J)OI/8Q7%;O0YDIRLOI11NV^+VW"KIU8C4%$4[MK/Z]/0D MF-(_Z$W2%^#3!6!(9(/QFDB!5QI8JF]O`=*<.TU^5O6=K&,!B"&?ZU`(T>`Q M,8IT&JEIDJQ6?BHVX!=B&P6S$"\SG?'/-(LH86HVC^?G^5* MIS])<4]?(V>HMK:--0K4H9BMFN5Y=20-=120$<`HIOPR\YJW3:Q1N[RBJG-8 MR)`SNLVK<\&(J]Z=5HYH6,R3(^F1A:TK*MALYI+9AN]$LLR,()>UB"E4P34`4U=+,87)H8'^3M& M,1S/9MO*:74^9+75L>E>10R=K4_=//.PE<48ST&05YPE]_MZ(_QNL/Y M&?G?X/U@2XW\HTQP`(+IH$32XB<=RL/>OGV1">6A).OQ+(<6\+?/8C"69TTT MC82Q04S!,1-'JRL-K3$36E6Z$[V6X[DS^]^U37A*EDN`U^/9$YH':(8\$,3Y M#5#Z\A61HU>Z6"LP$1^K)B*G/PAG@](7!MM/#$K?L-AF5&7",`2\AB9F=ZN9 M45I'@RD7(1,"B@N?G1)PZ&%88YG$P"F;&RO$U%MC5KAMA/U*66:!Z?I4-5T% MM=2S*=.SV$SMU$4!AM2%D_SG\-P^HI\GVA[7P;"0*)B7T-G'XQQ MB6:]1$]K)GLC)>X=ES1BMK?S_1&^A/X+\6/NPQCF]6DN0/"'Y+S_4IWW&XH# M2G*0TR2_R,E:;`.>%B&.Z56>BQ#C\)7PP'R7DM=22YCQMG370SQ99;I8,TLE MQ+P)(#;AJ;>3L7Q546$2?JU.0DKI/24UH+1Z,?G*S#-F77T3(]?>2B,1+:"U M;:V9C#RQ[]P]D^:BM]/O$?HTA_\!$,]_@D$0$5&48[>":?ACW5J84ARD)`=[ M-"V>BRQ),.:EN+F9Z]#UHY)W?14H6#.?956W>YNY'9^]G?&EW!G)2?Y3W4:7 M$AD45"R>UAMVA3M:;DNC^5TJ&U=V%VNFJX1*:I.]G)^:>V8Y&>O=']KIK*OSL^J\+B@-"*E!07VS=[ MI,LPBJ,4"'2`TZ+J`&,BMR5FY'%YV3%?E,9U98)EJ\N>VWQAL/I(:J.UG!CO? MZ<1:,8Y]Y`4@W,-KH*?E)*O)$+CG7*T(6F-)M*E[33KD]Y6(EHX#SMD+38& M''D(G0K%OD:,A\P0A=9"B8@UYJ&1:G?,1GN^>VLG;E&^L)J23GWG?>(63]1:>;#2XOAMS?C&9"PT M-I1&F,GX5#QB<5=K)K24FG;]WH;<]7:2I^_.14@E)E:3_+9'Q>*96Q32(#N< M9Q3L%G'>@SR_J8EY6S,B^9DKU]F:N2NCJ/+4;<%>;R?O#4`X+=%Z!P']M\J1 M6$U^'"4W2.D-]@A:/*$W,MBRPIK0_*8F)G3=B$3SF-O'FNDKHY;R]%7GJK>S M]A<(_'BQV4?0V^5R<_9C3>Y;1FR[P1WDY`X9=*IA2"[Z)-E1R_DS]UO<@V:Y MGM;,/'65;(Z.6W#:V]F8'9=#>`$#.$.QPFRL27H0QRM9]F4,@^9Y&BIV0T65C2Y_#>PC)8#:#S#6DCD MO[?VXAZ^ELH^X3`@?_54/.^/-W20ML8.:83,[GM('+G^Y MOOI^>ST8C?A].1N/[P?#^:O#K]^'MZ.;OH_N?!\/+R_'W^\F3W4:# M+R3!VQ*RG8UEM<>R=$LOID-82F07,+M:8!;6BT\HL&7_M1-?%C;IG M)25A(-.WKWAHS)LC3W?1UV4"0GLMAP56\YZJ7XF=7..?>JYQ9@UM.03(=N\I M(EJQI^O];L,(X51K+GZ528,!$>G^/<5(._XTO>1M,4CV_]T4+/5TW`.-`I^: MWO@V#9Y'2-;=!#Y"+R3;0OD=B;!?3\'1C"_C;WGK`<,$@RDLSK"+&`P1!23N M.)D37.LAU;>GH&C.F_&G7AD97Y?T5=$@WA3+Y$]ZF2X]4VUCEG*-?K--HU?Y MUU54*NK31YTVXJF(+9WUW(#OE^*36\L%O7J&@C9<%3CH>Y#Q>P3'L^LH1DL0 M0];+JKN->JIE"28*I?8^0+A<`833Q^OQ%8I6803\\8R^.G&+7N"TV,%X?C(E MPJO?RDC&%O5_J:?P.I0D"HSV/:0YG+Y`'*.("",MRRB'-T&OGF*G"5<%#LP% M+AGN9;KUR7PJ"<>2W;IGNFS"3:'#OL<5GY+G"/XK(?*[?MF>Q]X*9.@/&MJ1IS*AT1"Y+)5/9Q_//K7)4LF^=Q@_0?R"/)C' M.C.U<>VY?.^>S6D=W!E/3!&JG)]DIZ)^%4K]AD)K3CM+2S'QH+V29?]4M>SU MS]KWQ(J[_KY]XT03^Z:ZWK?L'4TZW@]3*$WNS]7)77G'OB?SVO$'[;=KV0T* M4`S3B%6M[N4O+4A3LL8BM'[P7A?SQMU$O:@*>>*X26(JU66(8_1GJN7K-WJ] M'BK!3<U3X-WY,UK5=OQ&]-ZQT@N$6T!&5V MNK)Y1UUM>9(C8XU-D'U97@N#/797-T]0*\WLG^H\U>U#U#V9T#U^D7H+V^O9 M#'HQ6;`V8WP$<9ID&7C(1]E5?$E170I4^P_N/2P[,AEO*U8BGQ"(HS,Q28._"T"SV2^Q4AP=M*26O\Q MU9[=SJ[Z'?H);Q77Y?RLZKI4'_+NB0/3RQ>]2VONWK@N0(0\`N,KY">[ME8;P5KF0#SFOR(Y@OAO?$%AS]T^';V;%]L'JG]"A5 MYSPKS'>QKCQJ/7P%.)LX0DO3DKXUMD?_<^+=RHAILXP<^?H@N`=+.'Q#K%L` MY2;6*/TPJJHY"18)PTKM7H5+@`*!?K-&UFE8*'&VDC@<&8]P,%*RBAKHH_0I M)?12=A0H6_33=W#Y#/&>-A5[6ZMFCL[V,K%:,MMC!)RU0L#9,2&`QZPKD2C1 MPL=:]\C^!8YBN&0M_.T)6X>Q0[L+'8G0%>0*M)'^-!HF\2+$Z$\X_4ZVP7AO MCA,U7;]![*$(/F":EDTE*Q]NZ>K#]B&_&R2J;YXZDJWQY?Q`4Z(<-Z(G?2A> M*T88FQ(^05JS[#JPXBN,R*R*U^E$..034%2V]#EU&E+)GU:/$I_>J!C.,ZIR"58H!CYU*VXA MF=!;>:@9GYK[2272@Y3VH$2\)X M'2"._A+%FX?0PO2:,&FL6,W@O.9:7(ETX<=NB?=D3>&(1^8-5)6^%IF61XHL MOS0=QBN(`1U^>^NB1ML:`],("!*&1X,X'%GFBNL<#PGV%H3UK<1%2)/HZ0Z. MFC+;VQ6*_U"ERB+UL6;C(WRNLB<+U1&\6[FUH/PG&=46)P5:UA@1#:]:ZA-` M;\,I8SP'07Y+F-CBBR1"`8RB*Q@#Y,N9E,]GY]6G+WH#SX]YRVY;:D MS,#.,V5$2@\EX:<5`3+(/)&?0%ZRJB::A@^MX)R.YQ&NZ/UR6N]T,U$NUODO M);-392E98W.T@H)Q_-1**%:E)FY8+^9^/OR(DXG*[6,-#G2KK080RG*P2_79 M:+E)J3MM[%.ML@)JE"CDT/BVE7'"26B%F+9>3V!$\5Q(@9V6*.ABGX*%RME+ M16S"H'']ZIG.:7(.QVIO?F^?ECNST'R>F9$&8^JKG;DU+:Q3(5_0#,6X/R?S MV"E7K3MM[%0L9VQ5U8KY<42Y'&-U*TKIENAJ'10Z=*2;BL/X^\(,U^P!8GH5 M`LR)L#*NJ#1R-O-"A.$DI$?`Z3_J?#55&O;AI:E6]WPZ+8)PQ.;<)]2JULB! M96G8'5S$2T.N.4=.!\_CE7O`02WV^[$:^U5YP:$?P6`#3SAH2MT`T8(>L9(_ M:$'K%^"G(8SX$F!,2]G3`O>L\[!&-*R9^6K/N;3GT9%%0$H0;8!B#4#TJ;XA MG`X%HYJ%QM39$;O(OM2!$;^[-?B_6$?)M7PDO* M+0GR97Z1+W%/ZQ#05&4*RA=P[\BJD%Z46(3^=+1ME;)`QXE)NXBP,AE_V]D:9REOA1^C#QHX;#Q,''TW&B9#+) MYD%"3G6B_38[./Y&!"W5"/<6*)D9[^ZZ9DO/_2=KYKQ:F:.#\?[+<^7^$ M+S!(T@<["4X]@Y2[4/8POX(SL/1YP^((B,M";$%^`Z15\ MKD>$,A%K`*+@ENAATE8/F1[=# MW5NG713J_JPCU/W9\E"W/7DN1Q?U5,B-T1/UM"Y:=?(Y;`I>'-`WZ7L6#RT. M4!05_I5(!,UHR8!\0I<>2.#=F5>B80WNU`[AV_-HU<6O+3N^'[X"XH[0"?!( MA(]?8"2X_2?7V1I%ZU,A#Q;*HK#J9CZ?#^Y-0)FN%F-!66^J(.!(P/@:PO!F M-GS0=]FVJ^4E&1#:/VED56A6I=$SB'"TNN>,:!&$<:1HVJ.59'$5)L_Q+/$+ M`\R]/RKNZ")^6G)O_#SVL"[JK>!VJ3(=BR'5A0?31BJ:H-;F-.`0CM`%\.F/ M&GE">=_>@HH/`%6OB">-PY2ELRJ6N[W/*8KE?M$1R_URBN5*!_:\D%@E\(Q\ ME!X^;&_K5.YMD-^FAQ7TP<@T73]/TN<$>S62M\:P*$2#NV;?K@*7#(AQ>(X8 M3-=!J0$9:R!S$##L84^7O(QOS5B;^"D19HPB,@\OPXAOAEAMK0&(@DU1XL61 M+5*)Y^NW%0PBEHM:;6B-BM655[-1EF//^)357>J8E@R)UWAH6N98F3EFYJJ-&J[^%,)[L.0=WK0A:0T:-.A9'33*DK'JA(N[9#K]3[^"@K,$J2!I(Q/AJP]IW!![T_:LW\B?[&*?2R#JE-]#(_DY`BD?C M:CR0TR`*H\L3L`XJ!UTN!')P9.=!YDRXA+1PS0T1-4,2#"1)]>T?B%0#Y4+N'=D:[)AEYL*MM>J/W`0*+$^UB#BU!'5=_>BA%N04.7:^"Z3$7NZ M27"`8N*CWZ`W^D=ZXCJ;(0_2ERS#Y2HAG^3;@\9T'(2'7EDX\IK$!(,@2I_- MIN.76URX?1P$3G.^'2GW<:BW:FR`RZ&V*D<1^&1RSZM2RN]D'6`::E@!*@I2N>;R6RWD[S[,,[#+99R94F,E]V@B[RX..Y506\.V&XVW!;-,&;"+ M8O&ZN(LM9:X[J)%GX)K#?NJLVI'-Y^J1S9;@(*/8E].:S:0CNE11/;9_`N?H9?I:AV` M&NM;!3H"_AUQ2#BBY!T+B;H=)V3$[]VY:VF.YRW4PT+*B@=3K0$9^PB'W^E( MP2,XR&F="M/XL2--I],.O\[=.I!_>K"[9D+<)#3/L"R:O.H&XY1+!TEW(*5= M"NXO6#42>80T&#*EC\C<$+$#_^\0L,)_&BA;`[_.4*3F3[41F_N;OAKQ4&E, M7D,M",UIG3#91E#N+],L@9#/JP>RN-1.2&PGJJ-4,J# MG#3Y!:7>EVL`3PL"I@G$RXL0X_"5<,,JO+WB[CW#QF;A_+H:"4KZS.J".H^`U@1"W>(XCY3_'N-K-.]VU- MN12#ECVMO!VQX.'<_8;6:4]*^GREV6S`&;<+KN!S/`J(EYC0^Q%E9B[(GH+^ MR;YM(-O7:E7+7S!HQ6[_]'^=X'`:^C[`31"PW]MY#$@Q[,CYZR,(YKR5>O-[ MZ[3>=HGFSKI4/F>];:%=8KB"YJA&)OMKQZEWJ$`+9,E5ZT[;>Q4+&=L M5=6*^7%%N>!-K-QR&Q>4*^3'D36S;N6Y%=S1Y/:Q3OEMUU9U;AW)W*AC/)\7 MFU#^)5B1W\1K!:2P2/0".'S%RX%'20#&UQ#&!DV%L6'T`+%'M3LPTG%D==O=%U_!R,-HE=T?V@N4,#>-*B2<`IHV`3B24;LK MAY3=)\(!F(Z#LAS.I7#$[GX$&%)DWK@[)16C?"S2=2@CXJ#D3G.G=-Z(64=R M3*F,HD)PEPG&[$K1=4V=PH$RHYKR.5\@?@[W4-!U.MYM&,QIBA.%O7H:WM=J M&AXE^)Y2'%"2/4N_*TN#D7=7W\3\LLY+M:MI: M+ZQK:HV25)508TMEV;-:?]R4C/K&UNE06A-B)=J:5,ZO M#UK;UGKU*V74R;/HB/YW#9[H>('1VCH,-#?C*APZ&8FCV)?SLDA#RQ7?+A;" M9-#XU)>*>HP"#]/W,$?!-5D`8Q3,M[<\Q$$07F]'M*Z#:R=-P"@@XX%13$-" M3S&M!K@]II`R#3P"CH!'$^/&`_!2IN0^H6[0>';]KP3XA",43I'W`-9I@72Q M+>%V=P0/6M@V'D[OPIKL<2YE0/;Z.(*1YKRZ$H,OA<(X,8:BB6-J%[+F2-6$ MG8C[^@[$"7UT3U#TDM_)&B3(!G,;L..(*UGF/.<;P>@1KO*%CSZOC`(/K8`_ M"N[A6SQYA?X+O`N#>,$+'3>F:0UV6F"##S`](C&^JS6`/WZYR2:D3FCC2N(8 MC9RHFF0S8B>@"61A?&MM"&J<8I&-:)V`QA>%(YOV]GLSPW7,M,."6Y>L[59\ M-Q5J^S+YI\.]3$Y^""?@#2H^2OY3W:/DE-8@)=:73*@-_\+7Q[DM34S5Z]D, M>C%ZV>J0QILOB6N/@@0%\_$*XA0?4?ZK1^B%`4T1S.8C?R>NB;HURX:$HLL6 MH$OV'=EBU8MH3P[Q#23,`I\>@R1D(.N=QDK84Z)L#>X.`2A9^+:7X!%!-SVX MHX_"DF'XI66R!699)$]@U2LZX^$%QG&J#*,/Q.T$`;W'A6:YWT:?)A['B_I* M.FUI'BGVNI.=(P$'>36T=B"/%(*:!.7(PXH;YO/:XA.+N[I@]*S0E:@RC=4*F"4+.0'-EBY%+)MU@5L?`!Q^IE M':HTZYX)+B6!N(6@G9V/(H[X?8\630W$XL@*>94/5M\2V8*B=?CK#GBZI>08 M''/SSI".`'G\SM:!3#<4V&!K(!A'ELY"`O510R5TR9`X8HPU%H\C%DP-5'W! M3W>X:0`1G9'4;8;%9S-XR047S&_#*+H$&*]G(7X%>,H*H[(['!%J%(7@2"Y6 M86.)1#>O)$IZXW5=C@@ORF)PY&95A6\:2)7Y1A5069ZT_9!TZE3$D`<-NI.28T[Z1U@,.B0&(UP\^ M"&(BH.M_)6C%O3PJ2^`HP*;&O2/^>,,I1_\D'"+P3"LH(F:6CR[R1P%`G;)Q M)*NB3LS\*J2<'D MM-:J<>6CVRYWY*Q5YHNV\EYT1)W>NG%< M3J\@&:&7)TN3K>`RQ#'Z,_UG`UQQJ)U@I2Z>MFN>,50)@SC-B)PP)"V5MIMQ M#G2ZO@=_"5:(./`3#(*(R(R>.:G=A_]6O0^?TQR4B?;E7OQ3''I_+$*?*#2B M@>-X32NA,_86HL9:9O]#@:'T:T\+,D^B81(OB$_T9PI`![CK#[O;\!/X`/$J8@8^R&YSCV$ MB@8&'3D]JILOXR2.8A#0>2(%C$HO9Q`AQYGQF`EC_;@,ETMZCYPP4I1D_HT^ M[L&8]5)]>JC:YGPYDE65L#A'(-E(8;]-7(27L!MXRG#`K2B MV4,0=<>W(XE8>X*9DHWW(XP1&?Y5@HGES*I]9P*2PQ27A#L04F?3D7+9LBE95GN0X>.SFY-0&;WR&: M+V*R/I*A@#G<]W@>:)1H]!(R[3G4%/DR#YCTT3N:'@[\?,)DV[=NKO> M@::>=W7-4]N(GEYRWU!1U8>^Y#JMLF'_V0 MU@!(WW5G1;ATT;?&ONB!S$YPK%,9,3?41L[W?1#<@R4?_(F%8J=VK<`G0?B9Q?2/K-"R4.%M)'(Z,IV\QUJJ9H[.]E(V6S/88`6>M$'!V3`C@,>M(BMZ$;@C& MLU$P12]HF@"?LY;7MK4."8=>U.6EPH2,%8K_'<6+U.NEV[\%6DW":S(MXC5W M^5>D8AU8Y)4GH?@&O-NZCJ33(CO=HUS=H0`MD^73"GIHALA<@9@:33"GLXR: M3?::THR2_4!IH.R]!4BC9(S#2(]->J2&F;,`;7YO'3P.O>CP)<$\Z3*FU%K[ M4-/".L7R!M.&SL5RQE;5;5B?AQ1KM"$L2S8+0K@*(9+ M9H)D:\+6P>C0AK\C$;IR&:6I=%AW+'0#F?4=^W#=#QL)[W MA?6PN5*$O.RDJTCAS+<9/*!W\L$C1_SA9&H\4,D+,301P_Y&N2H'LF=FAB(Z M^^+Q`=J44(TGE!04KG*H&3 M,+NW6_.@P^$'<)HFAF1L_/:^.?A?42-!R^FMQ_@*@GAA:!94QG&:#&9%;;Q$ M@>XY43X9WD@IBPEDLB,+9;J*WH8@&..?$T"S^-=W8'U!:\J\H&DEL&E^0*=9 M8HG,.ZO,T).C@-S\E"X&/H:^?Y,]D*C[/(#[L>.;$@;DFHSA`P;[R#?EB;\2M-:M$ MZ(1@6 MU>3L4+$8R8&X,W,,QFG:R+K8SYX=N4,O*4ZS$\>=V:(7Q,9F%W=*'4>(2#[? M:[.]ZF*":1[&::9IFVF'T,RQ1*7$LLPD97BJ*0SB--$..-':ZL5X]OC)5VSC MFIR?9I9ESN*YMF1W%^(8=4\'LTJ,'N2;[BQ.AXY.J(NUV#4Y<<^T?>XF3=KO M-(A=^8X[8&^,P2X.%V6D[-(5:SW",N!727[]-$VZG2;V[/W-%J/_^&X'/)QJ M]!\;5*,??#S5H^]W/?HL2V!;N^,[00?>J\,:7:QWMT9T.K8I4M_NH]:8SL-7 MKN]`<%85/-?,-:>080=?L@:7!M$DNZ;K%[0K.*ZRS"W_V\&7[,/Q@2"D%;Q* MTC6^MTL],13":OH0I, M-LU/,&DFH@YVKP>!"6FO9$]*'4Y0:2HDX^>OTOBX"1.L`H]M^Q,Z&LK(>-4L M"SWPVT95E=M^S#X(]WP_J2IKI]/!FDHL?(4XE]T2J1VGZ_FD?=/B<(CL>CI( M2-KX5M7"2?%]M3KTI-C[Y&E2=#8I9"1]6BFJ=3K(4J8XI-/\ZFSITJ$)X\6_]4RZ MZ^7*#]<0/D'\0GAEI*H7;VW(WSQK3=<:^.M/A^U&-HX$ZX9^2AQ.Z\5R_4;_ MRLK0ENML#;2Z!405>"W$X\CYB)2D)^#M`@9PAN(;HB9Y].DA?K3H[%!\O;T% MEAB)_CQ(_)KOI(9%Z5MXBO[HD>2^*3(_]>U';3PTVWTJO1VV_ M-MA^;G-7JK.;4JQL*GF);+AC^"KM2.EYJF63>R(_F+HK2NV(66-R="AW^P** M5G%8=1%#=`W(OLL['6BDNH+TZ"I-.M3:'-":%M9H44[0#,4<]CJ`":7F+P]S MU;K3QD[%4"][$RBVW<4&Y0GZ,1QU:NXFWC"SHIF2L47NG2ZY6 MZ1@'D1X+42C]GLTWN>\:(1 MAK9=CQY$`E$XDBQ;R[\*;(X9)YTF:(8Q\"L%&_"`/"1_;;Y1)%$]V'\E#S_ MD\S-24AOZJ"@;D4V/9P3P@W(MS./L^L,G4NP0L29H=G'MQ!$<.M`*:;D?*JF MY)1H#U+B@Q+U[C-P]#CAZ<"CG!5&[)O1QFQEX7PXZ=BFPRB*8'WNC4)/:TP+ M5RGUI7O5F+(JV>(!ARN(XS6]#A`3,W?]KP2MLL+K$_)M3B*-1$]K=-I6957E M-^6^'\JG+'"+T$KTM$[Y356FH'P!]XX0FPIP6$<2:% MB_4=^&>(+WT014//2Y9)6EOC"A)>/6[6CA[JKH--MVB,KT,=8),OG'O(O*^A M1,1YI#63@*[CWU)>F1;')IL(J%SP9Q)F;*7'WF76ZWP=E?[60$-X.*B'-1<7 MN)LD3C#,]_%%+:B'3'6_`3\AFP8R!?9^+[H0INT#_4'8@7AW<1VKE=)5`B\3 M3-71&&1;$M;`Z$`H:0)+@;0E`88;,B<4:I&8*_?=)&6!7G38P@V9$PBU2,R1 MQP^D9#%90`S!+&:>_BI2.4%0A\`<>4A`2A1M<'="6W,QZ:J;WSC2>RB,%>>] MV3TI.!T%Q6\:0X]-\H1([=++@?J3\\90I(C.PM(GT'8DPQRZW[3;V,XO4VZO MEV:W4>E55-(80<7+E)]K+E-N:1=ES;?4^W*9DB<@4;ESQ;YF+U^.5Q`#.L#R MP;3<[4MV5VL,3B,UUE_+5.36JJMY+MRS4)1_596GHN6GBQ:GBQ:GBQ:GBQ:Z ME'LL%RV.M:Q!ZR6W95T#.VX]GNH:'%E=`T:*:L%/K8VO:=$?U4I?4I?ETK@* M3Z4I#)>FZ/N27[OTW0IN5_([60<,C0M]`\X=R4?*+OQ0MFDQ/XRI%YW&FW9% M$CW"`+X"GY;G8Z"G`27K(-4`!U4PZ1*$(ZM0E>LX?X*5?5>*V\=-U*BS[.12 M569\$^^.Z0^!+[=N<2D<&W;D!.#(6K8G!E:ZB>`:E2*5HT!4(R$XDBPK*0K^ MM2DU(I9CJAD<&H/L".Y'24I">$-*F&*++4`THG0!WC+>>I,4A MNO>D3N@$N".\X"0O#<$5)W5")[P=X5TF26D(;S,ITSFA[?BN+4D*HQW$3L`Z MEAM*#PGV%J#\()'R4_0J)*P!5NOC\2SF MT:P1<(INQXP;K@P<"155>9<&RG%"H]-0CNXZT-7A%S_9W_^(FENC[,;[Y$8< M=N96=%V2X!;%A2U3JD#PI5J!8$NJ^W(##!R7N!&5"Q"VS_3\^>S'GWX\(U_Z M^OG\W%#5`*+E-!.76Q]@I]$.1L\I1C\:?.-=640.8`,>GI9K&Y M`B/H_3`/7SY,(AI`1 MXQK25=8GH<7)B/#B]3U8\JYNUS6U1L>-#*0R9YS(IA9+V:)`"ESE7O!PCF$J M@7VNN#>SI?M;IW%IY57UWHYIXQ:`8:-_(4C\,PPN_`1>TC?>Z%^>%@CZ4UK& M[?6_Z/!\T M%7`\V_ZX+@JE3L`Z6#1:=UORRSD"-KPP[S*6,\7=BW%Z6*?KEFH3X4#,O/'% M@+$+&P4SC/(Z'>/9`YD1C*I)@M:6:URLH+U=E2*GQM6KR0ALSEDNZ>:48_8K M#:T#0#/S+L<7)R7#M!G?84!8Z9#5W#IM2BI&I%$!A\:G,=-*$Y(/`,>(%CEY M0?"59Z/KVUJN4H%F*N99@4GC6NW(5[\5E+5C=[`."WI\<3Y_'=R"VYK[3YIF M^GU"83R>I3='Q[,,U=$"K>JF.K.Q=?I55-7>;%?C4]-T]_=5K)R\PU#Q91@1 ME_)[@"%:/B<$3-,GB%^05Y\IQV[MF)(5&=44@.E,R_O[CQS"V4XB&@7;U:\V MK4RZMV,H:,FXIBS*0Z'B`<:(CC"Z03Z<9LQ*P*&NF]LXD.98TQV+0P%@.)VB M;(0-H<`GX#8H&O"NZ2Y%9_`H[-VE#]`RN@<8AZ_;W.DZWV^WI6,*5V!2DW?/ MUFS7>?2C@/P7D%^JI=%_K:;1;RCUY=&^S8`9F?8UOS=S$NJOZ->)3[H=41`D MP+\,7R`&3-^&D[8[F^?B/;TXA>%(/80\#?\"?6O'+_?BA=#UO&[]BKZGOK MBA8LCLD?#Q@M`5ZG)K`VN-.&G@MX:,JF\9OT7'Q\7SYCZ/M`P4E0[-T[W3=F MJK/+[UV[\T]H'J`9\D`0/Z+H#WJ%^#MIBHD_'L3*SW7_6/7R2Q\8I%]('^W> M^49?_/]:`3'V`H*VFB+TA'@0XQ0$](.7!&/W`%$(P^EP23/VZR/VLKVM MF<92"BA%ZELQV)G?W_64_@4"/UYL3!A]ETUI%I.Q5V9Q1K.T9:=4C=U^K^-0 MZAJ\9$L'K)GCZ@K>3/CN!6(\%M`$:VF=,)J$LJ[;X#3$EPQ1YS'56`BV!@JX MW.[_",,E2I;%Q%%&$)^<\]AIP+ZMX8:--W6]7/GA&L(]FUH'#5$?%_3?B$=; M8P9<,!<,TB,TC)X35KZ(,A$78*"'Z=Y&&`H.+V``9RA6WXZ<5[YAE'IJF?571+H!G);1244]G,/QK%!"E'O2 M=1->I;\U<[V!@C:3O37#MFXQ&(P]PG\E*$(QS+,@B=.+0A4HU!-P&0L*'!O? M)^BQ>`Q!Y*>K18Q]^TNZ"R\F"_FKQSZ0UD"Y[U#K6A3&=QV=8I"F4T/)'ZFY<#ACYDR66KBD>A%;]M9O M)``=!<300YK7/7PAII7>UYR$-+#0>W>X&!CPK4MO6&@`TTJ(8 M!$*KX)B/L,__%?*3F+F?9+1V'10\-C5%NEBP,+1<_`[1?$%8'F9)`<4]L50: MT3B)HQ@$4R(BGOU0HF$-A#0L+.T9UW1FM@LJBW"43ZB*1-20Q*)R!%A28EW3 MUX/(6<)KX<(1^`WY21`:)7'TT6Q-^AYY'\V#5LKT_?JX)=5W^3I[X$OOA2 M8VP"9#N9,"@"&&Q4RGN)28F&-<9$395E&]*>7Z;O:Q8"OA^^TGR4*#TMB"!^ M@1&M<\8IK"C7V1JEZU,A#Q;*HN@1'KCE&66Z6HP%9;VI@L#F4HYZP+-A^R;$ M5V'R',\2OYA6W)+LXHX]`XY4<GY,5E*:=9#>NZ)"HA:6 MC8E&-%R$ASY!.))`)+MNWPI*C2K3L1A=77@P;:3B"-3NPIU\`G_ZHD?.=][4.6+H`H.J*\^2A M"4RK-)_W*08XMN4<@B^3RP7`WT]JA#<&K1/^&LC'D155X!## M:>*E^(R8FD;5K.MPQ5`9R#.&]K(ZZZ633/CQ-27('HRND)8^"S M%\S:([*_?LB4FQ\-D9_\?U!+`P04````"``B7"U&@7BS0`@3``"ZVP``$0`< M`&)R;&DM,C`Q-#$P,S$N>'-D550)``._2+54OTBU5'5X"P`!!"4.```$.0$` M`.U=W7/C-I)_OZK]'WA^N=R#1Y(_YC*NS&[)LC2C+=E2)#F3/&U!)"1A0Q$* M"-I6_OIK@*1$BB#X)8_I+*M2L8;L;J+[!S0:0`/XZ1\O&]MXPLPEU/E\UOG0 M/C.P8U*+.*O/9YY[CER3D+-__/UO__73?Y^?&SV&$<>6L=@9]Y@Q8MM&C[(M M98B#`./\/""\12Y0P9-?;ZM%K/S\\?%H0R MO,0,E,,?3+H1PJXZ[CN_.$A6Y8`3&+C#79X MC"#R&FSHN#=0DM@GGR\_4+:"#[4[K5_O1S-9R)!XP6R2MX`^ATV@-5#+UJ@ZY;_\7,4E4 MC:!PG4^?/K7DVY#4PB0.@(O-#ROZU((7T9)`RS(,V;:0XU`N6[=\%C[=;HFS MI,$C>"@^E-K$$H+?(%OK-UAAS]\P@ M4!%RT.T+$Q;'PDOB$%ET0*G=-LZ-O1CXW1L_S,:CX5UWWK\S;KNC[D.O;\R^ M]OOSV4^M8P''LCWP;V/G[_+WEF$71$HCB2H3<`(O]CD`'6@J#'KT+/7JS.?RY[S_,9\9X8(PG_6EW/@2"!L=2 M./:0NQ[8]#DOC`=Z/8I715#L=6=?C<%H_*U!48GB'7%-F[H>PS-OLT%L-U[. MR,J!D,1$#N^:)O4<#F'A`NX??D& M71J1+QB'3QCA-XP?@J\8E__;8*['?`C:.BNRL''7=:'W"RQW#&X:F1[%JW;G M&,6#(,.7M`>K@:H<5#U0YR(G7CZM'K2/[8L"H!D_")G&18.>&CUJ>J*+"O]V M':L/SHKOAA#ULHU4(\`N#Z6^6VQ_$MUB*"#Z$SF6X4LS(N(:R,J-)"8(6/@: M<^B![+S#BCA3UACC.O\8P_@A)KIIB.5BU=D:K+BFMH69V__#@Z:2,VA5,.K1 MO2P2O"JQW7"Z!8SOA,Q M#'C$K7!SQR@J:?28728Q"Z7X$4XHI\&GV$@B:_20@4N>85X#B1Z2*7ZB]A,X MF0?*\03M$)CN%HD)]S@TJ71ZB*Z3$.TE&4*4$KA%U5G,L5O$6 M7`53XKT>GH])>(2$Z*87\&+]&N\G/J\51,,1QD&WOA$M:#>.,@O\$X5^]%_L36 M"",7CQZ<'1S'?$.5N4-"C,$"$_8)L#]]#V`3_5@;@:B(] M+HHY!R'&D'*,J*`&(CU$7S&R^7K?.4QLE.CS521:>"X4DP^^D$,O9`@Q#3AY M1K48WV('"L)5X*A(].`HYAU"(48@I0$G!S@/^#F2AL"H`S]-M8O3D>K!4DPJ M@+!8DD),7`-:1G"';6QR;/WL(<8QLW<#XH`[(LB^0QPE0CL]M1XZQ4Q"*,_8 M"S3V$@TALH$O`SYSC2W/QD,B>OHPE>MGN:5R)R;K_':1C-'S\NDA5/H[XQ',*_?NF.'N46(J/[<&?\_-@=#0>_#1^^&-U>;_SXT.P0.TV*6+54 ML5PI8^!XDXGQ1?:DA+^:!-V30#X7V2HE`0]X=7!?5MV"Y'^C`;M$JJ`:6@VE M'LC+))#JM,$&M)+Y@VK`4JCT8%TEP5+L/FIP*I6EIL8IA4J/T\=A"B9D],`52TY)R50U!+K M8>LH(L/41)T&OI-G[*2TP*+\>I`5X7^Q[)T&^.II/&JDLQGTT"H&!-J4G@;) MZKD]*4AF,NB15(P6M'D^#9(GF19/Z5+S\&CQO%"TS,PI\@;3:MNB4TY\R:#6 MX7A5:)-T3.0KS2VD=X'E=S3-!) M,;^JA/E5)N97I\#\JL'\E)A?5\+\.A/SZU-@?MU@7F+=*Z7GUI'JT1:&R9F:;`R;F9D3KD^G>=/"`O1(5SY?HFG!)UBBUL1]&`6?QDBK0A?()`#Y7VG(H&E\(G5J2.UX_> MZU'1G5_1@'*JDRS2QA0YV?00ECO7H@&WPL;]%#PUE%H(RC([R!M83[V7/`W@@NQZJ*OO+/^/`E[\3]Q: M/,5+0UY4>\.!Z/.92\#5B0MNY;.UO,Q8W(I['MZ*_"]0]\/+Q@Y)A'S-E;FR MRAQ;*/AP*`(Q,R$E<9$N")$+\1#BM,+"GQFMDZD%6!15ZPB^.FH%%:6H5O&Z M54>E;+0HJA2P8/MU]/FI=7PO<_`D?G^SO+T95*.,&X[RIG3-_=_^/>LC:DIY M^;C.Q77=YYV+\\['#_#ML,"ERA&]4[Q86:CS<*KB**X?SU,6F[$85ZF"Z*[L M3BN%DD?\.#\PES=%]#;R/&:0+.)?^ZO2A2$NA2&*%$-]>7S.`H0,XLO7^;^I MO4Y>9WPE8PO;W`V?Z*"`0%$N#(@"?3[K6D_"!;@0F/2HR]WNPI7+!7Y4(QS4 MO]))?,\FKY>_@6=`,.1X([IE4,`#,L(]4?POC'K;D)``R9F!`B&?SSCS@-PA MMBTRF,)_^[3@G@BUYO(SEL>"DV?3E;%M^BSJP("R<-T#XJX>PQ:14[8BCI+! MUSW>+#"+*EF8U5<>/`&XD!N+;A!QWE;[6V2)I*+^RQ8[+H[H=OPB"MN&.A`= MLEWNHJN+NO"ON(1RX@7A)14(UC7DDH8[=&`4@UT^!><6T45#$P`":,!W31!; M`HXELMU3X2%N,9\@8BF:5/)5W9J26):@CEPQAIX.*OQX^0OE^.@6"E^93-*H M<@0P6V'VUMA01]00GTY,.?H-7?QZ=(B8Q,)6=R/:>TS1_$R5VEA.G;,;G=\G M9KS.9KPOP[ ML"9H1UDQQ-.%O-^:<`_-V@3/Y?\EU@0".!*>>9_3+JDR:FL6CXGKH_<)M'(W MQVZ.7_BM#:X]JGP692PTXN'S-W;Y(@0:@C]D\BIT*#P3,<30Z;\05ZRXWU+& MZ+/(3HRH6H3IN[I\4W8])S%%V&GW_X#:/)&2B`F-.')BK<(6&5Q5NOQ7@'L: M3O@>A9-:JO(!9;8&V3USO&B_($:$1%&R6S'9`W\3@YC\++4;O*07O>\Q:E'X M!"N@;Y*IAAI#98-6O'>CP?@L6(OKFB;(MD:@$K')X7Z)0/'"O/4(2$]@E\A` M_8YZ"[[T[/CIOKDLI)7R5['5'=XR;))P#0K&)A"#_(F.8IDJ0MZOI=+#FVS2 MFL8W2^)@F97(R$)^6RSG=U<8.NE@H=_MT2?HX:RXM@78HGB'9:JGWE/L7\>" M9Y@]$1/[(4JVXFE\M=3\T#*#^X?GU#\:]=&Q,(O.E<44+\+V?EHX-648(+9' M.U"FW=!94K;Q_59R:)^/O&Z#^OYRB4U.G@[['$6T,\4F=4SHZB4[U-@-5^9(=#U>.[7B/6J"ZP?G/)%]3QRR\3:1#0E0 M0VS/`E+9+QST/W`^4#[S%O\&1S*G8EL[<8ZCRS_DP8$:=`C0AXYY@M*HEY-X.,5#5#Y<`_0G]%+!Q;.2[&]LZL\;A9 M,`S?.$`N._)0-8EQPA;YF-Z1)02P+H9Z+58/G!4>4"\Y8:TGJU^PG2CNV$FN M.FBIWH%.\S6XZ1Q:Q>C>@U[/-(]6!ZK:Z33PF`.?9'A`7L0?.?>P7!+A+418 MNO4X9OO#ZQ+*EF.OG16^4&H]@R!%8)I\5;?P0K7'4!=JYZ1_5VJJ@N>\#'6( MDH>;+2),/!@OCR_S"F<#Q<%V(_*$+?]Q1--2W.^FXQ>3:+9]]P)_$_Y'\:YV MSB5M?70?M6M;:RGNNK7=$5I0(*)L-\=^4D]P(GT"T$S*VL$K!I[CI9^GJG=( MF92U7/2,EGJ`Q+H%W]VC%S&#N$_-ZJ$MO.&[^.15N-H_Q28F3Z(@*<:H+O9M M\X@B!Y_HFK*>K&YM-IR!OY-I>";WV*`CJF7KGB`>I-6.(&B'_B7IDM-):N>+HVYBBL6F,"%RAE=R&=J_ M&I7.*4=V(H8JSEJWF?@)"[)JY&*CW!?B=CV^IDP<8[9?XIF!5'CQ3\\A-`9S M*?:8UY(\W]7SAF>L)ROMT8OZ555&GXA8\1E0%NP><\?+&;*Q&ZSU!-DQ;ERK MW$R5XOM7#.5 M6K>P(ZC'0L>5?YA`?#TT:U/(G$))W;`YN#&SG5CR:P:=.2RE:O8/F-_B)94W M620\1<06)7A?TY]4VFH1G@83)E/F62V<'XU&*L@HT8`L?K/>B3KC+>2:Y2LU MI8-2`&V`%5$6P1ICK,G!W*JS\+*(?"Q0340GEL+P>>`V,HQ61GF(06 M3;^-ZEV[SN3)#3)/ MW=]S:8?J0D\*_[GY*UAQN7\->QYF.%0)"L5LF$_6^[&;&#Z*771RX1#@]WVQ M.#Y_)>EN=P>2H.)TGQ&S@N/V]PNO\K/=)<OH,AII@3)F5]7P"BW_TK63XZD(GE'XR7OG'`P7Y;$W,]HL@9 MLR\>$G=2[.[1[M:/]JW8AJ4W+D?=)M8RS>&FV:.[@M&".#ML`./S>\1^QUP$ MF7*XN3_1Y1OAZREVMS*W6EHGO)&$X<"(0@4PW7R-!X2Y?$XVN`A<;U.^OT[' MDVJ_O>?9$O\KPN&[@1XZ-^8H? MJJ7;65/;PDPTP6,MHKY6ZI*8`R\KH'9SY7+9Y0MV(+2UQ?YH"SIU(KXCME8E M#V/+1U[7^?'].5?A&/QH2!11-)OTW?C@;PR^.5XNQ\MPY2:BI^IE/>`+E4BL M=/^&$7/'2[])N6NR/3M:5E<1')6JDK/7%?YE8SNNZN1:<>U`Z]?[T4P>C:D] MX,GEX^6CPS#9+#P&#E>Q6J4CJ@=\BDQ0)B>'BJT.X2U& MN[!.!2OU0^>0:1)-/RG`].;9%D>%G<#`309$`V)CRR]ZNFIJZKKI=$CA*Z9= M%M^;ZQG6K)Z-R,9]0"*;*S:^3"-X\Y)_% M_PF>&B=S#0IQO;GO&#I+L4B%_>5BO_4K\FK3B6J@`<=,S'L2N89)\+.B_&DD MW[/T_G'N_CG3\,__!U!+`0(>`Q0````(`")<+48P$;'R"!L!`#QN%@`1`!@` M``````$```"D@0````!B`Q0````(`")<+48EGHN"=@P``)[````5`!@````` M``$```"D@5,;`0!B`L` M`00E#@``!#D!``!02P$"'@,4````"``B7"U&4PC\$W\>``";#P(`%0`8```` M```!````I($8*`$`8G)L:2TR,#$T,3`S,5]D968N>&UL550%``._2+54=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`(EPM1M`*%>S`?```^B4(`!4`&``` M`````0```*2!YD8!`&)R;&DM,C`Q-#$P,S%?;&%B+GAM;%54!0`#OTBU5'5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`")<+4:B;^^B)T@``/21!0`5`!@` M``````$```"D@?7#`0!B`L``00E#@``!#D!``!02P$"'@,4````"``B7"U&@7BS0`@3``"ZVP``$0`8 M```````!````I(%K#`(`8G)L:2TR,#$T,3`S,2YX`L` A`00E#@``!#D!``!02P4&``````8`!@`:`@``OA\"```` ` end XML 22 R55.htm IDEA: XBRL DOCUMENT v2.4.1.9
Earnings Per Share (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Oct. 31, 2014
Jul. 31, 2014
Apr. 30, 2014
Jan. 31, 2014
Oct. 31, 2013
Jul. 31, 2013
Apr. 30, 2013
Jan. 31, 2013
Oct. 31, 2012
Jul. 31, 2012
Apr. 30, 2012
Jan. 31, 2012
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Earnings Per Share                              
Income Available to Common Stockholders $ 18,281us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 15,250us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 10,273us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 2,954us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 11,120us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 14,701us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 11,338us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 8,665us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 12,889us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 12,596us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 9,306us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 7,365us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 46,758us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 45,825us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 42,156us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Weighted Average Common Shares Outstanding - Basic (in shares) 27,728,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,722,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,717,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,700,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,677,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,672,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,698,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,716,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,705,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,695,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,685,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,888,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,716,608us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,690,677us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,742,257us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Effect of Dilutive Securities: Warrants/Options (in shares)                         138,000us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants 161,000us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants 179,000us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants
Weighted Average Common Shares Outstanding - Diluted (in shares) 27,869,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,864,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,857,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,848,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,844,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,842,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,879,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,912,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,906,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,888,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,878,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 28,041,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,855,125us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,851,720us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,920,920us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
Net Income Per Share - Basic (in dollars per share) $ 0.66us-gaap_EarningsPerShareBasic $ 0.55us-gaap_EarningsPerShareBasic $ 0.37us-gaap_EarningsPerShareBasic $ 0.11us-gaap_EarningsPerShareBasic $ 0.40us-gaap_EarningsPerShareBasic $ 0.53us-gaap_EarningsPerShareBasic $ 0.41us-gaap_EarningsPerShareBasic $ 0.31us-gaap_EarningsPerShareBasic $ 0.47us-gaap_EarningsPerShareBasic $ 0.45us-gaap_EarningsPerShareBasic $ 0.34us-gaap_EarningsPerShareBasic $ 0.26us-gaap_EarningsPerShareBasic $ 1.69us-gaap_EarningsPerShareBasic $ 1.65us-gaap_EarningsPerShareBasic $ 1.52us-gaap_EarningsPerShareBasic
Net Income Per Share - Diluted (in dollars per share) $ 0.66us-gaap_EarningsPerShareDiluted $ 0.55us-gaap_EarningsPerShareDiluted $ 0.37us-gaap_EarningsPerShareDiluted $ 0.11us-gaap_EarningsPerShareDiluted $ 0.40us-gaap_EarningsPerShareDiluted $ 0.53us-gaap_EarningsPerShareDiluted $ 0.41us-gaap_EarningsPerShareDiluted $ 0.31us-gaap_EarningsPerShareDiluted $ 0.46us-gaap_EarningsPerShareDiluted $ 0.45us-gaap_EarningsPerShareDiluted $ 0.33us-gaap_EarningsPerShareDiluted $ 0.26us-gaap_EarningsPerShareDiluted $ 1.68us-gaap_EarningsPerShareDiluted $ 1.65us-gaap_EarningsPerShareDiluted $ 1.51us-gaap_EarningsPerShareDiluted
XML 23 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 3) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended
Oct. 31, 2014
Jul. 31, 2014
Apr. 30, 2014
Jan. 31, 2014
Oct. 31, 2013
Jul. 31, 2013
Apr. 30, 2013
Jan. 31, 2013
Oct. 31, 2012
Jul. 31, 2012
Apr. 30, 2012
Jan. 31, 2012
Oct. 31, 2014
item
Oct. 31, 2013
item
Oct. 31, 2012
item
Revenue Recognition and Contractual Adjustments                              
Gross Service Revenues                         $ 4,185,052us-gaap_SalesRevenueServicesGross $ 3,524,108us-gaap_SalesRevenueServicesGross $ 3,052,431us-gaap_SalesRevenueServicesGross
Contractual Adjustments and Discounts:                              
Medicare/Medicaid Portion                         391,659brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion 354,638brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion 320,697brli_ContractualAdjustmentsAndDiscountsMedicareMedicaidPortion
All Other Third Party Payors                         2,899,374brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors 2,393,872brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors 2,070,073brli_ContractualAdjustmentsAndDiscountsAllOtherThirdPartyPayors
Total Contractual Adjustments and Discounts                         3,291,033brli_ContractualAdjustmentsAndDiscounts 2,748,510brli_ContractualAdjustmentsAndDiscounts 2,390,770brli_ContractualAdjustmentsAndDiscounts
Service Revenues Net of Contractual Adjustments and Discounts                         894,019brli_SalesRevenueServicesNetBeforeProvisionForBadDebts 775,598brli_SalesRevenueServicesNetBeforeProvisionForBadDebts 661,661brli_SalesRevenueServicesNetBeforeProvisionForBadDebts
Patient Service Revenue Provision for Bad Debts                         61,737brli_ProvisionForBadDebtsOfSalesRevenueServices 60,244brli_ProvisionForBadDebtsOfSalesRevenueServices 47,406brli_ProvisionForBadDebtsOfSalesRevenueServices
Net Revenues $ 227,594us-gaap_SalesRevenueServicesNet $ 222,053us-gaap_SalesRevenueServicesNet $ 201,366us-gaap_SalesRevenueServicesNet $ 181,270us-gaap_SalesRevenueServicesNet $ 192,219us-gaap_SalesRevenueServicesNet $ 185,427us-gaap_SalesRevenueServicesNet $ 176,452us-gaap_SalesRevenueServicesNet $ 161,256us-gaap_SalesRevenueServicesNet $ 163,487us-gaap_SalesRevenueServicesNet $ 160,532us-gaap_SalesRevenueServicesNet $ 151,443us-gaap_SalesRevenueServicesNet $ 138,793us-gaap_SalesRevenueServicesNet $ 832,282us-gaap_SalesRevenueServicesNet $ 715,354us-gaap_SalesRevenueServicesNet $ 614,255us-gaap_SalesRevenueServicesNet
Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue.                         80.10%brli_RevenueRecognitionPercentageOfContractualAdjustmentsAndDiscountsToGrossRevenues 79.70%brli_RevenueRecognitionPercentageOfContractualAdjustmentsAndDiscountsToGrossRevenues 79.90%brli_RevenueRecognitionPercentageOfContractualAdjustmentsAndDiscountsToGrossRevenues
Number of distinct payors included in all other third party and Direct                         800brli_NumberOfDistinctPayorsIncludedInAllOtherThirdPartyAndDirectPayors 800brli_NumberOfDistinctPayorsIncludedInAllOtherThirdPartyAndDirectPayors 800brli_NumberOfDistinctPayorsIncludedInAllOtherThirdPartyAndDirectPayors
XML 24 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
Property and Equipment (Tables)
 12 Months Ended
Oct. 31, 2014
Property and Equipment  
Summary of property and equipment - at cost

 

                                                                                                                                                          

 

 

$

 

 

 

October 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Medical Equipment

 
77,682 

 
65,762 

 

Leasehold Improvements

 
32,157 

 
27,974 

 

Furniture, Fixtures and Office & Computer Equipment

 
26,076 

 
21,621 

 

Automobiles and Aircraft

 
20,427 

 
18,242 

 

 

 

 

 

 

 

Sub Totals

 
156,342 

 
133,599 

 

Less Accumulated Depreciation

 
89,954 

 
67,950 

 

 

 

 

 

 

 

Totals — Net of Accumulated Depreciation

 
66,388 

 
65,649 

 

 

XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 26 R57.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options and Warrants (Details 2) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Employee Incentive Stock Options      
Weighted Average, Shares Outstanding 222us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions    
Exercisable, Shares Outstanding 217us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions    
Compensation cost      
Compensation cost recognized (in dollars) $ 40us-gaap_AllocatedShareBasedCompensationExpense $ 40us-gaap_AllocatedShareBasedCompensationExpense $ 40us-gaap_AllocatedShareBasedCompensationExpense
Compensation cost, related tax benefit (in dollars) $ 0us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense $ 0us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense $ 0us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
7.25 to 7.25      
Employee Incentive Stock Options      
Exercise price range, low end of range (in dollars per share) $ 7.25us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeOneMember		    
Exercise price range, high end of range (in dollars per share) $ 7.25us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeOneMember		    
Weighted Average, Exercise Price (in dollars per share) $ 7.25us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeOneMember		    
Exercisable, Exercise Price (in dollars per share) $ 7.25us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeOneMember		    
7.41 to 7.67      
Employee Incentive Stock Options      
Exercise price range, low end of range (in dollars per share) $ 7.41us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeTwoMember		    
Exercise price range, high end of range (in dollars per share) $ 7.67us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeTwoMember		    
Weighted Average, Shares Outstanding 46us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeTwoMember		    
Weighted Average, Remaining Life 5 months 1 day    
Weighted Average, Exercise Price (in dollars per share) $ 7.41us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeTwoMember		    
Exercisable, Shares Outstanding 46us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeTwoMember		    
Exercisable, Exercise Price (in dollars per share) $ 7.41us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeTwoMember		    
9.12 to 9.12      
Employee Incentive Stock Options      
Exercise price range, low end of range (in dollars per share) $ 9.12us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeThreeMember		    
Exercise price range, high end of range (in dollars per share) $ 9.12us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeThreeMember		    
Weighted Average, Shares Outstanding 136us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeThreeMember		    
Weighted Average, Remaining Life 1 year    
Weighted Average, Exercise Price (in dollars per share) $ 9.13us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeThreeMember		    
Exercisable, Shares Outstanding 136us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeThreeMember		    
Exercisable, Exercise Price (in dollars per share) $ 9.13us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeThreeMember		    
17.50 to 17.50      
Employee Incentive Stock Options      
Exercise price range, low end of range (in dollars per share) $ 17.50us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeFourMember		    
Exercise price range, high end of range (in dollars per share) $ 17.50us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeFourMember		    
Weighted Average, Shares Outstanding 40us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeFourMember		    
Weighted Average, Remaining Life 3 years 29 days    
Weighted Average, Exercise Price (in dollars per share) $ 17.50us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeFourMember		    
Exercisable, Shares Outstanding 35us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeFourMember		    
Exercisable, Exercise Price (in dollars per share) $ 17.50us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis
= brli_ExercisePriceRangeFourMember		    
XML 27 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements
 12 Months Ended
Oct. 31, 2014
Fair Value Measurements  
Fair Value Measurements

[19] Fair Value of Financial Instruments

 

For certain financial instruments, including cash and cash equivalents, trade receivables, trade payables, and short-term debt, it was estimated that the carrying amount approximated fair value for the majority of these items because of their short maturities.  The fair value of the Company’s long-term debt is estimated based on the quoted market prices for similar issues or by discounting expected cash flows at the rates currently offered to the Company for debt of the same remaining maturities.

 

Due to the non-interest bearing nature and unspecified payment terms, it was not practicable to estimate the fair value of amounts due from related parties [See also Note 7].

 

XML 28 R50.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Intangible assets      
Cost $ 25,166us-gaap_FiniteLivedIntangibleAssetsGross $ 25,166us-gaap_FiniteLivedIntangibleAssetsGross  
Accumulated Amortization 10,763us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization 8,846us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization  
Net of Accumulated Amortization 14,403us-gaap_FiniteLivedIntangibleAssetsNet 16,320us-gaap_FiniteLivedIntangibleAssetsNet  
Amortization expenses 1,917us-gaap_AmortizationOfIntangibleAssets 994us-gaap_AmortizationOfIntangibleAssets 581us-gaap_AmortizationOfIntangibleAssets
Estimated amortization expense related to intangible assets      
2015 1,852us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear    
2016 1,540us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo    
2017 1,063us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree    
2018 946us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour    
2019 904us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive    
Thereafter 8,098us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive    
Net of Accumulated Amortization 14,403us-gaap_FiniteLivedIntangibleAssetsNet 16,320us-gaap_FiniteLivedIntangibleAssetsNet  
Customer Lists      
Intangible assets      
Weighted-Average Amortization Period 20 years 20 years  
Cost 8,738us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		 8,738us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		  
Accumulated Amortization 3,275us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		 2,878us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		  
Net of Accumulated Amortization 5,463us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		 5,860us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		  
Estimated amortization expense related to intangible assets      
Net of Accumulated Amortization 5,463us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		 5,860us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_CustomerListsMember		  
Noncompete Agreements      
Intangible assets      
Weighted-Average Amortization Period 3 years 3 years  
Cost 11,131us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		 11,131us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		  
Accumulated Amortization 5,738us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		 4,560us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		  
Net of Accumulated Amortization 5,393us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		 6,571us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		  
Estimated amortization expense related to intangible assets      
Net of Accumulated Amortization 5,393us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		 6,571us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_NoncompeteAgreementsMember		  
Patents and Licenses      
Intangible assets      
Weighted-Average Amortization Period 17 years 17 years  
Cost 5,297us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		 5,297us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		  
Accumulated Amortization 1,750us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		 1,408us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		  
Net of Accumulated Amortization 3,547us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		 3,889us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		  
Estimated amortization expense related to intangible assets      
Net of Accumulated Amortization $ 3,547us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		 $ 3,889us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= brli_PatentsAndLicensesMember		  
XML 29 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
Selected Quarterly Financial Data (Tables)
 12 Months Ended
Oct. 31, 2014
Selected Quarterly Financial Data  
Schedule of quarterly financial data

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2014

 

4/30/2014

 

7/31/2014

 

10/31/2014

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 
181,270 

 
201,366 

 
222,053 

 
227,594 

 
832,282 

 

Gross Profit

 
72,154 

 
88,549 

 
102,443 

 
106,853 

 
369,999 

 

Net Income

 
2,954 

 
10,273 

 
15,250 

 
18,281 

 
46,758 

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 
0.11 

 
0.37 

 
0.55 

 
0.66 

 
1.69 

 

Diluted

 
0.11 

 
0.37 

 
0.55 

 
0.66 

 
1.68 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 
27,700 

 
27,717 

 
27,722 

 
27,728 

 
27,717 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 
27,848 

 
27,857 

 
27,864 

 
27,869 

 
27,855 

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2013

 

4/30/2013

 

7/31/2013

 

10/31/2013

 

2013

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 
161,256 

 
176,452 

 
185,427 

 
192,219 

 
715,355 

 

Gross Profit

 
70,922 

 
80,676 

 
85,660 

 
85,282 

 
322,539 

 

Net Income

 
8,665 

 
11,338 

 
14,701 

 
11,120 

 
45,825 

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 
0.31 

 
0.41 

 
0.53 

 
0.40 

 
1.65 

 

Diluted

 
0.31 

 
0.41 

 
0.53 

 
0.40 

 
1.65 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 
27,716 

 
27,698 

 
27,672 

 
27,677 

 
27,691 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 
27,912 

 
27,879 

 
27,842 

 
27,844 

 
27,851 

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2012

 

4/30/2012

 

7/31/2012

 

10/31/2012

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 

$
138,793 

 

$
151,443 

 

$
160,532 

 

$
163,487 

 

$
614,255 

 

Gross Profit

 

$
60,118 

 

$
67,534 

 

$
74,279 

 

$
74,681 

 

$
276,611 

 

Net Income

 

$
7,365 

 

$
9,306 

 

$
12,596 

 

$
12,889 

 

$
42,156 

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$
0.26 

 

$
0.34 

 

$
0.45 

 

$
0.47 

 

$
1.52 

 

Diluted

 

$
0.26 

 

$
0.33 

 

$
0.45 

 

$
0.46 

 

$
1.51 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 
27,888 

 
27,685 

 
27,695 

 
27,705 

 
27,742 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 
28,041 

 
27,878 

 
27,888 

 
27,906 

 
27,921 

 

 

XML 30 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
Earnings Per Share (Tables)
 12 Months Ended
Oct. 31, 2014
Earnings Per Share  
Schedule of computation of basic and diluted net earnings per common share

The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:

 

 

 

$

 

 

 

For Years Ended October 31,

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Income Available to Common Stockholders

 
46,758 

 
45,825 

 
42,156 

 

Weighted Average Common Shares Outstanding

 
27,717 

 
27,691 

 
27,742 

 

 

 

 

 

 

 

 

 

Effect of Dilutive Securities:

 

 

 

 

 

 

 

Warrants/Options

 
138 

 
161 

 
179 

 

 

 

 

 

 

 

 

 

Weighted Average Diluted Common Shares Outstanding

 
27,855 

 
27,852 

 
27,921 

 

 

 

 

 

 

 

 

 

Net Income Per Share - Basic

 
1.69 

 
1.65 

 
1.52 

 

Net Income Per Share - Diluted

 
1.68 

 
1.65 

 
1.51 

 

 

XML 31 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9
Long-Term Debt - Bank (Details) (USD $)
In Thousands, unless otherwise specified
 1 Months Ended
Dec. 31, 2010
installment
Oct. 31, 2014
Long-term debt    
Debt outstanding   $ 3,669us-gaap_LongTermDebt
Principal repayment for each of the five succeeding fiscal years and thereafter    
2015   524us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2016   557us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2017   592us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2018   1,996us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
Totals   3,669us-gaap_LongTermDebt
Medium-term Notes    
Long-term debt    
Term of debt 7 years  
Debt issued 5,408brli_DebtInstrumentIncreaseInExistingBorrowings
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember		  
Debt instrument interest rate (as a percent)   6.12%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
Number of equal monthly installments 84brli_DebtInstrumentNumberOfEqualPeriodicPayments
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember		  
Monthly installment including principal and interest 61us-gaap_DebtInstrumentPeriodicPayment
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember		  
Debt outstanding   3,669us-gaap_LongTermDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
Principal repayment for each of the five succeeding fiscal years and thereafter    
Totals   $ 3,669us-gaap_LongTermDebt
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_MediumTermNotesMember
XML 32 R67.htm IDEA: XBRL DOCUMENT v2.4.1.9
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Valuation and qualifying accounts      
Balance at the Beginning of a Period $ 431,558us-gaap_ValuationAllowancesAndReservesBalance $ 319,195us-gaap_ValuationAllowancesAndReservesBalance $ 281,142us-gaap_ValuationAllowancesAndReservesBalance
Charged to Cost and Expenses 3,424,761us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense 2,867,671us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense 2,480,166us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
Deductions Charged to Valuation Allowance Accounts (3,259,577)us-gaap_ValuationAllowancesAndReservesDeductions (2,755,308)us-gaap_ValuationAllowancesAndReservesDeductions (2,442,113)us-gaap_ValuationAllowancesAndReservesDeductions
Balance at the End of a Period 596,742us-gaap_ValuationAllowancesAndReservesBalance 431,558us-gaap_ValuationAllowancesAndReservesBalance 319,195us-gaap_ValuationAllowancesAndReservesBalance
Allowance for Doubtful Accounts      
Valuation and qualifying accounts      
Balance at the Beginning of a Period 89,261us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 51,274us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 45,220us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember
Charged to Cost and Expenses 133,728us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 119,161us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 89,396us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember
Deductions Charged to Valuation Allowance Accounts (139,713)us-gaap_ValuationAllowancesAndReservesDeductions
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 (81,174)us-gaap_ValuationAllowancesAndReservesDeductions
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 (83,342)us-gaap_ValuationAllowancesAndReservesDeductions
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember
Balance at the End of a Period 83,276us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 89,261us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 51,274us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember
Allowance for Contractual Credits and Discounts      
Valuation and qualifying accounts      
Balance at the Beginning of a Period 342,297us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 267,921us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 235,922us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember
Charged to Cost and Expenses 3,291,033us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 2,748,510us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 2,390,770us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember
Deductions Charged to Valuation Allowance Accounts (3,119,864)us-gaap_ValuationAllowancesAndReservesDeductions
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 (2,674,134)us-gaap_ValuationAllowancesAndReservesDeductions
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 (2,358,771)us-gaap_ValuationAllowancesAndReservesDeductions
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember
Balance at the End of a Period $ 513,466us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 $ 342,297us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 $ 267,921us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember
XML 33 R61.htm IDEA: XBRL DOCUMENT v2.4.1.9
Litigation (Details) (USD $)
 0 Months Ended 12 Months Ended 0 Months Ended
Dec. 18, 2013
Oct. 31, 2014
Aug. 18, 2014
item
Oct. 16, 2013
item
Horizon Blue Cross Blue Shield of New Jersey Member | Minimum        
Litigation        
Number of years of membership 20 years      
Cost of unreimbursed services   $ 20,000,000brli_CostOfUnreimbursedServices
/ us-gaap_CounterpartyNameAxis
= brli_HorizonBlueCrossBlueShieldOfNewJerseyMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		    
GeneDx member | Inter parties review member        
Litigation        
Number of petitions filed     11brli_LossContingencyPetitionsFiledNumber
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LitigationCaseAxis
= brli_InterPartiesReviewMember		  
Number of additional petitions filed     2brli_LossContingencyAdditionalPetitionsFiledNumber
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LitigationCaseAxis
= brli_InterPartiesReviewMember		  
GeneDx member | Infringement of patent member        
Litigation        
Number of patents against which lawsuit was filed       16brli_LossContingencyNumberOfPatentsInLitigation
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LossContingenciesByNatureOfContingencyAxis
= brli_InfringementOfPatentMember
GeneDx member | Minimum | Inter parties review member        
Litigation        
Number of patents against which lawsuit was filed     14brli_LossContingencyNumberOfPatentsInLitigation
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LitigationCaseAxis
= brli_InterPartiesReviewMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		  
Number of claims narrowed     40brli_NumberOfClaimsNarrowed
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LitigationCaseAxis
= brli_InterPartiesReviewMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		  
GeneDx member | Maximum | Inter parties review member        
Litigation        
Number of patents against which lawsuit was filed     16brli_LossContingencyNumberOfPatentsInLitigation
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LitigationCaseAxis
= brli_InterPartiesReviewMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		  
Number of claims narrowed     67brli_NumberOfClaimsNarrowed
/ dei_LegalEntityAxis
= brli_GeneDxMember
/ us-gaap_LitigationCaseAxis
= brli_InterPartiesReviewMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		  
XML 34 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 4) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Oct. 31, 2011
Contractual Adjustments and Discounts:        
Percent of Contractual Allowances, Discounts and Patient Service Provision for Bad Debts to Gross Revenue. 80.10%brli_RevenueRecognitionPercentageOfContractualAdjustmentsAndDiscountsToGrossRevenues 79.70%brli_RevenueRecognitionPercentageOfContractualAdjustmentsAndDiscountsToGrossRevenues 79.90%brli_RevenueRecognitionPercentageOfContractualAdjustmentsAndDiscountsToGrossRevenues  
Allowances        
Total Allowance $ 596,742us-gaap_ValuationAllowancesAndReservesBalance $ 431,558us-gaap_ValuationAllowancesAndReservesBalance $ 319,195us-gaap_ValuationAllowancesAndReservesBalance $ 281,142us-gaap_ValuationAllowancesAndReservesBalance
Allowance for Contractual Credits and Discounts        
Allowances        
Total Allowance 513,466us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 342,297us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 267,921us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember		 235,922us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= brli_AllowanceForContractualCreditsAndDiscountsMember
Allowance for Doubtful Accounts        
Allowances        
Total Allowance $ 83,276us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 $ 89,261us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 $ 51,274us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember		 $ 45,220us-gaap_ValuationAllowancesAndReservesBalance
/ us-gaap_ValuationAllowancesAndReservesTypeAxis
= us-gaap_AllowanceForDoubtfulAccountsMember
XML 35 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Property and Equipment
 12 Months Ended
Oct. 31, 2014
Property and Equipment  
Property and Equipment

[3] Property and Equipment - Property and equipment - at cost is summarized as follows:

                                                                                                                                                           

 

 

$

 

 

 

October 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Medical Equipment

 
77,682 

 
65,762 

 

Leasehold Improvements

 
32,157 

 
27,974 

 

Furniture, Fixtures and Office & Computer Equipment

 
26,076 

 
21,621 

 

Automobiles and Aircraft

 
20,427 

 
18,242 

 

 

 

 

 

 

 

Sub Totals

 
156,342 

 
133,599 

 

Less Accumulated Depreciation

 
89,954 

 
67,950 

 

 

 

 

 

 

 

Totals — Net of Accumulated Depreciation

 
66,388 

 
65,649 

 

 

XML 36 R62.htm IDEA: XBRL DOCUMENT v2.4.1.9
Insurance (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Insurance  
Professional liability insurance coverage $ 3,000us-gaap_MalpracticeInsuranceAnnualCoverageLimit
Professional liability insurance coverage per occurrence 1,000us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident
Excess commercial insurance coverage per occurrence 5,000brli_ExcessCommercialInsuranceCoveragePerIncident
Excess commercial insurance coverage over the primary limits 5,000brli_ExcessCommercialInsuranceAdditionalCoverageOverPrimaryLimits
Excess umbrella coverage $ 15,000brli_ExcessUmbrellaInsuranceAnnualCoverageLimit
EXCEL 37 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C M86-F-F(Y9#(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N7V%N9%]"=7-I;F5S#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;W!E#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQO;F=497)M7T1E8G1?0F%N:SPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A M;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5M<&QO>6UE;G1?0V]N=')A8W1S7V%N9%]#;VYS=3PO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-E;&5C=&5D7U%U87)T97)L>5]&:6YA;F-I86Q?1#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-#2$5$54Q%7TE)7U9! M3%5!5$E/3E]!3D1?455!3#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O&5S7U1A M8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5A M#I7;W)K M#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D]R9V%N:7IA=&EO;E]A;F1?0G5S:6YE#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O5]O9E]3 M:6=N:69I8V%N=%]!8V-O=6YT-3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E)E=F]L=FEN9U].;W1E7U!A>6%B;&5?0F%N:U]$ M93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O&5S7T1E=&%I;',\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I% M>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D-A<&ET86QI>F5D7TQE87-E7T]B;&EG871I;VYS7S$\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-E;&5C=&5D7U%U87)T97)L>5]&:6YA;F-I M86Q?1#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV M95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!#96YT3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,#`P,#'0^,3`M2SQS<&%N M/CPO'0^+2TQ,"TS,3QS<&%N/CPO2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^06-C96QE2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\ M=&0@8VQA2!#;VUM;VX@ M4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y M9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF M,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!!6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA&5S(&%N9"!%>'!E;G-E6%B;&4@+2!"86YK/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPS.#`\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D(#$L-C8V+#8V-R!S:&%R97,L(&EN8VQU9&EN M9R`S+#`P,"!S:&%R97,@;V8@4V5R:65S($$@2G5N:6]R(%!R969E'0^)FYB'0^)FYBF5D(#,U+#`P,"PP,#`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS M,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B M8V%C9C9B.60R+U=O'0O:'1M;#L@8VAAF5D('-H87)EF5D('-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8T.3QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A M9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!O9B!/<'1I;VYS("T@16UP;&]Y965S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!O9B!/ M<'1I;VYS("T@16UP;&]Y965S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XS,2PU,#`\'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5R8VES92!O9B!/<'1I;VYS("T@ M16UP;&]Y965S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XT-BPP,#`\'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S65E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF%T:6]N/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PQ-C0\&5D($%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&]F($QO;F'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!O9B!/<'1I;VYS/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XR-3D\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!"=7-I;F5SF%T:6]N(&%N9"!"=7-I;F5S M'0^/&1I=CX@/&1I=B!S M='EL93TS1&UA3I4:6UE6QE/3-$)V1I MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^0FEO+5)E9F5R96YC92!,86)O#(P,4,[ M0E),228C>#(P,40[+"!O&EC;VQO9WD@ M*&EN8VQU9&EN9R!D"!L96%S960@9F%C:6QI='D@ M:6X@1V%I=&AE2XF;F)S<#LF;F)S<#M":6\M4F5F97)E;F-E(&UA2!T;R!P M:'ES:6-I86YS+"!G96YE=&EC:7-T3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M28C>#(P,3D[F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N M="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^ M4')I;F-I<&QE2!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)I M97,N)FYB2!A M8V-O=6YT3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M2X\+V9O;G0^#0H)"3PO<#X- M"@D)/'`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`@F4Z(#$R<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^3VX@F%T:6]N(&%R92!R96UO=F5D M(&9R;VT@=&AE(&%C8V]U;G1S+"!A;F0@86YY(')E;&%T960@9V%I;B!O'!E;G-E('=H96X@:6YC=7)R960N/"]F;VYT M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M#(P,4,[ M05-5)B-X,C`Q1#LI($YO+B9N8G-P.S(P,3$M,#@@:7-S=65D(&]N(%-E<'1E M;6)E2!A#(P,3D[6EN9R!V86QU92!IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&AE(&)A;&%N8V4@F%T:6]N(&]F("0R+#0P,2!A2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`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`E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/EEE87(F;F)S<#M%;F1E9"9N8G-P.T]C=&]B97(F;F)S<#LS,2P\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`Q+C(P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-#8N-C`E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`P)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`S+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3(\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C(P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$ M)W=I9'1H.C0V+C8P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1W)O M6QE/3-$)W=I9'1H.C`S+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS+#4R-"PQ,#@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C(P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N M-C`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$=VED=&@Z,30N-#`E.W!A9&1I;F'0M86QI M9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0V+C8P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0V]N=')A8W1U86P@061J=7-T;65N M=',@86YD($1I6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I M9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^365D:6-A6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C$T+C0P)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXS,C`L-CDW)FYB6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#,Y,RPX-S(F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C`Q+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N-C`E.W!A9&1I;F6QE/3-$)W=I9'1H.C$T+C0P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ M6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR M+#,Y,"PW-S`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXX.30L,#$Y)FYB6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^4&%T:65N="!3 M97)V:6-E(%)E=F5N=64@4')O=FES:6]N(&9O6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV,"PR-#0F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H M.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI M9VXZ6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$=VED=&@Z,30N-#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H M.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4')O M=FES:6]N(&9O6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,"XQ M)FYB6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`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`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#$N,38E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`S+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M6QE/3-$)VUAF4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$T+C,V)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$T+C,V)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)V1I6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C$T+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXS-#(L,CDW)FYB6QE/3-$)W=I9'1H.C`Q+C$V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N M,3(E.W!A9&1I;F6QE/3-$=VED=&@Z,#,N,#`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXX.2PR-C$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXU.38L-S0R)FYB6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXT,S$L-34X)FYB6QE/3-$)W=I9'1H.C`Q+C$V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^0W5R6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I"!B87-E"!L87=S(&%N9"!R871E&%B;&4@:6YC;VUE+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M2!A9&]P=&5D($=!05`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`D,RPR,#`@86YD("0R+#,V-B!F;W(@=&AE M('EE87)S(&5N9&5D($]C=&]B97(F;F)S<#LS,2P@,C`Q-"P@,C`Q,R!A;F0@ M,C`Q,BP@3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^4W5B3I4:6UE6QE/3-$)V1I3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A M9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O M'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!A;F0@17%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R M9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[)SY;,UT@ M4')O<&5R='D@86YD($5Q=6EP;65N="`M/"]F;VYT/CQF;VYT('-T>6QE/3-$ M)V1I2!A;F0@97%U:7!M96YT("T@ M870@8V]S="!IF5D(&%S(&9O;&QO=W,Z/"]F;VYT/@T*"0D\ M+W`^#0H)"3QP('-T>6QE/3-$)VUA6QE/3-$=VED M=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUAF4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H M.C0T+C,R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#DN M.3`E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C$R)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C8V)3MP M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#DN.3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z M,C`N,C8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`T+C$R)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C(P+C(V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV-2PW-C(F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS,BPQ-36QE/3-$)W=I9'1H.C(P+C(V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB'1U6QE/3-$)W=I9'1H M.C$Y+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXR-BPP-S8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C8V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#DN M.3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXR,"PT,C6QE/3-$)W=I9'1H.C(P M+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI M9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C$Y+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C(P M+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4W5B(%1O=&%L6QE/3-$=VED=&@Z,#0N,3(E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I M9'1H.C(P+C(V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C0Y+CDP)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3&5S6QE/3-$)W=I M9'1H.C$Y+CDT)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX M.2PY-30F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#DN.3`E.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,C`N,C8E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I9'1H.C`T M+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV-BPS.#@F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II M=&%L:6,[)SY;-%T@26YT86YG:6)L92!!3I4:6UE6QE/3-$ M)V1IF5D(&%S(&9O;&QO=W,Z/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[=&5X="UD96-O3I4:6UE6QE/3-$ M)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E=E:6=H=&5D+4%V97)A9V4\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D%C8W5M M=6QA=&5D/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$=VED=&@Z,3(N-3`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`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`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C$Q+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXX+#6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I'0M86QI9VXZ MF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S$N,C8E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C$R+C4P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE M/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N,C8E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S M+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^,3<\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC M;VQO6QE/3-$)W=I9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXU+#(Y-R9N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$R+C4P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#6QE/3-$)W=I M9'1H.C$R+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M+#4T-R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,2XR-B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE M/3-$=VED=&@Z,3'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N-3`E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C,Q+C(V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&]T86QS/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"PW M-C,F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C$Q+C(P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#AP="<^#0H)"0D\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.CAP=#LG M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z M,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S M='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/E=E:6=H=&5D+4%V97)A9V4\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S M+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/D%C8W5M=6QA=&5D/"]F;VYT/CPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,3(N-3`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L M9#MF;VYT+7-I>F4Z.'!T.R<^3F5T)FYB3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/D%C8W5M=6QA=&5D/"]F;VYT/CPO<#X- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^26YT M86YG:6)L929N8G-P.T%S6QE/3-$)W=I9'1H.C$W+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D-O6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D%M;W)T:7IA=&EO;CPO9F]N=#X\+W`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`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#$N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S M+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^,C`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC M;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M'0M86QI9VXZF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I M9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C$Q+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXU+#@V,"9N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XR-B4[ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^0V]V96YA;G1S($YO="UT;RU#;VUP971E/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED M=&@Z,3'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^,SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+#4V,"9N8G-P.PT*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV M+#4W,29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`Q+C(V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Q+C(V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^4&%T96YT6QE/3-$ M)W=I9'1H.C$W+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ MF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE M6QE/3-$=VED=&@Z,3(N-3`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q M+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR-2PQ-C8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$Q+C(P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)OF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$Q+C(P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I M9'1H.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z.'!T.R<^)FYB6QE/3-$)VUA'!E;G-E(')E;&%T960@=&\@:6YT86YG:6)L92!A65A6QE/3-$)VUA MF4Z(#AP="<^#0H)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N M=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@ M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D M97(M8V]L;&%P6QE/3-$)W=I9'1H.C(R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^,C`Q-3PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#0N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED M=&@Z,#$N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+#`V,R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`Q+C@X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^,C`Q.#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^,C`Q.3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#0N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE6QE/3-$)W=I9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-S`N.30E.W!A9&1I M;F6QE/3-$)VUA3I4:6UE3I4 M:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1IF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(Q M+C(P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I6%B;&4@+2!"86YK/"]F;VYT/@T*"0D\+W`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`@86YD("0R-BPQ,SD@;V8@=&AE(&-R961I M="!L:6YE+"!R97-P96-T:79E;'DN/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF M;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA6QE/3-$)V1IF4Z.'!T M.R<^)FYB6QE/3-$)VUA6UE;G0@;V8@=&AE('!R:6YC:7!A;"!A;F0@:6YT97)E M2`D,RPV-CDN/"]F;VYT/@T*"0D\ M+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#AP M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US M:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS M1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.R<^4')I;F-I<&%L(')E<&%Y;65N="!F;W(@96%C:"!O9B!T:&4@9FEV M92!S=6-C965D:6YG(&9I6QE/3-$)V1IF4Z.'!T.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I M9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`Q+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-S`N.30E.W!A9&1I;F6QE M/3-$)W=I9'1H.C(R+C4P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#$N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-S`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`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XX."4[8F%C:V=R;W5N M9"UC;VQO6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&]T86QS M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.C`Q+C0V)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)OF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C(Q+C`T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O MF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N.#@E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R M,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA MF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US='EL93II=&%L:6,[)SY;-UT@4F5L871E9"!087)T>2!4 M6QE/3-$ M)V1IF4Z.'!T.R<^)FYB6QE/3-$)VUA6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T* M"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO&5S/"]S=')O;F<^ M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US='EL93II=&%L:6,[)SY;.%T@26YC;VUE(%1A>&5S/"]F;VYT/@T* M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z M(#AP="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M"!F2!T87@@28C>#(P,3D["!R M871E(&ES(&%S(&9O;&QO=W,Z/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE M/3-$)VUAF4Z(#AP="<^#0H)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.CAP=#LG/B9N8G-P M.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\ M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS M1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED M=&@Z,#,N-#`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`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I M6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I'0M86QI9VXZ MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C$S+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXS-29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XQ,"4[8F%C:V=R;W5N9"UC;VQO M6QE/3-$=VED=&@Z-#0N-S0E.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+C$U)FYB6QE/3-$ M=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C$S+C8T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXX+C@W)FYB6QE/3-$=VED=&@Z,#0N,3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^ M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T M:#HT-"XW-"4[8F%C:V=R;W5N9"UC;VQO'0M:6YD96YT.B`M,3!P=#MF;VYT M+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$S+C8T)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+CDT)FYB6QE/3-$)W=I9'1H.C`S+C0P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I'0M86QI M9VXZF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^*24\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HQ,RXV-B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI9VXZF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*24\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@ M6QE M/3-$)V1I6QE/3-$=VED=&@Z M,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$=VED=&@Z,3,N-C8E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#0N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O M;&]R.B`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`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#$N-S(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)V1I M6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,3PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#$N-S(E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C,V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`S+C,V)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C6QE/3-$)VUA3I4:6UE M6QE/3-$=VED=&@Z,SDN,S(E.W!A9&1I;F6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,38N,S(E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^0W5R6QE/3-$)W=I9'1H.C$V+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE M/3-$)W=I9'1H.C$V+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H M.C$V+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1F5D97)A;#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,S8E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS."PR.34-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$V+C(T M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-S(E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$ M=VED=&@Z,38N,S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q M+C6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,SDN,S(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$V+C,R)3L[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,BPQ.#,-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H M.C,Y+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^4W1A=&4@86YD M($QO8V%L/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$=VED=&@Z,SDN,S(E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,38N,S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C,Y+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^5&]T86P@4')O M=FES:6]N(&9O6QE/3-$)W=I9'1H.C$V+C,R)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C`S+C,V)3MB M86-K9W)O=6YD+6-O;&]R.B`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`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`S+C,T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`Q+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-3DN,#0E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z M,38N,S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S0E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4Y+C`T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1&5F97)R960@5&%X($%S6QE/3-$)W=I M9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C0X)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,#0E.W!A9&1I M;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$V+C0X M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-#@E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C0X)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,#0E.W!A9&1I M;F6QE/3-$)W=I9'1H.C$V+C,R)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$)W=I9'1H.C$V+C0X)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H M.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C0X)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,#0E.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$=VED=&@Z,#,N,S0E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXT-"PR,S$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1I6QE M/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C0X)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,#0E M.W!A9&1I;F"!!6QE/3-$ M=VED=&@Z,#,N,S0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT,BPQ M-30F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE M6QE/3-$)V1I6QE/3-$)W=I9'1H.C$V+C,R)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXS+#0Q-"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXS-"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$V+C0X)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR+#`W-R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XT."4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$=VED=&@Z,38N,S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N,S0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C4Y+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^1&5F97)R960@ M5&%X($%S#(P,30[($YE=#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C,T M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT,RPT-30F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE M/3-$)VUA3I4 M:6UE6QE/3-$)V1I65A2`D,BPV,S,@:6X@86QL;W=A;F-E(&9OF%T:6]N('1I;6EN9R!D:69F97)E;F-E&%B;&4@:6YC;VUE(&EN(&9U='5R92!P97)I;V1S M+"!M86YA9V5M96YT+"!T:')O=6=H('-U9F9I8VEE;G0@<&]S:71I=F4@979I M9&5N8V4L)FYB"!AF5D+B!4:&4@86UO=6YT(&]F('1H92!D969E6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I65A7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA M3I4:6UE6QE/3-$)V1I6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3H@:6YL:6YE.R<^(%1H92!#;VUP86YY(&ES(&%U=&AOF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^2&]L9&5R28C>#(P,3D[2!I;B!A;&P@87-S M971S(')E;6%I;FEN9R!A9G1E3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0MFEN9R!T:&4@8G5Y8F%C:R!O9B!U<"!T;R`R+#`P,"PP M,#`@6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I2!4#(P,30[/"]F;VYT M/CQF;VYT('-T>6QE/3-$)V1I2!I65E M(&%N9"!C;VYS=6QT:6YG('-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/&1I=CX@ M/&1I=B!S='EL93TS1&UA3I4:6UE M6QE M/3-$)V1I3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED M=&@Z,#,N,3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,V)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$=VED=&@Z-3$N.#`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`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXT-2PX,C4F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-3$N.#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$R+C0V M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4Q+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYBF4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I M6QE/3-$=VED M=&@Z,3(N-#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,S@F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`S+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$ M=VED=&@Z,3(N-#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C0V)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPX-34F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`S+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3(N M-#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C8T)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C4R)FYB6QE/3-$)W=I M9'1H.C`Q+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-3$N.#`E.W!A9&1I;F6QE/3-$=VED=&@Z,#,N M,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I M9'1H.C$R+C0V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C4Q)FYB6QE/3-$=VED M=&@Z,#$N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y M9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF M,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$;6%R9VEN+6QE M9G0Z,'!T.VUAF4Z M(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[)SY;,3%=(%-T;V-K M($]P=&EO;G,@86YD(%=A6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I#(P,40[72XF;F)S<#LF;F)S<#M4:&4@,C`P,R!0;&%N(&%U M=&AO2!B92!D97-I9VYA=&5D(&%S)FYB&5R8VES86)L92!F;W(@=&AE M(&9I28C>#(P,3D[2!C M86QE;F1A&-E960@)#$P,"XF;F)S<#LF;F)S<#M/ M<'1I;VYS(&=R86YT960@=6YD97(@=&AE(#(P,#,@4&QA;B!A#(P,3D[2!O2!T;R!O M2!A;GD@;V)L:6=A=&EO;B!O9B!A;B!E;7!L;WEE92!F;W(@ M=&AE('!U&5R M8VES92!A;B!O<'1I;VX@9W)A;G1E9"!U;F1E2!P97)C96YT("@U,"4I(&]F('1H92!E>&5R8VES92!P65AF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^26X@075G=7-T)FYB65E($EN8V5N=&EV92!3=&]C:R!/<'1I;VX@4&QA;B!;)B-X,C`Q0SLR,#`P M(%!L86XF(W@R,#%$.UTN(%1H92`R,#`P(%!L86X@<')O=FED960@9F]R('1H M92!G65A2!B92!G&5R8VES960@:6X@9FES8V%L('EE87)S(&5N9&5D(&EN M($]C=&]B97(F;F)S<#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP@2X\+V9O M;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1I65E($EN8V5N M=&EV92!3=&]C:R!/<'1I;VX@4&QA;B!T6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;FF4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C,R M+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/E-H87)E6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5V5I9VAT960F;F)S<#M!=F5R86=E M)FYB6QE/3-$)V1I&5R8VES M929N8G-P.U!R:6-E)FYB6QE/3-$)VUA M3I4:6UE6QE/3-$)W=I9'1H.C8T M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR.34-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$)V1I#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,34N M,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB'!IF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^17AE6QE/3-$)W=I9'1H M.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY+CDU#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N,#`E M.W!A9&1I;F3H@:6YL M:6YE.R<^)FYB6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I M;F'0M86QI9VXZ6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1W)A;G1E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;F'!I6QE/3-$)W=I9'1H.C$U+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+C8T#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB&5R8VES960\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXH-`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO MF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-#D-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C,P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,"XP,@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE6QE/3-$)V1I M6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N,#`E.W!A M9&1I;F6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^17AP:7)E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;F&5R8VES960\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,C<-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXW+CDR#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB3H@:6YL:6YE.R<^ M3W5T6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`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`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`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$)V1I#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,3DN M-S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^17AP:7)E M9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-38N,C(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^17AE6QE/3-$)W=I9'1H.C$W+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS+C,Y#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^3W5T&5R8VES M92!A="!/8W1O8F5R)FYB6QE/3-$)W=I9'1H.C$W+C4P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH-3(-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$Y+C3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXU+C0W#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-38N,C(E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-S0E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X M,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C$P)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4V M+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$W+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,BXW-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$Y+C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HP,2XQ,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXH,@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W&5R8VES960\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,BXW,B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$W+C4P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH-#0-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`Q+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1I'0M86QI9VXZ M6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M6QE M/3-$)W=I9'1H.C$W+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^1W)A;G1E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z-38N,C(E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M17AP:7)E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-S(E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`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`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^4W5M;6%R>2!O9B!O=71S=&%N9&EN M9R!O<'1I;VYS(&%T($]C=&]B97(F;F)S<#LS,2P@,C`Q-#H\+V9O;G0^#0H) M"3PO<#X-"@D)/'`@3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`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`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/E-H87)E6QE/3-$=VED=&@Z,#(N-#`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E)E;6%I;FEN M9SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#(N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/D5X97)C:7-E/"]F;VYT/CPO<#X-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,#DN-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M4VAA6QE/3-$=VED=&@Z M,#DN-S`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`Y+C6QE/3-$)V1I6QE/3-$)W=I9'1H.C`Y+C6QE/3-$)V1I6QE M/3-$=VED=&@Z,#(N-#`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`Q+C6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`V+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW+C(U)FYB6QE/3-$)W=I9'1H.C`Q+C8X M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^4&5R(%-H87)E/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`Y+C3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXP+C`P)FYB6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Y+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW M+C(U)FYB6QE/3-$)W=I9'1H.C`Q+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;F3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H M.C`W+C@P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#$N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,3(N-#0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^4&5R(%-H87)E M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.C`Y+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Y+C'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXW+C0Q)FYB6QE/3-$=VED=&@Z,#(N-#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`Q+C6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`V+C8X)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY+C$R)FYB6QE/3-$)W=I M9'1H.C`Q+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4&5R(%-H M87)E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Y+C

3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXQ,S8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#`N.#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`V+C8X)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$=VED=&@Z,3(N-#0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^4&5R(%-H87)E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Y+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Y+C'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ-RXU,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C0P)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M-29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`R+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M-RXU,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`Q+C$V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C`Y+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`P+C@P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,C(F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Y+C6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`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`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`W M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C,R+C`R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXT+#4X,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXY-"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4S+C8T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE/3-$)W=I9'1H M.C,U+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXS+#6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4S+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)W=I9'1H.C,U+CDR M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXY M-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+CDT)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C4S+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`W+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+CDT)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3,N-C0E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`W+C4P)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,#(N.30E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O M;G0M6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I#(P,30[('=I M;&P@96UP;&]Y;65N="!A;F0@8V]N7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I3I4:6UE6QE/3-$)V1I'0M M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M2!L96%S97,@=F%R:6]U6QE/3-$=VED=&@Z-#@N-S`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`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-S`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^3V-T;V)E M6QE/3-$)VUA3I4:6UE3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^,C`Q,SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N.#8E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^365D:6-A;"!%<75I M<&UE;G0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XW,"4[8F%C:V=R;W5N9"UC;VQO M6QE M/3-$)W=I9'1H.C(P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF M;VYT+69A;6EL>3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`Q+C@V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-#@N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^075T;VUO8FEL97,\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`T+C6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,BPV M-S0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W=I9'1H.C(P+C`R)3L[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N.#8E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS,RPT-#6QE/3-$)W=I9'1H.C(P+C`R)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N.#8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^3&5SF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`T+C

6QE/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$=VED=&@Z,#0N M-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C(P+C`P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I M9'1H.C`T+C6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,BPT-CDF;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$ M)V1I'0M:6YD96YT.C,V<'0[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M&EM871E;'D@)#8L.#@Y+"`D-BPT.30L(&%N9"`D,RPW.3(@9F]R('1H M92!Y96%R2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@F4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^06=G M3I4:6UE6QE/3-$ M)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]C=&]B M97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`V+C(T)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/B@D*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^,C`Q-3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`V+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z-C$N,C8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^,C`Q-CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#8N,C0E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^,C`Q-SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`V+C(T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C$N M,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^,C`Q.#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#8N,C0E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^,C`Q.3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`V M+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M)FYB6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M=VED=&@Z,#8N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H M.C`V+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C$N,C8E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3&5S6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#`S,B9N8G-P.PT* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C8Q+C(V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C`V+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M-C$N,C8E.W!A9&1I;F3H@:6YL:6YE.R<^4')E6UE;G1S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.C,P+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)OF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)VUA3I4:6UE7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`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`P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I2@D M*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I M>F4Z.'!T.R<^17%U:7!M96YT*"0I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,C8N.#(E.W!A9&1I;F3H@:6YL:6YE.R<^ M,C`Q-CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C(V+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C(X+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,S$F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C(X+C`P)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C(V+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C(X+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXV,C8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C(X+C`P)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C(V+C@R)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)W=I9'1H.C`V M+C6QE/3-$)VUA3I4:6UE'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`V+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z,C8N.#(E.W!A9&1I;F3H@:6YL:6YE.R<^5&]T86QS M.CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#8N-S`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`S+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3,N M-38E.W!A9&1I;F3H@:6YL:6YE.R<^,C`Q-CPO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED M=&@Z,#F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C4S+C4V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I M9'1H.C,V+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXS-BPQ.#@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I9'1H.C,V M+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^,C`Q.3PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`W+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3,N-38E.W!A9&1I;F3H@:6YL M:6YE.R<^5&AE6QE/3-$=VED=&@Z,#F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`S+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4S+C4V)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE M6QE/3-$)V1I6QE/3-$)W=I M9'1H.C`W+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3,N M-38E.W!A9&1I;F3H@ M:6YL:6YE.R<^5&]T86QS.CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE M/3-$)VUA3I4 M:6UE6QE/3-$)V1I3I4:6UE6QE/3-$)V1I M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y M,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C M9C9B.60R+U=O'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA'0M:6YD96YT.C(N M,W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US='EL93II=&%L:6,[)SY;,35=($QI=&EG871I M;VX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@F4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^26X@=&AE(&YO3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M6QE/3-$)V1IF]N($)L M=64@0W)O3PO9F]N=#X-"@D) M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.FYO M3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M2!F:6QE9"!A;B!A8W1I;VX@:6X@=&AE(%-U<&5R:6]R($-O=7)T(&]F M($YE=R!*97)S97D@86=A:6YS="!(;W)I>F]N($)L=64@0W)O2`H)B-X,C`Q0SM(;W)I>F]N)B-X,C`Q1#LI M+"!C87!T:6]N960@0FEO+5)E9F5R96YC92!,86)OF]N($AE86QT:&-AF]N($)L=64@0W)O2P@1&]C:V5T($YO+B9N8G-P.T)%4B!,+3`P.3F]N)B-X,C`Q.3MS('!R969E#(P,4,[4%!/)B-X,C`Q1#LI(&UE;6)E6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I2!PF]N('!U2!397)V:6-E#(P,3D[2P@86YD M(&UU;FEC:7!A;"!W;W)K97)S(&%N9"!T96%C:&5RF]N(&AA2!M;W)E('1H86X@)#(P+#`P,"PP,#`@:6X@=6YR96EM8G5R MF]N(&9U2!B>2!M96%N3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M29N8G-P.S4L(#(P,30L M($AO2!O<'!O2!I M6EN9R!(;W)I>F]N)B-X,C`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`Q1#LI+B!4:&4@8V]M<&QA:6YT(&%L;&5G97,@=&AA="!'96YE1'@@;V9F M97)S(&QA8F]R871O7-I2X\ M+V9O;G0^#0H)"3PO<#X-"@D)/'`@F4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^3VX@1&5C96UB97(F;F)S<#LY+"`R,#$S M+"!'96YE1'@@9FEL960@:71S(&%N3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M2!A M;F0@2!'96YE+"9N8G-P.TQT9"X@*&9I;&5D($IU;'DF;F)S<#LQ,"P@,C`Q,RP@ M1"X@571A:"D[($-O=6YS>6PL)FYB6PL)FYB2`F(W@R,#%#.T1E9F5N9&%N=',F(W@R,#%$.RDN/"]F;VYT/@T*"0D\ M+W`^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)V1I29N8G-P.S$Y+"`R,#$T+"!F;VQL;W=I;F<@ M8G)I969I;F<@86YD(&$@:&5A3I4:6UE6QE/3-$ M)V1I'0M:6YD96YT.C,V<'0[9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M2!D M96-IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.R<^4&QA:6YT:69F2!I;FIU;F-T:6]N M('1O('1H92!#;W5R="!O9B!!<'!E86QS(&9O2!A<'!E86P@8G)I968@;VX@2G5N929N8G-P.S$S+"`R,#$T+B!4:&4@0V]U M#(P,3D[(')E<75EF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.R<^3VX@075G=7-T)FYB"!F:6QE9"!E M;&5V96X@<&5T:71I;VYS(&9O3H@:6YL:6YE.V9O;G0M#(P,4,[25!2)B-X,C`Q1#LI('=I=&@@=&AE(%4N4RX@4&%T96YT M(&%N9"!42!T M:&4@06UE2!A;GD@;V8@=&AE($1E9F5N9&%N=',@:6X@=&AE($UYF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^4VEN8V4@=&AE(&9I;&EN9R!O9B!T M:&5S92!)4%)S+"!0;&%I;G1I9F9S(&AA=F4@;F%R6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I2!A;F0@=&AI2!O9B!T:&4@;&ET:6=A M=&EO;BP@=V4@97AP96-T('1O(&EN8W5R('-I9VYI9FEC86YT(&-O2!D:79E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&AE($-O;7!A;GD@;6%I;G1A:6YS('!R;V9E2!L:6UI M=',N)FYB2!A;'-O(&UA:6YT M86EN&-E7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I3I4:6UE6QE/3-$)V1I'0M M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C,X+C9P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I3H@:6YL M:6YE.R<^($-R961I="!R:7-K('=I=&@@2!D:79E2!D;V5S(&AA=F4@2!T;R!S=7!P;W)T(&-UF4@<&]T96YT:6%L(&-R961I="!R:7-K'!OF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^02!N=6UB97(@;V8@<')O<&]S M86QS(&9O2!C;W5L9"!E>'!E7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^5&AE($-O;7!A;GD@9&ED(&YO="!M M86ME(&%N>2!A8W%U:7-I=&EO;G,@9'5R:6YG('1H92!F:7-C86P@>65A6%B M;&4@8F%L86YC97,@;VX@:71S(&)O;VMS('1H870@6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO M9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^1F]R(&-E M6%B;&5S+"!A;F0@28C>#(P,3D[2!D:7-C;W5N=&EN9R!E M>'!E8W1E9"!C87-H(&9L;W=S(&%T('1H92!R871E2!F;W(@9&5B="!O9B!T:&4@F4Z(#$R<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^1'5E('1O M('1H92!N;VXM:6YT97)E6UE;G0@=&5R;7,L(&ET('=A6QE/3-$)VUAF4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB MF4],T0Q/B`\+V9O M;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)VUA6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I7,@=&AE(&EN:71I86P@)#$U,"!O9B!C;W9E2!E>&-E2`D-RPS M-#8L("0V+#&EM871E;'D@)#0S+#0U M.2P@)#,R+#`Q-B!A;F0@)#(U+#DY-"!F;W(@=&AE('EE87)S(&5N9&5D($]C M=&]B97(F;F)S<#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,BP@6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P M/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65E($)E;F5F:70@4&QA;CPO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE/3-$)VUA6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I#(P,4,[4&QA;B8C>#(P,40[72XF;F)S<#L@16UP M;&]Y965S(&)E8V]M92!E;&EG:6)L92!F;W(@<&%R=&EC:7!A=&EO;B!A9G1E M65A&EM=6T@86QL;W=E9"!B>2!T:&4@26YT97)N86P@4F5V96YU92!397)V M:6-E+B9N8G-P.R!4:&4@0V]M<&%N>2!M87D@8VAO;W-E('1O(&UA:V4@82!M M871C:&EN9R!C;VYT65A2!T:&4@0V]M<&%N>2X@5&AE M($-O;7!A;GD@96QE8W1E9"!T;R!M86ME(&$@;6%T8VAI;F<@8V]N=')I8G5T M:6]N('=H:6-H(&%M;W5N=&5D('1O("0R+#$S,"!F;W(@,C`Q-"P@)#$L,S4X M(&9O65R(&-O;G1R:6)U=&EO;B!W:6QL(&)E(&9U;&QY M('9E65A3I4:6UE6QE/3-$)V1I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5? M83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@ M8VAA6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M='EL93II=&%L:6,[)SY;,C)=($YE=R!!=71H;W)I=&%T:79E($%C8V]U;G1I M;F<@4')O;F]U;F-E;65N=',\+V9O;G0^#0H)"3PO<#X-"@D)/'`@2!A<'!L:6-A=&EO;B!I65T(&1E=&5R;6EN960@=&AE(&5F9F5C="!T:&ES(&UA M>2!H879E(&]N(&]U6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!&:6YA;F-I86P@1&%T83PO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE/3-$)VUA6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z M,S8N-3`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^)FYB6QE/3-$)W=I9'1H.C0W+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE M6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C$O,S$O,C`Q-#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^-"\S M,"\R,#$T/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H M.C$P+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C$P+S,Q+S(P,30\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T M>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI M9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,3`N M,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,V+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1I6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,C(L,#4S)FYB6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX."PU-#DF;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O M;G0M'0M86QI9VXZ6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,#8L.#4S M)FYB6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I M9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ."PR.#$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3F5T($EN8V]M92!097(@0V]M;6]N(%-H M87)E.CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$)W=I9'1H M.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE M/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0F%S:6,\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C$Q)FYB6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C8V)FYB M6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C$Q M)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C8V)FYB6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,3`N M,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^5V5I9VAT960@079EF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPW,C(F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED M=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UEF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$ M)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR-RPX-C0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$ M=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C0W+C4P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C$O,S$O,C`Q,SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^-"\S,"\R,#$S/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@6QE/3-$ M)W=I9'1H.C$P+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C$P+S,Q+S(P M,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE M6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED M=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C,V+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ.#4L-#(W)FYB M6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,"PV-S8F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS,C(L-3,Y)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M3F5T($EN8V]M93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXQ-"PW,#$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE M/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C0Q)FYB M6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+C8U)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I M9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXP+C0Q)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M+C8U)FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$ M=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C,V+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPV.3@F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPV.3$F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI M9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE M.R<^5V5I9VAT960@079E6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR-RPX-SDF;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR M-RPX-3$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M M8V]L;&%P6QE M/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E1H M6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/D%U9&ET960\+V9O;G0^/&)R("\^/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D9I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^,2\S,2\R,#$R/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$P+C`P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^,3`O,S$O,C`Q,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q M,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#$N,#`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`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`X+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW-"PV M.#$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`X+C'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,V+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`X+C3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ,BPU.38F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE M/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^3F5T($EN8V]M M92!097(@0V]M;6]N(%-H87)E.CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$)W=I9'1H.C$P M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0F%S:6,\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`R+C4P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C(V)FYB6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N M,S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+C6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXP+C0W)FYB6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W'0M:6YD96YT.B`M,3!P=#MF;VYT M+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I M9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`Q+C,P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED M=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPX.#@F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR-RPW,#4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$ M=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,V+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR."PP-#$F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPY,#8F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/&1I=CX@/&1I=B!S M='EL93TS1&UA3I4:6UE6QE/3-$)V1I M6QE/3-$)VUA6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$ M=VED=&@Z,CDN,#`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^)FYB6QE/3-$=VED=&@Z,38N,#`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*&(I/"]F;VYT M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,30N,#`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^*&,I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*&0I/"]F;VYT/CPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I M>F4Z.'!T.R<^*&4I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#AP="<^#0H)"0D) M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*&$I/"]F;VYT/CQB6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^0F%L86YC929N8G-P.V%T M)FYB6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D-H87)G M960F;F)S<#MT;R9N8G-P.T-O3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/D5X<&5N6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^0F%L86YC929N8G-P.V%T)FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,CDN,#`E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE/3-$ M=VED=&@Z,38N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,34N,#`E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^665A6QE/3-$)W=I9'1H.C$V+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE M/3-$)W=I9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H M.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^06QL;W=A;F-E(&9O6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXQ,S,L-S(X#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U M+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXU,3,L-#8V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,CDN,#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$=VED=&@Z,38N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M'0M9&5C;W)A=&EO;CIU;F1E M6QE/3-$)W=I9'1H.C$V+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT,S$L-34X#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C(Y+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M)FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXU,2PR-S0-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.C$T+C`P)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXH.#$L,36QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C$U+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXS-#(L,CDW#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z,CDN,#`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$=VED=&@Z,38N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M'0M9&5C;W)A=&EO M;CIU;F1E6QE/3-$)W=I9'1H.C$V+C`P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS,3DL,3DU#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,BPW-34L,S`X#0H)"0D)/"]T9#X- M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C(Y+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$T+C`P)3L[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU,2PR-S0-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE M/3-$)W=I9'1H.C$T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF M;VYT+69A;6EL>3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,30N,#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXS,3DL,3DU#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M'0^/&1I=CX@/&1I=B!S='EL93TS1&UAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.R<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YTF4] M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=CX@/&1I=B!S='EL M93TS1&UAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^26YV96YT;W)Y("T@26YV M96YT;W)Y(&ES('-T871E9"!A="!T:&4@;&]W97(@;V8@8V]S="!;9&5T97)M M:6YE9"!O;B!A(&9IF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\6QE/3-$)VUA3I4:6UE6QE/3-$)V1I2!A;F0@97%U:7!M96YT(&%R92!C87)R:65D(&%T(&-O2!F:79E M('EE87)S+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ M,'!T.VQI;F4M:&5I9VAT.FYO3I4:6UE6QE/3-$)V1I M'0M:6YD96YT.C,V<'0[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M2!A;F0@97%U:7!M96YT(&]F("0R,RPR-#8L("0Q M."PW-#4@86YD("0Q-BPP.#(@9F]R('1H92!Y96%R2X\ M+V9O;G0^#0H)"3PO<#X-"@D)/'`@F4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^3VX@F%T:6]N(&%R92!R96UO=F5D(&9R;VT@=&AE(&%C M8V]U;G1S+"!A;F0@86YY(')E;&%T960@9V%I;B!O'!E;G-E('=H96X@:6YC=7)R960N/"]F;VYT/@T*"0D\+W`^#0H) M"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA'0M:6YD96YT M.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M#(P,4,[1D%30B8C>#(P,40[*29N8G-P M.R9N8G-P.W)U;&5S)FYB#(P,40[*2!.;RXF M;F)S<#LR,#$Q+3`X(&ES#(P,30[1V]O9'=I;&P@86YD($]T:&5R M("A4;W!I8R`S-3`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`\+V9O;G0^/"]P/@T*"3PO M9&EV/B`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`E.W!A9&1I;F6QE/3-$ M)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/EEE87(F;F)S<#M%;F1E M9"9N8G-P.T]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C(P M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N-C`E.W!A M9&1I;F6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`S+C`P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`P)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE M6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q M+C(P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0V+C8P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^1W)O6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#4R-"PQ,#@F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C(P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z-#8N-C`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,30N M-#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0V+C8P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^0V]N=')A8W1U86P@061J=7-T;65N=',@86YD($1I6QE/3-$ M)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T M+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^365D:6-A6QE/3-$=VED=&@Z M,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C$T+C0P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS,C`L M-CDW)FYB6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR+#,Y,RPX-S(F;F)S<#L-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C(P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N M-C`E.W!A9&1I;F6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#,Y,"PW-S`F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I M6QE/3-$)W=I9'1H.C$T+C0P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX.30L,#$Y)FYB6QE/3-$ M)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4&%T:65N="!397)V:6-E(%)E=F5N=64@ M4')O=FES:6]N(&9O6QE/3-$=VED=&@Z,#,N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXV,"PR-#0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H M.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$)W=I M9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M'0M86QI9VXZ6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,30N-#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^4')O=FES:6]N(&9O6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,"XQ)FYB6QE/3-$=VED=&@Z,#,N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`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`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`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#,N,#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^,C`Q,SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^1&]U8G1F=6P@06-C;W5N=',\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`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`\+V9O;G0^ M/"]P/@T*"3PO9&EV/B`\+V1I=CX\&5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE M/3-$;6%R9VEN+6QE9G0Z,'!T.VUA'0M:6YD96YT.C,V<'0[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M2!R96-O9VYI>F5S(&EN=&5R97-T M(&%N9"!P96YA;'1I97,@;VX@&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M/B`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`\+V9O;G0^/"]P/@T*"3PO9&EV/B`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`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U M7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)VUA6QE/3-$)V1IF4Z-W!T.R<^)FYB6QE/3-$)V)O6QE/3-$)V1I6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1I M6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N-C`E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/EEE87(F;F)S M<#M%;F1E9"9N8G-P.T]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`Q+C(P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N M-C`E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`P)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`P)3MP M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`Q+C(P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE6QE/3-$)W=I9'1H.C0V M+C8P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^1W)O6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#4R-"PQ M,#@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C(P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#8N-C`E.W!A9&1I M;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED M=&@Z,30N-#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C0V+C8P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0V]N=')A8W1U86P@061J=7-T;65N=',@86YD($1I M6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I M9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^365D:6-A6QE/3-$ M=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXS,C`L-CDW)FYB6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXR+#,Y,RPX-S(F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H M.C`Q+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z-#8N-C`E.W!A9&1I;F6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#,Y,"PW-S`F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H.C$T M+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX.30L,#$Y M)FYB6QE/3-$)W=I9'1H.C`S+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^4&%T:65N="!397)V:6-E(%)E M=F5N=64@4')O=FES:6]N(&9O6QE/3-$=VED M=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXV,"PR-#0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$T+C0P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M'0M86QI9VXZ6QE M/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O'0M86QI9VXZ6QE/3-$)W=I9'1H.C$T+C0P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O'0M86QI9VXZ M6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,30N-#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$T+C0P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$T+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^4')O=FES:6]N(&9O M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,"XQ)FYB6QE/3-$=VED M=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$T M+C0P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W3I4:6UE6QE/3-$)V1I6]R7-I8VEA;G,L(&AO3I4:6UE6QE/3-$)V1I6QE/3-$)VUAF4Z(#=P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C=P=#LG/B9N8G-P.SPO9F]N=#X-"@D) M/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F;VYT/CPO<#X-"@D\+V1I M=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I3I4:6UE3H@:6YL:6YE.V9O;G0M6QE/3-$ M)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,#`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`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,2P\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`Q+C$V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE6QE/3-$=VED=&@Z M-C0N,3(E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`P)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C$V M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C$R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0V]N=')A8W1U86P@0W)E9&ET6QE/3-$)W=I9'1H.C$T+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXU,3,L-#8V)FYB6QE/3-$)W=I9'1H.C`S+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)V1I6QE/3-$)W=I9'1H.C$T+C,V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$=VED=&@Z M,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^5&]T86P@06QL;W=A;F-E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R M7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+6QE9G0Z,'!T M.VUAF4Z(#$R<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE M/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C M:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUAF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$ M)W=I9'1H.C0T+C,R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$=VED M=&@Z-#DN.3`E.W!A9&1I;F6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C$R)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE M6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q M+C8V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#DN.3`E.W!A M9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$ M=VED=&@Z,C`N,C8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`T+C$R)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C(P+C(V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV-2PW-C(F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M,BPQ-36QE/3-$)W=I9'1H.C(P+C(V)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB'1U6QE/3-$ M)W=I9'1H.C$Y+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXR-BPP-S8F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H M.C`Q+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z-#DN.3`E.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,"PT,C6QE/3-$)W=I M9'1H.C(P+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#$N-C8E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$Y+CDT)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I M9'1H.C(P+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^4W5B(%1O=&%L6QE/3-$=VED=&@Z M,#0N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C(P+C(V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0Y+CDP)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3&5S6QE M/3-$)W=I9'1H.C$Y+CDT)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXX.2PY-30F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C8V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z-#DN.3`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,C`N M,C8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-C8E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`T+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV-BPS.#@F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\'0O:F%V87-C3X-"B`@("`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`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^06-C=6UU;&%T960\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`S+C$R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4:6UE6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$)W=I M9'1H.C,Q+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D%M;W)T:7IA=&EO;B9N8G-P M.U!E6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^0V]S=#PO9F]N=#X\+W`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`E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C,Q+C(V)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^0W5S=&]M97(@3&ES=',\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$W+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$Q+C(P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#(W-29N M8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ,2PQ,S$F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W=I9'1H.C$R+C4P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$)W=I9'1H.C$R+C4P)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE M/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z,S$N,C8E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,3(N-3`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#$N,C8E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$W+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C$Q+C(P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`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`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^06-C=6UU;&%T960\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$R)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1I MF4Z M.'!T.R<^06-C=6UU;&%T960\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`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`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`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE M/3-$)W=I9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C$Q+C(P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+#6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C(V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z,S$N,C8E.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C$R+C4P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z M,#$N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`S+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`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`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3(E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Q+C(V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&]T86QS/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C$R M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXX+#@T-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,RXQ,B4[8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O M3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ-BPS,C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UE3H@:6YL:6YE.V9O M;G0M'!E;G-E(')E;&%T M960@=&\@6QE/3-$;6%R9VEN M+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^5&AE(&5S=&EM871E9"!A;6]R=&EZ871I;VX@97AP96YS92!R96QA=&5D M('1O(&EN=&%N9VEB;&4@87-S971S(&9O3I4:6UE3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.W1E>'0M9&5C;W)A=&EO;CIU;F1EF4Z(#$R<'0G M/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ+#@U,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C@X)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^,C`Q-CPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C@X)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-S`N.30E M.W!A9&1I;F6QE/3-$)W=I9'1H.C(R+C4P M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)V1I6QE/3-$)W=I9'1H.C(R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY-#8F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY,#0F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V1I6QE/3-$)W=I9'1H.C(R+C4P M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+#`Y."9N8G-P M.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#HP,2XX."4[8F%C:V=R;W5N9"UC;VQO6QE M/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,C(N-3`E.W!A9&1I;F'0M86QI M9VXZ6QE/3-$=VED=&@Z,#$N.#@E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYBF4],T0Q M/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^("9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R`\+V9O;G0^#0H)"3PO<#X-"@D)/'`@6QE/3-$)V1I MF4Z.'!T.R<^)FYB6QE/3-$)V)O6QE/3-$)W=I9'1H.C`T+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z-S`N.30E.W!A9&1I;F6QE/3-$)W=I9'1H.C(R+C4P)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N.#@E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C@X)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-S`N.30E.W!A9&1I M;F6QE/3-$)W=I9'1H.C(R+C4P)3L[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M M86QI9VXZ6QE/3-$=VED=&@Z,#$N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I#(P,30[ M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)V1I6QE M/3-$)W=I9'1H.C(R+C4P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,2XX."4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&]T86QS/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Q+C0V)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)OF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(Q+C`T)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)OF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$=VED=&@Z,#$N.#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C M86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P M.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$"!R871E('1O('1H92!#;VUP86YY M)W,@969F96-T:79E(&EN8V]M92!T87@@'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I3I4:6UE3H@:6YL:6YE.V9O;G0M6QE/3-$)V1I6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]C=&]B97(F M;F)S<#LS,3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N,3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N-#`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED M=&@Z,#,N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q,SPO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^,C`Q,CPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N,3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,3,N-C8E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#0N,3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$S+C8T)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS-29N M8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,RXT,"4[8F%C:V=R;W5N9"UC;VQOF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^ M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H M.C0T+C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^4W1A=&4@86YD($QO8V%L(%1A>&5S+"!.970@;V8@52Y3+B!& M961E"!"96YE9FET/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$S+C8T M)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#,N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C8V)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ MF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`S+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`T+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z M-#0N-S0E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,3,N-C0E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#,N-#`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0T+C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^06-T=6%L(%)A=&4\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=W:61T:#HP,RXT,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$S M+C8T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)OF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C8T)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)OF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C8V)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)OF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)3PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D M:78^#0H)"3QP('-T>6QE/3-$)VUAF4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB MF4],T0Q/B`\+V9O M;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\9&EV/B`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`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N M-S(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#$N-S(E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`S+C,V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE6QE/3-$)VUA3I4:6UE3H@ M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,3,\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`S+C,V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/C(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,SDN,S(E.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,38N,S(E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^0W5R6QE/3-$)W=I9'1H.C$V+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$ M)W=I9'1H.C$V+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$V M+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1F5D97)A;#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,S8E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXS."PR.34-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$V+C(T)3L[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N-S(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED M=&@Z,38N,S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S8E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I M9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,SDN M,S(E.W!A9&1I;F6QE/3-$)W=I9'1H.C$V+C,R)3L[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M M86QI9VXZ6QE/3-$=VED=&@Z,#,N,S8E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,BPQ.#,-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C,Y M+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^4W1A=&4@86YD($QO M8V%L/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B M;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$ M=VED=&@Z,SDN,S(E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,38N,S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N M,S8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,Y M+C,R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^5&]T86P@4')O=FES M:6]N(&9O6QE/3-$)W=I9'1H.C$V+C,R)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C`S+C,V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^ M/"]P/@T*"3PO9&EV/B`\+V1I=CX\5T\+W1D/@T*("`@("`@("`\=&0@8VQA M6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/B9N8G-P.SPO9F]N=#X\+W`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`S+C,T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/C(P,3,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C0X)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,#0E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE M/3-$=VED=&@Z,38N,S(E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#,N,S0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4Y+C`T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1&5F97)R960@5&%X($%S6QE/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I M9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C0X M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN M,#0E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS-BPV-#(F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C$V+C0X)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED M=&@Z,#$N-#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C0X M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN M,#0E.W!A9&1I;F6QE/3-$)W=I9'1H.C$V M+C,R)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI M9VXZ6QE/3-$)W=I9'1H.C$V+C0X)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1I6QE M/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C0X)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,#0E M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,#,N,S0E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXT-"PR,S$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF M;VYT+69A;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`Q+C0X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED M=&@Z-3DN,#0E.W!A9&1I;F"!!6QE/3-$=VED=&@Z,#,N,S0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXT,BPQ-30F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$V+C,R)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#0Q-"9N8G-P.PT*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXS M-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$V+C0X)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#`W-R9N8G-P.PT*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XT M."4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYB6QE/3-$=VED=&@Z,38N,S(E.W!A9&1I M;F'0M86QI9VXZ6QE M/3-$=VED=&@Z,#,N,S0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C4Y+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUAF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M1&5F97)R960@5&%X($%S#(P,30[($YE=#PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`S+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT,RPT-30F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I M=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1I6QE/3-$ M)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,V)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3$N.#`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`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H M.C`S+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C$R+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXT-2PX,C4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C,V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3$N M.#`E.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR-RPW,36QE/3-$)W=I9'1H.C$R+C0V)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$ M)W=I9'1H.C4Q+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$=VED=&@Z,3(N-#8E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)V1I6QE/3-$)W=I M9'1H.C$R+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ,S@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`S+C$P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3(N-#8E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL M>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$R+C0V)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C`S+C$P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$=VED=&@Z,3(N-#8E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I M9'1H.C`S+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M6QE/3-$)W=I9'1H.C$R+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C4R)FYB6QE/3-$)W=I9'1H.C`Q+C,V)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3$N.#`E M.W!A9&1I;F6QE/3-$=VED=&@Z,#,N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$R+C0V)3L[ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C4Q)FYB6QE/3-$=VED=&@Z,#$N,S8E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE M6QE M/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5? M9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA2!O9B!O=71S=&%N9&EN9R!O<'1I;VYS/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$ M;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYB6QE/3-$ M)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z,S6QE M/3-$)V1I6QE/3-$)VUA3I4:6UE M6QE M/3-$)VUA3I4:6UE3H@:6YL:6YE M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E=E:6=H=&5D)FYB M6QE/3-$=VED=&@Z,#(N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^17AE6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I&5R8VES93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E-H87)E6QE/3-$=VED M=&@Z,#(N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D5X97)C:7-E/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^17AE6QE/3-$)W=I9'1H.C`Y+C6QE/3-$)V1I6QE M/3-$=VED=&@Z,#(N-#`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M3&EF93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^4')I8V4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C0P)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]U='-T86YD:6YG/"]F;VYT/CPO M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C`Y+C6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB3H@ M:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C`W+C@P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW+C(U)FYB6QE/3-$)W=I M9'1H.C`P+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^=&\\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XW,"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1I'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C$R+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`R+C@T)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Y M+C3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXW+C(U)FYB6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#0N,C`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^=&\\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C

6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXW+C8W)FYB6QE/3-$=VED=&@Z,#$N-C@E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I M6QE/3-$=VED=&@Z,#(N M.#0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N M-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I M9'1H.C`Y+C'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT-B9N8G-P.PT*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`R+C0P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW+C0Q)FYB6QE/3-$=VED M=&@Z,#$N,38E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C`W+C@P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY+C$R M)FYB6QE/3-$)W=I9'1H.C`P+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^=&\\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XW M,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I'0M86QI M9VXZ6QE/3-$)W=I9'1H.C$R+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)W=I9'1H M.C`R+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Y M+C3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ+C`P)FYB6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`R M+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXQ-RXU,"9N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`P+C@P)3MP M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,#$N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M=VED=&@Z,#$N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N.#0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z M,#(N-#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)W=I9'1H.C`Y+C'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`Y+C6QE/3-$)W=I9'1H.C`Y M+C'0M86QI9VXZ6QE/3-$)W=I9'1H.C`T+C(P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`W+CDX)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$R+C0T)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Y+C6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C0P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,3F4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E M(&EN8V5N=&EV92!S=&]C:R!O<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/&1I=CX@/&1I=B!S='EL93TS1&UA M3I4:6UE6QE/3-$)V1I3I4:6UE M6QE M/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<] M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`P,R9N8G-P.U!L M86X\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D) M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/EM);B9N8G-P.U1H;W5S86YD6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/E=E:6=H=&5D)FYBF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY+C@P#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N,#`E M.W!A9&1I;F6QE/3-$=VED=&@Z,34N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^17AP:7)E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)W=I9'1H.C`Q M+C,P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1I'0M86QI9VXZ6QE/3-$)VUA3I4 M:6UE6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A M;6EL>3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H M.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H M.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HP,2XP,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUA MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^17AP:7)E9#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D) M/'`@F4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$U+C`P)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8T+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^17AEF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\ M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C0N,#`E.W!A9&1I;F3H@:6YL:6YE.R<^3W5T6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S M+C'0M86QI M9VXZ6QE/3-$)W=I M9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)W=I9'1H.C$U+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1W)A;G1E9#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X M,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P)3MP861D:6YG.C!P=#L^#0H) M"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE M6QE/3-$)V1I6QE/3-$)W=I9'1H.C$U+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$U+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^17AE6QE/3-$)W=I9'1H.C$U+C`P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.SX-"@D)"0D)/'`@F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@8V]L6QE M/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@ M.V)O6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C8T+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1I6QE/3-$)W=I9'1H.C$U+C`P)3MB;W)D97(M=&]P.C%P="!N M;VYE("-$.40Y1#D@.V)O3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I&5R8VES92!P3I4:6UE6QE/3-$)V1I6QE/3-$)VUA&5R8VES92!P3I4:6UE6QE/3-$)V1I&5R8VES92!PF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\65E M($EN8V5N=&EV92!3=&]C:R!/<'1I;VX@4&QA;B`R,#`P/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\2!O9B!E;7!L;WEE92!I;F-E;G1I=F4@ M6QE/3-$;6%R9VEN+6QE M9G0Z,'!T.VUAF4Z M(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@6QE.G-O;&ED.V)O'0M:6YD96YT.C!P=#L^)FYB6QE/3-$8F]R9&5R+6-O M;&QA<'-E.F-O;&QA<'-E.VUA6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG M/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-S(E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^ M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`P,"9N8G-P.U!L86X\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1'=I9'1H.C`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`R+C6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE M/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT M.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z,3'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-S0E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C$P)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I M9'1H.C4V+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$W+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q M-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,BXW-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$Y+C6QE/3-$)VUAF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q M-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HP,2XQ,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-S(E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$ M=VED=&@Z,#(N-S0E.SX-"@D)"0D)/'`@F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@8V]L6QE/3-$)W=I9'1H M.C$Y+C6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C4V+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE M/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-S(E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1I#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D) M"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G M/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1I#(P,30[/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M'!I6QE/3-$)W=I9'1H.C$W+C4P)3L[9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M+C8P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^17AEF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$ M)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$=VED=&@Z,#(N-S(E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$Y+C6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4V+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)W=I9'1H.C$W+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXW-"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$Y+C6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1I#(P,30[/"]F M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$=VED=&@Z,3DN-S(E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#$N,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.R<^17AEF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^*3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L6QE/3-$)W=I9'1H.C$Y+C3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXW+C8W#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C$P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-38N,C(E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^3W5T&5R8VES92!A="!/8W1O8F5R)FYB6QE/3-$)VUA3I4:6UE6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUA3I4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`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`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`W M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C,R+C`R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXT+#4X,B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXY-"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4S+C8T)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE/3-$)W=I9'1H M.C,U+CDR)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXS+#6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4S+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)W=I9'1H.C,U+CDR M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXY M-"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)B-X,C`Q-#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+CDT)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H M.C4S+C8T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`W+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+CDT)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3,N-C0E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`W+C4P)3MP861D:6YG M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z,#(N.30E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M3I4:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C M86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P M.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%RF5D($QE87-E($]B;&EG871I;VYS("A486)L97,I/&)R/CPO MF5D($QE87-E($]B;&EG871I;VYS/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'!I'0^/&1I=CX@/&1I=B!S='EL M93TS1&UA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^("9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`\+V9O;G0^#0H)"3PO<#X- M"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG M/3-$,"!C96QL6QE/3-$=VED M=&@Z-#@N-S`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`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#0N-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^3V-T;V)E6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/B9N M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N-S`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q,SPO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#$N.#8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^365D M:6-A;"!%<75I<&UE;G0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP-"XW,"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W=I9'1H.C(P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,"PW-S0F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-#@N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^075T;VUO8FEL M97,\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`T+C6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ,BPV-S0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.C(P+C`R)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$=VED=&@Z,#$N.#8E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYBF4Z(#$R<'0G/@T*"0D)"0D) M)FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M,RPT-#6QE/3-$)W=I9'1H.C(P+C`R)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N.#8E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M3&5SF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`T+C6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#0N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$)W=I9'1H.C(P M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)W=I9'1H.C`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`\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL M93TS1'=I9'1H.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)W=I9'1H.C8Q+C(V)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C,P M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE M6QE/3-$)W=I9'1H.C8Q+C(V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C,P+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV M+#8R,R9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXU+#6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C8Q+C(V M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C,P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXT+#$X-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU,"4[8F%C:V=R M;W5N9"UC;VQO6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C8Q+C(V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C,P+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT.#4F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)W=I9'1H.C,P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C8Q+C(V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C`V+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M-C$N,C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^5&]T86P\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`V M+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C,P+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C,P M+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)W=I9'1H.C,P+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#8N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PS.#`F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)VUAF4Z(#$R<'0G M/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^ M/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-L=7-I=F4@;V8@6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA MF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$=VED=&@Z M,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S M='EL93TS1"=B;W)D97(M8V]L;&%PF4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^3V-T;V)E6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^4')O<&5R='DH)"D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`V+C6QE/3-$)VUA3I4:6UE M6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/D5Q=6EP;65N="@D*3PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M=VED=&@Z,#(N-C8E.W!A9&1I;F'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,C'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-C8E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^,C`Q-3PO9F]N=#X\+W`^#0H) M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I M9'1H.C`V+C6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`V+C6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXR+#$R,B9N8G-P.PT*"0D)"3PO=&0^#0H) M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`V+C6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR,#,F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`V+C6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z,C8N.#(E.W!A9&1I;F3H@ M:6YL:6YE.R<^,C`Q.#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#8N-S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`V+C6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C8V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z,C8N.#(E.W!A9&1I;F3H@ M:6YL:6YE.R<^5&AE6QE/3-$=VED=&@Z,#8N-S`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C(X M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C(W+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ,BPY,S4F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$)W=I9'1H.C(W+C`P)3MB;W)D97(M=&]P M.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-C8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB3I4:6UE6QE/3-$)V1I6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA MF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$ M=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D]C=&]B97(F;F)S<#LS,3PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^4F5A9V5N=',F;F)S<#LH)"D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C`P M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4S+C4V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE M/3-$)W=I9'1H.C,V+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF M;VYT+69A;6EL>3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I M9'1H.C,V+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED M=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^,C`Q-SPO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W=I9'1H.C`W+C0T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXR,2PR-#$F;F)S<#L-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z,S8N,#`E.W!A9&1I M;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#,N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^)FYBF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C,V+C`P)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O'0M86QI9VXZ6QE/3-$)VUA3I4:6UE7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!F:6YA;F-I86P@9&%T83PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/&1I=CX@/&1I=B!S='EL93TS1&UA M3I4:6UE6QE/3-$)V1I3I4:6UE M6QE M/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<] M,T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5&AR964F;F)S<#M- M;VYT:"9N8G-P.T5N9&5D/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^075D:71E9#PO9F]N M=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW M96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^1FES8V%L(%EE87(\+V9O;G0^ M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE M/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT M+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE/3-$)V1I6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C0O M,S`O,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF M;VYT+7-I>F4Z.'!T.R<^-R\S,2\R,#$T/"]F;VYT/CPO<#X-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$P+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$P+C`P)3MB M;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$ M)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H.C$P+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXQ.#$L,C6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR M,C6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW,BPQ-30F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS M-CDL.3DY)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^3F5T M($EN8V]M93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ M-2PR-3`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z M,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE M/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$ M=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A M9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R M<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$ M)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O M;G0M'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C,W)FYB6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C8Y M)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H M.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXP+C,W)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C8X M)FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED M=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M6QE/3-$)W=I9'1H.C,V+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4:6UE6QE/3-$ M)V1I6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPW,3F4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPW,3F4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ M6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@:6YL:6YE.R<^ M5V5I9VAT960@079E6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR-RPX-3F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPX M-34F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L M;&%P6QE/3-$ M)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D) M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^5&AR964F M;F)S<#M-;VYT:"9N8G-P.T5N9&5D/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T* M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^075D:71E M9#PO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^1FES8V%L(%EE87(\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#AP="<^#0H)"0D)"0D\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L M9#MF;VYT+7-I>F4Z.'!T.R<^)FYB6QE/3-$)W=I9'1H.C$P+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/C0O,S`O,C`Q,SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D) M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z M8F]L9#MF;VYT+7-I>F4Z.'!T.R<^-R\S,2\R,#$S/"]F;VYT/CPO<#X-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$P+C`P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$P M+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z M,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)W=I9'1H M.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL M>3I4:6UE6QE/3-$9FQO870Z;&5F M=#X\+V1I=CXQ-C$L,C4V)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UEF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$P M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ.3(L,C$Y)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW,"PY,C(F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M.V9O;G0M'0M86QI9VXZ6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX M-2PR.#(F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,V M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX+#8V-29N8G-P.PT*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,BXU M,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,2PS,S@F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT-2PX,C4F;F)S<#L-"@D) M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4 M:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,V+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H M.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;F6QE/3-$ M=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N.V9O;G0M'0M86QI9VXZ6QE M/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C4S M)FYB6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)W=I9'1H.C$P+C`P)3L[9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C,V+C4P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^1&EL=71E9#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI M9VXZ6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C4S)FYB6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED M=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE M6QE M/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF M;VYT+69A;6EL>3I4:6UEF4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I M9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A M;6EL>3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXR-RPV-SF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q M+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z M,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$=VED M=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I M;F'0M86QI9VXZ6QE M/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C,V+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPY,3(F M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPX-#0F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C0W+C4P)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.CAP=#LG/C$O,S$O,C`Q,CPO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N M-3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D) M"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^ M-"\S,"\R,#$R/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$P+C`P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)V1I6QE M/3-$)VUA3I4:6UE6QE/3-$)VUA3I4 M:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N M="US:7IE.CAP=#LG/C$P+S,Q+S(P,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C4P M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P M,3(\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C`P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;F3H@:6YL:6YE.R<^)FYB6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE M/3-$)VUAF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E M.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)W=I9'1H.C,V+C4P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,S@L-SDS)FYB6QE/3-$ M)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`X+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-3$L-#0S)FYB6QE/3-$)W=I9'1H.C`R M+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^ M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`X+C3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ-C`L-3,R)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X M+C3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ-C,L-#@W)FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV,30L M,C4U)FYB6QE/3-$)W=I9'1H.C`Q+C`P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z,S8N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^1W)O6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW M-"PR-SDF;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W=I9'1H.C`X+C'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`X+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY+#,P-B9N8G-P.PT*"0D)"3PO M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP M,BXU,"4[8F%C:V=R;W5N9"UC;VQO6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X M+C3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXQ,BPX.#DF;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z M,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N M,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4Z M(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UE MF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4 M:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6QE/3-$ M=VED=&@Z,#$N,S`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H M.C`X+C'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C,T)FYB6QE/3-$=VED=&@Z,#(N-3`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3)P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#$N,S`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`X+C6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXQ+C4R)FYB6QE/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z M(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB MF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA M3I4:6UE M3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M86QI M9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I M;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA MF4Z(#$R<'0G M/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I M;F'0M86QI9VXZ6QE M/3-$=VED=&@Z,#$N,#`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB M3H@:6YL:6YE.R<^5V5I9VAT960@079EF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPV.34F;F)S M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`R+C4P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#(N-3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUA3I4 M:6UE3I4:6UE6QE/3-$=VED=&@Z,3`N,#`E.W!A9&1I;F'0M M86QI9VXZ6QE/3-$=VED=&@Z,#(N-3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$ M)VUAF4Z(#$R M<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE3I4:6UEF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE M/3-$)W=I9'1H.C`R+C4P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$P+C`P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-RPX M.#@F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`R+C4P M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3)P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T* M"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4 M97-T:6YG($)UF%T:6]N(&%N9"!"=7-I M;F5S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R M,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA2!O9B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*2`H55-$ M("0I/&)R/DEN(%1H;W5S86YD'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^-2!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^ M,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^,34@ M>65A'1087)T M7SAC.3,P,#DR7S4X9C)?-&%D-5]A,C(U7V0T8F-A8V8V8CED,@T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R M-5]D-&)C86-F-F(Y9#(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y M9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF M,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A M:6QS(#,I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!M971H;V0@:6YV97-T;65N=#PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!A;F0@17%U:7!M96YT("A$ M971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X M8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5? M9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M,C`@>65A'!E;G-E(')E;&%T960@=&\@:6YT86YG:6)L92!A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N M(%!E'0^,R!Y96%R M65AF%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&5X<&5N'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3<@>65A'!E;G-E(')E;&%T960@=&\@:6YT86YG:6)L92!A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A M9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O M'0O:'1M M;#L@8VAA&EM=6T@8W)E9&ET(&QI;F4@879A:6QA8FQE(&%S('!E M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@+2!"86YK/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%B;&4@+2!" M86YK/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%B;&4@+2!"86YK/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@+2!"86YK/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A2!I;G-T86QL;65N M=',\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!R871E('1O('1H92!C;VUP86YY)W,@969F M96-T:79E(&EN8V]M92!T87@@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S M+"!.970@;V8@52Y3+B!&961E"!"96YE9FET("AA"!B96YE M9FET/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!E;G-E"!!"!!'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'!E;G-E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7SAC M.3,P,#DR7S4X9C)?-&%D-5]A,C(U7V0T8F-A8V8V8CED,@T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D M-&)C86-F-F(Y9#(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@ M4VAA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D M-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y M,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA&-E<'0@4VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^,3`@>65A&5R8VES86)L92!F;W(@=&AE(&9I&5R8VES92!P2!T;R!L96YD(&UO;F5Y(&]R(&=U87)A;G1Y(&%N>2!O M8FQI9V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"XP M,"4\65E($EN8V5N=&EV92!3=&]C:R!/<'1I;VX@4&QA;B`R,#`S M('P@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^-2!Y96%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!I'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65E(&EN8V5N=&EV92!S M=&]C:R!O<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M&-E<'0@4&5R(%-H87)E(&1A=&$L('5N M;&5S65E($EN8V5N=&EV M92!3=&]C:R!/<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R M8VES86)L92P@4VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$65E($EN8V5N=&EV92!3=&]C:R!/<'1I;VYS/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92P@17AE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!P3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92P@4VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R M8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92P@4VAA&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^,R!Y96%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92P@17AE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F M-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)? M-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M"!I;F-R96%S97,\+W-T'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G0@8V]N=')A8W1S(&%N9"!A9W)E96UE M;G1S+"!E>&-L=61I;F<@8V]M;6ES'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E(&]N(&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A;F0@97%U:7!M M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S+#0Q,3QS M<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6UE;G1S/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^-2!Y96%R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R M,C5?9#1B8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA2!I M;G-U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E65A&EM=6T@86UO M=6YT('!E'!E;G-E'!E;G-E3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U.&8R7S1A M9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B.60R+U=O M'0O:'1M M;#L@8VAA2!P87)T:6-I<&%N=',@*&%S M(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS M,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B M8V%C9C9B.60R+U=O'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X8SDS,#`Y,E\U M.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.&,Y,S`P.3)?-3AF,E\T860U7V$R,C5?9#1B8V%C9C9B M.60R+U=O&UL#0I#;VYT96YT+51R86YS9F5R M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E M>'0O:'1M;#L@8VAA&UL;G,Z;STS M1")U&UL/@T*+2TM+2TM/5].97AT M4&%R=%\X8SDS,#`Y,E\U.&8R7S1A9#5?83(R-5]D-&)C86-F-F(Y9#(M+0T* ` end XML 38 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9
Organization and Business (Details) (Laboratory Testing Business)
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Organization and Business      
Number of Reportable Segments 1us-gaap_NumberOfReportableSegments    
Minimum
      
Organization and Business      
Percentage of assets to consolidated assets 98.00%brli_PercentageOfReportableSegmentAssetsToTotalAssets
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_StatementBusinessSegmentsAxis
= brli_LaboratoryTestingBusinessMember		 98.00%brli_PercentageOfReportableSegmentAssetsToTotalAssets
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_StatementBusinessSegmentsAxis
= brli_LaboratoryTestingBusinessMember		 98.00%brli_PercentageOfReportableSegmentAssetsToTotalAssets
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_StatementBusinessSegmentsAxis
= brli_LaboratoryTestingBusinessMember

XML 39 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Selected Quarterly Financial Data
 12 Months Ended
Oct. 31, 2014
Selected Quarterly Financial Data  
Selected Quarterly Financial Data

[23] Selected Quarterly Financial Data [Unaudited]

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2014

 

4/30/2014

 

7/31/2014

 

10/31/2014

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 
181,270 

 
201,366 

 
222,053 

 
227,594 

 
832,282 

 

Gross Profit

 
72,154 

 
88,549 

 
102,443 

 
106,853 

 
369,999 

 

Net Income

 
2,954 

 
10,273 

 
15,250 

 
18,281 

 
46,758 

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 
0.11 

 
0.37 

 
0.55 

 
0.66 

 
1.69 

 

Diluted

 
0.11 

 
0.37 

 
0.55 

 
0.66 

 
1.68 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 
27,700 

 
27,717 

 
27,722 

 
27,728 

 
27,717 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 
27,848 

 
27,857 

 
27,864 

 
27,869 

 
27,855 

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2013

 

4/30/2013

 

7/31/2013

 

10/31/2013

 

2013

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 
161,256 

 
176,452 

 
185,427 

 
192,219 

 
715,355 

 

Gross Profit

 
70,922 

 
80,676 

 
85,660 

 
85,282 

 
322,539 

 

Net Income

 
8,665 

 
11,338 

 
14,701 

 
11,120 

 
45,825 

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 
0.31 

 
0.41 

 
0.53 

 
0.40 

 
1.65 

 

Diluted

 
0.31 

 
0.41 

 
0.53 

 
0.40 

 
1.65 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 
27,716 

 
27,698 

 
27,672 

 
27,677 

 
27,691 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 
27,912 

 
27,879 

 
27,842 

 
27,844 

 
27,851 

 

 

 

 

Three Month Ended

 

Audited
Fiscal Year

 

 

 

1/31/2012

 

4/30/2012

 

7/31/2012

 

10/31/2012

 

2012

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenues

 

$
138,793 

 

$
151,443 

 

$
160,532 

 

$
163,487 

 

$
614,255 

 

Gross Profit

 

$
60,118 

 

$
67,534 

 

$
74,279 

 

$
74,681 

 

$
276,611 

 

Net Income

 

$
7,365 

 

$
9,306 

 

$
12,596 

 

$
12,889 

 

$
42,156 

 

Net Income Per Common Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$
0.26 

 

$
0.34 

 

$
0.45 

 

$
0.47 

 

$
1.52 

 

Diluted

 

$
0.26 

 

$
0.33 

 

$
0.45 

 

$
0.46 

 

$
1.51 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding — Basic [in thousands]

 
27,888 

 
27,685 

 
27,695 

 
27,705 

 
27,742 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding - Diluted [in thousands]

 
28,041 

 
27,878 

 
27,888 

 
27,906 

 
27,921 

 

 

XML 40 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
New Accounting Pronouncements
 12 Months Ended
Oct. 31, 2014
New Accounting Pronouncements  
New Accounting Pronouncements

[22] New Authoritative Accounting Pronouncements

 

In May the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09 titled Revenues from Contracts with Customers. The update calls for a number of revisions in the revenue recognition rules. The update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. At this time the company is studying this update and has not yet determined the effect this may have on our consolidated financial statements.

 

XML 41 R56.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options and Warrants (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Oct. 31, 2011
Employee Incentive Stock Option Plan 2003        
Employee incentive stock options        
Maximum aggregate shares of common stock authorized under the plan 1,600,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		      
Minimum specified percentage of outstanding common stock for the holder of which the exercise price must be at least 110% of fair market value 10.00%brli_SharebasedCompensationArrangementBySharebasedPaymentAwardMinimumSpecifiedCommonStockPercentage
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		      
Period within which options must be exercised by the optionee after termination of his employment due to retirement 3 months      
Period within which options must be exercised by the optionee after termination of employment due to disability or death 1 year      
Shares Under Options        
Outstanding at the beginning of the period (in shares) 249,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 259,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 295,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Expired (in shares)   (6,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 (13,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Exercised (in shares) (27,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 (4,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 (23,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Outstanding at the end of the period (in shares) 222,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 249,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 259,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Weighted Average        
Outstanding at the beginning of the period (in dollars per share) $ 10.02us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.95us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.80us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Expired (in dollars per share)   $ 8.64us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.13us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Exercised (in dollars per share) $ 7.92us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 7.25us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 8.52us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Outstanding at the end of the period (in dollars per share) $ 10.28us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 10.02us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.95us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		  
Employee incentive stock option plan, additional disclosures        
Outstanding options, eligible for exercise (in shares) 217,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 239,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 244,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 275,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member
Outstanding options, eligible for exercise, weighted average exercise price (in dollars per share) $ 10.28us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.97us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.95us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member		 $ 9.80us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member
Employee Incentive Stock Option Plan 2003 | Maximum        
Employee incentive stock options        
Option term 10 years      
Aggregate fair market value of the common stock with respect to which options are exercisable for the first time by the grantee (in dollars) $ 100brli_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAggregateFairMarketValueOfCommonStockWithRespectToWhichOptionsAreExercisableForTheFirstTime
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		      
Percentage of exercise price of option for which the Board (or a Stock Option Committee) in its sole discretion, cause the company to lend money or guaranty any obligation 50.00%brli_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfExercisePriceOfOptionForWhichLoanOrGuarantyMayBeProvided
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		      
Employee Incentive Stock Option Plan 2003 | Shareholder with Minimum Specified Percentage of Stock        
Employee incentive stock options        
Exercise price as a percentage of fair value of common stock 110.00%us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2003Member
/ us-gaap_TitleOfIndividualAxis
= brli_ShareholderWithMinimumSpecifiedPercentageOfStockMember		      
Option term 5 years      
Employee Incentive Stock Option Plan 2000        
Employee incentive stock options        
Maximum aggregate shares of common stock authorized under the plan 1,600,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		      
Exercise price as a percentage of fair value of common stock 100.00%us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		      
Minimum specified percentage of outstanding common stock for the holder of which the exercise price must be at least 110% of fair market value 10.00%brli_SharebasedCompensationArrangementBySharebasedPaymentAwardMinimumSpecifiedCommonStockPercentage
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		      
Shares Under Options        
Outstanding at the beginning of the period (in shares) 6,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 52,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 60,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Granted (in shares) 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Expired (in shares) 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 (2,000)us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Exercised (in shares) (6,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 (44,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 (8,000)us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Outstanding at the end of the period (in shares)   6,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 52,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Weighted Average        
Outstanding at the beginning of the period (in dollars per share) $ 7.67us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 $ 5.47us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 $ 5.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Expired (in dollars per share)   $ 3.60us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		    
Exercised (in dollars per share)   $ 5.25us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 $ 3.39us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Outstanding at the end of the period (in dollars per share) $ 7.67us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 $ 7.67us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		 $ 5.47us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member		  
Employee Incentive Stock Option Plan 2000 | Maximum        
Employee incentive stock options        
Option term 10 years      
Employee Incentive Stock Option Plan 2000 | Shareholder with Minimum Specified Percentage of Stock        
Employee incentive stock options        
Exercise price as a percentage of fair value of common stock 110.00%us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
/ us-gaap_PlanNameAxis
= brli_EmployeeIncentiveStockOptionPlan2000Member
/ us-gaap_TitleOfIndividualAxis
= brli_ShareholderWithMinimumSpecifiedPercentageOfStockMember		      
XML 42 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Oct. 31, 2011
Cash and Cash Equivalents        
Cash and Cash Equivalents $ 17,507us-gaap_CashAndCashEquivalentsAtCarryingValue $ 17,952us-gaap_CashAndCashEquivalentsAtCarryingValue $ 25,143us-gaap_CashAndCashEquivalentsAtCarryingValue $ 22,013us-gaap_CashAndCashEquivalentsAtCarryingValue
Property and equipment        
Depreciation expense $ 23,246us-gaap_Depreciation $ 18,745us-gaap_Depreciation $ 16,082us-gaap_Depreciation  
Leasehold Improvements        
Property and equipment        
Estimated useful lives 5 years      
Minimum        
Property and equipment        
Estimated useful lives 2 years      
Maximum        
Property and equipment        
Estimated useful lives 15 years      
XML 43 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Oct. 31, 2014
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS  
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED OCTOBER 31, 2014, 2013 AND 2012

[In Thousands]

 

 

 

(b)

 

(c)

 

(d)

 

(e)

 

(a)
Description

 

Balance at the
Beginning of a Period

 

Charged to Cost and
Expenses

 

Deductions Charged to Valuation
Allowance Accounts

 

Balance at the End
of a Period

 

 

 

 

 

 

 

 

 

 

 

Year Ended October 31, 2014

 

 

 

 

 

 

 

 

 

Allowance for Doubtful Accounts

 
89,261

 
133,728

 
(139,713

)
83,276

 

Contractual Credits/Discounts

 
342,297

 
3,291,033

 
(3,119,864

)
513,466

 

 

 

 

 

 

 

 

 

 

 

Total Allowance

 
431,558

 
3,424,761

 
(3,259,577

)
596,742

 

 

 

 

 

 

 

 

 

 

 

Year Ended October 31, 2013

 

 

 

 

 

 

 

 

 

Allowance for Doubtful Accounts

 
51,274

 
119,161

 
(81,174

)
89,261

 

Contractual Credits/Discounts

 
267,921

 
2,748,510

 
(2,674,134

)
342,297

 

 

 

 

 

 

 

 

 

 

 

Total Allowance

 
319,195

 
2,867,671

 
(2,755,308

)
431,558

 

 

 

 

 

 

 

 

 

 

 

Year Ended October 31, 2012

 

 

 

 

 

 

 

 

 

Allowance for Doubtful Accounts

 
45,220

 
89,396

 
(83,342

)
51,274

 

Contractual Credits/Discounts

 
235,922

 
2,390,770

 
(2,358,771

)
267,921

 

 

 

 

 

 

 

 

 

 

 

Total Allowance

 
281,142

 
2,480,166

 
(2,442,113

)
319,195

 

 

XML 44 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Oct. 31, 2014
Summary of Significant Accounting Policies  
Principles of Consolidation

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.

Cash and Cash Equivalents

Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.  The Company had $17,507 and $17,952 in cash and cash equivalents at October 31, 2014 and 2013, respectively.

Inventory

Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.  Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.

Property and Equipment

Property and Equipment - Property and equipment are carried at cost.  Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.  Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.

 

The statements of operations reflect depreciation expense related to property and equipment of $23,246, $18,745 and $16,082 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.  Repairs and maintenance are charged to expense when incurred.

Goodwill

Goodwill - Effective November 1, 2011, the Company adopted revised Financial Accounting Standards Board (“FASB”)  rules promulgated under Accounting Standards Update (“ASU”) No. 2011-08 issued on September 15, 2011, Intangibles—Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.  Under ASU No. 2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit’s carrying value is greater than its fair value based on an assessment of events and circumstances. The “more likely than not” threshold is when there is a likelihood of more than 50% that a reporting unit’s carrying value is greater than its fair value.  No impairment loss was recognized in the years ended October 31, 2014, 2013 and 2012.

 

The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October 31, 2014 and 2013, respectively.

Other Intangible Assets

Other Intangible Assets - Intangible assets are amortized using the straight-line method.  The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $1,917, $994, and $581 for the years ended October 31, 2014, 2013 and 2012, respectively.  The balance sheet reflects accumulated amortization of $10,763, and $8,846 as of October 31, 2014, and 2013, respectively. During the 2014 and 2013 fiscal years, the Company did not write off any intangible assets.

Accounting for Revenue

Accounting for Revenue

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.  The majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly.  In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

 

 

($)

 

 

 

Year Ended October 31,

 

 

 

2014

 

2013

 

2012

 

Gross Service Revenues

 
4,185,052 

 
3,524,108 

 
3,052,431 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 
391,659 

 
354,638 

 
320,697 

 

All Other Third Party Payors*

 
2,899,374 

 
2,393,872 

 
2,070,073 

 

Total Contractual Adjustments and Discounts

 
3,291,033 

 
2,748,510 

 
2,390,770 

 

Service Revenues Net of Contractual Adjustments and Discounts

 
894,019 

 
775,598 

 
661,661 

 

Patient Service Revenue Provision for Bad Debts**

 
61,737 

 
60,244 

 
47,406 

 

Net Revenues

 
832,282 

 
715,354 

 
614,255 

 

 

 

 

 

 

 

 

 

Percent of Contractual Allowances, Discounts and Patient Service

 

 

 

 

 

 

 

Provision for Bad Debts to Gross Revenue.

 
80.1 

%
79.7 

%
79.9 

%

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

Accounting for Contractual Credits and Doubtful Accounts

Accounting for Contractual Credits and Doubtful Accounts

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses.  This represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information.  In the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.   BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

Contractual Credits/Discounts

 
513,466 

 
342,297 

 

Doubtful Accounts

 
83,276 

 
89,261 

 

Total Allowance

 
596,742 

 
431,558 

 

 

Current Income Taxes

Current Income Taxes — The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.  For the fiscal years 2011 through 2014, no material amounts for interest and penalties have been recorded.

Deferred Income Taxes

Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.

 

The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.  Under these rules the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.  For the years ended October 31, 2012 through October 31, 2014 the Company had no material uncertain tax positions to report.

Earnings Per Share

Earnings Per Share - Basic earnings per share [“EPS”] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.  Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.  The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.  This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.  Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.  Securities that could potentially dilute earnings in the future are disclosed in Note 10.

Use of Estimates

Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets

Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets — The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.  The Company reviews the recoverability of its long-lived assets on an annual basis.  Evaluation of possible impairment is based on the Company’s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.  No impairment loss was recognized in the fiscal years ended October 31, 2014, 2013 and 2012.

Advertising Costs

Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets — The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.  The Company reviews the recoverability of its long-lived assets on an annual basis.  Evaluation of possible impairment is based on the Company’s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.  No impairment loss was recognized in the fiscal years ended October 31, 2014, 2013 and 2012.

Other Income

Other Income — During the year ended October 31, 2014, the Company recorded a loss of $83 on its investment in IncellDx.  The loss represents the Company’s share of IncellDX undistributed net loss under the equity method of accounting.

Subsequent Events

Subsequent Events — The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.

XML 45 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies
 12 Months Ended
Oct. 31, 2014
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

[2] Summary of Significant Accounting Policies

 

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.

 

Cash and Cash Equivalents - Cash equivalents are comprised of certain highly liquid investments with a maturity of three months or less when purchased.  The Company had $17,507 and $17,952 in cash and cash equivalents at October 31, 2014 and 2013, respectively.

 

Inventory - Inventory is stated at the lower of cost [determined on a first-in, first-out basis] or market.  Inventory consists of purchased laboratory supplies, which is used in our various testing laboratories.

 

Property and Equipment - Property and equipment are carried at cost.  Depreciation is computed by the straight-line method over the estimated useful lives of the respective assets, which generally range from 2 to 15 years.  Leasehold improvements are amortized over the life of the lease or improvement, which is typically five years.

 

The statements of operations reflect depreciation expense related to property and equipment of $23,246, $18,745 and $16,082 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

On sale or retirement, the asset cost and related accumulated depreciation or amortization are removed from the accounts, and any related gain or loss is reflected in general and administrative expenses.  Repairs and maintenance are charged to expense when incurred.

 

Goodwill - Effective November 1, 2011, the Company adopted revised Financial Accounting Standards Board (“FASB”)  rules promulgated under Accounting Standards Update (“ASU”) No. 2011-08 issued on September 15, 2011, Intangibles—Goodwill and Other (Topic 350) Testing Goodwill for Impairment. Under these simplified goodwill impairment testing rules the Company assessed qualitative factors to determine whether events and circumstances lead to the conclusion that it is necessary to perform the two-step goodwill impairment test have occurred and determined that no such events had occurred.  Under ASU No. 2011-08, entities are not required to calculate the fair value of a reporting unit unless they conclude that it is more likely than not that the unit’s carrying value is greater than its fair value based on an assessment of events and circumstances. The “more likely than not” threshold is when there is a likelihood of more than 50% that a reporting unit’s carrying value is greater than its fair value.  No impairment loss was recognized in the years ended October 31, 2014, 2013 and 2012.

 

The balance sheet reflects prior Goodwill accumulated amortization of $2,401 as of October 31, 2014 and 2013, respectively.

 

Other Intangible Assets - Intangible assets are amortized using the straight-line method.  The estimated useful life of costs capitalized is evaluated for each specific project when completed, at which time such costs begin to be amortized. The statements of operations reflect amortization expense related to intangible assets of $1,917, $994, and $581 for the years ended October 31, 2014, 2013 and 2012, respectively.  The balance sheet reflects accumulated amortization of $10,763, and $8,846 as of October 31, 2014, and 2013, respectively. During the 2014 and 2013 fiscal years, the Company did not write off any intangible assets.

 

Accounting for Revenue

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses.  The majority of services provided by BRLI are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly.  In the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

 

 

($)

 

 

 

Year Ended October 31,

 

 

 

2014

 

2013

 

2012

 

Gross Service Revenues

 
4,185,052 

 
3,524,108 

 
3,052,431 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 
391,659 

 
354,638 

 
320,697 

 

All Other Third Party Payors*

 
2,899,374 

 
2,393,872 

 
2,070,073 

 

Total Contractual Adjustments and Discounts

 
3,291,033 

 
2,748,510 

 
2,390,770 

 

Service Revenues Net of Contractual Adjustments and Discounts

 
894,019 

 
775,598 

 
661,661 

 

Patient Service Revenue Provision for Bad Debts**

 
61,737 

 
60,244 

 
47,406 

 

Net Revenues

 
832,282 

 
715,354 

 
614,255 

 

 

 

 

 

 

 

 

 

Percent of Contractual Allowances, Discounts and Patient Service

 

 

 

 

 

 

 

Provision for Bad Debts to Gross Revenue.

 
80.1 

%
79.7 

%
79.9 

%

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

Accounting for Contractual Credits and Doubtful Accounts

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses.  This represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information.  In the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary.   BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

Contractual Credits/Discounts

 
513,466 

 
342,297 

 

Doubtful Accounts

 
83,276 

 
89,261 

 

Total Allowance

 
596,742 

 
431,558 

 

 

Current Income Taxes — The Company recognizes interest and penalties on settlement of tax liabilities in its income from operations.  For the fiscal years 2011 through 2014, no material amounts for interest and penalties have been recorded.

 

Deferred Income Taxes - Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.

 

The Company adopted GAAP guidance with respect to uncertain tax positions when it became effective.  Under these rules the Company may recognize the tax benefit from an uncertain tax position only if it meets the more-likely-than-not criteria (over 50% likelihood) of being realized on an examination by taxing authorities.  For the years ended October 31, 2012 through October 31, 2014 the Company had no material uncertain tax positions to report.

 

Earnings Per Share - Basic earnings per share [“EPS”] reflects the amount of income attributable to each share of common stock based on average common shares outstanding during the period.  Diluted EPS reflects Basic EPS while giving effect to all potential dilutive common shares that were outstanding during the period, such as common shares that could result from the exercise or conversion of securities into common stock.  The computation of Diluted EPS is calculated by using the treasury stock method, which assumes that any proceeds obtained from the exercise of such dilutive securities would be used to purchase common stock at the average market price of the common stock during the period.  This reduces the gross number of dilutive shares by the number of shares purchasable from the proceeds of the securities assumed to be exercised.  Securities whose conversion would have an anti-dilutive effect on EPS are not assumed converted.  Securities that could potentially dilute earnings in the future are disclosed in Note 10.

 

Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

 

Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets — The Company evaluates the possible impairment of its long-lived assets under the provisions of FASB codification 350-30-35 and 360-10-35.  The Company reviews the recoverability of its long-lived assets on an annual basis.  Evaluation of possible impairment is based on the Company’s ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying amount of the asset.  No impairment loss was recognized in the fiscal years ended October 31, 2014, 2013 and 2012.

 

Advertising Costs -Advertising costs are expensed when incurred.  Advertising costs amounted to approximately $3,188, $3,200 and $2,366 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

Other Income — During the year ended October 31, 2014, the Company recorded a loss of $83 on its investment in IncellDx.  The loss represents the Company’s share of IncellDX undistributed net loss under the equity method of accounting.

 

Subsequent Events — The management considered subsequent events through the date the financial statements are issued as defined in FASB Codification 855-10-50.

 

XML 46 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Oct. 31, 2014
Summary of Significant Accounting Policies  
Schedule of adjustments made to gross service revenues to arrive at net revenues

 

 

 

 

($)

 

 

 

Year Ended October 31,

 

 

 

2014

 

2013

 

2012

 

Gross Service Revenues

 
4,185,052 

 
3,524,108 

 
3,052,431 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 
391,659 

 
354,638 

 
320,697 

 

All Other Third Party Payors*

 
2,899,374 

 
2,393,872 

 
2,070,073 

 

Total Contractual Adjustments and Discounts

 
3,291,033 

 
2,748,510 

 
2,390,770 

 

Service Revenues Net of Contractual Adjustments and Discounts

 
894,019 

 
775,598 

 
661,661 

 

Patient Service Revenue Provision for Bad Debts**

 
61,737 

 
60,244 

 
47,406 

 

Net Revenues

 
832,282 

 
715,354 

 
614,255 

 

 

 

 

 

 

 

 

 

Percent of Contractual Allowances, Discounts and Patient Service

 

 

 

 

 

 

 

Provision for Bad Debts to Gross Revenue.

 
80.1 

%
79.7 

%
79.9 

%

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

** Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

Schedule of amounts for contractual credits and doubtful accounts

 

 

 

 

($)

 

 

 

October 31,

 

October 31,

 

 

 

2014

 

2013

 

Contractual Credits/Discounts

 
513,466 

 
342,297 

 

Doubtful Accounts

 
83,276 

 
89,261 

 

Total Allowance

 
596,742 

 
431,558 

 

 

XML 47 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9
Capitalized Lease Obligations (Tables)
 12 Months Ended
Oct. 31, 2014
Capitalized Lease Obligations  
Schedule of assets under capital leases expiring in fiscal 2018

 

                                                                                                                                                         

 

 

($)

 

 

 

October 31

 

 

 

2014

 

2013

 

Medical Equipment

 
20,774 

 
15,013 

 

Automobiles

 
12,674 

 
10,581 

 

 

 

 

 

 

 

Totals

 
33,447 

 
25,594 

 

Less: Accumulated Depreciation

 
17,656 

 
13,125 

 

 

 

 

 

 

 

Net

 
15,791 

 
12,469 

 

 

Schedule of aggregate future minimum rentals under capital leases

 

                                                                                                                                                         

October 31,

 

($)

 

2015

 
6,623 

 

2016

 
5,749 

 

2017

 
4,186 

 

2018

 
2,368 

 

2019

 
485 

 

Thereafter

 
1 

 

 

 

 

 

Total

 
19,412 

 

 

 

 

 

Less Interest:

 
1,032 

 

 

 

 

 

Present Value of Minimum Lease Payments

 
18,380 

 

 

XML 48 R53.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the company's effective income tax rate      
U.S. Federal Statutory Rate (as a percent) 35.00%us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate 35.00%us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate 35.00%us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
State and Local Taxes, Net of U.S. Federal Tax Benefit (as a percent) 6.15%us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes 11.20%us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes 8.87%us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
Permanent differences and Other (as a percent) 0.94%brli_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAndOther (2.78%)brli_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAndOther (0.44%)brli_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAndOther
Actual Rate (as a percent) 42.09%us-gaap_EffectiveIncomeTaxRateContinuingOperations 43.42%us-gaap_EffectiveIncomeTaxRateContinuingOperations 43.43%us-gaap_EffectiveIncomeTaxRateContinuingOperations
Current:      
Federal $ 25,732us-gaap_CurrentFederalTaxExpenseBenefit $ 38,295us-gaap_CurrentFederalTaxExpenseBenefit $ 25,794us-gaap_CurrentFederalTaxExpenseBenefit
State & Local 7,700us-gaap_CurrentStateAndLocalTaxExpenseBenefit 14,018us-gaap_CurrentStateAndLocalTaxExpenseBenefit 10,203us-gaap_CurrentStateAndLocalTaxExpenseBenefit
Net deferred tax benefit      
Federal 598us-gaap_DeferredFederalIncomeTaxExpenseBenefit (10,803)us-gaap_DeferredFederalIncomeTaxExpenseBenefit (2,183)us-gaap_DeferredFederalIncomeTaxExpenseBenefit
State and Local 179us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit (6,238)us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit (1,454)us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit
Provision for Income Taxes 34,209us-gaap_IncomeTaxExpenseBenefit 35,272us-gaap_IncomeTaxExpenseBenefit 32,360us-gaap_IncomeTaxExpenseBenefit
Net operating loss carry-forwards 0us-gaap_OperatingLossCarryforwards 0us-gaap_OperatingLossCarryforwards 0us-gaap_OperatingLossCarryforwards
Deferred Tax Asset:      
Bad Debt Allowance 36,642us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts 39,275us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts  
Depreciation and amortization 3,009us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment 1,815us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment  
Accrued Expenses 3,803us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities 3,141us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities  
Current Deferred Tax Asset - Net 40,040us-gaap_DeferredTaxAssetsNetCurrent 42,154us-gaap_DeferredTaxAssetsNetCurrent  
Long Term Deferred Tax Asset - Net 3,414us-gaap_DeferredTaxAssetsNetNoncurrent 2,077us-gaap_DeferredTaxAssetsNetNoncurrent  
Deferred Tax Asset - Net 43,454us-gaap_DeferredTaxAssetsNet 44,231us-gaap_DeferredTaxAssetsNet  
Net deferred tax benefit      
Deferred tax provision (benefit) 777us-gaap_DeferredIncomeTaxExpenseBenefit (17,041)us-gaap_DeferredIncomeTaxExpenseBenefit (3,638)us-gaap_DeferredIncomeTaxExpenseBenefit
Net benefit in allowance for bad debts 2,633brli_DeferredIncomeTaxExpenseBenefitAllowanceForDoubtfulAccounts    
Benefit from depreciation and amortization 1,194brli_DeferredIncomeTaxExpenseBenefitDepreciationAndAmortization    
Benefit in certain accrued expenses $ 661brli_DeferredIncomeTaxExpenseBenefitAccruedLiabilities    
XML 49 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Oct. 31, 2014
Oct. 31, 2013
CURRENT ASSETS:    
Cash and Cash Equivalents $ 17,507us-gaap_CashAndCashEquivalentsAtCarryingValue $ 17,952us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts Receivable - Net 263,346us-gaap_AccountsReceivableNetCurrent 206,261us-gaap_AccountsReceivableNetCurrent
Inventory 20,791us-gaap_InventoryNet 19,095us-gaap_InventoryNet
Other Current Assets 10,165us-gaap_OtherAssetsCurrent 9,416us-gaap_OtherAssetsCurrent
Deferred Tax Assets 40,040us-gaap_DeferredTaxAssetsNetCurrent 42,154us-gaap_DeferredTaxAssetsNetCurrent
TOTAL CURRENT ASSETS 351,849us-gaap_AssetsCurrent 294,878us-gaap_AssetsCurrent
PROPERTY AND EQUIPMENT - AT COST 156,342us-gaap_PropertyPlantAndEquipmentGross 133,599us-gaap_PropertyPlantAndEquipmentGross
Less: Accumulated Depreciation 89,954us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment 67,950us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
PROPERTY AND EQUIPMENT - NET 66,388us-gaap_PropertyPlantAndEquipmentNet 65,649us-gaap_PropertyPlantAndEquipmentNet
OTHER ASSETS:    
Investments in Unconsolidated Affiliate 5,153us-gaap_EquityMethodInvestments 5,237us-gaap_EquityMethodInvestments
Deposits 1,056us-gaap_DepositsAssetsNoncurrent 1,017us-gaap_DepositsAssetsNoncurrent
Goodwill - Net 35,185us-gaap_Goodwill 35,185us-gaap_Goodwill
Intangible Assets - Net 14,403us-gaap_IntangibleAssetsNetExcludingGoodwill 16,320us-gaap_IntangibleAssetsNetExcludingGoodwill
Other Assets 1,415us-gaap_OtherAssetsNoncurrent 1,165us-gaap_OtherAssetsNoncurrent
Deferred Tax Asset 3,414us-gaap_DeferredTaxAssetsNetNoncurrent 2,077us-gaap_DeferredTaxAssetsNetNoncurrent
TOTAL OTHER ASSETS 60,626us-gaap_AssetsNoncurrent 61,001us-gaap_AssetsNoncurrent
TOTAL ASSETS 478,863us-gaap_Assets 421,528us-gaap_Assets
CURRENT LIABILITIES:    
Accounts Payable 71,166us-gaap_AccountsPayableCurrent 61,614us-gaap_AccountsPayableCurrent
Accrued Salaries and Commissions Payable 15,822us-gaap_EmployeeRelatedLiabilitiesCurrent 19,601us-gaap_EmployeeRelatedLiabilitiesCurrent
Accrued Taxes and Expenses 15,620us-gaap_AccruedIncomeTaxesCurrent 18,292us-gaap_AccruedIncomeTaxesCurrent
Other Short Term Acquisition Payable 1,924us-gaap_OtherLoansPayableCurrent 2,438us-gaap_OtherLoansPayableCurrent
Revolving Note Payable - Bank 33,380us-gaap_LinesOfCreditCurrent 26,139us-gaap_LinesOfCreditCurrent
Current Maturities of Long-Term Debt 524us-gaap_LongTermDebtCurrent 493us-gaap_LongTermDebtCurrent
Capital Lease Obligations - Short-Term Portion 6,128us-gaap_CapitalLeaseObligationsCurrent 5,185us-gaap_CapitalLeaseObligationsCurrent
TOTAL CURRENT LIABILITIES 144,564us-gaap_LiabilitiesCurrent 133,762us-gaap_LiabilitiesCurrent
LONG-TERM LIABILITIES:    
Capital Lease Obligations - Long-Term Portion 12,252us-gaap_CapitalLeaseObligationsNoncurrent 10,712us-gaap_CapitalLeaseObligationsNoncurrent
Long Term Debt - Net of Current Portion 3,145us-gaap_LongTermDebtNoncurrent 3,670us-gaap_LongTermDebtNoncurrent
Long Term Acquisition Payable   1,789us-gaap_LongTermLoansPayable
TOTAL LONG-TERM LIABILITIES 15,397us-gaap_LiabilitiesNoncurrent 16,171us-gaap_LiabilitiesNoncurrent
SHAREHOLDERS' EQUITY:    
Preferred Stock $.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued      
Common Stock, $.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 27,727,644 and 27,683,213 at January 31, 2014 and at October 31, 2013, respectively 277us-gaap_CommonStockValue 277us-gaap_CommonStockValue
Additional Paid-In Capital 39,979us-gaap_AdditionalPaidInCapital 39,430us-gaap_AdditionalPaidInCapital
Retained Earnings 278,646us-gaap_RetainedEarningsAccumulatedDeficit 231,888us-gaap_RetainedEarningsAccumulatedDeficit
TOTAL SHAREHOLDERS' EQUITY 318,902us-gaap_StockholdersEquity 271,595us-gaap_StockholdersEquity
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 478,863us-gaap_LiabilitiesAndStockholdersEquity $ 421,528us-gaap_LiabilitiesAndStockholdersEquity
XML 50 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 2) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Goodwill      
Impairment loss $ 0us-gaap_GoodwillImpairmentLoss $ 0us-gaap_GoodwillImpairmentLoss $ 0us-gaap_GoodwillImpairmentLoss
Goodwill accumulated amortization 2,401us-gaap_GoodwillImpairedAccumulatedImpairmentLoss 2,401us-gaap_GoodwillImpairedAccumulatedImpairmentLoss  
Amortization expenses 1,917us-gaap_AmortizationOfIntangibleAssets 994us-gaap_AmortizationOfIntangibleAssets 581us-gaap_AmortizationOfIntangibleAssets
Accumulated Amortization $ 10,763us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization $ 8,846us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization  
XML 51 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
OPERATING ACTIVITIES:      
Net Income $ 46,758us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 45,825us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 42,156us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Adjustments to Reconcile Net Income to Cash Provided by Operating Activities:      
Depreciation and Amortization 25,164us-gaap_DepreciationDepletionAndAmortization 19,739us-gaap_DepreciationDepletionAndAmortization 16,663us-gaap_DepreciationDepletionAndAmortization
Deferred Income Taxes (Benefit) Expense 777us-gaap_DeferredIncomeTaxExpenseBenefit (17,041)us-gaap_DeferredIncomeTaxExpenseBenefit (3,638)us-gaap_DeferredIncomeTaxExpenseBenefit
Stock Based Compensation 290us-gaap_ShareBasedCompensation 290us-gaap_ShareBasedCompensation 290us-gaap_ShareBasedCompensation
(Gain) Loss on Disposal of Fixed Assets 220us-gaap_GainLossOnSaleOfPropertyPlantEquipment 1,408us-gaap_GainLossOnSaleOfPropertyPlantEquipment 537us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Undistributed Equity Method (Income) Loss 83us-gaap_IncomeLossFromEquityMethodInvestments 450us-gaap_IncomeLossFromEquityMethodInvestments 323us-gaap_IncomeLossFromEquityMethodInvestments
(Increase) Decrease in:      
Accounts Receivable (51,100)us-gaap_IncreaseDecreaseInAccountsReceivable (91,002)us-gaap_IncreaseDecreaseInAccountsReceivable (11,240)us-gaap_IncreaseDecreaseInAccountsReceivable
Provision for Doubtful Accounts (5,985)us-gaap_ProvisionForDoubtfulAccounts 37,988us-gaap_ProvisionForDoubtfulAccounts 6,053us-gaap_ProvisionForDoubtfulAccounts
Inventory (1,696)us-gaap_IncreaseDecreaseInInventories (4,193)us-gaap_IncreaseDecreaseInInventories (5,211)us-gaap_IncreaseDecreaseInInventories
Other Current Assets (749)us-gaap_IncreaseDecreaseInOtherCurrentAssets (4,043)us-gaap_IncreaseDecreaseInOtherCurrentAssets (916)us-gaap_IncreaseDecreaseInOtherCurrentAssets
Other Assets (250)us-gaap_IncreaseDecreaseInOtherOperatingAssets (299)us-gaap_IncreaseDecreaseInOtherOperatingAssets (141)us-gaap_IncreaseDecreaseInOtherOperatingAssets
Deposits (39)us-gaap_IncreaseDecreaseInCustomerDeposits (61)us-gaap_IncreaseDecreaseInCustomerDeposits (74)us-gaap_IncreaseDecreaseInCustomerDeposits
Increase (Decrease) in:      
Accounts Payable and Accrued Liabilities 3,102us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 28,601us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 8,296us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
NET CASH - OPERATING ACTIVITIES 16,575us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 17,662us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 53,098us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
INVESTING ACTIVITIES:      
Acquisition of Equipment and Leasehold Improvements (15,523)us-gaap_PaymentsToAcquireProductiveAssets (25,100)us-gaap_PaymentsToAcquireProductiveAssets (15,715)us-gaap_PaymentsToAcquireProductiveAssets
Business Acquisitions Related Costs (2,303)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired (19,013)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired (5,675)us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
NET CASH - INVESTING ACTIVITIES (17,826)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (44,113)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (21,390)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
FINANCING ACTIVITIES:      
Payments of Long-Term Debt (494)us-gaap_RepaymentsOfLongTermDebt (464)us-gaap_RepaymentsOfLongTermDebt (1,270)us-gaap_RepaymentsOfLongTermDebt
Payments of Capital Lease Obligations (6,200)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations (4,648)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations (3,710)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations
Increase (Decrease) in Revolving Line of Credit 7,241us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet 26,139us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet (18,632)us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet
Common Stock Repurchase   2,030us-gaap_PaymentsForRepurchaseOfCommonStock 5,193us-gaap_PaymentsForRepurchaseOfCommonStock
Proceeds from Exercise of Options 259us-gaap_ProceedsFromStockOptionsExercised 263us-gaap_ProceedsFromStockOptionsExercised 227us-gaap_ProceedsFromStockOptionsExercised
Common Stock Repurchase   (2,030)us-gaap_PaymentsForRepurchaseOfCommonStock (5,193)us-gaap_PaymentsForRepurchaseOfCommonStock
NET CASH - FINANCING ACTIVITIES 806us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 19,260us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations (28,578)us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (445)us-gaap_NetCashProvidedByUsedInContinuingOperations (7,191)us-gaap_NetCashProvidedByUsedInContinuingOperations 3,130us-gaap_NetCashProvidedByUsedInContinuingOperations
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS 17,952us-gaap_CashAndCashEquivalentsAtCarryingValue 25,143us-gaap_CashAndCashEquivalentsAtCarryingValue 22,013us-gaap_CashAndCashEquivalentsAtCarryingValue
CASH AND CASH EQUIVALENTS AT END OF PERIODS 17,507us-gaap_CashAndCashEquivalentsAtCarryingValue 17,952us-gaap_CashAndCashEquivalentsAtCarryingValue 25,143us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash paid during the period for:      
Interest 2,419us-gaap_InterestPaid 1,503us-gaap_InterestPaid 1,547us-gaap_InterestPaid
Income Taxes 36,505us-gaap_IncomeTaxesPaid 44,312us-gaap_IncomeTaxesPaid 36,697us-gaap_IncomeTaxesPaid
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:      
Capital Leases 8,683us-gaap_CapitalLeaseObligationsIncurred 7,125us-gaap_CapitalLeaseObligationsIncurred 7,777us-gaap_CapitalLeaseObligationsIncurred
Write-off of property $ 1,463brli_WriteOffOfProperty $ 4,464brli_WriteOffOfProperty $ 2,508brli_WriteOffOfProperty
XML 52 R59.htm IDEA: XBRL DOCUMENT v2.4.1.9
Capitalized Lease Obligations (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Assets under capital leases      
Totals $ 33,447us-gaap_CapitalLeasedAssetsGross $ 25,594us-gaap_CapitalLeasedAssetsGross  
Less: Accumulated Depreciation 17,656us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation 13,125us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation  
Net 15,791us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet 12,469us-gaap_CapitalLeasesBalanceSheetAssetsByMajorClassNet  
Depreciation expense on assets under capital leases 6,889brli_DepreciationRelatedToAssetsUnderCapitalLease 6,494brli_DepreciationRelatedToAssetsUnderCapitalLease 3,792brli_DepreciationRelatedToAssetsUnderCapitalLease
Future minimum rentals under capital leases      
2015 6,623us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent    
2016 5,749us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears    
2017 4,186us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears    
2018 2,368us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears    
2019 485us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears    
Thereafter 1us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter    
Total 19,412us-gaap_CapitalLeasesFutureMinimumPaymentsDue    
Less Interest 1,032us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments    
Total 18,380us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments    
Minimum      
Assets under capital leases      
Interest rate under capital leases 2.00%brli_CapitalLeasesInterestRate
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		    
Maximum      
Assets under capital leases      
Interest rate under capital leases 7.00%brli_CapitalLeasesInterestRate
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		    
Equipment      
Assets under capital leases      
Totals 20,774us-gaap_CapitalLeasedAssetsGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		 15,013us-gaap_CapitalLeasedAssetsGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		  
Automobiles [Member]      
Assets under capital leases      
Totals $ 12,674us-gaap_CapitalLeasedAssetsGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_AutomobilesMember		 $ 10,581us-gaap_CapitalLeasedAssetsGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_AutomobilesMember		  
XML 53 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Long-Term Debt - Bank (Tables)
 12 Months Ended
Oct. 31, 2014
Long-Term Debt - Bank  
Schedule of principal repayment for each of the five succeeding fiscal years and thereafter

                                                                                                                                                         

 

Year Ended October 31,

 

 

 

2015

 
524 

 

2016

 
557 

 

2017

 
592 

 

2018

 
1,996 

 

2019

 

—

 

Thereafter

 

—

 

Totals

 

$
3,669 

 

 

XML 54 R65.htm IDEA: XBRL DOCUMENT v2.4.1.9
Employee Benefit Plan (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Employee Benefit Plan      
Age requirement for employees to participate in the Plan 18 years    
Requisite service period 1 year    
Contribution by participants (as a percent) 10.00%us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent    
Entity's contribution under the Plan $ 2,130us-gaap_DefinedContributionPlanCostRecognized $ 1,358us-gaap_DefinedContributionPlanCostRecognized $ 1,106us-gaap_DefinedContributionPlanCostRecognized
XML 55 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Insurance
 12 Months Ended
Oct. 31, 2014
Insurance  
Insurance

[16] Insurance

 

The Company maintains professional liability insurance of $3,000 in the aggregate, with a per occurrence limit of $1,000.  In addition, the Company maintains excess commercial insurance of $5,000 per occurrence and $5,000 in aggregate over the primary limits.  In addition, the Company also maintains excess umbrella coverage of $15,000.

 

XML 56 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes (Tables)
 12 Months Ended
Oct. 31, 2014
Provision for Income Taxes  
Schedule of reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company's effective income tax rate

 

 

 

 

October 31

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

U.S. Federal Statutory Rate

 
35 

%
35 

%
35 

%

State and Local Taxes, Net of U.S. Federal Tax Benefit

 
6.15 

%
11.20 

%
8.87 

%

Permanent differences and Other

 
0.94 

%
(2.78 

)%
(0.44 

)%

 

 

 

 

 

 

 

 

Actual Rate

 
42.09 

%
43.42 

%
43.43 

%

 

Schedule of provision for income taxes

 

 

 

 

$

 

 

 

October 31

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Current:

 

 

 

 

 

 

 

Federal

 
25,732

 
38,295

 
25,794

 

State & Local

 
7,700

 
14,018

 
10,203

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

Federal

 
598

 
(10,803

)
(2,183

)

State and Local

 
179

 
(6,238

)
(1,454

)

 

 

 

 

 

 

 

 

Total Provision for Income Taxes

 
34,209

 
35,272

 
32,360

 

 

Schedule of net deferred tax asset [liability]

 

 

 

 

$

 

 

 

October 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Deferred Tax Asset:

 

 

 

 

 

Bad Debt Allowance

 
36,642 

 
39,275 

 

Depreciation and amortization

 
3,009 

 
1,815 

 

Accrued Expenses

 
3,803 

 
3,141 

 

 

 

 

 

 

 

Deferred Tax Asset - Net

 
43,454 

 
44,231 

 

 

 

 

 

 

 

Current Deferred Tax Asset - Net

 
40,040 

 
42,154 

 

Long Term Deferred Tax Asset - Net

 
3,414 

 
2,077 

 

 

 

 

 

 

 

Deferred Tax Asset — Net

 
43,454 

 
44,231 

 

 

XML 57 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Acquisitions
 12 Months Ended
Oct. 31, 2014
Acquisitions  
Business Combinations

[18] Acquisitions

 

The Company did not make any acquisitions during the fiscal year ended October 31, 2014.  The company still carries certain acquisition payable balances on its books that relate to prior period acquisitions.

 

XML 58 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 59 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Organization and Business
 12 Months Ended
Oct. 31, 2014
Basis of Presentation  
Organization and Business

[1] Organization and Business

 

Bio-Reference Laboratories, Inc. [“Bio-Reference”, “BRLI”, or the “Company”] was incorporated on December 24, 1981.  Bio-Reference is principally engaged in providing laboratory testing services, primarily to customers in the in larger metropolitan areas across New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts as well as to customers in a number of other states.  Bio-Reference offers a comprehensive list of chemical diagnostic tests including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology (including drug screening), pap smears, tissue pathology (biopsies) and other tissue analysis.  We perform cancer cytogenetic testing at our facilities in Elmwood Park, NJ, Smithtown, NY, Clarksburg, MD and Milford, MA, Miami Florida, Campbell California and genetic testing at our GeneDx leased facility in Gaithersburg, MD, as well as at our Elmwood Park facility.  We perform cytology testing in Frederick, MD, Milford, MA, Columbus, OH, Houston, TX and at our Elmwood Park facility.  Bio-Reference markets its laboratory testing services directly to physicians, geneticists, hospitals, clinics, correctional and other health facilities.

 

The Company’s laboratory testing business currently represents its one reportable business segment. The laboratory testing business accounts for over 98% of consolidated assets, net revenues and net income in each of the three years ended October 31, 2014.   All other operating segments include the Company’s non-clinical laboratory testing businesses and consist of our clinical knowledge management service through our PSIMedica business unit and a web-based connectivity portal solution for laboratories and physicians through its Care Evolve subsidiary.

XML 60 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Oct. 31, 2014
Oct. 31, 2013
Preferred Stock, Par Value (in dollars per share) $ 0.10us-gaap_PreferredStockParOrStatedValuePerShare $ 0.10us-gaap_PreferredStockParOrStatedValuePerShare
Preferred Stock, Authorized shares, including Series A Junior Preferred Stock 1,666,667brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior 1,666,667brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior
Preferred Stock, Authorized shares 1,666,667us-gaap_PreferredStockSharesAuthorized 1,666,667us-gaap_PreferredStockSharesAuthorized
Preferred Stock, Issued shares 0us-gaap_PreferredStockSharesIssued 0us-gaap_PreferredStockSharesIssued
Common Stock, Par Value (in dollars per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Common Stock, Authorized shares 35,000,000us-gaap_CommonStockSharesAuthorized 35,000,000us-gaap_CommonStockSharesAuthorized
Common Stock, Issued shares 27,727,644us-gaap_CommonStockSharesIssued 27,683,213us-gaap_CommonStockSharesIssued
Common Stock, Outstanding shares 27,727,644us-gaap_CommonStockSharesOutstanding 27,683,213us-gaap_CommonStockSharesOutstanding
Series A Preferred Stock    
Preferred Stock, Authorized shares, including Series A Junior Preferred Stock 3,000brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember		 3,000brli_PreferredStockSharesAuthorizedIncludingSeriesAJunior
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
XML 61 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options and Warrants
 12 Months Ended
Oct. 31, 2014
Stock Options and Warrants  
Stock Options and Warrants

[11] Stock Options and Warrants

 

Employee Incentive Stock Options - In June 2003, the Board of Directors adopted, and in July 2003, the stockholders approved, the 2003 Employee Incentive Stock Option Plan [the “2003 Plan”].  The 2003 Plan authorizes the grant of stock options, which may be designated as  incentive stock options, to purchase up to a maximum aggregate 1,600,000 shares of Company common stock.  The 2003 Plan provides that the exercise price of an option granted there under shall not be less than the fair market value of the Common Stock on the date the option is granted.  However, in the event an option is granted under the 2003 Plan to a holder of 10% or more of the Company’s outstanding Common Stock, the exercise price must be at least 110% of such fair market value.  Under the 2003 Plan, options must be granted before the June 2, 2013 Termination Date.  No option may have a term longer than ten years (limited to five years in the case of an option granted to a 10% or greater stockholder of the Company).  The aggregate fair market value of the Company’s Common Stock with respect to which options are exercisable for the first time by a grantee under all of the Company’s Stock Option Plans during any calendar year cannot exceed $100.  Options granted under the 2003 Plan are non-transferable and must be exercised by an optionee, if at all, while employed by the Company or a subsidiary or within three months after termination of such optionee’s employment due to retirement, or within one year of such termination if due to disability or death.  The Board (or a Stock Option Committee, if designated), may, in its sole discretion, cause the Company to lend money to or guaranty any obligation of an employee for the purpose of enabling such employee to exercise an option granted under the 2003 Plan provided that such loan or obligation cannot exceed fifty percent (50%) of the exercise price of such option. Options issued under the 2003 Plan must have been granted before the June 2 2013 termination date.  No additional options may be granted under the 2003 Plan. A total of 27,000, 4,000 and 23,500 incentive stock options issued under the 2003 Plan were exercised in fiscal years ended in October 31, 2014, 2013 and 2012, respectively.  A total of 0, 6,000 and 13,000 options were cancelled in fiscal years ended October 31, 2014, 2013 and 2012.

 

In August 2000, the Company adopted, and on December 15, 2000, the stockholders approved, the 2000 Employee Incentive Stock Option Plan [“2000 Plan”]. The 2000 Plan provided for the granting of stock options, which may have been designated as incentive stock options, to purchase an aggregate of 1,600,000 shares of the Company’s common stock at a price   not less than 100% of the fair market value per share of the common stock at the date of grant.  However, in the event an option was granted under the 2000 Plan to a holder of 10% or more of the Company’s outstanding common stock, the exercise price must have been at least 110% of fair market value at the date of grant.  Employees of the Company or its subsidiary, as determined, were eligible for the 2000 Plan.  The term of the options could not exceed ten years from the date of grant.  Options issued under the 2000 Plan must have been granted before the August 2010 termination date.  No additional options may be granted under the 2000 Plan. A total of 6,000, 44,000 and 8,000 incentive stock options issued under the 2000 Plan were exercised in fiscal years ended in October 31, 2014, 2013 and 2012, respectively. A total of 0, 2,000, and 0 options were cancelled in fiscal years ended October 31, 2014, 2013 and 2012, respectively.

 

The following is a summary of Employee Incentive Stock Option Plan transactions:

 

 

 

2003 Plan

 

 

 

Shares Under Options
[In Thousands]

 

Weighted Average 
Exercise Price Per Share

 

Outstanding at October 31, 2011*

 
295

 

$
9.80

 

Granted

 

—

 

—

 

Expired

 
(13

)
9.13

 

Exercised

 
(23

)
8.52

 

Outstanding at October 31, 2012**

 
259

 

$
9.95

 

 

 

 

 

 

 

Granted

 

—

 

—

 

Expired

 
(6

)
8.64

 

Exercised

 
(4

)
7.25

 

Outstanding at October 31, 2013***

 
249

 

$
10.02

 

 

 

 

 

 

 

Granted

 

—

 

 

 

Expired

 

—

 

 

 

Exercised

 
(27

)
7.92

 

Outstanding at October 31, 2014****

 
222

 

$
10.28

 

 

*Eligible for exercise at October 31, 2011 were 275 at a weighted average exercise price per share of $9.80

**Eligible for exercise at October 31, 2012 were 244 at a weighted average exercise price per share of $9.95

***Eligible for exercise at October 31, 2013 were 239 at a weighted average exercise price per share of $9.97

****Eligible for exercise at October 31, 2014 were 217 at a weighted average exercise price per share of $10.28

 

 

 

2000 Plan

 

 

 

Shares Under Options
[In Thousands]

 

Weighted Average
Exercise Price Per Share

 

Outstanding and Eligible for Exercise at October 31, 2011

 
60

 
5.19

 

Granted

 

—

 

—

 

Expired

 

—

 

—

 

Exercised

 
(8

)
3.39

 

Outstanding and Eligible for Exercise at October 31, 2012

 
(52

)
5.47

 

 

 

—

 

—

 

Granted

 

—

 

—

 

Expired

 
(2

)
3.60

 

Exercised

 
(44

)

$
5.25

 

Outstanding and Eligible for Exercise at October 31, 2013

 
6

 
7.67

 

Granted

 

—

 

 

 

Expired

 

—

 

 

 

Exercised

 
(6

)
7.67

 

Outstanding and Eligible for Exercise at October 31, 2014

 

—

 

 

 

 

Summary of outstanding options at October 31, 2014:

 

 

 

Weighted Average

 

Exercisable

 

 

 

Shares

 

Remaining

 

Exercise

 

Shares

 

Exercise

 

Exercise Price Range

 

Outstanding

 

Life

 

Price

 

Outstanding

 

Price

 

$
7.25 

 

to

 

$
7.25 

 

Per Share

 
0 

 
0.00 

 
7.25 

 
0 

 
7.25 

 

$
7.41 

 

to

 

$
7.67 

 

Per Share

 
46 

 
0.42 

 
7.41 

 
46 

 
7.41 

 

$
9.12 

 

to

 

$
9.12 

 

Per Share

 
136 

 
1.00 

 
9.13 

 
136 

 
9.13 

 

$
17.50 

 

to

 

$
17.50 

 

Per Share

 
40 

 
3.08 

 
17.50 

 
35 

 
17.50 

 

 

 

 

 

 

 

 

 
222 

 

 

 

 

 
217 

 

 

 

 

Compensation cost recognized for the years ended October 31, 2014, October 31, 2013 and October 31, 2012 was $40 for each one of the years, with a related tax benefit of $-0- with respect to these options.

 

XML 62 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information (USD $)
 12 Months Ended
Oct. 31, 2014
Jan. 09, 2015
Apr. 30, 2014
Document and Entity Information      
Entity Registrant Name BIO REFERENCE LABORATORIES INC    
Entity Central Index Key 0000792641    
Document Type 10-K    
Document Period End Date Oct. 31, 2014    
Amendment Flag false    
Current Fiscal Year End Date --10-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Accelerated Filer    
Entity Public Float     $ 623,605,643dei_EntityPublicFloat
Entity Common Stock, Shares Outstanding   27,749,644dei_EntityCommonStockSharesOutstanding  
Document Fiscal Year Focus 2014    
Document Fiscal Period Focus FY    
XML 63 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Employment Contracts and Consulting Agreements
 12 Months Ended
Oct. 31, 2014
Employment Contracts and Consulting Agreements  
Employment Contracts and Consulting Agreements

[12] Employment Contracts and Consulting Agreements

 

The Company has multiple employment contracts with its key executives with expiration dates ranging from January 31, 2015 through October 31, 2018.  At October 31, 2014, the approximate aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases, is as follows:

 

October 31

 

Employees
and
Consultants

 

2015

 

$
4,582 

 

2016

 
3,706 

 

2017

 
3,706 

 

2018

 
1,701 

 

2019

 

—

 

Thereafter

 

—

 

 

 

 

 

Total

 

$
13,695 

 

 

Some of these agreements provide bonuses and commissions based on a percentage of collected revenues ranging from 1% to 10% on accounts referred by or serviced by the employee or consultant.

 

In addition to the above, in fiscal 2014 the Company has entered into thirty two at — will employment and consulting agreements which together with prior at — will agreements provide for annual aggregate minimum commitments of approximately $39,254 which have no termination dates.

 

XML 64 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS      
NET REVENUES: $ 832,282us-gaap_SalesRevenueServicesNet $ 715,354us-gaap_SalesRevenueServicesNet $ 614,255us-gaap_SalesRevenueServicesNet
COST OF SERVICES:      
Depreciation and Amortization 19,515us-gaap_CostOfServicesDepreciationAndAmortization 15,598us-gaap_CostOfServicesDepreciationAndAmortization 13,101us-gaap_CostOfServicesDepreciationAndAmortization
Employee Related Expenses 206,198us-gaap_LaborAndRelatedExpense 173,137us-gaap_LaborAndRelatedExpense 146,292us-gaap_LaborAndRelatedExpense
Reagents and Lab Supplies 158,296us-gaap_CostOfServicesDirectMaterials 135,486us-gaap_CostOfServicesDirectMaterials 121,446us-gaap_CostOfServicesDirectMaterials
Other Cost of Services 78,274us-gaap_OtherCostOfServices 68,594us-gaap_OtherCostOfServices 56,805us-gaap_OtherCostOfServices
TOTAL COST OF SERVICES 462,283us-gaap_CostOfServices 392,815us-gaap_CostOfServices 337,644us-gaap_CostOfServices
GROSS PROFIT ON REVENUES 369,999us-gaap_GrossProfit 322,539us-gaap_GrossProfit 276,611us-gaap_GrossProfit
General and Administrative Expenses:      
Depreciation and Amortization 5,649us-gaap_DepreciationAndAmortization 4,141us-gaap_DepreciationAndAmortization 3,562us-gaap_DepreciationAndAmortization
Other General and Administrative Expenses 208,934us-gaap_GeneralAndAdministrativeExpense 177,508us-gaap_GeneralAndAdministrativeExpense 154,928us-gaap_GeneralAndAdministrativeExpense
Bad Debt Expense 71,991brli_BadDebtExpense 58,917brli_BadDebtExpense 41,990brli_BadDebtExpense
TOTAL GENERAL AND ADMIN. EXPENSES 286,574brli_TotalGeneralAndAdministrativeExpense 240,566brli_TotalGeneralAndAdministrativeExpense 200,480brli_TotalGeneralAndAdministrativeExpense
OPERATING INCOME 83,425us-gaap_OperatingIncomeLoss 81,973us-gaap_OperatingIncomeLoss 76,131us-gaap_OperatingIncomeLoss
OTHER (INCOME) EXPENSES:      
Interest Expense 2,446us-gaap_InterestExpense 1,606us-gaap_InterestExpense 1,455us-gaap_InterestExpense
Other (Income) Expense 83us-gaap_InvestmentIncomeInterest (612)us-gaap_InvestmentIncomeInterest 323us-gaap_InvestmentIncomeInterest
Interest Income (71)us-gaap_OtherNonoperatingExpense (118)us-gaap_OtherNonoperatingExpense (163)us-gaap_OtherNonoperatingExpense
TOTAL OTHER (INCOME) EXPENSES - NET 2,458us-gaap_OtherNonoperatingIncomeExpense 876us-gaap_OtherNonoperatingIncomeExpense 1,615us-gaap_OtherNonoperatingIncomeExpense
INCOME BEFORE INCOME TAXES 80,967us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 81,097us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 74,516us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Provision for Income Taxes 34,209us-gaap_IncomeTaxExpenseBenefit 35,272us-gaap_IncomeTaxExpenseBenefit 32,360us-gaap_IncomeTaxExpenseBenefit
NET INCOME $ 46,758us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 45,825us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 42,156us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
NET INCOME PER SHARE - BASIC: (in dollars per share) $ 1.69us-gaap_EarningsPerShareBasic $ 1.65us-gaap_EarningsPerShareBasic $ 1.52us-gaap_EarningsPerShareBasic
WEIGHTED AVERAGE NUMBER OF SHARES BASIC: (in shares) 27,716,608us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,690,677us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,742,257us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
NET INCOME PER SHARE - DILUTED: (in dollars per share) $ 1.68us-gaap_EarningsPerShareDiluted $ 1.65us-gaap_EarningsPerShareDiluted $ 1.51us-gaap_EarningsPerShareDiluted
WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED: (in shares) 27,855,125us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,851,720us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,920,920us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
XML 65 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Long-Term Debt - Bank
 12 Months Ended
Oct. 31, 2014
Long-Term Debt - Bank  
Long-Term Debt - Bank

[6] Long-Term Debt - Bank

 

In December 2010, the Company issued a seven year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in eighty-four equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of  December 29, 2017.  The balance on this note as of October 31, 2014 is approximately $3,669.

 

Principal repayment for each of the five succeeding fiscal years and thereafter as of October 31, 2014 is as follows:

 

Year Ended October 31,

 

 

 

2015

 
524 

 

2016

 
557 

 

2017

 
592 

 

2018

 
1,996 

 

2019

 

—

 

Thereafter

 

—

 

Totals

 

$
3,669 

 

 

XML 66 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revolving Note Payable - Bank
 12 Months Ended
Oct. 31, 2014
Revolving Note Payable - Bank  
Revolving Note Payable - Bank

[5] Revolving Note Payable - Bank

 

In October 2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $45,000 or (ii) 50% of the Company’s qualified accounts receivable [as defined in the agreement].  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  At October 31, 2014, the Company had elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.50%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent, thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures, fixed charge coverage, and the prohibition of the payment by the Company of cash dividends. As of October 31, 2014 and October 31, 2013, the Company utilized $33,380 and $26,139 of the credit line, respectively.

XML 67 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Significant Risks and Uncertainties
 12 Months Ended
Oct. 31, 2014
Significant Risks and Uncertainties  
Significant Risks and Uncertainties

[17] Significant Risks and Uncertainties

 

[A] Concentrations of Credit Risk - Cash - At October 31, 2014 and 2013, the Company had approximately $15,314 and $14,720, respectively, in cash and certificate of deposit balances at financial institutions which were in excess of the federally insured limits.

 

[B] Concentration of Credit Risk - Accounts Receivable - Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base.  The Company does have significant receivable balances with government payors and various insurance carriers.  Generally, the Company does not require collateral or other security to support customer receivables.  However, the Company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

 

A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid (CMS) reimbursements to clinical laboratories.  Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid (CMS), which could have a material adverse effect on the Company.  The Company is unable to predict, however, the extent to which such actions will be taken.

 

XML 68 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Capitalized Lease Obligations
 12 Months Ended
Oct. 31, 2014
Capitalized Lease Obligations  
Capitalized Lease Obligations

[13] Capitalized Lease Obligations

 

The Company leases various assets under capital leases expiring in fiscal 2020 with interest rates ranging between 2% to 7% as follows:

 

 

 

($)

 

 

 

October 31

 

 

 

2014

 

2013

 

Medical Equipment

 
20,774 

 
15,013 

 

Automobiles

 
12,674 

 
10,581 

 

 

 

 

 

 

 

Totals

 
33,447 

 
25,594 

 

Less: Accumulated Depreciation

 
17,656 

 
13,125 

 

 

 

 

 

 

 

Net

 
15,791 

 
12,469 

 

 

Depreciation expense on assets under capital leases was approximately $6,889, $6,494, and $3,792 for the years ended October 31, 2014, 2013 and 2012, respectively.

 

Aggregate future minimum rentals under capital leases are:

 

October 31,

 

($)

 

2015

 
6,623 

 

2016

 
5,749 

 

2017

 
4,186 

 

2018

 
2,368 

 

2019

 
485 

 

Thereafter

 
1 

 

 

 

 

 

Total

 
19,412 

 

 

 

 

 

Less Interest:

 
1,032 

 

 

 

 

 

Present Value of Minimum Lease Payments

 
18,380 

 

 

XML 69 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Capital Transactions
 12 Months Ended
Oct. 31, 2014
Capital Transactions  
Common Stock Repurchase

[9] Capital Transactions

 

[A] Preferred Stock and Common Stock - The Company is authorized to issue an aggregate of 1,666,667 shares of preferred stock, $.10 par value.  None was outstanding as of October 31, 2014 and October 31, 2013.

 

Holders of the Company’s Common Stock are entitled to one vote per share on matters submitted for shareholder vote.  Holders are also entitled to receive dividends ratably, if declared.  In the event of dissolution or liquidation, holders are entitled to share ratably in all assets remaining after payment of liabilities.

 

On December 19, 2013 the Company announced that its board of directors has approved a new Stock Repurchase Program authorizing the buyback of up to 2,000,000 shares of its Common Stock in the over-the-counter market at prevailing market prices through October 31, 2015.  As of October 31, 2014 no shares have been repurchased under this plan.

 

[B] Equity Transactions for Services — For the fiscal years ended in 2014, 2013 and 2012, the Company issued 11,431, 11,431 and 11,432 shares of the Company’s common stock for employment or consulting services [See Note 11 for common stock options issued for employee and consulting services].

 

XML 70 R60.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Operating Leases      
Total rental expenses for property and equipment $ 13,411us-gaap_OperatingLeasesRentExpenseNet $ 10,568us-gaap_OperatingLeasesRentExpenseNet $ 8,787us-gaap_OperatingLeasesRentExpenseNet
Contingent rental amounts 0us-gaap_OperatingLeasesRentExpenseContingentRentals    
Minimum purchase commitments      
2015 73,709us-gaap_PurchaseObligationDueInNextTwelveMonths    
2016 62,534us-gaap_PurchaseObligationDueInSecondYear    
2017 36,188us-gaap_PurchaseObligationDueInThirdYear    
2018 21,241us-gaap_PurchaseObligationDueInFourthYear    
2019 8,663us-gaap_PurchaseObligationDueInFifthYear    
Totals 202,335us-gaap_PurchaseObligation    
Regent supplies expenses 60,777brli_PurchaseObligationPurchases 7,873brli_PurchaseObligationPurchases 13,338brli_PurchaseObligationPurchases
Property [Member]      
Aggregate future minimum rental payments      
2015 8,564us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
2016 2,122us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
2017 831us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
2018 689us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
2019 626us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
Thereafter 103us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
Totals 12,935us-gaap_OperatingLeasesFutureMinimumPaymentsDue
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_PropertyMember		    
Equipment      
Aggregate future minimum rental payments      
2015 345us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		    
2016 203us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		    
2017 63us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		    
Totals $ 611us-gaap_OperatingLeasesFutureMinimumPaymentsDue
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		    
Minimum      
Operating Leases      
Period of renewal options 1 year    
Maximum      
Operating Leases      
Period of renewal options 5 years    
XML 71 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Related Party Transactions
 12 Months Ended
Oct. 31, 2014
Related Party Transactions  
Related Party Transactions

[7] Related Party Transactions

 

There were no material related party transactions during fiscal 2014 and fiscal 2013.

 

XML 72 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Income Taxes
 12 Months Ended
Oct. 31, 2014
Provision for Income Taxes  
Provision for Income Taxes

[8] Income Taxes

 

The reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company’s effective income tax rate is as follows:

 

 

 

October 31

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

U.S. Federal Statutory Rate

 
35 

%
35 

%
35 

%

State and Local Taxes, Net of U.S. Federal Tax Benefit

 
6.15 

%
11.20 

%
8.87 

%

Permanent differences and Other

 
0.94 

%
(2.78 

)%
(0.44 

)%

 

 

 

 

 

 

 

 

Actual Rate

 
42.09 

%
43.42 

%
43.43 

%

 

The provision for income taxes shown in the consolidated statements of operations consists of the following:

 

 

 

$

 

 

 

October 31

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Current:

 

 

 

 

 

 

 

Federal

 
25,732

 
38,295

 
25,794

 

State & Local

 
7,700

 
14,018

 
10,203

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

Federal

 
598

 
(10,803

)
(2,183

)

State and Local

 
179

 
(6,238

)
(1,454

)

 

 

 

 

 

 

 

 

Total Provision for Income Taxes

 
34,209

 
35,272

 
32,360

 

 

At October 31, 2014 and 2013, the Company had a net deferred tax asset of approximately $43,454 and $44,231, respectively.  The deferred taxes primarily relate to timing differences associated with the deductibility of depreciation and amortization, bad debts and certain accrued expenses and deferred costs.  For fiscal years ended October 31 2012 through October 31, 2014, the Company had no material net operating loss carry-forwards available to reduce current year taxable income.

 

 

 

$

 

 

 

October 31,

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Deferred Tax Asset:

 

 

 

 

 

Bad Debt Allowance

 
36,642 

 
39,275 

 

Depreciation and amortization

 
3,009 

 
1,815 

 

Accrued Expenses

 
3,803 

 
3,141 

 

 

 

 

 

 

 

Deferred Tax Asset - Net

 
43,454 

 
44,231 

 

 

 

 

 

 

 

Current Deferred Tax Asset - Net

 
40,040 

 
42,154 

 

Long Term Deferred Tax Asset - Net

 
3,414 

 
2,077 

 

 

 

 

 

 

 

Deferred Tax Asset — Net

 
43,454 

 
44,231 

 

 

During fiscal year ended October 31, 2014 the Company recorded a net deferred tax expense of $777.  This reflects an expense of approximately $2,633 in allowance for bad debts, a benefit of approximately $1,194 from depreciation and amortization timing differences, and a benefit of approximately $661 in certain accrued expenses. Although realization is not assured and dependent upon things such as generating sufficient taxable income in future periods, management, through sufficient positive evidence,  believes it is more likely than not that all of the deferred tax asset will be realized. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income or changes in the accrued expenses during the future periods are reduced.

 

At October 31, 2014, fiscal 2011 through 2014 are generally subject to examination by US federal and state tax authorities.  In certain instances examinations that were ongoing on October 31, 2014 are still open for years 2009 and 2010.  Through the issuance of these financial statements the outcome of all of these examinations has not been determined.

 

XML 73 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Earnings Per Share
 12 Months Ended
Oct. 31, 2014
Earnings Per Share  
Earnings Per Share

[10] Earnings Per Share

 

The computation of basic and diluted net earnings per common share is as follows [in thousands, except per share data rounded]:

 

 

 

$

 

 

 

For Years Ended October 31,

 

 

 

2014

 

2013

 

2012

 

 

 

 

 

 

 

 

 

Income Available to Common Stockholders

 
46,758 

 
45,825 

 
42,156 

 

Weighted Average Common Shares Outstanding

 
27,717 

 
27,691 

 
27,742 

 

 

 

 

 

 

 

 

 

Effect of Dilutive Securities:

 

 

 

 

 

 

 

Warrants/Options

 
138 

 
161 

 
179 

 

 

 

 

 

 

 

 

 

Weighted Average Diluted Common Shares Outstanding

 
27,855 

 
27,852 

 
27,921 

 

 

 

 

 

 

 

 

 

Net Income Per Share - Basic

 
1.69 

 
1.65 

 
1.52 

 

Net Income Per Share - Diluted

 
1.68 

 
1.65 

 
1.51 

 

 

XML 74 R64.htm IDEA: XBRL DOCUMENT v2.4.1.9
Health Insurance Plan (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Health Insurance Plan      
Initial amount the entity pays for covered medical expenses per person each year $ 150brli_SelfFundedHealthInsurancePlanInitialPaymentForCoveredMedicalExpensesPerPerson    
Maximum amount per person, covered by the third party insurance carrier for any excess 50,178brli_SelfFundedHealthInsurancePlanThirdPartyInsuranceCoveragePerPerson    
Health insurance premium expenses 7,346brli_SelfFundedHealthInsurancePlanHealthInsurancePremiumExpenses 6,797brli_SelfFundedHealthInsurancePlanHealthInsurancePremiumExpenses 5,792brli_SelfFundedHealthInsurancePlanHealthInsurancePremiumExpenses
Uninsured employee medical expenses 43,459brli_UninsuredEmployeeMedicalExpenses 32,016brli_UninsuredEmployeeMedicalExpenses 25,994brli_UninsuredEmployeeMedicalExpenses
Employee contributions for limited health insurance plan $ 6,063brli_SelfFundedHealthInsurancePlanEmployeeContribution $ 4,713brli_SelfFundedHealthInsurancePlanEmployeeContribution $ 4,124brli_SelfFundedHealthInsurancePlanEmployeeContribution
XML 75 R66.htm IDEA: XBRL DOCUMENT v2.4.1.9
Selected Quarterly Financial Data (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Oct. 31, 2014
Jul. 31, 2014
Apr. 30, 2014
Jan. 31, 2014
Oct. 31, 2013
Jul. 31, 2013
Apr. 30, 2013
Jan. 31, 2013
Oct. 31, 2012
Jul. 31, 2012
Apr. 30, 2012
Jan. 31, 2012
Oct. 31, 2014
Oct. 31, 2013
Oct. 31, 2012
Selected Quarterly Financial Data                              
Net Revenues $ 227,594us-gaap_SalesRevenueServicesNet $ 222,053us-gaap_SalesRevenueServicesNet $ 201,366us-gaap_SalesRevenueServicesNet $ 181,270us-gaap_SalesRevenueServicesNet $ 192,219us-gaap_SalesRevenueServicesNet $ 185,427us-gaap_SalesRevenueServicesNet $ 176,452us-gaap_SalesRevenueServicesNet $ 161,256us-gaap_SalesRevenueServicesNet $ 163,487us-gaap_SalesRevenueServicesNet $ 160,532us-gaap_SalesRevenueServicesNet $ 151,443us-gaap_SalesRevenueServicesNet $ 138,793us-gaap_SalesRevenueServicesNet $ 832,282us-gaap_SalesRevenueServicesNet $ 715,354us-gaap_SalesRevenueServicesNet $ 614,255us-gaap_SalesRevenueServicesNet
Gross Profit 106,853us-gaap_GrossProfit 102,443us-gaap_GrossProfit 88,549us-gaap_GrossProfit 72,154us-gaap_GrossProfit 85,282us-gaap_GrossProfit 85,660us-gaap_GrossProfit 80,676us-gaap_GrossProfit 70,922us-gaap_GrossProfit 74,681us-gaap_GrossProfit 74,279us-gaap_GrossProfit 67,534us-gaap_GrossProfit 60,118us-gaap_GrossProfit 369,999us-gaap_GrossProfit 322,539us-gaap_GrossProfit 276,611us-gaap_GrossProfit
Net Income $ 18,281us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 15,250us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 10,273us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 2,954us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 11,120us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 14,701us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 11,338us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 8,665us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 12,889us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 12,596us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 9,306us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 7,365us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 46,758us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 45,825us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ 42,156us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Net Income Per Common Share:                              
Net Income Per Share - Basic (in dollars per share) $ 0.66us-gaap_EarningsPerShareBasic $ 0.55us-gaap_EarningsPerShareBasic $ 0.37us-gaap_EarningsPerShareBasic $ 0.11us-gaap_EarningsPerShareBasic $ 0.40us-gaap_EarningsPerShareBasic $ 0.53us-gaap_EarningsPerShareBasic $ 0.41us-gaap_EarningsPerShareBasic $ 0.31us-gaap_EarningsPerShareBasic $ 0.47us-gaap_EarningsPerShareBasic $ 0.45us-gaap_EarningsPerShareBasic $ 0.34us-gaap_EarningsPerShareBasic $ 0.26us-gaap_EarningsPerShareBasic $ 1.69us-gaap_EarningsPerShareBasic $ 1.65us-gaap_EarningsPerShareBasic $ 1.52us-gaap_EarningsPerShareBasic
Net Income Per Share - Diluted (in dollars per share) $ 0.66us-gaap_EarningsPerShareDiluted $ 0.55us-gaap_EarningsPerShareDiluted $ 0.37us-gaap_EarningsPerShareDiluted $ 0.11us-gaap_EarningsPerShareDiluted $ 0.40us-gaap_EarningsPerShareDiluted $ 0.53us-gaap_EarningsPerShareDiluted $ 0.41us-gaap_EarningsPerShareDiluted $ 0.31us-gaap_EarningsPerShareDiluted $ 0.46us-gaap_EarningsPerShareDiluted $ 0.45us-gaap_EarningsPerShareDiluted $ 0.33us-gaap_EarningsPerShareDiluted $ 0.26us-gaap_EarningsPerShareDiluted $ 1.68us-gaap_EarningsPerShareDiluted $ 1.65us-gaap_EarningsPerShareDiluted $ 1.51us-gaap_EarningsPerShareDiluted
Weighted Average Common Shares Outstanding - Basic (in shares) 27,728,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,722,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,717,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,700,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,677,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,672,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,698,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,716,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,705,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,695,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,685,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,888,000us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,716,608us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,690,677us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 27,742,257us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Weighted Average Common Shares Outstanding - Diluted (in shares) 27,869,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,864,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,857,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,848,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,844,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,842,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,879,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,912,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,906,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,888,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,878,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 28,041,000us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,855,125us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,851,720us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 27,920,920us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding
XML 76 R63.htm IDEA: XBRL DOCUMENT v2.4.1.9
Significant Risks and Uncertainties (Details) (USD $)
In Thousands, unless otherwise specified
Oct. 31, 2014
Oct. 31, 2013
Significant Risks and Uncertainties    
Cash and certificate of deposit balances at financial institutions in excess of the federally insured limits $ 15,314brli_ConcentrationRiskCreditRiskUninsuredAmount $ 14,720brli_ConcentrationRiskCreditRiskUninsuredAmount
XML 77 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Tables)
 12 Months Ended
Oct. 31, 2014
Intangible Assets  
Schedule of information on intangible assets

 

 

October 31, 2014

 

 

 

Weighted-Average

 

 

 

Accumulated

 

Net of 
Accumulated

 

Intangible Asset

 

Amortization Period

 

Cost

 

Amortization

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$
8,738 

 

$
3,275 

 

$
5,463 

 

Covenants Not-to-Compete

 

3

 
11,131 

 
5,738 

 
5,393 

 

Patents and Licenses

 

17

 
5,297 

 
1,750 

 
3,547 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$
25,166 

 

$
10,763 

 

$
14,403 

 

 

October 31, 2013

 

 

 

Weighted-Average

 

 

 

Accumulated

 

Net of 
Accumulated

 

Intangible Asset

 

Amortization Period

 

Cost

 

Amortization

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$
8,738 

 

$
2,878 

 

$
5,860 

 

Covenants Not-to-Compete

 

3

 
11,131 

 
4,560 

 
6,571 

 

Patents and Licenses

 

17

 
5,297 

 
1,408 

 
3,889 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$
25,166 

 

$
8,846 

 

$
16,320 

 

 

Schedule of estimated amortization expense related to remaining intangible assets

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of October 31, 2014 is as follows:

 

October 31,

 

 

 

2015

 

$
1,852 

 

2016

 
1,540 

 

2017

 
1,063 

 

2018

 
946 

 

2019

 
904 

 

Thereafter

 
8,098 

 

 

 

 

 

Total

 

$
14,403 

 

 

XML 78 R51.htm IDEA: XBRL DOCUMENT v2.4.1.9
Revolving Note Payable - Bank (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Revolving note payable - Bank    
Amount of credit utilized 33,380us-gaap_LinesOfCreditCurrent $ 26,139us-gaap_LinesOfCreditCurrent
Revolving Credit Facility    
Revolving note payable - Bank    
Maximum amount of the credit line available pursuant to the loan agreement 45,000us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember		  
Maximum credit line available as percentage of accounts receivable 50.00%brli_LineOfCreditFacilityMaximumBorrowingCapacityAsPercentageOfAccountsReceivable
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember		  
Revolving Credit Facility | Debt Instrument, Variable Rate Base Rate    
Revolving note payable - Bank    
Variable rate basis base rate  
Variable rate of interest (as a percent) 3.50%brli_DebtInstrumentReferenceRate
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember		  
Revolving Credit Facility | Debt Instrument, Variable Rate Base Rate | Minimum    
Revolving note payable - Bank    
Percentage of additional interest 1.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember		  
Revolving Credit Facility | Debt Instrument, Variable Rate Base Rate | Maximum    
Revolving note payable - Bank    
Percentage of additional interest 4.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateBaseRateMember		  
Revolving Credit Facility | Debt Instrument, Variable Rate Eurodollar    
Revolving note payable - Bank    
Variable rate basis Eurodollar  
Revolving Credit Facility | Debt Instrument, Variable Rate Eurodollar | Minimum    
Revolving note payable - Bank    
Percentage of additional interest 1.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateEurodollarMember		  
Revolving Credit Facility | Debt Instrument, Variable Rate Eurodollar | Maximum    
Revolving note payable - Bank    
Percentage of additional interest 4.00%us-gaap_DebtInstrumentBasisSpreadOnVariableRate1
/ us-gaap_CreditFacilityAxis
= us-gaap_RevolvingCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_VariableRateAxis
= brli_DebtInstrumentVariableRateEurodollarMember		  
XML 79 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Litigation
 12 Months Ended
Oct. 31, 2014
Litigation  
Litigation

[15] Litigation

 

In the normal course of business, the Company is exposed to a number of asserted and unasserted potential claims.  In the opinion of management, the resolution of these matters will not have a material adverse effect on the Company’s financial position or results of operations.

 

Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey

 

On December 18, 2013, the Company filed an action in the Superior Court of New Jersey against Horizon Blue Cross Blue Shield of New Jersey (“Horizon”), captioned Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey, Docket No. BER L-009748-13 (N.J. Super. Ct. Bergen Cnty.).  The Company has been an in-network provider to Horizon’s preferred provider organization (“PPO”) members for more than 20 years and filed the lawsuit after attempts to resolve its dispute with Horizon were unsuccessful.

 

The Company currently provides services to Horizon pursuant to an Ancillary Services Provider Agreement entered into in 2003 and amended in 2007.  The central claims in the lawsuit arise from the Company’s performance of laboratory services since at least 2008 for members of Horizon’s NJ DIRECT plan, who receive benefits under a program that Horizon has bid, promoted, and represented to be a PPO product for New Jersey state, county, and municipal workers and teachers.  The lawsuit alleges that, despite these representations, Horizon has been improperly treating NJ DIRECT as a Managed Care program in its dealings with the Company, thereby costing the Company more than $20,000,000 in unreimbursed services and depriving state beneficiaries of valuable rights and benefits to which they are entitled.  The lawsuit alleges that Horizon furthered its fraud against the Company by means of a sham Request for Proposal issued in 2011 and through false and incorrect communications to the Company and other providers.  The Company asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud against Horizon.  In addition to compensatory damages, the Company seeks to recover punitive damages from Horizon due to Horizon’s intentional and malicious misconduct.  The Company also seeks declaratory and injunctive relief.

 

On February 5, 2014, Horizon filed a motion to dismiss the complaint, which the Company opposed.  On March 28, 2014, the Honorable Robert C. Wilson of the Superior Court of New Jersey issued an oral ruling denying Horizon’s motion to dismiss without prejudice pending the completion of discovery.  The Company and Horizon are conducting discovery, which is currently scheduled to close in mid 2015.  The Company intends to vigorously prosecute its claims against Horizon.

 

University of Utah Research Foundation, et al. v. GeneDx, Inc., Civil Action No. 2:13cv00954 (D. Utah)

 

On October 16, 2013, Myriad Genetics, Inc., Endorecherche, Inc., HSC Research and Development Limited Partnership, Trustees of the University of Pennsylvania, and University of Utah Research Foundation (“Plaintiffs”) filed a complaint for patent infringement against GeneDx, Inc., a wholly-owned subsidiary of Bio-Reference Laboratories, Inc., in the United States District Court for the District of Utah, Central Division in Salt Lake City, Utah (“District of Utah litigation”). The complaint alleges that GeneDx offers laboratory services, including testing and analysis of BRCA1, BRCA2, and MUTYH genes, that infringe sixteen (16) U.S. Patents owned or controlled by the plaintiffs. Plaintiffs seek to recover damages, including enhanced damages, together with attorney’s fees, interest, and costs. Plaintiffs also seek other relief, including enjoining GeneDx from continuing its allegedly infringing activity.

 

On December 9, 2013, GeneDx filed its answer, affirmative defenses, and counterclaims alleging, among other things, that the asserted patent claims are invalid, unenforceable, and/or not infringed.

 

Plaintiff Myriad and several of the other Plaintiffs have previously and subsequently filed complaints against other laboratories or have been named as defendants in declaratory judgment actions by certain laboratories. Those cases involve some of the patents and claims asserted against GeneDx. The parties involved in those cases who are adverse to Plaintiffs are: Ambry Genetics Corp. (filed July 9, 2013, D. Utah); Gene by Gene, Ltd. (filed July 10, 2013, D. Utah); Counsyl, Inc. (filed September 20, 2013, N.D. Cal.); Quest Diagnostics Inc., et al. (filed October 10, 2013, C.D. Cal.); Quest Diagnostics Inc., et al. (filed October 22, 2013, D. Utah); Invitae Corp. (filed November 25, 2013, D. Utah); Invitae Corp. (filed November 26, 2013, N.D. Cal.); Laboratory Corporation of America Holdings (filed December 3, 2013, D. Utah); Counsyl, Inc. (filed June 13, 2014, D. Utah); and Pathway Genomics Corp. (filed June 13, 2014, D. Utah) (collectively “Defendants”).

 

On November 8, 2013, Plaintiffs filed a motion with the Judicial Panel on Multidistrict Litigation requesting centralization and consolidation in the District of Utah of each of the outstanding district court actions. On February 19, 2014, following briefing and a hearing, the Panel ordered centralization in the District of Utah before District Court Judge Robert J. Shelby, including the action against GeneDx. The Court held an initial scheduling conference on April 25, 2014.

 

In the first-filed actions against Defendants Ambry Genetics Corp. and Gene by Gene, Ltd., on July 9 and July 10, 2013, respectively, Plaintiffs filed a motion for preliminary injunction with each complaint. The parties in each action provided the Court with briefing on the issues, as well as a technology tutorial on August 23, 2013, and the Court held multi-day hearings on the motion in September and October 2013. Prior to any decision, Plaintiffs and Defendant Gene by Gene entered a stipulated dismissal of that action on February 7, 2014. On March 10, 2014, the Court denied Plaintiffs’ request for a preliminary injunction against Defendant Ambry Genetics Corp.

 

Plaintiffs appealed that decision denying their request for a preliminary injunction to the Court of Appeals for the Federal Circuit. Plaintiffs submitted their appeal brief on April 18, 2014, and Defendant Ambry Genetics Corp. submitted its appeal brief on June 2, 2014. Plaintiffs filed their reply appeal brief on June 13, 2014. The Court of Appeals heard oral argument on the denial of Plaintiffs’ request for a preliminary injunction on October 6, 2014, and a decision is expected soon.

 

On August 18, 2014, GeneDx filed eleven petitions for Inter Partes Review (“IPR”) with the U.S. Patent and Trademark Office, challenging the validity of certain of the patents asserted against it in the District of Utah litigation. The eleven patents involved in these petitions are U.S. Patent Nos. 5,654,155; 5,753,441; 6,033,857; 6,051,379; 6,083,698; 6,951,721; 7,470,510; 7,563,571; 7,622,258; 7,670,776, and 7,838,237. On October 24, 2014, GeneDx filed two additional petitions for IPR challenging the validity of U.S. Patent Nos. 5,747,282 and 5,837,492, which are also asserted against GeneDx in the District of Utah litigation. IPR is a relatively new procedure established by the America Invents Act of 2011 as a means to challenge patentability at the U.S. Patent and Trademark Office; and these petitions are the first, and so far only, use of the IPR procedure by any of the Defendants in the Myriad cases.

 

Since the filing of these IPRs, Plaintiffs have narrowed their asserted claims to 40 across 14 patents from the 67 claims across 16 patents originally asserted in Plaintiffs’ complaint against GeneDx.

 

We intend to vigorously defend ourselves in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against us and we could be required to pay substantial damages. During the pendency of the litigation, we expect to incur significant costs, and the defense of this litigation may divert, and until resolved will continue to divert, the attention of our management and other resources that would otherwise be engaged in other activities.

 

XML 80 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
Health Insurance Plan
 12 Months Ended
Oct. 31, 2014
Health Insurance Plan  
Health Insurance Plan

[20] Health Insurance Plan

 

The Company has a limited self-funded health insurance plan for its employees under which the Company pays the initial $150 of covered medical expenses per person each year.  The Company has a contract with an insurance carrier for any excess up to a maximum of $50,178 in the aggregate.  Health insurance premium expense for the years ended October 31, 2014, 2013 and 2012 amounted to approximately $7,346, $6,797 and $5,792, respectively.  Uninsured employee medical expenses incurred by the Company amounted to approximately $43,459, $32,016 and $25,994 for the years ended October 31, 2014, 2013 and 2012, respectively.  During fiscal years ended October 31, 2014, 2013 and 2012, employee contributions of $6,063, $4,713 and $4,124 offset the above health plan costs.

 

XML 81 R49.htm IDEA: XBRL DOCUMENT v2.4.1.9
Property and Equipment (Details) (USD $)
In Thousands, unless otherwise specified
Oct. 31, 2014
Oct. 31, 2013
Property and equipment    
PROPERTY AND EQUIPMENT - AT COST $ 156,342us-gaap_PropertyPlantAndEquipmentGross $ 133,599us-gaap_PropertyPlantAndEquipmentGross
Less: Accumulated Depreciation 89,954us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment 67,950us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
PROPERTY AND EQUIPMENT - NET 66,388us-gaap_PropertyPlantAndEquipmentNet 65,649us-gaap_PropertyPlantAndEquipmentNet
Equipment    
Property and equipment    
PROPERTY AND EQUIPMENT - AT COST 77,682us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		 65,762us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember
Leasehold Improvements    
Property and equipment    
PROPERTY AND EQUIPMENT - AT COST 32,157us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LeaseholdImprovementsMember		 27,974us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LeaseholdImprovementsMember
Furniture Fixtures and Office and Computer Equipment    
Property and equipment    
PROPERTY AND EQUIPMENT - AT COST 26,076us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_FurnitureFixturesAndOfficeAndComputerEquipmentMember		 21,621us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= brli_FurnitureFixturesAndOfficeAndComputerEquipmentMember
Transportation Equipment    
Property and equipment    
PROPERTY AND EQUIPMENT - AT COST $ 20,427us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_TransportationEquipmentMember		 $ 18,242us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_TransportationEquipmentMember
XML 82 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Tables)
 12 Months Ended
Oct. 31, 2014
Commitments and Contingencies  
Schedule of aggregate future minimum rental payments on non cancelable operating leases (exclusive of several month to month leases)

 

                                                                                                                                                         

October 31,

 

Property($)

 

Equipment($)

 

 

 

 

 

 

 

2015

 
8,564 

 
345 

 

2016

 
2,122 

 
203 

 

2017

 
831 

 
63 

 

2018

 
689 

 

 

 

2019

 
626 

 

 

 

Thereafter

 
103 

 

 

 

 

 

 

 

 

 

Totals:

 
12,935 

 
611 

 

 

Schedule of minimum purchase commitments

 

                                                                                                                                                          

October 31

 

Reagents ($)

 

2015

 
73,709 

 

2016

 
62,534 

 

2017

 
36,188 

 

2018

 
21,241 

 

2019

 
8,663 

 

Thereafter

 

—

 

 

 

 

 

Totals:

 
202,335 

 

 

XML 83 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)
In Thousands, except Share data, unless otherwise specified
Common Stock
Additional Paid-in Capital
Retained Earnings
Total
Balance at Oct. 31, 2011 $ 279us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		 $ 45,581us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ 143,907us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 $ 189,767us-gaap_StockholdersEquity
Balance (in shares) at Oct. 31, 2011 27,949,900us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Increase (Decrease) in Stockholders' Equity        
Exercise of Options - Employees 1us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		 226us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   227us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
Exercise of Options - Employees (in shares) 31,500us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Stock Based Compensation   290us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   290us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation
Stock Based Compensation (in shares) 23,096us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Stock Issued for Acquisition   482us-gaap_StockIssuedDuringPeriodValueAcquisitions
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   482us-gaap_StockIssuedDuringPeriodValueAcquisitions
Stock Issued for Acquisition (in shares) 23,096us-gaap_StockIssuedDuringPeriodSharesAcquisitions
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Net Income     42,156us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 42,156us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Common Stock Repurchased and Canceled (3)us-gaap_StockRepurchasedAndRetiredDuringPeriodValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		 (5,190)us-gaap_StockRepurchasedAndRetiredDuringPeriodValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   (5,193)us-gaap_StockRepurchasedAndRetiredDuringPeriodValue
Common Stock Repurchased and Canceled (in shares) (285,450)us-gaap_StockRepurchasedAndRetiredDuringPeriodShares
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		     285,450us-gaap_StockRepurchasedAndRetiredDuringPeriodShares
Balance at Oct. 31, 2012 277us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		 40,907us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		 186,063us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 227,247us-gaap_StockholdersEquity
Balance (in shares) at Oct. 31, 2012 27,707,382us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Increase (Decrease) in Stockholders' Equity        
Exercise of Options - Employees   263us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   263us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
Exercise of Options - Employees (in shares) 46,000us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Stock Based Compensation   290us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   290us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation
Stock Based Compensation (in shares) 11,431us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Net Income     45,825us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 45,825us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Common Stock Repurchased and Canceled   (2,030)us-gaap_StockRepurchasedAndRetiredDuringPeriodValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   (2,030)us-gaap_StockRepurchasedAndRetiredDuringPeriodValue
Common Stock Repurchased and Canceled (in shares) (81,600)us-gaap_StockRepurchasedAndRetiredDuringPeriodShares
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		     81,600us-gaap_StockRepurchasedAndRetiredDuringPeriodShares
Balance at Oct. 31, 2013 277us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		 39,430us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		 231,888us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 271,595us-gaap_StockholdersEquity
Balance (in shares) at Oct. 31, 2013 27,683,213us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Increase (Decrease) in Stockholders' Equity        
Exercise of Options - Employees   259us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   259us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
Exercise of Options - Employees (in shares) 33,000us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Stock Based Compensation   290us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		   290us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation
Stock Based Compensation (in shares) 11,431us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
Net Income     46,758us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 46,758us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Balance at Oct. 31, 2014 $ 277us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		 $ 39,979us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ 278,464us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RetainedEarningsMember		 $ 318,902us-gaap_StockholdersEquity
Balance (in shares) at Oct. 31, 2014 27,727,644us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember		      
XML 84 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets
 12 Months Ended
Oct. 31, 2014
Intangible Assets  
Intangible Assets

[4] Intangible Assets

Intangible assets are summarized as follows:

 

October 31, 2014

 

 

 

Weighted-Average

 

 

 

Accumulated

 

Net of 
Accumulated

 

Intangible Asset

 

Amortization Period

 

Cost

 

Amortization

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$
8,738 

 

$
3,275 

 

$
5,463 

 

Covenants Not-to-Compete

 

3

 
11,131 

 
5,738 

 
5,393 

 

Patents and Licenses

 

17

 
5,297 

 
1,750 

 
3,547 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$
25,166 

 

$
10,763 

 

$
14,403 

 

 

October 31, 2013

 

 

 

Weighted-Average

 

 

 

Accumulated

 

Net of 
Accumulated

 

Intangible Asset

 

Amortization Period

 

Cost

 

Amortization

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

$
8,738 

 

$
2,878 

 

$
5,860 

 

Covenants Not-to-Compete

 

3

 
11,131 

 
4,560 

 
6,571 

 

Patents and Licenses

 

17

 
5,297 

 
1,408 

 
3,889 

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

$
25,166 

 

$
8,846 

 

$
16,320 

 

 

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of October 31, 2014 is as follows:

 

October 31,

 

 

 

2015

 

$
1,852 

 

2016

 
1,540 

 

2017

 
1,063 

 

2018

 
946 

 

2019

 
904 

 

Thereafter

 
8,098 

 

 

 

 

 

Total

 

$
14,403 

 

 

XML 85 R58.htm IDEA: XBRL DOCUMENT v2.4.1.9
Employment Contracts and Consulting Agreements (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Oct. 31, 2014
agreement
Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases  
2015 $ 4,582us-gaap_ContractualObligationDueInNextTwelveMonths
2016 3,706us-gaap_ContractualObligationDueInSecondYear
2017 3,706us-gaap_ContractualObligationDueInThirdYear
2018 1,701us-gaap_ContractualObligationDueInFourthYear
Total 13,695us-gaap_ContractualObligation
Number of additional at-will employment and consulting agreements 70brli_EmploymentContractsAndConsultingAgreementsAdditionalNumberOfAgreements
Annual aggregate commitments under agreement $ 39,254brli_EmploymentContractsAndConsultingAgreementsAnnualMinimumCommitmentsIncludingUnderAdditionalAgreementsNotSubjectToTermination
Minimum  
Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases  
Bonuses and commissions based on percentage of collected revenues (as a percent) 1.00%brli_EmploymentContractsAndConsultingAgreementsBonusesAndCommissionsAsPercentageOfCollectedRevenue
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
Maximum  
Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases  
Bonuses and commissions based on percentage of collected revenues (as a percent) 10.00%brli_EmploymentContractsAndConsultingAgreementsBonusesAndCommissionsAsPercentageOfCollectedRevenue
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
XML 86 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
Employee Benefit Plan
 12 Months Ended
Oct. 31, 2014
Employee Benefit Plan  
Employee Benefit Plan

[21] Employee Benefit Plan

 

The Company sponsors a 401(k) Profit-Sharing Plan [the “Plan”].  Employees become eligible for participation after attaining the age of eighteen and completing one year of service.  Participants may elect to contribute up to ten percent of their compensation, as defined in the Plan, to a maximum allowed by the Internal Revenue Service.  The Company may choose to make a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year, at a percentage determined each year by the Company. The Company elected to make a matching contribution which amounted to $2,130 for 2014, $1,358 for 2013 and $1,106 for 2012.  These amounts were charged to the Statement of Operations. The Employer contribution will be fully vested after the third year of service.

 

XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 134 325 1 false 34 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.bioreference.com/role/DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bioreference.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioreference.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bioreference.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.bioreference.com/role/StatementConsolidatedStatementsOfShareholdersEquity CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioreference.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 10101 - Disclosure - Organization and Business Sheet http://www.bioreference.com/role/DisclosureOrganizationAndBusiness Organization and Business false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 10301 - Disclosure - Property and Equipment Sheet http://www.bioreference.com/role/DisclosurePropertyAndEquipment Property and Equipment false false R10.htm 10401 - Disclosure - Intangible Assets Sheet http://www.bioreference.com/role/DisclosureIntangibleAssets Intangible Assets false false R11.htm 10501 - Disclosure - Revolving Note Payable - Bank Sheet http://www.bioreference.com/role/DisclosureRevolvingNotePayableBank Revolving Note Payable - Bank false false R12.htm 10601 - Disclosure - Long-Term Debt - Bank Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBank Long-Term Debt - Bank false false R13.htm 10701 - Disclosure - Related Party Transactions Sheet http://www.bioreference.com/role/DisclosureRelatedPartyTransactions Related Party Transactions false false R14.htm 10801 - Disclosure - Income Taxes Sheet http://www.bioreference.com/role/DisclosureIncomeTaxes Income Taxes false false R15.htm 10901 - Disclosure - Capital Transactions Sheet http://www.bioreference.com/role/DisclosureCapitalTransactions Capital Transactions false false R16.htm 11001 - Disclosure - Earnings Per Share Sheet http://www.bioreference.com/role/DisclosureEarningsPerShare Earnings Per Share false false R17.htm 11101 - Disclosure - Stock Options and Warrants Sheet http://www.bioreference.com/role/DisclosureStockOptionsAndWarrants Stock Options and Warrants false false R18.htm 11201 - Disclosure - Employment Contracts and Consulting Agreements Sheet http://www.bioreference.com/role/DisclosureEmploymentContractsAndConsultingAgreements Employment Contracts and Consulting Agreements false false R19.htm 11301 - Disclosure - Capitalized Lease Obligations Sheet http://www.bioreference.com/role/DisclosureCapitalizedLeaseObligations Capitalized Lease Obligations false false R20.htm 11401 - Disclosure - Commitments and Contingencies Sheet http://www.bioreference.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies false false R21.htm 11501 - Disclosure - Litigation Sheet http://www.bioreference.com/role/DisclosureLitigation Litigation false false R22.htm 11601 - Disclosure - Insurance Sheet http://www.bioreference.com/role/DisclosureInsurance Insurance false false R23.htm 11701 - Disclosure - Significant Risks and Uncertainties Sheet http://www.bioreference.com/role/DisclosureSignificantRisksAndUncertainties Significant Risks and Uncertainties false false R24.htm 11801 - Disclosure - Acquisitions Sheet http://www.bioreference.com/role/DisclosureAcquisitions Acquisitions false false R25.htm 11901 - Disclosure - Fair Value Measurements Sheet http://www.bioreference.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R26.htm 12001 - Disclosure - Health Insurance Plan Sheet http://www.bioreference.com/role/DisclosureHealthInsurancePlan Health Insurance Plan false false R27.htm 12101 - Disclosure - Employee Benefit Plan Sheet http://www.bioreference.com/role/DisclosureEmployeeBenefitPlan Employee Benefit Plan false false R28.htm 12201 - Disclosure - New Accounting Pronouncements Sheet http://www.bioreference.com/role/DisclosureNewAccountingPronouncements New Accounting Pronouncements false false R29.htm 12301 - Disclosure - Selected Quarterly Financial Data Sheet http://www.bioreference.com/role/DisclosureSelectedQuarterlyFinancialData Selected Quarterly Financial Data false false R30.htm 12401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Sheet http://www.bioreference.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS false false R31.htm 20102 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R32.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R33.htm 30303 - Disclosure - Property and Equipment (Tables) Sheet http://www.bioreference.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) false false R34.htm 30403 - Disclosure - Intangible Assets (Tables) Sheet http://www.bioreference.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) false false R35.htm 30603 - Disclosure - Long-Term Debt - Bank (Tables) Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBankTables Long-Term Debt - Bank (Tables) false false R36.htm 30803 - Disclosure - Income Taxes (Tables) Sheet http://www.bioreference.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) false false R37.htm 31003 - Disclosure - Earnings Per Share (Tables) Sheet http://www.bioreference.com/role/DisclosureEarningsPerShareTables Earnings Per Share (Tables) false false R38.htm 31103 - Disclosure - Stock Options and Warrants (Tables) Sheet http://www.bioreference.com/role/DisclosureStockOptionsAndWarrantsTables Stock Options and Warrants (Tables) false false R39.htm 31203 - Disclosure - Employment Contracts and Consulting Agreements (Tables) Sheet http://www.bioreference.com/role/DisclosureEmploymentContractsAndConsultingAgreementsTables Employment Contracts and Consulting Agreements (Tables) false false R40.htm 31303 - Disclosure - Capitalized Lease Obligations (Tables) Sheet http://www.bioreference.com/role/DisclosureCapitalizedLeaseObligationsTables Capitalized Lease Obligations (Tables) false false R41.htm 31403 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.bioreference.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R42.htm 32303 - Disclosure - Selected Quarterly Financial Data (Tables) Sheet http://www.bioreference.com/role/DisclosureSelectedQuarterlyFinancialDataTables Selected Quarterly Financial Data (Tables) false false R43.htm 40101 - Disclosure - Organization and Business (Details) Sheet http://www.bioreference.com/role/DisclosureOrganizationAndBusinessDetails Organization and Business (Details) false false R44.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R45.htm 40202 - Disclosure - Summary of Significant Accounting Policies (Details 2) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details 2) false false R46.htm 40203 - Disclosure - Summary of Significant Accounting Policies (Details 3) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3 Summary of Significant Accounting Policies (Details 3) false false R47.htm 40204 - Disclosure - Summary of Significant Accounting Policies (Details 4) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4 Summary of Significant Accounting Policies (Details 4) false false R48.htm 40205 - Disclosure - Summary of Significant Accounting Policies (Details 5) Sheet http://www.bioreference.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5 Summary of Significant Accounting Policies (Details 5) false false R49.htm 40301 - Disclosure - Property and Equipment (Details) Sheet http://www.bioreference.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) false false R50.htm 40401 - Disclosure - Intangible Assets (Details) Sheet http://www.bioreference.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) false false R51.htm 40501 - Disclosure - Revolving Note Payable - Bank (Details) Sheet http://www.bioreference.com/role/DisclosureRevolvingNotePayableBankDetails Revolving Note Payable - Bank (Details) false false R52.htm 40601 - Disclosure - Long-Term Debt - Bank (Details) Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBankDetails Long-Term Debt - Bank (Details) false false R53.htm 40801 - Disclosure - Income Taxes (Details) Sheet http://www.bioreference.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) false false R54.htm 40901 - Disclosure - Capital Transactions (Details) Sheet http://www.bioreference.com/role/DisclosureCapitalTransactionsDetails Capital Transactions (Details) false false R55.htm 41001 - Disclosure - Earnings Per Share (Details) Sheet http://www.bioreference.com/role/DisclosureEarningsPerShareDetails Earnings Per Share (Details) false false R56.htm 41101 - Disclosure - Stock Options and Warrants (Details) Sheet http://www.bioreference.com/role/DisclosureStockOptionsAndWarrantsDetails Stock Options and Warrants (Details) false false R57.htm 41102 - Disclosure - Stock Options and Warrants (Details 2) Sheet http://www.bioreference.com/role/DisclosureStockOptionsAndWarrantsDetails2 Stock Options and Warrants (Details 2) false false R58.htm 41201 - Disclosure - Employment Contracts and Consulting Agreements (Details) Sheet http://www.bioreference.com/role/DisclosureEmploymentContractsAndConsultingAgreementsDetails Employment Contracts and Consulting Agreements (Details) false false R59.htm 41301 - Disclosure - Capitalized Lease Obligations (Details) Sheet http://www.bioreference.com/role/DisclosureCapitalizedLeaseObligationsDetails Capitalized Lease Obligations (Details) false false R60.htm 41401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bioreference.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R61.htm 41501 - Disclosure - Litigation (Details) Sheet http://www.bioreference.com/role/DisclosureLitigationDetails Litigation (Details) false false R62.htm 41601 - Disclosure - Insurance (Details) Sheet http://www.bioreference.com/role/DisclosureInsuranceDetails Insurance (Details) false false R63.htm 41701 - Disclosure - Significant Risks and Uncertainties (Details) Sheet http://www.bioreference.com/role/DisclosureSignificantRisksAndUncertaintiesDetails Significant Risks and Uncertainties (Details) false false R64.htm 42001 - Disclosure - Health Insurance Plan (Details) Sheet http://www.bioreference.com/role/DisclosureHealthInsurancePlanDetails Health Insurance Plan (Details) false false R65.htm 42101 - Disclosure - Employee Benefit Plan (Details) Sheet http://www.bioreference.com/role/DisclosureEmployeeBenefitPlanDetails Employee Benefit Plan (Details) false false R66.htm 42301 - Disclosure - Selected Quarterly Financial Data (Details) Sheet http://www.bioreference.com/role/DisclosureSelectedQuarterlyFinancialDataDetails Selected Quarterly Financial Data (Details) false false R67.htm 42401 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) Sheet http://www.bioreference.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) false false All Reports Book All Reports Element brli_SharebasedCompensationArrangementBySharebasedPaymentAwardMinimumSpecifiedCommonStockPercentage had a mix of decimals attribute values: 0 2. Element us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent had a mix of decimals attribute values: 0 2. Element us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised had a mix of decimals attribute values: -3 0. Element us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding had a mix of decimals attribute values: -3 0. Element us-gaap_WeightedAverageNumberOfSharesOutstandingBasic had a mix of decimals attribute values: -3 0. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '11/1/2011 - 1/31/2012' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '2/1/2012 - 4/30/2012' is shorter (89 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '5/1/2012 - 7/31/2012' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '8/1/2012 - 10/31/2012' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '11/1/2012 - 1/31/2013' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '2/1/2013 - 4/30/2013' is shorter (88 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '5/1/2013 - 7/31/2013' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '8/1/2013 - 10/31/2013' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '11/1/2013 - 1/31/2014' is shorter (91 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '2/1/2014 - 4/30/2014' is shorter (88 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '5/1/2014 - 7/31/2014' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 31 values. Shorter duration columns must have at least one fourth (7) as many values. Column '8/1/2014 - 10/31/2014' is shorter (91 days) and has only 2 values, so it is being removed. Process Flow-Through: 00100 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Oct. 31, 2012' Process Flow-Through: Removing column 'Oct. 31, 2011' Process Flow-Through: 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: Removing column '3 Months Ended Oct. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Jul. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Apr. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Jan. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Oct. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Jul. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Apr. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jan. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Oct. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Jul. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Apr. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jan. 31, 2012' Process Flow-Through: 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS brli-20141031.xml brli-20141031.xsd brli-20141031_cal.xml brli-20141031_def.xml brli-20141031_lab.xml brli-20141031_pre.xml true true XML 88 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options and Warrants (Tables)
 12 Months Ended
Oct. 31, 2014
Employee incentive stock options  
Summary of outstanding options

 

 

 

 

Weighted Average

 

Exercisable

 

 

 

Shares

 

Remaining

 

Exercise

 

Shares

 

Exercise

 

Exercise Price Range

 

Outstanding

 

Life

 

Price

 

Outstanding

 

Price

 

$
7.25 

 

to

 

$
7.25 

 

Per Share

 
0 

 
0.00 

 
7.25 

 
0 

 
7.25 

 

$
7.41 

 

to

 

$
7.67 

 

Per Share

 
46 

 
0.42 

 
7.41 

 
46 

 
7.41 

 

$
9.12 

 

to

 

$
9.12 

 

Per Share

 
136 

 
1.00 

 
9.13 

 
136 

 
9.13 

 

$
17.50 

 

to

 

$
17.50 

 

Per Share

 
40 

 
3.08 

 
17.50 

 
35 

 
17.50 

 

 

 

 

 

 

 

 

 
222 

 

 

 

 

 
217 

 

 

 

 

Employee Incentive Stock Option Plan 2003  
Employee incentive stock options  
Summary of employee incentive stock option plan transactions

 

 

 

 

2003 Plan

 

 

 

Shares Under Options
[In Thousands]

 

Weighted Average 
Exercise Price Per Share

 

Outstanding at October 31, 2011*

 
295

 

$
9.80

 

Granted

 

—

 

—

 

Expired

 
(13

)
9.13

 

Exercised

 
(23

)
8.52

 

Outstanding at October 31, 2012**

 
259

 

$
9.95

 

 

 

 

 

 

 

Granted

 

—

 

—

 

Expired

 
(6

)
8.64

 

Exercised

 
(4

)
7.25

 

Outstanding at October 31, 2013***

 
249

 

$
10.02

 

 

 

 

 

 

 

Granted

 

—

 

 

 

Expired

 

—

 

 

 

Exercised

 
(27

)
7.92

 

Outstanding at October 31, 2014****

 
222

 

$
10.28

 

 

*Eligible for exercise at October 31, 2011 were 275 at a weighted average exercise price per share of $9.80

**Eligible for exercise at October 31, 2012 were 244 at a weighted average exercise price per share of $9.95

***Eligible for exercise at October 31, 2013 were 239 at a weighted average exercise price per share of $9.97

****Eligible for exercise at October 31, 2014 were 217 at a weighted average exercise price per share of $10.28

Employee Incentive Stock Option Plan 2000  
Employee incentive stock options  
Summary of employee incentive stock option plan transactions

 

 

 

 

2000 Plan

 

 

 

Shares Under Options
[In Thousands]

 

Weighted Average
Exercise Price Per Share

 

Outstanding and Eligible for Exercise at October 31, 2011

 
60

 
5.19

 

Granted

 

—

 

—

 

Expired

 

—

 

—

 

Exercised

 
(8

)
3.39

 

Outstanding and Eligible for Exercise at October 31, 2012

 
(52

)
5.47

 

 

 

—

 

—

 

Granted

 

—

 

—

 

Expired

 
(2

)
3.60

 

Exercised

 
(44

)

$
5.25

 

Outstanding and Eligible for Exercise at October 31, 2013

 
6

 
7.67

 

Granted

 

—

 

 

 

Expired

 

—

 

 

 

Exercised

 
(6

)
7.67

 

Outstanding and Eligible for Exercise at October 31, 2014

 

—

 

 

 

 

XML 89 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies
 12 Months Ended
Oct. 31, 2014
Commitments and Contingencies  
Commitments and Contingencies

[14] Commitments and Contingencies

 

The Company leases various office and laboratory facilities and equipment under operating leases expiring from 2015 to 2020.  Several of these leases contain renewal options for one to five year periods.

 

Total expense for property and equipment rental for the years ended October 31, 2014, 2013 and 2012 was $13,411, $10,568 and $8,787, respectively.  There were no contingent rental amounts due through October 31, 2014.

 

Aggregate future minimum rental payments on non cancelable operating leases [exclusive of several month to month leases] are as follows:

 

October 31,

 

Property($)

 

Equipment($)

 

 

 

 

 

 

 

2015

 
8,564 

 
345 

 

2016

 
2,122 

 
203 

 

2017

 
831 

 
63 

 

2018

 
689 

 

 

 

2019

 
626 

 

 

 

Thereafter

 
103 

 

 

 

 

 

 

 

 

 

Totals:

 
12,935 

 
611 

 

 

The Company has entered into several purchase agreements for reagent supplies through October, 2019.  Minimum purchase commitments as of October 31, 2014 are as follows:

 

October 31

 

Reagents ($)

 

2015

 
73,709 

 

2016

 
62,534 

 

2017

 
36,188 

 

2018

 
21,241 

 

2019

 
8,663 

 

Thereafter

 

—

 

 

 

 

 

Totals:

 
202,335 

 

 

Reagent supplies expensed under purchase agreements amount to $60,777, $7,873, and $13,338 for the years ended October 31, 2014, 2013 and 2012, respectively.